id	sid	tid	token	lemma	pos
cord-263455-dquztf5l	1	1	key	key	NN
cord-263455-dquztf5l	1	2	:	:	:
cord-263455-dquztf5l	2	1	cord-263455-dquztf5l	cord-263455-dquztf5l	NN
cord-263455-dquztf5l	2	2	authors	author	NNS
cord-263455-dquztf5l	2	3	:	:	:
cord-263455-dquztf5l	2	4	Schoenmakers	Schoenmakers	NNP
cord-263455-dquztf5l	2	5	,	,	,
cord-263455-dquztf5l	2	6	Anne	Anne	NNP
cord-263455-dquztf5l	2	7	;	;	:
cord-263455-dquztf5l	2	8	Mieras	Mieras	NNP
cord-263455-dquztf5l	2	9	,	,	,
cord-263455-dquztf5l	2	10	Liesbeth	Liesbeth	NNP
cord-263455-dquztf5l	2	11	;	;	:
cord-263455-dquztf5l	2	12	Budiawan	Budiawan	NNP
cord-263455-dquztf5l	2	13	,	,	,
cord-263455-dquztf5l	2	14	Teky	Teky	NNP
cord-263455-dquztf5l	2	15	;	;	:
cord-263455-dquztf5l	2	16	van	van	NNP
cord-263455-dquztf5l	2	17	Brakel	Brakel	NNP
cord-263455-dquztf5l	2	18	,	,	,
cord-263455-dquztf5l	2	19	Wim	Wim	NNP
cord-263455-dquztf5l	2	20	H	H	NNP
cord-263455-dquztf5l	2	21	title	title	NN
cord-263455-dquztf5l	2	22	:	:	:
cord-263455-dquztf5l	2	23	The	the	DT
cord-263455-dquztf5l	2	24	State	State	NNP
cord-263455-dquztf5l	2	25	of	of	IN
cord-263455-dquztf5l	2	26	Affairs	Affairs	NNPS
cord-263455-dquztf5l	2	27	in	in	IN
cord-263455-dquztf5l	2	28	Post	Post	NNP
cord-263455-dquztf5l	2	29	-	-	NNP
cord-263455-dquztf5l	2	30	Exposure	Exposure	NNP
cord-263455-dquztf5l	2	31	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	2	32	Prevention	Prevention	NNP
cord-263455-dquztf5l	2	33	:	:	:
cord-263455-dquztf5l	3	1	A	a	DT
cord-263455-dquztf5l	3	2	Descriptive	descriptive	JJ
cord-263455-dquztf5l	3	3	Meta	Meta	NNP
cord-263455-dquztf5l	3	4	-	-	HYPH
cord-263455-dquztf5l	3	5	Analysis	Analysis	NNP
cord-263455-dquztf5l	3	6	on	on	IN
cord-263455-dquztf5l	3	7	Immuno-	Immuno-	NNP
cord-263455-dquztf5l	3	8	and	and	CC
cord-263455-dquztf5l	3	9	Chemo	Chemo	NNP
cord-263455-dquztf5l	3	10	-	-	HYPH
cord-263455-dquztf5l	3	11	Prophylaxis	Prophylaxis	NNP
cord-263455-dquztf5l	3	12	date	date	NN
cord-263455-dquztf5l	3	13	:	:	:
cord-263455-dquztf5l	3	14	2020	2020	CD
cord-263455-dquztf5l	3	15	-	-	SYM
cord-263455-dquztf5l	3	16	10	10	CD
cord-263455-dquztf5l	3	17	-	-	SYM
cord-263455-dquztf5l	3	18	15	15	CD
cord-263455-dquztf5l	3	19	journal	journal	NN
cord-263455-dquztf5l	3	20	:	:	:
cord-263455-dquztf5l	4	1	Res	Res	NNP
cord-263455-dquztf5l	4	2	Rep	Rep	NNP
cord-263455-dquztf5l	4	3	Trop	Trop	NNP
cord-263455-dquztf5l	4	4	Med	Med	NNP
cord-263455-dquztf5l	4	5	DOI	doi	NN
cord-263455-dquztf5l	4	6	:	:	:
cord-263455-dquztf5l	4	7	10.2147	10.2147	CD
cord-263455-dquztf5l	4	8	/	/	SYM
cord-263455-dquztf5l	4	9	rrtm.s190300	rrtm.s190300	CD
cord-263455-dquztf5l	4	10	sha	sha	NNP
cord-263455-dquztf5l	4	11	:	:	:
cord-263455-dquztf5l	4	12	76ff7132a40f3044bbe371bf98e950738da20b74	76ff7132a40f3044bbe371bf98e950738da20b74	NNP
cord-263455-dquztf5l	4	13	doc_id	doc_id	CD
cord-263455-dquztf5l	4	14	:	:	:
cord-263455-dquztf5l	4	15	263455	263455	CD
cord-263455-dquztf5l	4	16	cord_uid	cord_uid	NNS
cord-263455-dquztf5l	4	17	:	:	:
cord-263455-dquztf5l	5	1	dquztf5l	dquztf5l	NNP
cord-263455-dquztf5l	5	2	OBJECTIVE	OBJECTIVE	NNP
cord-263455-dquztf5l	5	3	:	:	:
cord-263455-dquztf5l	6	1	Annually	annually	RB
cord-263455-dquztf5l	6	2	,	,	,
cord-263455-dquztf5l	6	3	over	over	IN
cord-263455-dquztf5l	6	4	200,000	200,000	CD
cord-263455-dquztf5l	6	5	people	people	NNS
cord-263455-dquztf5l	6	6	are	be	VBP
cord-263455-dquztf5l	6	7	diagnosed	diagnose	VBN
cord-263455-dquztf5l	6	8	with	with	IN
cord-263455-dquztf5l	6	9	leprosy	leprosy	NN
cord-263455-dquztf5l	6	10	,	,	,
cord-263455-dquztf5l	6	11	also	also	RB
cord-263455-dquztf5l	6	12	called	call	VBD
cord-263455-dquztf5l	6	13	Hansen	Hansen	NNP
cord-263455-dquztf5l	6	14	’s	’s	POS
cord-263455-dquztf5l	6	15	disease	disease	NN
cord-263455-dquztf5l	6	16	.	.	.
cord-263455-dquztf5l	7	1	This	this	DT
cord-263455-dquztf5l	7	2	number	number	NN
cord-263455-dquztf5l	7	3	has	have	VBZ
cord-263455-dquztf5l	7	4	been	be	VBN
cord-263455-dquztf5l	7	5	relatively	relatively	RB
cord-263455-dquztf5l	7	6	stable	stable	JJ
cord-263455-dquztf5l	7	7	over	over	IN
cord-263455-dquztf5l	7	8	the	the	DT
cord-263455-dquztf5l	7	9	past	past	JJ
cord-263455-dquztf5l	7	10	years	year	NNS
cord-263455-dquztf5l	7	11	.	.	.
cord-263455-dquztf5l	8	1	Progress	progress	NN
cord-263455-dquztf5l	8	2	has	have	VBZ
cord-263455-dquztf5l	8	3	been	be	VBN
cord-263455-dquztf5l	8	4	made	make	VBN
cord-263455-dquztf5l	8	5	in	in	IN
cord-263455-dquztf5l	8	6	the	the	DT
cord-263455-dquztf5l	8	7	fields	field	NNS
cord-263455-dquztf5l	8	8	of	of	IN
cord-263455-dquztf5l	8	9	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	8	10	and	and	CC
cord-263455-dquztf5l	8	11	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	8	12	to	to	TO
cord-263455-dquztf5l	8	13	prevent	prevent	VB
cord-263455-dquztf5l	8	14	leprosy	leprosy	NN
cord-263455-dquztf5l	8	15	,	,	,
cord-263455-dquztf5l	8	16	with	with	IN
cord-263455-dquztf5l	8	17	a	a	DT
cord-263455-dquztf5l	8	18	primary	primary	JJ
cord-263455-dquztf5l	8	19	focus	focus	NN
cord-263455-dquztf5l	8	20	on	on	IN
cord-263455-dquztf5l	8	21	close	close	JJ
cord-263455-dquztf5l	8	22	contacts	contact	NNS
cord-263455-dquztf5l	8	23	of	of	IN
cord-263455-dquztf5l	8	24	patients	patient	NNS
cord-263455-dquztf5l	8	25	.	.	.
cord-263455-dquztf5l	9	1	In	in	IN
cord-263455-dquztf5l	9	2	this	this	DT
cord-263455-dquztf5l	9	3	descriptive	descriptive	JJ
cord-263455-dquztf5l	9	4	meta	meta	NN
cord-263455-dquztf5l	9	5	-	-	HYPH
cord-263455-dquztf5l	9	6	analysis	analysis	NN
cord-263455-dquztf5l	9	7	,	,	,
cord-263455-dquztf5l	9	8	we	-PRON-	PRP
cord-263455-dquztf5l	9	9	summarize	summarize	VBP
cord-263455-dquztf5l	9	10	the	the	DT
cord-263455-dquztf5l	9	11	evidence	evidence	NN
cord-263455-dquztf5l	9	12	and	and	CC
cord-263455-dquztf5l	9	13	identify	identify	VB
cord-263455-dquztf5l	9	14	knowledge	knowledge	NN
cord-263455-dquztf5l	9	15	gaps	gap	NNS
cord-263455-dquztf5l	9	16	regarding	regard	VBG
cord-263455-dquztf5l	9	17	post	post	JJ
cord-263455-dquztf5l	9	18	-	-	JJ
cord-263455-dquztf5l	9	19	exposure	exposure	JJ
cord-263455-dquztf5l	9	20	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	9	21	against	against	IN
cord-263455-dquztf5l	9	22	leprosy	leprosy	NN
cord-263455-dquztf5l	9	23	.	.	.
cord-263455-dquztf5l	10	1	METHODS	methods	NN
cord-263455-dquztf5l	10	2	:	:	:
cord-263455-dquztf5l	11	1	A	a	DT
cord-263455-dquztf5l	11	2	systematic	systematic	JJ
cord-263455-dquztf5l	11	3	literature	literature	NN
cord-263455-dquztf5l	11	4	search	search	NN
cord-263455-dquztf5l	11	5	according	accord	VBG
cord-263455-dquztf5l	11	6	to	to	IN
cord-263455-dquztf5l	11	7	the	the	DT
cord-263455-dquztf5l	11	8	Preferred	Preferred	NNP
cord-263455-dquztf5l	11	9	Reporting	Reporting	NNP
cord-263455-dquztf5l	11	10	Items	Items	NNP
cord-263455-dquztf5l	11	11	for	for	IN
cord-263455-dquztf5l	11	12	Systematic	Systematic	NNP
cord-263455-dquztf5l	11	13	Reviews	Reviews	NNPS
cord-263455-dquztf5l	11	14	and	and	CC
cord-263455-dquztf5l	11	15	Meta	Meta	NNP
cord-263455-dquztf5l	11	16	-	-	HYPH
cord-263455-dquztf5l	11	17	Analyses	Analyses	NNP
cord-263455-dquztf5l	12	1	(	(	-LRB-
cord-263455-dquztf5l	12	2	PRISMA	PRISMA	NNP
cord-263455-dquztf5l	12	3	)	)	-RRB-
cord-263455-dquztf5l	12	4	methodology	methodology	NN
cord-263455-dquztf5l	12	5	was	be	VBD
cord-263455-dquztf5l	12	6	conducted	conduct	VBN
cord-263455-dquztf5l	12	7	by	by	IN
cord-263455-dquztf5l	12	8	searching	search	VBG
cord-263455-dquztf5l	12	9	the	the	DT
cord-263455-dquztf5l	12	10	medical	medical	JJ
cord-263455-dquztf5l	12	11	scientific	scientific	JJ
cord-263455-dquztf5l	12	12	databases	database	NNS
cord-263455-dquztf5l	12	13	Cochrane	Cochrane	NNP
cord-263455-dquztf5l	12	14	,	,	,
cord-263455-dquztf5l	12	15	Embase	Embase	NNP
cord-263455-dquztf5l	12	16	,	,	,
cord-263455-dquztf5l	12	17	Pubmed	Pubmed	NNP
cord-263455-dquztf5l	12	18	/	/	SYM
cord-263455-dquztf5l	12	19	MEDLINE	MEDLINE	NNP
cord-263455-dquztf5l	12	20	,	,	,
cord-263455-dquztf5l	12	21	Research	Research	NNP
cord-263455-dquztf5l	12	22	Gate	Gate	NNP
cord-263455-dquztf5l	12	23	,	,	,
cord-263455-dquztf5l	12	24	Scopus	Scopus	NNP
cord-263455-dquztf5l	12	25	and	and	CC
cord-263455-dquztf5l	12	26	Web	Web	NNP
cord-263455-dquztf5l	12	27	of	of	IN
cord-263455-dquztf5l	12	28	Science	Science	NNP
cord-263455-dquztf5l	12	29	on	on	IN
cord-263455-dquztf5l	12	30	Jan.	January	NNP
cord-263455-dquztf5l	12	31	22	22	CD
cord-263455-dquztf5l	12	32	,	,	,
cord-263455-dquztf5l	12	33	2020	2020	CD
cord-263455-dquztf5l	12	34	,	,	,
cord-263455-dquztf5l	12	35	using	use	VBG
cord-263455-dquztf5l	12	36	a	a	DT
cord-263455-dquztf5l	12	37	combination	combination	NN
cord-263455-dquztf5l	12	38	of	of	IN
cord-263455-dquztf5l	12	39	synonyms	synonyms	NN
cord-263455-dquztf5l	12	40	for	for	IN
cord-263455-dquztf5l	12	41	index	index	NN
cord-263455-dquztf5l	12	42	terms	term	NNS
cord-263455-dquztf5l	12	43	in	in	IN
cord-263455-dquztf5l	12	44	four	four	CD
cord-263455-dquztf5l	12	45	languages	language	NNS
cord-263455-dquztf5l	12	46	:	:	:
cord-263455-dquztf5l	12	47	“	"	``
cord-263455-dquztf5l	12	48	leprosy	leprosy	NN
cord-263455-dquztf5l	12	49	”	"	''
cord-263455-dquztf5l	12	50	and	and	CC
cord-263455-dquztf5l	12	51	“	"	``
cord-263455-dquztf5l	12	52	population	population	NN
cord-263455-dquztf5l	12	53	”	"	''
cord-263455-dquztf5l	12	54	or	or	CC
cord-263455-dquztf5l	12	55	“	"	``
cord-263455-dquztf5l	12	56	contacts	contact	NNS
cord-263455-dquztf5l	12	57	”	"	''
cord-263455-dquztf5l	12	58	and	and	CC
cord-263455-dquztf5l	12	59	“	"	``
cord-263455-dquztf5l	12	60	prevention	prevention	NN
cord-263455-dquztf5l	12	61	”	"	''
cord-263455-dquztf5l	12	62	or	or	CC
cord-263455-dquztf5l	12	63	“	"	``
cord-263455-dquztf5l	12	64	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	12	65	.	.	.
cord-263455-dquztf5l	12	66	”	"	''
cord-263455-dquztf5l	13	1	Subsequently	subsequently	RB
cord-263455-dquztf5l	13	2	,	,	,
cord-263455-dquztf5l	13	3	Infolep.org	Infolep.org	NNP
cord-263455-dquztf5l	13	4	and	and	CC
cord-263455-dquztf5l	13	5	Google	Google	NNP
cord-263455-dquztf5l	13	6	Scholar	Scholar	NNP
cord-263455-dquztf5l	13	7	were	be	VBD
cord-263455-dquztf5l	13	8	searched	search	VBN
cord-263455-dquztf5l	13	9	and	and	CC
cord-263455-dquztf5l	13	10	the	the	DT
cord-263455-dquztf5l	13	11	"	"	``
cord-263455-dquztf5l	13	12	snowball	snowball	NN
cord-263455-dquztf5l	13	13	method	method	NN
cord-263455-dquztf5l	13	14	"	"	''
cord-263455-dquztf5l	13	15	was	be	VBD
cord-263455-dquztf5l	13	16	used	use	VBN
cord-263455-dquztf5l	13	17	to	to	TO
cord-263455-dquztf5l	13	18	retrieve	retrieve	VB
cord-263455-dquztf5l	13	19	other	other	JJ
cord-263455-dquztf5l	13	20	potentially	potentially	RB
cord-263455-dquztf5l	13	21	relevant	relevant	JJ
cord-263455-dquztf5l	13	22	literature	literature	NN
cord-263455-dquztf5l	13	23	.	.	.
cord-263455-dquztf5l	14	1	The	the	DT
cord-263455-dquztf5l	14	2	found	find	VBN
cord-263455-dquztf5l	14	3	articles	article	NNS
cord-263455-dquztf5l	14	4	were	be	VBD
cord-263455-dquztf5l	14	5	screened	screen	VBN
cord-263455-dquztf5l	14	6	for	for	IN
cord-263455-dquztf5l	14	7	eligibility	eligibility	NN
cord-263455-dquztf5l	14	8	using	use	VBG
cord-263455-dquztf5l	14	9	predetermined	predetermine	VBN
cord-263455-dquztf5l	14	10	inclusion	inclusion	NN
cord-263455-dquztf5l	14	11	and	and	CC
cord-263455-dquztf5l	14	12	exclusion	exclusion	NN
cord-263455-dquztf5l	14	13	criteria	criterion	NNS
cord-263455-dquztf5l	14	14	.	.	.
cord-263455-dquztf5l	15	1	RESULTS	result	NNS
cord-263455-dquztf5l	15	2	:	:	:
cord-263455-dquztf5l	16	1	After	after	IN
cord-263455-dquztf5l	16	2	deduplication	deduplication	NN
cord-263455-dquztf5l	16	3	,	,	,
cord-263455-dquztf5l	16	4	1,515	1,515	CD
cord-263455-dquztf5l	16	5	articles	article	NNS
cord-263455-dquztf5l	16	6	were	be	VBD
cord-263455-dquztf5l	16	7	screened	screen	VBN
cord-263455-dquztf5l	16	8	,	,	,
cord-263455-dquztf5l	16	9	and	and	CC
cord-263455-dquztf5l	16	10	125	125	CD
cord-263455-dquztf5l	16	11	articles	article	NNS
cord-263455-dquztf5l	16	12	were	be	VBD
cord-263455-dquztf5l	16	13	included	include	VBN
cord-263455-dquztf5l	16	14	in	in	IN
cord-263455-dquztf5l	16	15	this	this	DT
cord-263455-dquztf5l	16	16	descriptive	descriptive	JJ
cord-263455-dquztf5l	16	17	meta	meta	NN
cord-263455-dquztf5l	16	18	-	-	HYPH
cord-263455-dquztf5l	16	19	analysis	analysis	NN
cord-263455-dquztf5l	16	20	.	.	.
cord-263455-dquztf5l	17	1	Immunoprophylaxis	Immunoprophylaxis	NNP
cord-263455-dquztf5l	17	2	by	by	IN
cord-263455-dquztf5l	17	3	bacillus	bacillus	NN
cord-263455-dquztf5l	17	4	Calmette	Calmette	NNP
cord-263455-dquztf5l	17	5	-	-	HYPH
cord-263455-dquztf5l	17	6	Guérin	Guérin	NNP
cord-263455-dquztf5l	17	7	(	(	-LRB-
cord-263455-dquztf5l	17	8	BCG	BCG	NNP
cord-263455-dquztf5l	17	9	)	)	-RRB-
cord-263455-dquztf5l	17	10	vaccination	vaccination	NN
cord-263455-dquztf5l	17	11	is	be	VBZ
cord-263455-dquztf5l	17	12	known	know	VBN
cord-263455-dquztf5l	17	13	to	to	TO
cord-263455-dquztf5l	17	14	provide	provide	VB
cord-263455-dquztf5l	17	15	protection	protection	NN
cord-263455-dquztf5l	17	16	against	against	IN
cord-263455-dquztf5l	17	17	leprosy	leprosy	NN
cord-263455-dquztf5l	17	18	.	.	.
cord-263455-dquztf5l	18	1	The	the	DT
cord-263455-dquztf5l	18	2	protection	protection	NN
cord-263455-dquztf5l	18	3	it	-PRON-	PRP
cord-263455-dquztf5l	18	4	offers	offer	VBZ
cord-263455-dquztf5l	18	5	is	be	VBZ
cord-263455-dquztf5l	18	6	higher	high	JJR
cord-263455-dquztf5l	18	7	in	in	IN
cord-263455-dquztf5l	18	8	household	household	NN
cord-263455-dquztf5l	18	9	contacts	contact	NNS
cord-263455-dquztf5l	18	10	of	of	IN
cord-263455-dquztf5l	18	11	leprosy	leprosy	NN
cord-263455-dquztf5l	18	12	patients	patient	NNS
cord-263455-dquztf5l	18	13	compared	compare	VBN
cord-263455-dquztf5l	18	14	with	with	IN
cord-263455-dquztf5l	18	15	the	the	DT
cord-263455-dquztf5l	18	16	general	general	JJ
cord-263455-dquztf5l	18	17	population	population	NN
cord-263455-dquztf5l	18	18	and	and	CC
cord-263455-dquztf5l	18	19	is	be	VBZ
cord-263455-dquztf5l	18	20	seen	see	VBN
cord-263455-dquztf5l	18	21	to	to	TO
cord-263455-dquztf5l	18	22	decline	decline	VB
cord-263455-dquztf5l	18	23	over	over	IN
cord-263455-dquztf5l	18	24	time	time	NN
cord-263455-dquztf5l	18	25	.	.	.
cord-263455-dquztf5l	19	1	Contact	contact	NN
cord-263455-dquztf5l	19	2	follow	follow	VB
cord-263455-dquztf5l	19	3	-	-	HYPH
cord-263455-dquztf5l	19	4	up	up	NN
cord-263455-dquztf5l	19	5	screening	screening	NN
cord-263455-dquztf5l	19	6	is	be	VBZ
cord-263455-dquztf5l	19	7	important	important	JJ
cord-263455-dquztf5l	19	8	in	in	IN
cord-263455-dquztf5l	19	9	the	the	DT
cord-263455-dquztf5l	19	10	first	first	JJ
cord-263455-dquztf5l	19	11	period	period	NN
cord-263455-dquztf5l	19	12	after	after	IN
cord-263455-dquztf5l	19	13	BCG	BCG	NNP
cord-263455-dquztf5l	19	14	administration	administration	NN
cord-263455-dquztf5l	19	15	,	,	,
cord-263455-dquztf5l	19	16	as	as	IN
cord-263455-dquztf5l	19	17	a	a	DT
cord-263455-dquztf5l	19	18	substantial	substantial	JJ
cord-263455-dquztf5l	19	19	number	number	NN
cord-263455-dquztf5l	19	20	of	of	IN
cord-263455-dquztf5l	19	21	new	new	JJ
cord-263455-dquztf5l	19	22	leprosy	leprosy	NN
cord-263455-dquztf5l	19	23	patients	patient	NNS
cord-263455-dquztf5l	19	24	presents	present	VBZ
cord-263455-dquztf5l	19	25	three	three	CD
cord-263455-dquztf5l	19	26	months	month	NNS
cord-263455-dquztf5l	19	27	post	post	NN
cord-263455-dquztf5l	19	28	-	-	NN
cord-263455-dquztf5l	19	29	vaccination	vaccination	NN
cord-263455-dquztf5l	19	30	.	.	.
cord-263455-dquztf5l	20	1	Evidence	evidence	NN
cord-263455-dquztf5l	20	2	for	for	IN
cord-263455-dquztf5l	20	3	the	the	DT
cord-263455-dquztf5l	20	4	benefit	benefit	NN
cord-263455-dquztf5l	20	5	of	of	IN
cord-263455-dquztf5l	20	6	re	re	NN
cord-263455-dquztf5l	20	7	-	-	NN
cord-263455-dquztf5l	20	8	vaccination	vaccination	NN
cord-263455-dquztf5l	20	9	is	be	VBZ
cord-263455-dquztf5l	20	10	conflicting	conflict	VBG
cord-263455-dquztf5l	20	11	.	.	.
cord-263455-dquztf5l	21	1	The	the	DT
cord-263455-dquztf5l	21	2	World	World	NNP
cord-263455-dquztf5l	21	3	Health	Health	NNP
cord-263455-dquztf5l	21	4	Organization	Organization	NNP
cord-263455-dquztf5l	21	5	(	(	-LRB-
cord-263455-dquztf5l	21	6	WHO	who	WP
cord-263455-dquztf5l	21	7	)	)	-RRB-
cord-263455-dquztf5l	21	8	included	include	VBD
cord-263455-dquztf5l	21	9	BCG	BCG	NNP
cord-263455-dquztf5l	21	10	in	in	IN
cord-263455-dquztf5l	21	11	its	-PRON-	PRP$
cord-263455-dquztf5l	21	12	Guidelines	guideline	NNS
cord-263455-dquztf5l	21	13	for	for	IN
cord-263455-dquztf5l	21	14	the	the	DT
cord-263455-dquztf5l	21	15	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	21	16	,	,	,
cord-263455-dquztf5l	21	17	Treatment	Treatment	NNP
cord-263455-dquztf5l	21	18	and	and	CC
cord-263455-dquztf5l	21	19	Prevention	Prevention	NNP
cord-263455-dquztf5l	21	20	of	of	IN
cord-263455-dquztf5l	21	21	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	21	22	by	by	IN
cord-263455-dquztf5l	21	23	stating	state	VBG
cord-263455-dquztf5l	21	24	that	that	IN
cord-263455-dquztf5l	21	25	BCG	BCG	NNP
cord-263455-dquztf5l	21	26	at	at	IN
cord-263455-dquztf5l	21	27	birth	birth	NN
cord-263455-dquztf5l	21	28	should	should	MD
cord-263455-dquztf5l	21	29	be	be	VB
cord-263455-dquztf5l	21	30	maintained	maintain	VBN
cord-263455-dquztf5l	21	31	in	in	IN
cord-263455-dquztf5l	21	32	at	at	IN
cord-263455-dquztf5l	21	33	least	least	JJS
cord-263455-dquztf5l	21	34	all	all	DT
cord-263455-dquztf5l	21	35	leprosy	leprosy	NN
cord-263455-dquztf5l	21	36	high	high	JJ
cord-263455-dquztf5l	21	37	-	-	HYPH
cord-263455-dquztf5l	21	38	burden	burden	NN
cord-263455-dquztf5l	21	39	regions	region	NNS
cord-263455-dquztf5l	21	40	.	.	.
cord-263455-dquztf5l	22	1	Literature	literature	NN
cord-263455-dquztf5l	22	2	shows	show	VBZ
cord-263455-dquztf5l	22	3	that	that	IN
cord-263455-dquztf5l	22	4	several	several	JJ
cord-263455-dquztf5l	22	5	vaccination	vaccination	NN
cord-263455-dquztf5l	22	6	interventions	intervention	NNS
cord-263455-dquztf5l	22	7	with	with	IN
cord-263455-dquztf5l	22	8	other	other	JJ
cord-263455-dquztf5l	22	9	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	22	10	agents	agent	NNS
cord-263455-dquztf5l	22	11	demonstrate	demonstrate	VBP
cord-263455-dquztf5l	22	12	similar	similar	JJ
cord-263455-dquztf5l	22	13	or	or	CC
cord-263455-dquztf5l	22	14	slightly	slightly	RB
cord-263455-dquztf5l	22	15	less	less	JJR
cord-263455-dquztf5l	22	16	efficacy	efficacy	NN
cord-263455-dquztf5l	22	17	in	in	IN
cord-263455-dquztf5l	22	18	leprosy	leprosy	NN
cord-263455-dquztf5l	22	19	risk	risk	NN
cord-263455-dquztf5l	22	20	reduction	reduction	NN
cord-263455-dquztf5l	22	21	compared	compare	VBN
cord-263455-dquztf5l	22	22	with	with	IN
cord-263455-dquztf5l	22	23	BCG	BCG	NNP
cord-263455-dquztf5l	22	24	.	.	.
cord-263455-dquztf5l	23	1	However	however	RB
cord-263455-dquztf5l	23	2	,	,	,
cord-263455-dquztf5l	23	3	most	most	JJS
cord-263455-dquztf5l	23	4	of	of	IN
cord-263455-dquztf5l	23	5	these	these	DT
cord-263455-dquztf5l	23	6	studies	study	NNS
cord-263455-dquztf5l	23	7	do	do	VBP
cord-263455-dquztf5l	23	8	not	not	RB
cord-263455-dquztf5l	23	9	exclusively	exclusively	RB
cord-263455-dquztf5l	23	10	focus	focus	VB
cord-263455-dquztf5l	23	11	on	on	IN
cord-263455-dquztf5l	23	12	post	post	JJ
cord-263455-dquztf5l	23	13	-	-	JJ
cord-263455-dquztf5l	23	14	exposure	exposure	JJ
cord-263455-dquztf5l	23	15	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	23	16	.	.	.
cord-263455-dquztf5l	24	1	Two	two	CD
cord-263455-dquztf5l	24	2	vaccines	vaccine	NNS
cord-263455-dquztf5l	24	3	are	be	VBP
cord-263455-dquztf5l	24	4	considered	consider	VBN
cord-263455-dquztf5l	24	5	future	future	JJ
cord-263455-dquztf5l	24	6	candidates	candidate	NNS
cord-263455-dquztf5l	24	7	for	for	IN
cord-263455-dquztf5l	24	8	leprosy	leprosy	NN
cord-263455-dquztf5l	24	9	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	24	10	:	:	:
cord-263455-dquztf5l	25	1	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	25	2	indicus	indicus	NN
cord-263455-dquztf5l	25	3	pranii	pranii	NNP
cord-263455-dquztf5l	25	4	(	(	-LRB-
cord-263455-dquztf5l	25	5	MiP	MiP	NNP
cord-263455-dquztf5l	25	6	)	)	-RRB-
cord-263455-dquztf5l	25	7	and	and	CC
cord-263455-dquztf5l	25	8	LepVax	LepVax	NNP
cord-263455-dquztf5l	25	9	.	.	.
cord-263455-dquztf5l	26	1	For	for	IN
cord-263455-dquztf5l	26	2	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	26	3	,	,	,
cord-263455-dquztf5l	26	4	trials	trial	NNS
cord-263455-dquztf5l	26	5	were	be	VBD
cord-263455-dquztf5l	26	6	performed	perform	VBN
cord-263455-dquztf5l	26	7	with	with	IN
cord-263455-dquztf5l	26	8	dapsone	dapsone	NNP
cord-263455-dquztf5l	26	9	/	/	SYM
cord-263455-dquztf5l	26	10	acedapsone	acedapsone	NN
cord-263455-dquztf5l	26	11	,	,	,
cord-263455-dquztf5l	26	12	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	26	13	,	,	,
cord-263455-dquztf5l	26	14	and	and	CC
cord-263455-dquztf5l	26	15	ROM	rom	NN
cord-263455-dquztf5l	26	16	,	,	,
cord-263455-dquztf5l	26	17	a	a	DT
cord-263455-dquztf5l	26	18	combination	combination	NN
cord-263455-dquztf5l	26	19	of	of	IN
cord-263455-dquztf5l	26	20	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	26	21	,	,	,
cord-263455-dquztf5l	26	22	ofloxacin	ofloxacin	NNS
cord-263455-dquztf5l	26	23	,	,	,
cord-263455-dquztf5l	26	24	and	and	CC
cord-263455-dquztf5l	26	25	minocycline	minocycline	NN
cord-263455-dquztf5l	26	26	.	.	.
cord-263455-dquztf5l	27	1	Single	single	JJ
cord-263455-dquztf5l	27	2	-	-	HYPH
cord-263455-dquztf5l	27	3	dose	dose	NN
cord-263455-dquztf5l	27	4	rifampicin	rifampicin	NN
cord-263455-dquztf5l	27	5	is	be	VBZ
cord-263455-dquztf5l	27	6	favored	favor	VBN
cord-263455-dquztf5l	27	7	as	as	IN
cord-263455-dquztf5l	27	8	post	post	JJ
cord-263455-dquztf5l	27	9	-	-	JJ
cord-263455-dquztf5l	27	10	exposure	exposure	JJ
cord-263455-dquztf5l	27	11	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	27	12	,	,	,
cord-263455-dquztf5l	27	13	abbreviated	abbreviate	VBN
cord-263455-dquztf5l	27	14	as	as	IN
cord-263455-dquztf5l	27	15	SDR	SDR	NNP
cord-263455-dquztf5l	27	16	-	-	HYPH
cord-263455-dquztf5l	27	17	PEP	PEP	NNP
cord-263455-dquztf5l	27	18	.	.	.
cord-263455-dquztf5l	28	1	It	-PRON-	PRP
cord-263455-dquztf5l	28	2	demonstrated	demonstrate	VBD
cord-263455-dquztf5l	28	3	a	a	DT
cord-263455-dquztf5l	28	4	protective	protective	JJ
cord-263455-dquztf5l	28	5	effect	effect	NN
cord-263455-dquztf5l	28	6	of	of	IN
cord-263455-dquztf5l	28	7	57	57	CD
cord-263455-dquztf5l	28	8	%	%	NN
cord-263455-dquztf5l	28	9	in	in	IN
cord-263455-dquztf5l	28	10	the	the	DT
cord-263455-dquztf5l	28	11	first	first	JJ
cord-263455-dquztf5l	28	12	two	two	CD
cord-263455-dquztf5l	28	13	years	year	NNS
cord-263455-dquztf5l	28	14	after	after	IN
cord-263455-dquztf5l	28	15	administration	administration	NN
cord-263455-dquztf5l	28	16	to	to	IN
cord-263455-dquztf5l	28	17	contacts	contact	NNS
cord-263455-dquztf5l	28	18	of	of	IN
cord-263455-dquztf5l	28	19	leprosy	leprosy	NN
cord-263455-dquztf5l	28	20	patients	patient	NNS
cord-263455-dquztf5l	28	21	.	.	.
cord-263455-dquztf5l	29	1	It	-PRON-	PRP
cord-263455-dquztf5l	29	2	is	be	VBZ
cord-263455-dquztf5l	29	3	inexpensive	inexpensive	JJ
cord-263455-dquztf5l	29	4	,	,	,
cord-263455-dquztf5l	29	5	and	and	CC
cord-263455-dquztf5l	29	6	adverse	adverse	JJ
cord-263455-dquztf5l	29	7	events	event	NNS
cord-263455-dquztf5l	29	8	are	be	VBP
cord-263455-dquztf5l	29	9	rare	rare	JJ
cord-263455-dquztf5l	29	10	.	.	.
cord-263455-dquztf5l	30	1	The	the	DT
cord-263455-dquztf5l	30	2	risk	risk	NN
cord-263455-dquztf5l	30	3	of	of	IN
cord-263455-dquztf5l	30	4	SDR	SDR	NNP
cord-263455-dquztf5l	30	5	-	-	HYPH
cord-263455-dquztf5l	30	6	PEP	PEP	NNP
cord-263455-dquztf5l	30	7	inducing	induce	VBG
cord-263455-dquztf5l	30	8	rifampicin	rifampicin	NN
cord-263455-dquztf5l	30	9	resistance	resistance	NN
cord-263455-dquztf5l	30	10	is	be	VBZ
cord-263455-dquztf5l	30	11	considered	consider	VBN
cord-263455-dquztf5l	30	12	negligible	negligible	JJ
cord-263455-dquztf5l	30	13	,	,	,
cord-263455-dquztf5l	30	14	but	but	CC
cord-263455-dquztf5l	30	15	continuous	continuous	JJ
cord-263455-dquztf5l	30	16	monitoring	monitoring	NN
cord-263455-dquztf5l	30	17	in	in	IN
cord-263455-dquztf5l	30	18	accordance	accordance	NN
cord-263455-dquztf5l	30	19	with	with	IN
cord-263455-dquztf5l	30	20	WHO	WHO	NNP
cord-263455-dquztf5l	30	21	policies	policy	NNS
cord-263455-dquztf5l	30	22	should	should	MD
cord-263455-dquztf5l	30	23	be	be	VB
cord-263455-dquztf5l	30	24	encouraged	encourage	VBN
cord-263455-dquztf5l	30	25	.	.	.
cord-263455-dquztf5l	31	1	The	the	DT
cord-263455-dquztf5l	31	2	integration	integration	NN
cord-263455-dquztf5l	31	3	of	of	IN
cord-263455-dquztf5l	31	4	contact	contact	NN
cord-263455-dquztf5l	31	5	screening	screening	NN
cord-263455-dquztf5l	31	6	and	and	CC
cord-263455-dquztf5l	31	7	SDR	SDR	NNP
cord-263455-dquztf5l	31	8	-	-	HYPH
cord-263455-dquztf5l	31	9	PEP	PEP	NNP
cord-263455-dquztf5l	31	10	administration	administration	NN
cord-263455-dquztf5l	31	11	into	into	IN
cord-263455-dquztf5l	31	12	different	different	JJ
cord-263455-dquztf5l	31	13	leprosy	leprosy	NN
cord-263455-dquztf5l	31	14	control	control	NN
cord-263455-dquztf5l	31	15	programs	program	NNS
cord-263455-dquztf5l	31	16	was	be	VBD
cord-263455-dquztf5l	31	17	found	find	VBN
cord-263455-dquztf5l	31	18	to	to	TO
cord-263455-dquztf5l	31	19	be	be	VB
cord-263455-dquztf5l	31	20	feasible	feasible	JJ
cord-263455-dquztf5l	31	21	and	and	CC
cord-263455-dquztf5l	31	22	well	well	RB
cord-263455-dquztf5l	31	23	accepted	accepted	JJ
cord-263455-dquztf5l	31	24	.	.	.
cord-263455-dquztf5l	32	1	Since	since	IN
cord-263455-dquztf5l	32	2	2018	2018	CD
cord-263455-dquztf5l	32	3	,	,	,
cord-263455-dquztf5l	32	4	SDR	SDR	NNP
cord-263455-dquztf5l	32	5	-	-	HYPH
cord-263455-dquztf5l	32	6	PEP	PEP	NNP
cord-263455-dquztf5l	32	7	is	be	VBZ
cord-263455-dquztf5l	32	8	included	include	VBN
cord-263455-dquztf5l	32	9	in	in	IN
cord-263455-dquztf5l	32	10	the	the	DT
cord-263455-dquztf5l	32	11	WHO	WHO	NNP
cord-263455-dquztf5l	32	12	Guidelines	Guidelines	NNPS
cord-263455-dquztf5l	32	13	for	for	IN
cord-263455-dquztf5l	32	14	the	the	DT
cord-263455-dquztf5l	32	15	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	32	16	,	,	,
cord-263455-dquztf5l	32	17	Treatment	Treatment	NNP
cord-263455-dquztf5l	32	18	and	and	CC
cord-263455-dquztf5l	32	19	Prevention	Prevention	NNP
cord-263455-dquztf5l	32	20	of	of	IN
cord-263455-dquztf5l	32	21	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	32	22	.	.	.
cord-263455-dquztf5l	33	1	CONCLUSION	conclusion	NN
cord-263455-dquztf5l	33	2	:	:	:
cord-263455-dquztf5l	34	1	Progress	progress	NN
cord-263455-dquztf5l	34	2	has	have	VBZ
cord-263455-dquztf5l	34	3	been	be	VBN
cord-263455-dquztf5l	34	4	made	make	VBN
cord-263455-dquztf5l	34	5	in	in	IN
cord-263455-dquztf5l	34	6	the	the	DT
cord-263455-dquztf5l	34	7	areas	area	NNS
cord-263455-dquztf5l	34	8	of	of	IN
cord-263455-dquztf5l	34	9	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	34	10	and	and	CC
cord-263455-dquztf5l	34	11	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	34	12	to	to	TO
cord-263455-dquztf5l	34	13	prevent	prevent	VB
cord-263455-dquztf5l	34	14	leprosy	leprosy	NN
cord-263455-dquztf5l	34	15	in	in	IN
cord-263455-dquztf5l	34	16	contacts	contact	NNS
cord-263455-dquztf5l	34	17	of	of	IN
cord-263455-dquztf5l	34	18	patients	patient	NNS
cord-263455-dquztf5l	34	19	.	.	.
cord-263455-dquztf5l	35	1	Investing	invest	VBG
cord-263455-dquztf5l	35	2	in	in	IN
cord-263455-dquztf5l	35	3	vaccine	vaccine	NN
cord-263455-dquztf5l	35	4	studies	study	NNS
cord-263455-dquztf5l	35	5	,	,	,
cord-263455-dquztf5l	35	6	like	like	IN
cord-263455-dquztf5l	35	7	LepVax	LepVax	NNP
cord-263455-dquztf5l	35	8	and	and	CC
cord-263455-dquztf5l	35	9	MiP	mip	NN
cord-263455-dquztf5l	35	10	,	,	,
cord-263455-dquztf5l	35	11	and	and	CC
cord-263455-dquztf5l	35	12	increasing	increase	VBG
cord-263455-dquztf5l	35	13	harmonization	harmonization	NN
cord-263455-dquztf5l	35	14	between	between	IN
cord-263455-dquztf5l	35	15	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	35	16	(	(	-LRB-
cord-263455-dquztf5l	35	17	TB	TB	NNP
cord-263455-dquztf5l	35	18	)	)	-RRB-
cord-263455-dquztf5l	35	19	and	and	CC
cord-263455-dquztf5l	35	20	leprosy	leprosy	NN
cord-263455-dquztf5l	35	21	research	research	NN
cord-263455-dquztf5l	35	22	groups	group	NNS
cord-263455-dquztf5l	35	23	is	be	VBZ
cord-263455-dquztf5l	35	24	important	important	JJ
cord-263455-dquztf5l	35	25	.	.	.
cord-263455-dquztf5l	36	1	SDR	SDR	NNP
cord-263455-dquztf5l	36	2	-	-	HYPH
cord-263455-dquztf5l	36	3	PEP	PEP	NNP
cord-263455-dquztf5l	36	4	is	be	VBZ
cord-263455-dquztf5l	36	5	promising	promise	VBG
cord-263455-dquztf5l	36	6	as	as	IN
cord-263455-dquztf5l	36	7	a	a	DT
cord-263455-dquztf5l	36	8	chemoprophylactic	chemoprophylactic	JJ
cord-263455-dquztf5l	36	9	agent	agent	NN
cord-263455-dquztf5l	36	10	,	,	,
cord-263455-dquztf5l	36	11	and	and	CC
cord-263455-dquztf5l	36	12	further	further	JJ
cord-263455-dquztf5l	36	13	implementation	implementation	NN
cord-263455-dquztf5l	36	14	should	should	MD
cord-263455-dquztf5l	36	15	be	be	VB
cord-263455-dquztf5l	36	16	promoted	promote	VBN
cord-263455-dquztf5l	36	17	.	.	.
cord-263455-dquztf5l	37	1	More	More	JJR
cord-263455-dquztf5l	37	2	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	37	3	research	research	NN
cord-263455-dquztf5l	37	4	is	be	VBZ
cord-263455-dquztf5l	37	5	needed	need	VBN
cord-263455-dquztf5l	37	6	on	on	IN
cord-263455-dquztf5l	37	7	:	:	:
cord-263455-dquztf5l	37	8	enhanced	enhance	VBN
cord-263455-dquztf5l	37	9	medication	medication	NN
cord-263455-dquztf5l	37	10	regimens	regimen	NNS
cord-263455-dquztf5l	37	11	;	;	:
cord-263455-dquztf5l	37	12	interventions	intervention	NNS
cord-263455-dquztf5l	37	13	in	in	IN
cord-263455-dquztf5l	37	14	varying	vary	VBG
cord-263455-dquztf5l	37	15	(	(	-LRB-
cord-263455-dquztf5l	37	16	epidemiological	epidemiological	JJ
cord-263455-dquztf5l	37	17	)	)	-RRB-
cord-263455-dquztf5l	37	18	settings	setting	NNS
cord-263455-dquztf5l	37	19	,	,	,
cord-263455-dquztf5l	37	20	including	include	VBG
cord-263455-dquztf5l	37	21	focal	focal	JJ
cord-263455-dquztf5l	37	22	mass	mass	JJ
cord-263455-dquztf5l	37	23	drug	drug	NN
cord-263455-dquztf5l	37	24	administration	administration	NNP
cord-263455-dquztf5l	37	25	(	(	-LRB-
cord-263455-dquztf5l	37	26	fMDA	fmda	NN
cord-263455-dquztf5l	37	27	)	)	-RRB-
cord-263455-dquztf5l	37	28	;	;	,
cord-263455-dquztf5l	37	29	specific	specific	JJ
cord-263455-dquztf5l	37	30	approaches	approach	NNS
cord-263455-dquztf5l	37	31	per	per	IN
cord-263455-dquztf5l	37	32	contact	contact	NN
cord-263455-dquztf5l	37	33	type	type	NN
cord-263455-dquztf5l	37	34	;	;	:
cord-263455-dquztf5l	37	35	combinations	combination	NNS
cord-263455-dquztf5l	37	36	with	with	IN
cord-263455-dquztf5l	37	37	screening	screening	NN
cord-263455-dquztf5l	37	38	variations	variation	NNS
cord-263455-dquztf5l	37	39	and	and	CC
cord-263455-dquztf5l	37	40	field	field	NN
cord-263455-dquztf5l	37	41	-	-	HYPH
cord-263455-dquztf5l	37	42	friendly	friendly	JJ
cord-263455-dquztf5l	37	43	rapid	rapid	JJ
cord-263455-dquztf5l	37	44	tests	test	NNS
cord-263455-dquztf5l	37	45	,	,	,
cord-263455-dquztf5l	37	46	if	if	IN
cord-263455-dquztf5l	37	47	available	available	JJ
cord-263455-dquztf5l	37	48	in	in	IN
cord-263455-dquztf5l	37	49	the	the	DT
cord-263455-dquztf5l	37	50	future	future	NN
cord-263455-dquztf5l	37	51	;	;	:
cord-263455-dquztf5l	37	52	community	community	NN
cord-263455-dquztf5l	37	53	and	and	CC
cord-263455-dquztf5l	37	54	health	health	NN
cord-263455-dquztf5l	37	55	staff	staff	NN
cord-263455-dquztf5l	37	56	education	education	NN
cord-263455-dquztf5l	37	57	;	;	,
cord-263455-dquztf5l	37	58	ongoing	ongoing	JJ
cord-263455-dquztf5l	37	59	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	37	60	resistance	resistance	NN
cord-263455-dquztf5l	37	61	surveillance	surveillance	NN
cord-263455-dquztf5l	37	62	;	;	,
cord-263455-dquztf5l	37	63	and	and	CC
cord-263455-dquztf5l	37	64	administering	administer	VBG
cord-263455-dquztf5l	37	65	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	37	66	with	with	IN
cord-263455-dquztf5l	37	67	SDR	SDR	NNP
cord-263455-dquztf5l	37	68	-	-	HYPH
cord-263455-dquztf5l	37	69	PEP	PEP	NNP
cord-263455-dquztf5l	37	70	prior	prior	RB
cord-263455-dquztf5l	37	71	to	to	IN
cord-263455-dquztf5l	37	72	BCG	BCG	NNP
cord-263455-dquztf5l	37	73	administration	administration	NN
cord-263455-dquztf5l	37	74	.	.	.
cord-263455-dquztf5l	38	1	Additionally	additionally	RB
cord-263455-dquztf5l	38	2	,	,	,
cord-263455-dquztf5l	38	3	both	both	DT
cord-263455-dquztf5l	38	4	leprosy	leprosy	NN
cord-263455-dquztf5l	38	5	prophylactic	prophylactic	JJ
cord-263455-dquztf5l	38	6	drug	drug	NN
cord-263455-dquztf5l	38	7	registration	registration	NN
cord-263455-dquztf5l	38	8	nationally	nationally	RB
cord-263455-dquztf5l	38	9	and	and	CC
cord-263455-dquztf5l	38	10	prophylactic	prophylactic	JJ
cord-263455-dquztf5l	38	11	drug	drug	NN
cord-263455-dquztf5l	38	12	availability	availability	NN
cord-263455-dquztf5l	38	13	globally	globally	RB
cord-263455-dquztf5l	38	14	at	at	IN
cord-263455-dquztf5l	38	15	low	low	JJ
cord-263455-dquztf5l	38	16	or	or	CC
cord-263455-dquztf5l	38	17	no	no	DT
cord-263455-dquztf5l	38	18	cost	cost	NN
cord-263455-dquztf5l	38	19	are	be	VBP
cord-263455-dquztf5l	38	20	important	important	JJ
cord-263455-dquztf5l	38	21	for	for	IN
cord-263455-dquztf5l	38	22	the	the	DT
cord-263455-dquztf5l	38	23	implementation	implementation	NN
cord-263455-dquztf5l	38	24	and	and	CC
cord-263455-dquztf5l	38	25	further	further	JJ
cord-263455-dquztf5l	38	26	upscaling	upscaling	NN
cord-263455-dquztf5l	38	27	of	of	IN
cord-263455-dquztf5l	38	28	preventive	preventive	JJ
cord-263455-dquztf5l	38	29	measures	measure	NNS
cord-263455-dquztf5l	38	30	against	against	IN
cord-263455-dquztf5l	38	31	leprosy	leprosy	NN
cord-263455-dquztf5l	38	32	,	,	,
cord-263455-dquztf5l	38	33	such	such	JJ
cord-263455-dquztf5l	38	34	as	as	IN
cord-263455-dquztf5l	38	35	SDR	SDR	NNP
cord-263455-dquztf5l	38	36	-	-	HYPH
cord-263455-dquztf5l	38	37	PEP	PEP	NNP
cord-263455-dquztf5l	38	38	and	and	CC
cord-263455-dquztf5l	38	39	new	new	JJ
cord-263455-dquztf5l	38	40	vaccines	vaccine	NNS
cord-263455-dquztf5l	38	41	.	.	.
cord-263455-dquztf5l	39	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	39	2	is	be	VBZ
cord-263455-dquztf5l	39	3	a	a	DT
cord-263455-dquztf5l	39	4	communicable	communicable	JJ
cord-263455-dquztf5l	39	5	disease	disease	NN
cord-263455-dquztf5l	39	6	caused	cause	VBN
cord-263455-dquztf5l	39	7	by	by	IN
cord-263455-dquztf5l	39	8	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	39	9	leprae	leprae	NNP
cord-263455-dquztf5l	39	10	(	(	-LRB-
cord-263455-dquztf5l	39	11	M.	M.	NNP
cord-263455-dquztf5l	39	12	leprae	leprae	NNP
cord-263455-dquztf5l	39	13	)	)	-RRB-
cord-263455-dquztf5l	39	14	.	.	.
cord-263455-dquztf5l	40	1	It	-PRON-	PRP
cord-263455-dquztf5l	40	2	can	can	MD
cord-263455-dquztf5l	40	3	result	result	VB
cord-263455-dquztf5l	40	4	in	in	IN
cord-263455-dquztf5l	40	5	disabilities	disability	NNS
cord-263455-dquztf5l	40	6	,	,	,
cord-263455-dquztf5l	40	7	disfigurements	disfigurement	NNS
cord-263455-dquztf5l	40	8	,	,	,
cord-263455-dquztf5l	40	9	blindness	blindness	NN
cord-263455-dquztf5l	40	10	,	,	,
cord-263455-dquztf5l	40	11	and	and	CC
cord-263455-dquztf5l	40	12	internal	internal	JJ
cord-263455-dquztf5l	40	13	organ	organ	NN
cord-263455-dquztf5l	40	14	problems	problem	NNS
cord-263455-dquztf5l	40	15	.	.	.
cord-263455-dquztf5l	41	1	1	1	LS
cord-263455-dquztf5l	42	1	It	-PRON-	PRP
cord-263455-dquztf5l	42	2	is	be	VBZ
cord-263455-dquztf5l	42	3	estimated	estimate	VBN
cord-263455-dquztf5l	42	4	that	that	IN
cord-263455-dquztf5l	42	5	1	1	CD
cord-263455-dquztf5l	42	6	million	million	CD
cord-263455-dquztf5l	42	7	to	to	TO
cord-263455-dquztf5l	42	8	2	2	CD
cord-263455-dquztf5l	42	9	million	million	CD
cord-263455-dquztf5l	42	10	people	people	NNS
cord-263455-dquztf5l	42	11	are	be	VBP
cord-263455-dquztf5l	42	12	living	live	VBG
cord-263455-dquztf5l	42	13	with	with	IN
cord-263455-dquztf5l	42	14	leprosy	leprosy	NN
cord-263455-dquztf5l	42	15	-	-	HYPH
cord-263455-dquztf5l	42	16	related	relate	VBN
cord-263455-dquztf5l	42	17	disabilities	disability	NNS
cord-263455-dquztf5l	42	18	,	,	,
cord-263455-dquztf5l	42	19	which	which	WDT
cord-263455-dquztf5l	42	20	cause	cause	VBP
cord-263455-dquztf5l	42	21	severe	severe	JJ
cord-263455-dquztf5l	42	22	socioeconomic	socioeconomic	JJ
cord-263455-dquztf5l	42	23	consequences	consequence	NNS
cord-263455-dquztf5l	42	24	,	,	,
cord-263455-dquztf5l	42	25	including	include	VBG
cord-263455-dquztf5l	42	26	stigma	stigma	NN
cord-263455-dquztf5l	42	27	and	and	CC
cord-263455-dquztf5l	42	28	poverty	poverty	NN
cord-263455-dquztf5l	42	29	.	.	.
cord-263455-dquztf5l	43	1	[	[	-LRB-
cord-263455-dquztf5l	43	2	2	2	LS
cord-263455-dquztf5l	43	3	]	]	-RRB-
cord-263455-dquztf5l	43	4	[	[	-LRB-
cord-263455-dquztf5l	43	5	3	3	CD
cord-263455-dquztf5l	43	6	]	]	-RRB-
cord-263455-dquztf5l	43	7	[	[	-LRB-
cord-263455-dquztf5l	43	8	4	4	CD
cord-263455-dquztf5l	43	9	]	]	-RRB-
cord-263455-dquztf5l	43	10	Leprosy	leprosy	NN
cord-263455-dquztf5l	43	11	is	be	VBZ
cord-263455-dquztf5l	43	12	one	one	CD
cord-263455-dquztf5l	43	13	of	of	IN
cord-263455-dquztf5l	43	14	the	the	DT
cord-263455-dquztf5l	43	15	oldest	old	JJS
cord-263455-dquztf5l	43	16	diseases	disease	NNS
cord-263455-dquztf5l	43	17	known	know	VBN
cord-263455-dquztf5l	43	18	to	to	IN
cord-263455-dquztf5l	43	19	mankind	mankind	NN
cord-263455-dquztf5l	43	20	and	and	CC
cord-263455-dquztf5l	43	21	was	be	VBD
cord-263455-dquztf5l	43	22	once	once	RB
cord-263455-dquztf5l	43	23	endemic	endemic	JJ
cord-263455-dquztf5l	43	24	on	on	IN
cord-263455-dquztf5l	43	25	all	all	DT
cord-263455-dquztf5l	43	26	continents	continent	NNS
cord-263455-dquztf5l	43	27	.	.	.
cord-263455-dquztf5l	44	1	5	5	LS
cord-263455-dquztf5l	45	1	Today	today	NN
cord-263455-dquztf5l	45	2	,	,	,
cord-263455-dquztf5l	45	3	the	the	DT
cord-263455-dquztf5l	45	4	disease	disease	NN
cord-263455-dquztf5l	45	5	exists	exist	VBZ
cord-263455-dquztf5l	45	6	primarily	primarily	RB
cord-263455-dquztf5l	45	7	in	in	IN
cord-263455-dquztf5l	45	8	resource	resource	NN
cord-263455-dquztf5l	45	9	-	-	HYPH
cord-263455-dquztf5l	45	10	poor	poor	JJ
cord-263455-dquztf5l	45	11	countries	country	NNS
cord-263455-dquztf5l	45	12	with	with	IN
cord-263455-dquztf5l	45	13	often	often	RB
cord-263455-dquztf5l	45	14	warmer	warm	JJR
cord-263455-dquztf5l	45	15	climates	climate	NNS
cord-263455-dquztf5l	45	16	and	and	CC
cord-263455-dquztf5l	45	17	it	-PRON-	PRP
cord-263455-dquztf5l	45	18	is	be	VBZ
cord-263455-dquztf5l	45	19	considered	consider	VBN
cord-263455-dquztf5l	45	20	a	a	DT
cord-263455-dquztf5l	45	21	neglected	neglect	VBN
cord-263455-dquztf5l	45	22	tropical	tropical	JJ
cord-263455-dquztf5l	45	23	disease	disease	NN
cord-263455-dquztf5l	45	24	(	(	-LRB-
cord-263455-dquztf5l	45	25	NTD	NTD	NNP
cord-263455-dquztf5l	45	26	)	)	-RRB-
cord-263455-dquztf5l	45	27	.	.	.
cord-263455-dquztf5l	46	1	1	1	CD
cord-263455-dquztf5l	46	2	,	,	,
cord-263455-dquztf5l	46	3	3	3	CD
cord-263455-dquztf5l	46	4	,	,	,
cord-263455-dquztf5l	46	5	4	4	CD
cord-263455-dquztf5l	46	6	,	,	,
cord-263455-dquztf5l	46	7	6	6	CD
cord-263455-dquztf5l	47	1	In	in	IN
cord-263455-dquztf5l	47	2	2018	2018	CD
cord-263455-dquztf5l	47	3	,	,	,
cord-263455-dquztf5l	47	4	the	the	DT
cord-263455-dquztf5l	47	5	World	World	NNP
cord-263455-dquztf5l	47	6	Health	Health	NNP
cord-263455-dquztf5l	47	7	Organization	Organization	NNP
cord-263455-dquztf5l	47	8	(	(	-LRB-
cord-263455-dquztf5l	47	9	WHO	who	WP
cord-263455-dquztf5l	47	10	)	)	-RRB-
cord-263455-dquztf5l	47	11	reported	report	VBD
cord-263455-dquztf5l	47	12	a	a	DT
cord-263455-dquztf5l	47	13	total	total	NN
cord-263455-dquztf5l	47	14	of	of	IN
cord-263455-dquztf5l	47	15	208,641	208,641	CD
cord-263455-dquztf5l	47	16	new	new	JJ
cord-263455-dquztf5l	47	17	leprosy	leprosy	NN
cord-263455-dquztf5l	47	18	patients	patient	NNS
cord-263455-dquztf5l	47	19	worldwide	worldwide	RB
cord-263455-dquztf5l	47	20	,	,	,
cord-263455-dquztf5l	47	21	a	a	DT
cord-263455-dquztf5l	47	22	number	number	NN
cord-263455-dquztf5l	47	23	that	that	WDT
cord-263455-dquztf5l	47	24	has	have	VBZ
cord-263455-dquztf5l	47	25	been	be	VBN
cord-263455-dquztf5l	47	26	relatively	relatively	RB
cord-263455-dquztf5l	47	27	stable	stable	JJ
cord-263455-dquztf5l	47	28	in	in	IN
cord-263455-dquztf5l	47	29	the	the	DT
cord-263455-dquztf5l	47	30	past	past	JJ
cord-263455-dquztf5l	47	31	decade	decade	NN
cord-263455-dquztf5l	47	32	.	.	.
cord-263455-dquztf5l	48	1	7	7	CD
cord-263455-dquztf5l	48	2	M.	M.	NNP
cord-263455-dquztf5l	48	3	leprae	leprae	NNP
cord-263455-dquztf5l	48	4	was	be	VBD
cord-263455-dquztf5l	48	5	discovered	discover	VBN
cord-263455-dquztf5l	48	6	,	,	,
cord-263455-dquztf5l	48	7	as	as	IN
cord-263455-dquztf5l	48	8	the	the	DT
cord-263455-dquztf5l	48	9	first	first	JJ
cord-263455-dquztf5l	48	10	bacterium	bacterium	NN
cord-263455-dquztf5l	48	11	that	that	WDT
cord-263455-dquztf5l	48	12	caused	cause	VBD
cord-263455-dquztf5l	48	13	disease	disease	NN
cord-263455-dquztf5l	48	14	in	in	IN
cord-263455-dquztf5l	48	15	people	people	NNS
cord-263455-dquztf5l	48	16	,	,	,
cord-263455-dquztf5l	48	17	by	by	IN
cord-263455-dquztf5l	48	18	the	the	DT
cord-263455-dquztf5l	48	19	Norwegian	norwegian	JJ
cord-263455-dquztf5l	48	20	doctor	doctor	NN
cord-263455-dquztf5l	48	21	Armauer	Armauer	NNP
cord-263455-dquztf5l	48	22	Hansen	Hansen	NNP
cord-263455-dquztf5l	48	23	in	in	IN
cord-263455-dquztf5l	48	24	1873	1873	CD
cord-263455-dquztf5l	48	25	.	.	.
cord-263455-dquztf5l	49	1	5	5	LS
cord-263455-dquztf5l	49	2	,	,	,
cord-263455-dquztf5l	49	3	8	8	CD
cord-263455-dquztf5l	49	4	Almost	almost	RB
cord-263455-dquztf5l	49	5	150	150	CD
cord-263455-dquztf5l	49	6	years	year	NNS
cord-263455-dquztf5l	49	7	after	after	IN
cord-263455-dquztf5l	49	8	Hansen	Hansen	NNP
cord-263455-dquztf5l	49	9	's	's	POS
cord-263455-dquztf5l	49	10	discovery	discovery	NN
cord-263455-dquztf5l	49	11	,	,	,
cord-263455-dquztf5l	49	12	modern	modern	JJ
cord-263455-dquztf5l	49	13	science	science	NN
cord-263455-dquztf5l	49	14	still	still	RB
cord-263455-dquztf5l	49	15	has	have	VBZ
cord-263455-dquztf5l	49	16	not	not	RB
cord-263455-dquztf5l	49	17	succeeded	succeed	VBN
cord-263455-dquztf5l	49	18	in	in	IN
cord-263455-dquztf5l	49	19	growing	grow	VBG
cord-263455-dquztf5l	49	20	the	the	DT
cord-263455-dquztf5l	49	21	bacterium	bacterium	NN
cord-263455-dquztf5l	49	22	in	in	IN
cord-263455-dquztf5l	49	23	vitro	vitro	FW
cord-263455-dquztf5l	49	24	;	;	:
cord-263455-dquztf5l	49	25	it	-PRON-	PRP
cord-263455-dquztf5l	49	26	grows	grow	VBZ
cord-263455-dquztf5l	49	27	in	in	IN
cord-263455-dquztf5l	49	28	humans	human	NNS
cord-263455-dquztf5l	49	29	,	,	,
cord-263455-dquztf5l	49	30	in	in	IN
cord-263455-dquztf5l	49	31	nine	nine	CD
cord-263455-dquztf5l	49	32	-	-	HYPH
cord-263455-dquztf5l	49	33	banded	banded	JJ
cord-263455-dquztf5l	49	34	armadillos	armadillo	NNS
cord-263455-dquztf5l	49	35	,	,	,
cord-263455-dquztf5l	49	36	and	and	CC
cord-263455-dquztf5l	49	37	in	in	IN
cord-263455-dquztf5l	49	38	immunecompromised	immunecompromised	JJ
cord-263455-dquztf5l	49	39	mice	mouse	NNS
cord-263455-dquztf5l	49	40	.	.	.
cord-263455-dquztf5l	50	1	5	5	CD
cord-263455-dquztf5l	50	2	,	,	,
cord-263455-dquztf5l	50	3	9	9	CD
cord-263455-dquztf5l	50	4	,	,	,
cord-263455-dquztf5l	50	5	10	10	CD
cord-263455-dquztf5l	51	1	Both	both	DT
cord-263455-dquztf5l	51	2	people	people	NNS
cord-263455-dquztf5l	51	3	and	and	CC
cord-263455-dquztf5l	51	4	nine	nine	CD
cord-263455-dquztf5l	51	5	-	-	HYPH
cord-263455-dquztf5l	51	6	banded	banded	JJ
cord-263455-dquztf5l	51	7	armadillos	armadillo	NNS
cord-263455-dquztf5l	51	8	are	be	VBP
cord-263455-dquztf5l	51	9	able	able	JJ
cord-263455-dquztf5l	51	10	to	to	TO
cord-263455-dquztf5l	51	11	transmit	transmit	VB
cord-263455-dquztf5l	51	12	M.	M.	NNP
cord-263455-dquztf5l	51	13	leprae	leprae	NN
cord-263455-dquztf5l	51	14	to	to	IN
cord-263455-dquztf5l	51	15	humans	human	NNS
cord-263455-dquztf5l	51	16	.	.	.
cord-263455-dquztf5l	52	1	The	the	DT
cord-263455-dquztf5l	52	2	infection	infection	NN
cord-263455-dquztf5l	52	3	mechanism	mechanism	NN
cord-263455-dquztf5l	52	4	of	of	IN
cord-263455-dquztf5l	52	5	leprosy	leprosy	NN
cord-263455-dquztf5l	52	6	is	be	VBZ
cord-263455-dquztf5l	52	7	not	not	RB
cord-263455-dquztf5l	52	8	fully	fully	RB
cord-263455-dquztf5l	52	9	understood	understand	VBN
cord-263455-dquztf5l	52	10	,	,	,
cord-263455-dquztf5l	52	11	but	but	CC
cord-263455-dquztf5l	52	12	it	-PRON-	PRP
cord-263455-dquztf5l	52	13	is	be	VBZ
cord-263455-dquztf5l	52	14	generally	generally	RB
cord-263455-dquztf5l	52	15	thought	think	VBN
cord-263455-dquztf5l	52	16	to	to	TO
cord-263455-dquztf5l	52	17	spread	spread	VB
cord-263455-dquztf5l	52	18	via	via	IN
cord-263455-dquztf5l	52	19	the	the	DT
cord-263455-dquztf5l	52	20	respiratory	respiratory	JJ
cord-263455-dquztf5l	52	21	route	route	NN
cord-263455-dquztf5l	52	22	.	.	.
cord-263455-dquztf5l	53	1	1	1	CD
cord-263455-dquztf5l	53	2	,	,	,
cord-263455-dquztf5l	53	3	8	8	CD
cord-263455-dquztf5l	53	4	The	the	DT
cord-263455-dquztf5l	53	5	average	average	JJ
cord-263455-dquztf5l	53	6	incubation	incubation	NN
cord-263455-dquztf5l	53	7	time	time	NN
cord-263455-dquztf5l	53	8	of	of	IN
cord-263455-dquztf5l	53	9	the	the	DT
cord-263455-dquztf5l	53	10	disease	disease	NN
cord-263455-dquztf5l	53	11	is	be	VBZ
cord-263455-dquztf5l	53	12	5	5	CD
cord-263455-dquztf5l	53	13	years	year	NNS
cord-263455-dquztf5l	53	14	,	,	,
cord-263455-dquztf5l	53	15	but	but	CC
cord-263455-dquztf5l	53	16	it	-PRON-	PRP
cord-263455-dquztf5l	53	17	can	can	MD
cord-263455-dquztf5l	53	18	take	take	VB
cord-263455-dquztf5l	53	19	up	up	IN
cord-263455-dquztf5l	53	20	to	to	TO
cord-263455-dquztf5l	53	21	20	20	CD
cord-263455-dquztf5l	53	22	years	year	NNS
cord-263455-dquztf5l	53	23	before	before	IN
cord-263455-dquztf5l	53	24	symptoms	symptom	NNS
cord-263455-dquztf5l	53	25	appear	appear	VBP
cord-263455-dquztf5l	53	26	.	.	.
cord-263455-dquztf5l	54	1	3	3	LS
cord-263455-dquztf5l	54	2	During	during	IN
cord-263455-dquztf5l	54	3	this	this	DT
cord-263455-dquztf5l	54	4	period	period	NN
cord-263455-dquztf5l	54	5	,	,	,
cord-263455-dquztf5l	54	6	a	a	DT
cord-263455-dquztf5l	54	7	leprosy	leprosy	NN
cord-263455-dquztf5l	54	8	patient	patient	NN
cord-263455-dquztf5l	54	9	is	be	VBZ
cord-263455-dquztf5l	54	10	contagious	contagious	JJ
cord-263455-dquztf5l	54	11	.	.	.
cord-263455-dquztf5l	55	1	6	6	CD
cord-263455-dquztf5l	55	2	Ongoing	ongoing	JJ
cord-263455-dquztf5l	55	3	transmission	transmission	NN
cord-263455-dquztf5l	55	4	is	be	VBZ
cord-263455-dquztf5l	55	5	implied	imply	VBN
cord-263455-dquztf5l	55	6	by	by	IN
cord-263455-dquztf5l	55	7	the	the	DT
cord-263455-dquztf5l	55	8	fact	fact	NN
cord-263455-dquztf5l	55	9	that	that	IN
cord-263455-dquztf5l	55	10	almost	almost	RB
cord-263455-dquztf5l	55	11	10	10	CD
cord-263455-dquztf5l	55	12	%	%	NN
cord-263455-dquztf5l	55	13	of	of	IN
cord-263455-dquztf5l	55	14	global	global	JJ
cord-263455-dquztf5l	55	15	new	new	JJ
cord-263455-dquztf5l	55	16	leprosy	leprosy	NN
cord-263455-dquztf5l	55	17	cases	case	NNS
cord-263455-dquztf5l	55	18	are	be	VBP
cord-263455-dquztf5l	55	19	children	child	NNS
cord-263455-dquztf5l	55	20	.	.	.
cord-263455-dquztf5l	56	1	7	7	CD
cord-263455-dquztf5l	57	1	Whether	whether	IN
cord-263455-dquztf5l	57	2	colonization	colonization	NN
cord-263455-dquztf5l	57	3	with	with	IN
cord-263455-dquztf5l	57	4	M.	M.	NNP
cord-263455-dquztf5l	57	5	leprae	leprae	NNP
cord-263455-dquztf5l	57	6	leads	lead	VBZ
cord-263455-dquztf5l	57	7	to	to	IN
cord-263455-dquztf5l	57	8	infection	infection	NN
cord-263455-dquztf5l	57	9	and	and	CC
cord-263455-dquztf5l	57	10	disease	disease	NN
cord-263455-dquztf5l	57	11	depends	depend	VBZ
cord-263455-dquztf5l	57	12	on	on	IN
cord-263455-dquztf5l	57	13	the	the	DT
cord-263455-dquztf5l	57	14	host	host	NN
cord-263455-dquztf5l	57	15	's	's	POS
cord-263455-dquztf5l	57	16	resistance	resistance	NN
cord-263455-dquztf5l	57	17	and	and	CC
cord-263455-dquztf5l	57	18	genetics	genetic	NNS
cord-263455-dquztf5l	57	19	,	,	,
cord-263455-dquztf5l	57	20	as	as	RB
cord-263455-dquztf5l	57	21	well	well	RB
cord-263455-dquztf5l	57	22	as	as	IN
cord-263455-dquztf5l	57	23	environmental	environmental	JJ
cord-263455-dquztf5l	57	24	factors	factor	NNS
cord-263455-dquztf5l	57	25	.	.	.
cord-263455-dquztf5l	58	1	Up	up	IN
cord-263455-dquztf5l	58	2	to	to	TO
cord-263455-dquztf5l	58	3	95	95	CD
cord-263455-dquztf5l	58	4	%	%	NN
cord-263455-dquztf5l	58	5	of	of	IN
cord-263455-dquztf5l	58	6	people	people	NNS
cord-263455-dquztf5l	58	7	exposed	expose	VBN
cord-263455-dquztf5l	58	8	to	to	IN
cord-263455-dquztf5l	58	9	M.	M.	NNP
cord-263455-dquztf5l	58	10	leprae	leprae	NNP
cord-263455-dquztf5l	58	11	do	do	VBP
cord-263455-dquztf5l	58	12	not	not	RB
cord-263455-dquztf5l	58	13	develop	develop	VB
cord-263455-dquztf5l	58	14	the	the	DT
cord-263455-dquztf5l	58	15	disease	disease	NN
cord-263455-dquztf5l	58	16	.	.	.
cord-263455-dquztf5l	59	1	7	7	CD
cord-263455-dquztf5l	60	1	As	as	IN
cord-263455-dquztf5l	60	2	mentioned	mention	VBN
cord-263455-dquztf5l	60	3	,	,	,
cord-263455-dquztf5l	60	4	most	most	JJS
cord-263455-dquztf5l	60	5	people	people	NNS
cord-263455-dquztf5l	60	6	who	who	WP
cord-263455-dquztf5l	60	7	do	do	VBP
cord-263455-dquztf5l	60	8	develop	develop	VB
cord-263455-dquztf5l	60	9	the	the	DT
cord-263455-dquztf5l	60	10	disease	disease	NN
cord-263455-dquztf5l	60	11	live	live	VB
cord-263455-dquztf5l	60	12	in	in	IN
cord-263455-dquztf5l	60	13	resource	resource	NN
cord-263455-dquztf5l	60	14	-	-	HYPH
cord-263455-dquztf5l	60	15	poor	poor	JJ
cord-263455-dquztf5l	60	16	settings	setting	NNS
cord-263455-dquztf5l	60	17	;	;	:
cord-263455-dquztf5l	60	18	poor	poor	JJ
cord-263455-dquztf5l	60	19	living	living	NN
cord-263455-dquztf5l	60	20	conditions	condition	NNS
cord-263455-dquztf5l	60	21	(	(	-LRB-
cord-263455-dquztf5l	60	22	eg	eg	IN
cord-263455-dquztf5l	60	23	,	,	,
cord-263455-dquztf5l	60	24	insufficient	insufficient	JJ
cord-263455-dquztf5l	60	25	food	food	NN
cord-263455-dquztf5l	60	26	availability	availability	NN
cord-263455-dquztf5l	60	27	,	,	,
cord-263455-dquztf5l	60	28	pollution	pollution	NN
cord-263455-dquztf5l	60	29	,	,	,
cord-263455-dquztf5l	60	30	lacking	lack	VBG
cord-263455-dquztf5l	60	31	health	health	NN
cord-263455-dquztf5l	60	32	care	care	NN
cord-263455-dquztf5l	60	33	systems	system	NNS
cord-263455-dquztf5l	60	34	and	and	CC
cord-263455-dquztf5l	60	35	secondary	secondary	JJ
cord-263455-dquztf5l	60	36	chronic	chronic	JJ
cord-263455-dquztf5l	60	37	psychological	psychological	JJ
cord-263455-dquztf5l	60	38	stress	stress	NN
cord-263455-dquztf5l	60	39	)	)	-RRB-
cord-263455-dquztf5l	60	40	can	can	MD
cord-263455-dquztf5l	60	41	negatively	negatively	RB
cord-263455-dquztf5l	60	42	affect	affect	VB
cord-263455-dquztf5l	60	43	immune	immune	JJ
cord-263455-dquztf5l	60	44	function	function	NN
cord-263455-dquztf5l	60	45	.	.	.
cord-263455-dquztf5l	61	1	4	4	LS
cord-263455-dquztf5l	61	2	,	,	,
cord-263455-dquztf5l	61	3	5	5	CD
cord-263455-dquztf5l	61	4	,	,	,
cord-263455-dquztf5l	61	5	11	11	CD
cord-263455-dquztf5l	62	1	For	for	IN
cord-263455-dquztf5l	62	2	transmission	transmission	NN
cord-263455-dquztf5l	62	3	,	,	,
cord-263455-dquztf5l	62	4	prolonged	prolong	VBN
cord-263455-dquztf5l	62	5	contact	contact	NN
cord-263455-dquztf5l	62	6	with	with	IN
cord-263455-dquztf5l	62	7	an	an	DT
cord-263455-dquztf5l	62	8	untreated	untreated	JJ
cord-263455-dquztf5l	62	9	patient	patient	NN
cord-263455-dquztf5l	62	10	is	be	VBZ
cord-263455-dquztf5l	62	11	considered	consider	VBN
cord-263455-dquztf5l	62	12	necessary	necessary	JJ
cord-263455-dquztf5l	62	13	.	.	.
cord-263455-dquztf5l	63	1	1	1	LS
cord-263455-dquztf5l	64	1	The	the	DT
cord-263455-dquztf5l	64	2	genetic	genetic	JJ
cord-263455-dquztf5l	64	3	and	and	CC
cord-263455-dquztf5l	64	4	physical	physical	JJ
cord-263455-dquztf5l	64	5	distance	distance	NN
cord-263455-dquztf5l	64	6	to	to	IN
cord-263455-dquztf5l	64	7	a	a	DT
cord-263455-dquztf5l	64	8	leprosy	leprosy	NN
cord-263455-dquztf5l	64	9	patient	patient	NN
cord-263455-dquztf5l	64	10	are	be	VBP
cord-263455-dquztf5l	64	11	independently	independently	RB
cord-263455-dquztf5l	64	12	associated	associate	VBN
cord-263455-dquztf5l	64	13	with	with	IN
cord-263455-dquztf5l	64	14	the	the	DT
cord-263455-dquztf5l	64	15	risk	risk	NN
cord-263455-dquztf5l	64	16	of	of	IN
cord-263455-dquztf5l	64	17	developing	develop	VBG
cord-263455-dquztf5l	64	18	clinical	clinical	JJ
cord-263455-dquztf5l	64	19	disease	disease	NN
cord-263455-dquztf5l	64	20	.	.	.
cord-263455-dquztf5l	65	1	12	12	CD
cord-263455-dquztf5l	66	1	Hence	hence	RB
cord-263455-dquztf5l	66	2	,	,	,
cord-263455-dquztf5l	66	3	the	the	DT
cord-263455-dquztf5l	66	4	risk	risk	NN
cord-263455-dquztf5l	66	5	for	for	IN
cord-263455-dquztf5l	66	6	developing	develop	VBG
cord-263455-dquztf5l	66	7	leprosy	leprosy	NN
cord-263455-dquztf5l	66	8	is	be	VBZ
cord-263455-dquztf5l	66	9	increased	increase	VBN
cord-263455-dquztf5l	66	10	not	not	RB
cord-263455-dquztf5l	66	11	only	only	RB
cord-263455-dquztf5l	66	12	in	in	IN
cord-263455-dquztf5l	66	13	household	household	NN
cord-263455-dquztf5l	66	14	contacts	contact	NNS
cord-263455-dquztf5l	66	15	,	,	,
cord-263455-dquztf5l	66	16	but	but	CC
cord-263455-dquztf5l	66	17	also	also	RB
cord-263455-dquztf5l	66	18	in	in	IN
cord-263455-dquztf5l	66	19	neighbors	neighbor	NNS
cord-263455-dquztf5l	66	20	and	and	CC
cord-263455-dquztf5l	66	21	social	social	JJ
cord-263455-dquztf5l	66	22	contacts	contact	NNS
cord-263455-dquztf5l	66	23	.	.	.
cord-263455-dquztf5l	67	1	13	13	CD
cord-263455-dquztf5l	67	2	,	,	,
cord-263455-dquztf5l	67	3	14	14	CD
cord-263455-dquztf5l	68	1	In	in	IN
cord-263455-dquztf5l	68	2	the	the	DT
cord-263455-dquztf5l	68	3	late	late	JJ
cord-263455-dquztf5l	68	4	1940s	1940	NNS
cord-263455-dquztf5l	68	5	,	,	,
cord-263455-dquztf5l	68	6	the	the	DT
cord-263455-dquztf5l	68	7	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	68	8	dapsone	dapsone	NN
cord-263455-dquztf5l	68	9	was	be	VBD
cord-263455-dquztf5l	68	10	the	the	DT
cord-263455-dquztf5l	68	11	first	first	JJ
cord-263455-dquztf5l	68	12	breakthrough	breakthrough	NN
cord-263455-dquztf5l	68	13	in	in	IN
cord-263455-dquztf5l	68	14	leprosy	leprosy	NN
cord-263455-dquztf5l	68	15	treatment	treatment	NN
cord-263455-dquztf5l	68	16	.	.	.
cord-263455-dquztf5l	69	1	The	the	DT
cord-263455-dquztf5l	69	2	duration	duration	NN
cord-263455-dquztf5l	69	3	of	of	IN
cord-263455-dquztf5l	69	4	treatment	treatment	NN
cord-263455-dquztf5l	69	5	often	often	RB
cord-263455-dquztf5l	69	6	lasted	last	VBD
cord-263455-dquztf5l	69	7	a	a	DT
cord-263455-dquztf5l	69	8	lifetime	lifetime	NN
cord-263455-dquztf5l	69	9	,	,	,
cord-263455-dquztf5l	69	10	which	which	WDT
cord-263455-dquztf5l	69	11	challenged	challenge	VBD
cord-263455-dquztf5l	69	12	compliance	compliance	NN
cord-263455-dquztf5l	69	13	and	and	CC
cord-263455-dquztf5l	69	14	fostered	foster	VBD
cord-263455-dquztf5l	69	15	dapsone	dapsone	NN
cord-263455-dquztf5l	69	16	resistance	resistance	NN
cord-263455-dquztf5l	69	17	in	in	IN
cord-263455-dquztf5l	69	18	the	the	DT
cord-263455-dquztf5l	69	19	1960s	1960	NNS
cord-263455-dquztf5l	69	20	.	.	.
cord-263455-dquztf5l	70	1	3	3	LS
cord-263455-dquztf5l	71	1	When	when	WRB
cord-263455-dquztf5l	71	2	clofazimine	clofazimine	JJ
cord-263455-dquztf5l	71	3	and	and	CC
cord-263455-dquztf5l	71	4	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	71	5	were	be	VBD
cord-263455-dquztf5l	71	6	discovered	discover	VBN
cord-263455-dquztf5l	71	7	in	in	IN
cord-263455-dquztf5l	71	8	the	the	DT
cord-263455-dquztf5l	71	9	1950s	1950	NNS
cord-263455-dquztf5l	71	10	and	and	CC
cord-263455-dquztf5l	71	11	1960s	1960	NNS
cord-263455-dquztf5l	71	12	,	,	,
cord-263455-dquztf5l	71	13	these	these	DT
cord-263455-dquztf5l	71	14	drugs	drug	NNS
cord-263455-dquztf5l	71	15	were	be	VBD
cord-263455-dquztf5l	71	16	combined	combine	VBN
cord-263455-dquztf5l	71	17	with	with	IN
cord-263455-dquztf5l	71	18	dapsone	dapsone	NN
cord-263455-dquztf5l	71	19	,	,	,
cord-263455-dquztf5l	71	20	later	later	RB
cord-263455-dquztf5l	71	21	labeled	label	VBN
cord-263455-dquztf5l	71	22	as	as	IN
cord-263455-dquztf5l	71	23	multidrug	multidrug	NN
cord-263455-dquztf5l	71	24	therapy	therapy	NN
cord-263455-dquztf5l	71	25	(	(	-LRB-
cord-263455-dquztf5l	71	26	MDT	MDT	NNP
cord-263455-dquztf5l	71	27	)	)	-RRB-
cord-263455-dquztf5l	71	28	.	.	.
cord-263455-dquztf5l	72	1	MDT	MDT	NNP
cord-263455-dquztf5l	72	2	has	have	VBZ
cord-263455-dquztf5l	72	3	been	be	VBN
cord-263455-dquztf5l	72	4	provided	provide	VBN
cord-263455-dquztf5l	72	5	free	free	JJ
cord-263455-dquztf5l	72	6	of	of	IN
cord-263455-dquztf5l	72	7	charge	charge	NN
cord-263455-dquztf5l	72	8	since	since	IN
cord-263455-dquztf5l	72	9	1995	1995	CD
cord-263455-dquztf5l	72	10	via	via	IN
cord-263455-dquztf5l	72	11	WHO	WHO	NNP
cord-263455-dquztf5l	72	12	.	.	.
cord-263455-dquztf5l	73	1	3	3	LS
cord-263455-dquztf5l	74	1	Within	within	IN
cord-263455-dquztf5l	74	2	a	a	DT
cord-263455-dquztf5l	74	3	few	few	JJ
cord-263455-dquztf5l	74	4	days	day	NNS
cord-263455-dquztf5l	74	5	after	after	IN
cord-263455-dquztf5l	74	6	starting	start	VBG
cord-263455-dquztf5l	74	7	MDT	MDT	NNP
cord-263455-dquztf5l	74	8	,	,	,
cord-263455-dquztf5l	74	9	patients	patient	NNS
cord-263455-dquztf5l	74	10	are	be	VBP
cord-263455-dquztf5l	74	11	no	no	RB
cord-263455-dquztf5l	74	12	longer	long	RBR
cord-263455-dquztf5l	74	13	considered	consider	VBN
cord-263455-dquztf5l	74	14	to	to	TO
cord-263455-dquztf5l	74	15	be	be	VB
cord-263455-dquztf5l	74	16	contagious	contagious	JJ
cord-263455-dquztf5l	74	17	.	.	.
cord-263455-dquztf5l	75	1	15	15	CD
cord-263455-dquztf5l	76	1	The	the	DT
cord-263455-dquztf5l	76	2	first	first	JJ
cord-263455-dquztf5l	76	3	focus	focus	NN
cord-263455-dquztf5l	76	4	on	on	IN
cord-263455-dquztf5l	76	5	leprosy	leprosy	NN
cord-263455-dquztf5l	76	6	prevention	prevention	NN
cord-263455-dquztf5l	76	7	started	start	VBD
cord-263455-dquztf5l	76	8	shortly	shortly	RB
cord-263455-dquztf5l	76	9	after	after	IN
cord-263455-dquztf5l	76	10	the	the	DT
cord-263455-dquztf5l	76	11	discovery	discovery	NN
cord-263455-dquztf5l	76	12	of	of	IN
cord-263455-dquztf5l	76	13	M.	M.	NNP
cord-263455-dquztf5l	76	14	leprae	leprae	NNP
cord-263455-dquztf5l	76	15	.	.	.
cord-263455-dquztf5l	77	1	Compulsory	compulsory	JJ
cord-263455-dquztf5l	77	2	isolation	isolation	NN
cord-263455-dquztf5l	77	3	for	for	IN
cord-263455-dquztf5l	77	4	persons	person	NNS
cord-263455-dquztf5l	77	5	affected	affect	VBN
cord-263455-dquztf5l	77	6	by	by	IN
cord-263455-dquztf5l	77	7	leprosy	leprosy	NN
cord-263455-dquztf5l	77	8	,	,	,
cord-263455-dquztf5l	77	9	mainly	mainly	RB
cord-263455-dquztf5l	77	10	in	in	IN
cord-263455-dquztf5l	77	11	leprosy	leprosy	NN
cord-263455-dquztf5l	77	12	colonies	colony	NNS
cord-263455-dquztf5l	77	13	,	,	,
cord-263455-dquztf5l	77	14	was	be	VBD
cord-263455-dquztf5l	77	15	internationally	internationally	RB
cord-263455-dquztf5l	77	16	promoted	promote	VBN
cord-263455-dquztf5l	77	17	from	from	IN
cord-263455-dquztf5l	77	18	the	the	DT
cord-263455-dquztf5l	77	19	19th	19th	JJ
cord-263455-dquztf5l	77	20	century	century	NN
cord-263455-dquztf5l	77	21	onward	onward	RB
cord-263455-dquztf5l	77	22	as	as	IN
cord-263455-dquztf5l	77	23	one	one	CD
cord-263455-dquztf5l	77	24	of	of	IN
cord-263455-dquztf5l	77	25	the	the	DT
cord-263455-dquztf5l	77	26	few	few	JJ
cord-263455-dquztf5l	77	27	existing	exist	VBG
cord-263455-dquztf5l	77	28	prevention	prevention	NN
cord-263455-dquztf5l	77	29	methods	method	NNS
cord-263455-dquztf5l	77	30	.	.	.
cord-263455-dquztf5l	78	1	16	16	CD
cord-263455-dquztf5l	78	2	,	,	,
cord-263455-dquztf5l	78	3	17	17	CD
cord-263455-dquztf5l	78	4	Healthy	Healthy	NNP
cord-263455-dquztf5l	78	5	-	-	HYPH
cord-263455-dquztf5l	78	6	appearing	appear	VBG
cord-263455-dquztf5l	78	7	children	child	NNS
cord-263455-dquztf5l	78	8	were	be	VBD
cord-263455-dquztf5l	78	9	frequently	frequently	RB
cord-263455-dquztf5l	78	10	seperated	seperate	VBN
cord-263455-dquztf5l	78	11	from	from	IN
cord-263455-dquztf5l	78	12	their	-PRON-	PRP$
cord-263455-dquztf5l	78	13	parents	parent	NNS
cord-263455-dquztf5l	78	14	with	with	IN
cord-263455-dquztf5l	78	15	clinical	clinical	JJ
cord-263455-dquztf5l	78	16	leprosy	leprosy	NN
cord-263455-dquztf5l	78	17	.	.	.
cord-263455-dquztf5l	79	1	At	at	IN
cord-263455-dquztf5l	79	2	the	the	DT
cord-263455-dquztf5l	79	3	1958	1958	CD
cord-263455-dquztf5l	79	4	International	International	NNP
cord-263455-dquztf5l	79	5	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	79	6	Congress	Congress	NNP
cord-263455-dquztf5l	79	7	in	in	IN
cord-263455-dquztf5l	79	8	Japan	Japan	NNP
cord-263455-dquztf5l	79	9	,	,	,
cord-263455-dquztf5l	79	10	isolation	isolation	NN
cord-263455-dquztf5l	79	11	was	be	VBD
cord-263455-dquztf5l	79	12	finally	finally	RB
cord-263455-dquztf5l	79	13	labeled	label	VBN
cord-263455-dquztf5l	79	14	as	as	IN
cord-263455-dquztf5l	79	15	outdated	outdated	JJ
cord-263455-dquztf5l	79	16	and	and	CC
cord-263455-dquztf5l	79	17	inhumane	inhumane	JJ
cord-263455-dquztf5l	79	18	,	,	,
cord-263455-dquztf5l	79	19	also	also	RB
cord-263455-dquztf5l	79	20	because	because	IN
cord-263455-dquztf5l	79	21	dapsone	dapsone	NN
cord-263455-dquztf5l	79	22	as	as	IN
cord-263455-dquztf5l	79	23	a	a	DT
cord-263455-dquztf5l	79	24	treatment	treatment	NN
cord-263455-dquztf5l	79	25	option	option	NN
cord-263455-dquztf5l	79	26	became	become	VBD
cord-263455-dquztf5l	79	27	available	available	JJ
cord-263455-dquztf5l	79	28	.	.	.
cord-263455-dquztf5l	80	1	16	16	CD
cord-263455-dquztf5l	80	2	,	,	,
cord-263455-dquztf5l	80	3	17	17	CD
cord-263455-dquztf5l	80	4	When	when	WRB
cord-263455-dquztf5l	80	5	MDT	MDT	NNP
cord-263455-dquztf5l	80	6	was	be	VBD
cord-263455-dquztf5l	80	7	introduced	introduce	VBN
cord-263455-dquztf5l	80	8	,	,	,
cord-263455-dquztf5l	80	9	it	-PRON-	PRP
cord-263455-dquztf5l	80	10	was	be	VBD
cord-263455-dquztf5l	80	11	expected	expect	VBN
cord-263455-dquztf5l	80	12	that	that	IN
cord-263455-dquztf5l	80	13	early	early	JJ
cord-263455-dquztf5l	80	14	detection	detection	NN
cord-263455-dquztf5l	80	15	and	and	CC
cord-263455-dquztf5l	80	16	prompt	prompt	JJ
cord-263455-dquztf5l	80	17	treatment	treatment	NN
cord-263455-dquztf5l	80	18	would	would	MD
cord-263455-dquztf5l	80	19	break	break	VB
cord-263455-dquztf5l	80	20	the	the	DT
cord-263455-dquztf5l	80	21	transmission	transmission	NN
cord-263455-dquztf5l	80	22	chain	chain	NN
cord-263455-dquztf5l	80	23	of	of	IN
cord-263455-dquztf5l	80	24	M.	M.	NNP
cord-263455-dquztf5l	80	25	leprae	leprae	NNP
cord-263455-dquztf5l	80	26	.	.	.
cord-263455-dquztf5l	81	1	18	18	CD
cord-263455-dquztf5l	82	1	However	however	RB
cord-263455-dquztf5l	82	2	,	,	,
cord-263455-dquztf5l	82	3	the	the	DT
cord-263455-dquztf5l	82	4	incidence	incidence	NN
cord-263455-dquztf5l	82	5	decline	decline	NN
cord-263455-dquztf5l	82	6	was	be	VBD
cord-263455-dquztf5l	82	7	slower	slow	JJR
cord-263455-dquztf5l	82	8	than	than	IN
cord-263455-dquztf5l	82	9	anticipated	anticipate	VBN
cord-263455-dquztf5l	82	10	.	.	.
cord-263455-dquztf5l	83	1	19	19	CD
cord-263455-dquztf5l	83	2	,	,	,
cord-263455-dquztf5l	83	3	20	20	CD
cord-263455-dquztf5l	83	4	This	this	DT
cord-263455-dquztf5l	83	5	implies	imply	VBZ
cord-263455-dquztf5l	83	6	that	that	IN
cord-263455-dquztf5l	83	7	there	there	EX
cord-263455-dquztf5l	83	8	could	could	MD
cord-263455-dquztf5l	83	9	be	be	VB
cord-263455-dquztf5l	83	10	an	an	DT
cord-263455-dquztf5l	83	11	accumulation	accumulation	NN
cord-263455-dquztf5l	83	12	of	of	IN
cord-263455-dquztf5l	83	13	people	people	NNS
cord-263455-dquztf5l	83	14	with	with	IN
cord-263455-dquztf5l	83	15	leprosy	leprosy	NN
cord-263455-dquztf5l	83	16	in	in	IN
cord-263455-dquztf5l	83	17	communities	community	NNS
cord-263455-dquztf5l	83	18	who	who	WP
cord-263455-dquztf5l	83	19	remain	remain	VBP
cord-263455-dquztf5l	83	20	undiagnosed	undiagnosed	JJ
cord-263455-dquztf5l	83	21	and/or	and/or	CC
cord-263455-dquztf5l	83	22	untreated	untreated	JJ
cord-263455-dquztf5l	83	23	.	.	.
cord-263455-dquztf5l	84	1	21	21	CD
cord-263455-dquztf5l	85	1	These	these	DT
cord-263455-dquztf5l	85	2	"	"	``
cord-263455-dquztf5l	85	3	missing	miss	VBG
cord-263455-dquztf5l	85	4	millions	million	NNS
cord-263455-dquztf5l	85	5	"	"	''
cord-263455-dquztf5l	85	6	contribute	contribute	VBP
cord-263455-dquztf5l	85	7	to	to	IN
cord-263455-dquztf5l	85	8	further	further	JJ
cord-263455-dquztf5l	85	9	transmission	transmission	NN
cord-263455-dquztf5l	85	10	of	of	IN
cord-263455-dquztf5l	85	11	the	the	DT
cord-263455-dquztf5l	85	12	disease	disease	NN
cord-263455-dquztf5l	85	13	.	.	.
cord-263455-dquztf5l	86	1	21	21	CD
cord-263455-dquztf5l	87	1	Consequently	consequently	RB
cord-263455-dquztf5l	87	2	,	,	,
cord-263455-dquztf5l	87	3	in	in	IN
cord-263455-dquztf5l	87	4	the	the	DT
cord-263455-dquztf5l	87	5	Global	Global	NNP
cord-263455-dquztf5l	87	6	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	87	7	Strategy	Strategy	NNP
cord-263455-dquztf5l	87	8	2016	2016	CD
cord-263455-dquztf5l	87	9	-	-	SYM
cord-263455-dquztf5l	87	10	2020	2020	CD
cord-263455-dquztf5l	87	11	,	,	,
cord-263455-dquztf5l	87	12	WHO	who	WP
cord-263455-dquztf5l	87	13	determined	determine	VBD
cord-263455-dquztf5l	87	14	that	that	IN
cord-263455-dquztf5l	87	15	early	early	JJ
cord-263455-dquztf5l	87	16	case	case	NN
cord-263455-dquztf5l	87	17	detection	detection	NN
cord-263455-dquztf5l	87	18	and	and	CC
cord-263455-dquztf5l	87	19	targeted	target	VBN
cord-263455-dquztf5l	87	20	active	active	JJ
cord-263455-dquztf5l	87	21	case	case	NN
cord-263455-dquztf5l	87	22	finding	find	VBG
cord-263455-dquztf5l	87	23	among	among	IN
cord-263455-dquztf5l	87	24	highrisk	highrisk	JJ
cord-263455-dquztf5l	87	25	groups	group	NNS
cord-263455-dquztf5l	87	26	are	be	VBP
cord-263455-dquztf5l	87	27	key	key	JJ
cord-263455-dquztf5l	87	28	to	to	TO
cord-263455-dquztf5l	87	29	control	control	VB
cord-263455-dquztf5l	87	30	leprosy	leprosy	NN
cord-263455-dquztf5l	87	31	and	and	CC
cord-263455-dquztf5l	87	32	avert	avert	VB
cord-263455-dquztf5l	87	33	disabilities	disability	NNS
cord-263455-dquztf5l	87	34	.	.	.
cord-263455-dquztf5l	88	1	22	22	CD
cord-263455-dquztf5l	89	1	At	at	IN
cord-263455-dquztf5l	89	2	the	the	DT
cord-263455-dquztf5l	89	3	same	same	JJ
cord-263455-dquztf5l	89	4	time	time	NN
cord-263455-dquztf5l	89	5	,	,	,
cord-263455-dquztf5l	89	6	intensified	intensify	VBD
cord-263455-dquztf5l	89	7	populationbased	populationbased	JJ
cord-263455-dquztf5l	89	8	approaches	approach	NNS
cord-263455-dquztf5l	89	9	for	for	IN
cord-263455-dquztf5l	89	10	case	case	NN
cord-263455-dquztf5l	89	11	detection	detection	NN
cord-263455-dquztf5l	89	12	are	be	VBP
cord-263455-dquztf5l	89	13	no	no	RB
cord-263455-dquztf5l	89	14	longer	long	RBR
cord-263455-dquztf5l	89	15	considered	consider	VBN
cord-263455-dquztf5l	89	16	cost	cost	NN
cord-263455-dquztf5l	89	17	-	-	HYPH
cord-263455-dquztf5l	89	18	effective	effective	JJ
cord-263455-dquztf5l	89	19	in	in	IN
cord-263455-dquztf5l	89	20	all	all	DT
cord-263455-dquztf5l	89	21	contexts	context	NNS
cord-263455-dquztf5l	89	22	.	.	.
cord-263455-dquztf5l	90	1	21	21	CD
cord-263455-dquztf5l	90	2	,	,	,
cord-263455-dquztf5l	90	3	23	23	CD
cord-263455-dquztf5l	90	4	,	,	,
cord-263455-dquztf5l	90	5	24	24	CD
cord-263455-dquztf5l	91	1	The	the	DT
cord-263455-dquztf5l	91	2	risk	risk	NN
cord-263455-dquztf5l	91	3	of	of	IN
cord-263455-dquztf5l	91	4	leprosy	leprosy	NN
cord-263455-dquztf5l	91	5	exposure	exposure	NN
cord-263455-dquztf5l	91	6	in	in	IN
cord-263455-dquztf5l	91	7	general	general	JJ
cord-263455-dquztf5l	91	8	populations	population	NNS
cord-263455-dquztf5l	91	9	is	be	VBZ
cord-263455-dquztf5l	91	10	usually	usually	RB
cord-263455-dquztf5l	91	11	low	low	JJ
cord-263455-dquztf5l	91	12	,	,	,
cord-263455-dquztf5l	91	13	and	and	CC
cord-263455-dquztf5l	91	14	,	,	,
cord-263455-dquztf5l	91	15	as	as	IN
cord-263455-dquztf5l	91	16	stated	state	VBN
cord-263455-dquztf5l	91	17	,	,	,
cord-263455-dquztf5l	91	18	geographically	geographically	RB
cord-263455-dquztf5l	91	19	closer	close	JJR
cord-263455-dquztf5l	91	20	contacts	contact	NNS
cord-263455-dquztf5l	91	21	of	of	IN
cord-263455-dquztf5l	91	22	patients	patient	NNS
cord-263455-dquztf5l	91	23	are	be	VBP
cord-263455-dquztf5l	91	24	more	more	RBR
cord-263455-dquztf5l	91	25	likely	likely	JJ
cord-263455-dquztf5l	91	26	to	to	TO
cord-263455-dquztf5l	91	27	develop	develop	VB
cord-263455-dquztf5l	91	28	the	the	DT
cord-263455-dquztf5l	91	29	disease	disease	NN
cord-263455-dquztf5l	91	30	.	.	.
cord-263455-dquztf5l	92	1	[	[	-LRB-
cord-263455-dquztf5l	92	2	12	12	CD
cord-263455-dquztf5l	92	3	]	]	-RRB-
cord-263455-dquztf5l	92	4	[	[	-LRB-
cord-263455-dquztf5l	92	5	13	13	CD
cord-263455-dquztf5l	92	6	]	]	-RRB-
cord-263455-dquztf5l	93	1	[	[	-LRB-
cord-263455-dquztf5l	93	2	14	14	CD
cord-263455-dquztf5l	93	3	]	]	-RRB-
cord-263455-dquztf5l	94	1	Therefore	therefore	RB
cord-263455-dquztf5l	94	2	,	,	,
cord-263455-dquztf5l	94	3	more	more	RBR
cord-263455-dquztf5l	94	4	targeted	target	VBN
cord-263455-dquztf5l	94	5	prevention	prevention	NN
cord-263455-dquztf5l	94	6	methods	method	NNS
cord-263455-dquztf5l	94	7	were	be	VBD
cord-263455-dquztf5l	94	8	considered	consider	VBN
cord-263455-dquztf5l	94	9	necessary	necessary	JJ
cord-263455-dquztf5l	94	10	to	to	TO
cord-263455-dquztf5l	94	11	stop	stop	VB
cord-263455-dquztf5l	94	12	transmission	transmission	NN
cord-263455-dquztf5l	94	13	.	.	.
cord-263455-dquztf5l	95	1	24	24	CD
cord-263455-dquztf5l	96	1	Over	over	IN
cord-263455-dquztf5l	96	2	the	the	DT
cord-263455-dquztf5l	96	3	past	past	JJ
cord-263455-dquztf5l	96	4	years	year	NNS
cord-263455-dquztf5l	96	5	,	,	,
cord-263455-dquztf5l	96	6	progress	progress	NN
cord-263455-dquztf5l	96	7	has	have	VBZ
cord-263455-dquztf5l	96	8	been	be	VBN
cord-263455-dquztf5l	96	9	made	make	VBN
cord-263455-dquztf5l	96	10	in	in	IN
cord-263455-dquztf5l	96	11	the	the	DT
cord-263455-dquztf5l	96	12	fields	field	NNS
cord-263455-dquztf5l	96	13	of	of	IN
cord-263455-dquztf5l	96	14	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	96	15	and	and	CC
cord-263455-dquztf5l	96	16	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	96	17	to	to	TO
cord-263455-dquztf5l	96	18	prevent	prevent	VB
cord-263455-dquztf5l	96	19	leprosy	leprosy	NN
cord-263455-dquztf5l	96	20	,	,	,
cord-263455-dquztf5l	96	21	with	with	IN
cord-263455-dquztf5l	96	22	a	a	DT
cord-263455-dquztf5l	96	23	primary	primary	JJ
cord-263455-dquztf5l	96	24	focus	focus	NN
cord-263455-dquztf5l	96	25	on	on	IN
cord-263455-dquztf5l	96	26	close	close	JJ
cord-263455-dquztf5l	96	27	contacts	contact	NNS
cord-263455-dquztf5l	96	28	of	of	IN
cord-263455-dquztf5l	96	29	patients	patient	NNS
cord-263455-dquztf5l	96	30	.	.	.
cord-263455-dquztf5l	97	1	23	23	CD
cord-263455-dquztf5l	98	1	In	in	IN
cord-263455-dquztf5l	98	2	this	this	DT
cord-263455-dquztf5l	98	3	article	article	NN
cord-263455-dquztf5l	98	4	,	,	,
cord-263455-dquztf5l	98	5	we	-PRON-	PRP
cord-263455-dquztf5l	98	6	present	present	VBP
cord-263455-dquztf5l	98	7	a	a	DT
cord-263455-dquztf5l	98	8	descriptive	descriptive	JJ
cord-263455-dquztf5l	98	9	metaanalysis	metaanalysis	NN
cord-263455-dquztf5l	98	10	on	on	IN
cord-263455-dquztf5l	98	11	leprosy	leprosy	NN
cord-263455-dquztf5l	98	12	post	post	JJ
cord-263455-dquztf5l	98	13	-	-	JJ
cord-263455-dquztf5l	98	14	exposure	exposure	JJ
cord-263455-dquztf5l	98	15	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	98	16	.	.	.
cord-263455-dquztf5l	99	1	The	the	DT
cord-263455-dquztf5l	99	2	aim	aim	NN
cord-263455-dquztf5l	99	3	of	of	IN
cord-263455-dquztf5l	99	4	this	this	DT
cord-263455-dquztf5l	99	5	review	review	NN
cord-263455-dquztf5l	99	6	is	be	VBZ
cord-263455-dquztf5l	99	7	to	to	TO
cord-263455-dquztf5l	99	8	summarize	summarize	VB
cord-263455-dquztf5l	99	9	the	the	DT
cord-263455-dquztf5l	99	10	evidence	evidence	NN
cord-263455-dquztf5l	99	11	on	on	IN
cord-263455-dquztf5l	99	12	post	post	JJ
cord-263455-dquztf5l	99	13	-	-	JJ
cord-263455-dquztf5l	99	14	exposure	exposure	JJ
cord-263455-dquztf5l	99	15	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	99	16	for	for	IN
cord-263455-dquztf5l	99	17	leprosy	leprosy	NN
cord-263455-dquztf5l	99	18	and	and	CC
cord-263455-dquztf5l	99	19	to	to	TO
cord-263455-dquztf5l	99	20	identify	identify	VB
cord-263455-dquztf5l	99	21	knowledge	knowledge	NN
cord-263455-dquztf5l	99	22	gaps	gap	NNS
cord-263455-dquztf5l	99	23	and	and	CC
cord-263455-dquztf5l	99	24	topics	topic	NNS
cord-263455-dquztf5l	99	25	for	for	IN
cord-263455-dquztf5l	99	26	future	future	JJ
cord-263455-dquztf5l	99	27	studies	study	NNS
cord-263455-dquztf5l	99	28	.	.	.
cord-263455-dquztf5l	100	1	A	a	DT
cord-263455-dquztf5l	100	2	descriptive	descriptive	JJ
cord-263455-dquztf5l	100	3	meta	meta	JJ
cord-263455-dquztf5l	100	4	-	-	HYPH
cord-263455-dquztf5l	100	5	analysis	analysis	NN
cord-263455-dquztf5l	100	6	method	method	NN
cord-263455-dquztf5l	100	7	was	be	VBD
cord-263455-dquztf5l	100	8	chosen	choose	VBN
cord-263455-dquztf5l	100	9	.	.	.
cord-263455-dquztf5l	101	1	25	25	CD
cord-263455-dquztf5l	102	1	A	a	DT
cord-263455-dquztf5l	102	2	systematic	systematic	JJ
cord-263455-dquztf5l	102	3	literature	literature	NN
cord-263455-dquztf5l	102	4	search	search	NN
cord-263455-dquztf5l	102	5	was	be	VBD
cord-263455-dquztf5l	102	6	conducted	conduct	VBN
cord-263455-dquztf5l	102	7	using	use	VBG
cord-263455-dquztf5l	102	8	six	six	CD
cord-263455-dquztf5l	102	9	electronic	electronic	JJ
cord-263455-dquztf5l	102	10	medical	medical	JJ
cord-263455-dquztf5l	102	11	databases	database	NNS
cord-263455-dquztf5l	102	12	:	:	:
cord-263455-dquztf5l	102	13	Cochrane	Cochrane	NNP
cord-263455-dquztf5l	102	14	,	,	,
cord-263455-dquztf5l	102	15	Embase	Embase	NNP
cord-263455-dquztf5l	102	16	,	,	,
cord-263455-dquztf5l	102	17	PubMed/	PubMed/	NNP
cord-263455-dquztf5l	102	18	MEDLINE	MEDLINE	NNP
cord-263455-dquztf5l	102	19	,	,	,
cord-263455-dquztf5l	102	20	Research	Research	NNP
cord-263455-dquztf5l	102	21	Gate	Gate	NNP
cord-263455-dquztf5l	102	22	,	,	,
cord-263455-dquztf5l	102	23	Scopus	Scopus	NNP
cord-263455-dquztf5l	102	24	,	,	,
cord-263455-dquztf5l	102	25	and	and	CC
cord-263455-dquztf5l	102	26	Web	web	NN
cord-263455-dquztf5l	102	27	of	of	IN
cord-263455-dquztf5l	102	28	Science	Science	NNP
cord-263455-dquztf5l	102	29	(	(	-LRB-
cord-263455-dquztf5l	102	30	Table	Table	NNP
cord-263455-dquztf5l	102	31	1	1	CD
cord-263455-dquztf5l	102	32	)	)	-RRB-
cord-263455-dquztf5l	102	33	.	.	.
cord-263455-dquztf5l	103	1	The	the	DT
cord-263455-dquztf5l	103	2	search	search	NN
cord-263455-dquztf5l	103	3	was	be	VBD
cord-263455-dquztf5l	103	4	performed	perform	VBN
cord-263455-dquztf5l	103	5	using	use	VBG
cord-263455-dquztf5l	103	6	a	a	DT
cord-263455-dquztf5l	103	7	combination	combination	NN
cord-263455-dquztf5l	103	8	of	of	IN
cord-263455-dquztf5l	103	9	synonyms	synonyms	NN
cord-263455-dquztf5l	103	10	of	of	IN
cord-263455-dquztf5l	103	11	the	the	DT
cord-263455-dquztf5l	103	12	following	follow	VBG
cord-263455-dquztf5l	103	13	index	index	NN
cord-263455-dquztf5l	103	14	terms	term	NNS
cord-263455-dquztf5l	103	15	:	:	:
cord-263455-dquztf5l	103	16	"	"	``
cord-263455-dquztf5l	103	17	leprosy	leprosy	NN
cord-263455-dquztf5l	103	18	"	"	''
cord-263455-dquztf5l	103	19	and	and	CC
cord-263455-dquztf5l	103	20	"	"	``
cord-263455-dquztf5l	103	21	population	population	NN
cord-263455-dquztf5l	103	22	"	"	''
cord-263455-dquztf5l	103	23	or	or	CC
cord-263455-dquztf5l	103	24	"	"	``
cord-263455-dquztf5l	103	25	contacts	contact	NNS
cord-263455-dquztf5l	103	26	"	"	''
cord-263455-dquztf5l	103	27	and	and	CC
cord-263455-dquztf5l	103	28	"	"	``
cord-263455-dquztf5l	103	29	prevention	prevention	NN
cord-263455-dquztf5l	103	30	"	"	''
cord-263455-dquztf5l	103	31	or	or	CC
cord-263455-dquztf5l	103	32	"	"	``
cord-263455-dquztf5l	103	33	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	103	34	,	,	,
cord-263455-dquztf5l	103	35	"	"	''
cord-263455-dquztf5l	103	36	with	with	IN
cord-263455-dquztf5l	103	37	a	a	DT
cord-263455-dquztf5l	103	38	query	query	NN
cord-263455-dquztf5l	103	39	translated	translate	VBN
cord-263455-dquztf5l	103	40	in	in	IN
cord-263455-dquztf5l	103	41	English	English	NNP
cord-263455-dquztf5l	103	42	,	,	,
cord-263455-dquztf5l	103	43	French	french	JJ
cord-263455-dquztf5l	103	44	,	,	,
cord-263455-dquztf5l	103	45	Spanish	spanish	JJ
cord-263455-dquztf5l	103	46	,	,	,
cord-263455-dquztf5l	103	47	and	and	CC
cord-263455-dquztf5l	103	48	Portuguese	Portuguese	NNP
cord-263455-dquztf5l	103	49	.	.	.
cord-263455-dquztf5l	104	1	When	when	WRB
cord-263455-dquztf5l	104	2	possible	possible	JJ
cord-263455-dquztf5l	104	3	,	,	,
cord-263455-dquztf5l	104	4	the	the	DT
cord-263455-dquztf5l	104	5	search	search	NN
cord-263455-dquztf5l	104	6	was	be	VBD
cord-263455-dquztf5l	104	7	limited	limit	VBN
cord-263455-dquztf5l	104	8	to	to	IN
cord-263455-dquztf5l	104	9	the	the	DT
cord-263455-dquztf5l	104	10	Title	Title	NNP
cord-263455-dquztf5l	104	11	/	/	SYM
cord-263455-dquztf5l	104	12	Abstract	Abstract	NNP
cord-263455-dquztf5l	104	13	search	search	NN
cord-263455-dquztf5l	104	14	fields	field	NNS
cord-263455-dquztf5l	104	15	in	in	IN
cord-263455-dquztf5l	104	16	the	the	DT
cord-263455-dquztf5l	104	17	search	search	NN
cord-263455-dquztf5l	104	18	engines	engine	NNS
cord-263455-dquztf5l	104	19	.	.	.
cord-263455-dquztf5l	105	1	Medical	medical	JJ
cord-263455-dquztf5l	105	2	Subject	Subject	NNP
cord-263455-dquztf5l	105	3	Headings	heading	NNS
cord-263455-dquztf5l	105	4	(	(	-LRB-
cord-263455-dquztf5l	105	5	MESH	mesh	NN
cord-263455-dquztf5l	105	6	)	)	-RRB-
cord-263455-dquztf5l	105	7	terms	term	NNS
cord-263455-dquztf5l	105	8	were	be	VBD
cord-263455-dquztf5l	105	9	added	add	VBN
cord-263455-dquztf5l	105	10	to	to	IN
cord-263455-dquztf5l	105	11	the	the	DT
cord-263455-dquztf5l	105	12	search	search	NN
cord-263455-dquztf5l	105	13	query	query	NN
cord-263455-dquztf5l	105	14	if	if	IN
cord-263455-dquztf5l	105	15	available	available	JJ
cord-263455-dquztf5l	105	16	.	.	.
cord-263455-dquztf5l	106	1	In	in	IN
cord-263455-dquztf5l	106	2	addition	addition	NN
cord-263455-dquztf5l	106	3	,	,	,
cord-263455-dquztf5l	106	4	an	an	DT
cord-263455-dquztf5l	106	5	article	article	NN
cord-263455-dquztf5l	106	6	search	search	NN
cord-263455-dquztf5l	106	7	via	via	IN
cord-263455-dquztf5l	106	8	Infolep.org	Infolep.org	NNP
cord-263455-dquztf5l	106	9	and	and	CC
cord-263455-dquztf5l	106	10	Google	Google	NNP
cord-263455-dquztf5l	106	11	Scholar	Scholar	NNP
cord-263455-dquztf5l	106	12	was	be	VBD
cord-263455-dquztf5l	106	13	performed	perform	VBN
cord-263455-dquztf5l	106	14	.	.	.
cord-263455-dquztf5l	107	1	Infolep	Infolep	NNP
cord-263455-dquztf5l	107	2	is	be	VBZ
cord-263455-dquztf5l	107	3	the	the	DT
cord-263455-dquztf5l	107	4	international	international	JJ
cord-263455-dquztf5l	107	5	knowledge	knowledge	NN
cord-263455-dquztf5l	107	6	center	center	NN
cord-263455-dquztf5l	107	7	for	for	IN
cord-263455-dquztf5l	107	8	information	information	NN
cord-263455-dquztf5l	107	9	resources	resource	NNS
cord-263455-dquztf5l	107	10	on	on	IN
cord-263455-dquztf5l	107	11	leprosy	leprosy	NN
cord-263455-dquztf5l	107	12	.	.	.
cord-263455-dquztf5l	108	1	26	26	CD
cord-263455-dquztf5l	109	1	Their	-PRON-	PRP$
cord-263455-dquztf5l	109	2	online	online	JJ
cord-263455-dquztf5l	109	3	database	database	NN
cord-263455-dquztf5l	109	4	also	also	RB
cord-263455-dquztf5l	109	5	includes	include	VBZ
cord-263455-dquztf5l	109	6	"	"	``
cord-263455-dquztf5l	109	7	grey	grey	NNP
cord-263455-dquztf5l	109	8	litrature	litrature	NNP
cord-263455-dquztf5l	109	9	"	"	''
cord-263455-dquztf5l	109	10	,	,	,
cord-263455-dquztf5l	109	11	such	such	JJ
cord-263455-dquztf5l	109	12	as	as	IN
cord-263455-dquztf5l	109	13	meeting	meeting	NN
cord-263455-dquztf5l	109	14	reports	report	NNS
cord-263455-dquztf5l	109	15	and	and	CC
cord-263455-dquztf5l	109	16	these	these	DT
cord-263455-dquztf5l	109	17	s	s	NNS
cord-263455-dquztf5l	109	18	.	.	.
cord-263455-dquztf5l	110	1	Bibliographies	bibliography	NNS
cord-263455-dquztf5l	110	2	of	of	IN
cord-263455-dquztf5l	110	3	the	the	DT
cord-263455-dquztf5l	110	4	relevant	relevant	JJ
cord-263455-dquztf5l	110	5	articles	article	NNS
cord-263455-dquztf5l	110	6	were	be	VBD
cord-263455-dquztf5l	110	7	screened	screen	VBN
cord-263455-dquztf5l	110	8	for	for	IN
cord-263455-dquztf5l	110	9	additional	additional	JJ
cord-263455-dquztf5l	110	10	articles	article	NNS
cord-263455-dquztf5l	110	11	missing	miss	VBG
cord-263455-dquztf5l	110	12	in	in	IN
cord-263455-dquztf5l	110	13	the	the	DT
cord-263455-dquztf5l	110	14	existing	exist	VBG
cord-263455-dquztf5l	110	15	yield	yield	NN
cord-263455-dquztf5l	110	16	(	(	-LRB-
cord-263455-dquztf5l	110	17	"	"	``
cord-263455-dquztf5l	110	18	snowball	snowball	NN
cord-263455-dquztf5l	110	19	method	method	NN
cord-263455-dquztf5l	110	20	"	"	''
cord-263455-dquztf5l	110	21	)	)	-RRB-
cord-263455-dquztf5l	110	22	.	.	.
cord-263455-dquztf5l	111	1	The	the	DT
cord-263455-dquztf5l	111	2	articles	article	NNS
cord-263455-dquztf5l	111	3	were	be	VBD
cord-263455-dquztf5l	111	4	deduplicated	deduplicate	VBN
cord-263455-dquztf5l	111	5	,	,	,
cord-263455-dquztf5l	111	6	and	and	CC
cord-263455-dquztf5l	111	7	consequently	consequently	RB
cord-263455-dquztf5l	111	8	,	,	,
cord-263455-dquztf5l	111	9	a	a	DT
cord-263455-dquztf5l	111	10	content	content	NN
cord-263455-dquztf5l	111	11	review	review	NN
cord-263455-dquztf5l	111	12	was	be	VBD
cord-263455-dquztf5l	111	13	performed	perform	VBN
cord-263455-dquztf5l	111	14	,	,	,
cord-263455-dquztf5l	111	15	first	first	RB
cord-263455-dquztf5l	111	16	in	in	IN
cord-263455-dquztf5l	111	17	titles	title	NNS
cord-263455-dquztf5l	111	18	and	and	CC
cord-263455-dquztf5l	111	19	abstracts	abstract	NNS
cord-263455-dquztf5l	111	20	and	and	CC
cord-263455-dquztf5l	111	21	second	second	JJ
cord-263455-dquztf5l	111	22	in	in	IN
cord-263455-dquztf5l	111	23	full	full	JJ
cord-263455-dquztf5l	111	24	texts	text	NNS
cord-263455-dquztf5l	111	25	.	.	.
cord-263455-dquztf5l	112	1	Uncertainties	uncertainty	NNS
cord-263455-dquztf5l	112	2	in	in	IN
cord-263455-dquztf5l	112	3	the	the	DT
cord-263455-dquztf5l	112	4	selection	selection	NN
cord-263455-dquztf5l	112	5	were	be	VBD
cord-263455-dquztf5l	112	6	discussed	discuss	VBN
cord-263455-dquztf5l	112	7	with	with	IN
cord-263455-dquztf5l	112	8	a	a	DT
cord-263455-dquztf5l	112	9	second	second	JJ
cord-263455-dquztf5l	112	10	researcher	researcher	NN
cord-263455-dquztf5l	112	11	until	until	IN
cord-263455-dquztf5l	112	12	consensus	consensus	NN
cord-263455-dquztf5l	112	13	was	be	VBD
cord-263455-dquztf5l	112	14	reached	reach	VBN
cord-263455-dquztf5l	112	15	.	.	.
cord-263455-dquztf5l	113	1	Regarding	regard	VBG
cord-263455-dquztf5l	113	2	inclusion	inclusion	NN
cord-263455-dquztf5l	113	3	criteria	criterion	NNS
cord-263455-dquztf5l	113	4	,	,	,
cord-263455-dquztf5l	113	5	all	all	DT
cord-263455-dquztf5l	113	6	human	human	JJ
cord-263455-dquztf5l	113	7	studies	study	NNS
cord-263455-dquztf5l	113	8	as	as	RB
cord-263455-dquztf5l	113	9	well	well	RB
cord-263455-dquztf5l	113	10	as	as	IN
cord-263455-dquztf5l	113	11	meeting	meeting	NN
cord-263455-dquztf5l	113	12	reports	report	NNS
cord-263455-dquztf5l	113	13	,	,	,
cord-263455-dquztf5l	113	14	expert	expert	NN
cord-263455-dquztf5l	113	15	opinions	opinion	NNS
cord-263455-dquztf5l	113	16	,	,	,
cord-263455-dquztf5l	113	17	editorials	editorial	NNS
cord-263455-dquztf5l	113	18	,	,	,
cord-263455-dquztf5l	113	19	and	and	CC
cord-263455-dquztf5l	113	20	other	other	JJ
cord-263455-dquztf5l	113	21	relevant	relevant	JJ
cord-263455-dquztf5l	113	22	articles	article	NNS
cord-263455-dquztf5l	113	23	were	be	VBD
cord-263455-dquztf5l	113	24	included	include	VBN
cord-263455-dquztf5l	113	25	if	if	IN
cord-263455-dquztf5l	113	26	methods	method	NNS
cord-263455-dquztf5l	113	27	for	for	IN
cord-263455-dquztf5l	113	28	postexposure	postexposure	NN
cord-263455-dquztf5l	113	29	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	113	30	and	and	CC
cord-263455-dquztf5l	113	31	post	post	JJ
cord-263455-dquztf5l	113	32	-	-	JJ
cord-263455-dquztf5l	113	33	exposure	exposure	JJ
cord-263455-dquztf5l	113	34	immunoprophylaxis	immunoprophylaxis	NN
cord-263455-dquztf5l	113	35	or	or	CC
cord-263455-dquztf5l	113	36	vaccines	vaccine	NNS
cord-263455-dquztf5l	113	37	against	against	IN
cord-263455-dquztf5l	113	38	leprosy	leprosy	NN
cord-263455-dquztf5l	113	39	were	be	VBD
cord-263455-dquztf5l	113	40	discussed	discuss	VBN
cord-263455-dquztf5l	113	41	.	.	.
cord-263455-dquztf5l	114	1	Exclusion	exclusion	NN
cord-263455-dquztf5l	114	2	criteria	criterion	NNS
cord-263455-dquztf5l	114	3	were	be	VBD
cord-263455-dquztf5l	114	4	as	as	IN
cord-263455-dquztf5l	114	5	follow	follow	NN
cord-263455-dquztf5l	114	6	:	:	:
cord-263455-dquztf5l	114	7	(	(	-LRB-
cord-263455-dquztf5l	114	8	a	a	LS
cord-263455-dquztf5l	114	9	)	)	-RRB-
cord-263455-dquztf5l	114	10	studies	study	NNS
cord-263455-dquztf5l	114	11	in	in	IN
cord-263455-dquztf5l	114	12	languages	language	NNS
cord-263455-dquztf5l	114	13	other	other	JJ
cord-263455-dquztf5l	114	14	than	than	IN
cord-263455-dquztf5l	114	15	English	English	NNP
cord-263455-dquztf5l	114	16	,	,	,
cord-263455-dquztf5l	114	17	French	french	JJ
cord-263455-dquztf5l	114	18	,	,	,
cord-263455-dquztf5l	114	19	Spanish	spanish	JJ
cord-263455-dquztf5l	114	20	,	,	,
cord-263455-dquztf5l	114	21	or	or	CC
cord-263455-dquztf5l	114	22	Portuguese	portuguese	JJ
cord-263455-dquztf5l	114	23	;	;	,
cord-263455-dquztf5l	114	24	(	(	-LRB-
cord-263455-dquztf5l	114	25	b	b	NN
cord-263455-dquztf5l	114	26	)	)	-RRB-
cord-263455-dquztf5l	114	27	studies	study	NNS
cord-263455-dquztf5l	114	28	for	for	IN
cord-263455-dquztf5l	114	29	which	which	WDT
cord-263455-dquztf5l	114	30	no	no	DT
cord-263455-dquztf5l	114	31	full	full	JJ
cord-263455-dquztf5l	114	32	text	text	NN
cord-263455-dquztf5l	114	33	was	be	VBD
cord-263455-dquztf5l	114	34	available	available	JJ
cord-263455-dquztf5l	114	35	;	;	:
cord-263455-dquztf5l	114	36	(	(	-LRB-
cord-263455-dquztf5l	114	37	c	c	NN
cord-263455-dquztf5l	114	38	)	)	-RRB-
cord-263455-dquztf5l	114	39	studies	study	NNS
cord-263455-dquztf5l	114	40	that	that	WDT
cord-263455-dquztf5l	114	41	focused	focus	VBD
cord-263455-dquztf5l	114	42	predominantly	predominantly	RB
cord-263455-dquztf5l	114	43	on	on	IN
cord-263455-dquztf5l	114	44	leprosy	leprosy	NN
cord-263455-dquztf5l	114	45	treatment	treatment	NN
cord-263455-dquztf5l	114	46	instead	instead	RB
cord-263455-dquztf5l	114	47	of	of	IN
cord-263455-dquztf5l	114	48	prevention	prevention	NN
cord-263455-dquztf5l	114	49	;	;	,
cord-263455-dquztf5l	114	50	(	(	-LRB-
cord-263455-dquztf5l	114	51	d	d	NN
cord-263455-dquztf5l	114	52	)	)	-RRB-
cord-263455-dquztf5l	114	53	studies	study	NNS
cord-263455-dquztf5l	114	54	that	that	WDT
cord-263455-dquztf5l	114	55	focused	focus	VBD
cord-263455-dquztf5l	114	56	solely	solely	RB
cord-263455-dquztf5l	114	57	on	on	IN
cord-263455-dquztf5l	114	58	primary	primary	JJ
cord-263455-dquztf5l	114	59	prevention	prevention	NN
cord-263455-dquztf5l	114	60	interventions	intervention	NNS
cord-263455-dquztf5l	114	61	(	(	-LRB-
cord-263455-dquztf5l	114	62	eg	eg	IN
cord-263455-dquztf5l	114	63	,	,	,
cord-263455-dquztf5l	114	64	primary	primary	JJ
cord-263455-dquztf5l	114	65	vaccination	vaccination	NN
cord-263455-dquztf5l	114	66	in	in	IN
cord-263455-dquztf5l	114	67	newborns	newborn	NNS
cord-263455-dquztf5l	114	68	)	)	-RRB-
cord-263455-dquztf5l	114	69	;	;	:
cord-263455-dquztf5l	114	70	(	(	-LRB-
cord-263455-dquztf5l	114	71	e	e	NN
cord-263455-dquztf5l	114	72	)	)	-RRB-
cord-263455-dquztf5l	114	73	studies	study	NNS
cord-263455-dquztf5l	114	74	that	that	WDT
cord-263455-dquztf5l	114	75	solely	solely	RB
cord-263455-dquztf5l	114	76	assessed	assess	VBD
cord-263455-dquztf5l	114	77	immunological	immunological	JJ
cord-263455-dquztf5l	114	78	status	status	NN
cord-263455-dquztf5l	114	79	changes	change	NNS
cord-263455-dquztf5l	114	80	after	after	IN
cord-263455-dquztf5l	114	81	vaccination	vaccination	NN
cord-263455-dquztf5l	114	82	without	without	IN
cord-263455-dquztf5l	114	83	assessing	assess	VBG
cord-263455-dquztf5l	114	84	clinical	clinical	JJ
cord-263455-dquztf5l	114	85	infection	infection	NN
cord-263455-dquztf5l	114	86	;	;	,
cord-263455-dquztf5l	114	87	(	(	-LRB-
cord-263455-dquztf5l	114	88	f	f	LS
cord-263455-dquztf5l	114	89	)	)	-RRB-
cord-263455-dquztf5l	114	90	study	study	NN
cord-263455-dquztf5l	114	91	protocol	protocol	NN
cord-263455-dquztf5l	114	92	descriptions	description	NNS
cord-263455-dquztf5l	114	93	or	or	CC
cord-263455-dquztf5l	114	94	preliminary	preliminary	JJ
cord-263455-dquztf5l	114	95	reports	report	NNS
cord-263455-dquztf5l	114	96	of	of	IN
cord-263455-dquztf5l	114	97	clinical	clinical	JJ
cord-263455-dquztf5l	114	98	trial	trial	NN
cord-263455-dquztf5l	114	99	data	datum	NNS
cord-263455-dquztf5l	114	100	that	that	WDT
cord-263455-dquztf5l	114	101	were	be	VBD
cord-263455-dquztf5l	114	102	later	later	RB
cord-263455-dquztf5l	114	103	similarly	similarly	RB
cord-263455-dquztf5l	114	104	described	describe	VBN
cord-263455-dquztf5l	114	105	in	in	IN
cord-263455-dquztf5l	114	106	more	more	RBR
cord-263455-dquztf5l	114	107	complete	complete	JJ
cord-263455-dquztf5l	114	108	publications	publication	NNS
cord-263455-dquztf5l	114	109	;	;	:
cord-263455-dquztf5l	114	110	and	and	CC
cord-263455-dquztf5l	114	111	(	(	-LRB-
cord-263455-dquztf5l	114	112	g	g	NN
cord-263455-dquztf5l	114	113	)	)	-RRB-
cord-263455-dquztf5l	114	114	articles	article	NNS
cord-263455-dquztf5l	114	115	in	in	IN
cord-263455-dquztf5l	114	116	which	which	WDT
cord-263455-dquztf5l	114	117	no	no	DT
cord-263455-dquztf5l	114	118	new	new	JJ
cord-263455-dquztf5l	114	119	information	information	NN
cord-263455-dquztf5l	114	120	was	be	VBD
cord-263455-dquztf5l	114	121	discovered	discover	VBN
cord-263455-dquztf5l	114	122	(	(	-LRB-
cord-263455-dquztf5l	114	123	data	data	NN
cord-263455-dquztf5l	114	124	-	-	HYPH
cord-263455-dquztf5l	114	125	saturation	saturation	NN
cord-263455-dquztf5l	114	126	)	)	-RRB-
cord-263455-dquztf5l	114	127	.	.	.
cord-263455-dquztf5l	115	1	Every	every	DT
cord-263455-dquztf5l	115	2	step	step	NN
cord-263455-dquztf5l	115	3	in	in	IN
cord-263455-dquztf5l	115	4	the	the	DT
cord-263455-dquztf5l	115	5	search	search	NN
cord-263455-dquztf5l	115	6	phase	phase	NN
cord-263455-dquztf5l	115	7	was	be	VBD
cord-263455-dquztf5l	115	8	documented	document	VBN
cord-263455-dquztf5l	115	9	according	accord	VBG
cord-263455-dquztf5l	115	10	to	to	IN
cord-263455-dquztf5l	115	11	the	the	DT
cord-263455-dquztf5l	115	12	Preferred	Preferred	NNP
cord-263455-dquztf5l	115	13	Reporting	Reporting	NNP
cord-263455-dquztf5l	115	14	Items	Items	NNP
cord-263455-dquztf5l	115	15	for	for	IN
cord-263455-dquztf5l	115	16	Systematic	Systematic	NNP
cord-263455-dquztf5l	115	17	Reviews	Reviews	NNPS
cord-263455-dquztf5l	115	18	and	and	CC
cord-263455-dquztf5l	115	19	Meta	Meta	NNP
cord-263455-dquztf5l	115	20	-	-	HYPH
cord-263455-dquztf5l	115	21	Analyses	Analyses	NNP
cord-263455-dquztf5l	115	22	(	(	-LRB-
cord-263455-dquztf5l	115	23	PRISMA	PRISMA	NNP
cord-263455-dquztf5l	115	24	)	)	-RRB-
cord-263455-dquztf5l	115	25	literature	literature	NN
cord-263455-dquztf5l	115	26	review	review	NN
cord-263455-dquztf5l	115	27	methodology	methodology	NN
cord-263455-dquztf5l	115	28	.	.	.
cord-263455-dquztf5l	116	1	27	27	CD
cord-263455-dquztf5l	117	1	After	after	IN
cord-263455-dquztf5l	117	2	the	the	DT
cord-263455-dquztf5l	117	3	search	search	NN
cord-263455-dquztf5l	117	4	,	,	,
cord-263455-dquztf5l	117	5	a	a	DT
cord-263455-dquztf5l	117	6	data	data	NN
cord-263455-dquztf5l	117	7	and	and	CC
cord-263455-dquztf5l	117	8	text	text	NN
cord-263455-dquztf5l	117	9	mining	mining	NN
cord-263455-dquztf5l	117	10	process	process	NN
cord-263455-dquztf5l	117	11	was	be	VBD
cord-263455-dquztf5l	117	12	performed	perform	VBN
cord-263455-dquztf5l	117	13	.	.	.
cord-263455-dquztf5l	118	1	25	25	CD
cord-263455-dquztf5l	119	1	The	the	DT
cord-263455-dquztf5l	119	2	authors	author	NNS
cord-263455-dquztf5l	119	3	,	,	,
cord-263455-dquztf5l	119	4	year	year	NN
cord-263455-dquztf5l	119	5	of	of	IN
cord-263455-dquztf5l	119	6	publication	publication	NN
cord-263455-dquztf5l	119	7	,	,	,
cord-263455-dquztf5l	119	8	and	and	CC
cord-263455-dquztf5l	119	9	study	study	NN
cord-263455-dquztf5l	119	10	characteristics	characteristic	NNS
cord-263455-dquztf5l	119	11	(	(	-LRB-
cord-263455-dquztf5l	119	12	ie	ie	FW
cord-263455-dquztf5l	119	13	,	,	,
cord-263455-dquztf5l	119	14	study	study	NN
cord-263455-dquztf5l	119	15	design	design	NN
cord-263455-dquztf5l	119	16	,	,	,
cord-263455-dquztf5l	119	17	population	population	NN
cord-263455-dquztf5l	119	18	,	,	,
cord-263455-dquztf5l	119	19	period	period	NN
cord-263455-dquztf5l	119	20	,	,	,
cord-263455-dquztf5l	119	21	geographic	geographic	JJ
cord-263455-dquztf5l	119	22	area	area	NN
cord-263455-dquztf5l	119	23	,	,	,
cord-263455-dquztf5l	119	24	intervention	intervention	NN
cord-263455-dquztf5l	119	25	type	type	NN
cord-263455-dquztf5l	119	26	,	,	,
cord-263455-dquztf5l	119	27	results	result	NNS
cord-263455-dquztf5l	119	28	)	)	-RRB-
cord-263455-dquztf5l	119	29	were	be	VBD
cord-263455-dquztf5l	119	30	extracted	extract	VBN
cord-263455-dquztf5l	119	31	 	 	_SP
cord-263455-dquztf5l	119	32	The	the	DT
cord-263455-dquztf5l	119	33	search	search	NN
cord-263455-dquztf5l	119	34	in	in	IN
cord-263455-dquztf5l	119	35	the	the	DT
cord-263455-dquztf5l	119	36	six	six	CD
cord-263455-dquztf5l	119	37	medical	medical	JJ
cord-263455-dquztf5l	119	38	literature	literature	NN
cord-263455-dquztf5l	119	39	databases	database	NNS
cord-263455-dquztf5l	119	40	on	on	IN
cord-263455-dquztf5l	119	41	January	January	NNP
cord-263455-dquztf5l	119	42	22	22	CD
cord-263455-dquztf5l	119	43	,	,	,
cord-263455-dquztf5l	119	44	2020	2020	CD
cord-263455-dquztf5l	119	45	(	(	-LRB-
cord-263455-dquztf5l	119	46	Table	table	NN
cord-263455-dquztf5l	119	47	1	1	CD
cord-263455-dquztf5l	119	48	)	)	-RRB-
cord-263455-dquztf5l	119	49	and	and	CC
cord-263455-dquztf5l	119	50	the	the	DT
cord-263455-dquztf5l	119	51	additional	additional	JJ
cord-263455-dquztf5l	119	52	search	search	NN
cord-263455-dquztf5l	119	53	via	via	IN
cord-263455-dquztf5l	119	54	Infolep.org	Infolep.org	NNP
cord-263455-dquztf5l	119	55	,	,	,
cord-263455-dquztf5l	119	56	Google	Google	NNP
cord-263455-dquztf5l	119	57	Scholar	Scholar	NNP
cord-263455-dquztf5l	119	58	and	and	CC
cord-263455-dquztf5l	119	59	articles	article	NNS
cord-263455-dquztf5l	119	60	'	'	POS
cord-263455-dquztf5l	119	61	bibliographies	bibliography	NNS
cord-263455-dquztf5l	119	62	resulted	result	VBD
cord-263455-dquztf5l	119	63	in	in	IN
cord-263455-dquztf5l	119	64	2,536	2,536	CD
cord-263455-dquztf5l	119	65	articles	article	NNS
cord-263455-dquztf5l	119	66	after	after	IN
cord-263455-dquztf5l	119	67	deduplication	deduplication	NN
cord-263455-dquztf5l	119	68	(	(	-LRB-
cord-263455-dquztf5l	119	69	Figure	figure	NN
cord-263455-dquztf5l	119	70	1	1	CD
cord-263455-dquztf5l	119	71	)	)	-RRB-
cord-263455-dquztf5l	119	72	.	.	.
cord-263455-dquztf5l	120	1	A	a	DT
cord-263455-dquztf5l	120	2	total	total	NN
cord-263455-dquztf5l	120	3	of	of	IN
cord-263455-dquztf5l	120	4	125	125	CD
cord-263455-dquztf5l	120	5	articles	article	NNS
cord-263455-dquztf5l	120	6	included	include	VBD
cord-263455-dquztf5l	120	7	relevant	relevant	JJ
cord-263455-dquztf5l	120	8	information	information	NN
cord-263455-dquztf5l	120	9	for	for	IN
cord-263455-dquztf5l	120	10	this	this	DT
cord-263455-dquztf5l	120	11	descriptive	descriptive	JJ
cord-263455-dquztf5l	120	12	review	review	NN
cord-263455-dquztf5l	120	13	on	on	IN
cord-263455-dquztf5l	120	14	leprosy	leprosy	NN
cord-263455-dquztf5l	120	15	post	post	JJ
cord-263455-dquztf5l	120	16	-	-	JJ
cord-263455-dquztf5l	120	17	exposure	exposure	JJ
cord-263455-dquztf5l	120	18	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	120	19	.	.	.
cord-263455-dquztf5l	121	1	The	the	DT
cord-263455-dquztf5l	121	2	bacillus	bacillus	NN
cord-263455-dquztf5l	121	3	Calmette	Calmette	NNP
cord-263455-dquztf5l	121	4	-	-	HYPH
cord-263455-dquztf5l	121	5	Guérin	Guérin	NNP
cord-263455-dquztf5l	121	6	(	(	-LRB-
cord-263455-dquztf5l	121	7	BCG	BCG	NNP
cord-263455-dquztf5l	121	8	)	)	-RRB-
cord-263455-dquztf5l	121	9	vaccine	vaccine	NN
cord-263455-dquztf5l	121	10	is	be	VBZ
cord-263455-dquztf5l	121	11	a	a	DT
cord-263455-dquztf5l	121	12	live	live	JJ
cord-263455-dquztf5l	121	13	attenuated	attenuated	JJ
cord-263455-dquztf5l	121	14	vaccine	vaccine	NN
cord-263455-dquztf5l	121	15	prepared	prepare	VBN
cord-263455-dquztf5l	121	16	from	from	IN
cord-263455-dquztf5l	121	17	a	a	DT
cord-263455-dquztf5l	121	18	strain	strain	NN
cord-263455-dquztf5l	121	19	of	of	IN
cord-263455-dquztf5l	121	20	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	121	21	bovis	bovis	NN
cord-263455-dquztf5l	121	22	,	,	,
cord-263455-dquztf5l	121	23	derived	derive	VBN
cord-263455-dquztf5l	121	24	from	from	IN
cord-263455-dquztf5l	121	25	a	a	DT
cord-263455-dquztf5l	121	26	tuberculous	tuberculous	JJ
cord-263455-dquztf5l	121	27	cow	cow	NN
cord-263455-dquztf5l	121	28	.	.	.
cord-263455-dquztf5l	122	1	28	28	CD
cord-263455-dquztf5l	122	2	,	,	,
cord-263455-dquztf5l	122	3	29	29	CD
cord-263455-dquztf5l	123	1	The	the	DT
cord-263455-dquztf5l	123	2	first	first	JJ
cord-263455-dquztf5l	123	3	BCG	BCG	NNP
cord-263455-dquztf5l	123	4	vaccine	vaccine	NN
cord-263455-dquztf5l	123	5	,	,	,
cord-263455-dquztf5l	123	6	originally	originally	RB
cord-263455-dquztf5l	123	7	developed	develop	VBN
cord-263455-dquztf5l	123	8	against	against	IN
cord-263455-dquztf5l	123	9	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	123	10	(	(	-LRB-
cord-263455-dquztf5l	123	11	TB	TB	NNP
cord-263455-dquztf5l	123	12	)	)	-RRB-
cord-263455-dquztf5l	123	13	,	,	,
cord-263455-dquztf5l	123	14	was	be	VBD
cord-263455-dquztf5l	123	15	produced	produce	VBN
cord-263455-dquztf5l	123	16	by	by	IN
cord-263455-dquztf5l	123	17	Albert	Albert	NNP
cord-263455-dquztf5l	123	18	Calmette	Calmette	NNP
cord-263455-dquztf5l	123	19	and	and	CC
cord-263455-dquztf5l	123	20	Camille	Camille	NNP
cord-263455-dquztf5l	123	21	Guérin	Guérin	NNP
cord-263455-dquztf5l	123	22	in	in	IN
cord-263455-dquztf5l	123	23	1924	1924	CD
cord-263455-dquztf5l	123	24	at	at	IN
cord-263455-dquztf5l	123	25	the	the	DT
cord-263455-dquztf5l	123	26	Pasteur	Pasteur	NNP
cord-263455-dquztf5l	123	27	Institute	Institute	NNP
cord-263455-dquztf5l	123	28	.	.	.
cord-263455-dquztf5l	124	1	30	30	CD
cord-263455-dquztf5l	124	2	,	,	,
cord-263455-dquztf5l	124	3	31	31	CD
cord-263455-dquztf5l	125	1	The	the	DT
cord-263455-dquztf5l	125	2	influence	influence	NN
cord-263455-dquztf5l	125	3	of	of	IN
cord-263455-dquztf5l	125	4	BCG	BCG	NNP
cord-263455-dquztf5l	125	5	on	on	IN
cord-263455-dquztf5l	125	6	the	the	DT
cord-263455-dquztf5l	125	7	lepromin	lepromin	NNP
cord-263455-dquztf5l	125	8	reaction	reaction	NN
cord-263455-dquztf5l	125	9	,	,	,
cord-263455-dquztf5l	125	10	described	describe	VBN
cord-263455-dquztf5l	125	11	by	by	IN
cord-263455-dquztf5l	125	12	José	José	NNP
cord-263455-dquztf5l	125	13	Fernández	Fernández	NNP
cord-263455-dquztf5l	125	14	in	in	IN
cord-263455-dquztf5l	125	15	1939	1939	CD
cord-263455-dquztf5l	125	16	,	,	,
cord-263455-dquztf5l	125	17	indicated	indicate	VBD
cord-263455-dquztf5l	125	18	that	that	IN
cord-263455-dquztf5l	125	19	BCG	BCG	NNP
cord-263455-dquztf5l	125	20	might	may	MD
cord-263455-dquztf5l	125	21	also	also	RB
cord-263455-dquztf5l	125	22	provide	provide	VB
cord-263455-dquztf5l	125	23	leprosy	leprosy	NN
cord-263455-dquztf5l	125	24	protection	protection	NN
cord-263455-dquztf5l	125	25	.	.	.
cord-263455-dquztf5l	126	1	32	32	CD
cord-263455-dquztf5l	126	2	,	,	,
cord-263455-dquztf5l	126	3	33	33	CD
cord-263455-dquztf5l	126	4	Currently	currently	RB
cord-263455-dquztf5l	126	5	,	,	,
cord-263455-dquztf5l	126	6	over	over	IN
cord-263455-dquztf5l	126	7	10	10	CD
cord-263455-dquztf5l	126	8	substrains	substrain	NNS
cord-263455-dquztf5l	126	9	of	of	IN
cord-263455-dquztf5l	126	10	BCG	BCG	NNP
cord-263455-dquztf5l	126	11	are	be	VBP
cord-263455-dquztf5l	126	12	being	be	VBG
cord-263455-dquztf5l	126	13	manufactured	manufacture	VBN
cord-263455-dquztf5l	126	14	.	.	.
cord-263455-dquztf5l	127	1	29	29	CD
cord-263455-dquztf5l	128	1	Approximately	approximately	RB
cord-263455-dquztf5l	128	2	100	100	CD
cord-263455-dquztf5l	128	3	million	million	CD
cord-263455-dquztf5l	128	4	newborns	newborn	NNS
cord-263455-dquztf5l	128	5	each	each	DT
cord-263455-dquztf5l	128	6	year	year	NN
cord-263455-dquztf5l	128	7	receive	receive	VBP
cord-263455-dquztf5l	128	8	the	the	DT
cord-263455-dquztf5l	128	9	BCG	BCG	NNP
cord-263455-dquztf5l	128	10	vaccine	vaccine	NN
cord-263455-dquztf5l	128	11	,	,	,
cord-263455-dquztf5l	128	12	mainly	mainly	RB
cord-263455-dquztf5l	128	13	as	as	IN
cord-263455-dquztf5l	128	14	primary	primary	JJ
cord-263455-dquztf5l	128	15	protection	protection	NN
cord-263455-dquztf5l	128	16	against	against	IN
cord-263455-dquztf5l	128	17	TB	TB	NNP
cord-263455-dquztf5l	128	18	.	.	.
cord-263455-dquztf5l	129	1	BCG	BCG	NNP
cord-263455-dquztf5l	129	2	is	be	VBZ
cord-263455-dquztf5l	129	3	contraindicated	contraindicate	VBN
cord-263455-dquztf5l	129	4	in	in	IN
cord-263455-dquztf5l	129	5	immunocompromised	immunocompromised	JJ
cord-263455-dquztf5l	129	6	persons	person	NNS
cord-263455-dquztf5l	129	7	and	and	CC
cord-263455-dquztf5l	129	8	pregnant	pregnant	JJ
cord-263455-dquztf5l	129	9	women	woman	NNS
cord-263455-dquztf5l	129	10	.	.	.
cord-263455-dquztf5l	130	1	29	29	CD
cord-263455-dquztf5l	130	2	About	about	IN
cord-263455-dquztf5l	130	3	95	95	CD
cord-263455-dquztf5l	130	4	%	%	NN
cord-263455-dquztf5l	130	5	of	of	IN
cord-263455-dquztf5l	130	6	the	the	DT
cord-263455-dquztf5l	130	7	people	people	NNS
cord-263455-dquztf5l	130	8	who	who	WP
cord-263455-dquztf5l	130	9	receive	receive	VBP
cord-263455-dquztf5l	130	10	the	the	DT
cord-263455-dquztf5l	130	11	BCG	BCG	NNP
cord-263455-dquztf5l	130	12	vaccine	vaccine	NN
cord-263455-dquztf5l	130	13	experience	experience	VB
cord-263455-dquztf5l	130	14	a	a	DT
cord-263455-dquztf5l	130	15	reaction	reaction	NN
cord-263455-dquztf5l	130	16	at	at	IN
cord-263455-dquztf5l	130	17	the	the	DT
cord-263455-dquztf5l	130	18	injection	injection	NN
cord-263455-dquztf5l	130	19	site	site	NN
cord-263455-dquztf5l	130	20	,	,	,
cord-263455-dquztf5l	130	21	often	often	RB
cord-263455-dquztf5l	130	22	leaving	leave	VBG
cord-263455-dquztf5l	130	23	a	a	DT
cord-263455-dquztf5l	130	24	superficial	superficial	JJ
cord-263455-dquztf5l	130	25	scar	scar	NN
cord-263455-dquztf5l	130	26	.	.	.
cord-263455-dquztf5l	131	1	29	29	CD
cord-263455-dquztf5l	131	2	,	,	,
cord-263455-dquztf5l	131	3	34	34	CD
cord-263455-dquztf5l	132	1	The	the	DT
cord-263455-dquztf5l	132	2	protective	protective	JJ
cord-263455-dquztf5l	132	3	effect	effect	NN
cord-263455-dquztf5l	132	4	against	against	IN
cord-263455-dquztf5l	132	5	leprosy	leprosy	NN
cord-263455-dquztf5l	132	6	of	of	IN
cord-263455-dquztf5l	132	7	BCG	BCG	NNP
cord-263455-dquztf5l	132	8	,	,	,
cord-263455-dquztf5l	132	9	usually	usually	RB
cord-263455-dquztf5l	132	10	given	give	VBN
cord-263455-dquztf5l	132	11	as	as	IN
cord-263455-dquztf5l	132	12	primary	primary	JJ
cord-263455-dquztf5l	132	13	TB	TB	NNP
cord-263455-dquztf5l	132	14	prevention	prevention	NN
cord-263455-dquztf5l	132	15	to	to	IN
cord-263455-dquztf5l	132	16	newborns	newborn	NNS
cord-263455-dquztf5l	132	17	,	,	,
cord-263455-dquztf5l	132	18	varies	vary	VBZ
cord-263455-dquztf5l	132	19	widely	widely	RB
cord-263455-dquztf5l	132	20	in	in	IN
cord-263455-dquztf5l	132	21	different	different	JJ
cord-263455-dquztf5l	132	22	countries	country	NNS
cord-263455-dquztf5l	132	23	.	.	.
cord-263455-dquztf5l	133	1	[	[	-LRB-
cord-263455-dquztf5l	133	2	35	35	CD
cord-263455-dquztf5l	133	3	]	]	-RRB-
cord-263455-dquztf5l	133	4	[	[	-LRB-
cord-263455-dquztf5l	133	5	36	36	CD
cord-263455-dquztf5l	133	6	]	]	-RRB-
cord-263455-dquztf5l	134	1	[	[	-LRB-
cord-263455-dquztf5l	134	2	37	37	CD
cord-263455-dquztf5l	134	3	]	]	-RRB-
cord-263455-dquztf5l	135	1	Observational	observational	JJ
cord-263455-dquztf5l	135	2	studies	study	NNS
cord-263455-dquztf5l	135	3	demonstrated	demonstrate	VBD
cord-263455-dquztf5l	135	4	a	a	DT
cord-263455-dquztf5l	135	5	larger	large	JJR
cord-263455-dquztf5l	135	6	protective	protective	JJ
cord-263455-dquztf5l	135	7	effect	effect	NN
cord-263455-dquztf5l	135	8	against	against	IN
cord-263455-dquztf5l	135	9	leprosy	leprosy	NN
cord-263455-dquztf5l	135	10	,	,	,
cord-263455-dquztf5l	135	11	possibly	possibly	RB
cord-263455-dquztf5l	135	12	caused	cause	VBN
cord-263455-dquztf5l	135	13	by	by	IN
cord-263455-dquztf5l	135	14	the	the	DT
cord-263455-dquztf5l	135	15	shorter	short	JJR
cord-263455-dquztf5l	135	16	follow	follow	VB
cord-263455-dquztf5l	135	17	-	-	HYPH
cord-263455-dquztf5l	135	18	up	up	NN
cord-263455-dquztf5l	135	19	periods	period	NNS
cord-263455-dquztf5l	135	20	,	,	,
cord-263455-dquztf5l	135	21	compared	compare	VBN
cord-263455-dquztf5l	135	22	with	with	IN
cord-263455-dquztf5l	135	23	experimental	experimental	JJ
cord-263455-dquztf5l	135	24	trials	trial	NNS
cord-263455-dquztf5l	135	25	(	(	-LRB-
cord-263455-dquztf5l	135	26	60	60	CD
cord-263455-dquztf5l	135	27	%	%	NN
cord-263455-dquztf5l	135	28	versus	versus	IN
cord-263455-dquztf5l	135	29	41	41	CD
cord-263455-dquztf5l	135	30	%	%	NN
cord-263455-dquztf5l	135	31	)	)	-RRB-
cord-263455-dquztf5l	135	32	.	.	.
cord-263455-dquztf5l	136	1	37	37	CD
cord-263455-dquztf5l	136	2	Long	long	JJ
cord-263455-dquztf5l	136	3	follow	follow	NN
cord-263455-dquztf5l	136	4	-	-	HYPH
cord-263455-dquztf5l	136	5	up	up	NN
cord-263455-dquztf5l	136	6	periods	period	NNS
cord-263455-dquztf5l	136	7	are	be	VBP
cord-263455-dquztf5l	136	8	needed	need	VBN
cord-263455-dquztf5l	136	9	because	because	IN
cord-263455-dquztf5l	136	10	of	of	IN
cord-263455-dquztf5l	136	11	the	the	DT
cord-263455-dquztf5l	136	12	long	long	JJ
cord-263455-dquztf5l	136	13	incubation	incubation	NN
cord-263455-dquztf5l	136	14	period	period	NN
cord-263455-dquztf5l	136	15	of	of	IN
cord-263455-dquztf5l	136	16	leprosy	leprosy	NN
cord-263455-dquztf5l	136	17	.	.	.
cord-263455-dquztf5l	137	1	The	the	DT
cord-263455-dquztf5l	137	2	meta	meta	JJ
cord-263455-dquztf5l	137	3	-	-	HYPH
cord-263455-dquztf5l	137	4	analysis	analysis	NN
cord-263455-dquztf5l	137	5	of	of	IN
cord-263455-dquztf5l	137	6	Merle	Merle	NNP
cord-263455-dquztf5l	137	7	et	et	NNP
cord-263455-dquztf5l	137	8	al	al	NNP
cord-263455-dquztf5l	137	9	in	in	IN
cord-263455-dquztf5l	137	10	2010	2010	CD
cord-263455-dquztf5l	137	11	stated	state	VBD
cord-263455-dquztf5l	137	12	that	that	IN
cord-263455-dquztf5l	137	13	primary	primary	JJ
cord-263455-dquztf5l	137	14	BCG	BCG	NNP
cord-263455-dquztf5l	137	15	vaccination	vaccination	NN
cord-263455-dquztf5l	137	16	in	in	IN
cord-263455-dquztf5l	137	17	newborns	newborn	NNS
cord-263455-dquztf5l	137	18	is	be	VBZ
cord-263455-dquztf5l	137	19	effective	effective	JJ
cord-263455-dquztf5l	137	20	in	in	IN
cord-263455-dquztf5l	137	21	reducing	reduce	VBG
cord-263455-dquztf5l	137	22	the	the	DT
cord-263455-dquztf5l	137	23	risk	risk	NN
cord-263455-dquztf5l	137	24	of	of	IN
cord-263455-dquztf5l	137	25	leprosy	leprosy	NN
cord-263455-dquztf5l	137	26	by	by	IN
cord-263455-dquztf5l	137	27	55	55	CD
cord-263455-dquztf5l	137	28	%	%	NN
cord-263455-dquztf5l	137	29	(	(	-LRB-
cord-263455-dquztf5l	137	30	95	95	CD
cord-263455-dquztf5l	137	31	%	%	NN
cord-263455-dquztf5l	137	32	CI	CI	NNP
cord-263455-dquztf5l	137	33	.	.	.
cord-263455-dquztf5l	138	1	The	the	DT
cord-263455-dquztf5l	138	2	over	over	RB
cord-263455-dquztf5l	138	3	-	-	HYPH
cord-263455-dquztf5l	138	4	all	all	DT
cord-263455-dquztf5l	138	5	protection	protection	NN
cord-263455-dquztf5l	138	6	of	of	IN
cord-263455-dquztf5l	138	7	BCG	BCG	NNP
cord-263455-dquztf5l	138	8	vaccination	vaccination	NN
cord-263455-dquztf5l	138	9	against	against	IN
cord-263455-dquztf5l	138	10	leprosy	leprosy	NN
cord-263455-dquztf5l	138	11	in	in	IN
cord-263455-dquztf5l	138	12	this	this	DT
cord-263455-dquztf5l	138	13	analysis	analysis	NN
cord-263455-dquztf5l	138	14	ranged	range	VBD
cord-263455-dquztf5l	138	15	from	from	IN
cord-263455-dquztf5l	138	16	20	20	CD
cord-263455-dquztf5l	138	17	%	%	NN
cord-263455-dquztf5l	138	18	to	to	TO
cord-263455-dquztf5l	138	19	90	90	CD
cord-263455-dquztf5l	138	20	%	%	NN
cord-263455-dquztf5l	138	21	.	.	.
cord-263455-dquztf5l	139	1	37	37	CD
cord-263455-dquztf5l	139	2	Similarly	similarly	RB
cord-263455-dquztf5l	139	3	to	to	IN
cord-263455-dquztf5l	139	4	TB	TB	NNP
cord-263455-dquztf5l	139	5	,	,	,
cord-263455-dquztf5l	139	6	the	the	DT
cord-263455-dquztf5l	139	7	protection	protection	NN
cord-263455-dquztf5l	139	8	by	by	IN
cord-263455-dquztf5l	139	9	BCG	BCG	NNP
cord-263455-dquztf5l	139	10	against	against	IN
cord-263455-dquztf5l	139	11	leprosy	leprosy	NN
cord-263455-dquztf5l	139	12	is	be	VBZ
cord-263455-dquztf5l	139	13	most	most	RBS
cord-263455-dquztf5l	139	14	evident	evident	JJ
cord-263455-dquztf5l	139	15	in	in	IN
cord-263455-dquztf5l	139	16	children	child	NNS
cord-263455-dquztf5l	139	17	.	.	.
cord-263455-dquztf5l	140	1	38	38	CD
cord-263455-dquztf5l	140	2	,	,	,
cord-263455-dquztf5l	140	3	39	39	CD
cord-263455-dquztf5l	140	4	WHO	who	WP
cord-263455-dquztf5l	140	5	's	be	VBZ
cord-263455-dquztf5l	140	6	Guidelines	guideline	NNS
cord-263455-dquztf5l	140	7	for	for	IN
cord-263455-dquztf5l	140	8	the	the	DT
cord-263455-dquztf5l	140	9	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	140	10	,	,	,
cord-263455-dquztf5l	140	11	Treatment	Treatment	NNP
cord-263455-dquztf5l	140	12	and	and	CC
cord-263455-dquztf5l	140	13	Prevention	Prevention	NNP
cord-263455-dquztf5l	140	14	state	state	NN
cord-263455-dquztf5l	140	15	that	that	IN
cord-263455-dquztf5l	140	16	BCG	BCG	NNP
cord-263455-dquztf5l	140	17	at	at	IN
cord-263455-dquztf5l	140	18	birth	birth	NN
cord-263455-dquztf5l	140	19	should	should	MD
cord-263455-dquztf5l	140	20	therefore	therefore	RB
cord-263455-dquztf5l	140	21	be	be	VB
cord-263455-dquztf5l	140	22	maintained	maintain	VBN
cord-263455-dquztf5l	140	23	in	in	IN
cord-263455-dquztf5l	140	24	at	at	IN
cord-263455-dquztf5l	140	25	least	least	JJS
cord-263455-dquztf5l	140	26	all	all	DT
cord-263455-dquztf5l	140	27	leprosy	leprosy	NN
cord-263455-dquztf5l	140	28	high	high	JJ
cord-263455-dquztf5l	140	29	-	-	HYPH
cord-263455-dquztf5l	140	30	burden	burden	NN
cord-263455-dquztf5l	140	31	regions	region	NNS
cord-263455-dquztf5l	140	32	.	.	.
cord-263455-dquztf5l	141	1	7	7	CD
cord-263455-dquztf5l	142	1	The	the	DT
cord-263455-dquztf5l	142	2	heterogeneity	heterogeneity	NN
cord-263455-dquztf5l	142	3	in	in	IN
cord-263455-dquztf5l	142	4	the	the	DT
cord-263455-dquztf5l	142	5	protective	protective	JJ
cord-263455-dquztf5l	142	6	effect	effect	NN
cord-263455-dquztf5l	142	7	is	be	VBZ
cord-263455-dquztf5l	142	8	thought	think	VBN
cord-263455-dquztf5l	142	9	to	to	TO
cord-263455-dquztf5l	142	10	have	have	VB
cord-263455-dquztf5l	142	11	multiple	multiple	JJ
cord-263455-dquztf5l	142	12	causes	cause	NNS
cord-263455-dquztf5l	142	13	,	,	,
cord-263455-dquztf5l	142	14	including	include	VBG
cord-263455-dquztf5l	142	15	the	the	DT
cord-263455-dquztf5l	142	16	use	use	NN
cord-263455-dquztf5l	142	17	of	of	IN
cord-263455-dquztf5l	142	18	different	different	JJ
cord-263455-dquztf5l	142	19	BCG	BCG	NNP
cord-263455-dquztf5l	142	20	vaccine	vaccine	NN
cord-263455-dquztf5l	142	21	strains	strain	NNS
cord-263455-dquztf5l	142	22	and	and	CC
cord-263455-dquztf5l	142	23	batches	batch	NNS
cord-263455-dquztf5l	142	24	;	;	,
cord-263455-dquztf5l	142	25	varying	vary	VBG
cord-263455-dquztf5l	142	26	study	study	NN
cord-263455-dquztf5l	142	27	populations	population	NNS
cord-263455-dquztf5l	142	28	(	(	-LRB-
cord-263455-dquztf5l	142	29	eg	eg	IN
cord-263455-dquztf5l	142	30	,	,	,
cord-263455-dquztf5l	142	31	immunogenic	immunogenic	JJ
cord-263455-dquztf5l	142	32	characteristics	characteristic	NNS
cord-263455-dquztf5l	142	33	,	,	,
cord-263455-dquztf5l	142	34	age	age	NN
cord-263455-dquztf5l	142	35	groups	group	NNS
cord-263455-dquztf5l	142	36	)	)	-RRB-
cord-263455-dquztf5l	142	37	;	;	:
cord-263455-dquztf5l	142	38	different	different	JJ
cord-263455-dquztf5l	142	39	time	time	NN
cord-263455-dquztf5l	142	40	periods	period	NNS
cord-263455-dquztf5l	142	41	and	and	CC
cord-263455-dquztf5l	142	42	follow	follow	VB
cord-263455-dquztf5l	142	43	-	-	HYPH
cord-263455-dquztf5l	142	44	up	up	NN
cord-263455-dquztf5l	142	45	schedules	schedule	NNS
cord-263455-dquztf5l	142	46	;	;	,
cord-263455-dquztf5l	142	47	varying	vary	VBG
cord-263455-dquztf5l	142	48	geographical	geographical	JJ
cord-263455-dquztf5l	142	49	settings	setting	NNS
cord-263455-dquztf5l	142	50	regarding	regard	VBG
cord-263455-dquztf5l	142	51	environmental	environmental	JJ
cord-263455-dquztf5l	142	52	mycobacteria	mycobacterium	NNS
cord-263455-dquztf5l	142	53	variations	variation	NNS
cord-263455-dquztf5l	142	54	and	and	CC
cord-263455-dquztf5l	142	55	M.	M.	NNP
cord-263455-dquztf5l	142	56	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	142	57	;	;	:
cord-263455-dquztf5l	142	58	differences	difference	NNS
cord-263455-dquztf5l	142	59	in	in	IN
cord-263455-dquztf5l	142	60	leprosy	leprosy	NN
cord-263455-dquztf5l	142	61	burden	burden	NN
cord-263455-dquztf5l	142	62	;	;	:
cord-263455-dquztf5l	142	63	variations	variation	NNS
cord-263455-dquztf5l	142	64	in	in	IN
cord-263455-dquztf5l	142	65	clinical	clinical	JJ
cord-263455-dquztf5l	142	66	experience	experience	NN
cord-263455-dquztf5l	142	67	of	of	IN
cord-263455-dquztf5l	142	68	health	health	NN
cord-263455-dquztf5l	142	69	staff	staff	NN
cord-263455-dquztf5l	142	70	;	;	:
cord-263455-dquztf5l	142	71	and	and	CC
cord-263455-dquztf5l	142	72	discrepancies	discrepancy	NNS
cord-263455-dquztf5l	142	73	in	in	IN
cord-263455-dquztf5l	142	74	study	study	NN
cord-263455-dquztf5l	142	75	methodology	methodology	NN
cord-263455-dquztf5l	142	76	.	.	.
cord-263455-dquztf5l	143	1	23	23	CD
cord-263455-dquztf5l	143	2	,	,	,
cord-263455-dquztf5l	143	3	29	29	CD
cord-263455-dquztf5l	143	4	,	,	,
cord-263455-dquztf5l	143	5	35	35	CD
cord-263455-dquztf5l	143	6	,	,	,
cord-263455-dquztf5l	143	7	37	37	CD
cord-263455-dquztf5l	143	8	,	,	,
cord-263455-dquztf5l	143	9	38	38	CD
cord-263455-dquztf5l	143	10	,	,	,
cord-263455-dquztf5l	143	11	[	[	-LRB-
cord-263455-dquztf5l	143	12	40	40	CD
cord-263455-dquztf5l	143	13	]	]	-RRB-
cord-263455-dquztf5l	143	14	[	[	-LRB-
cord-263455-dquztf5l	143	15	41	41	CD
cord-263455-dquztf5l	143	16	]	]	-RRB-
cord-263455-dquztf5l	144	1	[	[	-LRB-
cord-263455-dquztf5l	144	2	42	42	CD
cord-263455-dquztf5l	144	3	]	]	-RRB-
cord-263455-dquztf5l	144	4	[	[	-LRB-
cord-263455-dquztf5l	144	5	43	43	CD
cord-263455-dquztf5l	144	6	]	]	-RRB-
cord-263455-dquztf5l	145	1	Additionally	additionally	RB
cord-263455-dquztf5l	145	2	,	,	,
cord-263455-dquztf5l	145	3	the	the	DT
cord-263455-dquztf5l	145	4	protective	protective	JJ
cord-263455-dquztf5l	145	5	effect	effect	NN
cord-263455-dquztf5l	145	6	of	of	IN
cord-263455-dquztf5l	145	7	BCG	BCG	NNP
cord-263455-dquztf5l	145	8	in	in	IN
cord-263455-dquztf5l	145	9	leprosy	leprosy	NN
cord-263455-dquztf5l	145	10	may	may	MD
cord-263455-dquztf5l	145	11	decrease	decrease	VB
cord-263455-dquztf5l	145	12	over	over	IN
cord-263455-dquztf5l	145	13	time	time	NN
cord-263455-dquztf5l	145	14	.	.	.
cord-263455-dquztf5l	146	1	40	40	CD
cord-263455-dquztf5l	147	1	When	when	WRB
cord-263455-dquztf5l	147	2	focusing	focus	VBG
cord-263455-dquztf5l	147	3	on	on	IN
cord-263455-dquztf5l	147	4	BCG	BCG	NNP
cord-263455-dquztf5l	147	5	as	as	IN
cord-263455-dquztf5l	147	6	a	a	DT
cord-263455-dquztf5l	147	7	post	post	JJ
cord-263455-dquztf5l	147	8	-	-	JJ
cord-263455-dquztf5l	147	9	exposure	exposure	JJ
cord-263455-dquztf5l	147	10	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	147	11	agent	agent	NN
cord-263455-dquztf5l	147	12	for	for	IN
cord-263455-dquztf5l	147	13	leprosy	leprosy	NN
cord-263455-dquztf5l	147	14	contacts	contact	NNS
cord-263455-dquztf5l	147	15	,	,	,
cord-263455-dquztf5l	147	16	the	the	DT
cord-263455-dquztf5l	147	17	number	number	NN
cord-263455-dquztf5l	147	18	of	of	IN
cord-263455-dquztf5l	147	19	studies	study	NNS
cord-263455-dquztf5l	147	20	is	be	VBZ
cord-263455-dquztf5l	147	21	relatively	relatively	RB
cord-263455-dquztf5l	147	22	limited	limited	JJ
cord-263455-dquztf5l	147	23	.	.	.
cord-263455-dquztf5l	148	1	37	37	CD
cord-263455-dquztf5l	148	2	,	,	,
cord-263455-dquztf5l	148	3	[	[	-LRB-
cord-263455-dquztf5l	148	4	43	43	CD
cord-263455-dquztf5l	148	5	]	]	-RRB-
cord-263455-dquztf5l	148	6	[	[	-LRB-
cord-263455-dquztf5l	148	7	44	44	CD
cord-263455-dquztf5l	148	8	]	]	-RRB-
cord-263455-dquztf5l	148	9	[	[	-LRB-
cord-263455-dquztf5l	148	10	45	45	CD
cord-263455-dquztf5l	148	11	]	]	-RRB-
cord-263455-dquztf5l	149	1	[	[	-LRB-
cord-263455-dquztf5l	149	2	46	46	CD
cord-263455-dquztf5l	149	3	]	]	-RRB-
cord-263455-dquztf5l	150	1	[	[	-LRB-
cord-263455-dquztf5l	150	2	47	47	CD
cord-263455-dquztf5l	150	3	]	]	-RRB-
cord-263455-dquztf5l	151	1	[	[	-LRB-
cord-263455-dquztf5l	151	2	48	48	CD
cord-263455-dquztf5l	151	3	]	]	-RRB-
cord-263455-dquztf5l	152	1	In	in	IN
cord-263455-dquztf5l	152	2	1981	1981	CD
cord-263455-dquztf5l	152	3	,	,	,
cord-263455-dquztf5l	152	4	Stanley	Stanley	NNP
cord-263455-dquztf5l	152	5	et	et	NNP
cord-263455-dquztf5l	152	6	al	al	NNP
cord-263455-dquztf5l	152	7	described	describe	VBD
cord-263455-dquztf5l	152	8	a	a	DT
cord-263455-dquztf5l	152	9	randomized	randomized	JJ
cord-263455-dquztf5l	152	10	controlled	control	VBN
cord-263455-dquztf5l	152	11	trial	trial	NN
cord-263455-dquztf5l	152	12	in	in	IN
cord-263455-dquztf5l	152	13	which	which	WDT
cord-263455-dquztf5l	152	14	16,150	16,150	CD
cord-263455-dquztf5l	152	15	Ugandan	ugandan	JJ
cord-263455-dquztf5l	152	16	children	child	NNS
cord-263455-dquztf5l	152	17	,	,	,
cord-263455-dquztf5l	152	18	who	who	WP
cord-263455-dquztf5l	152	19	were	be	VBD
cord-263455-dquztf5l	152	20	contacts	contact	NNS
cord-263455-dquztf5l	152	21	of	of	IN
cord-263455-dquztf5l	152	22	leprosy	leprosy	NN
cord-263455-dquztf5l	152	23	patients	patient	NNS
cord-263455-dquztf5l	152	24	,	,	,
cord-263455-dquztf5l	152	25	were	be	VBD
cord-263455-dquztf5l	152	26	included	include	VBN
cord-263455-dquztf5l	152	27	between	between	IN
cord-263455-dquztf5l	152	28	1960	1960	CD
cord-263455-dquztf5l	152	29	and	and	CC
cord-263455-dquztf5l	152	30	1964	1964	CD
cord-263455-dquztf5l	152	31	(	(	-LRB-
cord-263455-dquztf5l	152	32	Table	table	NN
cord-263455-dquztf5l	152	33	2	2	CD
cord-263455-dquztf5l	152	34	)	)	-RRB-
cord-263455-dquztf5l	152	35	.	.	.
cord-263455-dquztf5l	153	1	47	47	CD
cord-263455-dquztf5l	154	1	The	the	DT
cord-263455-dquztf5l	154	2	children	child	NNS
cord-263455-dquztf5l	154	3	did	do	VBD
cord-263455-dquztf5l	154	4	not	not	RB
cord-263455-dquztf5l	154	5	show	show	VB
cord-263455-dquztf5l	154	6	clinical	clinical	JJ
cord-263455-dquztf5l	154	7	symptoms	symptom	NNS
cord-263455-dquztf5l	154	8	and	and	CC
cord-263455-dquztf5l	154	9	scored	score	VBD
cord-263455-dquztf5l	154	10	negative	negative	JJ
cord-263455-dquztf5l	154	11	or	or	CC
cord-263455-dquztf5l	154	12	weakly	weakly	RB
cord-263455-dquztf5l	154	13	positive	positive	JJ
cord-263455-dquztf5l	154	14	at	at	IN
cord-263455-dquztf5l	154	15	the	the	DT
cord-263455-dquztf5l	154	16	tuberculin	tuberculin	NN
cord-263455-dquztf5l	154	17	test	test	NN
cord-263455-dquztf5l	154	18	.	.	.
cord-263455-dquztf5l	155	1	One	one	CD
cord-263455-dquztf5l	155	2	group	group	NN
cord-263455-dquztf5l	155	3	received	receive	VBD
cord-263455-dquztf5l	155	4	BCG	BCG	NNP
cord-263455-dquztf5l	155	5	vaccination	vaccination	NN
cord-263455-dquztf5l	155	6	;	;	:
cord-263455-dquztf5l	155	7	the	the	DT
cord-263455-dquztf5l	155	8	control	control	NN
cord-263455-dquztf5l	155	9	group	group	NN
cord-263455-dquztf5l	155	10	was	be	VBD
cord-263455-dquztf5l	155	11	not	not	RB
cord-263455-dquztf5l	155	12	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	155	13	.	.	.
cord-263455-dquztf5l	156	1	The	the	DT
cord-263455-dquztf5l	156	2	children	child	NNS
cord-263455-dquztf5l	156	3	were	be	VBD
cord-263455-dquztf5l	156	4	monitored	monitor	VBN
cord-263455-dquztf5l	156	5	for	for	IN
cord-263455-dquztf5l	156	6	up	up	IN
cord-263455-dquztf5l	156	7	to	to	TO
cord-263455-dquztf5l	156	8	four	four	CD
cord-263455-dquztf5l	156	9	times	time	NNS
cord-263455-dquztf5l	156	10	,	,	,
cord-263455-dquztf5l	156	11	over	over	IN
cord-263455-dquztf5l	156	12	an	an	DT
cord-263455-dquztf5l	156	13	average	average	JJ
cord-263455-dquztf5l	156	14	period	period	NN
cord-263455-dquztf5l	156	15	of	of	IN
cord-263455-dquztf5l	156	16	eight	eight	CD
cord-263455-dquztf5l	156	17	years	year	NNS
cord-263455-dquztf5l	156	18	.	.	.
cord-263455-dquztf5l	157	1	In	in	IN
cord-263455-dquztf5l	157	2	the	the	DT
cord-263455-dquztf5l	157	3	BCG	BCG	NNP
cord-263455-dquztf5l	157	4	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	157	5	group	group	NN
cord-263455-dquztf5l	157	6	,	,	,
cord-263455-dquztf5l	157	7	41	41	CD
cord-263455-dquztf5l	157	8	children	child	NNS
cord-263455-dquztf5l	157	9	developed	develop	VBD
cord-263455-dquztf5l	157	10	leprosy	leprosy	NN
cord-263455-dquztf5l	157	11	;	;	:
cord-263455-dquztf5l	157	12	in	in	IN
cord-263455-dquztf5l	157	13	the	the	DT
cord-263455-dquztf5l	157	14	control	control	NN
cord-263455-dquztf5l	157	15	group	group	NN
cord-263455-dquztf5l	157	16	,	,	,
cord-263455-dquztf5l	157	17	201	201	CD
cord-263455-dquztf5l	157	18	developed	develop	VBD
cord-263455-dquztf5l	157	19	the	the	DT
cord-263455-dquztf5l	157	20	disease	disease	NN
cord-263455-dquztf5l	157	21	.	.	.
cord-263455-dquztf5l	158	1	The	the	DT
cord-263455-dquztf5l	158	2	protective	protective	JJ
cord-263455-dquztf5l	158	3	effect	effect	NN
cord-263455-dquztf5l	158	4	against	against	IN
cord-263455-dquztf5l	158	5	leprosy	leprosy	NN
cord-263455-dquztf5l	158	6	was	be	VBD
cord-263455-dquztf5l	158	7	80	80	CD
cord-263455-dquztf5l	158	8	%	%	NN
cord-263455-dquztf5l	158	9	(	(	-LRB-
cord-263455-dquztf5l	158	10	95	95	CD
cord-263455-dquztf5l	158	11	%	%	NN
cord-263455-dquztf5l	158	12	CI	CI	NNP
cord-263455-dquztf5l	158	13	72	72	CD
cord-263455-dquztf5l	158	14	-	-	SYM
cord-263455-dquztf5l	158	15	86	86	CD
cord-263455-dquztf5l	158	16	)	)	-RRB-
cord-263455-dquztf5l	158	17	and	and	CC
cord-263455-dquztf5l	158	18	did	do	VBD
cord-263455-dquztf5l	158	19	not	not	RB
cord-263455-dquztf5l	158	20	depend	depend	VB
cord-263455-dquztf5l	158	21	upon	upon	IN
cord-263455-dquztf5l	158	22	vaccination	vaccination	NN
cord-263455-dquztf5l	158	23	age	age	NN
cord-263455-dquztf5l	158	24	,	,	,
cord-263455-dquztf5l	158	25	gender	gender	NN
cord-263455-dquztf5l	158	26	,	,	,
cord-263455-dquztf5l	158	27	or	or	CC
cord-263455-dquztf5l	158	28	grades	grade	NNS
cord-263455-dquztf5l	158	29	of	of	IN
cord-263455-dquztf5l	158	30	physical	physical	JJ
cord-263455-dquztf5l	158	31	contact	contact	NN
cord-263455-dquztf5l	158	32	and	and	CC
cord-263455-dquztf5l	158	33	genetic	genetic	JJ
cord-263455-dquztf5l	158	34	relationship	relationship	NN
cord-263455-dquztf5l	158	35	with	with	IN
cord-263455-dquztf5l	158	36	a	a	DT
cord-263455-dquztf5l	158	37	patient	patient	NN
cord-263455-dquztf5l	158	38	.	.	.
cord-263455-dquztf5l	159	1	A	a	DT
cord-263455-dquztf5l	159	2	small	small	JJ
cord-263455-dquztf5l	159	3	decline	decline	NN
cord-263455-dquztf5l	159	4	in	in	IN
cord-263455-dquztf5l	159	5	protection	protection	NN
cord-263455-dquztf5l	159	6	seemed	seem	VBD
cord-263455-dquztf5l	159	7	to	to	TO
cord-263455-dquztf5l	159	8	appear	appear	VB
cord-263455-dquztf5l	159	9	at	at	IN
cord-263455-dquztf5l	159	10	eight	eight	CD
cord-263455-dquztf5l	159	11	years	year	NNS
cord-263455-dquztf5l	159	12	follow	follow	NN
cord-263455-dquztf5l	159	13	-	-	HYPH
cord-263455-dquztf5l	159	14	up	up	NN
cord-263455-dquztf5l	159	15	,	,	,
cord-263455-dquztf5l	159	16	with	with	IN
cord-263455-dquztf5l	159	17	a	a	DT
cord-263455-dquztf5l	159	18	leprosy	leprosy	NN
cord-263455-dquztf5l	159	19	incidence	incidence	NN
cord-263455-dquztf5l	159	20	reduction	reduction	NN
cord-263455-dquztf5l	159	21	of	of	IN
cord-263455-dquztf5l	159	22	64	64	CD
cord-263455-dquztf5l	159	23	%	%	NN
cord-263455-dquztf5l	159	24	.	.	.
cord-263455-dquztf5l	160	1	47	47	CD
cord-263455-dquztf5l	161	1	Lwin	Lwin	NNP
cord-263455-dquztf5l	161	2	et	et	NNP
cord-263455-dquztf5l	161	3	al	al	NNP
cord-263455-dquztf5l	161	4	published	publish	VBD
cord-263455-dquztf5l	161	5	a	a	DT
cord-263455-dquztf5l	161	6	randomized	randomized	JJ
cord-263455-dquztf5l	161	7	controlled	control	VBN
cord-263455-dquztf5l	161	8	trial	trial	NN
cord-263455-dquztf5l	161	9	performed	perform	VBN
cord-263455-dquztf5l	161	10	in	in	IN
cord-263455-dquztf5l	161	11	Myanmar	Myanmar	NNP
cord-263455-dquztf5l	161	12	(	(	-LRB-
cord-263455-dquztf5l	161	13	Burma	Burma	NNP
cord-263455-dquztf5l	161	14	)	)	-RRB-
cord-263455-dquztf5l	161	15	in	in	IN
cord-263455-dquztf5l	161	16	1985	1985	CD
cord-263455-dquztf5l	161	17	(	(	-LRB-
cord-263455-dquztf5l	161	18	Table	table	NN
cord-263455-dquztf5l	161	19	2	2	CD
cord-263455-dquztf5l	161	20	)	)	-RRB-
cord-263455-dquztf5l	161	21	.	.	.
cord-263455-dquztf5l	162	1	43	43	CD
cord-263455-dquztf5l	163	1	A	a	DT
cord-263455-dquztf5l	163	2	group	group	NN
cord-263455-dquztf5l	163	3	of	of	IN
cord-263455-dquztf5l	163	4	13,066	13,066	CD
cord-263455-dquztf5l	163	5	children	child	NNS
cord-263455-dquztf5l	163	6	aged	age	VBN
cord-263455-dquztf5l	163	7	0	0	CD
cord-263455-dquztf5l	163	8	-	-	SYM
cord-263455-dquztf5l	163	9	14	14	CD
cord-263455-dquztf5l	163	10	years	year	NNS
cord-263455-dquztf5l	163	11	received	receive	VBD
cord-263455-dquztf5l	163	12	BCG	BCG	NNP
cord-263455-dquztf5l	163	13	;	;	:
cord-263455-dquztf5l	163	14	1,531	1,531	CD
cord-263455-dquztf5l	163	15	(	(	-LRB-
cord-263455-dquztf5l	163	16	11.7	11.7	CD
cord-263455-dquztf5l	163	17	%	%	NN
cord-263455-dquztf5l	163	18	)	)	-RRB-
cord-263455-dquztf5l	163	19	of	of	IN
cord-263455-dquztf5l	163	20	these	these	DT
cord-263455-dquztf5l	163	21	children	child	NNS
cord-263455-dquztf5l	163	22	were	be	VBD
cord-263455-dquztf5l	163	23	household	household	NN
cord-263455-dquztf5l	163	24	contacts	contact	NNS
cord-263455-dquztf5l	163	25	of	of	IN
cord-263455-dquztf5l	163	26	leprosy	leprosy	NN
cord-263455-dquztf5l	163	27	patients	patient	NNS
cord-263455-dquztf5l	163	28	.	.	.
cord-263455-dquztf5l	164	1	The	the	DT
cord-263455-dquztf5l	164	2	control	control	NN
cord-263455-dquztf5l	164	3	group	group	NN
cord-263455-dquztf5l	164	4	counted	count	VBD
cord-263455-dquztf5l	164	5	13,176	13,176	CD
cord-263455-dquztf5l	164	6	children	child	NNS
cord-263455-dquztf5l	164	7	,	,	,
cord-263455-dquztf5l	164	8	including	include	VBG
cord-263455-dquztf5l	164	9	1,493	1,493	CD
cord-263455-dquztf5l	164	10	(	(	-LRB-
cord-263455-dquztf5l	164	11	11.3	11.3	CD
cord-263455-dquztf5l	164	12	%	%	NN
cord-263455-dquztf5l	164	13	)	)	-RRB-
cord-263455-dquztf5l	164	14	household	household	NN
cord-263455-dquztf5l	164	15	contacts	contact	NNS
cord-263455-dquztf5l	164	16	.	.	.
cord-263455-dquztf5l	165	1	The	the	DT
cord-263455-dquztf5l	165	2	inclusion	inclusion	NN
cord-263455-dquztf5l	165	3	period	period	NN
cord-263455-dquztf5l	165	4	ranged	range	VBD
cord-263455-dquztf5l	165	5	from	from	IN
cord-263455-dquztf5l	165	6	1964	1964	CD
cord-263455-dquztf5l	165	7	to	to	IN
cord-263455-dquztf5l	165	8	1968	1968	CD
cord-263455-dquztf5l	165	9	.	.	.
cord-263455-dquztf5l	166	1	Annual	annual	JJ
cord-263455-dquztf5l	166	2	follow	follow	NN
cord-263455-dquztf5l	166	3	-	-	HYPH
cord-263455-dquztf5l	166	4	up	up	RP
cord-263455-dquztf5l	166	5	assessments	assessment	NNS
cord-263455-dquztf5l	166	6	were	be	VBD
cord-263455-dquztf5l	166	7	performed	perform	VBN
cord-263455-dquztf5l	166	8	until	until	IN
cord-263455-dquztf5l	166	9	1978	1978	CD
cord-263455-dquztf5l	166	10	-	-	SYM
cord-263455-dquztf5l	166	11	1979	1979	CD
cord-263455-dquztf5l	166	12	.	.	.
cord-263455-dquztf5l	167	1	The	the	DT
cord-263455-dquztf5l	167	2	overall	overall	JJ
cord-263455-dquztf5l	167	3	protective	protective	JJ
cord-263455-dquztf5l	167	4	effect	effect	NN
cord-263455-dquztf5l	167	5	of	of	IN
cord-263455-dquztf5l	167	6	BCG	BCG	NNP
cord-263455-dquztf5l	167	7	was	be	VBD
cord-263455-dquztf5l	167	8	20.4	20.4	CD
cord-263455-dquztf5l	167	9	%	%	NN
cord-263455-dquztf5l	167	10	(	(	-LRB-
cord-263455-dquztf5l	167	11	95	95	CD
cord-263455-dquztf5l	167	12	%	%	NN
cord-263455-dquztf5l	167	13	CI	CI	NNP
cord-263455-dquztf5l	167	14	12	12	CD
cord-263455-dquztf5l	167	15	-	-	SYM
cord-263455-dquztf5l	167	16	28	28	CD
cord-263455-dquztf5l	167	17	)	)	-RRB-
cord-263455-dquztf5l	167	18	.	.	.
cord-263455-dquztf5l	168	1	The	the	DT
cord-263455-dquztf5l	168	2	leprosy	leprosy	NN
cord-263455-dquztf5l	168	3	incidence	incidence	NN
cord-263455-dquztf5l	168	4	in	in	IN
cord-263455-dquztf5l	168	5	the	the	DT
cord-263455-dquztf5l	168	6	vaccinated	vaccinated	JJ
cord-263455-dquztf5l	168	7	group	group	NN
cord-263455-dquztf5l	168	8	was	be	VBD
cord-263455-dquztf5l	168	9	0.41	0.41	CD
cord-263455-dquztf5l	168	10	%	%	NN
cord-263455-dquztf5l	168	11	for	for	IN
cord-263455-dquztf5l	168	12	females	female	NNS
cord-263455-dquztf5l	168	13	and	and	CC
cord-263455-dquztf5l	168	14	0.46	0.46	CD
cord-263455-dquztf5l	168	15	%	%	NN
cord-263455-dquztf5l	168	16	for	for	IN
cord-263455-dquztf5l	168	17	males	male	NNS
cord-263455-dquztf5l	168	18	,	,	,
cord-263455-dquztf5l	168	19	compared	compare	VBN
cord-263455-dquztf5l	168	20	to	to	IN
cord-263455-dquztf5l	168	21	0.48	0.48	CD
cord-263455-dquztf5l	168	22	%	%	NN
cord-263455-dquztf5l	168	23	and	and	CC
cord-263455-dquztf5l	168	24	0.63	0.63	CD
cord-263455-dquztf5l	168	25	%	%	NN
cord-263455-dquztf5l	168	26	for	for	IN
cord-263455-dquztf5l	168	27	controls	control	NNS
cord-263455-dquztf5l	168	28	,	,	,
cord-263455-dquztf5l	168	29	respectively	respectively	RB
cord-263455-dquztf5l	168	30	.	.	.
cord-263455-dquztf5l	169	1	A	a	DT
cord-263455-dquztf5l	169	2	higher	high	JJR
cord-263455-dquztf5l	169	3	protective	protective	JJ
cord-263455-dquztf5l	169	4	effect	effect	NN
cord-263455-dquztf5l	169	5	was	be	VBD
cord-263455-dquztf5l	169	6	found	find	VBN
cord-263455-dquztf5l	169	7	in	in	IN
cord-263455-dquztf5l	169	8	younger	young	JJR
cord-263455-dquztf5l	169	9	children	child	NNS
cord-263455-dquztf5l	169	10	.	.	.
cord-263455-dquztf5l	170	1	BCG	BCG	NNP
cord-263455-dquztf5l	170	2	protection	protection	NN
cord-263455-dquztf5l	170	3	showed	show	VBD
cord-263455-dquztf5l	170	4	to	to	TO
cord-263455-dquztf5l	170	5	be	be	VB
cord-263455-dquztf5l	170	6	independent	independent	JJ
cord-263455-dquztf5l	170	7	of	of	IN
cord-263455-dquztf5l	170	8	the	the	DT
cord-263455-dquztf5l	170	9	initial	initial	JJ
cord-263455-dquztf5l	170	10	tuberculin	tuberculin	NN
cord-263455-dquztf5l	170	11	status	status	NN
cord-263455-dquztf5l	170	12	.	.	.
cord-263455-dquztf5l	171	1	A	a	DT
cord-263455-dquztf5l	171	2	protective	protective	JJ
cord-263455-dquztf5l	171	3	effect	effect	NN
cord-263455-dquztf5l	171	4	of	of	IN
cord-263455-dquztf5l	171	5	31.3	31.3	CD
cord-263455-dquztf5l	171	6	%	%	NN
cord-263455-dquztf5l	171	7	was	be	VBD
cord-263455-dquztf5l	171	8	seen	see	VBN
cord-263455-dquztf5l	171	9	in	in	IN
cord-263455-dquztf5l	171	10	contacts	contact	NNS
cord-263455-dquztf5l	171	11	of	of	IN
cord-263455-dquztf5l	171	12	lepromatous	lepromatous	JJ
cord-263455-dquztf5l	171	13	/	/	SYM
cord-263455-dquztf5l	171	14	borderline	borderline	JJ
cord-263455-dquztf5l	171	15	patients	patient	NNS
cord-263455-dquztf5l	171	16	,	,	,
cord-263455-dquztf5l	171	17	of	of	IN
cord-263455-dquztf5l	171	18	27.7	27.7	CD
cord-263455-dquztf5l	171	19	%	%	NN
cord-263455-dquztf5l	171	20	in	in	IN
cord-263455-dquztf5l	171	21	contacts	contact	NNS
cord-263455-dquztf5l	171	22	of	of	IN
cord-263455-dquztf5l	171	23	patients	patient	NNS
cord-263455-dquztf5l	171	24	with	with	IN
cord-263455-dquztf5l	171	25	other	other	JJ
cord-263455-dquztf5l	171	26	leprosy	leprosy	NN
cord-263455-dquztf5l	171	27	forms	form	NNS
cord-263455-dquztf5l	171	28	,	,	,
cord-263455-dquztf5l	171	29	and	and	CC
cord-263455-dquztf5l	171	30	of	of	IN
cord-263455-dquztf5l	171	31	18.7	18.7	CD
cord-263455-dquztf5l	171	32	%	%	NN
cord-263455-dquztf5l	171	33	among	among	IN
cord-263455-dquztf5l	171	34	non	non	JJ
cord-263455-dquztf5l	171	35	-	-	NNS
cord-263455-dquztf5l	171	36	contacts	contact	NNS
cord-263455-dquztf5l	171	37	.	.	.
cord-263455-dquztf5l	172	1	Weaknesses	weakness	NNS
cord-263455-dquztf5l	172	2	in	in	IN
cord-263455-dquztf5l	172	3	this	this	DT
cord-263455-dquztf5l	172	4	study	study	NN
cord-263455-dquztf5l	172	5	are	be	VBP
cord-263455-dquztf5l	172	6	that	that	IN
cord-263455-dquztf5l	172	7	two	two	CD
cord-263455-dquztf5l	172	8	strains	strain	NNS
cord-263455-dquztf5l	172	9	with	with	IN
cord-263455-dquztf5l	172	10	varying	vary	VBG
cord-263455-dquztf5l	172	11	bacillary	bacillary	NN
cord-263455-dquztf5l	172	12	count	count	NN
cord-263455-dquztf5l	172	13	were	be	VBD
cord-263455-dquztf5l	172	14	used	use	VBN
cord-263455-dquztf5l	172	15	,	,	,
cord-263455-dquztf5l	172	16	resulting	result	VBG
cord-263455-dquztf5l	172	17	in	in	IN
cord-263455-dquztf5l	172	18	varying	vary	VBG
cord-263455-dquztf5l	172	19	protection	protection	NN
cord-263455-dquztf5l	172	20	rates	rate	NNS
cord-263455-dquztf5l	172	21	.	.	.
cord-263455-dquztf5l	173	1	In	in	IN
cord-263455-dquztf5l	173	2	addition	addition	NN
cord-263455-dquztf5l	173	3	,	,	,
cord-263455-dquztf5l	173	4	the	the	DT
cord-263455-dquztf5l	173	5	described	describe	VBN
cord-263455-dquztf5l	173	6	total	total	JJ
cord-263455-dquztf5l	173	7	number	number	NN
cord-263455-dquztf5l	173	8	of	of	IN
cord-263455-dquztf5l	173	9	contacts	contact	NNS
cord-263455-dquztf5l	173	10	in	in	IN
cord-263455-dquztf5l	173	11	this	this	DT
cord-263455-dquztf5l	173	12	study	study	NN
cord-263455-dquztf5l	173	13	was	be	VBD
cord-263455-dquztf5l	173	14	relatively	relatively	RB
cord-263455-dquztf5l	173	15	low	low	JJ
cord-263455-dquztf5l	173	16	,	,	,
cord-263455-dquztf5l	173	17	and	and	CC
cord-263455-dquztf5l	173	18	the	the	DT
cord-263455-dquztf5l	173	19	number	number	NN
cord-263455-dquztf5l	173	20	of	of	IN
cord-263455-dquztf5l	173	21	follow	follow	VB
cord-263455-dquztf5l	173	22	-	-	HYPH
cord-263455-dquztf5l	173	23	up	up	NN
cord-263455-dquztf5l	173	24	moments	moment	NNS
cord-263455-dquztf5l	173	25	varied	varied	JJ
cord-263455-dquztf5l	173	26	(	(	-LRB-
cord-263455-dquztf5l	173	27	11	11	CD
cord-263455-dquztf5l	173	28	-	-	SYM
cord-263455-dquztf5l	173	29	14	14	CD
cord-263455-dquztf5l	173	30	times	time	NNS
cord-263455-dquztf5l	173	31	)	)	-RRB-
cord-263455-dquztf5l	173	32	.	.	.
cord-263455-dquztf5l	174	1	43	43	CD
cord-263455-dquztf5l	175	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	175	2	,	,	,
cord-263455-dquztf5l	175	3	non	non	JJ
cord-263455-dquztf5l	175	4	-	-	NNS
cord-263455-dquztf5l	175	5	contacts	contact	NNS
cord-263455-dquztf5l	175	6	may	may	MD
cord-263455-dquztf5l	175	7	have	have	VB
cord-263455-dquztf5l	175	8	become	become	VBN
cord-263455-dquztf5l	175	9	contacts	contact	NNS
cord-263455-dquztf5l	175	10	during	during	IN
cord-263455-dquztf5l	175	11	follow	follow	NN
cord-263455-dquztf5l	175	12	-	-	HYPH
cord-263455-dquztf5l	175	13	up	up	NN
cord-263455-dquztf5l	175	14	.	.	.
cord-263455-dquztf5l	176	1	In	in	IN
cord-263455-dquztf5l	176	2	Brazil	Brazil	NNP
cord-263455-dquztf5l	176	3	in	in	IN
cord-263455-dquztf5l	176	4	2008	2008	CD
cord-263455-dquztf5l	176	5	,	,	,
cord-263455-dquztf5l	176	6	Düppre	Düppre	NNP
cord-263455-dquztf5l	176	7	et	et	NNP
cord-263455-dquztf5l	176	8	al	al	NNP
cord-263455-dquztf5l	176	9	published	publish	VBD
cord-263455-dquztf5l	176	10	a	a	DT
cord-263455-dquztf5l	176	11	cohort	cohort	NN
cord-263455-dquztf5l	176	12	study	study	NN
cord-263455-dquztf5l	176	13	on	on	IN
cord-263455-dquztf5l	176	14	the	the	DT
cord-263455-dquztf5l	176	15	effectiveness	effectiveness	NN
cord-263455-dquztf5l	176	16	of	of	IN
cord-263455-dquztf5l	176	17	BCG	BCG	NNP
cord-263455-dquztf5l	176	18	vaccination	vaccination	NN
cord-263455-dquztf5l	176	19	among	among	IN
cord-263455-dquztf5l	176	20	contacts	contact	NNS
cord-263455-dquztf5l	176	21	of	of	IN
cord-263455-dquztf5l	176	22	1,161	1,161	CD
cord-263455-dquztf5l	176	23	leprosy	leprosy	NN
cord-263455-dquztf5l	176	24	patients	patient	NNS
cord-263455-dquztf5l	176	25	between	between	IN
cord-263455-dquztf5l	176	26	1987	1987	CD
cord-263455-dquztf5l	176	27	and	and	CC
cord-263455-dquztf5l	176	28	2006	2006	CD
cord-263455-dquztf5l	176	29	(	(	-LRB-
cord-263455-dquztf5l	176	30	Table	table	NN
cord-263455-dquztf5l	176	31	2	2	CD
cord-263455-dquztf5l	176	32	)	)	-RRB-
cord-263455-dquztf5l	176	33	.	.	.
cord-263455-dquztf5l	177	1	48	48	CD
cord-263455-dquztf5l	178	1	Of	of	IN
cord-263455-dquztf5l	178	2	the	the	DT
cord-263455-dquztf5l	178	3	3,536	3,536	CD
cord-263455-dquztf5l	178	4	leprosy	leprosy	NN
cord-263455-dquztf5l	178	5	patient	patient	NN
cord-263455-dquztf5l	178	6	contacts	contact	NNS
cord-263455-dquztf5l	178	7	who	who	WP
cord-263455-dquztf5l	178	8	received	receive	VBD
cord-263455-dquztf5l	178	9	BCG	BCG	NNP
cord-263455-dquztf5l	178	10	vaccination	vaccination	NN
cord-263455-dquztf5l	178	11	,	,	,
cord-263455-dquztf5l	178	12	2,337	2,337	CD
cord-263455-dquztf5l	178	13	people	people	NNS
cord-263455-dquztf5l	178	14	already	already	RB
cord-263455-dquztf5l	178	15	had	have	VBD
cord-263455-dquztf5l	178	16	a	a	DT
cord-263455-dquztf5l	178	17	BCG	BCG	NNP
cord-263455-dquztf5l	178	18	scar	scar	NN
cord-263455-dquztf5l	178	19	,	,	,
cord-263455-dquztf5l	178	20	suggesting	suggest	VBG
cord-263455-dquztf5l	178	21	previous	previous	JJ
cord-263455-dquztf5l	178	22	vaccination	vaccination	NN
cord-263455-dquztf5l	178	23	.	.	.
cord-263455-dquztf5l	179	1	The	the	DT
cord-263455-dquztf5l	179	2	unvaccinated	unvaccinated	JJ
cord-263455-dquztf5l	179	3	group	group	NN
cord-263455-dquztf5l	179	4	counted	count	VBD
cord-263455-dquztf5l	179	5	1,810	1,810	CD
cord-263455-dquztf5l	179	6	contacts	contact	NNS
cord-263455-dquztf5l	179	7	,	,	,
cord-263455-dquztf5l	179	8	of	of	IN
cord-263455-dquztf5l	179	9	whom	whom	WP
cord-263455-dquztf5l	179	10	1,087	1,087	CD
cord-263455-dquztf5l	179	11	already	already	RB
cord-263455-dquztf5l	179	12	had	have	VBD
cord-263455-dquztf5l	179	13	a	a	DT
cord-263455-dquztf5l	179	14	BCG	BCG	NNP
cord-263455-dquztf5l	179	15	scar	scar	NN
cord-263455-dquztf5l	179	16	.	.	.
cord-263455-dquztf5l	180	1	The	the	DT
cord-263455-dquztf5l	180	2	protection	protection	NN
cord-263455-dquztf5l	180	3	against	against	IN
cord-263455-dquztf5l	180	4	leprosy	leprosy	NN
cord-263455-dquztf5l	180	5	from	from	IN
cord-263455-dquztf5l	180	6	the	the	DT
cord-263455-dquztf5l	180	7	BCG	BCG	NNP
cord-263455-dquztf5l	180	8	post	post	JJ
cord-263455-dquztf5l	180	9	-	-	JJ
cord-263455-dquztf5l	180	10	exposure	exposure	JJ
cord-263455-dquztf5l	180	11	vaccination	vaccination	NN
cord-263455-dquztf5l	180	12	was	be	VBD
cord-263455-dquztf5l	180	13	found	find	VBN
cord-263455-dquztf5l	180	14	to	to	TO
cord-263455-dquztf5l	180	15	be	be	VB
cord-263455-dquztf5l	180	16	56	56	CD
cord-263455-dquztf5l	180	17	%	%	NN
cord-263455-dquztf5l	180	18	(	(	-LRB-
cord-263455-dquztf5l	180	19	95	95	CD
cord-263455-dquztf5l	180	20	%	%	NN
cord-263455-dquztf5l	180	21	CI	CI	NNP
cord-263455-dquztf5l	180	22	31	31	CD
cord-263455-dquztf5l	180	23	-	-	SYM
cord-263455-dquztf5l	180	24	71	71	CD
cord-263455-dquztf5l	180	25	)	)	-RRB-
cord-263455-dquztf5l	180	26	.	.	.
cord-263455-dquztf5l	181	1	For	for	IN
cord-263455-dquztf5l	181	2	those	those	DT
cord-263455-dquztf5l	181	3	without	without	IN
cord-263455-dquztf5l	181	4	a	a	DT
cord-263455-dquztf5l	181	5	primary	primary	JJ
cord-263455-dquztf5l	181	6	scar	scar	NN
cord-263455-dquztf5l	181	7	,	,	,
cord-263455-dquztf5l	181	8	protection	protection	NN
cord-263455-dquztf5l	181	9	reached	reach	VBD
cord-263455-dquztf5l	181	10	59	59	CD
cord-263455-dquztf5l	181	11	%	%	NN
cord-263455-dquztf5l	181	12	(	(	-LRB-
cord-263455-dquztf5l	181	13	95	95	CD
cord-263455-dquztf5l	181	14	%	%	NN
cord-263455-dquztf5l	181	15	CI	CI	NNP
cord-263455-dquztf5l	181	16	27	27	CD
cord-263455-dquztf5l	181	17	-	-	SYM
cord-263455-dquztf5l	181	18	77	77	CD
cord-263455-dquztf5l	181	19	)	)	-RRB-
cord-263455-dquztf5l	181	20	;	;	:
cord-263455-dquztf5l	181	21	for	for	IN
cord-263455-dquztf5l	181	22	those	those	DT
cord-263455-dquztf5l	181	23	with	with	IN
cord-263455-dquztf5l	181	24	a	a	DT
cord-263455-dquztf5l	181	25	primary	primary	JJ
cord-263455-dquztf5l	181	26	scar	scar	NN
cord-263455-dquztf5l	181	27	,	,	,
cord-263455-dquztf5l	181	28	protection	protection	NN
cord-263455-dquztf5l	181	29	was	be	VBD
cord-263455-dquztf5l	181	30	50	50	CD
cord-263455-dquztf5l	181	31	%	%	NN
cord-263455-dquztf5l	181	32	(	(	-LRB-
cord-263455-dquztf5l	181	33	95	95	CD
cord-263455-dquztf5l	181	34	%	%	NN
cord-263455-dquztf5l	181	35	CI	CI	NNP
cord-263455-dquztf5l	181	36	.	.	.
cord-263455-dquztf5l	182	1	It	-PRON-	PRP
cord-263455-dquztf5l	182	2	was	be	VBD
cord-263455-dquztf5l	182	3	stated	state	VBN
cord-263455-dquztf5l	182	4	that	that	IN
cord-263455-dquztf5l	182	5	BCG	BCG	NNP
cord-263455-dquztf5l	182	6	protection	protection	NN
cord-263455-dquztf5l	182	7	in	in	IN
cord-263455-dquztf5l	182	8	contacts	contact	NNS
cord-263455-dquztf5l	182	9	was	be	VBD
cord-263455-dquztf5l	182	10	not	not	RB
cord-263455-dquztf5l	182	11	substantially	substantially	RB
cord-263455-dquztf5l	182	12	affected	affect	VBN
cord-263455-dquztf5l	182	13	by	by	IN
cord-263455-dquztf5l	182	14	previous	previous	JJ
cord-263455-dquztf5l	182	15	BCG	BCG	NNP
cord-263455-dquztf5l	182	16	vaccination	vaccination	NN
cord-263455-dquztf5l	182	17	.	.	.
cord-263455-dquztf5l	183	1	The	the	DT
cord-263455-dquztf5l	183	2	study	study	NN
cord-263455-dquztf5l	183	3	strongly	strongly	RB
cord-263455-dquztf5l	183	4	supported	support	VBD
cord-263455-dquztf5l	183	5	the	the	DT
cord-263455-dquztf5l	183	6	routine	routine	JJ
cord-263455-dquztf5l	183	7	BCG	BCG	NNP
cord-263455-dquztf5l	183	8	vaccination	vaccination	NN
cord-263455-dquztf5l	183	9	of	of	IN
cord-263455-dquztf5l	183	10	leprosy	leprosy	NN
cord-263455-dquztf5l	183	11	contacts	contact	NNS
cord-263455-dquztf5l	183	12	regardless	regardless	RB
cord-263455-dquztf5l	183	13	of	of	IN
cord-263455-dquztf5l	183	14	previous	previous	JJ
cord-263455-dquztf5l	183	15	vaccination	vaccination	NN
cord-263455-dquztf5l	183	16	.	.	.
cord-263455-dquztf5l	184	1	Remarkably	remarkably	RB
cord-263455-dquztf5l	184	2	,	,	,
cord-263455-dquztf5l	184	3	during	during	IN
cord-263455-dquztf5l	184	4	the	the	DT
cord-263455-dquztf5l	184	5	first	first	JJ
cord-263455-dquztf5l	184	6	2	2	CD
cord-263455-dquztf5l	184	7	-	-	SYM
cord-263455-dquztf5l	184	8	10	10	CD
cord-263455-dquztf5l	184	9	months	month	NNS
cord-263455-dquztf5l	184	10	,	,	,
cord-263455-dquztf5l	184	11	28	28	CD
cord-263455-dquztf5l	184	12	new	new	JJ
cord-263455-dquztf5l	184	13	leprosy	leprosy	NN
cord-263455-dquztf5l	184	14	cases-21	cases-21	,
cord-263455-dquztf5l	184	15	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	184	16	(	(	-LRB-
cord-263455-dquztf5l	184	17	16	16	CD
cord-263455-dquztf5l	184	18	without	without	IN
cord-263455-dquztf5l	184	19	a	a	DT
cord-263455-dquztf5l	184	20	primary	primary	JJ
cord-263455-dquztf5l	184	21	BCG	BCG	NNP
cord-263455-dquztf5l	184	22	scar	scar	NN
cord-263455-dquztf5l	184	23	)	)	-RRB-
cord-263455-dquztf5l	184	24	and	and	CC
cord-263455-dquztf5l	184	25	seven	seven	CD
cord-263455-dquztf5l	184	26	unvaccinated	unvaccinated	JJ
cord-263455-dquztf5l	184	27	-	-	,
cord-263455-dquztf5l	184	28	were	be	VBD
cord-263455-dquztf5l	184	29	detected	detect	VBN
cord-263455-dquztf5l	184	30	.	.	.
cord-263455-dquztf5l	185	1	Tuberculoid	Tuberculoid	NNP
cord-263455-dquztf5l	185	2	forms	form	NNS
cord-263455-dquztf5l	185	3	predominated	predominate	VBD
cord-263455-dquztf5l	185	4	.	.	.
cord-263455-dquztf5l	186	1	Of	of	IN
cord-263455-dquztf5l	186	2	these	these	DT
cord-263455-dquztf5l	186	3	new	new	JJ
cord-263455-dquztf5l	186	4	cases	case	NNS
cord-263455-dquztf5l	186	5	,	,	,
cord-263455-dquztf5l	186	6	25	25	CD
cord-263455-dquztf5l	186	7	(	(	-LRB-
cord-263455-dquztf5l	186	8	90	90	CD
cord-263455-dquztf5l	186	9	%	%	NN
cord-263455-dquztf5l	186	10	)	)	-RRB-
cord-263455-dquztf5l	186	11	had	have	VBD
cord-263455-dquztf5l	186	12	a	a	DT
cord-263455-dquztf5l	186	13	multibacillary	multibacillary	JJ
cord-263455-dquztf5l	186	14	leprosy	leprosy	NN
cord-263455-dquztf5l	186	15	index	index	NN
cord-263455-dquztf5l	186	16	case	case	NN
cord-263455-dquztf5l	186	17	in	in	IN
cord-263455-dquztf5l	186	18	their	-PRON-	PRP$
cord-263455-dquztf5l	186	19	family	family	NN
cord-263455-dquztf5l	186	20	.	.	.
cord-263455-dquztf5l	187	1	However	however	RB
cord-263455-dquztf5l	187	2	,	,	,
cord-263455-dquztf5l	187	3	misclassification	misclassification	NN
cord-263455-dquztf5l	187	4	of	of	IN
cord-263455-dquztf5l	187	5	contact	contact	NN
cord-263455-dquztf5l	187	6	type	type	NN
cord-263455-dquztf5l	187	7	may	may	MD
cord-263455-dquztf5l	187	8	have	have	VB
cord-263455-dquztf5l	187	9	led	lead	VBN
cord-263455-dquztf5l	187	10	to	to	IN
cord-263455-dquztf5l	187	11	residual	residual	JJ
cord-263455-dquztf5l	187	12	confounding	confounding	NN
cord-263455-dquztf5l	187	13	.	.	.
cord-263455-dquztf5l	188	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	188	2	,	,	,
cord-263455-dquztf5l	188	3	this	this	DT
cord-263455-dquztf5l	188	4	study	study	NN
cord-263455-dquztf5l	188	5	stated	state	VBD
cord-263455-dquztf5l	188	6	that	that	IN
cord-263455-dquztf5l	188	7	no	no	DT
cord-263455-dquztf5l	188	8	solid	solid	JJ
cord-263455-dquztf5l	188	9	reason	reason	NN
cord-263455-dquztf5l	188	10	exists	exist	VBZ
cord-263455-dquztf5l	188	11	to	to	TO
cord-263455-dquztf5l	188	12	doubt	doubt	VB
cord-263455-dquztf5l	188	13	the	the	DT
cord-263455-dquztf5l	188	14	disease	disease	NN
cord-263455-dquztf5l	188	15	classification	classification	NN
cord-263455-dquztf5l	188	16	data	datum	NNS
cord-263455-dquztf5l	188	17	and	and	CC
cord-263455-dquztf5l	188	18	BCG	BCG	NNP
cord-263455-dquztf5l	188	19	exposure	exposure	NN
cord-263455-dquztf5l	188	20	,	,	,
cord-263455-dquztf5l	188	21	while	while	IN
cord-263455-dquztf5l	188	22	this	this	DT
cord-263455-dquztf5l	188	23	is	be	VBZ
cord-263455-dquztf5l	188	24	debatable	debatable	JJ
cord-263455-dquztf5l	188	25	when	when	WRB
cord-263455-dquztf5l	188	26	examining	examine	VBG
cord-263455-dquztf5l	188	27	other	other	JJ
cord-263455-dquztf5l	188	28	studies	study	NNS
cord-263455-dquztf5l	188	29	.	.	.
cord-263455-dquztf5l	189	1	29	29	CD
cord-263455-dquztf5l	189	2	,	,	,
cord-263455-dquztf5l	189	3	37	37	CD
cord-263455-dquztf5l	189	4	,	,	,
cord-263455-dquztf5l	189	5	48	48	CD
cord-263455-dquztf5l	190	1	Moreover	moreover	RB
cord-263455-dquztf5l	190	2	,	,	,
cord-263455-dquztf5l	190	3	this	this	DT
cord-263455-dquztf5l	190	4	study	study	NN
cord-263455-dquztf5l	190	5	assumed	assume	VBD
cord-263455-dquztf5l	190	6	that	that	IN
cord-263455-dquztf5l	190	7	the	the	DT
cord-263455-dquztf5l	190	8	contacts	contact	NNS
cord-263455-dquztf5l	190	9	who	who	WP
cord-263455-dquztf5l	190	10	did	do	VBD
cord-263455-dquztf5l	190	11	not	not	RB
cord-263455-dquztf5l	190	12	return	return	VB
cord-263455-dquztf5l	190	13	after	after	IN
cord-263455-dquztf5l	190	14	the	the	DT
cord-263455-dquztf5l	190	15	initial	initial	JJ
cord-263455-dquztf5l	190	16	examination	examination	NN
cord-263455-dquztf5l	190	17	were	be	VBD
cord-263455-dquztf5l	190	18	healthy	healthy	JJ
cord-263455-dquztf5l	190	19	,	,	,
cord-263455-dquztf5l	190	20	which	which	WDT
cord-263455-dquztf5l	190	21	may	may	MD
cord-263455-dquztf5l	190	22	not	not	RB
cord-263455-dquztf5l	190	23	always	always	RB
cord-263455-dquztf5l	190	24	have	have	VB
cord-263455-dquztf5l	190	25	been	be	VBN
cord-263455-dquztf5l	190	26	the	the	DT
cord-263455-dquztf5l	190	27	case	case	NN
cord-263455-dquztf5l	190	28	.	.	.
cord-263455-dquztf5l	191	1	48	48	CD
cord-263455-dquztf5l	192	1	Merle	Merle	NNP
cord-263455-dquztf5l	192	2	et	et	NNP
cord-263455-dquztf5l	192	3	al	al	NNP
cord-263455-dquztf5l	192	4	found	find	VBD
cord-263455-dquztf5l	192	5	that	that	IN
cord-263455-dquztf5l	192	6	BCG	BCG	NNP
cord-263455-dquztf5l	192	7	efficacy	efficacy	NN
cord-263455-dquztf5l	192	8	in	in	IN
cord-263455-dquztf5l	192	9	studies	study	NNS
cord-263455-dquztf5l	192	10	focusing	focus	VBG
cord-263455-dquztf5l	192	11	on	on	IN
cord-263455-dquztf5l	192	12	household	household	NN
cord-263455-dquztf5l	192	13	contacts	contact	NNS
cord-263455-dquztf5l	192	14	was	be	VBD
cord-263455-dquztf5l	192	15	significantly	significantly	RB
cord-263455-dquztf5l	192	16	higher	high	JJR
cord-263455-dquztf5l	192	17	compared	compare	VBN
cord-263455-dquztf5l	192	18	with	with	IN
cord-263455-dquztf5l	192	19	studies	study	NNS
cord-263455-dquztf5l	192	20	targeting	target	VBG
cord-263455-dquztf5l	192	21	the	the	DT
cord-263455-dquztf5l	192	22	general	general	JJ
cord-263455-dquztf5l	192	23	population	population	NN
cord-263455-dquztf5l	192	24	(	(	-LRB-
cord-263455-dquztf5l	192	25	66	66	CD
cord-263455-dquztf5l	192	26	%	%	NN
cord-263455-dquztf5l	192	27	and	and	CC
cord-263455-dquztf5l	192	28	53	53	CD
cord-263455-dquztf5l	192	29	%	%	NN
cord-263455-dquztf5l	192	30	,	,	,
cord-263455-dquztf5l	192	31	respectively	respectively	RB
cord-263455-dquztf5l	192	32	)	)	-RRB-
cord-263455-dquztf5l	192	33	.	.	.
cord-263455-dquztf5l	193	1	37	37	CD
cord-263455-dquztf5l	194	1	But	but	CC
cord-263455-dquztf5l	194	2	it	-PRON-	PRP
cord-263455-dquztf5l	194	3	was	be	VBD
cord-263455-dquztf5l	194	4	mentioned	mention	VBN
cord-263455-dquztf5l	194	5	that	that	IN
cord-263455-dquztf5l	194	6	the	the	DT
cord-263455-dquztf5l	194	7	risk	risk	NN
cord-263455-dquztf5l	194	8	of	of	IN
cord-263455-dquztf5l	194	9	misclassification	misclassification	NN
cord-263455-dquztf5l	194	10	of	of	IN
cord-263455-dquztf5l	194	11	cases	case	NNS
cord-263455-dquztf5l	194	12	and	and	CC
cord-263455-dquztf5l	194	13	controls	control	NNS
cord-263455-dquztf5l	194	14	should	should	MD
cord-263455-dquztf5l	194	15	be	be	VB
cord-263455-dquztf5l	194	16	considered	consider	VBN
cord-263455-dquztf5l	194	17	given	give	VBN
cord-263455-dquztf5l	194	18	the	the	DT
cord-263455-dquztf5l	194	19	long	long	JJ
cord-263455-dquztf5l	194	20	incubation	incubation	NN
cord-263455-dquztf5l	194	21	time	time	NN
cord-263455-dquztf5l	194	22	of	of	IN
cord-263455-dquztf5l	194	23	leprosy	leprosy	NN
cord-263455-dquztf5l	194	24	.	.	.
cord-263455-dquztf5l	195	1	Included	include	VBN
cord-263455-dquztf5l	195	2	studies	study	NNS
cord-263455-dquztf5l	195	3	were	be	VBD
cord-263455-dquztf5l	195	4	found	find	VBN
cord-263455-dquztf5l	195	5	to	to	TO
cord-263455-dquztf5l	195	6	be	be	VB
cord-263455-dquztf5l	195	7	heterogeneous	heterogeneous	JJ
cord-263455-dquztf5l	195	8	,	,	,
cord-263455-dquztf5l	195	9	caused	cause	VBN
cord-263455-dquztf5l	195	10	by	by	IN
cord-263455-dquztf5l	195	11	eg	eg	NN
cord-263455-dquztf5l	195	12	,	,	,
cord-263455-dquztf5l	195	13	varying	vary	VBG
cord-263455-dquztf5l	195	14	study	study	NN
cord-263455-dquztf5l	195	15	designs	design	NNS
cord-263455-dquztf5l	195	16	and	and	CC
cord-263455-dquztf5l	195	17	some	some	DT
cord-263455-dquztf5l	195	18	study	study	NN
cord-263455-dquztf5l	195	19	groups	group	NNS
cord-263455-dquztf5l	195	20	receiving	receive	VBG
cord-263455-dquztf5l	195	21	multiple	multiple	JJ
cord-263455-dquztf5l	195	22	doses	dose	NNS
cord-263455-dquztf5l	195	23	of	of	IN
cord-263455-dquztf5l	195	24	BCG	BCG	NNP
cord-263455-dquztf5l	195	25	.	.	.
cord-263455-dquztf5l	196	1	Studies	study	NNS
cord-263455-dquztf5l	196	2	including	include	VBG
cord-263455-dquztf5l	196	3	BCG	BCG	NNP
cord-263455-dquztf5l	196	4	revaccination	revaccination	NN
cord-263455-dquztf5l	196	5	only	only	RB
cord-263455-dquztf5l	196	6	or	or	CC
cord-263455-dquztf5l	196	7	studies	study	NNS
cord-263455-dquztf5l	196	8	that	that	WDT
cord-263455-dquztf5l	196	9	did	do	VBD
cord-263455-dquztf5l	196	10	not	not	RB
cord-263455-dquztf5l	196	11	(	(	-LRB-
cord-263455-dquztf5l	196	12	also	also	RB
cord-263455-dquztf5l	196	13	)	)	-RRB-
cord-263455-dquztf5l	196	14	estimate	estimate	VB
cord-263455-dquztf5l	196	15	the	the	DT
cord-263455-dquztf5l	196	16	efficacy	efficacy	NN
cord-263455-dquztf5l	196	17	of	of	IN
cord-263455-dquztf5l	196	18	one	one	CD
cord-263455-dquztf5l	196	19	post	post	JJ
cord-263455-dquztf5l	196	20	-	-	JJ
cord-263455-dquztf5l	196	21	exposure	exposure	JJ
cord-263455-dquztf5l	196	22	dose	dose	NN
cord-263455-dquztf5l	196	23	of	of	IN
cord-263455-dquztf5l	196	24	the	the	DT
cord-263455-dquztf5l	196	25	BCG	BCG	NNP
cord-263455-dquztf5l	196	26	vaccine	vaccine	NN
cord-263455-dquztf5l	196	27	were	be	VBD
cord-263455-dquztf5l	196	28	not	not	RB
cord-263455-dquztf5l	196	29	included	include	VBN
cord-263455-dquztf5l	196	30	in	in	IN
cord-263455-dquztf5l	196	31	this	this	DT
cord-263455-dquztf5l	196	32	metaanalysis	metaanalysis	NN
cord-263455-dquztf5l	196	33	.	.	.
cord-263455-dquztf5l	197	1	Literature	literature	NN
cord-263455-dquztf5l	197	2	states	state	VBZ
cord-263455-dquztf5l	197	3	that	that	IN
cord-263455-dquztf5l	197	4	several	several	JJ
cord-263455-dquztf5l	197	5	vaccination	vaccination	NN
cord-263455-dquztf5l	197	6	interventions	intervention	NNS
cord-263455-dquztf5l	197	7	show	show	VBP
cord-263455-dquztf5l	197	8	similar	similar	JJ
cord-263455-dquztf5l	197	9	or	or	CC
cord-263455-dquztf5l	197	10	slightly	slightly	RB
cord-263455-dquztf5l	197	11	less	less	JJR
cord-263455-dquztf5l	197	12	efficacy	efficacy	NN
cord-263455-dquztf5l	197	13	in	in	IN
cord-263455-dquztf5l	197	14	reducing	reduce	VBG
cord-263455-dquztf5l	197	15	the	the	DT
cord-263455-dquztf5l	197	16	risk	risk	NN
cord-263455-dquztf5l	197	17	of	of	IN
cord-263455-dquztf5l	197	18	leprosy	leprosy	NN
cord-263455-dquztf5l	197	19	compared	compare	VBN
cord-263455-dquztf5l	197	20	to	to	IN
cord-263455-dquztf5l	197	21	BCG	BCG	NNP
cord-263455-dquztf5l	197	22	,	,	,
cord-263455-dquztf5l	197	23	but	but	CC
cord-263455-dquztf5l	197	24	few	few	JJ
cord-263455-dquztf5l	197	25	studies	study	NNS
cord-263455-dquztf5l	197	26	focus	focus	VBP
cord-263455-dquztf5l	197	27	primarily	primarily	RB
cord-263455-dquztf5l	197	28	on	on	IN
cord-263455-dquztf5l	197	29	post	post	JJ
cord-263455-dquztf5l	197	30	-	-	JJ
cord-263455-dquztf5l	197	31	exposure	exposure	JJ
cord-263455-dquztf5l	197	32	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	197	33	.	.	.
cord-263455-dquztf5l	198	1	23	23	CD
cord-263455-dquztf5l	199	1	Sharma	Sharma	NNP
cord-263455-dquztf5l	199	2	et	et	NNP
cord-263455-dquztf5l	199	3	al	al	NNP
cord-263455-dquztf5l	199	4	performed	perform	VBD
cord-263455-dquztf5l	199	5	a	a	DT
cord-263455-dquztf5l	199	6	double	double	JJ
cord-263455-dquztf5l	199	7	-	-	HYPH
cord-263455-dquztf5l	199	8	blind	blind	JJ
cord-263455-dquztf5l	199	9	trial	trial	NN
cord-263455-dquztf5l	199	10	on	on	IN
cord-263455-dquztf5l	199	11	the	the	DT
cord-263455-dquztf5l	199	12	Mw	Mw	NNP
cord-263455-dquztf5l	199	13	vaccine	vaccine	NN
cord-263455-dquztf5l	199	14	in	in	IN
cord-263455-dquztf5l	199	15	India	India	NNP
cord-263455-dquztf5l	199	16	in	in	IN
cord-263455-dquztf5l	199	17	the	the	DT
cord-263455-dquztf5l	199	18	1990s	1990	NNS
cord-263455-dquztf5l	199	19	that	that	WDT
cord-263455-dquztf5l	199	20	did	do	VBD
cord-263455-dquztf5l	199	21	include	include	VB
cord-263455-dquztf5l	199	22	household	household	NN
cord-263455-dquztf5l	199	23	contacts	contact	NNS
cord-263455-dquztf5l	199	24	of	of	IN
cord-263455-dquztf5l	199	25	leprosy	leprosy	NN
cord-263455-dquztf5l	199	26	patients	patient	NNS
cord-263455-dquztf5l	199	27	.	.	.
cord-263455-dquztf5l	200	1	50	50	CD
cord-263455-dquztf5l	201	1	When	when	WRB
cord-263455-dquztf5l	201	2	contacts	contact	NNS
cord-263455-dquztf5l	201	3	only	only	RB
cord-263455-dquztf5l	201	4	were	be	VBD
cord-263455-dquztf5l	201	5	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	201	6	,	,	,
cord-263455-dquztf5l	201	7	the	the	DT
cord-263455-dquztf5l	201	8	Mw	Mw	NNP
cord-263455-dquztf5l	201	9	vaccine	vaccine	NN
cord-263455-dquztf5l	201	10	showed	show	VBD
cord-263455-dquztf5l	201	11	a	a	DT
cord-263455-dquztf5l	201	12	protective	protective	JJ
cord-263455-dquztf5l	201	13	efficacy	efficacy	NN
cord-263455-dquztf5l	201	14	of	of	IN
cord-263455-dquztf5l	201	15	68.6	68.6	CD
cord-263455-dquztf5l	201	16	%	%	NN
cord-263455-dquztf5l	201	17	at	at	IN
cord-263455-dquztf5l	201	18	the	the	DT
cord-263455-dquztf5l	201	19	end	end	NN
cord-263455-dquztf5l	201	20	of	of	IN
cord-263455-dquztf5l	201	21	the	the	DT
cord-263455-dquztf5l	201	22	3-year	3-year	JJ
cord-263455-dquztf5l	201	23	follow	follow	NN
cord-263455-dquztf5l	201	24	-	-	HYPH
cord-263455-dquztf5l	201	25	up	up	NN
cord-263455-dquztf5l	201	26	period	period	NN
cord-263455-dquztf5l	201	27	,	,	,
cord-263455-dquztf5l	201	28	59	59	CD
cord-263455-dquztf5l	201	29	%	%	NN
cord-263455-dquztf5l	201	30	at	at	IN
cord-263455-dquztf5l	201	31	6	6	CD
cord-263455-dquztf5l	201	32	years	year	NNS
cord-263455-dquztf5l	201	33	,	,	,
cord-263455-dquztf5l	201	34	and	and	CC
cord-263455-dquztf5l	201	35	39.3	39.3	CD
cord-263455-dquztf5l	201	36	%	%	NN
cord-263455-dquztf5l	201	37	at	at	IN
cord-263455-dquztf5l	201	38	9	9	CD
cord-263455-dquztf5l	201	39	years	year	NNS
cord-263455-dquztf5l	201	40	follow	follow	NN
cord-263455-dquztf5l	201	41	-	-	HYPH
cord-263455-dquztf5l	201	42	up	up	NN
cord-263455-dquztf5l	201	43	.	.	.
cord-263455-dquztf5l	202	1	When	when	WRB
cord-263455-dquztf5l	202	2	both	both	DT
cord-263455-dquztf5l	202	3	patients	patient	NNS
cord-263455-dquztf5l	202	4	and	and	CC
cord-263455-dquztf5l	202	5	contacts	contact	NNS
cord-263455-dquztf5l	202	6	received	receive	VBD
cord-263455-dquztf5l	202	7	the	the	DT
cord-263455-dquztf5l	202	8	Mw	Mw	NNP
cord-263455-dquztf5l	202	9	vaccine	vaccine	NN
cord-263455-dquztf5l	202	10	,	,	,
cord-263455-dquztf5l	202	11	the	the	DT
cord-263455-dquztf5l	202	12	observed	observed	JJ
cord-263455-dquztf5l	202	13	protective	protective	JJ
cord-263455-dquztf5l	202	14	efficacy	efficacy	NN
cord-263455-dquztf5l	202	15	was	be	VBD
cord-263455-dquztf5l	202	16	68	68	CD
cord-263455-dquztf5l	202	17	%	%	NN
cord-263455-dquztf5l	202	18	at	at	IN
cord-263455-dquztf5l	202	19	3	3	CD
cord-263455-dquztf5l	202	20	years	year	NNS
cord-263455-dquztf5l	202	21	,	,	,
cord-263455-dquztf5l	202	22	60	60	CD
cord-263455-dquztf5l	202	23	%	%	NN
cord-263455-dquztf5l	202	24	at	at	IN
cord-263455-dquztf5l	202	25	6	6	CD
cord-263455-dquztf5l	202	26	years	year	NNS
cord-263455-dquztf5l	202	27	,	,	,
cord-263455-dquztf5l	202	28	and	and	CC
cord-263455-dquztf5l	202	29	28	28	CD
cord-263455-dquztf5l	202	30	%	%	NN
cord-263455-dquztf5l	202	31	at	at	IN
cord-263455-dquztf5l	202	32	9	9	CD
cord-263455-dquztf5l	202	33	years	year	NNS
cord-263455-dquztf5l	202	34	,	,	,
cord-263455-dquztf5l	202	35	with	with	IN
cord-263455-dquztf5l	202	36	significance	significance	NN
cord-263455-dquztf5l	202	37	found	find	VBN
cord-263455-dquztf5l	202	38	at	at	IN
cord-263455-dquztf5l	202	39	the	the	DT
cord-263455-dquztf5l	202	40	first	first	JJ
cord-263455-dquztf5l	202	41	two	two	CD
cord-263455-dquztf5l	202	42	survey	survey	NN
cord-263455-dquztf5l	202	43	moments	moment	NNS
cord-263455-dquztf5l	202	44	(	(	-LRB-
cord-263455-dquztf5l	202	45	p	p	NN
cord-263455-dquztf5l	202	46	<	<	XX
cord-263455-dquztf5l	202	47	0.00005	0.00005	CD
cord-263455-dquztf5l	202	48	)	)	-RRB-
cord-263455-dquztf5l	202	49	and	and	CC
cord-263455-dquztf5l	202	50	in	in	IN
cord-263455-dquztf5l	202	51	a	a	DT
cord-263455-dquztf5l	202	52	lesser	less	JJR
cord-263455-dquztf5l	202	53	degree	degree	NN
cord-263455-dquztf5l	202	54	at	at	IN
cord-263455-dquztf5l	202	55	the	the	DT
cord-263455-dquztf5l	202	56	third	third	JJ
cord-263455-dquztf5l	202	57	survey	survey	NN
cord-263455-dquztf5l	202	58	moment	moment	NN
cord-263455-dquztf5l	203	1	(	(	-LRB-
cord-263455-dquztf5l	203	2	p	p	NN
cord-263455-dquztf5l	203	3	<	<	XX
cord-263455-dquztf5l	203	4	0.01	0.01	CD
cord-263455-dquztf5l	203	5	)	)	-RRB-
cord-263455-dquztf5l	203	6	.	.	.
cord-263455-dquztf5l	204	1	50	50	CD
cord-263455-dquztf5l	205	1	However	however	RB
cord-263455-dquztf5l	205	2	,	,	,
cord-263455-dquztf5l	205	3	this	this	DT
cord-263455-dquztf5l	205	4	study	study	NN
cord-263455-dquztf5l	205	5	stated	state	VBD
cord-263455-dquztf5l	205	6	that	that	IN
cord-263455-dquztf5l	205	7	early	early	JJ
cord-263455-dquztf5l	205	8	post	post	JJ
cord-263455-dquztf5l	205	9	-	-	JJ
cord-263455-dquztf5l	205	10	vaccination	vaccination	JJ
cord-263455-dquztf5l	205	11	cases	case	NNS
cord-263455-dquztf5l	205	12	detected	detect	VBN
cord-263455-dquztf5l	205	13	within	within	IN
cord-263455-dquztf5l	205	14	1	1	CD
cord-263455-dquztf5l	205	15	year	year	NN
cord-263455-dquztf5l	205	16	of	of	IN
cord-263455-dquztf5l	205	17	administering	administer	VBG
cord-263455-dquztf5l	205	18	the	the	DT
cord-263455-dquztf5l	205	19	vaccine	vaccine	NN
cord-263455-dquztf5l	205	20	were	be	VBD
cord-263455-dquztf5l	205	21	not	not	RB
cord-263455-dquztf5l	205	22	included	include	VBN
cord-263455-dquztf5l	205	23	in	in	IN
cord-263455-dquztf5l	205	24	the	the	DT
cord-263455-dquztf5l	205	25	analysis	analysis	NN
cord-263455-dquztf5l	205	26	,	,	,
cord-263455-dquztf5l	205	27	as	as	IN
cord-263455-dquztf5l	205	28	these	these	DT
cord-263455-dquztf5l	205	29	vaccine	vaccine	NN
cord-263455-dquztf5l	205	30	recipients	recipient	NNS
cord-263455-dquztf5l	205	31	were	be	VBD
cord-263455-dquztf5l	205	32	thought	think	VBN
cord-263455-dquztf5l	205	33	to	to	TO
cord-263455-dquztf5l	205	34	be	be	VB
cord-263455-dquztf5l	205	35	harboring	harbor	VBG
cord-263455-dquztf5l	205	36	the	the	DT
cord-263455-dquztf5l	205	37	infection	infection	NN
cord-263455-dquztf5l	205	38	.	.	.
cord-263455-dquztf5l	206	1	This	this	DT
cord-263455-dquztf5l	206	2	is	be	VBZ
cord-263455-dquztf5l	206	3	a	a	DT
cord-263455-dquztf5l	206	4	major	major	JJ
cord-263455-dquztf5l	206	5	limitation	limitation	NN
cord-263455-dquztf5l	206	6	and	and	CC
cord-263455-dquztf5l	206	7	makes	make	VBZ
cord-263455-dquztf5l	206	8	the	the	DT
cord-263455-dquztf5l	206	9	results	result	NNS
cord-263455-dquztf5l	206	10	of	of	IN
cord-263455-dquztf5l	206	11	this	this	DT
cord-263455-dquztf5l	206	12	trial	trial	NN
cord-263455-dquztf5l	206	13	difficult	difficult	JJ
cord-263455-dquztf5l	206	14	to	to	TO
cord-263455-dquztf5l	206	15	interpret	interpret	VB
cord-263455-dquztf5l	206	16	.	.	.
cord-263455-dquztf5l	207	1	Truoc	Truoc	NNP
cord-263455-dquztf5l	207	2	et	et	NNP
cord-263455-dquztf5l	207	3	al	al	NNP
cord-263455-dquztf5l	207	4	published	publish	VBD
cord-263455-dquztf5l	207	5	a	a	DT
cord-263455-dquztf5l	207	6	study	study	NN
cord-263455-dquztf5l	207	7	on	on	IN
cord-263455-dquztf5l	207	8	BCG	BCG	NNP
cord-263455-dquztf5l	207	9	alone	alone	RB
cord-263455-dquztf5l	207	10	,	,	,
cord-263455-dquztf5l	207	11	BCG	BCG	NNP
cord-263455-dquztf5l	207	12	plus	plus	CC
cord-263455-dquztf5l	207	13	10	10	CD
cord-263455-dquztf5l	207	14	7	7	CD
cord-263455-dquztf5l	207	15	killed	kill	VBN
cord-263455-dquztf5l	207	16	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	207	17	vaccae	vaccae	NN
cord-263455-dquztf5l	207	18	(	(	-LRB-
cord-263455-dquztf5l	207	19	M.	M.	NNP
cord-263455-dquztf5l	207	20	vaccae	vaccae	NN
cord-263455-dquztf5l	207	21	or	or	CC
cord-263455-dquztf5l	207	22	Mv	Mv	NNP
cord-263455-dquztf5l	207	23	)	)	-RRB-
cord-263455-dquztf5l	207	24	,	,	,
cord-263455-dquztf5l	207	25	and	and	CC
cord-263455-dquztf5l	207	26	10	10	CD
cord-263455-dquztf5l	207	27	8	8	CD
cord-263455-dquztf5l	207	28	killed	kill	VBN
cord-263455-dquztf5l	207	29	Mv	Mv	NNP
cord-263455-dquztf5l	207	30	alone	alone	JJ
cord-263455-dquztf5l	207	31	.	.	.
cord-263455-dquztf5l	208	1	The	the	DT
cord-263455-dquztf5l	208	2	study	study	NN
cord-263455-dquztf5l	208	3	included	include	VBD
cord-263455-dquztf5l	208	4	young	young	JJ
cord-263455-dquztf5l	208	5	people	people	NNS
cord-263455-dquztf5l	208	6	,	,	,
cord-263455-dquztf5l	208	7	3	3	CD
cord-263455-dquztf5l	208	8	-	-	SYM
cord-263455-dquztf5l	208	9	20	20	CD
cord-263455-dquztf5l	208	10	years	year	NNS
cord-263455-dquztf5l	208	11	old	old	JJ
cord-263455-dquztf5l	208	12	,	,	,
cord-263455-dquztf5l	208	13	living	live	VBG
cord-263455-dquztf5l	208	14	in	in	IN
cord-263455-dquztf5l	208	15	close	close	JJ
cord-263455-dquztf5l	208	16	contact	contact	NN
cord-263455-dquztf5l	208	17	with	with	IN
cord-263455-dquztf5l	208	18	leprosy	leprosy	NN
cord-263455-dquztf5l	208	19	patients	patient	NNS
cord-263455-dquztf5l	208	20	in	in	IN
cord-263455-dquztf5l	208	21	1988	1988	CD
cord-263455-dquztf5l	208	22	in	in	IN
cord-263455-dquztf5l	208	23	Ho	Ho	NNP
cord-263455-dquztf5l	208	24	Chi	Chi	NNP
cord-263455-dquztf5l	208	25	Minh	Minh	NNP
cord-263455-dquztf5l	208	26	City	City	NNP
cord-263455-dquztf5l	208	27	,	,	,
cord-263455-dquztf5l	208	28	Vietnam	Vietnam	NNP
cord-263455-dquztf5l	208	29	.	.	.
cord-263455-dquztf5l	209	1	55	55	CD
cord-263455-dquztf5l	210	1	At	at	IN
cord-263455-dquztf5l	210	2	least	least	JJS
cord-263455-dquztf5l	210	3	twice	twice	PDT
cord-263455-dquztf5l	210	4	a	a	DT
cord-263455-dquztf5l	210	5	year	year	NN
cord-263455-dquztf5l	210	6	,	,	,
cord-263455-dquztf5l	210	7	signs	sign	NNS
cord-263455-dquztf5l	210	8	of	of	IN
cord-263455-dquztf5l	210	9	leprosy	leprosy	NN
cord-263455-dquztf5l	210	10	were	be	VBD
cord-263455-dquztf5l	210	11	routinely	routinely	RB
cord-263455-dquztf5l	210	12	sought	seek	VBN
cord-263455-dquztf5l	210	13	.	.	.
cord-263455-dquztf5l	211	1	The	the	DT
cord-263455-dquztf5l	211	2	study	study	NN
cord-263455-dquztf5l	211	3	was	be	VBD
cord-263455-dquztf5l	211	4	non	non	JJ
cord-263455-dquztf5l	211	5	-	-	JJ
cord-263455-dquztf5l	211	6	randomized	randomized	JJ
cord-263455-dquztf5l	211	7	,	,	,
cord-263455-dquztf5l	211	8	and	and	CC
cord-263455-dquztf5l	211	9	intervention	intervention	NN
cord-263455-dquztf5l	211	10	allocation	allocation	NN
cord-263455-dquztf5l	211	11	in	in	IN
cord-263455-dquztf5l	211	12	this	this	DT
cord-263455-dquztf5l	211	13	study	study	NN
cord-263455-dquztf5l	211	14	was	be	VBD
cord-263455-dquztf5l	211	15	also	also	RB
cord-263455-dquztf5l	211	16	doubtful	doubtful	JJ
cord-263455-dquztf5l	211	17	:	:	:
cord-263455-dquztf5l	211	18	for	for	IN
cord-263455-dquztf5l	211	19	example	example	NN
cord-263455-dquztf5l	211	20	,	,	,
cord-263455-dquztf5l	211	21	74	74	CD
cord-263455-dquztf5l	211	22	children	child	NNS
cord-263455-dquztf5l	211	23	who	who	WP
cord-263455-dquztf5l	211	24	did	do	VBD
cord-263455-dquztf5l	211	25	not	not	RB
cord-263455-dquztf5l	211	26	attend	attend	VB
cord-263455-dquztf5l	211	27	the	the	DT
cord-263455-dquztf5l	211	28	initial	initial	JJ
cord-263455-dquztf5l	211	29	examination	examination	NN
cord-263455-dquztf5l	211	30	moment	moment	NN
cord-263455-dquztf5l	211	31	were	be	VBD
cord-263455-dquztf5l	211	32	chosen	choose	VBN
cord-263455-dquztf5l	211	33	as	as	IN
cord-263455-dquztf5l	211	34	the	the	DT
cord-263455-dquztf5l	211	35	control	control	NN
cord-263455-dquztf5l	211	36	group	group	NN
cord-263455-dquztf5l	211	37	.	.	.
cord-263455-dquztf5l	212	1	37	37	CD
cord-263455-dquztf5l	212	2	,	,	,
cord-263455-dquztf5l	212	3	55	55	CD
cord-263455-dquztf5l	212	4	Over	over	IN
cord-263455-dquztf5l	212	5	the	the	DT
cord-263455-dquztf5l	212	6	entire	entire	JJ
cord-263455-dquztf5l	212	7	8	8	CD
cord-263455-dquztf5l	212	8	years	year	NNS
cord-263455-dquztf5l	212	9	,	,	,
cord-263455-dquztf5l	212	10	14	14	CD
cord-263455-dquztf5l	212	11	of	of	IN
cord-263455-dquztf5l	212	12	74	74	CD
cord-263455-dquztf5l	212	13	(	(	-LRB-
cord-263455-dquztf5l	212	14	18.9	18.9	CD
cord-263455-dquztf5l	212	15	%	%	NN
cord-263455-dquztf5l	212	16	)	)	-RRB-
cord-263455-dquztf5l	212	17	unvaccinated	unvaccinated	JJ
cord-263455-dquztf5l	212	18	controls	control	NNS
cord-263455-dquztf5l	212	19	and	and	CC
cord-263455-dquztf5l	212	20	25	25	CD
cord-263455-dquztf5l	212	21	of	of	IN
cord-263455-dquztf5l	212	22	343	343	CD
cord-263455-dquztf5l	212	23	(	(	-LRB-
cord-263455-dquztf5l	212	24	7.3	7.3	CD
cord-263455-dquztf5l	212	25	%	%	NN
cord-263455-dquztf5l	212	26	)	)	-RRB-
cord-263455-dquztf5l	212	27	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	212	28	children	child	NNS
cord-263455-dquztf5l	212	29	developed	develop	VBD
cord-263455-dquztf5l	212	30	leprosy	leprosy	NN
cord-263455-dquztf5l	212	31	(	(	-LRB-
cord-263455-dquztf5l	212	32	p	p	NN
cord-263455-dquztf5l	212	33	<	<	XX
cord-263455-dquztf5l	212	34	0.001	0.001	CD
cord-263455-dquztf5l	212	35	)	)	-RRB-
cord-263455-dquztf5l	212	36	,	,	,
cord-263455-dquztf5l	212	37	showing	show	VBG
cord-263455-dquztf5l	212	38	a	a	DT
cord-263455-dquztf5l	212	39	protective	protective	JJ
cord-263455-dquztf5l	212	40	effect	effect	NN
cord-263455-dquztf5l	212	41	of	of	IN
cord-263455-dquztf5l	212	42	61.4	61.4	CD
cord-263455-dquztf5l	212	43	%	%	NN
cord-263455-dquztf5l	212	44	without	without	IN
cord-263455-dquztf5l	212	45	significant	significant	JJ
cord-263455-dquztf5l	212	46	differences	difference	NNS
cord-263455-dquztf5l	212	47	among	among	IN
cord-263455-dquztf5l	212	48	the	the	DT
cord-263455-dquztf5l	212	49	three	three	CD
cord-263455-dquztf5l	212	50	vaccines	vaccine	NNS
cord-263455-dquztf5l	212	51	.	.	.
cord-263455-dquztf5l	213	1	The	the	DT
cord-263455-dquztf5l	213	2	small	small	JJ
cord-263455-dquztf5l	213	3	sample	sample	NN
cord-263455-dquztf5l	213	4	size	size	NN
cord-263455-dquztf5l	213	5	and	and	CC
cord-263455-dquztf5l	213	6	uncertainties	uncertainty	NNS
cord-263455-dquztf5l	213	7	in	in	IN
cord-263455-dquztf5l	213	8	scar	scar	NN
cord-263455-dquztf5l	213	9	-	-	HYPH
cord-263455-dquztf5l	213	10	reading	reading	NN
cord-263455-dquztf5l	213	11	could	could	MD
cord-263455-dquztf5l	213	12	potentially	potentially	RB
cord-263455-dquztf5l	213	13	further	further	RB
cord-263455-dquztf5l	213	14	have	have	VB
cord-263455-dquztf5l	213	15	influenced	influence	VBN
cord-263455-dquztf5l	213	16	the	the	DT
cord-263455-dquztf5l	213	17	outcome	outcome	NN
cord-263455-dquztf5l	213	18	of	of	IN
cord-263455-dquztf5l	213	19	this	this	DT
cord-263455-dquztf5l	213	20	study	study	NN
cord-263455-dquztf5l	213	21	.	.	.
cord-263455-dquztf5l	214	1	29	29	CD
cord-263455-dquztf5l	214	2	,	,	,
cord-263455-dquztf5l	214	3	37	37	CD
cord-263455-dquztf5l	214	4	,	,	,
cord-263455-dquztf5l	214	5	55	55	CD
cord-263455-dquztf5l	214	6	Promising	promise	VBG
cord-263455-dquztf5l	214	7	Vaccines	vaccine	NNS
cord-263455-dquztf5l	215	1	At	at	IN
cord-263455-dquztf5l	215	2	the	the	DT
cord-263455-dquztf5l	215	3	moment	moment	NN
cord-263455-dquztf5l	215	4	,	,	,
cord-263455-dquztf5l	215	5	besides	besides	IN
cord-263455-dquztf5l	215	6	BCG	BCG	NNP
cord-263455-dquztf5l	215	7	,	,	,
cord-263455-dquztf5l	215	8	two	two	CD
cord-263455-dquztf5l	215	9	vaccines	vaccine	NNS
cord-263455-dquztf5l	215	10	are	be	VBP
cord-263455-dquztf5l	215	11	considered	consider	VBN
cord-263455-dquztf5l	215	12	potential	potential	JJ
cord-263455-dquztf5l	215	13	candidates	candidate	NNS
cord-263455-dquztf5l	215	14	for	for	IN
cord-263455-dquztf5l	215	15	leprosy	leprosy	NN
cord-263455-dquztf5l	215	16	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	215	17	:	:	:
cord-263455-dquztf5l	215	18	the	the	DT
cord-263455-dquztf5l	215	19	Mw	Mw	NNP
cord-263455-dquztf5l	215	20	vaccine	vaccine	NN
cord-263455-dquztf5l	215	21	,	,	,
cord-263455-dquztf5l	215	22	developed	develop	VBN
cord-263455-dquztf5l	215	23	in	in	IN
cord-263455-dquztf5l	215	24	India	India	NNP
cord-263455-dquztf5l	215	25	,	,	,
cord-263455-dquztf5l	215	26	and	and	CC
cord-263455-dquztf5l	215	27	LepVax	LepVax	NNP
cord-263455-dquztf5l	215	28	,	,	,
cord-263455-dquztf5l	215	29	developed	develop	VBN
cord-263455-dquztf5l	215	30	in	in	IN
cord-263455-dquztf5l	215	31	the	the	DT
cord-263455-dquztf5l	215	32	United	United	NNP
cord-263455-dquztf5l	215	33	States	States	NNP
cord-263455-dquztf5l	215	34	.	.	.
cord-263455-dquztf5l	216	1	[	[	-LRB-
cord-263455-dquztf5l	216	2	56	56	CD
cord-263455-dquztf5l	216	3	]	]	-RRB-
cord-263455-dquztf5l	216	4	[	[	-LRB-
cord-263455-dquztf5l	216	5	57	57	CD
cord-263455-dquztf5l	216	6	]	]	-RRB-
cord-263455-dquztf5l	216	7	[	[	-LRB-
cord-263455-dquztf5l	216	8	58	58	CD
cord-263455-dquztf5l	216	9	]	]	-RRB-
cord-263455-dquztf5l	217	1	[	[	-LRB-
cord-263455-dquztf5l	217	2	59	59	CD
cord-263455-dquztf5l	217	3	]	]	-RRB-
cord-263455-dquztf5l	217	4	[	[	-LRB-
cord-263455-dquztf5l	217	5	60	60	CD
cord-263455-dquztf5l	217	6	]	]	-RRB-
cord-263455-dquztf5l	218	1	Because	because	IN
cord-263455-dquztf5l	218	2	of	of	IN
cord-263455-dquztf5l	218	3	the	the	DT
cord-263455-dquztf5l	218	4	described	describe	VBN
cord-263455-dquztf5l	218	5	positive	positive	JJ
cord-263455-dquztf5l	218	6	protective	protective	JJ
cord-263455-dquztf5l	218	7	efficacy	efficacy	NN
cord-263455-dquztf5l	218	8	of	of	IN
cord-263455-dquztf5l	218	9	Mw	Mw	NNP
cord-263455-dquztf5l	218	10	,	,	,
cord-263455-dquztf5l	218	11	this	this	DT
cord-263455-dquztf5l	218	12	cultivable	cultivable	JJ
cord-263455-dquztf5l	218	13	,	,	,
cord-263455-dquztf5l	218	14	non	non	JJ
cord-263455-dquztf5l	218	15	-	-	JJ
cord-263455-dquztf5l	218	16	pathogenic	pathogenic	JJ
cord-263455-dquztf5l	218	17	mycobacterium	mycobacterium	NN
cord-263455-dquztf5l	218	18	was	be	VBD
cord-263455-dquztf5l	218	19	selected	select	VBN
cord-263455-dquztf5l	218	20	for	for	IN
cord-263455-dquztf5l	218	21	further	further	JJ
cord-263455-dquztf5l	218	22	development	development	NN
cord-263455-dquztf5l	218	23	.	.	.
cord-263455-dquztf5l	219	1	It	-PRON-	PRP
cord-263455-dquztf5l	219	2	has	have	VBZ
cord-263455-dquztf5l	219	3	been	be	VBN
cord-263455-dquztf5l	219	4	sequenced	sequence	VBN
cord-263455-dquztf5l	219	5	and	and	CC
cord-263455-dquztf5l	219	6	is	be	VBZ
cord-263455-dquztf5l	219	7	now	now	RB
cord-263455-dquztf5l	219	8	named	name	VBN
cord-263455-dquztf5l	219	9	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	219	10	indicus	indicus	NN
cord-263455-dquztf5l	219	11	pranii	pranii	NNP
cord-263455-dquztf5l	219	12	(	(	-LRB-
cord-263455-dquztf5l	219	13	MiP	MiP	NNP
cord-263455-dquztf5l	219	14	)	)	-RRB-
cord-263455-dquztf5l	219	15	to	to	TO
cord-263455-dquztf5l	219	16	avoid	avoid	VB
cord-263455-dquztf5l	219	17	confusion	confusion	NN
cord-263455-dquztf5l	219	18	with	with	IN
cord-263455-dquztf5l	219	19	M.	M.	NNP
cord-263455-dquztf5l	219	20	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	219	21	-	-	HYPH
cord-263455-dquztf5l	219	22	W.	W.	NNP
cord-263455-dquztf5l	219	23	61	61	CD
cord-263455-dquztf5l	219	24	,	,	,
cord-263455-dquztf5l	219	25	62	62	CD
cord-263455-dquztf5l	219	26	MiP	mip	NN
cord-263455-dquztf5l	219	27	expedites	expedite	VBZ
cord-263455-dquztf5l	219	28	bacterial	bacterial	JJ
cord-263455-dquztf5l	219	29	clearance	clearance	NN
cord-263455-dquztf5l	219	30	and	and	CC
cord-263455-dquztf5l	219	31	shortens	shorten	VBZ
cord-263455-dquztf5l	219	32	the	the	DT
cord-263455-dquztf5l	219	33	recovery	recovery	NN
cord-263455-dquztf5l	219	34	time	time	NN
cord-263455-dquztf5l	219	35	in	in	IN
cord-263455-dquztf5l	219	36	leprosy	leprosy	NN
cord-263455-dquztf5l	219	37	patients	patient	NNS
cord-263455-dquztf5l	219	38	.	.	.
cord-263455-dquztf5l	220	1	[	[	-LRB-
cord-263455-dquztf5l	220	2	61	61	CD
cord-263455-dquztf5l	220	3	]	]	-RRB-
cord-263455-dquztf5l	220	4	[	[	-LRB-
cord-263455-dquztf5l	220	5	62	62	CD
cord-263455-dquztf5l	220	6	]	]	-RRB-
cord-263455-dquztf5l	221	1	[	[	-LRB-
cord-263455-dquztf5l	221	2	63	63	CD
cord-263455-dquztf5l	221	3	]	]	-RRB-
cord-263455-dquztf5l	222	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	222	2	,	,	,
cord-263455-dquztf5l	222	3	the	the	DT
cord-263455-dquztf5l	222	4	addition	addition	NN
cord-263455-dquztf5l	222	5	of	of	IN
cord-263455-dquztf5l	222	6	MiP	MiP	NNP
cord-263455-dquztf5l	222	7	vaccine	vaccine	NN
cord-263455-dquztf5l	222	8	as	as	IN
cord-263455-dquztf5l	222	9	an	an	DT
cord-263455-dquztf5l	222	10	immunomodulator	immunomodulator	NN
cord-263455-dquztf5l	222	11	to	to	IN
cord-263455-dquztf5l	222	12	MDT	MDT	NNP
cord-263455-dquztf5l	222	13	in	in	IN
cord-263455-dquztf5l	222	14	leprosy	leprosy	NN
cord-263455-dquztf5l	222	15	patients	patient	NNS
cord-263455-dquztf5l	222	16	leads	lead	VBZ
cord-263455-dquztf5l	222	17	to	to	IN
cord-263455-dquztf5l	222	18	speedier	speedy	JJR
cord-263455-dquztf5l	222	19	attainment	attainment	NN
cord-263455-dquztf5l	222	20	of	of	IN
cord-263455-dquztf5l	222	21	slit	slit	NN
cord-263455-dquztf5l	222	22	-	-	HYPH
cord-263455-dquztf5l	222	23	skin	skin	NN
cord-263455-dquztf5l	222	24	smear	smear	NN
cord-263455-dquztf5l	222	25	test	test	NN
cord-263455-dquztf5l	222	26	negativity	negativity	NN
cord-263455-dquztf5l	222	27	,	,	,
cord-263455-dquztf5l	222	28	and	and	CC
cord-263455-dquztf5l	222	29	it	-PRON-	PRP
cord-263455-dquztf5l	222	30	seems	seem	VBZ
cord-263455-dquztf5l	222	31	to	to	TO
cord-263455-dquztf5l	222	32	have	have	VB
cord-263455-dquztf5l	222	33	a	a	DT
cord-263455-dquztf5l	222	34	positive	positive	JJ
cord-263455-dquztf5l	222	35	effect	effect	NN
cord-263455-dquztf5l	222	36	on	on	IN
cord-263455-dquztf5l	222	37	leprosy	leprosy	NN
cord-263455-dquztf5l	222	38	reactions	reaction	NNS
cord-263455-dquztf5l	222	39	from	from	IN
cord-263455-dquztf5l	222	40	six	six	CD
cord-263455-dquztf5l	222	41	months	month	NNS
cord-263455-dquztf5l	222	42	onwards	onwards	RB
cord-263455-dquztf5l	222	43	.	.	.
cord-263455-dquztf5l	223	1	60	60	CD
cord-263455-dquztf5l	223	2	,	,	,
cord-263455-dquztf5l	223	3	64	64	CD
cord-263455-dquztf5l	224	1	The	the	DT
cord-263455-dquztf5l	224	2	MiP	mip	NN
cord-263455-dquztf5l	224	3	vaccine	vaccine	NN
cord-263455-dquztf5l	224	4	has	have	VBZ
cord-263455-dquztf5l	224	5	received	receive	VBN
cord-263455-dquztf5l	224	6	approval	approval	NN
cord-263455-dquztf5l	224	7	from	from	IN
cord-263455-dquztf5l	224	8	both	both	CC
cord-263455-dquztf5l	224	9	the	the	DT
cord-263455-dquztf5l	224	10	Drugs	Drugs	NNPS
cord-263455-dquztf5l	224	11	Controller	Controller	NNP
cord-263455-dquztf5l	224	12	General	General	NNP
cord-263455-dquztf5l	224	13	of	of	IN
cord-263455-dquztf5l	224	14	India	India	NNP
cord-263455-dquztf5l	224	15	and	and	CC
cord-263455-dquztf5l	224	16	the	the	DT
cord-263455-dquztf5l	224	17	American	American	NNP
cord-263455-dquztf5l	224	18	Food	Food	NNP
cord-263455-dquztf5l	224	19	and	and	CC
cord-263455-dquztf5l	224	20	Drug	Drug	NNP
cord-263455-dquztf5l	224	21	Administration	Administration	NNP
cord-263455-dquztf5l	224	22	(	(	-LRB-
cord-263455-dquztf5l	224	23	AFDA	AFDA	NNP
cord-263455-dquztf5l	224	24	)	)	-RRB-
cord-263455-dquztf5l	224	25	and	and	CC
cord-263455-dquztf5l	224	26	is	be	VBZ
cord-263455-dquztf5l	224	27	now	now	RB
cord-263455-dquztf5l	224	28	being	be	VBG
cord-263455-dquztf5l	224	29	manufactured	manufacture	VBN
cord-263455-dquztf5l	224	30	as	as	IN
cord-263455-dquztf5l	224	31	Immuvac/	Immuvac/	NNP
cord-263455-dquztf5l	225	1	Cadi-05	Cadi-05	NNP
cord-263455-dquztf5l	225	2	by	by	IN
cord-263455-dquztf5l	225	3	Cadila	Cadila	NNP
cord-263455-dquztf5l	225	4	Pharmaceuticals	Pharmaceuticals	NNPS
cord-263455-dquztf5l	225	5	.	.	.
cord-263455-dquztf5l	226	1	It	-PRON-	PRP
cord-263455-dquztf5l	226	2	also	also	RB
cord-263455-dquztf5l	226	3	seems	seem	VBZ
cord-263455-dquztf5l	226	4	effective	effective	JJ
cord-263455-dquztf5l	226	5	in	in	IN
cord-263455-dquztf5l	226	6	other	other	JJ
cord-263455-dquztf5l	226	7	conditions	condition	NNS
cord-263455-dquztf5l	226	8	,	,	,
cord-263455-dquztf5l	226	9	such	such	JJ
cord-263455-dquztf5l	226	10	as	as	IN
cord-263455-dquztf5l	226	11	TB	TB	NNP
cord-263455-dquztf5l	226	12	and	and	CC
cord-263455-dquztf5l	226	13	warts	wart	NNS
cord-263455-dquztf5l	226	14	.	.	.
cord-263455-dquztf5l	227	1	61	61	CD
cord-263455-dquztf5l	228	1	In	in	IN
cord-263455-dquztf5l	228	2	2002	2002	CD
cord-263455-dquztf5l	228	3	,	,	,
cord-263455-dquztf5l	228	4	the	the	DT
cord-263455-dquztf5l	228	5	American	American	NNP
cord-263455-dquztf5l	228	6	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	228	7	Missions	Missions	NNPS
cord-263455-dquztf5l	228	8	(	(	-LRB-
cord-263455-dquztf5l	228	9	ALM	ALM	NNP
cord-263455-dquztf5l	228	10	)	)	-RRB-
cord-263455-dquztf5l	228	11	partnered	partner	VBD
cord-263455-dquztf5l	228	12	with	with	IN
cord-263455-dquztf5l	228	13	the	the	DT
cord-263455-dquztf5l	228	14	Infectious	Infectious	NNP
cord-263455-dquztf5l	228	15	Disease	Disease	NNP
cord-263455-dquztf5l	228	16	Research	Research	NNP
cord-263455-dquztf5l	228	17	Institute	Institute	NNP
cord-263455-dquztf5l	228	18	(	(	-LRB-
cord-263455-dquztf5l	228	19	IDRI	IDRI	NNP
cord-263455-dquztf5l	228	20	)	)	-RRB-
cord-263455-dquztf5l	228	21	in	in	IN
cord-263455-dquztf5l	228	22	Seattle	Seattle	NNP
cord-263455-dquztf5l	228	23	to	to	TO
cord-263455-dquztf5l	228	24	start	start	VB
cord-263455-dquztf5l	228	25	a	a	DT
cord-263455-dquztf5l	228	26	leprosy	leprosy	NN
cord-263455-dquztf5l	228	27	vaccine	vaccine	NN
cord-263455-dquztf5l	228	28	development	development	NN
cord-263455-dquztf5l	228	29	trajectory	trajectory	NN
cord-263455-dquztf5l	228	30	.	.	.
cord-263455-dquztf5l	229	1	65	65	CD
cord-263455-dquztf5l	229	2	LepVax	LepVax	NNP
cord-263455-dquztf5l	229	3	was	be	VBD
cord-263455-dquztf5l	229	4	developed	develop	VBN
cord-263455-dquztf5l	229	5	to	to	TO
cord-263455-dquztf5l	229	6	provide	provide	VB
cord-263455-dquztf5l	229	7	both	both	DT
cord-263455-dquztf5l	229	8	effective	effective	JJ
cord-263455-dquztf5l	229	9	preexposure	preexposure	NN
cord-263455-dquztf5l	229	10	and	and	CC
cord-263455-dquztf5l	229	11	post	post	JJ
cord-263455-dquztf5l	229	12	-	-	JJ
cord-263455-dquztf5l	229	13	exposure	exposure	JJ
cord-263455-dquztf5l	229	14	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	229	15	against	against	IN
cord-263455-dquztf5l	229	16	M.	M.	NNP
cord-263455-dquztf5l	229	17	leprae	leprae	JJ
cord-263455-dquztf5l	229	18	infection	infection	NN
cord-263455-dquztf5l	229	19	.	.	.
cord-263455-dquztf5l	230	1	57	57	CD
cord-263455-dquztf5l	231	1	It	-PRON-	PRP
cord-263455-dquztf5l	231	2	was	be	VBD
cord-263455-dquztf5l	231	3	shown	show	VBN
cord-263455-dquztf5l	231	4	to	to	TO
cord-263455-dquztf5l	231	5	be	be	VB
cord-263455-dquztf5l	231	6	safe	safe	JJ
cord-263455-dquztf5l	231	7	.	.	.
cord-263455-dquztf5l	232	1	A	a	DT
cord-263455-dquztf5l	232	2	decrease	decrease	NN
cord-263455-dquztf5l	232	3	and/or	and/or	CC
cord-263455-dquztf5l	232	4	delay	delay	NN
cord-263455-dquztf5l	232	5	of	of	IN
cord-263455-dquztf5l	232	6	neuropathy	neuropathy	NN
cord-263455-dquztf5l	232	7	caused	cause	VBN
cord-263455-dquztf5l	232	8	by	by	IN
cord-263455-dquztf5l	232	9	M.	M.	NNP
cord-263455-dquztf5l	232	10	leprae	leprae	NNP
cord-263455-dquztf5l	232	11	in	in	IN
cord-263455-dquztf5l	232	12	nine	nine	CD
cord-263455-dquztf5l	232	13	-	-	HYPH
cord-263455-dquztf5l	232	14	banded	banded	JJ
cord-263455-dquztf5l	232	15	armadillos	armadillo	NNS
cord-263455-dquztf5l	232	16	was	be	VBD
cord-263455-dquztf5l	232	17	also	also	RB
cord-263455-dquztf5l	232	18	observed	observe	VBN
cord-263455-dquztf5l	232	19	,	,	,
cord-263455-dquztf5l	232	20	making	make	VBG
cord-263455-dquztf5l	232	21	LepVax	LepVax	NNP
cord-263455-dquztf5l	232	22	promising	promising	JJ
cord-263455-dquztf5l	232	23	as	as	IN
cord-263455-dquztf5l	232	24	immunotherapy	immunotherapy	NN
cord-263455-dquztf5l	232	25	.	.	.
cord-263455-dquztf5l	233	1	57	57	CD
cord-263455-dquztf5l	234	1	In	in	IN
cord-263455-dquztf5l	234	2	August	August	NNP
cord-263455-dquztf5l	234	3	2017	2017	CD
cord-263455-dquztf5l	234	4	,	,	,
cord-263455-dquztf5l	234	5	the	the	DT
cord-263455-dquztf5l	234	6	vaccine	vaccine	NN
cord-263455-dquztf5l	234	7	was	be	VBD
cord-263455-dquztf5l	234	8	approved	approve	VBN
cord-263455-dquztf5l	234	9	by	by	IN
cord-263455-dquztf5l	234	10	the	the	DT
cord-263455-dquztf5l	234	11	AFDA	AFDA	NNP
cord-263455-dquztf5l	234	12	.	.	.
cord-263455-dquztf5l	235	1	65	65	CD
cord-263455-dquztf5l	236	1	LepVax	LepVax	NNP
cord-263455-dquztf5l	236	2	testing	testing	NN
cord-263455-dquztf5l	236	3	in	in	IN
cord-263455-dquztf5l	236	4	humans	human	NNS
cord-263455-dquztf5l	236	5	is	be	VBZ
cord-263455-dquztf5l	236	6	ongoing	ongoing	JJ
cord-263455-dquztf5l	236	7	.	.	.
cord-263455-dquztf5l	237	1	When	when	WRB
cord-263455-dquztf5l	237	2	dapsone	dapsone	NNP
cord-263455-dquztf5l	237	3	was	be	VBD
cord-263455-dquztf5l	237	4	the	the	DT
cord-263455-dquztf5l	237	5	sole	sole	JJ
cord-263455-dquztf5l	237	6	treatment	treatment	NN
cord-263455-dquztf5l	237	7	of	of	IN
cord-263455-dquztf5l	237	8	choice	choice	NN
cord-263455-dquztf5l	237	9	for	for	IN
cord-263455-dquztf5l	237	10	leprosy	leprosy	NN
cord-263455-dquztf5l	237	11	,	,	,
cord-263455-dquztf5l	237	12	people	people	NNS
cord-263455-dquztf5l	237	13	sought	seek	VBD
cord-263455-dquztf5l	237	14	ways	way	NNS
cord-263455-dquztf5l	237	15	to	to	TO
cord-263455-dquztf5l	237	16	protect	protect	VB
cord-263455-dquztf5l	237	17	contacts	contact	NNS
cord-263455-dquztf5l	237	18	of	of	IN
cord-263455-dquztf5l	237	19	leprosy	leprosy	NN
cord-263455-dquztf5l	237	20	patients	patient	NNS
cord-263455-dquztf5l	237	21	.	.	.
cord-263455-dquztf5l	238	1	The	the	DT
cord-263455-dquztf5l	238	2	idea	idea	NN
cord-263455-dquztf5l	238	3	to	to	TO
cord-263455-dquztf5l	238	4	introduce	introduce	VB
cord-263455-dquztf5l	238	5	post	post	JJ
cord-263455-dquztf5l	238	6	-	-	JJ
cord-263455-dquztf5l	238	7	exposure	exposure	JJ
cord-263455-dquztf5l	238	8	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	238	9	(	(	-LRB-
cord-263455-dquztf5l	238	10	PEP	pep	NN
cord-263455-dquztf5l	238	11	)	)	-RRB-
cord-263455-dquztf5l	238	12	was	be	VBD
cord-263455-dquztf5l	238	13	based	base	VBN
cord-263455-dquztf5l	238	14	on	on	IN
cord-263455-dquztf5l	238	15	the	the	DT
cord-263455-dquztf5l	238	16	hypothesis	hypothesis	NN
cord-263455-dquztf5l	238	17	that	that	IN
cord-263455-dquztf5l	238	18	close	close	JJ
cord-263455-dquztf5l	238	19	contacts	contact	NNS
cord-263455-dquztf5l	238	20	of	of	IN
cord-263455-dquztf5l	238	21	leprosy	leprosy	NN
cord-263455-dquztf5l	238	22	patients	patient	NNS
cord-263455-dquztf5l	238	23	have	have	VBP
cord-263455-dquztf5l	238	24	already	already	RB
cord-263455-dquztf5l	238	25	been	be	VBN
cord-263455-dquztf5l	238	26	infected	infect	VBN
cord-263455-dquztf5l	238	27	by	by	IN
cord-263455-dquztf5l	238	28	M.	M.	NNP
cord-263455-dquztf5l	238	29	leprae	leprae	NNP
cord-263455-dquztf5l	238	30	by	by	IN
cord-263455-dquztf5l	238	31	the	the	DT
cord-263455-dquztf5l	238	32	time	time	NN
cord-263455-dquztf5l	238	33	the	the	DT
cord-263455-dquztf5l	238	34	patient	patient	NN
cord-263455-dquztf5l	238	35	is	be	VBZ
cord-263455-dquztf5l	238	36	diagnosed	diagnose	VBN
cord-263455-dquztf5l	238	37	and	and	CC
cord-263455-dquztf5l	238	38	that	that	IN
cord-263455-dquztf5l	238	39	post	post	JJ
cord-263455-dquztf5l	238	40	-	-	JJ
cord-263455-dquztf5l	238	41	exposure	exposure	JJ
cord-263455-dquztf5l	238	42	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	238	43	would	would	MD
cord-263455-dquztf5l	238	44	prevent	prevent	VB
cord-263455-dquztf5l	238	45	the	the	DT
cord-263455-dquztf5l	238	46	contacts	contact	NNS
cord-263455-dquztf5l	238	47	from	from	IN
cord-263455-dquztf5l	238	48	developing	develop	VBG
cord-263455-dquztf5l	238	49	the	the	DT
cord-263455-dquztf5l	238	50	clinical	clinical	JJ
cord-263455-dquztf5l	238	51	disease	disease	NN
cord-263455-dquztf5l	238	52	.	.	.
cord-263455-dquztf5l	239	1	The	the	DT
cord-263455-dquztf5l	239	2	first	first	JJ
cord-263455-dquztf5l	239	3	reports	report	NNS
cord-263455-dquztf5l	239	4	on	on	IN
cord-263455-dquztf5l	239	5	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	239	6	trials	trial	NNS
cord-263455-dquztf5l	239	7	,	,	,
cord-263455-dquztf5l	239	8	using	use	VBG
cord-263455-dquztf5l	239	9	dapsone	dapsone	NN
cord-263455-dquztf5l	239	10	,	,	,
cord-263455-dquztf5l	239	11	in	in	IN
cord-263455-dquztf5l	239	12	India	India	NNP
cord-263455-dquztf5l	239	13	and	and	CC
cord-263455-dquztf5l	239	14	Seoul	Seoul	NNP
cord-263455-dquztf5l	239	15	were	be	VBD
cord-263455-dquztf5l	239	16	published	publish	VBN
cord-263455-dquztf5l	239	17	in	in	IN
cord-263455-dquztf5l	239	18	the	the	DT
cord-263455-dquztf5l	239	19	1960s	1960	NNS
cord-263455-dquztf5l	239	20	.	.	.
cord-263455-dquztf5l	240	1	[	[	-LRB-
cord-263455-dquztf5l	240	2	66	66	CD
cord-263455-dquztf5l	240	3	]	]	-RRB-
cord-263455-dquztf5l	240	4	[	[	-LRB-
cord-263455-dquztf5l	240	5	67	67	CD
cord-263455-dquztf5l	240	6	]	]	-RRB-
cord-263455-dquztf5l	241	1	[	[	-LRB-
cord-263455-dquztf5l	241	2	68	68	CD
cord-263455-dquztf5l	241	3	]	]	-RRB-
cord-263455-dquztf5l	242	1	These	these	DT
cord-263455-dquztf5l	242	2	first	first	JJ
cord-263455-dquztf5l	242	3	results	result	NNS
cord-263455-dquztf5l	242	4	suggested	suggest	VBD
cord-263455-dquztf5l	242	5	that	that	IN
cord-263455-dquztf5l	242	6	weekly	weekly	JJ
cord-263455-dquztf5l	242	7	or	or	CC
cord-263455-dquztf5l	242	8	biweekly	biweekly	JJ
cord-263455-dquztf5l	242	9	doses	dose	NNS
cord-263455-dquztf5l	242	10	of	of	IN
cord-263455-dquztf5l	242	11	dapsone	dapsone	NN
cord-263455-dquztf5l	242	12	given	give	VBN
cord-263455-dquztf5l	242	13	to	to	IN
cord-263455-dquztf5l	242	14	contacts	contact	NNS
cord-263455-dquztf5l	242	15	of	of	IN
cord-263455-dquztf5l	242	16	leprosy	leprosy	NN
cord-263455-dquztf5l	242	17	patients	patient	NNS
cord-263455-dquztf5l	242	18	for	for	IN
cord-263455-dquztf5l	242	19	a	a	DT
cord-263455-dquztf5l	242	20	longer	long	JJR
cord-263455-dquztf5l	242	21	duration	duration	NN
cord-263455-dquztf5l	242	22	(	(	-LRB-
cord-263455-dquztf5l	242	23	months	month	NNS
cord-263455-dquztf5l	242	24	to	to	IN
cord-263455-dquztf5l	242	25	years	year	NNS
cord-263455-dquztf5l	242	26	)	)	-RRB-
cord-263455-dquztf5l	242	27	had	have	VBD
cord-263455-dquztf5l	242	28	a	a	DT
cord-263455-dquztf5l	242	29	protective	protective	JJ
cord-263455-dquztf5l	242	30	effect	effect	NN
cord-263455-dquztf5l	242	31	against	against	IN
cord-263455-dquztf5l	242	32	leprosy	leprosy	NN
cord-263455-dquztf5l	242	33	.	.	.
cord-263455-dquztf5l	243	1	In	in	IN
cord-263455-dquztf5l	243	2	subsequent	subsequent	JJ
cord-263455-dquztf5l	243	3	years	year	NNS
cord-263455-dquztf5l	243	4	,	,	,
cord-263455-dquztf5l	243	5	this	this	DT
cord-263455-dquztf5l	243	6	was	be	VBD
cord-263455-dquztf5l	243	7	confirmed	confirm	VBN
cord-263455-dquztf5l	243	8	by	by	IN
cord-263455-dquztf5l	243	9	additional	additional	JJ
cord-263455-dquztf5l	243	10	studies	study	NNS
cord-263455-dquztf5l	243	11	in	in	IN
cord-263455-dquztf5l	243	12	other	other	JJ
cord-263455-dquztf5l	243	13	contexts	context	NNS
cord-263455-dquztf5l	243	14	.	.	.
cord-263455-dquztf5l	244	1	[	[	-LRB-
cord-263455-dquztf5l	244	2	69	69	CD
cord-263455-dquztf5l	244	3	]	]	-RRB-
cord-263455-dquztf5l	244	4	[	[	-LRB-
cord-263455-dquztf5l	244	5	70	70	CD
cord-263455-dquztf5l	244	6	]	]	-RRB-
cord-263455-dquztf5l	244	7	[	[	-LRB-
cord-263455-dquztf5l	244	8	71	71	CD
cord-263455-dquztf5l	244	9	]	]	-RRB-
cord-263455-dquztf5l	244	10	[	[	-LRB-
cord-263455-dquztf5l	244	11	72	72	CD
cord-263455-dquztf5l	244	12	]	]	-RRB-
cord-263455-dquztf5l	244	13	[	[	-LRB-
cord-263455-dquztf5l	244	14	73	73	CD
cord-263455-dquztf5l	244	15	]	]	-RRB-
cord-263455-dquztf5l	244	16	[	[	-LRB-
cord-263455-dquztf5l	244	17	74	74	CD
cord-263455-dquztf5l	244	18	]	]	-RRB-
cord-263455-dquztf5l	245	1	In	in	IN
cord-263455-dquztf5l	245	2	the	the	DT
cord-263455-dquztf5l	245	3	1970s	1970	NNS
cord-263455-dquztf5l	245	4	,	,	,
cord-263455-dquztf5l	245	5	several	several	JJ
cord-263455-dquztf5l	245	6	studies	study	NNS
cord-263455-dquztf5l	245	7	were	be	VBD
cord-263455-dquztf5l	245	8	published	publish	VBN
cord-263455-dquztf5l	245	9	on	on	IN
cord-263455-dquztf5l	245	10	the	the	DT
cord-263455-dquztf5l	245	11	use	use	NN
cord-263455-dquztf5l	245	12	of	of	IN
cord-263455-dquztf5l	245	13	diacetyldapsone	diacetyldapsone	NN
cord-263455-dquztf5l	245	14	(	(	-LRB-
cord-263455-dquztf5l	245	15	DADDS	DADDS	NNP
cord-263455-dquztf5l	245	16	)	)	-RRB-
cord-263455-dquztf5l	245	17	or	or	CC
cord-263455-dquztf5l	245	18	acedapsone	acedapsone	NN
cord-263455-dquztf5l	245	19	,	,	,
cord-263455-dquztf5l	245	20	a	a	DT
cord-263455-dquztf5l	245	21	long	long	RB
cord-263455-dquztf5l	245	22	-	-	HYPH
cord-263455-dquztf5l	245	23	acting	act	VBG
cord-263455-dquztf5l	245	24	repository	repository	NN
cord-263455-dquztf5l	245	25	sulphone	sulphone	NN
cord-263455-dquztf5l	245	26	given	give	VBN
cord-263455-dquztf5l	245	27	by	by	IN
cord-263455-dquztf5l	245	28	injection	injection	NN
cord-263455-dquztf5l	245	29	.	.	.
cord-263455-dquztf5l	246	1	The	the	DT
cord-263455-dquztf5l	246	2	administration	administration	NN
cord-263455-dquztf5l	246	3	intervals	interval	NNS
cord-263455-dquztf5l	246	4	of	of	IN
cord-263455-dquztf5l	246	5	approximately	approximately	RB
cord-263455-dquztf5l	246	6	10	10	CD
cord-263455-dquztf5l	246	7	weeks	week	NNS
cord-263455-dquztf5l	246	8	added	add	VBD
cord-263455-dquztf5l	246	9	to	to	IN
cord-263455-dquztf5l	246	10	the	the	DT
cord-263455-dquztf5l	246	11	operational	operational	JJ
cord-263455-dquztf5l	246	12	feasibility	feasibility	NN
cord-263455-dquztf5l	246	13	;	;	:
cord-263455-dquztf5l	246	14	also	also	RB
cord-263455-dquztf5l	246	15	,	,	,
cord-263455-dquztf5l	246	16	no	no	DT
cord-263455-dquztf5l	246	17	toxicity	toxicity	NN
cord-263455-dquztf5l	246	18	was	be	VBD
cord-263455-dquztf5l	246	19	found	find	VBN
cord-263455-dquztf5l	246	20	.	.	.
cord-263455-dquztf5l	247	1	[	[	-LRB-
cord-263455-dquztf5l	247	2	75	75	CD
cord-263455-dquztf5l	247	3	]	]	-RRB-
cord-263455-dquztf5l	247	4	[	[	-LRB-
cord-263455-dquztf5l	247	5	76	76	CD
cord-263455-dquztf5l	247	6	]	]	-RRB-
cord-263455-dquztf5l	248	1	[	[	-LRB-
cord-263455-dquztf5l	248	2	77	77	CD
cord-263455-dquztf5l	248	3	]	]	-RRB-
cord-263455-dquztf5l	248	4	Neelan	Neelan	NNP
cord-263455-dquztf5l	248	5	et	et	NNP
cord-263455-dquztf5l	248	6	al	al	NNP
cord-263455-dquztf5l	248	7	found	find	VBD
cord-263455-dquztf5l	248	8	that	that	IN
cord-263455-dquztf5l	248	9	even	even	RB
cord-263455-dquztf5l	248	10	a	a	DT
cord-263455-dquztf5l	248	11	short	short	JJ
cord-263455-dquztf5l	248	12	duration	duration	NN
cord-263455-dquztf5l	248	13	of	of	IN
cord-263455-dquztf5l	248	14	chemoprophylactic	chemoprophylactic	JJ
cord-263455-dquztf5l	248	15	treatment	treatment	NN
cord-263455-dquztf5l	248	16	with	with	IN
cord-263455-dquztf5l	248	17	acedapsone	acedapsone	NN
cord-263455-dquztf5l	248	18	through	through	IN
cord-263455-dquztf5l	248	19	a	a	DT
cord-263455-dquztf5l	248	20	series	series	NN
cord-263455-dquztf5l	248	21	of	of	IN
cord-263455-dquztf5l	248	22	three	three	CD
cord-263455-dquztf5l	248	23	injections	injection	NNS
cord-263455-dquztf5l	248	24	provided	provide	VBD
cord-263455-dquztf5l	248	25	protection	protection	NN
cord-263455-dquztf5l	248	26	after	after	IN
cord-263455-dquztf5l	248	27	four	four	CD
cord-263455-dquztf5l	248	28	years	year	NNS
cord-263455-dquztf5l	248	29	of	of	IN
cord-263455-dquztf5l	248	30	followup	followup	NN
cord-263455-dquztf5l	248	31	.	.	.
cord-263455-dquztf5l	249	1	78	78	CD
cord-263455-dquztf5l	249	2	Smith	Smith	NNP
cord-263455-dquztf5l	249	3	and	and	CC
cord-263455-dquztf5l	249	4	Smith	Smith	NNP
cord-263455-dquztf5l	249	5	conducted	conduct	VBD
cord-263455-dquztf5l	249	6	a	a	DT
cord-263455-dquztf5l	249	7	meta	meta	JJ
cord-263455-dquztf5l	249	8	-	-	HYPH
cord-263455-dquztf5l	249	9	analysis	analysis	NN
cord-263455-dquztf5l	249	10	in	in	IN
cord-263455-dquztf5l	249	11	2000	2000	CD
cord-263455-dquztf5l	249	12	to	to	TO
cord-263455-dquztf5l	249	13	quantify	quantify	VB
cord-263455-dquztf5l	249	14	the	the	DT
cord-263455-dquztf5l	249	15	efficacy	efficacy	NN
cord-263455-dquztf5l	249	16	of	of	IN
cord-263455-dquztf5l	249	17	dapsone	dapsone	NNP
cord-263455-dquztf5l	249	18	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	249	19	against	against	IN
cord-263455-dquztf5l	249	20	leprosy	leprosy	NN
cord-263455-dquztf5l	249	21	.	.	.
cord-263455-dquztf5l	250	1	79	79	CD
cord-263455-dquztf5l	251	1	They	-PRON-	PRP
cord-263455-dquztf5l	251	2	concluded	conclude	VBD
cord-263455-dquztf5l	251	3	that	that	IN
cord-263455-dquztf5l	251	4	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	251	5	is	be	VBZ
cord-263455-dquztf5l	251	6	an	an	DT
cord-263455-dquztf5l	251	7	effective	effective	JJ
cord-263455-dquztf5l	251	8	method	method	NN
cord-263455-dquztf5l	251	9	to	to	TO
cord-263455-dquztf5l	251	10	reduce	reduce	VB
cord-263455-dquztf5l	251	11	the	the	DT
cord-263455-dquztf5l	251	12	leprosy	leprosy	NN
cord-263455-dquztf5l	251	13	incidence	incidence	NN
cord-263455-dquztf5l	251	14	.	.	.
cord-263455-dquztf5l	252	1	They	-PRON-	PRP
cord-263455-dquztf5l	252	2	also	also	RB
cord-263455-dquztf5l	252	3	stated	state	VBD
cord-263455-dquztf5l	252	4	that	that	IN
cord-263455-dquztf5l	252	5	it	-PRON-	PRP
cord-263455-dquztf5l	252	6	is	be	VBZ
cord-263455-dquztf5l	252	7	more	more	RBR
cord-263455-dquztf5l	252	8	cost	cost	NN
cord-263455-dquztf5l	252	9	-	-	HYPH
cord-263455-dquztf5l	252	10	effective	effective	JJ
cord-263455-dquztf5l	252	11	in	in	IN
cord-263455-dquztf5l	252	12	household	household	NN
cord-263455-dquztf5l	252	13	contacts	contact	NNS
cord-263455-dquztf5l	252	14	than	than	IN
cord-263455-dquztf5l	252	15	when	when	WRB
cord-263455-dquztf5l	252	16	administered	administer	VBN
cord-263455-dquztf5l	252	17	to	to	IN
cord-263455-dquztf5l	252	18	entire	entire	JJ
cord-263455-dquztf5l	252	19	communities	community	NNS
cord-263455-dquztf5l	252	20	.	.	.
cord-263455-dquztf5l	253	1	They	-PRON-	PRP
cord-263455-dquztf5l	253	2	advised	advise	VBD
cord-263455-dquztf5l	253	3	more	more	JJR
cord-263455-dquztf5l	253	4	research	research	NN
cord-263455-dquztf5l	253	5	on	on	IN
cord-263455-dquztf5l	253	6	simple	simple	JJ
cord-263455-dquztf5l	253	7	,	,	,
cord-263455-dquztf5l	253	8	single	single	JJ
cord-263455-dquztf5l	253	9	-	-	HYPH
cord-263455-dquztf5l	253	10	dose	dose	NN
cord-263455-dquztf5l	253	11	regimens	regimen	NNS
cord-263455-dquztf5l	253	12	.	.	.
cord-263455-dquztf5l	254	1	This	this	DT
cord-263455-dquztf5l	254	2	could	could	MD
cord-263455-dquztf5l	254	3	improve	improve	VB
cord-263455-dquztf5l	254	4	compliance	compliance	NN
cord-263455-dquztf5l	254	5	and	and	CC
cord-263455-dquztf5l	254	6	feasibility	feasibility	NN
cord-263455-dquztf5l	254	7	in	in	IN
cord-263455-dquztf5l	254	8	more	more	JJR
cord-263455-dquztf5l	254	9	remote	remote	JJ
cord-263455-dquztf5l	254	10	settings	setting	NNS
cord-263455-dquztf5l	254	11	.	.	.
cord-263455-dquztf5l	255	1	In	in	IN
cord-263455-dquztf5l	255	2	1999	1999	CD
cord-263455-dquztf5l	255	3	,	,	,
cord-263455-dquztf5l	255	4	a	a	DT
cord-263455-dquztf5l	255	5	workshop	workshop	NN
cord-263455-dquztf5l	255	6	on	on	IN
cord-263455-dquztf5l	255	7	leprosy	leprosy	NN
cord-263455-dquztf5l	255	8	prevention	prevention	NN
cord-263455-dquztf5l	255	9	with	with	IN
cord-263455-dquztf5l	255	10	international	international	JJ
cord-263455-dquztf5l	255	11	experts	expert	NNS
cord-263455-dquztf5l	255	12	was	be	VBD
cord-263455-dquztf5l	255	13	held	hold	VBN
cord-263455-dquztf5l	255	14	in	in	IN
cord-263455-dquztf5l	255	15	the	the	DT
cord-263455-dquztf5l	255	16	Federated	Federated	NNP
cord-263455-dquztf5l	255	17	States	States	NNPS
cord-263455-dquztf5l	255	18	of	of	IN
cord-263455-dquztf5l	255	19	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	255	20	.	.	.
cord-263455-dquztf5l	256	1	80	80	CD
cord-263455-dquztf5l	257	1	During	during	IN
cord-263455-dquztf5l	257	2	this	this	DT
cord-263455-dquztf5l	257	3	workshop	workshop	NN
cord-263455-dquztf5l	257	4	,	,	,
cord-263455-dquztf5l	257	5	studies	study	NNS
cord-263455-dquztf5l	257	6	were	be	VBD
cord-263455-dquztf5l	257	7	presented	present	VBN
cord-263455-dquztf5l	257	8	introducing	introduce	VBG
cord-263455-dquztf5l	257	9	new	new	JJ
cord-263455-dquztf5l	257	10	regimens	regimen	NNS
cord-263455-dquztf5l	257	11	comprising	comprise	VBG
cord-263455-dquztf5l	257	12	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	257	13	alone	alone	RB
cord-263455-dquztf5l	257	14	or	or	CC
cord-263455-dquztf5l	257	15	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	257	16	combined	combine	VBN
cord-263455-dquztf5l	257	17	with	with	IN
cord-263455-dquztf5l	257	18	ofloxacin	ofloxacin	NNS
cord-263455-dquztf5l	257	19	and	and	CC
cord-263455-dquztf5l	257	20	minocycline	minocycline	NNP
cord-263455-dquztf5l	257	21	(	(	-LRB-
cord-263455-dquztf5l	257	22	ROM	ROM	NNP
cord-263455-dquztf5l	257	23	)	)	-RRB-
cord-263455-dquztf5l	257	24	.	.	.
cord-263455-dquztf5l	258	1	An	an	DT
cord-263455-dquztf5l	258	2	important	important	JJ
cord-263455-dquztf5l	258	3	improvement	improvement	NN
cord-263455-dquztf5l	258	4	of	of	IN
cord-263455-dquztf5l	258	5	these	these	DT
cord-263455-dquztf5l	258	6	new	new	JJ
cord-263455-dquztf5l	258	7	regimens	regimen	NNS
cord-263455-dquztf5l	258	8	was	be	VBD
cord-263455-dquztf5l	258	9	that	that	IN
cord-263455-dquztf5l	258	10	they	-PRON-	PRP
cord-263455-dquztf5l	258	11	were	be	VBD
cord-263455-dquztf5l	258	12	given	give	VBN
cord-263455-dquztf5l	258	13	either	either	CC
cord-263455-dquztf5l	258	14	as	as	IN
cord-263455-dquztf5l	258	15	a	a	DT
cord-263455-dquztf5l	258	16	singledose	singledose	NN
cord-263455-dquztf5l	258	17	or	or	CC
cord-263455-dquztf5l	258	18	were	be	VBD
cord-263455-dquztf5l	258	19	repeated	repeat	VBN
cord-263455-dquztf5l	258	20	once	once	RB
cord-263455-dquztf5l	258	21	,	,	,
cord-263455-dquztf5l	258	22	as	as	IN
cord-263455-dquztf5l	258	23	compared	compare	VBN
cord-263455-dquztf5l	258	24	to	to	IN
cord-263455-dquztf5l	258	25	dapsone	dapsone	NN
cord-263455-dquztf5l	258	26	that	that	WDT
cord-263455-dquztf5l	258	27	was	be	VBD
cord-263455-dquztf5l	258	28	given	give	VBN
cord-263455-dquztf5l	258	29	repeatedly	repeatedly	RB
cord-263455-dquztf5l	258	30	for	for	IN
cord-263455-dquztf5l	258	31	several	several	JJ
cord-263455-dquztf5l	258	32	years	year	NNS
cord-263455-dquztf5l	258	33	.	.	.
cord-263455-dquztf5l	259	1	The	the	DT
cord-263455-dquztf5l	259	2	first	first	JJ
cord-263455-dquztf5l	259	3	experience	experience	NN
cord-263455-dquztf5l	259	4	with	with	IN
cord-263455-dquztf5l	259	5	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	259	6	as	as	IN
cord-263455-dquztf5l	259	7	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	259	8	was	be	VBD
cord-263455-dquztf5l	259	9	gained	gain	VBN
cord-263455-dquztf5l	259	10	in	in	IN
cord-263455-dquztf5l	259	11	1988	1988	CD
cord-263455-dquztf5l	259	12	in	in	IN
cord-263455-dquztf5l	259	13	French	French	NNP
cord-263455-dquztf5l	259	14	Polynesia	Polynesia	NNP
cord-263455-dquztf5l	259	15	on	on	IN
cord-263455-dquztf5l	259	16	the	the	DT
cord-263455-dquztf5l	259	17	South	South	NNP
cord-263455-dquztf5l	259	18	Marquesas	Marquesas	NNP
cord-263455-dquztf5l	259	19	Islands	Islands	NNP
cord-263455-dquztf5l	259	20	,	,	,
cord-263455-dquztf5l	259	21	involving	involve	VBG
cord-263455-dquztf5l	259	22	the	the	DT
cord-263455-dquztf5l	259	23	screening	screening	NN
cord-263455-dquztf5l	259	24	of	of	IN
cord-263455-dquztf5l	259	25	2,786	2,786	CD
cord-263455-dquztf5l	259	26	inhabitants	inhabitant	NNS
cord-263455-dquztf5l	259	27	and	and	CC
cord-263455-dquztf5l	259	28	administering	administer	VBG
cord-263455-dquztf5l	259	29	25	25	CD
cord-263455-dquztf5l	259	30	mg	mg	NNP
cord-263455-dquztf5l	259	31	/	/	SYM
cord-263455-dquztf5l	259	32	kg	kg	NN
cord-263455-dquztf5l	259	33	single	single	JJ
cord-263455-dquztf5l	259	34	dose	dose	NN
cord-263455-dquztf5l	259	35	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	259	36	(	(	-LRB-
cord-263455-dquztf5l	259	37	SDR	SDR	NNP
cord-263455-dquztf5l	259	38	)	)	-RRB-
cord-263455-dquztf5l	259	39	to	to	IN
cord-263455-dquztf5l	259	40	2,751	2,751	CD
cord-263455-dquztf5l	259	41	inhabitants	inhabitant	NNS
cord-263455-dquztf5l	259	42	(	(	-LRB-
cord-263455-dquztf5l	259	43	98.7	98.7	CD
cord-263455-dquztf5l	259	44	%	%	NN
cord-263455-dquztf5l	259	45	)	)	-RRB-
cord-263455-dquztf5l	259	46	(	(	-LRB-
cord-263455-dquztf5l	259	47	Table	table	NN
cord-263455-dquztf5l	259	48	4	4	CD
cord-263455-dquztf5l	259	49	)	)	-RRB-
cord-263455-dquztf5l	259	50	and	and	CC
cord-263455-dquztf5l	259	51	also	also	RB
cord-263455-dquztf5l	259	52	3144	3144	CD
cord-263455-dquztf5l	259	53	South	South	NNP
cord-263455-dquztf5l	259	54	Marquesan	Marquesan	NNP
cord-263455-dquztf5l	259	55	"	"	``
cord-263455-dquztf5l	259	56	emigrants	emigrant	NNS
cord-263455-dquztf5l	259	57	"	"	''
cord-263455-dquztf5l	259	58	with	with	IN
cord-263455-dquztf5l	259	59	their	-PRON-	PRP$
cord-263455-dquztf5l	259	60	families	family	NNS
cord-263455-dquztf5l	259	61	.	.	.
cord-263455-dquztf5l	260	1	81	81	CD
cord-263455-dquztf5l	260	2	,	,	,
cord-263455-dquztf5l	260	3	82	82	CD
cord-263455-dquztf5l	261	1	During	during	IN
cord-263455-dquztf5l	261	2	the	the	DT
cord-263455-dquztf5l	261	3	four	four	CD
cord-263455-dquztf5l	261	4	-	-	HYPH
cord-263455-dquztf5l	261	5	year	year	NN
cord-263455-dquztf5l	261	6	follow	follow	NN
cord-263455-dquztf5l	261	7	-	-	HYPH
cord-263455-dquztf5l	261	8	up	up	NN
cord-263455-dquztf5l	261	9	,	,	,
cord-263455-dquztf5l	261	10	a	a	DT
cord-263455-dquztf5l	261	11	decrease	decrease	NN
cord-263455-dquztf5l	261	12	in	in	IN
cord-263455-dquztf5l	261	13	the	the	DT
cord-263455-dquztf5l	261	14	new	new	JJ
cord-263455-dquztf5l	261	15	case	case	NN
cord-263455-dquztf5l	261	16	detection	detection	NN
cord-263455-dquztf5l	261	17	rate	rate	NN
cord-263455-dquztf5l	261	18	of	of	IN
cord-263455-dquztf5l	261	19	80	80	CD
cord-263455-dquztf5l	261	20	%	%	NN
cord-263455-dquztf5l	261	21	was	be	VBD
cord-263455-dquztf5l	261	22	observed	observe	VBN
cord-263455-dquztf5l	261	23	.	.	.
cord-263455-dquztf5l	262	1	Against	against	IN
cord-263455-dquztf5l	262	2	a	a	DT
cord-263455-dquztf5l	262	3	background	background	NN
cord-263455-dquztf5l	262	4	of	of	IN
cord-263455-dquztf5l	262	5	an	an	DT
cord-263455-dquztf5l	262	6	already	already	RB
cord-263455-dquztf5l	262	7	declining	decline	VBG
cord-263455-dquztf5l	262	8	incidence	incidence	NN
cord-263455-dquztf5l	262	9	after	after	IN
cord-263455-dquztf5l	262	10	MDT	MDT	NNP
cord-263455-dquztf5l	262	11	introduction	introduction	NN
cord-263455-dquztf5l	262	12	,	,	,
cord-263455-dquztf5l	262	13	the	the	DT
cord-263455-dquztf5l	262	14	intervention	intervention	NN
cord-263455-dquztf5l	262	15	's	's	POS
cord-263455-dquztf5l	262	16	efficacy	efficacy	NN
cord-263455-dquztf5l	262	17	was	be	VBD
cord-263455-dquztf5l	262	18	estimated	estimate	VBN
cord-263455-dquztf5l	262	19	to	to	TO
cord-263455-dquztf5l	262	20	be	be	VB
cord-263455-dquztf5l	262	21	50	50	CD
cord-263455-dquztf5l	262	22	%	%	NN
cord-263455-dquztf5l	262	23	.	.	.
cord-263455-dquztf5l	263	1	82	82	CD
cord-263455-dquztf5l	264	1	In	in	IN
cord-263455-dquztf5l	264	2	addition	addition	NN
cord-263455-dquztf5l	264	3	,	,	,
cord-263455-dquztf5l	264	4	experiences	experience	NNS
cord-263455-dquztf5l	264	5	were	be	VBD
cord-263455-dquztf5l	264	6	reported	report	VBN
cord-263455-dquztf5l	264	7	with	with	IN
cord-263455-dquztf5l	264	8	SDR	SDR	NNP
cord-263455-dquztf5l	264	9	or	or	CC
cord-263455-dquztf5l	264	10	the	the	DT
cord-263455-dquztf5l	264	11	regimen	regimen	NN
cord-263455-dquztf5l	264	12	ROM	rom	NN
cord-263455-dquztf5l	264	13	as	as	IN
cord-263455-dquztf5l	264	14	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	264	15	,	,	,
cord-263455-dquztf5l	264	16	aiming	aim	VBG
cord-263455-dquztf5l	264	17	at	at	IN
cord-263455-dquztf5l	264	18	a	a	DT
cord-263455-dquztf5l	264	19	decrease	decrease	NN
cord-263455-dquztf5l	264	20	in	in	IN
cord-263455-dquztf5l	264	21	the	the	DT
cord-263455-dquztf5l	264	22	new	new	JJ
cord-263455-dquztf5l	264	23	case	case	NN
cord-263455-dquztf5l	264	24	detection	detection	NN
cord-263455-dquztf5l	264	25	rate	rate	NN
cord-263455-dquztf5l	264	26	in	in	IN
cord-263455-dquztf5l	264	27	the	the	DT
cord-263455-dquztf5l	264	28	Federated	Federated	NNP
cord-263455-dquztf5l	264	29	States	States	NNPS
cord-263455-dquztf5l	264	30	of	of	IN
cord-263455-dquztf5l	264	31	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	264	32	,	,	,
cord-263455-dquztf5l	264	33	Kiribati	Kiribati	NNP
cord-263455-dquztf5l	264	34	,	,	,
cord-263455-dquztf5l	264	35	and	and	CC
cord-263455-dquztf5l	264	36	the	the	DT
cord-263455-dquztf5l	264	37	Republic	Republic	NNP
cord-263455-dquztf5l	264	38	of	of	IN
cord-263455-dquztf5l	264	39	the	the	DT
cord-263455-dquztf5l	264	40	Marshall	Marshall	NNP
cord-263455-dquztf5l	264	41	Islands	Islands	NNP
cord-263455-dquztf5l	264	42	.	.	.
cord-263455-dquztf5l	265	1	[	[	-LRB-
cord-263455-dquztf5l	265	2	83	83	CD
cord-263455-dquztf5l	265	3	]	]	-RRB-
cord-263455-dquztf5l	265	4	[	[	-LRB-
cord-263455-dquztf5l	265	5	84	84	CD
cord-263455-dquztf5l	265	6	]	]	-RRB-
cord-263455-dquztf5l	265	7	[	[	-LRB-
cord-263455-dquztf5l	265	8	85	85	CD
cord-263455-dquztf5l	265	9	]	]	-RRB-
cord-263455-dquztf5l	265	10	[	[	-LRB-
cord-263455-dquztf5l	265	11	86	86	CD
cord-263455-dquztf5l	265	12	]	]	-RRB-
cord-263455-dquztf5l	265	13	[	[	-LRB-
cord-263455-dquztf5l	265	14	87	87	CD
cord-263455-dquztf5l	265	15	]	]	-RRB-
cord-263455-dquztf5l	266	1	[	[	-LRB-
cord-263455-dquztf5l	266	2	88	88	CD
cord-263455-dquztf5l	266	3	]	]	-RRB-
cord-263455-dquztf5l	266	4	No	no	DT
cord-263455-dquztf5l	266	5	serious	serious	JJ
cord-263455-dquztf5l	266	6	side	side	NN
cord-263455-dquztf5l	266	7	effects	effect	NNS
cord-263455-dquztf5l	266	8	were	be	VBD
cord-263455-dquztf5l	266	9	recorded	record	VBN
cord-263455-dquztf5l	266	10	.	.	.
cord-263455-dquztf5l	267	1	Some	some	DT
cord-263455-dquztf5l	267	2	concerns	concern	NNS
cord-263455-dquztf5l	267	3	about	about	IN
cord-263455-dquztf5l	267	4	the	the	DT
cord-263455-dquztf5l	267	5	complexity	complexity	NN
cord-263455-dquztf5l	267	6	of	of	IN
cord-263455-dquztf5l	267	7	the	the	DT
cord-263455-dquztf5l	267	8	intervention	intervention	NN
cord-263455-dquztf5l	267	9	and	and	CC
cord-263455-dquztf5l	267	10	the	the	DT
cord-263455-dquztf5l	267	11	costs	cost	NNS
cord-263455-dquztf5l	267	12	involved	involve	VBN
cord-263455-dquztf5l	267	13	in	in	IN
cord-263455-dquztf5l	267	14	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	267	15	against	against	IN
cord-263455-dquztf5l	267	16	leprosy	leprosy	NN
cord-263455-dquztf5l	267	17	were	be	VBD
cord-263455-dquztf5l	267	18	discussed	discuss	VBN
cord-263455-dquztf5l	267	19	.	.	.
cord-263455-dquztf5l	268	1	89	89	CD
cord-263455-dquztf5l	268	2	,	,	,
cord-263455-dquztf5l	268	3	90	90	CD
cord-263455-dquztf5l	268	4	A	a	DT
cord-263455-dquztf5l	268	5	plea	plea	NN
cord-263455-dquztf5l	268	6	was	be	VBD
cord-263455-dquztf5l	268	7	made	make	VBN
cord-263455-dquztf5l	268	8	for	for	IN
cord-263455-dquztf5l	268	9	a	a	DT
cord-263455-dquztf5l	268	10	simple	simple	JJ
cord-263455-dquztf5l	268	11	regimen	regimen	NN
cord-263455-dquztf5l	268	12	to	to	TO
cord-263455-dquztf5l	268	13	target	target	VB
cord-263455-dquztf5l	268	14	high	high	JJ
cord-263455-dquztf5l	268	15	-	-	HYPH
cord-263455-dquztf5l	268	16	risk	risk	NN
cord-263455-dquztf5l	268	17	groups	group	NNS
cord-263455-dquztf5l	268	18	,	,	,
cord-263455-dquztf5l	268	19	maximizing	maximize	VBG
cord-263455-dquztf5l	268	20	the	the	DT
cord-263455-dquztf5l	268	21	costbenefit	costbenefit	NNP
cord-263455-dquztf5l	268	22	ratio	ratio	NN
cord-263455-dquztf5l	268	23	.	.	.
cord-263455-dquztf5l	269	1	It	-PRON-	PRP
cord-263455-dquztf5l	269	2	was	be	VBD
cord-263455-dquztf5l	269	3	also	also	RB
cord-263455-dquztf5l	269	4	acknowledged	acknowledge	VBN
cord-263455-dquztf5l	269	5	that	that	IN
cord-263455-dquztf5l	269	6	more	more	JJR
cord-263455-dquztf5l	269	7	operational	operational	JJ
cord-263455-dquztf5l	269	8	research	research	NN
cord-263455-dquztf5l	269	9	was	be	VBD
cord-263455-dquztf5l	269	10	needed	need	VBN
cord-263455-dquztf5l	269	11	to	to	TO
cord-263455-dquztf5l	269	12	better	better	RB
cord-263455-dquztf5l	269	13	define	define	VB
cord-263455-dquztf5l	269	14	the	the	DT
cord-263455-dquztf5l	269	15	populations	population	NNS
cord-263455-dquztf5l	269	16	that	that	WDT
cord-263455-dquztf5l	269	17	could	could	MD
cord-263455-dquztf5l	269	18	benefit	benefit	VB
cord-263455-dquztf5l	269	19	the	the	DT
cord-263455-dquztf5l	269	20	most	most	RBS
cord-263455-dquztf5l	269	21	.	.	.
cord-263455-dquztf5l	270	1	91	91	CD
cord-263455-dquztf5l	271	1	In	in	IN
cord-263455-dquztf5l	271	2	the	the	DT
cord-263455-dquztf5l	271	3	years	year	NNS
cord-263455-dquztf5l	271	4	after	after	IN
cord-263455-dquztf5l	271	5	the	the	DT
cord-263455-dquztf5l	271	6	workshop	workshop	NN
cord-263455-dquztf5l	271	7	,	,	,
cord-263455-dquztf5l	271	8	more	more	JJR
cord-263455-dquztf5l	271	9	publications	publication	NNS
cord-263455-dquztf5l	271	10	provided	provide	VBD
cord-263455-dquztf5l	271	11	evidence	evidence	NN
cord-263455-dquztf5l	271	12	on	on	IN
cord-263455-dquztf5l	271	13	the	the	DT
cord-263455-dquztf5l	271	14	effect	effect	NN
cord-263455-dquztf5l	271	15	of	of	IN
cord-263455-dquztf5l	271	16	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	271	17	,	,	,
cord-263455-dquztf5l	271	18	but	but	CC
cord-263455-dquztf5l	271	19	it	-PRON-	PRP
cord-263455-dquztf5l	271	20	was	be	VBD
cord-263455-dquztf5l	271	21	also	also	RB
cord-263455-dquztf5l	271	22	recognized	recognize	VBN
cord-263455-dquztf5l	271	23	that	that	IN
cord-263455-dquztf5l	271	24	the	the	DT
cord-263455-dquztf5l	271	25	studies	study	NNS
cord-263455-dquztf5l	271	26	were	be	VBD
cord-263455-dquztf5l	271	27	not	not	RB
cord-263455-dquztf5l	271	28	placebo	placebo	NN
cord-263455-dquztf5l	271	29	controlled	control	VBN
cord-263455-dquztf5l	271	30	and/or	and/or	CC
cord-263455-dquztf5l	271	31	could	could	MD
cord-263455-dquztf5l	271	32	not	not	RB
cord-263455-dquztf5l	271	33	distinguish	distinguish	VB
cord-263455-dquztf5l	271	34	between	between	IN
cord-263455-dquztf5l	271	35	the	the	DT
cord-263455-dquztf5l	271	36	effect	effect	NN
cord-263455-dquztf5l	271	37	of	of	IN
cord-263455-dquztf5l	271	38	the	the	DT
cord-263455-dquztf5l	271	39	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	271	40	and	and	CC
cord-263455-dquztf5l	271	41	the	the	DT
cord-263455-dquztf5l	271	42	effect	effect	NN
cord-263455-dquztf5l	271	43	of	of	IN
cord-263455-dquztf5l	271	44	intensified	intensify	VBN
cord-263455-dquztf5l	271	45	case	case	NN
cord-263455-dquztf5l	271	46	detection	detection	NN
cord-263455-dquztf5l	271	47	interventions	intervention	NNS
cord-263455-dquztf5l	271	48	.	.	.
cord-263455-dquztf5l	272	1	92	92	CD
cord-263455-dquztf5l	272	2	,	,	,
cord-263455-dquztf5l	272	3	93	93	CD
cord-263455-dquztf5l	272	4	Cuba	Cuba	NNP
cord-263455-dquztf5l	272	5	,	,	,
cord-263455-dquztf5l	272	6	a	a	DT
cord-263455-dquztf5l	272	7	low	low	JJ
cord-263455-dquztf5l	272	8	endemic	endemic	JJ
cord-263455-dquztf5l	272	9	country	country	NN
cord-263455-dquztf5l	272	10	,	,	,
cord-263455-dquztf5l	272	11	was	be	VBD
cord-263455-dquztf5l	272	12	alone	alone	JJ
cord-263455-dquztf5l	272	13	in	in	IN
cord-263455-dquztf5l	272	14	starting	start	VBG
cord-263455-dquztf5l	272	15	early	early	RB
cord-263455-dquztf5l	272	16	with	with	IN
cord-263455-dquztf5l	272	17	nationwide	nationwide	JJ
cord-263455-dquztf5l	272	18	implementation	implementation	NN
cord-263455-dquztf5l	272	19	of	of	IN
cord-263455-dquztf5l	272	20	SDR	SDR	NNP
cord-263455-dquztf5l	272	21	-	-	HYPH
cord-263455-dquztf5l	272	22	PEP	PEP	NNP
cord-263455-dquztf5l	272	23	in	in	IN
cord-263455-dquztf5l	272	24	2002	2002	CD
cord-263455-dquztf5l	272	25	.	.	.
cord-263455-dquztf5l	273	1	94	94	CD
cord-263455-dquztf5l	274	1	The	the	DT
cord-263455-dquztf5l	274	2	COLEP	COLEP	NNP
cord-263455-dquztf5l	274	3	Study	Study	NNP
cord-263455-dquztf5l	274	4	Moet	Moet	NNP
cord-263455-dquztf5l	274	5	et	et	NNP
cord-263455-dquztf5l	274	6	al	al	NNP
cord-263455-dquztf5l	274	7	conducted	conduct	VBD
cord-263455-dquztf5l	274	8	a	a	DT
cord-263455-dquztf5l	274	9	large	large	JJ
cord-263455-dquztf5l	274	10	cluster	cluster	NN
cord-263455-dquztf5l	274	11	-	-	HYPH
cord-263455-dquztf5l	274	12	randomized	randomized	JJ
cord-263455-dquztf5l	274	13	controlled	control	VBN
cord-263455-dquztf5l	274	14	trial	trial	NN
cord-263455-dquztf5l	274	15	in	in	IN
cord-263455-dquztf5l	274	16	Bangladesh	Bangladesh	NNP
cord-263455-dquztf5l	274	17	,	,	,
cord-263455-dquztf5l	274	18	the	the	DT
cord-263455-dquztf5l	274	19	COLEP	COLEP	NNP
cord-263455-dquztf5l	274	20	study	study	NN
cord-263455-dquztf5l	274	21	,	,	,
cord-263455-dquztf5l	274	22	to	to	TO
cord-263455-dquztf5l	274	23	determine	determine	VB
cord-263455-dquztf5l	274	24	the	the	DT
cord-263455-dquztf5l	274	25	effectiveness	effectiveness	NN
cord-263455-dquztf5l	274	26	of	of	IN
cord-263455-dquztf5l	274	27	SDR	SDR	NNP
cord-263455-dquztf5l	274	28	in	in	IN
cord-263455-dquztf5l	274	29	preventing	prevent	VBG
cord-263455-dquztf5l	274	30	leprosy	leprosy	NN
cord-263455-dquztf5l	274	31	in	in	IN
cord-263455-dquztf5l	274	32	close	close	JJ
cord-263455-dquztf5l	274	33	contacts	contact	NNS
cord-263455-dquztf5l	274	34	of	of	IN
cord-263455-dquztf5l	274	35	leprosy	leprosy	NN
cord-263455-dquztf5l	274	36	patients	patient	NNS
cord-263455-dquztf5l	274	37	(	(	-LRB-
cord-263455-dquztf5l	274	38	Table	Table	NNP
cord-263455-dquztf5l	274	39	4	4	CD
cord-263455-dquztf5l	274	40	)	)	-RRB-
cord-263455-dquztf5l	274	41	.	.	.
cord-263455-dquztf5l	275	1	95	95	CD
cord-263455-dquztf5l	276	1	The	the	DT
cord-263455-dquztf5l	276	2	study	study	NN
cord-263455-dquztf5l	276	3	focused	focus	VBD
cord-263455-dquztf5l	276	4	on	on	IN
cord-263455-dquztf5l	276	5	household	household	NN
cord-263455-dquztf5l	276	6	contacts	contact	NNS
cord-263455-dquztf5l	276	7	,	,	,
cord-263455-dquztf5l	276	8	neighbors	neighbor	NNS
cord-263455-dquztf5l	276	9	,	,	,
cord-263455-dquztf5l	276	10	and	and	CC
cord-263455-dquztf5l	276	11	social	social	JJ
cord-263455-dquztf5l	276	12	contacts	contact	NNS
cord-263455-dquztf5l	276	13	,	,	,
cord-263455-dquztf5l	276	14	because	because	IN
cord-263455-dquztf5l	276	15	these	these	DT
cord-263455-dquztf5l	276	16	contacts	contact	NNS
cord-263455-dquztf5l	276	17	were	be	VBD
cord-263455-dquztf5l	276	18	identified	identify	VBN
cord-263455-dquztf5l	276	19	as	as	IN
cord-263455-dquztf5l	276	20	most	most	JJS
cord-263455-dquztf5l	276	21	at	at	IN
cord-263455-dquztf5l	276	22	risk	risk	NN
cord-263455-dquztf5l	276	23	.	.	.
cord-263455-dquztf5l	277	1	12	12	CD
cord-263455-dquztf5l	278	1	Approximately	approximately	RB
cord-263455-dquztf5l	278	2	10,000	10,000	CD
cord-263455-dquztf5l	278	3	contacts	contact	NNS
cord-263455-dquztf5l	278	4	received	receive	VBD
cord-263455-dquztf5l	278	5	SDR	SDR	NNP
cord-263455-dquztf5l	278	6	,	,	,
cord-263455-dquztf5l	278	7	while	while	IN
cord-263455-dquztf5l	278	8	another	another	DT
cord-263455-dquztf5l	278	9	10,000	10,000	CD
cord-263455-dquztf5l	278	10	received	receive	VBN
cord-263455-dquztf5l	278	11	placebo	placebo	NN
cord-263455-dquztf5l	278	12	.	.	.
cord-263455-dquztf5l	279	1	Exclusion	exclusion	NN
cord-263455-dquztf5l	279	2	criteria	criterion	NNS
cord-263455-dquztf5l	279	3	were	be	VBD
cord-263455-dquztf5l	279	4	as	as	IN
cord-263455-dquztf5l	279	5	follow	follow	NN
cord-263455-dquztf5l	279	6	:	:	:
cord-263455-dquztf5l	279	7	age	age	NN
cord-263455-dquztf5l	279	8	<	<	XX
cord-263455-dquztf5l	279	9	5	5	CD
cord-263455-dquztf5l	279	10	years	year	NNS
cord-263455-dquztf5l	279	11	,	,	,
cord-263455-dquztf5l	279	12	pregnancy	pregnancy	NN
cord-263455-dquztf5l	279	13	,	,	,
cord-263455-dquztf5l	279	14	liver	liver	NN
cord-263455-dquztf5l	279	15	or	or	CC
cord-263455-dquztf5l	279	16	renal	renal	JJ
cord-263455-dquztf5l	279	17	disease	disease	NN
cord-263455-dquztf5l	279	18	,	,	,
cord-263455-dquztf5l	279	19	signs	sign	NNS
cord-263455-dquztf5l	279	20	or	or	CC
cord-263455-dquztf5l	279	21	symptoms	symptom	NNS
cord-263455-dquztf5l	279	22	of	of	IN
cord-263455-dquztf5l	279	23	leprosy	leprosy	NN
cord-263455-dquztf5l	279	24	or	or	CC
cord-263455-dquztf5l	279	25	TB	TB	NNP
cord-263455-dquztf5l	279	26	and	and	CC
cord-263455-dquztf5l	279	27	previous	previous	JJ
cord-263455-dquztf5l	279	28	rifampicin	rifampicin	NN
cord-263455-dquztf5l	279	29	intake	intake	NN
cord-263455-dquztf5l	279	30	,	,	,
cord-263455-dquztf5l	279	31	refusal	refusal	NN
cord-263455-dquztf5l	279	32	,	,	,
cord-263455-dquztf5l	279	33	or	or	CC
cord-263455-dquztf5l	279	34	contacts	contact	NNS
cord-263455-dquztf5l	279	35	who	who	WP
cord-263455-dquztf5l	279	36	were	be	VBD
cord-263455-dquztf5l	279	37	residing	reside	VBG
cord-263455-dquztf5l	279	38	only	only	RB
cord-263455-dquztf5l	279	39	temporarily	temporarily	RB
cord-263455-dquztf5l	279	40	in	in	IN
cord-263455-dquztf5l	279	41	that	that	DT
cord-263455-dquztf5l	279	42	area	area	NN
cord-263455-dquztf5l	279	43	.	.	.
cord-263455-dquztf5l	280	1	The	the	DT
cord-263455-dquztf5l	280	2	study	study	NN
cord-263455-dquztf5l	280	3	showed	show	VBD
cord-263455-dquztf5l	280	4	that	that	IN
cord-263455-dquztf5l	280	5	SDR	SDR	NNP
cord-263455-dquztf5l	280	6	given	give	VBN
cord-263455-dquztf5l	280	7	to	to	IN
cord-263455-dquztf5l	280	8	contacts	contact	NNS
cord-263455-dquztf5l	280	9	of	of	IN
cord-263455-dquztf5l	280	10	new	new	JJ
cord-263455-dquztf5l	280	11	leprosy	leprosy	NN
cord-263455-dquztf5l	280	12	patients	patient	NNS
cord-263455-dquztf5l	280	13	reduced	reduce	VBD
cord-263455-dquztf5l	280	14	their	-PRON-	PRP$
cord-263455-dquztf5l	280	15	risk	risk	NN
cord-263455-dquztf5l	280	16	of	of	IN
cord-263455-dquztf5l	280	17	developing	develop	VBG
cord-263455-dquztf5l	280	18	clinical	clinical	JJ
cord-263455-dquztf5l	280	19	leprosy	leprosy	NN
cord-263455-dquztf5l	280	20	by	by	IN
cord-263455-dquztf5l	280	21	57	57	CD
cord-263455-dquztf5l	280	22	%	%	NN
cord-263455-dquztf5l	280	23	(	(	-LRB-
cord-263455-dquztf5l	280	24	95	95	CD
cord-263455-dquztf5l	280	25	%	%	NN
cord-263455-dquztf5l	280	26	CI	CI	NNP
cord-263455-dquztf5l	280	27	.	.	.
cord-263455-dquztf5l	281	1	96	96	CD
cord-263455-dquztf5l	282	1	The	the	DT
cord-263455-dquztf5l	282	2	effect	effect	NN
cord-263455-dquztf5l	282	3	was	be	VBD
cord-263455-dquztf5l	282	4	more	more	RBR
cord-263455-dquztf5l	282	5	pronounced	pronounce	VBN
cord-263455-dquztf5l	282	6	in	in	IN
cord-263455-dquztf5l	282	7	more	more	RBR
cord-263455-dquztf5l	282	8	distant	distant	JJ
cord-263455-dquztf5l	282	9	contacts	contact	NNS
cord-263455-dquztf5l	282	10	and	and	CC
cord-263455-dquztf5l	282	11	less	less	JJR
cord-263455-dquztf5l	282	12	in	in	IN
cord-263455-dquztf5l	282	13	blood	blood	NN
cord-263455-dquztf5l	282	14	-	-	HYPH
cord-263455-dquztf5l	282	15	related	relate	VBN
cord-263455-dquztf5l	282	16	family	family	NN
cord-263455-dquztf5l	282	17	.	.	.
cord-263455-dquztf5l	283	1	As	as	IN
cord-263455-dquztf5l	283	2	part	part	NN
cord-263455-dquztf5l	283	3	of	of	IN
cord-263455-dquztf5l	283	4	the	the	DT
cord-263455-dquztf5l	283	5	COLEP	COLEP	NNP
cord-263455-dquztf5l	283	6	study	study	NN
cord-263455-dquztf5l	283	7	,	,	,
cord-263455-dquztf5l	283	8	the	the	DT
cord-263455-dquztf5l	283	9	cost	cost	NN
cord-263455-dquztf5l	283	10	-	-	HYPH
cord-263455-dquztf5l	283	11	effectiveness	effectiveness	NN
cord-263455-dquztf5l	283	12	of	of	IN
cord-263455-dquztf5l	283	13	using	use	VBG
cord-263455-dquztf5l	283	14	SDR	SDR	NNP
cord-263455-dquztf5l	283	15	to	to	TO
cord-263455-dquztf5l	283	16	prevent	prevent	VB
cord-263455-dquztf5l	283	17	leprosy	leprosy	NN
cord-263455-dquztf5l	283	18	was	be	VBD
cord-263455-dquztf5l	283	19	assessed	assess	VBN
cord-263455-dquztf5l	283	20	to	to	TO
cord-263455-dquztf5l	283	21	be	be	VB
cord-263455-dquztf5l	283	22	good	good	JJ
cord-263455-dquztf5l	283	23	at	at	IN
cord-263455-dquztf5l	283	24	all	all	DT
cord-263455-dquztf5l	283	25	contact	contact	NN
cord-263455-dquztf5l	283	26	levels	level	NNS
cord-263455-dquztf5l	283	27	.	.	.
cord-263455-dquztf5l	284	1	97	97	CD
cord-263455-dquztf5l	285	1	The	the	DT
cord-263455-dquztf5l	285	2	incremental	incremental	JJ
cord-263455-dquztf5l	285	3	cost	cost	NN
cord-263455-dquztf5l	285	4	-	-	HYPH
cord-263455-dquztf5l	285	5	effectiveness	effectiveness	NN
cord-263455-dquztf5l	285	6	ratio	ratio	NN
cord-263455-dquztf5l	285	7	(	(	-LRB-
cord-263455-dquztf5l	285	8	ICER	ICER	NNP
cord-263455-dquztf5l	285	9	)	)	-RRB-
cord-263455-dquztf5l	285	10	was	be	VBD
cord-263455-dquztf5l	285	11	US$	us$	$
cord-263455-dquztf5l	285	12	158	158	CD
cord-263455-dquztf5l	285	13	per	per	IN
cord-263455-dquztf5l	285	14	one	one	CD
cord-263455-dquztf5l	285	15	prevented	prevent	VBN
cord-263455-dquztf5l	285	16	leprosy	leprosy	NN
cord-263455-dquztf5l	285	17	patient	patient	JJ
cord-263455-dquztf5l	285	18	.	.	.
cord-263455-dquztf5l	286	1	97	97	CD
cord-263455-dquztf5l	287	1	Overall	overall	RB
cord-263455-dquztf5l	287	2	,	,	,
cord-263455-dquztf5l	287	3	rifampicin	rifampicin	JJ
cord-263455-dquztf5l	287	4	administration	administration	NN
cord-263455-dquztf5l	287	5	to	to	IN
cord-263455-dquztf5l	287	6	screened	screen	VBN
cord-263455-dquztf5l	287	7	contacts	contact	NNS
cord-263455-dquztf5l	287	8	of	of	IN
cord-263455-dquztf5l	287	9	leprosy	leprosy	NN
cord-263455-dquztf5l	287	10	patients	patient	NNS
cord-263455-dquztf5l	287	11	was	be	VBD
cord-263455-dquztf5l	287	12	shown	show	VBN
cord-263455-dquztf5l	287	13	to	to	TO
cord-263455-dquztf5l	287	14	be	be	VB
cord-263455-dquztf5l	287	15	affordable	affordable	JJ
cord-263455-dquztf5l	287	16	and	and	CC
cord-263455-dquztf5l	287	17	feasible	feasible	JJ
cord-263455-dquztf5l	287	18	.	.	.
cord-263455-dquztf5l	288	1	95	95	CD
cord-263455-dquztf5l	288	2	,	,	,
cord-263455-dquztf5l	288	3	97	97	CD
cord-263455-dquztf5l	289	1	An	an	DT
cord-263455-dquztf5l	289	2	additional	additional	JJ
cord-263455-dquztf5l	289	3	post	post	FW
cord-263455-dquztf5l	289	4	hoc	hoc	FW
cord-263455-dquztf5l	289	5	finding	finding	NN
cord-263455-dquztf5l	289	6	during	during	IN
cord-263455-dquztf5l	289	7	the	the	DT
cord-263455-dquztf5l	289	8	COLEP	COLEP	NNP
cord-263455-dquztf5l	289	9	study	study	NN
cord-263455-dquztf5l	289	10	was	be	VBD
cord-263455-dquztf5l	289	11	that	that	IN
cord-263455-dquztf5l	289	12	rifampicin	rifampicin	NN
cord-263455-dquztf5l	289	13	given	give	VBN
cord-263455-dquztf5l	289	14	to	to	IN
cord-263455-dquztf5l	289	15	contacts	contact	NNS
cord-263455-dquztf5l	289	16	who	who	WP
cord-263455-dquztf5l	289	17	have	have	VBP
cord-263455-dquztf5l	289	18	had	have	VBN
cord-263455-dquztf5l	289	19	a	a	DT
cord-263455-dquztf5l	289	20	childhood	childhood	NN
cord-263455-dquztf5l	289	21	BCG	BCG	NNP
cord-263455-dquztf5l	289	22	vaccination	vaccination	NN
cord-263455-dquztf5l	289	23	,	,	,
cord-263455-dquztf5l	289	24	had	have	VBD
cord-263455-dquztf5l	289	25	a	a	DT
cord-263455-dquztf5l	289	26	protective	protective	JJ
cord-263455-dquztf5l	289	27	effect	effect	NN
cord-263455-dquztf5l	289	28	of	of	IN
cord-263455-dquztf5l	289	29	80	80	CD
cord-263455-dquztf5l	289	30	%	%	NN
cord-263455-dquztf5l	289	31	(	(	-LRB-
cord-263455-dquztf5l	289	32	95	95	CD
cord-263455-dquztf5l	289	33	%	%	NN
cord-263455-dquztf5l	289	34	CI	CI	NNP
cord-263455-dquztf5l	289	35	50	50	CD
cord-263455-dquztf5l	289	36	-	-	SYM
cord-263455-dquztf5l	289	37	92	92	CD
cord-263455-dquztf5l	289	38	)	)	-RRB-
cord-263455-dquztf5l	289	39	.	.	.
cord-263455-dquztf5l	290	1	98	98	CD
cord-263455-dquztf5l	291	1	In	in	IN
cord-263455-dquztf5l	291	2	another	another	DT
cord-263455-dquztf5l	291	3	COLEP	COLEP	NNP
cord-263455-dquztf5l	291	4	substudy	substudy	NN
cord-263455-dquztf5l	291	5	,	,	,
cord-263455-dquztf5l	291	6	the	the	DT
cord-263455-dquztf5l	291	7	acceptability	acceptability	NN
cord-263455-dquztf5l	291	8	of	of	IN
cord-263455-dquztf5l	291	9	SDR	SDR	NNP
cord-263455-dquztf5l	291	10	was	be	VBD
cord-263455-dquztf5l	291	11	assessed	assess	VBN
cord-263455-dquztf5l	291	12	among	among	IN
cord-263455-dquztf5l	291	13	healthy	healthy	JJ
cord-263455-dquztf5l	291	14	community	community	NN
cord-263455-dquztf5l	291	15	members	member	NNS
cord-263455-dquztf5l	291	16	.	.	.
cord-263455-dquztf5l	292	1	99	99	CD
cord-263455-dquztf5l	293	1	All	all	DT
cord-263455-dquztf5l	293	2	study	study	NN
cord-263455-dquztf5l	293	3	participants	participant	NNS
cord-263455-dquztf5l	293	4	expressed	express	VBD
cord-263455-dquztf5l	293	5	that	that	IN
cord-263455-dquztf5l	293	6	they	-PRON-	PRP
cord-263455-dquztf5l	293	7	would	would	MD
cord-263455-dquztf5l	293	8	be	be	VB
cord-263455-dquztf5l	293	9	willing	willing	JJ
cord-263455-dquztf5l	293	10	to	to	TO
cord-263455-dquztf5l	293	11	take	take	VB
cord-263455-dquztf5l	293	12	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	293	13	,	,	,
cord-263455-dquztf5l	293	14	even	even	RB
cord-263455-dquztf5l	293	15	after	after	IN
cord-263455-dquztf5l	293	16	it	-PRON-	PRP
cord-263455-dquztf5l	293	17	was	be	VBD
cord-263455-dquztf5l	293	18	explained	explain	VBN
cord-263455-dquztf5l	293	19	that	that	IN
cord-263455-dquztf5l	293	20	full	full	JJ
cord-263455-dquztf5l	293	21	protection	protection	NN
cord-263455-dquztf5l	293	22	against	against	IN
cord-263455-dquztf5l	293	23	leprosy	leprosy	NN
cord-263455-dquztf5l	293	24	was	be	VBD
cord-263455-dquztf5l	293	25	not	not	RB
cord-263455-dquztf5l	293	26	guaranteed	guarantee	VBN
cord-263455-dquztf5l	293	27	.	.	.
cord-263455-dquztf5l	294	1	However	however	RB
cord-263455-dquztf5l	294	2	,	,	,
cord-263455-dquztf5l	294	3	many	many	JJ
cord-263455-dquztf5l	294	4	participants	participant	NNS
cord-263455-dquztf5l	294	5	also	also	RB
cord-263455-dquztf5l	294	6	expressed	express	VBD
cord-263455-dquztf5l	294	7	that	that	IN
cord-263455-dquztf5l	294	8	they	-PRON-	PRP
cord-263455-dquztf5l	294	9	would	would	MD
cord-263455-dquztf5l	294	10	not	not	RB
cord-263455-dquztf5l	294	11	like	like	VB
cord-263455-dquztf5l	294	12	to	to	TO
cord-263455-dquztf5l	294	13	share	share	VB
cord-263455-dquztf5l	294	14	information	information	NN
cord-263455-dquztf5l	294	15	on	on	IN
cord-263455-dquztf5l	294	16	their	-PRON-	PRP$
cord-263455-dquztf5l	294	17	disease	disease	NN
cord-263455-dquztf5l	294	18	status	status	NN
cord-263455-dquztf5l	294	19	with	with	IN
cord-263455-dquztf5l	294	20	neighbors	neighbor	NNS
cord-263455-dquztf5l	294	21	and	and	CC
cord-263455-dquztf5l	294	22	social	social	JJ
cord-263455-dquztf5l	294	23	contacts	contact	NNS
cord-263455-dquztf5l	294	24	if	if	IN
cord-263455-dquztf5l	294	25	they	-PRON-	PRP
cord-263455-dquztf5l	294	26	would	would	MD
cord-263455-dquztf5l	294	27	have	have	VB
cord-263455-dquztf5l	294	28	leprosy	leprosy	NN
cord-263455-dquztf5l	294	29	.	.	.
cord-263455-dquztf5l	295	1	99	99	CD
cord-263455-dquztf5l	296	1	In	in	IN
cord-263455-dquztf5l	296	2	Follow	follow	NN
cord-263455-dquztf5l	296	3	-	-	HYPH
cord-263455-dquztf5l	296	4	Up	up	NN
cord-263455-dquztf5l	296	5	of	of	IN
cord-263455-dquztf5l	296	6	the	the	DT
cord-263455-dquztf5l	296	7	COLEP	COLEP	NNP
cord-263455-dquztf5l	296	8	Study	Study	NNP
cord-263455-dquztf5l	296	9	Another	another	DT
cord-263455-dquztf5l	296	10	workshop	workshop	NN
cord-263455-dquztf5l	296	11	on	on	IN
cord-263455-dquztf5l	296	12	the	the	DT
cord-263455-dquztf5l	296	13	use	use	NN
cord-263455-dquztf5l	296	14	of	of	IN
cord-263455-dquztf5l	296	15	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	296	16	against	against	IN
cord-263455-dquztf5l	296	17	leprosy	leprosy	NN
cord-263455-dquztf5l	296	18	was	be	VBD
cord-263455-dquztf5l	296	19	held	hold	VBN
cord-263455-dquztf5l	296	20	in	in	IN
cord-263455-dquztf5l	296	21	2006	2006	CD
cord-263455-dquztf5l	296	22	,	,	,
cord-263455-dquztf5l	296	23	in	in	IN
cord-263455-dquztf5l	296	24	the	the	DT
cord-263455-dquztf5l	296	25	Netherlands	Netherlands	NNP
cord-263455-dquztf5l	296	26	.	.	.
cord-263455-dquztf5l	297	1	100	100	CD
cord-263455-dquztf5l	298	1	Here	here	RB
cord-263455-dquztf5l	298	2	,	,	,
cord-263455-dquztf5l	298	3	the	the	DT
cord-263455-dquztf5l	298	4	preliminary	preliminary	JJ
cord-263455-dquztf5l	298	5	COLEP	COLEP	NNP
cord-263455-dquztf5l	298	6	data	datum	NNS
cord-263455-dquztf5l	298	7	were	be	VBD
cord-263455-dquztf5l	298	8	presented	present	VBN
cord-263455-dquztf5l	298	9	as	as	RB
cord-263455-dquztf5l	298	10	well	well	RB
cord-263455-dquztf5l	298	11	as	as	IN
cord-263455-dquztf5l	298	12	results	result	NNS
cord-263455-dquztf5l	298	13	from	from	IN
cord-263455-dquztf5l	298	14	another	another	DT
cord-263455-dquztf5l	298	15	controlled	control	VBN
cord-263455-dquztf5l	298	16	trial	trial	NN
cord-263455-dquztf5l	298	17	using	use	VBG
cord-263455-dquztf5l	298	18	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	298	19	in	in	IN
cord-263455-dquztf5l	298	20	two	two	CD
cord-263455-dquztf5l	298	21	repeated	repeat	VBN
cord-263455-dquztf5l	298	22	doses	dose	NNS
cord-263455-dquztf5l	298	23	on	on	IN
cord-263455-dquztf5l	298	24	a	a	DT
cord-263455-dquztf5l	298	25	group	group	NN
cord-263455-dquztf5l	298	26	of	of	IN
cord-263455-dquztf5l	298	27	five	five	CD
cord-263455-dquztf5l	298	28	islands	island	NNS
cord-263455-dquztf5l	298	29	in	in	IN
cord-263455-dquztf5l	298	30	the	the	DT
cord-263455-dquztf5l	298	31	Flores	Flores	NNP
cord-263455-dquztf5l	298	32	Sea	Sea	NNP
cord-263455-dquztf5l	298	33	in	in	IN
cord-263455-dquztf5l	298	34	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	298	35	(	(	-LRB-
cord-263455-dquztf5l	298	36	Table	Table	NNP
cord-263455-dquztf5l	298	37	4	4	CD
cord-263455-dquztf5l	298	38	)	)	-RRB-
cord-263455-dquztf5l	298	39	.	.	.
cord-263455-dquztf5l	299	1	95	95	CD
cord-263455-dquztf5l	299	2	,	,	,
cord-263455-dquztf5l	299	3	101	101	CD
cord-263455-dquztf5l	300	1	This	this	DT
cord-263455-dquztf5l	300	2	trial	trial	NN
cord-263455-dquztf5l	300	3	showed	show	VBD
cord-263455-dquztf5l	300	4	similar	similar	JJ
cord-263455-dquztf5l	300	5	results	result	NNS
cord-263455-dquztf5l	300	6	to	to	IN
cord-263455-dquztf5l	300	7	the	the	DT
cord-263455-dquztf5l	300	8	COLEP	COLEP	NNP
cord-263455-dquztf5l	300	9	study	study	NN
cord-263455-dquztf5l	300	10	,	,	,
cord-263455-dquztf5l	300	11	with	with	IN
cord-263455-dquztf5l	300	12	a	a	DT
cord-263455-dquztf5l	300	13	risk	risk	NN
cord-263455-dquztf5l	300	14	reduction	reduction	NN
cord-263455-dquztf5l	300	15	of	of	IN
cord-263455-dquztf5l	300	16	about	about	RB
cord-263455-dquztf5l	300	17	60	60	CD
cord-263455-dquztf5l	300	18	%	%	NN
cord-263455-dquztf5l	300	19	on	on	IN
cord-263455-dquztf5l	300	20	the	the	DT
cord-263455-dquztf5l	300	21	island	island	NN
cord-263455-dquztf5l	300	22	where	where	WRB
cord-263455-dquztf5l	300	23	the	the	DT
cord-263455-dquztf5l	300	24	total	total	JJ
cord-263455-dquztf5l	300	25	population	population	NN
cord-263455-dquztf5l	300	26	was	be	VBD
cord-263455-dquztf5l	300	27	screened	screen	VBN
cord-263455-dquztf5l	300	28	and	and	CC
cord-263455-dquztf5l	300	29	received	receive	VBD
cord-263455-dquztf5l	300	30	two	two	CD
cord-263455-dquztf5l	300	31	dosages	dosage	NNS
cord-263455-dquztf5l	300	32	of	of	IN
cord-263455-dquztf5l	300	33	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	300	34	when	when	WRB
cord-263455-dquztf5l	300	35	eligible	eligible	JJ
cord-263455-dquztf5l	300	36	.	.	.
cord-263455-dquztf5l	301	1	95	95	CD
cord-263455-dquztf5l	301	2	,	,	,
cord-263455-dquztf5l	301	3	101	101	CD
cord-263455-dquztf5l	301	4	Preliminary	preliminary	JJ
cord-263455-dquztf5l	301	5	data	datum	NNS
cord-263455-dquztf5l	301	6	of	of	IN
cord-263455-dquztf5l	301	7	a	a	DT
cord-263455-dquztf5l	301	8	randomized	randomized	JJ
cord-263455-dquztf5l	301	9	controlled	control	VBN
cord-263455-dquztf5l	301	10	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	301	11	trial	trial	NN
cord-263455-dquztf5l	301	12	in	in	IN
cord-263455-dquztf5l	301	13	India	India	NNP
cord-263455-dquztf5l	301	14	,	,	,
cord-263455-dquztf5l	301	15	the	the	DT
cord-263455-dquztf5l	301	16	results	result	NNS
cord-263455-dquztf5l	301	17	of	of	IN
cord-263455-dquztf5l	301	18	which	which	WDT
cord-263455-dquztf5l	301	19	were	be	VBD
cord-263455-dquztf5l	301	20	never	never	RB
cord-263455-dquztf5l	301	21	individually	individually	RB
cord-263455-dquztf5l	301	22	published	publish	VBN
cord-263455-dquztf5l	301	23	,	,	,
cord-263455-dquztf5l	301	24	were	be	VBD
cord-263455-dquztf5l	301	25	presented	present	VBN
cord-263455-dquztf5l	301	26	by	by	IN
cord-263455-dquztf5l	301	27	Declercq	Declercq	NNP
cord-263455-dquztf5l	301	28	in	in	IN
cord-263455-dquztf5l	301	29	this	this	DT
cord-263455-dquztf5l	301	30	workshop	workshop	NN
cord-263455-dquztf5l	301	31	.	.	.
cord-263455-dquztf5l	302	1	100	100	CD
cord-263455-dquztf5l	302	2	SDR	SDR	NNP
cord-263455-dquztf5l	302	3	given	give	VBN
cord-263455-dquztf5l	302	4	to	to	IN
cord-263455-dquztf5l	302	5	household	household	NN
cord-263455-dquztf5l	302	6	contacts	contact	NNS
cord-263455-dquztf5l	302	7	was	be	VBD
cord-263455-dquztf5l	302	8	compared	compare	VBN
cord-263455-dquztf5l	302	9	with	with	IN
cord-263455-dquztf5l	302	10	placebo	placebo	NN
cord-263455-dquztf5l	302	11	and	and	CC
cord-263455-dquztf5l	302	12	showed	show	VBD
cord-263455-dquztf5l	302	13	a	a	DT
cord-263455-dquztf5l	302	14	74	74	CD
cord-263455-dquztf5l	302	15	%	%	NN
cord-263455-dquztf5l	302	16	risk	risk	NN
cord-263455-dquztf5l	302	17	reduction	reduction	NN
cord-263455-dquztf5l	302	18	after	after	IN
cord-263455-dquztf5l	302	19	4	4	CD
cord-263455-dquztf5l	302	20	-	-	SYM
cord-263455-dquztf5l	302	21	5	5	CD
cord-263455-dquztf5l	302	22	years	year	NNS
cord-263455-dquztf5l	302	23	follow	follow	NN
cord-263455-dquztf5l	302	24	-	-	HYPH
cord-263455-dquztf5l	302	25	up	up	NN
cord-263455-dquztf5l	302	26	.	.	.
cord-263455-dquztf5l	303	1	During	during	IN
cord-263455-dquztf5l	303	2	the	the	DT
cord-263455-dquztf5l	303	3	workshop	workshop	NN
cord-263455-dquztf5l	303	4	,	,	,
cord-263455-dquztf5l	303	5	concerns	concern	NNS
cord-263455-dquztf5l	303	6	were	be	VBD
cord-263455-dquztf5l	303	7	raised	raise	VBN
cord-263455-dquztf5l	303	8	regarding	regard	VBG
cord-263455-dquztf5l	303	9	the	the	DT
cord-263455-dquztf5l	303	10	risk	risk	NN
cord-263455-dquztf5l	303	11	of	of	IN
cord-263455-dquztf5l	303	12	inducing	induce	VBG
cord-263455-dquztf5l	303	13	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	303	14	resistance	resistance	NN
cord-263455-dquztf5l	303	15	when	when	WRB
cord-263455-dquztf5l	303	16	using	use	VBG
cord-263455-dquztf5l	303	17	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	303	18	on	on	IN
cord-263455-dquztf5l	303	19	a	a	DT
cord-263455-dquztf5l	303	20	large	large	JJ
cord-263455-dquztf5l	303	21	scale	scale	NN
cord-263455-dquztf5l	303	22	.	.	.
cord-263455-dquztf5l	304	1	100	100	CD
cord-263455-dquztf5l	305	1	Ji	Ji	NNP
cord-263455-dquztf5l	305	2	addressed	address	VBD
cord-263455-dquztf5l	305	3	these	these	DT
cord-263455-dquztf5l	305	4	concerns	concern	NNS
cord-263455-dquztf5l	305	5	with	with	IN
cord-263455-dquztf5l	305	6	the	the	DT
cord-263455-dquztf5l	305	7	argument	argument	NN
cord-263455-dquztf5l	305	8	that	that	IN
cord-263455-dquztf5l	305	9	resistance	resistance	NN
cord-263455-dquztf5l	305	10	is	be	VBZ
cord-263455-dquztf5l	305	11	very	very	RB
cord-263455-dquztf5l	305	12	unlikely	unlikely	JJ
cord-263455-dquztf5l	305	13	to	to	TO
cord-263455-dquztf5l	305	14	emerge	emerge	VB
cord-263455-dquztf5l	305	15	because	because	IN
cord-263455-dquztf5l	305	16	SDR	SDR	NNP
cord-263455-dquztf5l	305	17	is	be	VBZ
cord-263455-dquztf5l	305	18	proven	prove	VBN
cord-263455-dquztf5l	305	19	not	not	RB
cord-263455-dquztf5l	305	20	to	to	TO
cord-263455-dquztf5l	305	21	select	select	VB
cord-263455-dquztf5l	305	22	resistant	resistant	JJ
cord-263455-dquztf5l	305	23	mutants	mutant	NNS
cord-263455-dquztf5l	305	24	,	,	,
cord-263455-dquztf5l	305	25	as	as	IN
cord-263455-dquztf5l	305	26	shown	show	VBN
cord-263455-dquztf5l	305	27	in	in	IN
cord-263455-dquztf5l	305	28	publications	publication	NNS
cord-263455-dquztf5l	305	29	on	on	IN
cord-263455-dquztf5l	305	30	multibacillary	multibacillary	JJ
cord-263455-dquztf5l	305	31	patients	patient	NNS
cord-263455-dquztf5l	305	32	who	who	WP
cord-263455-dquztf5l	305	33	relapse	relapse	VBP
cord-263455-dquztf5l	305	34	after	after	IN
cord-263455-dquztf5l	305	35	SDR	SDR	NNP
cord-263455-dquztf5l	305	36	treatment	treatment	NN
cord-263455-dquztf5l	305	37	.	.	.
cord-263455-dquztf5l	306	1	89	89	CD
cord-263455-dquztf5l	306	2	,	,	,
cord-263455-dquztf5l	306	3	100	100	CD
cord-263455-dquztf5l	306	4	Experts	expert	NNS
cord-263455-dquztf5l	306	5	agreed	agree	VBD
cord-263455-dquztf5l	306	6	that	that	IN
cord-263455-dquztf5l	306	7	the	the	DT
cord-263455-dquztf5l	306	8	use	use	NN
cord-263455-dquztf5l	306	9	of	of	IN
cord-263455-dquztf5l	306	10	a	a	DT
cord-263455-dquztf5l	306	11	single	single	JJ
cord-263455-dquztf5l	306	12	dose	dose	NN
cord-263455-dquztf5l	306	13	as	as	IN
cord-263455-dquztf5l	306	14	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	306	15	was	be	VBD
cord-263455-dquztf5l	306	16	to	to	TO
cord-263455-dquztf5l	306	17	be	be	VB
cord-263455-dquztf5l	306	18	preferred	prefer	VBN
cord-263455-dquztf5l	306	19	,	,	,
cord-263455-dquztf5l	306	20	that	that	DT
cord-263455-dquztf5l	306	21	powerful	powerful	JJ
cord-263455-dquztf5l	306	22	bactericidal	bactericidal	JJ
cord-263455-dquztf5l	306	23	activity	activity	NN
cord-263455-dquztf5l	306	24	was	be	VBD
cord-263455-dquztf5l	306	25	a	a	DT
cord-263455-dquztf5l	306	26	necessity	necessity	NN
cord-263455-dquztf5l	306	27	,	,	,
cord-263455-dquztf5l	306	28	and	and	CC
cord-263455-dquztf5l	306	29	that	that	IN
cord-263455-dquztf5l	306	30	adverse	adverse	JJ
cord-263455-dquztf5l	306	31	events	event	NNS
cord-263455-dquztf5l	306	32	risk	risk	NN
cord-263455-dquztf5l	306	33	should	should	MD
cord-263455-dquztf5l	306	34	be	be	VB
cord-263455-dquztf5l	306	35	minimal	minimal	JJ
cord-263455-dquztf5l	306	36	.	.	.
cord-263455-dquztf5l	307	1	Several	several	JJ
cord-263455-dquztf5l	307	2	drugs	drug	NNS
cord-263455-dquztf5l	307	3	in	in	IN
cord-263455-dquztf5l	307	4	the	the	DT
cord-263455-dquztf5l	307	5	rifamycin	rifamycin	NNP
cord-263455-dquztf5l	307	6	and	and	CC
cord-263455-dquztf5l	307	7	quinolone	quinolone	NNP
cord-263455-dquztf5l	307	8	group	group	NNP
cord-263455-dquztf5l	307	9	were	be	VBD
cord-263455-dquztf5l	307	10	considered	consider	VBN
cord-263455-dquztf5l	307	11	suitable	suitable	JJ
cord-263455-dquztf5l	307	12	candidates	candidate	NNS
cord-263455-dquztf5l	307	13	for	for	IN
cord-263455-dquztf5l	307	14	leprosy	leprosy	NN
cord-263455-dquztf5l	307	15	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	307	16	,	,	,
cord-263455-dquztf5l	307	17	though	though	IN
cord-263455-dquztf5l	307	18	the	the	DT
cord-263455-dquztf5l	307	19	experts	expert	NNS
cord-263455-dquztf5l	307	20	agreed	agree	VBD
cord-263455-dquztf5l	307	21	that	that	IN
cord-263455-dquztf5l	307	22	clinical	clinical	JJ
cord-263455-dquztf5l	307	23	trials	trial	NNS
cord-263455-dquztf5l	307	24	were	be	VBD
cord-263455-dquztf5l	307	25	needed	need	VBN
cord-263455-dquztf5l	307	26	to	to	TO
cord-263455-dquztf5l	307	27	provide	provide	VB
cord-263455-dquztf5l	307	28	evidence	evidence	NN
cord-263455-dquztf5l	307	29	of	of	IN
cord-263455-dquztf5l	307	30	their	-PRON-	PRP$
cord-263455-dquztf5l	307	31	effectiveness	effectiveness	NN
cord-263455-dquztf5l	307	32	and	and	CC
cord-263455-dquztf5l	307	33	that	that	IN
cord-263455-dquztf5l	307	34	drug	drug	NN
cord-263455-dquztf5l	307	35	prices	price	NNS
cord-263455-dquztf5l	307	36	should	should	MD
cord-263455-dquztf5l	307	37	be	be	VB
cord-263455-dquztf5l	307	38	considered	consider	VBN
cord-263455-dquztf5l	307	39	.	.	.
cord-263455-dquztf5l	308	1	95	95	CD
cord-263455-dquztf5l	309	1	The	the	DT
cord-263455-dquztf5l	309	2	following	following	JJ
cord-263455-dquztf5l	309	3	requirements	requirement	NNS
cord-263455-dquztf5l	309	4	were	be	VBD
cord-263455-dquztf5l	309	5	formulated	formulate	VBN
cord-263455-dquztf5l	309	6	for	for	IN
cord-263455-dquztf5l	309	7	operational	operational	JJ
cord-263455-dquztf5l	309	8	research	research	NN
cord-263455-dquztf5l	309	9	programs	program	NNS
cord-263455-dquztf5l	309	10	:	:	:
cord-263455-dquztf5l	309	11	(	(	-LRB-
cord-263455-dquztf5l	309	12	a	a	LS
cord-263455-dquztf5l	309	13	)	)	-RRB-
cord-263455-dquztf5l	309	14	screening	screening	NN
cord-263455-dquztf5l	309	15	of	of	IN
cord-263455-dquztf5l	309	16	contacts	contact	NNS
cord-263455-dquztf5l	309	17	for	for	IN
cord-263455-dquztf5l	309	18	signs	sign	NNS
cord-263455-dquztf5l	309	19	and	and	CC
cord-263455-dquztf5l	309	20	symptoms	symptom	NNS
cord-263455-dquztf5l	309	21	of	of	IN
cord-263455-dquztf5l	309	22	leprosy	leprosy	NN
cord-263455-dquztf5l	309	23	and	and	CC
cord-263455-dquztf5l	309	24	TB	TB	NNP
cord-263455-dquztf5l	309	25	;	;	:
cord-263455-dquztf5l	309	26	(	(	-LRB-
cord-263455-dquztf5l	309	27	b	b	NN
cord-263455-dquztf5l	309	28	)	)	-RRB-
cord-263455-dquztf5l	309	29	provision	provision	NN
cord-263455-dquztf5l	309	30	of	of	IN
cord-263455-dquztf5l	309	31	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	309	32	under	under	IN
cord-263455-dquztf5l	309	33	direct	direct	JJ
cord-263455-dquztf5l	309	34	supervision	supervision	NN
cord-263455-dquztf5l	309	35	;	;	,
cord-263455-dquztf5l	309	36	(	(	-LRB-
cord-263455-dquztf5l	309	37	c	c	NN
cord-263455-dquztf5l	309	38	)	)	-RRB-
cord-263455-dquztf5l	309	39	a	a	DT
cord-263455-dquztf5l	309	40	recording	recording	NN
cord-263455-dquztf5l	309	41	and	and	CC
cord-263455-dquztf5l	309	42	reporting	reporting	NN
cord-263455-dquztf5l	309	43	system	system	NN
cord-263455-dquztf5l	309	44	;	;	:
cord-263455-dquztf5l	309	45	(	(	-LRB-
cord-263455-dquztf5l	309	46	d	d	NN
cord-263455-dquztf5l	309	47	)	)	-RRB-
cord-263455-dquztf5l	309	48	training	training	NN
cord-263455-dquztf5l	309	49	of	of	IN
cord-263455-dquztf5l	309	50	health	health	NN
cord-263455-dquztf5l	309	51	workers	worker	NNS
cord-263455-dquztf5l	309	52	;	;	,
cord-263455-dquztf5l	309	53	(	(	-LRB-
cord-263455-dquztf5l	309	54	e	e	LS
cord-263455-dquztf5l	309	55	)	)	-RRB-
cord-263455-dquztf5l	309	56	proper	proper	JJ
cord-263455-dquztf5l	309	57	information	information	NN
cord-263455-dquztf5l	309	58	for	for	IN
cord-263455-dquztf5l	309	59	people	people	NNS
cord-263455-dquztf5l	309	60	receiving	receive	VBG
cord-263455-dquztf5l	309	61	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	309	62	;	;	:
cord-263455-dquztf5l	309	63	and	and	CC
cord-263455-dquztf5l	309	64	(	(	-LRB-
cord-263455-dquztf5l	309	65	f	f	LS
cord-263455-dquztf5l	309	66	)	)	-RRB-
cord-263455-dquztf5l	309	67	a	a	DT
cord-263455-dquztf5l	309	68	system	system	NN
cord-263455-dquztf5l	309	69	for	for	IN
cord-263455-dquztf5l	309	70	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	309	71	resistance	resistance	NN
cord-263455-dquztf5l	309	72	monitoring	monitoring	NN
cord-263455-dquztf5l	309	73	.	.	.
cord-263455-dquztf5l	309	74	95	95	CD
cord-263455-dquztf5l	310	1	In	in	IN
cord-263455-dquztf5l	310	2	2009	2009	CD
cord-263455-dquztf5l	310	3	,	,	,
cord-263455-dquztf5l	310	4	an	an	DT
cord-263455-dquztf5l	310	5	updated	update	VBN
cord-263455-dquztf5l	310	6	meta	meta	NN
cord-263455-dquztf5l	310	7	-	-	HYPH
cord-263455-dquztf5l	310	8	analysis	analysis	NN
cord-263455-dquztf5l	310	9	of	of	IN
cord-263455-dquztf5l	310	10	randomized	randomized	JJ
cord-263455-dquztf5l	310	11	controlled	control	VBN
cord-263455-dquztf5l	310	12	trials	trial	NNS
cord-263455-dquztf5l	310	13	of	of	IN
cord-263455-dquztf5l	310	14	leprosy	leprosy	NN
cord-263455-dquztf5l	310	15	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	310	16	was	be	VBD
cord-263455-dquztf5l	310	17	published	publish	VBN
cord-263455-dquztf5l	310	18	by	by	IN
cord-263455-dquztf5l	310	19	Reveiz	Reveiz	NNP
cord-263455-dquztf5l	310	20	et	et	FW
cord-263455-dquztf5l	310	21	al	al	NNP
cord-263455-dquztf5l	310	22	.	.	.
cord-263455-dquztf5l	311	1	102	102	CD
cord-263455-dquztf5l	312	1	They	-PRON-	PRP
cord-263455-dquztf5l	312	2	confirmed	confirm	VBD
cord-263455-dquztf5l	312	3	the	the	DT
cord-263455-dquztf5l	312	4	review	review	NN
cord-263455-dquztf5l	312	5	by	by	IN
cord-263455-dquztf5l	312	6	Smith	Smith	NNP
cord-263455-dquztf5l	312	7	and	and	CC
cord-263455-dquztf5l	312	8	Smith	Smith	NNP
cord-263455-dquztf5l	312	9	,	,	,
cord-263455-dquztf5l	312	10	concluding	conclude	VBG
cord-263455-dquztf5l	312	11	that	that	IN
cord-263455-dquztf5l	312	12	the	the	DT
cord-263455-dquztf5l	312	13	use	use	NN
cord-263455-dquztf5l	312	14	of	of	IN
cord-263455-dquztf5l	312	15	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	312	16	and	and	CC
cord-263455-dquztf5l	312	17	acedapsone/	acedapsone/	CD
cord-263455-dquztf5l	312	18	dapsone	dapsone	NN
cord-263455-dquztf5l	312	19	as	as	IN
cord-263455-dquztf5l	312	20	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	312	21	can	can	MD
cord-263455-dquztf5l	312	22	help	help	VB
cord-263455-dquztf5l	312	23	reduce	reduce	VB
cord-263455-dquztf5l	312	24	leprosy	leprosy	NN
cord-263455-dquztf5l	312	25	incidence	incidence	NN
cord-263455-dquztf5l	312	26	and	and	CC
cord-263455-dquztf5l	312	27	that	that	IN
cord-263455-dquztf5l	312	28	post	post	JJ
cord-263455-dquztf5l	312	29	-	-	JJ
cord-263455-dquztf5l	312	30	exposure	exposure	JJ
cord-263455-dquztf5l	312	31	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	312	32	should	should	MD
cord-263455-dquztf5l	312	33	become	become	VB
cord-263455-dquztf5l	312	34	embedded	embed	VBN
cord-263455-dquztf5l	312	35	in	in	IN
cord-263455-dquztf5l	312	36	leprosy	leprosy	NN
cord-263455-dquztf5l	312	37	control	control	NN
cord-263455-dquztf5l	312	38	programs	program	NNS
cord-263455-dquztf5l	312	39	.	.	.
cord-263455-dquztf5l	313	1	79	79	CD
cord-263455-dquztf5l	313	2	,	,	,
cord-263455-dquztf5l	313	3	102	102	CD
cord-263455-dquztf5l	314	1	In	in	IN
cord-263455-dquztf5l	314	2	the	the	DT
cord-263455-dquztf5l	314	3	same	same	JJ
cord-263455-dquztf5l	314	4	year	year	NN
cord-263455-dquztf5l	314	5	,	,	,
cord-263455-dquztf5l	314	6	the	the	DT
cord-263455-dquztf5l	314	7	WHO	WHO	NNP
cord-263455-dquztf5l	314	8	South	South	NNP
cord-263455-dquztf5l	314	9	-	-	HYPH
cord-263455-dquztf5l	314	10	East	East	NNP
cord-263455-dquztf5l	314	11	Asia	Asia	NNP
cord-263455-dquztf5l	314	12	Regional	Regional	NNP
cord-263455-dquztf5l	314	13	Office	Office	NNP
cord-263455-dquztf5l	314	14	addressed	address	VBD
cord-263455-dquztf5l	314	15	the	the	DT
cord-263455-dquztf5l	314	16	need	need	NN
cord-263455-dquztf5l	314	17	for	for	IN
cord-263455-dquztf5l	314	18	further	further	JJ
cord-263455-dquztf5l	314	19	research	research	NN
cord-263455-dquztf5l	314	20	,	,	,
cord-263455-dquztf5l	314	21	based	base	VBN
cord-263455-dquztf5l	314	22	on	on	IN
cord-263455-dquztf5l	314	23	an	an	DT
cord-263455-dquztf5l	314	24	information	information	NN
cord-263455-dquztf5l	314	25	consultation	consultation	NN
cord-263455-dquztf5l	314	26	in	in	IN
cord-263455-dquztf5l	314	27	the	the	DT
cord-263455-dquztf5l	314	28	United	United	NNP
cord-263455-dquztf5l	314	29	Kingdom	Kingdom	NNP
cord-263455-dquztf5l	314	30	.	.	.
cord-263455-dquztf5l	315	1	103	103	CD
cord-263455-dquztf5l	316	1	In	in	IN
cord-263455-dquztf5l	316	2	2010	2010	CD
cord-263455-dquztf5l	316	3	,	,	,
cord-263455-dquztf5l	316	4	the	the	DT
cord-263455-dquztf5l	316	5	Technical	Technical	NNP
cord-263455-dquztf5l	316	6	Commission	Commission	NNP
cord-263455-dquztf5l	316	7	of	of	IN
cord-263455-dquztf5l	316	8	the	the	DT
cord-263455-dquztf5l	316	9	International	International	NNP
cord-263455-dquztf5l	316	10	Federation	Federation	NNP
cord-263455-dquztf5l	316	11	of	of	IN
cord-263455-dquztf5l	316	12	Anti	Anti	NNP
cord-263455-dquztf5l	316	13	-	-	NNP
cord-263455-dquztf5l	316	14	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	316	15	Associations	Associations	NNPS
cord-263455-dquztf5l	316	16	(	(	-LRB-
cord-263455-dquztf5l	316	17	ILEP	ILEP	NNP
cord-263455-dquztf5l	316	18	)	)	-RRB-
cord-263455-dquztf5l	316	19	published	publish	VBD
cord-263455-dquztf5l	316	20	a	a	DT
cord-263455-dquztf5l	316	21	Review	Review	NNP
cord-263455-dquztf5l	316	22	of	of	IN
cord-263455-dquztf5l	316	23	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	316	24	Research	Research	NNP
cord-263455-dquztf5l	316	25	Evidence	evidence	NN
cord-263455-dquztf5l	316	26	(	(	-LRB-
cord-263455-dquztf5l	316	27	2002	2002	CD
cord-263455-dquztf5l	316	28	-	-	SYM
cord-263455-dquztf5l	316	29	2009	2009	CD
cord-263455-dquztf5l	316	30	)	)	-RRB-
cord-263455-dquztf5l	316	31	and	and	CC
cord-263455-dquztf5l	316	32	Implications	implication	NNS
cord-263455-dquztf5l	316	33	for	for	IN
cord-263455-dquztf5l	316	34	Current	current	JJ
cord-263455-dquztf5l	316	35	Policy	Policy	NNP
cord-263455-dquztf5l	316	36	and	and	CC
cord-263455-dquztf5l	316	37	Practice	practice	NN
cord-263455-dquztf5l	316	38	.	.	.
cord-263455-dquztf5l	317	1	104	104	CD
cord-263455-dquztf5l	318	1	They	-PRON-	PRP
cord-263455-dquztf5l	318	2	strongly	strongly	RB
cord-263455-dquztf5l	318	3	recommended	recommend	VBD
cord-263455-dquztf5l	318	4	additional	additional	JJ
cord-263455-dquztf5l	318	5	research	research	NN
cord-263455-dquztf5l	318	6	on	on	IN
cord-263455-dquztf5l	318	7	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	318	8	implementation	implementation	NN
cord-263455-dquztf5l	318	9	to	to	TO
cord-263455-dquztf5l	318	10	evaluate	evaluate	VB
cord-263455-dquztf5l	318	11	acceptability	acceptability	NN
cord-263455-dquztf5l	318	12	,	,	,
cord-263455-dquztf5l	318	13	cost	cost	NN
cord-263455-dquztf5l	318	14	-	-	HYPH
cord-263455-dquztf5l	318	15	effectiveness	effectiveness	NN
cord-263455-dquztf5l	318	16	,	,	,
cord-263455-dquztf5l	318	17	feasibility	feasibility	NN
cord-263455-dquztf5l	318	18	,	,	,
cord-263455-dquztf5l	318	19	and	and	CC
cord-263455-dquztf5l	318	20	ethical	ethical	JJ
cord-263455-dquztf5l	318	21	issues	issue	NNS
cord-263455-dquztf5l	318	22	concerning	concern	VBG
cord-263455-dquztf5l	318	23	disease	disease	NN
cord-263455-dquztf5l	318	24	disclosure	disclosure	NN
cord-263455-dquztf5l	318	25	and	and	CC
cord-263455-dquztf5l	318	26	new	new	JJ
cord-263455-dquztf5l	318	27	regimens	regimen	NNS
cord-263455-dquztf5l	318	28	.	.	.
cord-263455-dquztf5l	319	1	104	104	CD
cord-263455-dquztf5l	320	1	After	after	IN
cord-263455-dquztf5l	320	2	Cuba	Cuba	NNP
cord-263455-dquztf5l	320	3	,	,	,
cord-263455-dquztf5l	320	4	SDR	SDR	NNP
cord-263455-dquztf5l	320	5	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	320	6	against	against	IN
cord-263455-dquztf5l	320	7	leprosy	leprosy	NN
cord-263455-dquztf5l	320	8	was	be	VBD
cord-263455-dquztf5l	320	9	introduced	introduce	VBN
cord-263455-dquztf5l	320	10	in	in	IN
cord-263455-dquztf5l	320	11	Morocco	Morocco	NNP
cord-263455-dquztf5l	320	12	in	in	IN
cord-263455-dquztf5l	320	13	2012	2012	CD
cord-263455-dquztf5l	320	14	,	,	,
cord-263455-dquztf5l	320	15	another	another	DT
cord-263455-dquztf5l	320	16	low	low	JJ
cord-263455-dquztf5l	320	17	-	-	HYPH
cord-263455-dquztf5l	320	18	endemic	endemic	JJ
cord-263455-dquztf5l	320	19	country	country	NN
cord-263455-dquztf5l	320	20	.	.	.
cord-263455-dquztf5l	321	1	105	105	CD
cord-263455-dquztf5l	322	1	There	there	RB
cord-263455-dquztf5l	322	2	,	,	,
cord-263455-dquztf5l	322	3	leprosy	leprosy	NN
cord-263455-dquztf5l	322	4	detection	detection	NN
cord-263455-dquztf5l	322	5	declined	decline	VBD
cord-263455-dquztf5l	322	6	over	over	IN
cord-263455-dquztf5l	322	7	the	the	DT
cord-263455-dquztf5l	322	8	years	year	NNS
cord-263455-dquztf5l	322	9	,	,	,
cord-263455-dquztf5l	322	10	showing	show	VBG
cord-263455-dquztf5l	322	11	an	an	DT
cord-263455-dquztf5l	322	12	annual	annual	JJ
cord-263455-dquztf5l	322	13	percentage	percentage	NN
cord-263455-dquztf5l	322	14	reduction	reduction	NN
cord-263455-dquztf5l	322	15	in	in	IN
cord-263455-dquztf5l	322	16	leprosy	leprosy	NN
cord-263455-dquztf5l	322	17	detection	detection	NN
cord-263455-dquztf5l	322	18	rate	rate	NN
cord-263455-dquztf5l	322	19	of	of	IN
cord-263455-dquztf5l	322	20	16	16	CD
cord-263455-dquztf5l	322	21	 	 	_SP
cord-263455-dquztf5l	323	1	To	to	TO
cord-263455-dquztf5l	323	2	better	well	RBR
cord-263455-dquztf5l	323	3	understand	understand	VB
cord-263455-dquztf5l	323	4	the	the	DT
cord-263455-dquztf5l	323	5	long	long	JJ
cord-263455-dquztf5l	323	6	-	-	HYPH
cord-263455-dquztf5l	323	7	term	term	NN
cord-263455-dquztf5l	323	8	effects	effect	NNS
cord-263455-dquztf5l	323	9	of	of	IN
cord-263455-dquztf5l	323	10	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	323	11	on	on	IN
cord-263455-dquztf5l	323	12	leprosy	leprosy	NN
cord-263455-dquztf5l	323	13	,	,	,
cord-263455-dquztf5l	323	14	several	several	JJ
cord-263455-dquztf5l	323	15	modeling	modeling	NN
cord-263455-dquztf5l	323	16	studies	study	NNS
cord-263455-dquztf5l	323	17	have	have	VBP
cord-263455-dquztf5l	323	18	been	be	VBN
cord-263455-dquztf5l	323	19	performed	perform	VBN
cord-263455-dquztf5l	323	20	using	use	VBG
cord-263455-dquztf5l	323	21	the	the	DT
cord-263455-dquztf5l	323	22	mathematical	mathematical	JJ
cord-263455-dquztf5l	323	23	SIMCOLEP	SIMCOLEP	NNP
cord-263455-dquztf5l	323	24	model	model	NN
cord-263455-dquztf5l	323	25	developed	develop	VBN
cord-263455-dquztf5l	323	26	by	by	IN
cord-263455-dquztf5l	323	27	Erasmus	Erasmus	NNP
cord-263455-dquztf5l	323	28	MC	MC	NNP
cord-263455-dquztf5l	323	29	.	.	.
cord-263455-dquztf5l	324	1	107	107	CD
cord-263455-dquztf5l	325	1	Using	use	VBG
cord-263455-dquztf5l	325	2	this	this	DT
cord-263455-dquztf5l	325	3	model	model	NN
cord-263455-dquztf5l	325	4	,	,	,
cord-263455-dquztf5l	325	5	Fisher	Fisher	NNP
cord-263455-dquztf5l	325	6	et	et	NNP
cord-263455-dquztf5l	325	7	al	al	NNP
cord-263455-dquztf5l	325	8	demonstrated	demonstrate	VBD
cord-263455-dquztf5l	325	9	that	that	IN
cord-263455-dquztf5l	325	10	leprosy	leprosy	NN
cord-263455-dquztf5l	325	11	incidence	incidence	NN
cord-263455-dquztf5l	325	12	would	would	MD
cord-263455-dquztf5l	325	13	be	be	VB
cord-263455-dquztf5l	325	14	substantially	substantially	RB
cord-263455-dquztf5l	325	15	reduced	reduce	VBN
cord-263455-dquztf5l	325	16	in	in	IN
cord-263455-dquztf5l	325	17	a	a	DT
cord-263455-dquztf5l	325	18	context	context	NN
cord-263455-dquztf5l	325	19	similar	similar	JJ
cord-263455-dquztf5l	325	20	to	to	IN
cord-263455-dquztf5l	325	21	the	the	DT
cord-263455-dquztf5l	325	22	COLEP	COLEP	NNP
cord-263455-dquztf5l	325	23	study	study	NN
cord-263455-dquztf5l	325	24	location	location	NN
cord-263455-dquztf5l	325	25	(	(	-LRB-
cord-263455-dquztf5l	325	26	Bangladesh	Bangladesh	NNP
cord-263455-dquztf5l	325	27	)	)	-RRB-
cord-263455-dquztf5l	325	28	by	by	IN
cord-263455-dquztf5l	325	29	a	a	DT
cord-263455-dquztf5l	325	30	combination	combination	NN
cord-263455-dquztf5l	325	31	of	of	IN
cord-263455-dquztf5l	325	32	childhood	childhood	NN
cord-263455-dquztf5l	325	33	BCG	BCG	NNP
cord-263455-dquztf5l	325	34	and	and	CC
cord-263455-dquztf5l	325	35	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	325	36	for	for	IN
cord-263455-dquztf5l	325	37	screened	screen	VBN
cord-263455-dquztf5l	325	38	household	household	NN
cord-263455-dquztf5l	325	39	contacts	contact	NNS
cord-263455-dquztf5l	325	40	.	.	.
cord-263455-dquztf5l	326	1	107	107	CD
cord-263455-dquztf5l	327	1	De	De	NNP
cord-263455-dquztf5l	327	2	Matos	Matos	NNP
cord-263455-dquztf5l	327	3	et	et	NNP
cord-263455-dquztf5l	327	4	al	al	NNP
cord-263455-dquztf5l	327	5	predicted	predict	VBD
cord-263455-dquztf5l	327	6	a	a	DT
cord-263455-dquztf5l	327	7	declining	decline	VBG
cord-263455-dquztf5l	327	8	new	new	JJ
cord-263455-dquztf5l	327	9	case	case	NN
cord-263455-dquztf5l	327	10	detection	detection	NN
cord-263455-dquztf5l	327	11	rate	rate	NN
cord-263455-dquztf5l	327	12	in	in	IN
cord-263455-dquztf5l	327	13	Para	Para	NNP
cord-263455-dquztf5l	327	14	State	State	NNP
cord-263455-dquztf5l	327	15	in	in	IN
cord-263455-dquztf5l	327	16	Brazil	Brazil	NNP
cord-263455-dquztf5l	327	17	,	,	,
cord-263455-dquztf5l	327	18	combining	combine	VBG
cord-263455-dquztf5l	327	19	contract	contract	NN
cord-263455-dquztf5l	327	20	screening	screening	NN
cord-263455-dquztf5l	327	21	with	with	IN
cord-263455-dquztf5l	327	22	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	327	23	.	.	.
cord-263455-dquztf5l	328	1	108	108	CD
cord-263455-dquztf5l	328	2	Mathematical	mathematical	JJ
cord-263455-dquztf5l	328	3	modeling	modeling	NN
cord-263455-dquztf5l	328	4	by	by	IN
cord-263455-dquztf5l	328	5	Gilkison	Gilkison	NNP
cord-263455-dquztf5l	328	6	et	et	NNP
cord-263455-dquztf5l	328	7	al	al	NNP
cord-263455-dquztf5l	328	8	for	for	IN
cord-263455-dquztf5l	328	9	Kiribati	Kiribati	NNP
cord-263455-dquztf5l	328	10	,	,	,
cord-263455-dquztf5l	328	11	a	a	DT
cord-263455-dquztf5l	328	12	high	high	JJ
cord-263455-dquztf5l	328	13	leprosy	leprosy	NN
cord-263455-dquztf5l	328	14	burden	burden	VBD
cord-263455-dquztf5l	328	15	Pacific	Pacific	NNP
cord-263455-dquztf5l	328	16	island	island	NN
cord-263455-dquztf5l	328	17	,	,	,
cord-263455-dquztf5l	328	18	also	also	RB
cord-263455-dquztf5l	328	19	suggested	suggest	VBD
cord-263455-dquztf5l	328	20	that	that	IN
cord-263455-dquztf5l	328	21	leprosy	leprosy	NN
cord-263455-dquztf5l	328	22	incidence	incidence	NN
cord-263455-dquztf5l	328	23	can	can	MD
cord-263455-dquztf5l	328	24	decrease	decrease	VB
cord-263455-dquztf5l	328	25	when	when	WRB
cord-263455-dquztf5l	328	26	using	use	VBG
cord-263455-dquztf5l	328	27	an	an	DT
cord-263455-dquztf5l	328	28	intensive	intensive	JJ
cord-263455-dquztf5l	328	29	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	328	30	approach	approach	NN
cord-263455-dquztf5l	328	31	.	.	.
cord-263455-dquztf5l	329	1	109	109	CD
cord-263455-dquztf5l	330	1	The	the	DT
cord-263455-dquztf5l	330	2	model	model	NN
cord-263455-dquztf5l	330	3	predicted	predict	VBD
cord-263455-dquztf5l	330	4	the	the	DT
cord-263455-dquztf5l	330	5	best	good	JJS
cord-263455-dquztf5l	330	6	results	result	NNS
cord-263455-dquztf5l	330	7	for	for	IN
cord-263455-dquztf5l	330	8	the	the	DT
cord-263455-dquztf5l	330	9	intensive	intensive	JJ
cord-263455-dquztf5l	330	10	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	330	11	approach	approach	NN
cord-263455-dquztf5l	330	12	that	that	WDT
cord-263455-dquztf5l	330	13	combined	combine	VBD
cord-263455-dquztf5l	330	14	a	a	DT
cord-263455-dquztf5l	330	15	household	household	NN
cord-263455-dquztf5l	330	16	contact	contact	NN
cord-263455-dquztf5l	330	17	approach	approach	NN
cord-263455-dquztf5l	330	18	with	with	IN
cord-263455-dquztf5l	330	19	more	more	JJR
cord-263455-dquztf5l	330	20	than	than	IN
cord-263455-dquztf5l	330	21	one	one	CD
cord-263455-dquztf5l	330	22	round	round	NN
cord-263455-dquztf5l	330	23	of	of	IN
cord-263455-dquztf5l	330	24	mass	mass	JJ
cord-263455-dquztf5l	330	25	SDR	SDR	NNP
cord-263455-dquztf5l	330	26	in	in	IN
cord-263455-dquztf5l	330	27	consecutive	consecutive	JJ
cord-263455-dquztf5l	330	28	years	year	NNS
cord-263455-dquztf5l	330	29	rather	rather	RB
cord-263455-dquztf5l	330	30	than	than	IN
cord-263455-dquztf5l	330	31	every	every	DT
cord-263455-dquztf5l	330	32	second	second	JJ
cord-263455-dquztf5l	330	33	year	year	NN
cord-263455-dquztf5l	330	34	.	.	.
cord-263455-dquztf5l	331	1	109	109	CD
cord-263455-dquztf5l	332	1	An	an	DT
cord-263455-dquztf5l	332	2	expert	expert	NN
cord-263455-dquztf5l	332	3	meeting	meeting	NN
cord-263455-dquztf5l	332	4	on	on	IN
cord-263455-dquztf5l	332	5	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	332	6	against	against	IN
cord-263455-dquztf5l	332	7	leprosy	leprosy	NN
cord-263455-dquztf5l	332	8	in	in	IN
cord-263455-dquztf5l	332	9	2014	2014	CD
cord-263455-dquztf5l	332	10	in	in	IN
cord-263455-dquztf5l	332	11	Switzerland	Switzerland	NNP
cord-263455-dquztf5l	332	12	re	re	NNS
cord-263455-dquztf5l	332	13	-	-	VBN
cord-263455-dquztf5l	332	14	emphasized	emphasize	VBN
cord-263455-dquztf5l	333	1	the	the	DT
cord-263455-dquztf5l	333	2	importance	importance	NN
cord-263455-dquztf5l	333	3	of	of	IN
cord-263455-dquztf5l	333	4	operational	operational	JJ
cord-263455-dquztf5l	333	5	research	research	NN
cord-263455-dquztf5l	333	6	on	on	IN
cord-263455-dquztf5l	333	7	SDR	SDR	NNP
cord-263455-dquztf5l	333	8	-	-	HYPH
cord-263455-dquztf5l	333	9	PEP	PEP	NNP
cord-263455-dquztf5l	333	10	.	.	.
cord-263455-dquztf5l	333	11	110	110	CD
cord-263455-dquztf5l	333	12	Some	some	DT
cord-263455-dquztf5l	333	13	lessons	lesson	NNS
cord-263455-dquztf5l	333	14	learned	learn	VBD
cord-263455-dquztf5l	333	15	from	from	IN
cord-263455-dquztf5l	333	16	a	a	DT
cord-263455-dquztf5l	333	17	pilot	pilot	NN
cord-263455-dquztf5l	333	18	project	project	NN
cord-263455-dquztf5l	333	19	implementing	implement	VBG
cord-263455-dquztf5l	333	20	SDR	SDR	NNP
cord-263455-dquztf5l	333	21	-	-	HYPH
cord-263455-dquztf5l	333	22	PEP	PEP	NNP
cord-263455-dquztf5l	333	23	in	in	IN
cord-263455-dquztf5l	333	24	Sampang	Sampang	NNP
cord-263455-dquztf5l	333	25	District	District	NNP
cord-263455-dquztf5l	333	26	,	,	,
cord-263455-dquztf5l	333	27	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	333	28	,	,	,
cord-263455-dquztf5l	333	29	were	be	VBD
cord-263455-dquztf5l	333	30	presented	present	VBN
cord-263455-dquztf5l	333	31	by	by	IN
cord-263455-dquztf5l	333	32	Dandel	Dandel	NNP
cord-263455-dquztf5l	333	33	.	.	.
cord-263455-dquztf5l	334	1	He	-PRON-	PRP
cord-263455-dquztf5l	334	2	stated	state	VBD
cord-263455-dquztf5l	334	3	that	that	IN
cord-263455-dquztf5l	334	4	SDR	SDR	NNP
cord-263455-dquztf5l	334	5	-	-	HYPH
cord-263455-dquztf5l	334	6	PEP	PEP	NNP
cord-263455-dquztf5l	334	7	implementation	implementation	NN
cord-263455-dquztf5l	334	8	requires	require	VBZ
cord-263455-dquztf5l	334	9	:	:	:
cord-263455-dquztf5l	334	10	(	(	-LRB-
cord-263455-dquztf5l	334	11	a	a	LS
cord-263455-dquztf5l	334	12	)	)	-RRB-
cord-263455-dquztf5l	334	13	ongoing	ongoing	JJ
cord-263455-dquztf5l	334	14	support	support	NN
cord-263455-dquztf5l	334	15	and	and	CC
cord-263455-dquztf5l	334	16	supervision	supervision	NN
cord-263455-dquztf5l	334	17	;	;	,
cord-263455-dquztf5l	334	18	(	(	-LRB-
cord-263455-dquztf5l	334	19	b	b	NN
cord-263455-dquztf5l	334	20	)	)	-RRB-
cord-263455-dquztf5l	334	21	strong	strong	JJ
cord-263455-dquztf5l	334	22	local	local	JJ
cord-263455-dquztf5l	334	23	ownership	ownership	NN
cord-263455-dquztf5l	334	24	;	;	,
cord-263455-dquztf5l	334	25	(	(	-LRB-
cord-263455-dquztf5l	334	26	c	c	NN
cord-263455-dquztf5l	334	27	)	)	-RRB-
cord-263455-dquztf5l	334	28	continuous	continuous	JJ
cord-263455-dquztf5l	334	29	motivation	motivation	NN
cord-263455-dquztf5l	334	30	of	of	IN
cord-263455-dquztf5l	334	31	healthcare	healthcare	NN
cord-263455-dquztf5l	334	32	workers	worker	NNS
cord-263455-dquztf5l	334	33	;	;	:
cord-263455-dquztf5l	334	34	and	and	CC
cord-263455-dquztf5l	334	35	(	(	-LRB-
cord-263455-dquztf5l	334	36	d	d	LS
cord-263455-dquztf5l	334	37	)	)	-RRB-
cord-263455-dquztf5l	334	38	adequate	adequate	JJ
cord-263455-dquztf5l	334	39	loose	loose	JJ
cord-263455-dquztf5l	334	40	rifampicin	rifampicin	NN
cord-263455-dquztf5l	334	41	supply	supply	NN
cord-263455-dquztf5l	334	42	routes	route	NNS
cord-263455-dquztf5l	334	43	.	.	.
cord-263455-dquztf5l	335	1	Stakeholders	stakeholder	NNS
cord-263455-dquztf5l	335	2	received	receive	VBD
cord-263455-dquztf5l	335	3	the	the	DT
cord-263455-dquztf5l	335	4	intervention	intervention	NN
cord-263455-dquztf5l	335	5	positively	positively	RB
cord-263455-dquztf5l	335	6	.	.	.
cord-263455-dquztf5l	336	1	It	-PRON-	PRP
cord-263455-dquztf5l	336	2	was	be	VBD
cord-263455-dquztf5l	336	3	also	also	RB
cord-263455-dquztf5l	336	4	seen	see	VBN
cord-263455-dquztf5l	336	5	as	as	IN
cord-263455-dquztf5l	336	6	an	an	DT
cord-263455-dquztf5l	336	7	opportunity	opportunity	NN
cord-263455-dquztf5l	336	8	to	to	TO
cord-263455-dquztf5l	336	9	present	present	VB
cord-263455-dquztf5l	336	10	health	health	NN
cord-263455-dquztf5l	336	11	education	education	NN
cord-263455-dquztf5l	336	12	,	,	,
cord-263455-dquztf5l	336	13	but	but	CC
cord-263455-dquztf5l	336	14	stigma	stigma	NN
cord-263455-dquztf5l	336	15	caused	cause	VBD
cord-263455-dquztf5l	336	16	index	index	NN
cord-263455-dquztf5l	336	17	patients	patient	NNS
cord-263455-dquztf5l	336	18	to	to	TO
cord-263455-dquztf5l	336	19	hesitate	hesitate	VB
cord-263455-dquztf5l	336	20	in	in	IN
cord-263455-dquztf5l	336	21	disclosing	disclose	VBG
cord-263455-dquztf5l	336	22	their	-PRON-	PRP$
cord-263455-dquztf5l	336	23	disease	disease	NN
cord-263455-dquztf5l	336	24	status	status	NN
cord-263455-dquztf5l	336	25	to	to	IN
cord-263455-dquztf5l	336	26	people	people	NNS
cord-263455-dquztf5l	336	27	outside	outside	IN
cord-263455-dquztf5l	336	28	their	-PRON-	PRP$
cord-263455-dquztf5l	336	29	household	household	NN
cord-263455-dquztf5l	336	30	.	.	.
cord-263455-dquztf5l	337	1	Nevertheless	nevertheless	RB
cord-263455-dquztf5l	337	2	,	,	,
cord-263455-dquztf5l	337	3	an	an	DT
cord-263455-dquztf5l	337	4	average	average	NN
cord-263455-dquztf5l	337	5	of	of	IN
cord-263455-dquztf5l	337	6	22	22	CD
cord-263455-dquztf5l	337	7	contacts	contact	NNS
cord-263455-dquztf5l	337	8	per	per	IN
cord-263455-dquztf5l	337	9	index	index	NN
cord-263455-dquztf5l	337	10	patient	patient	NN
cord-263455-dquztf5l	337	11	were	be	VBD
cord-263455-dquztf5l	337	12	included	include	VBN
cord-263455-dquztf5l	337	13	in	in	IN
cord-263455-dquztf5l	337	14	the	the	DT
cord-263455-dquztf5l	337	15	first	first	JJ
cord-263455-dquztf5l	337	16	year	year	NN
cord-263455-dquztf5l	337	17	(	(	-LRB-
cord-263455-dquztf5l	337	18	Budiawan	Budiawan	NNP
cord-263455-dquztf5l	337	19	,	,	,
cord-263455-dquztf5l	337	20	unpublished	unpublished	JJ
cord-263455-dquztf5l	337	21	report	report	NN
cord-263455-dquztf5l	337	22	)	)	-RRB-
cord-263455-dquztf5l	337	23	.	.	.
cord-263455-dquztf5l	338	1	During	during	IN
cord-263455-dquztf5l	338	2	the	the	DT
cord-263455-dquztf5l	338	3	expert	expert	NN
cord-263455-dquztf5l	338	4	meeting	meeting	NN
cord-263455-dquztf5l	338	5	,	,	,
cord-263455-dquztf5l	338	6	Mahotarn	Mahotarn	NNP
cord-263455-dquztf5l	338	7	presented	present	VBD
cord-263455-dquztf5l	338	8	results	result	NNS
cord-263455-dquztf5l	338	9	of	of	IN
cord-263455-dquztf5l	338	10	another	another	DT
cord-263455-dquztf5l	338	11	randomized	randomized	JJ
cord-263455-dquztf5l	338	12	,	,	,
cord-263455-dquztf5l	338	13	placebo	placebo	NN
cord-263455-dquztf5l	338	14	-	-	HYPH
cord-263455-dquztf5l	338	15	controlled	control	VBN
cord-263455-dquztf5l	338	16	trial	trial	NN
cord-263455-dquztf5l	338	17	with	with	IN
cord-263455-dquztf5l	338	18	SDR	SDR	NNP
cord-263455-dquztf5l	338	19	conducted	conduct	VBN
cord-263455-dquztf5l	338	20	in	in	IN
cord-263455-dquztf5l	338	21	Thailand	Thailand	NNP
cord-263455-dquztf5l	338	22	with	with	IN
cord-263455-dquztf5l	338	23	a	a	DT
cord-263455-dquztf5l	338	24	similar	similar	JJ
cord-263455-dquztf5l	338	25	set	set	NN
cord-263455-dquztf5l	338	26	-	-	HYPH
cord-263455-dquztf5l	338	27	up	up	NN
cord-263455-dquztf5l	338	28	as	as	IN
cord-263455-dquztf5l	338	29	the	the	DT
cord-263455-dquztf5l	338	30	COLEP	COLEP	NNP
cord-263455-dquztf5l	338	31	study	study	NN
cord-263455-dquztf5l	338	32	.	.	.
cord-263455-dquztf5l	339	1	95	95	CD
cord-263455-dquztf5l	339	2	,	,	,
cord-263455-dquztf5l	340	1	110	110	CD
cord-263455-dquztf5l	340	2	After	after	IN
cord-263455-dquztf5l	340	3	5	5	CD
cord-263455-dquztf5l	340	4	years	year	NNS
cord-263455-dquztf5l	340	5	,	,	,
cord-263455-dquztf5l	340	6	the	the	DT
cord-263455-dquztf5l	340	7	relative	relative	JJ
cord-263455-dquztf5l	340	8	risk	risk	NN
cord-263455-dquztf5l	340	9	in	in	IN
cord-263455-dquztf5l	340	10	the	the	DT
cord-263455-dquztf5l	340	11	rifampicin	rifampicin	NNP
cord-263455-dquztf5l	340	12	group	group	NN
cord-263455-dquztf5l	340	13	was	be	VBD
cord-263455-dquztf5l	340	14	0.48	0.48	CD
cord-263455-dquztf5l	340	15	when	when	WRB
cord-263455-dquztf5l	340	16	compared	compare	VBN
cord-263455-dquztf5l	340	17	with	with	IN
cord-263455-dquztf5l	340	18	controls	control	NNS
cord-263455-dquztf5l	340	19	.	.	.
cord-263455-dquztf5l	341	1	This	this	DT
cord-263455-dquztf5l	341	2	was	be	VBD
cord-263455-dquztf5l	341	3	similar	similar	JJ
cord-263455-dquztf5l	341	4	to	to	IN
cord-263455-dquztf5l	341	5	the	the	DT
cord-263455-dquztf5l	341	6	difference	difference	NN
cord-263455-dquztf5l	341	7	observed	observe	VBN
cord-263455-dquztf5l	341	8	in	in	IN
cord-263455-dquztf5l	341	9	the	the	DT
cord-263455-dquztf5l	341	10	COLEP	COLEP	NNP
cord-263455-dquztf5l	341	11	trial	trial	NN
cord-263455-dquztf5l	341	12	,	,	,
cord-263455-dquztf5l	341	13	though	though	IN
cord-263455-dquztf5l	341	14	not	not	RB
cord-263455-dquztf5l	341	15	statistically	statistically	RB
cord-263455-dquztf5l	341	16	significant	significant	JJ
cord-263455-dquztf5l	341	17	(	(	-LRB-
cord-263455-dquztf5l	341	18	p	p	NN
cord-263455-dquztf5l	341	19	=	=	SYM
cord-263455-dquztf5l	341	20	0.105	0.105	CD
cord-263455-dquztf5l	341	21	)	)	-RRB-
cord-263455-dquztf5l	341	22	because	because	IN
cord-263455-dquztf5l	341	23	the	the	DT
cord-263455-dquztf5l	341	24	study	study	NN
cord-263455-dquztf5l	341	25	was	be	VBD
cord-263455-dquztf5l	341	26	not	not	RB
cord-263455-dquztf5l	341	27	powered	power	VBN
cord-263455-dquztf5l	341	28	to	to	TO
cord-263455-dquztf5l	341	29	detect	detect	VB
cord-263455-dquztf5l	341	30	risk	risk	NN
cord-263455-dquztf5l	341	31	reductions	reduction	NNS
cord-263455-dquztf5l	341	32	below	below	IN
cord-263455-dquztf5l	341	33	50	50	CD
cord-263455-dquztf5l	341	34	%	%	NN
cord-263455-dquztf5l	341	35	.	.	.
cord-263455-dquztf5l	342	1	95	95	CD
cord-263455-dquztf5l	342	2	,	,	,
cord-263455-dquztf5l	342	3	110	110	CD
cord-263455-dquztf5l	343	1	The	the	DT
cord-263455-dquztf5l	343	2	expert	expert	NN
cord-263455-dquztf5l	343	3	meeting	meeting	NN
cord-263455-dquztf5l	343	4	identified	identify	VBD
cord-263455-dquztf5l	343	5	several	several	JJ
cord-263455-dquztf5l	343	6	important	important	JJ
cord-263455-dquztf5l	343	7	factors	factor	NNS
cord-263455-dquztf5l	343	8	for	for	IN
cord-263455-dquztf5l	343	9	the	the	DT
cord-263455-dquztf5l	343	10	success	success	NN
cord-263455-dquztf5l	343	11	of	of	IN
cord-263455-dquztf5l	343	12	interventions	intervention	NNS
cord-263455-dquztf5l	343	13	that	that	WDT
cord-263455-dquztf5l	343	14	target	target	VBP
cord-263455-dquztf5l	343	15	contacts	contact	NNS
cord-263455-dquztf5l	343	16	of	of	IN
cord-263455-dquztf5l	343	17	leprosy	leprosy	NN
cord-263455-dquztf5l	343	18	patients	patient	NNS
cord-263455-dquztf5l	343	19	(	(	-LRB-
cord-263455-dquztf5l	343	20	Table	Table	NNP
cord-263455-dquztf5l	343	21	3	3	CD
cord-263455-dquztf5l	343	22	)	)	-RRB-
cord-263455-dquztf5l	343	23	.	.	.
cord-263455-dquztf5l	344	1	110	110	CD
cord-263455-dquztf5l	345	1	The	the	DT
cord-263455-dquztf5l	345	2	meeting	meeting	NN
cord-263455-dquztf5l	345	3	stated	state	VBD
cord-263455-dquztf5l	345	4	that	that	IN
cord-263455-dquztf5l	345	5	high	high	JJ
cord-263455-dquztf5l	345	6	-	-	HYPH
cord-263455-dquztf5l	345	7	endemic	endemic	JJ
cord-263455-dquztf5l	345	8	pockets	pocket	NNS
cord-263455-dquztf5l	345	9	would	would	MD
cord-263455-dquztf5l	345	10	most	most	RBS
cord-263455-dquztf5l	345	11	likely	likely	RB
cord-263455-dquztf5l	345	12	benefit	benefit	VB
cord-263455-dquztf5l	345	13	more	more	JJR
cord-263455-dquztf5l	345	14	from	from	IN
cord-263455-dquztf5l	345	15	a	a	DT
cord-263455-dquztf5l	345	16	mass	mass	NNP
cord-263455-dquztf5l	345	17	drug	drug	NN
cord-263455-dquztf5l	345	18	administration	administration	NN
cord-263455-dquztf5l	345	19	(	(	-LRB-
cord-263455-dquztf5l	345	20	MDA	MDA	NNP
cord-263455-dquztf5l	345	21	)	)	-RRB-
cord-263455-dquztf5l	345	22	or	or	CC
cord-263455-dquztf5l	345	23	"	"	``
cord-263455-dquztf5l	345	24	blanket	blanket	NN
cord-263455-dquztf5l	345	25	"	"	''
cord-263455-dquztf5l	345	26	approach	approach	NN
cord-263455-dquztf5l	345	27	than	than	IN
cord-263455-dquztf5l	345	28	the	the	DT
cord-263455-dquztf5l	345	29	contactbased	contactbased	JJ
cord-263455-dquztf5l	345	30	strategy	strategy	NN
cord-263455-dquztf5l	345	31	.	.	.
cord-263455-dquztf5l	346	1	110	110	CD
cord-263455-dquztf5l	347	1	In	in	IN
cord-263455-dquztf5l	347	2	such	such	JJ
cord-263455-dquztf5l	347	3	settings	setting	NNS
cord-263455-dquztf5l	347	4	,	,	,
cord-263455-dquztf5l	347	5	the	the	DT
cord-263455-dquztf5l	347	6	entire	entire	JJ
cord-263455-dquztf5l	347	7	community	community	NN
cord-263455-dquztf5l	347	8	may	may	MD
cord-263455-dquztf5l	347	9	be	be	VB
cord-263455-dquztf5l	347	10	considered	consider	VBN
cord-263455-dquztf5l	347	11	contacts	contact	NNS
cord-263455-dquztf5l	347	12	.	.	.
cord-263455-dquztf5l	348	1	The	the	DT
cord-263455-dquztf5l	348	2	experts	expert	NNS
cord-263455-dquztf5l	348	3	recognized	recognize	VBD
cord-263455-dquztf5l	348	4	that	that	IN
cord-263455-dquztf5l	348	5	PEP	pep	NN
cord-263455-dquztf5l	348	6	implementation	implementation	NN
cord-263455-dquztf5l	348	7	against	against	IN
cord-263455-dquztf5l	348	8	leprosy	leprosy	NN
cord-263455-dquztf5l	348	9	should	should	MD
cord-263455-dquztf5l	348	10	not	not	RB
cord-263455-dquztf5l	348	11	be	be	VB
cord-263455-dquztf5l	348	12	limited	limit	VBN
cord-263455-dquztf5l	348	13	to	to	IN
cord-263455-dquztf5l	348	14	high	high	JJ
cord-263455-dquztf5l	348	15	-	-	HYPH
cord-263455-dquztf5l	348	16	endemic	endemic	JJ
cord-263455-dquztf5l	348	17	settings	setting	NNS
cord-263455-dquztf5l	348	18	because	because	IN
cord-263455-dquztf5l	348	19	low	low	JJ
cord-263455-dquztf5l	348	20	-	-	HYPH
cord-263455-dquztf5l	348	21	endemic	endemic	JJ
cord-263455-dquztf5l	348	22	areas	area	NNS
cord-263455-dquztf5l	348	23	are	be	VBP
cord-263455-dquztf5l	348	24	likely	likely	JJ
cord-263455-dquztf5l	348	25	to	to	TO
cord-263455-dquztf5l	348	26	show	show	VB
cord-263455-dquztf5l	348	27	a	a	DT
cord-263455-dquztf5l	348	28	high	high	JJ
cord-263455-dquztf5l	348	29	clustering	clustering	NN
cord-263455-dquztf5l	348	30	level	level	NN
cord-263455-dquztf5l	348	31	.	.	.
cord-263455-dquztf5l	349	1	110	110	CD
cord-263455-dquztf5l	350	1	Richardus	Richardus	NNP
cord-263455-dquztf5l	350	2	et	et	NNP
cord-263455-dquztf5l	350	3	al	al	NNP
cord-263455-dquztf5l	350	4	found	find	VBD
cord-263455-dquztf5l	350	5	that	that	IN
cord-263455-dquztf5l	350	6	when	when	WRB
cord-263455-dquztf5l	350	7	the	the	DT
cord-263455-dquztf5l	350	8	endemicity	endemicity	NN
cord-263455-dquztf5l	350	9	of	of	IN
cord-263455-dquztf5l	350	10	leprosy	leprosy	NN
cord-263455-dquztf5l	350	11	declines	decline	VBZ
cord-263455-dquztf5l	350	12	,	,	,
cord-263455-dquztf5l	350	13	a	a	DT
cord-263455-dquztf5l	350	14	gradually	gradually	RB
cord-263455-dquztf5l	350	15	higher	high	JJR
cord-263455-dquztf5l	350	16	proportion	proportion	NN
cord-263455-dquztf5l	350	17	of	of	IN
cord-263455-dquztf5l	350	18	new	new	JJ
cord-263455-dquztf5l	350	19	patients	patient	NNS
cord-263455-dquztf5l	350	20	is	be	VBZ
cord-263455-dquztf5l	350	21	found	find	VBN
cord-263455-dquztf5l	350	22	amongst	amongst	IN
cord-263455-dquztf5l	350	23	the	the	DT
cord-263455-dquztf5l	350	24	contacts	contact	NNS
cord-263455-dquztf5l	350	25	of	of	IN
cord-263455-dquztf5l	350	26	known	know	VBN
cord-263455-dquztf5l	350	27	cases	case	NNS
cord-263455-dquztf5l	350	28	.	.	.
cord-263455-dquztf5l	351	1	111	111	CD
cord-263455-dquztf5l	352	1	This	this	DT
cord-263455-dquztf5l	352	2	aligns	align	VBZ
cord-263455-dquztf5l	352	3	with	with	IN
cord-263455-dquztf5l	352	4	field	field	NN
cord-263455-dquztf5l	352	5	observations	observation	NNS
cord-263455-dquztf5l	352	6	in	in	IN
cord-263455-dquztf5l	352	7	West	West	NNP
cord-263455-dquztf5l	352	8	Java	Java	NNP
cord-263455-dquztf5l	352	9	,	,	,
cord-263455-dquztf5l	352	10	where	where	WRB
cord-263455-dquztf5l	352	11	leprosy	leprosy	NN
cord-263455-dquztf5l	352	12	endemicity	endemicity	NN
cord-263455-dquztf5l	352	13	varies	vary	VBZ
cord-263455-dquztf5l	352	14	;	;	,
cord-263455-dquztf5l	352	15	in	in	IN
cord-263455-dquztf5l	352	16	the	the	DT
cord-263455-dquztf5l	352	17	lowendemic	lowendemic	JJ
cord-263455-dquztf5l	352	18	districts	district	NNS
cord-263455-dquztf5l	352	19	,	,	,
cord-263455-dquztf5l	352	20	the	the	DT
cord-263455-dquztf5l	352	21	proportion	proportion	NN
cord-263455-dquztf5l	352	22	of	of	IN
cord-263455-dquztf5l	352	23	new	new	JJ
cord-263455-dquztf5l	352	24	cases	case	NNS
cord-263455-dquztf5l	352	25	detected	detect	VBN
cord-263455-dquztf5l	352	26	through	through	IN
cord-263455-dquztf5l	352	27	contact	contact	NN
cord-263455-dquztf5l	352	28	screening	screening	NN
cord-263455-dquztf5l	352	29	is	be	VBZ
cord-263455-dquztf5l	352	30	relatively	relatively	RB
cord-263455-dquztf5l	352	31	high	high	JJ
cord-263455-dquztf5l	352	32	(	(	-LRB-
cord-263455-dquztf5l	352	33	Budiawan	Budiawan	NNP
cord-263455-dquztf5l	352	34	,	,	,
cord-263455-dquztf5l	352	35	unpublished	unpublished	JJ
cord-263455-dquztf5l	352	36	report	report	NN
cord-263455-dquztf5l	352	37	)	)	-RRB-
cord-263455-dquztf5l	352	38	.	.	.
cord-263455-dquztf5l	353	1	The	the	DT
cord-263455-dquztf5l	353	2	need	need	NN
cord-263455-dquztf5l	353	3	for	for	IN
cord-263455-dquztf5l	353	4	more	more	JJR
cord-263455-dquztf5l	353	5	research	research	NN
cord-263455-dquztf5l	353	6	on	on	IN
cord-263455-dquztf5l	353	7	the	the	DT
cord-263455-dquztf5l	353	8	feasibility	feasibility	NN
cord-263455-dquztf5l	353	9	of	of	IN
cord-263455-dquztf5l	353	10	implementing	implement	VBG
cord-263455-dquztf5l	353	11	SDR	SDR	NNP
cord-263455-dquztf5l	353	12	-	-	HYPH
cord-263455-dquztf5l	353	13	PEP	PEP	NNP
cord-263455-dquztf5l	353	14	,	,	,
cord-263455-dquztf5l	353	15	including	include	VBG
cord-263455-dquztf5l	353	16	its	-PRON-	PRP$
cord-263455-dquztf5l	353	17	cost	cost	NN
cord-263455-dquztf5l	353	18	-	-	HYPH
cord-263455-dquztf5l	353	19	effectiveness	effectiveness	NN
cord-263455-dquztf5l	353	20	and	and	CC
cord-263455-dquztf5l	353	21	acceptability	acceptability	NN
cord-263455-dquztf5l	353	22	in	in	IN
cord-263455-dquztf5l	353	23	different	different	JJ
cord-263455-dquztf5l	353	24	geographical	geographical	JJ
cord-263455-dquztf5l	353	25	and	and	CC
cord-263455-dquztf5l	353	26	sociocultural	sociocultural	JJ
cord-263455-dquztf5l	353	27	environments	environment	NNS
cord-263455-dquztf5l	353	28	,	,	,
cord-263455-dquztf5l	353	29	was	be	VBD
cord-263455-dquztf5l	353	30	recognized	recognize	VBN
cord-263455-dquztf5l	353	31	.	.	.
cord-263455-dquztf5l	354	1	112	112	CD
cord-263455-dquztf5l	355	1	This	this	DT
cord-263455-dquztf5l	355	2	and	and	CC
cord-263455-dquztf5l	355	3	the	the	DT
cord-263455-dquztf5l	355	4	urge	urge	NN
cord-263455-dquztf5l	355	5	to	to	TO
cord-263455-dquztf5l	355	6	learn	learn	VB
cord-263455-dquztf5l	355	7	how	how	WRB
cord-263455-dquztf5l	355	8	to	to	TO
cord-263455-dquztf5l	355	9	operationalize	operationalize	VB
cord-263455-dquztf5l	355	10	this	this	DT
cord-263455-dquztf5l	355	11	innovative	innovative	JJ
cord-263455-dquztf5l	355	12	intervention	intervention	NN
cord-263455-dquztf5l	355	13	led	lead	VBD
cord-263455-dquztf5l	355	14	to	to	IN
cord-263455-dquztf5l	355	15	the	the	DT
cord-263455-dquztf5l	355	16	development	development	NN
cord-263455-dquztf5l	355	17	of	of	IN
cord-263455-dquztf5l	355	18	the	the	DT
cord-263455-dquztf5l	355	19	LPEP	LPEP	NNP
cord-263455-dquztf5l	355	20	program	program	NN
cord-263455-dquztf5l	355	21	.	.	.
cord-263455-dquztf5l	356	1	In	in	IN
cord-263455-dquztf5l	356	2	2014	2014	CD
cord-263455-dquztf5l	356	3	,	,	,
cord-263455-dquztf5l	356	4	a	a	DT
cord-263455-dquztf5l	356	5	multicountry	multicountry	NN
cord-263455-dquztf5l	356	6	research	research	NN
cord-263455-dquztf5l	356	7	project	project	NN
cord-263455-dquztf5l	356	8	was	be	VBD
cord-263455-dquztf5l	356	9	developed	develop	VBN
cord-263455-dquztf5l	356	10	involving	involve	VBG
cord-263455-dquztf5l	356	11	ministries	ministry	NNS
cord-263455-dquztf5l	356	12	of	of	IN
cord-263455-dquztf5l	356	13	health	health	NN
cord-263455-dquztf5l	356	14	,	,	,
cord-263455-dquztf5l	356	15	international	international	JJ
cord-263455-dquztf5l	356	16	non	non	JJ
cord-263455-dquztf5l	356	17	-	-	JJ
cord-263455-dquztf5l	356	18	governmental	governmental	JJ
cord-263455-dquztf5l	356	19	organizations	organization	NNS
cord-263455-dquztf5l	356	20	(	(	-LRB-
cord-263455-dquztf5l	356	21	NGOs	NGOs	NNPS
cord-263455-dquztf5l	356	22	)	)	-RRB-
cord-263455-dquztf5l	356	23	,	,	,
cord-263455-dquztf5l	356	24	scientific	scientific	JJ
cord-263455-dquztf5l	356	25	institutes	institutes	NN
cord-263455-dquztf5l	356	26	,	,	,
cord-263455-dquztf5l	356	27	leprosy	leprosy	NN
cord-263455-dquztf5l	356	28	experts	expert	NNS
cord-263455-dquztf5l	356	29	,	,	,
cord-263455-dquztf5l	356	30	and	and	CC
cord-263455-dquztf5l	356	31	a	a	DT
cord-263455-dquztf5l	356	32	donor	donor	NN
cord-263455-dquztf5l	356	33	(	(	-LRB-
cord-263455-dquztf5l	356	34	Table	Table	NNP
cord-263455-dquztf5l	356	35	4	4	CD
cord-263455-dquztf5l	356	36	)	)	-RRB-
cord-263455-dquztf5l	356	37	.	.	.
cord-263455-dquztf5l	357	1	24	24	CD
cord-263455-dquztf5l	357	2	,	,	,
cord-263455-dquztf5l	357	3	110	110	CD
cord-263455-dquztf5l	358	1	The	the	DT
cord-263455-dquztf5l	358	2	LPEP	LPEP	NNP
cord-263455-dquztf5l	358	3	program	program	NN
cord-263455-dquztf5l	358	4	,	,	,
cord-263455-dquztf5l	358	5	as	as	IN
cord-263455-dquztf5l	358	6	operational	operational	JJ
cord-263455-dquztf5l	358	7	study	study	NN
cord-263455-dquztf5l	358	8	,	,	,
cord-263455-dquztf5l	358	9	aimed	aim	VBN
cord-263455-dquztf5l	358	10	to	to	TO
cord-263455-dquztf5l	358	11	accelerate	accelerate	VB
cord-263455-dquztf5l	358	12	the	the	DT
cord-263455-dquztf5l	358	13	uptake	uptake	NN
cord-263455-dquztf5l	358	14	of	of	IN
cord-263455-dquztf5l	358	15	evidence	evidence	NN
cord-263455-dquztf5l	358	16	on	on	IN
cord-263455-dquztf5l	358	17	SDR	SDR	NNP
cord-263455-dquztf5l	358	18	-	-	HYPH
cord-263455-dquztf5l	358	19	PEP	PEP	NNP
cord-263455-dquztf5l	358	20	effectiveness	effectiveness	NN
cord-263455-dquztf5l	358	21	by	by	IN
cord-263455-dquztf5l	358	22	gathering	gather	VBG
cord-263455-dquztf5l	358	23	data	datum	NNS
cord-263455-dquztf5l	358	24	on	on	IN
cord-263455-dquztf5l	358	25	the	the	DT
cord-263455-dquztf5l	358	26	impact	impact	NN
cord-263455-dquztf5l	358	27	and	and	CC
cord-263455-dquztf5l	358	28	feasibility	feasibility	NN
cord-263455-dquztf5l	358	29	of	of	IN
cord-263455-dquztf5l	358	30	implementing	implement	VBG
cord-263455-dquztf5l	358	31	SDR	SDR	NNP
cord-263455-dquztf5l	358	32	-	-	HYPH
cord-263455-dquztf5l	358	33	PEP	PEP	NNP
cord-263455-dquztf5l	358	34	as	as	IN
cord-263455-dquztf5l	358	35	part	part	NN
cord-263455-dquztf5l	358	36	of	of	IN
cord-263455-dquztf5l	358	37	routine	routine	JJ
cord-263455-dquztf5l	358	38	leprosy	leprosy	NN
cord-263455-dquztf5l	358	39	control	control	NN
cord-263455-dquztf5l	358	40	.	.	.
cord-263455-dquztf5l	359	1	24	24	CD
cord-263455-dquztf5l	360	1	The	the	DT
cord-263455-dquztf5l	360	2	program	program	NN
cord-263455-dquztf5l	360	3	was	be	VBD
cord-263455-dquztf5l	360	4	implemented	implement	VBN
cord-263455-dquztf5l	360	5	in	in	IN
cord-263455-dquztf5l	360	6	highendemic	highendemic	JJ
cord-263455-dquztf5l	360	7	areas	area	NNS
cord-263455-dquztf5l	360	8	in	in	IN
cord-263455-dquztf5l	360	9	India	India	NNP
cord-263455-dquztf5l	360	10	,	,	,
cord-263455-dquztf5l	360	11	Brazil	Brazil	NNP
cord-263455-dquztf5l	360	12	,	,	,
cord-263455-dquztf5l	360	13	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	360	14	,	,	,
cord-263455-dquztf5l	360	15	Myanmar	Myanmar	NNP
cord-263455-dquztf5l	360	16	,	,	,
cord-263455-dquztf5l	360	17	Nepal	Nepal	NNP
cord-263455-dquztf5l	360	18	,	,	,
cord-263455-dquztf5l	360	19	Tanzania	Tanzania	NNP
cord-263455-dquztf5l	360	20	,	,	,
cord-263455-dquztf5l	360	21	and	and	CC
cord-263455-dquztf5l	360	22	Sri	Sri	NNP
cord-263455-dquztf5l	360	23	Lanka	Lanka	NNP
cord-263455-dquztf5l	360	24	.	.	.
cord-263455-dquztf5l	361	1	Cambodia	Cambodia	NNP
cord-263455-dquztf5l	361	2	was	be	VBD
cord-263455-dquztf5l	361	3	also	also	RB
cord-263455-dquztf5l	361	4	inlcuded	inlcude	VBN
cord-263455-dquztf5l	361	5	,	,	,
cord-263455-dquztf5l	361	6	but	but	CC
cord-263455-dquztf5l	361	7	followed	follow	VBD
cord-263455-dquztf5l	361	8	a	a	DT
cord-263455-dquztf5l	361	9	different	different	JJ
cord-263455-dquztf5l	361	10	study	study	NN
cord-263455-dquztf5l	361	11	protocol	protocol	NN
cord-263455-dquztf5l	361	12	.	.	.
cord-263455-dquztf5l	362	1	24	24	CD
cord-263455-dquztf5l	362	2	,	,	,
cord-263455-dquztf5l	362	3	117	117	CD
cord-263455-dquztf5l	362	4	Before	before	IN
cord-263455-dquztf5l	362	5	implementation	implementation	NN
cord-263455-dquztf5l	362	6	,	,	,
cord-263455-dquztf5l	362	7	an	an	DT
cord-263455-dquztf5l	362	8	expert	expert	NN
cord-263455-dquztf5l	362	9	meeting	meeting	NN
cord-263455-dquztf5l	362	10	was	be	VBD
cord-263455-dquztf5l	362	11	convened	convene	VBN
cord-263455-dquztf5l	362	12	to	to	TO
cord-263455-dquztf5l	362	13	address	address	VB
cord-263455-dquztf5l	362	14	concerns	concern	NNS
cord-263455-dquztf5l	362	15	regarding	regard	VBG
cord-263455-dquztf5l	362	16	the	the	DT
cord-263455-dquztf5l	362	17	risk	risk	NN
cord-263455-dquztf5l	362	18	of	of	IN
cord-263455-dquztf5l	362	19	inducing	induce	VBG
cord-263455-dquztf5l	362	20	rifampicin	rifampicin	NN
cord-263455-dquztf5l	362	21	resistance	resistance	NN
cord-263455-dquztf5l	362	22	in	in	IN
cord-263455-dquztf5l	362	23	TB	TB	NNP
cord-263455-dquztf5l	362	24	.	.	.
cord-263455-dquztf5l	363	1	113	113	CD
cord-263455-dquztf5l	364	1	The	the	DT
cord-263455-dquztf5l	364	2	experts	expert	NNS
cord-263455-dquztf5l	364	3	concluded	conclude	VBD
cord-263455-dquztf5l	364	4	that	that	IN
cord-263455-dquztf5l	364	5	SDR	SDR	NNP
cord-263455-dquztf5l	364	6	given	give	VBN
cord-263455-dquztf5l	364	7	to	to	IN
cord-263455-dquztf5l	364	8	contacts	contact	NNS
cord-263455-dquztf5l	364	9	of	of	IN
cord-263455-dquztf5l	364	10	leprosy	leprosy	NN
cord-263455-dquztf5l	364	11	patients	patient	NNS
cord-263455-dquztf5l	364	12	,	,	,
cord-263455-dquztf5l	364	13	in	in	IN
cord-263455-dquztf5l	364	14	the	the	DT
cord-263455-dquztf5l	364	15	absence	absence	NN
cord-263455-dquztf5l	364	16	of	of	IN
cord-263455-dquztf5l	364	17	symptoms	symptom	NNS
cord-263455-dquztf5l	364	18	of	of	IN
cord-263455-dquztf5l	364	19	active	active	JJ
cord-263455-dquztf5l	364	20	TB	TB	NNP
cord-263455-dquztf5l	364	21	,	,	,
cord-263455-dquztf5l	364	22	poses	pose	VBZ
cord-263455-dquztf5l	364	23	a	a	DT
cord-263455-dquztf5l	364	24	negligible	negligible	JJ
cord-263455-dquztf5l	364	25	risk	risk	NN
cord-263455-dquztf5l	364	26	of	of	IN
cord-263455-dquztf5l	364	27	generating	generate	VBG
cord-263455-dquztf5l	364	28	resistance	resistance	NN
cord-263455-dquztf5l	364	29	in	in	IN
cord-263455-dquztf5l	364	30	M.	M.	NNP
cord-263455-dquztf5l	364	31	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	364	32	in	in	IN
cord-263455-dquztf5l	364	33	individuals	individual	NNS
cord-263455-dquztf5l	364	34	and	and	CC
cord-263455-dquztf5l	364	35	populations	population	NNS
cord-263455-dquztf5l	364	36	.	.	.
cord-263455-dquztf5l	365	1	113	113	CD
cord-263455-dquztf5l	365	2	Two	two	CD
cord-263455-dquztf5l	365	3	years	year	NNS
cord-263455-dquztf5l	365	4	into	into	IN
cord-263455-dquztf5l	365	5	the	the	DT
cord-263455-dquztf5l	365	6	LPEP	LPEP	NNP
cord-263455-dquztf5l	365	7	program	program	NN
cord-263455-dquztf5l	365	8	,	,	,
cord-263455-dquztf5l	365	9	the	the	DT
cord-263455-dquztf5l	365	10	integration	integration	NN
cord-263455-dquztf5l	365	11	of	of	IN
cord-263455-dquztf5l	365	12	contact	contact	NN
cord-263455-dquztf5l	365	13	screening	screening	NN
cord-263455-dquztf5l	365	14	and	and	CC
cord-263455-dquztf5l	365	15	SDR	SDR	NNP
cord-263455-dquztf5l	365	16	-	-	HYPH
cord-263455-dquztf5l	365	17	PEP	PEP	NNP
cord-263455-dquztf5l	365	18	administration	administration	NN
cord-263455-dquztf5l	365	19	into	into	IN
cord-263455-dquztf5l	365	20	different	different	JJ
cord-263455-dquztf5l	365	21	leprosy	leprosy	NN
cord-263455-dquztf5l	365	22	control	control	NN
cord-263455-dquztf5l	365	23	programs	program	NNS
cord-263455-dquztf5l	365	24	had	have	VBD
cord-263455-dquztf5l	365	25	proved	prove	VBN
cord-263455-dquztf5l	365	26	to	to	TO
cord-263455-dquztf5l	365	27	be	be	VB
cord-263455-dquztf5l	365	28	feasible	feasible	JJ
cord-263455-dquztf5l	365	29	and	and	CC
cord-263455-dquztf5l	365	30	well	well	RB
cord-263455-dquztf5l	365	31	accepted	accept	VBN
cord-263455-dquztf5l	365	32	by	by	IN
cord-263455-dquztf5l	365	33	all	all	DT
cord-263455-dquztf5l	365	34	stakeholders	stakeholder	NNS
cord-263455-dquztf5l	365	35	.	.	.
cord-263455-dquztf5l	366	1	114	114	CD
cord-263455-dquztf5l	367	1	The	the	DT
cord-263455-dquztf5l	367	2	program	program	NN
cord-263455-dquztf5l	367	3	was	be	VBD
cord-263455-dquztf5l	367	4	reported	report	VBN
cord-263455-dquztf5l	367	5	to	to	TO
cord-263455-dquztf5l	367	6	have	have	VB
cord-263455-dquztf5l	367	7	invigorated	invigorate	VBN
cord-263455-dquztf5l	367	8	leprosy	leprosy	NN
cord-263455-dquztf5l	367	9	control	control	NN
cord-263455-dquztf5l	367	10	.	.	.
cord-263455-dquztf5l	368	1	After	after	IN
cord-263455-dquztf5l	368	2	three	three	CD
cord-263455-dquztf5l	368	3	years	year	NNS
cord-263455-dquztf5l	368	4	,	,	,
cord-263455-dquztf5l	368	5	approximately	approximately	RB
cord-263455-dquztf5l	368	6	175,000	175,000	CD
cord-263455-dquztf5l	368	7	contacts	contact	NNS
cord-263455-dquztf5l	368	8	of	of	IN
cord-263455-dquztf5l	368	9	recently	recently	RB
cord-263455-dquztf5l	368	10	diagnosed	diagnose	VBN
cord-263455-dquztf5l	368	11	leprosy	leprosy	NN
cord-263455-dquztf5l	368	12	patients	patient	NNS
cord-263455-dquztf5l	368	13	had	have	VBD
cord-263455-dquztf5l	368	14	been	be	VBN
cord-263455-dquztf5l	368	15	screened	screen	VBN
cord-263455-dquztf5l	368	16	.	.	.
cord-263455-dquztf5l	369	1	Only	only	RB
cord-263455-dquztf5l	369	2	10	10	CD
cord-263455-dquztf5l	369	3	%	%	NN
cord-263455-dquztf5l	369	4	were	be	VBD
cord-263455-dquztf5l	369	5	not	not	RB
cord-263455-dquztf5l	369	6	eligible	eligible	JJ
cord-263455-dquztf5l	369	7	for	for	IN
cord-263455-dquztf5l	369	8	SDR	SDR	NNP
cord-263455-dquztf5l	369	9	-	-	HYPH
cord-263455-dquztf5l	369	10	PEP	PEP	NNP
cord-263455-dquztf5l	369	11	,	,	,
cord-263455-dquztf5l	369	12	because	because	IN
cord-263455-dquztf5l	369	13	of	of	IN
cord-263455-dquztf5l	369	14	young	young	JJ
cord-263455-dquztf5l	369	15	age	age	NN
cord-263455-dquztf5l	369	16	(	(	-LRB-
cord-263455-dquztf5l	369	17	<	<	XX
cord-263455-dquztf5l	369	18	2	2	CD
cord-263455-dquztf5l	369	19	years	year	NNS
cord-263455-dquztf5l	369	20	or	or	CC
cord-263455-dquztf5l	369	21	<	<	XX
cord-263455-dquztf5l	369	22	5	5	CD
cord-263455-dquztf5l	369	23	years	year	NNS
cord-263455-dquztf5l	369	24	,	,	,
cord-263455-dquztf5l	369	25	depending	depend	VBG
cord-263455-dquztf5l	369	26	on	on	IN
cord-263455-dquztf5l	369	27	the	the	DT
cord-263455-dquztf5l	369	28	country	country	NN
cord-263455-dquztf5l	369	29	)	)	-RRB-
cord-263455-dquztf5l	369	30	,	,	,
cord-263455-dquztf5l	369	31	liver	liver	NN
cord-263455-dquztf5l	369	32	or	or	CC
cord-263455-dquztf5l	369	33	renal	renal	JJ
cord-263455-dquztf5l	369	34	disease	disease	NN
cord-263455-dquztf5l	369	35	,	,	,
cord-263455-dquztf5l	369	36	signs	sign	NNS
cord-263455-dquztf5l	369	37	and	and	CC
cord-263455-dquztf5l	369	38	symptoms	symptom	NNS
cord-263455-dquztf5l	369	39	of	of	IN
cord-263455-dquztf5l	369	40	leprosy	leprosy	NN
cord-263455-dquztf5l	369	41	or	or	CC
cord-263455-dquztf5l	369	42	TB	TB	NNP
cord-263455-dquztf5l	369	43	,	,	,
cord-263455-dquztf5l	369	44	pregnancy	pregnancy	NN
cord-263455-dquztf5l	369	45	,	,	,
cord-263455-dquztf5l	369	46	known	know	VBN
cord-263455-dquztf5l	369	47	allergy	allergy	NN
cord-263455-dquztf5l	369	48	to	to	IN
cord-263455-dquztf5l	369	49	rifampicin	rifampicin	VB
cord-263455-dquztf5l	369	50	,	,	,
cord-263455-dquztf5l	369	51	rifampicin	rifampicin	VBZ
cord-263455-dquztf5l	369	52	use	use	NN
cord-263455-dquztf5l	369	53	in	in	IN
cord-263455-dquztf5l	369	54	the	the	DT
cord-263455-dquztf5l	369	55	past	past	JJ
cord-263455-dquztf5l	369	56	2	2	CD
cord-263455-dquztf5l	369	57	years	year	NNS
cord-263455-dquztf5l	369	58	,	,	,
cord-263455-dquztf5l	369	59	or	or	CC
cord-263455-dquztf5l	369	60	refusal	refusal	VB
cord-263455-dquztf5l	369	61	(	(	-LRB-
cord-263455-dquztf5l	369	62	<	<	NNP
cord-263455-dquztf5l	369	63	1	1	CD
cord-263455-dquztf5l	369	64	%	%	NN
cord-263455-dquztf5l	369	65	)	)	-RRB-
cord-263455-dquztf5l	369	66	.	.	.
cord-263455-dquztf5l	370	1	SDR	SDR	NNP
cord-263455-dquztf5l	370	2	-	-	HYPH
cord-263455-dquztf5l	370	3	PEP	PEP	NNP
cord-263455-dquztf5l	370	4	was	be	VBD
cord-263455-dquztf5l	370	5	found	find	VBN
cord-263455-dquztf5l	370	6	to	to	TO
cord-263455-dquztf5l	370	7	be	be	VB
cord-263455-dquztf5l	370	8	safe	safe	JJ
cord-263455-dquztf5l	370	9	;	;	:
cord-263455-dquztf5l	370	10	adverse	adverse	JJ
cord-263455-dquztf5l	370	11	events	event	NNS
cord-263455-dquztf5l	370	12	were	be	VBD
cord-263455-dquztf5l	370	13	very	very	RB
cord-263455-dquztf5l	370	14	rarely	rarely	RB
cord-263455-dquztf5l	370	15	reported	report	VBN
cord-263455-dquztf5l	371	1	(	(	-LRB-
cord-263455-dquztf5l	371	2	Richardus	Richardus	NNP
cord-263455-dquztf5l	371	3	et	et	FW
cord-263455-dquztf5l	371	4	al	al	NNP
cord-263455-dquztf5l	371	5	,	,	,
cord-263455-dquztf5l	371	6	full	full	JJ
cord-263455-dquztf5l	371	7	article	article	NN
cord-263455-dquztf5l	371	8	under	under	IN
cord-263455-dquztf5l	371	9	publication	publication	NN
cord-263455-dquztf5l	371	10	)	)	-RRB-
cord-263455-dquztf5l	371	11	.	.	.
cord-263455-dquztf5l	372	1	115	115	CD
cord-263455-dquztf5l	372	2	Mathematical	mathematical	JJ
cord-263455-dquztf5l	372	3	modeling	modeling	NN
cord-263455-dquztf5l	372	4	predicted	predict	VBD
cord-263455-dquztf5l	372	5	that	that	IN
cord-263455-dquztf5l	372	6	implementing	implement	VBG
cord-263455-dquztf5l	372	7	SDR	SDR	NNP
cord-263455-dquztf5l	372	8	-	-	HYPH
cord-263455-dquztf5l	372	9	PEP	PEP	NNP
cord-263455-dquztf5l	372	10	could	could	MD
cord-263455-dquztf5l	372	11	potentially	potentially	RB
cord-263455-dquztf5l	372	12	accelerate	accelerate	VB
cord-263455-dquztf5l	372	13	the	the	DT
cord-263455-dquztf5l	372	14	reduction	reduction	NN
cord-263455-dquztf5l	372	15	of	of	IN
cord-263455-dquztf5l	372	16	new	new	JJ
cord-263455-dquztf5l	372	17	cases	case	NNS
cord-263455-dquztf5l	372	18	and	and	CC
cord-263455-dquztf5l	372	19	,	,	,
cord-263455-dquztf5l	372	20	therefore	therefore	RB
cord-263455-dquztf5l	372	21	,	,	,
cord-263455-dquztf5l	372	22	could	could	MD
cord-263455-dquztf5l	372	23	potentially	potentially	RB
cord-263455-dquztf5l	372	24	accelerate	accelerate	VB
cord-263455-dquztf5l	372	25	the	the	DT
cord-263455-dquztf5l	372	26	cessation	cessation	NN
cord-263455-dquztf5l	372	27	of	of	IN
cord-263455-dquztf5l	372	28	M.	M.	NNP
cord-263455-dquztf5l	372	29	leprae	leprae	NNP
cord-263455-dquztf5l	372	30	transmission	transmission	NN
cord-263455-dquztf5l	372	31	(	(	-LRB-
cord-263455-dquztf5l	372	32	Blok	Blok	NNP
cord-263455-dquztf5l	372	33	et	et	NNP
cord-263455-dquztf5l	372	34	al	al	NNP
cord-263455-dquztf5l	372	35	,	,	,
cord-263455-dquztf5l	372	36	under	under	IN
cord-263455-dquztf5l	372	37	publication	publication	NN
cord-263455-dquztf5l	372	38	)	)	-RRB-
cord-263455-dquztf5l	372	39	.	.	.
cord-263455-dquztf5l	373	1	It	-PRON-	PRP
cord-263455-dquztf5l	373	2	is	be	VBZ
cord-263455-dquztf5l	373	3	also	also	RB
cord-263455-dquztf5l	373	4	estimated	estimate	VBN
cord-263455-dquztf5l	373	5	to	to	TO
cord-263455-dquztf5l	373	6	be	be	VB
cord-263455-dquztf5l	373	7	cost	cost	NN
cord-263455-dquztf5l	373	8	-	-	HYPH
cord-263455-dquztf5l	373	9	effective	effective	JJ
cord-263455-dquztf5l	373	10	when	when	WRB
cord-263455-dquztf5l	373	11	assessing	assess	VBG
cord-263455-dquztf5l	373	12	SDR	SDR	NNP
cord-263455-dquztf5l	373	13	-	-	HYPH
cord-263455-dquztf5l	373	14	PEP	PEP	NNP
cord-263455-dquztf5l	373	15	in	in	IN
cord-263455-dquztf5l	373	16	the	the	DT
cord-263455-dquztf5l	373	17	Indian	indian	JJ
cord-263455-dquztf5l	373	18	health	health	NN
cord-263455-dquztf5l	373	19	system	system	NN
cord-263455-dquztf5l	373	20	(	(	-LRB-
cord-263455-dquztf5l	373	21	US$	us$	$
cord-263455-dquztf5l	373	22	2,873	2,873	CD
cord-263455-dquztf5l	373	23	per	per	IN
cord-263455-dquztf5l	373	24	new	new	JJ
cord-263455-dquztf5l	373	25	leprosy	leprosy	NN
cord-263455-dquztf5l	373	26	case	case	NN
cord-263455-dquztf5l	373	27	averted	avert	VBD
cord-263455-dquztf5l	373	28	)	)	-RRB-
cord-263455-dquztf5l	373	29	.	.	.
cord-263455-dquztf5l	374	1	116	116	CD
cord-263455-dquztf5l	375	1	Demonstrating	demonstrate	VBG
cord-263455-dquztf5l	375	2	the	the	DT
cord-263455-dquztf5l	375	3	operational	operational	JJ
cord-263455-dquztf5l	375	4	feasibility	feasibility	NN
cord-263455-dquztf5l	375	5	of	of	IN
cord-263455-dquztf5l	375	6	integrating	integrate	VBG
cord-263455-dquztf5l	375	7	SDR	SDR	NNP
cord-263455-dquztf5l	375	8	-	-	HYPH
cord-263455-dquztf5l	375	9	PEP	PEP	NNP
cord-263455-dquztf5l	375	10	into	into	IN
cord-263455-dquztf5l	375	11	leprosy	leprosy	NN
cord-263455-dquztf5l	375	12	programs	program	NNS
cord-263455-dquztf5l	375	13	on	on	IN
cord-263455-dquztf5l	375	14	such	such	PDT
cord-263455-dquztf5l	375	15	a	a	DT
cord-263455-dquztf5l	375	16	large	large	JJ
cord-263455-dquztf5l	375	17	scale	scale	NN
cord-263455-dquztf5l	375	18	in	in	IN
cord-263455-dquztf5l	375	19	multiple	multiple	JJ
cord-263455-dquztf5l	375	20	settings	setting	NNS
cord-263455-dquztf5l	375	21	has	have	VBZ
cord-263455-dquztf5l	375	22	contributed	contribute	VBN
cord-263455-dquztf5l	375	23	to	to	IN
cord-263455-dquztf5l	375	24	WHO	who	WP
cord-263455-dquztf5l	375	25	recommending	recommend	VBG
cord-263455-dquztf5l	375	26	SDR	SDR	NNP
cord-263455-dquztf5l	375	27	-	-	HYPH
cord-263455-dquztf5l	375	28	PEP	PEP	NNP
cord-263455-dquztf5l	375	29	in	in	IN
cord-263455-dquztf5l	375	30	its	-PRON-	PRP$
cord-263455-dquztf5l	375	31	Guidelines	guideline	NNS
cord-263455-dquztf5l	375	32	for	for	IN
cord-263455-dquztf5l	375	33	the	the	DT
cord-263455-dquztf5l	375	34	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	375	35	,	,	,
cord-263455-dquztf5l	375	36	Treatment	Treatment	NNP
cord-263455-dquztf5l	375	37	and	and	CC
cord-263455-dquztf5l	375	38	Prevention	Prevention	NNP
cord-263455-dquztf5l	375	39	of	of	IN
cord-263455-dquztf5l	375	40	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	375	41	.	.	.
cord-263455-dquztf5l	376	1	52	52	CD
cord-263455-dquztf5l	377	1	As	as	IN
cord-263455-dquztf5l	377	2	part	part	NN
cord-263455-dquztf5l	377	3	of	of	IN
cord-263455-dquztf5l	377	4	the	the	DT
cord-263455-dquztf5l	377	5	LPEP	LPEP	NNP
cord-263455-dquztf5l	377	6	program	program	NN
cord-263455-dquztf5l	377	7	,	,	,
cord-263455-dquztf5l	377	8	two	two	CD
cord-263455-dquztf5l	377	9	specific	specific	JJ
cord-263455-dquztf5l	377	10	approaches	approach	NNS
cord-263455-dquztf5l	377	11	for	for	IN
cord-263455-dquztf5l	377	12	implementing	implement	VBG
cord-263455-dquztf5l	377	13	SDR	SDR	NNP
cord-263455-dquztf5l	377	14	-	-	HYPH
cord-263455-dquztf5l	377	15	PEP	PEP	NNP
cord-263455-dquztf5l	377	16	were	be	VBD
cord-263455-dquztf5l	377	17	piloted	pilot	VBN
cord-263455-dquztf5l	377	18	.	.	.
cord-263455-dquztf5l	378	1	One	one	CD
cord-263455-dquztf5l	378	2	was	be	VBD
cord-263455-dquztf5l	378	3	a	a	DT
cord-263455-dquztf5l	378	4	blanket	blanket	NN
cord-263455-dquztf5l	378	5	approach	approach	NN
cord-263455-dquztf5l	378	6	in	in	IN
cord-263455-dquztf5l	378	7	Lingat	Lingat	NNP
cord-263455-dquztf5l	378	8	village	village	NN
cord-263455-dquztf5l	378	9	on	on	IN
cord-263455-dquztf5l	378	10	Selaru	Selaru	NNP
cord-263455-dquztf5l	378	11	Island	Island	NNP
cord-263455-dquztf5l	378	12	,	,	,
cord-263455-dquztf5l	378	13	a	a	DT
cord-263455-dquztf5l	378	14	remote	remote	JJ
cord-263455-dquztf5l	378	15	highendemic	highendemic	JJ
cord-263455-dquztf5l	378	16	village	village	NN
cord-263455-dquztf5l	378	17	in	in	IN
cord-263455-dquztf5l	378	18	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	378	19	.	.	.
cord-263455-dquztf5l	379	1	116	116	CD
cord-263455-dquztf5l	380	1	The	the	DT
cord-263455-dquztf5l	380	2	blanket	blanket	NN
cord-263455-dquztf5l	380	3	approach	approach	NN
cord-263455-dquztf5l	380	4	involved	involve	VBD
cord-263455-dquztf5l	380	5	total	total	JJ
cord-263455-dquztf5l	380	6	population	population	NN
cord-263455-dquztf5l	380	7	screening	screening	NN
cord-263455-dquztf5l	380	8	in	in	IN
cord-263455-dquztf5l	380	9	2016	2016	CD
cord-263455-dquztf5l	380	10	(	(	-LRB-
cord-263455-dquztf5l	380	11	n	n	NN
cord-263455-dquztf5l	380	12	=	=	SYM
cord-263455-dquztf5l	380	13	2065	2065	CD
cord-263455-dquztf5l	380	14	)	)	-RRB-
cord-263455-dquztf5l	380	15	.	.	.
cord-263455-dquztf5l	381	1	During	during	IN
cord-263455-dquztf5l	381	2	two	two	CD
cord-263455-dquztf5l	381	3	visits	visit	NNS
cord-263455-dquztf5l	381	4	in	in	IN
cord-263455-dquztf5l	381	5	consecutive	consecutive	JJ
cord-263455-dquztf5l	381	6	years	year	NNS
cord-263455-dquztf5l	381	7	,	,	,
cord-263455-dquztf5l	381	8	1,671	1,671	CD
cord-263455-dquztf5l	381	9	inhabitants	inhabitant	NNS
cord-263455-dquztf5l	381	10	were	be	VBD
cord-263455-dquztf5l	381	11	screened	screen	VBN
cord-263455-dquztf5l	381	12	(	(	-LRB-
cord-263455-dquztf5l	381	13	88	88	CD
cord-263455-dquztf5l	381	14	%	%	NN
cord-263455-dquztf5l	381	15	)	)	-RRB-
cord-263455-dquztf5l	381	16	,	,	,
cord-263455-dquztf5l	381	17	and	and	CC
cord-263455-dquztf5l	381	18	1,499	1,499	CD
cord-263455-dquztf5l	381	19	(	(	-LRB-
cord-263455-dquztf5l	381	20	79	79	CD
cord-263455-dquztf5l	381	21	%	%	NN
cord-263455-dquztf5l	381	22	)	)	-RRB-
cord-263455-dquztf5l	381	23	received	receive	VBD
cord-263455-dquztf5l	381	24	SDR	SDR	NNP
cord-263455-dquztf5l	381	25	-	-	HYPH
cord-263455-dquztf5l	381	26	PEP	PEP	NNP
cord-263455-dquztf5l	381	27	.	.	.
cord-263455-dquztf5l	382	1	During	during	IN
cord-263455-dquztf5l	382	2	these	these	DT
cord-263455-dquztf5l	382	3	visits	visit	NNS
cord-263455-dquztf5l	382	4	,	,	,
cord-263455-dquztf5l	382	5	43	43	CD
cord-263455-dquztf5l	382	6	new	new	JJ
cord-263455-dquztf5l	382	7	leprosy	leprosy	NN
cord-263455-dquztf5l	382	8	patients	patient	NNS
cord-263455-dquztf5l	382	9	were	be	VBD
cord-263455-dquztf5l	382	10	diagnosed	diagnose	VBN
cord-263455-dquztf5l	382	11	with	with	IN
cord-263455-dquztf5l	382	12	leprosy	leprosy	NN
cord-263455-dquztf5l	382	13	(	(	-LRB-
cord-263455-dquztf5l	382	14	2,263/100,000	2,263/100,000	CD
cord-263455-dquztf5l	382	15	)	)	-RRB-
cord-263455-dquztf5l	382	16	.	.	.
cord-263455-dquztf5l	383	1	During	during	IN
cord-263455-dquztf5l	383	2	the	the	DT
cord-263455-dquztf5l	383	3	third	third	JJ
cord-263455-dquztf5l	383	4	visit	visit	NN
cord-263455-dquztf5l	383	5	,	,	,
cord-263455-dquztf5l	383	6	10	10	CD
cord-263455-dquztf5l	383	7	new	new	JJ
cord-263455-dquztf5l	383	8	leprosy	leprosy	NN
cord-263455-dquztf5l	383	9	cases	case	NNS
cord-263455-dquztf5l	383	10	in	in	IN
cord-263455-dquztf5l	383	11	1,481	1,481	CD
cord-263455-dquztf5l	383	12	screened	screen	VBN
cord-263455-dquztf5l	383	13	persons	person	NNS
cord-263455-dquztf5l	383	14	(	(	-LRB-
cord-263455-dquztf5l	383	15	484/100,000	484/100,000	CD
cord-263455-dquztf5l	383	16	)	)	-RRB-
cord-263455-dquztf5l	383	17	were	be	VBD
cord-263455-dquztf5l	383	18	detected	detect	VBN
cord-263455-dquztf5l	383	19	.	.	.
cord-263455-dquztf5l	384	1	The	the	DT
cord-263455-dquztf5l	384	2	other	other	JJ
cord-263455-dquztf5l	384	3	approach	approach	NN
cord-263455-dquztf5l	384	4	made	make	VBD
cord-263455-dquztf5l	384	5	use	use	NN
cord-263455-dquztf5l	384	6	of	of	IN
cord-263455-dquztf5l	384	7	"	"	``
cord-263455-dquztf5l	384	8	drives	drive	NNS
cord-263455-dquztf5l	384	9	"	"	''
cord-263455-dquztf5l	384	10	and	and	CC
cord-263455-dquztf5l	384	11	was	be	VBD
cord-263455-dquztf5l	384	12	implemented	implement	VBN
cord-263455-dquztf5l	384	13	in	in	IN
cord-263455-dquztf5l	384	14	Cambodia	Cambodia	NNP
cord-263455-dquztf5l	384	15	,	,	,
cord-263455-dquztf5l	384	16	a	a	DT
cord-263455-dquztf5l	384	17	low	low	JJ
cord-263455-dquztf5l	384	18	-	-	HYPH
cord-263455-dquztf5l	384	19	endemic	endemic	JJ
cord-263455-dquztf5l	384	20	country	country	NN
cord-263455-dquztf5l	384	21	.	.	.
cord-263455-dquztf5l	385	1	The	the	DT
cord-263455-dquztf5l	385	2	drives	drive	NNS
cord-263455-dquztf5l	385	3	in	in	IN
cord-263455-dquztf5l	385	4	Cambodia	Cambodia	NNP
cord-263455-dquztf5l	385	5	were	be	VBD
cord-263455-dquztf5l	385	6	carried	carry	VBN
cord-263455-dquztf5l	385	7	out	out	RP
cord-263455-dquztf5l	385	8	by	by	IN
cord-263455-dquztf5l	385	9	a	a	DT
cord-263455-dquztf5l	385	10	mobile	mobile	JJ
cord-263455-dquztf5l	385	11	team	team	NN
cord-263455-dquztf5l	385	12	with	with	IN
cord-263455-dquztf5l	385	13	leprosy	leprosy	NN
cord-263455-dquztf5l	385	14	experts	expert	NNS
cord-263455-dquztf5l	385	15	who	who	WP
cord-263455-dquztf5l	385	16	screened	screen	VBD
cord-263455-dquztf5l	385	17	the	the	DT
cord-263455-dquztf5l	385	18	contacts	contact	NNS
cord-263455-dquztf5l	385	19	of	of	IN
cord-263455-dquztf5l	385	20	all	all	DT
cord-263455-dquztf5l	385	21	patients	patient	NNS
cord-263455-dquztf5l	385	22	diagnosed	diagnose	VBN
cord-263455-dquztf5l	385	23	in	in	IN
cord-263455-dquztf5l	385	24	the	the	DT
cord-263455-dquztf5l	385	25	previous	previous	JJ
cord-263455-dquztf5l	385	26	10	10	CD
cord-263455-dquztf5l	385	27	years	year	NNS
cord-263455-dquztf5l	385	28	,	,	,
cord-263455-dquztf5l	385	29	and	and	CC
cord-263455-dquztf5l	385	30	administered	administer	VBN
cord-263455-dquztf5l	385	31	SDR	SDR	NNP
cord-263455-dquztf5l	385	32	-	-	HYPH
cord-263455-dquztf5l	385	33	PEP	PEP	NNP
cord-263455-dquztf5l	385	34	.	.	.
cord-263455-dquztf5l	385	35	117	117	CD
cord-263455-dquztf5l	386	1	In	in	IN
cord-263455-dquztf5l	386	2	the	the	DT
cord-263455-dquztf5l	386	3	first	first	JJ
cord-263455-dquztf5l	386	4	four	four	CD
cord-263455-dquztf5l	386	5	operational	operational	JJ
cord-263455-dquztf5l	386	6	districts	district	NNS
cord-263455-dquztf5l	386	7	,	,	,
cord-263455-dquztf5l	386	8	855	855	CD
cord-263455-dquztf5l	386	9	contacts	contact	NNS
cord-263455-dquztf5l	386	10	of	of	IN
cord-263455-dquztf5l	386	11	86	86	CD
cord-263455-dquztf5l	386	12	index	index	NN
cord-263455-dquztf5l	386	13	patients	patient	NNS
cord-263455-dquztf5l	386	14	were	be	VBD
cord-263455-dquztf5l	386	15	traced	trace	VBN
cord-263455-dquztf5l	386	16	and	and	CC
cord-263455-dquztf5l	386	17	screened	screen	VBN
cord-263455-dquztf5l	386	18	,	,	,
cord-263455-dquztf5l	386	19	828	828	CD
cord-263455-dquztf5l	386	20	(	(	-LRB-
cord-263455-dquztf5l	386	21	97	97	CD
cord-263455-dquztf5l	386	22	%	%	NN
cord-263455-dquztf5l	386	23	)	)	-RRB-
cord-263455-dquztf5l	386	24	received	receive	VBD
cord-263455-dquztf5l	386	25	SDR	SDR	NNP
cord-263455-dquztf5l	386	26	-	-	HYPH
cord-263455-dquztf5l	386	27	PEP	PEP	NNP
cord-263455-dquztf5l	386	28	,	,	,
cord-263455-dquztf5l	386	29	and	and	CC
cord-263455-dquztf5l	386	30	four	four	CD
cord-263455-dquztf5l	386	31	new	new	JJ
cord-263455-dquztf5l	386	32	leprosy	leprosy	NN
cord-263455-dquztf5l	386	33	patients	patient	NNS
cord-263455-dquztf5l	386	34	were	be	VBD
cord-263455-dquztf5l	386	35	identified	identify	VBN
cord-263455-dquztf5l	386	36	(	(	-LRB-
cord-263455-dquztf5l	386	37	468/100,000	468/100,000	CD
cord-263455-dquztf5l	386	38	)	)	-RRB-
cord-263455-dquztf5l	386	39	.	.	.
cord-263455-dquztf5l	387	1	Both	both	DT
cord-263455-dquztf5l	387	2	the	the	DT
cord-263455-dquztf5l	387	3	blanket	blanket	NN
cord-263455-dquztf5l	387	4	approach	approach	NN
cord-263455-dquztf5l	387	5	and	and	CC
cord-263455-dquztf5l	387	6	the	the	DT
cord-263455-dquztf5l	387	7	drive	drive	NN
cord-263455-dquztf5l	387	8	approach	approach	NN
cord-263455-dquztf5l	387	9	required	require	VBD
cord-263455-dquztf5l	387	10	sufficient	sufficient	JJ
cord-263455-dquztf5l	387	11	resources	resource	NNS
cord-263455-dquztf5l	387	12	and	and	CC
cord-263455-dquztf5l	387	13	thorough	thorough	JJ
cord-263455-dquztf5l	387	14	logistic	logistic	JJ
cord-263455-dquztf5l	387	15	preparation	preparation	NN
cord-263455-dquztf5l	387	16	,	,	,
cord-263455-dquztf5l	387	17	but	but	CC
cord-263455-dquztf5l	387	18	were	be	VBD
cord-263455-dquztf5l	387	19	operationally	operationally	RB
cord-263455-dquztf5l	387	20	feasible	feasible	JJ
cord-263455-dquztf5l	387	21	.	.	.
cord-263455-dquztf5l	388	1	Regular	regular	JJ
cord-263455-dquztf5l	388	2	monitoring	monitoring	NN
cord-263455-dquztf5l	388	3	is	be	VBZ
cord-263455-dquztf5l	388	4	required	require	VBN
cord-263455-dquztf5l	388	5	to	to	TO
cord-263455-dquztf5l	388	6	identify	identify	VB
cord-263455-dquztf5l	388	7	the	the	DT
cord-263455-dquztf5l	388	8	long	long	JJ
cord-263455-dquztf5l	388	9	-	-	HYPH
cord-263455-dquztf5l	388	10	term	term	NN
cord-263455-dquztf5l	388	11	impact	impact	NN
cord-263455-dquztf5l	388	12	.	.	.
cord-263455-dquztf5l	389	1	An	an	DT
cord-263455-dquztf5l	389	2	LPEP	LPEP	NNP
cord-263455-dquztf5l	389	3	substudy	substudy	NN
cord-263455-dquztf5l	389	4	in	in	IN
cord-263455-dquztf5l	389	5	India	India	NNP
cord-263455-dquztf5l	389	6	,	,	,
cord-263455-dquztf5l	389	7	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	389	8	,	,	,
cord-263455-dquztf5l	389	9	and	and	CC
cord-263455-dquztf5l	389	10	Nepal	Nepal	NNP
cord-263455-dquztf5l	389	11	assessed	assess	VBD
cord-263455-dquztf5l	389	12	how	how	WRB
cord-263455-dquztf5l	389	13	the	the	DT
cord-263455-dquztf5l	389	14	intervention	intervention	NN
cord-263455-dquztf5l	389	15	changed	change	VBD
cord-263455-dquztf5l	389	16	the	the	DT
cord-263455-dquztf5l	389	17	perception	perception	NN
cord-263455-dquztf5l	389	18	of	of	IN
cord-263455-dquztf5l	389	19	main	main	JJ
cord-263455-dquztf5l	389	20	stakeholders	stakeholder	NNS
cord-263455-dquztf5l	389	21	regarding	regard	VBG
cord-263455-dquztf5l	389	22	leprosy	leprosy	NN
cord-263455-dquztf5l	389	23	.	.	.
cord-263455-dquztf5l	390	1	118	118	CD
cord-263455-dquztf5l	391	1	The	the	DT
cord-263455-dquztf5l	391	2	LPEP	LPEP	NNP
cord-263455-dquztf5l	391	3	program	program	NN
cord-263455-dquztf5l	391	4	was	be	VBD
cord-263455-dquztf5l	391	5	perceived	perceive	VBN
cord-263455-dquztf5l	391	6	positively	positively	RB
cord-263455-dquztf5l	391	7	,	,	,
cord-263455-dquztf5l	391	8	though	though	IN
cord-263455-dquztf5l	391	9	more	more	JJR
cord-263455-dquztf5l	391	10	research	research	NN
cord-263455-dquztf5l	391	11	was	be	VBD
cord-263455-dquztf5l	391	12	recommended	recommend	VBN
cord-263455-dquztf5l	391	13	on	on	IN
cord-263455-dquztf5l	391	14	providing	provide	VBG
cord-263455-dquztf5l	391	15	accurate	accurate	JJ
cord-263455-dquztf5l	391	16	and	and	CC
cord-263455-dquztf5l	391	17	understandable	understandable	JJ
cord-263455-dquztf5l	391	18	health	health	NN
cord-263455-dquztf5l	391	19	information	information	NN
cord-263455-dquztf5l	391	20	to	to	IN
cord-263455-dquztf5l	391	21	contacts	contact	NNS
cord-263455-dquztf5l	391	22	,	,	,
cord-263455-dquztf5l	391	23	and	and	CC
cord-263455-dquztf5l	391	24	on	on	IN
cord-263455-dquztf5l	391	25	approaches	approach	NNS
cord-263455-dquztf5l	391	26	that	that	WDT
cord-263455-dquztf5l	391	27	do	do	VBP
cord-263455-dquztf5l	391	28	not	not	RB
cord-263455-dquztf5l	391	29	require	require	VB
cord-263455-dquztf5l	391	30	disclosure	disclosure	NN
cord-263455-dquztf5l	391	31	of	of	IN
cord-263455-dquztf5l	391	32	the	the	DT
cord-263455-dquztf5l	391	33	index	index	NN
cord-263455-dquztf5l	391	34	patient	patient	NN
cord-263455-dquztf5l	391	35	.	.	.
cord-263455-dquztf5l	392	1	The	the	DT
cord-263455-dquztf5l	392	2	LPEP	LPEP	NNP
cord-263455-dquztf5l	392	3	program	program	NN
cord-263455-dquztf5l	392	4	also	also	RB
cord-263455-dquztf5l	392	5	had	have	VBD
cord-263455-dquztf5l	392	6	a	a	DT
cord-263455-dquztf5l	392	7	positive	positive	JJ
cord-263455-dquztf5l	392	8	effect	effect	NN
cord-263455-dquztf5l	392	9	on	on	IN
cord-263455-dquztf5l	392	10	people	people	NNS
cord-263455-dquztf5l	392	11	's	's	POS
cord-263455-dquztf5l	392	12	knowledge	knowledge	NN
cord-263455-dquztf5l	392	13	regarding	regard	VBG
cord-263455-dquztf5l	392	14	leprosy	leprosy	NN
cord-263455-dquztf5l	392	15	(	(	-LRB-
cord-263455-dquztf5l	392	16	Mieras	Mieras	NNP
cord-263455-dquztf5l	392	17	et	et	NNP
cord-263455-dquztf5l	392	18	al	al	NNP
cord-263455-dquztf5l	392	19	,	,	,
cord-263455-dquztf5l	392	20	unpublished	unpublished	JJ
cord-263455-dquztf5l	392	21	report	report	NN
cord-263455-dquztf5l	392	22	)	)	-RRB-
cord-263455-dquztf5l	392	23	.	.	.
cord-263455-dquztf5l	393	1	Another	another	DT
cord-263455-dquztf5l	393	2	side	side	NN
cord-263455-dquztf5l	393	3	study	study	NN
cord-263455-dquztf5l	393	4	was	be	VBD
cord-263455-dquztf5l	393	5	an	an	DT
cord-263455-dquztf5l	393	6	acceptability	acceptability	NN
cord-263455-dquztf5l	393	7	study	study	NN
cord-263455-dquztf5l	393	8	carried	carry	VBN
cord-263455-dquztf5l	393	9	out	out	RP
cord-263455-dquztf5l	393	10	in	in	IN
cord-263455-dquztf5l	393	11	India	India	NNP
cord-263455-dquztf5l	393	12	.	.	.
cord-263455-dquztf5l	394	1	119	119	CD
cord-263455-dquztf5l	395	1	The	the	DT
cord-263455-dquztf5l	395	2	results	result	NNS
cord-263455-dquztf5l	395	3	of	of	IN
cord-263455-dquztf5l	395	4	this	this	DT
cord-263455-dquztf5l	395	5	study	study	NN
cord-263455-dquztf5l	395	6	aligned	align	VBN
cord-263455-dquztf5l	395	7	with	with	IN
cord-263455-dquztf5l	395	8	the	the	DT
cord-263455-dquztf5l	395	9	results	result	NNS
cord-263455-dquztf5l	395	10	of	of	IN
cord-263455-dquztf5l	395	11	the	the	DT
cord-263455-dquztf5l	395	12	main	main	JJ
cord-263455-dquztf5l	395	13	study	study	NN
cord-263455-dquztf5l	395	14	and	and	CC
cord-263455-dquztf5l	395	15	the	the	DT
cord-263455-dquztf5l	395	16	perception	perception	NN
cord-263455-dquztf5l	395	17	study	study	NN
cord-263455-dquztf5l	395	18	,	,	,
cord-263455-dquztf5l	395	19	illustrating	illustrate	VBG
cord-263455-dquztf5l	395	20	that	that	IN
cord-263455-dquztf5l	395	21	contact	contact	NN
cord-263455-dquztf5l	395	22	screening	screening	NN
cord-263455-dquztf5l	395	23	and	and	CC
cord-263455-dquztf5l	395	24	SDR	SDR	NNP
cord-263455-dquztf5l	395	25	-	-	HYPH
cord-263455-dquztf5l	395	26	PEP	pep	NN
cord-263455-dquztf5l	395	27	distribution	distribution	NN
cord-263455-dquztf5l	395	28	in	in	IN
cord-263455-dquztf5l	395	29	Dadra	Dadra	NNP
cord-263455-dquztf5l	395	30	and	and	CC
cord-263455-dquztf5l	395	31	Nagar	Nagar	NNP
cord-263455-dquztf5l	395	32	Haveli	Haveli	NNP
cord-263455-dquztf5l	395	33	,	,	,
cord-263455-dquztf5l	395	34	India	India	NNP
cord-263455-dquztf5l	395	35	,	,	,
cord-263455-dquztf5l	395	36	were	be	VBD
cord-263455-dquztf5l	395	37	well	well	RB
cord-263455-dquztf5l	395	38	accepted	accept	VBN
cord-263455-dquztf5l	395	39	by	by	IN
cord-263455-dquztf5l	395	40	the	the	DT
cord-263455-dquztf5l	395	41	stakeholders	stakeholder	NNS
cord-263455-dquztf5l	395	42	.	.	.
cord-263455-dquztf5l	396	1	115	115	CD
cord-263455-dquztf5l	396	2	,	,	,
cord-263455-dquztf5l	396	3	[	[	-LRB-
cord-263455-dquztf5l	396	4	118	118	CD
cord-263455-dquztf5l	396	5	]	]	-RRB-
cord-263455-dquztf5l	396	6	[	[	-LRB-
cord-263455-dquztf5l	396	7	119	119	CD
cord-263455-dquztf5l	396	8	]	]	-RRB-
cord-263455-dquztf5l	396	9	[	[	-LRB-
cord-263455-dquztf5l	396	10	120	120	CD
cord-263455-dquztf5l	396	11	]	]	-RRB-
cord-263455-dquztf5l	397	1	The	the	DT
cord-263455-dquztf5l	397	2	lessons	lesson	NNS
cord-263455-dquztf5l	397	3	learned	learn	VBD
cord-263455-dquztf5l	397	4	from	from	IN
cord-263455-dquztf5l	397	5	the	the	DT
cord-263455-dquztf5l	397	6	LPEP	LPEP	NNP
cord-263455-dquztf5l	397	7	program	program	NN
cord-263455-dquztf5l	397	8	led	lead	VBD
cord-263455-dquztf5l	397	9	to	to	IN
cord-263455-dquztf5l	397	10	a	a	DT
cord-263455-dquztf5l	397	11	recommended	recommend	VBN
cord-263455-dquztf5l	397	12	minimal	minimal	JJ
cord-263455-dquztf5l	397	13	set	set	NN
cord-263455-dquztf5l	397	14	of	of	IN
cord-263455-dquztf5l	397	15	data	datum	NNS
cord-263455-dquztf5l	397	16	required	require	VBN
cord-263455-dquztf5l	397	17	to	to	TO
cord-263455-dquztf5l	397	18	monitor	monitor	VB
cord-263455-dquztf5l	397	19	contact	contact	NN
cord-263455-dquztf5l	397	20	tracing	tracing	NN
cord-263455-dquztf5l	397	21	activities	activity	NNS
cord-263455-dquztf5l	397	22	and	and	CC
cord-263455-dquztf5l	397	23	SDR	SDR	NNP
cord-263455-dquztf5l	397	24	-	-	HYPH
cord-263455-dquztf5l	397	25	PEP	PEP	NNP
cord-263455-dquztf5l	397	26	administration	administration	NN
cord-263455-dquztf5l	397	27	for	for	IN
cord-263455-dquztf5l	397	28	leprosy	leprosy	NN
cord-263455-dquztf5l	397	29	control	control	NN
cord-263455-dquztf5l	397	30	in	in	IN
cord-263455-dquztf5l	397	31	a	a	DT
cord-263455-dquztf5l	397	32	routine	routine	JJ
cord-263455-dquztf5l	397	33	setting	setting	NN
cord-263455-dquztf5l	397	34	.	.	.
cord-263455-dquztf5l	398	1	121	121	CD
cord-263455-dquztf5l	399	1	Based	base	VBN
cord-263455-dquztf5l	399	2	on	on	IN
cord-263455-dquztf5l	399	3	the	the	DT
cord-263455-dquztf5l	399	4	experiences	experience	NNS
cord-263455-dquztf5l	399	5	gained	gain	VBN
cord-263455-dquztf5l	399	6	from	from	IN
cord-263455-dquztf5l	399	7	the	the	DT
cord-263455-dquztf5l	399	8	LPEP	LPEP	NNP
cord-263455-dquztf5l	399	9	program	program	NN
cord-263455-dquztf5l	399	10	,	,	,
cord-263455-dquztf5l	399	11	an	an	DT
cord-263455-dquztf5l	399	12	SDR	SDR	NNP
cord-263455-dquztf5l	399	13	-	-	HYPH
cord-263455-dquztf5l	399	14	PEP	PEP	NNP
cord-263455-dquztf5l	399	15	Toolkit	Toolkit	NNP
cord-263455-dquztf5l	399	16	was	be	VBD
cord-263455-dquztf5l	399	17	developed	develop	VBN
cord-263455-dquztf5l	399	18	to	to	TO
cord-263455-dquztf5l	399	19	support	support	VB
cord-263455-dquztf5l	399	20	national	national	JJ
cord-263455-dquztf5l	399	21	leprosy	leprosy	NN
cord-263455-dquztf5l	399	22	program	program	NN
cord-263455-dquztf5l	399	23	managers	manager	NNS
cord-263455-dquztf5l	399	24	concerned	concern	VBN
cord-263455-dquztf5l	399	25	with	with	IN
cord-263455-dquztf5l	399	26	the	the	DT
cord-263455-dquztf5l	399	27	practical	practical	JJ
cord-263455-dquztf5l	399	28	aspects	aspect	NNS
cord-263455-dquztf5l	399	29	of	of	IN
cord-263455-dquztf5l	399	30	implementing	implement	VBG
cord-263455-dquztf5l	399	31	SDR	SDR	NNP
cord-263455-dquztf5l	399	32	-	-	HYPH
cord-263455-dquztf5l	399	33	PEP	PEP	NNP
cord-263455-dquztf5l	399	34	,	,	,
cord-263455-dquztf5l	399	35	such	such	JJ
cord-263455-dquztf5l	399	36	as	as	IN
cord-263455-dquztf5l	399	37	advocacy	advocacy	NN
cord-263455-dquztf5l	399	38	,	,	,
cord-263455-dquztf5l	399	39	training	training	NN
cord-263455-dquztf5l	399	40	,	,	,
cord-263455-dquztf5l	399	41	and	and	CC
cord-263455-dquztf5l	399	42	reporting	reporting	NN
cord-263455-dquztf5l	399	43	and	and	CC
cord-263455-dquztf5l	399	44	recording	recording	NN
cord-263455-dquztf5l	399	45	.	.	.
cord-263455-dquztf5l	400	1	120	120	CD
cord-263455-dquztf5l	401	1	In	in	IN
cord-263455-dquztf5l	401	2	2017	2017	CD
cord-263455-dquztf5l	401	3	,	,	,
cord-263455-dquztf5l	401	4	Gillini	Gillini	NNP
cord-263455-dquztf5l	401	5	et	et	NNP
cord-263455-dquztf5l	401	6	al	al	NNP
cord-263455-dquztf5l	401	7	collected	collect	VBD
cord-263455-dquztf5l	401	8	information	information	NN
cord-263455-dquztf5l	401	9	to	to	TO
cord-263455-dquztf5l	401	10	determine	determine	VB
cord-263455-dquztf5l	401	11	the	the	DT
cord-263455-dquztf5l	401	12	extent	extent	NN
cord-263455-dquztf5l	401	13	of	of	IN
cord-263455-dquztf5l	401	14	leprosy	leprosy	NN
cord-263455-dquztf5l	401	15	post	post	JJ
cord-263455-dquztf5l	401	16	-	-	JJ
cord-263455-dquztf5l	401	17	exposure	exposure	JJ
cord-263455-dquztf5l	401	18	immuno	immuno	JJ
cord-263455-dquztf5l	401	19	-	-	:
cord-263455-dquztf5l	401	20	and	and	CC
cord-263455-dquztf5l	401	21	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	401	22	in	in	IN
cord-263455-dquztf5l	401	23	countries	country	NNS
cord-263455-dquztf5l	401	24	around	around	IN
cord-263455-dquztf5l	401	25	the	the	DT
cord-263455-dquztf5l	401	26	world	world	NN
cord-263455-dquztf5l	401	27	as	as	IN
cord-263455-dquztf5l	401	28	national	national	JJ
cord-263455-dquztf5l	401	29	policy	policy	NN
cord-263455-dquztf5l	401	30	.	.	.
cord-263455-dquztf5l	402	1	122	122	CD
cord-263455-dquztf5l	403	1	A	a	DT
cord-263455-dquztf5l	403	2	total	total	NN
cord-263455-dquztf5l	403	3	of	of	IN
cord-263455-dquztf5l	403	4	66	66	CD
cord-263455-dquztf5l	403	5	countries	country	NNS
cord-263455-dquztf5l	403	6	responded	respond	VBD
cord-263455-dquztf5l	403	7	,	,	,
cord-263455-dquztf5l	403	8	representing	represent	VBG
cord-263455-dquztf5l	403	9	95	95	CD
cord-263455-dquztf5l	403	10	%	%	NN
cord-263455-dquztf5l	403	11	of	of	IN
cord-263455-dquztf5l	403	12	the	the	DT
cord-263455-dquztf5l	403	13	total	total	JJ
cord-263455-dquztf5l	403	14	reported	reported	JJ
cord-263455-dquztf5l	403	15	global	global	JJ
cord-263455-dquztf5l	403	16	leprosy	leprosy	NN
cord-263455-dquztf5l	403	17	burden	burden	NN
cord-263455-dquztf5l	403	18	.	.	.
cord-263455-dquztf5l	404	1	Nationwide	nationwide	JJ
cord-263455-dquztf5l	404	2	routine	routine	JJ
cord-263455-dquztf5l	404	3	implementation	implementation	NN
cord-263455-dquztf5l	404	4	of	of	IN
cord-263455-dquztf5l	404	5	SDR	SDR	NNP
cord-263455-dquztf5l	404	6	-	-	HYPH
cord-263455-dquztf5l	404	7	PEP	PEP	NNP
cord-263455-dquztf5l	404	8	was	be	VBD
cord-263455-dquztf5l	404	9	reported	report	VBN
cord-263455-dquztf5l	404	10	by	by	IN
cord-263455-dquztf5l	404	11	only	only	RB
cord-263455-dquztf5l	404	12	a	a	DT
cord-263455-dquztf5l	404	13	few	few	JJ
cord-263455-dquztf5l	404	14	countries	country	NNS
cord-263455-dquztf5l	404	15	with	with	IN
cord-263455-dquztf5l	404	16	a	a	DT
cord-263455-dquztf5l	404	17	low	low	JJ
cord-263455-dquztf5l	404	18	burden	burden	NN
cord-263455-dquztf5l	404	19	,	,	,
cord-263455-dquztf5l	404	20	such	such	JJ
cord-263455-dquztf5l	404	21	as	as	IN
cord-263455-dquztf5l	404	22	Cuba	Cuba	NNP
cord-263455-dquztf5l	404	23	(	(	-LRB-
cord-263455-dquztf5l	404	24	2002	2002	CD
cord-263455-dquztf5l	404	25	)	)	-RRB-
cord-263455-dquztf5l	404	26	,	,	,
cord-263455-dquztf5l	404	27	Morocco	Morocco	NNP
cord-263455-dquztf5l	404	28	(	(	-LRB-
cord-263455-dquztf5l	404	29	2012	2012	CD
cord-263455-dquztf5l	404	30	)	)	-RRB-
cord-263455-dquztf5l	404	31	,	,	,
cord-263455-dquztf5l	404	32	and	and	CC
cord-263455-dquztf5l	404	33	Samoa	Samoa	NNP
cord-263455-dquztf5l	404	34	(	(	-LRB-
cord-263455-dquztf5l	404	35	2015	2015	CD
cord-263455-dquztf5l	404	36	)	)	-RRB-
cord-263455-dquztf5l	404	37	.	.	.
cord-263455-dquztf5l	405	1	Since	since	IN
cord-263455-dquztf5l	405	2	SDR	SDR	NNP
cord-263455-dquztf5l	405	3	-	-	HYPH
cord-263455-dquztf5l	405	4	PEP	PEP	NNP
cord-263455-dquztf5l	405	5	is	be	VBZ
cord-263455-dquztf5l	405	6	addressed	address	VBN
cord-263455-dquztf5l	405	7	in	in	IN
cord-263455-dquztf5l	405	8	the	the	DT
cord-263455-dquztf5l	405	9	2018	2018	CD
cord-263455-dquztf5l	405	10	WHO	who	WP
cord-263455-dquztf5l	405	11	Guidelines	Guidelines	NNPS
cord-263455-dquztf5l	405	12	for	for	IN
cord-263455-dquztf5l	405	13	the	the	DT
cord-263455-dquztf5l	405	14	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	405	15	,	,	,
cord-263455-dquztf5l	405	16	Treatment	Treatment	NNP
cord-263455-dquztf5l	405	17	and	and	CC
cord-263455-dquztf5l	405	18	Prevention	Prevention	NNP
cord-263455-dquztf5l	405	19	of	of	IN
cord-263455-dquztf5l	405	20	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	405	21	,	,	,
cord-263455-dquztf5l	405	22	more	more	JJR
cord-263455-dquztf5l	405	23	countries	country	NNS
cord-263455-dquztf5l	405	24	are	be	VBP
cord-263455-dquztf5l	405	25	implementing	implement	VBG
cord-263455-dquztf5l	405	26	SDR	SDR	NNP
cord-263455-dquztf5l	405	27	-	-	HYPH
cord-263455-dquztf5l	405	28	PEP	PEP	NNP
cord-263455-dquztf5l	405	29	in	in	IN
cord-263455-dquztf5l	405	30	their	-PRON-	PRP$
cord-263455-dquztf5l	405	31	national	national	JJ
cord-263455-dquztf5l	405	32	leprosy	leprosy	NN
cord-263455-dquztf5l	405	33	control	control	NN
cord-263455-dquztf5l	405	34	programs	program	NNS
cord-263455-dquztf5l	405	35	.	.	.
cord-263455-dquztf5l	406	1	52	52	CD
cord-263455-dquztf5l	407	1	For	for	IN
cord-263455-dquztf5l	407	2	example	example	NN
cord-263455-dquztf5l	407	3	,	,	,
cord-263455-dquztf5l	407	4	in	in	IN
cord-263455-dquztf5l	407	5	India	India	NNP
cord-263455-dquztf5l	407	6	and	and	CC
cord-263455-dquztf5l	407	7	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	407	8	,	,	,
cord-263455-dquztf5l	407	9	the	the	DT
cord-263455-dquztf5l	407	10	ministries	ministry	NNS
cord-263455-dquztf5l	407	11	of	of	IN
cord-263455-dquztf5l	407	12	health	health	NN
cord-263455-dquztf5l	407	13	adopted	adopt	VBD
cord-263455-dquztf5l	407	14	SDR	SDR	NNP
cord-263455-dquztf5l	407	15	-	-	HYPH
cord-263455-dquztf5l	407	16	PEP	PEP	NNP
cord-263455-dquztf5l	407	17	as	as	IN
cord-263455-dquztf5l	407	18	a	a	DT
cord-263455-dquztf5l	407	19	main	main	JJ
cord-263455-dquztf5l	407	20	strategy	strategy	NN
cord-263455-dquztf5l	407	21	in	in	IN
cord-263455-dquztf5l	407	22	leprosy	leprosy	NN
cord-263455-dquztf5l	407	23	prevention	prevention	NN
cord-263455-dquztf5l	407	24	in	in	IN
cord-263455-dquztf5l	407	25	2018	2018	CD
cord-263455-dquztf5l	407	26	and	and	CC
cord-263455-dquztf5l	407	27	2019	2019	CD
cord-263455-dquztf5l	407	28	,	,	,
cord-263455-dquztf5l	407	29	respectively	respectively	RB
cord-263455-dquztf5l	407	30	.	.	.
cord-263455-dquztf5l	408	1	144	144	CD
cord-263455-dquztf5l	408	2	,	,	,
cord-263455-dquztf5l	408	3	122	122	CD
cord-263455-dquztf5l	408	4	,	,	,
cord-263455-dquztf5l	408	5	123	123	CD
cord-263455-dquztf5l	408	6	This	this	DT
cord-263455-dquztf5l	408	7	year	year	NN
cord-263455-dquztf5l	408	8	,	,	,
cord-263455-dquztf5l	408	9	WHO	who	WP
cord-263455-dquztf5l	408	10	is	be	VBZ
cord-263455-dquztf5l	408	11	expected	expect	VBN
cord-263455-dquztf5l	408	12	to	to	TO
cord-263455-dquztf5l	408	13	publish	publish	VB
cord-263455-dquztf5l	408	14	a	a	DT
cord-263455-dquztf5l	408	15	technical	technical	JJ
cord-263455-dquztf5l	408	16	guidance	guidance	NN
cord-263455-dquztf5l	408	17	document	document	NN
cord-263455-dquztf5l	408	18	whith	whith	IN
cord-263455-dquztf5l	408	19	a	a	DT
cord-263455-dquztf5l	408	20	description	description	NN
cord-263455-dquztf5l	408	21	of	of	IN
cord-263455-dquztf5l	408	22	the	the	DT
cord-263455-dquztf5l	408	23	steps	step	NNS
cord-263455-dquztf5l	408	24	that	that	WDT
cord-263455-dquztf5l	408	25	could	could	MD
cord-263455-dquztf5l	408	26	be	be	VB
cord-263455-dquztf5l	408	27	taken	take	VBN
cord-263455-dquztf5l	408	28	for	for	IN
cord-263455-dquztf5l	408	29	the	the	DT
cord-263455-dquztf5l	408	30	implementation	implementation	NN
cord-263455-dquztf5l	408	31	of	of	IN
cord-263455-dquztf5l	408	32	both	both	DT
cord-263455-dquztf5l	408	33	contact	contact	NN
cord-263455-dquztf5l	408	34	tracing	tracing	NN
cord-263455-dquztf5l	408	35	and	and	CC
cord-263455-dquztf5l	408	36	postexposure	postexposure	NN
cord-263455-dquztf5l	408	37	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	408	38	(	(	-LRB-
cord-263455-dquztf5l	408	39	WHO	who	WP
cord-263455-dquztf5l	408	40	,	,	,
cord-263455-dquztf5l	408	41	under	under	IN
cord-263455-dquztf5l	408	42	publication	publication	NN
cord-263455-dquztf5l	408	43	)	)	-RRB-
cord-263455-dquztf5l	408	44	.	.	.
cord-263455-dquztf5l	409	1	The	the	DT
cord-263455-dquztf5l	409	2	availability	availability	NN
cord-263455-dquztf5l	409	3	of	of	IN
cord-263455-dquztf5l	409	4	preventive	preventive	JJ
cord-263455-dquztf5l	409	5	measures	measure	NNS
cord-263455-dquztf5l	409	6	contributed	contribute	VBD
cord-263455-dquztf5l	409	7	to	to	IN
cord-263455-dquztf5l	409	8	a	a	DT
cord-263455-dquztf5l	409	9	new	new	JJ
cord-263455-dquztf5l	409	10	momentum	momentum	NN
cord-263455-dquztf5l	409	11	to	to	TO
cord-263455-dquztf5l	409	12	work	work	VB
cord-263455-dquztf5l	409	13	toward	toward	IN
cord-263455-dquztf5l	409	14	stopping	stop	VBG
cord-263455-dquztf5l	409	15	the	the	DT
cord-263455-dquztf5l	409	16	transmission	transmission	NN
cord-263455-dquztf5l	409	17	of	of	IN
cord-263455-dquztf5l	409	18	leprosy	leprosy	NN
cord-263455-dquztf5l	409	19	.	.	.
cord-263455-dquztf5l	410	1	124	124	CD
cord-263455-dquztf5l	410	2	 	 	_SP
cord-263455-dquztf5l	411	1	Lwin	Lwin	NNP
cord-263455-dquztf5l	411	2	et	et	NNP
cord-263455-dquztf5l	411	3	al	al	NNP
cord-263455-dquztf5l	411	4	concluded	conclude	VBD
cord-263455-dquztf5l	411	5	that	that	IN
cord-263455-dquztf5l	411	6	BCG	BCG	NNP
cord-263455-dquztf5l	411	7	vaccination	vaccination	NN
cord-263455-dquztf5l	411	8	alone	alone	RB
cord-263455-dquztf5l	411	9	is	be	VBZ
cord-263455-dquztf5l	411	10	not	not	RB
cord-263455-dquztf5l	411	11	likely	likely	JJ
cord-263455-dquztf5l	411	12	to	to	TO
cord-263455-dquztf5l	411	13	be	be	VB
cord-263455-dquztf5l	411	14	the	the	DT
cord-263455-dquztf5l	411	15	solution	solution	NN
cord-263455-dquztf5l	411	16	for	for	IN
cord-263455-dquztf5l	411	17	leprosy	leprosy	NN
cord-263455-dquztf5l	411	18	control	control	NN
cord-263455-dquztf5l	411	19	.	.	.
cord-263455-dquztf5l	412	1	43	43	CD
cord-263455-dquztf5l	413	1	As	as	IN
cord-263455-dquztf5l	413	2	described	describe	VBN
cord-263455-dquztf5l	413	3	,	,	,
cord-263455-dquztf5l	413	4	Schuring	Schuring	NNP
cord-263455-dquztf5l	413	5	et	et	FW
cord-263455-dquztf5l	413	6	al	al	NNP
cord-263455-dquztf5l	413	7	performed	perform	VBD
cord-263455-dquztf5l	413	8	a	a	DT
cord-263455-dquztf5l	413	9	secondary	secondary	JJ
cord-263455-dquztf5l	413	10	analysis	analysis	NN
cord-263455-dquztf5l	413	11	on	on	IN
cord-263455-dquztf5l	413	12	the	the	DT
cord-263455-dquztf5l	413	13	COLEP	COLEP	NNP
cord-263455-dquztf5l	413	14	trial	trial	NN
cord-263455-dquztf5l	413	15	.	.	.
cord-263455-dquztf5l	414	1	The	the	DT
cord-263455-dquztf5l	414	2	individual	individual	JJ
cord-263455-dquztf5l	414	3	protective	protective	JJ
cord-263455-dquztf5l	414	4	effect	effect	NN
cord-263455-dquztf5l	414	5	of	of	IN
cord-263455-dquztf5l	414	6	BCG	BCG	NNP
cord-263455-dquztf5l	414	7	57	57	CD
cord-263455-dquztf5l	414	8	%	%	NN
cord-263455-dquztf5l	414	9	(	(	-LRB-
cord-263455-dquztf5l	414	10	95	95	CD
cord-263455-dquztf5l	414	11	%	%	NN
cord-263455-dquztf5l	414	12	CI	CI	NNP
cord-263455-dquztf5l	414	13	24	24	CD
cord-263455-dquztf5l	414	14	-	-	SYM
cord-263455-dquztf5l	414	15	75	75	CD
cord-263455-dquztf5l	414	16	)	)	-RRB-
cord-263455-dquztf5l	414	17	and	and	CC
cord-263455-dquztf5l	414	18	SDR	SDR	NNP
cord-263455-dquztf5l	414	19	-	-	HYPH
cord-263455-dquztf5l	414	20	PEP	PEP	NNP
cord-263455-dquztf5l	414	21	58	58	CD
cord-263455-dquztf5l	414	22	%	%	NN
cord-263455-dquztf5l	414	23	(	(	-LRB-
cord-263455-dquztf5l	414	24	95	95	CD
cord-263455-dquztf5l	414	25	%	%	NN
cord-263455-dquztf5l	414	26	CI	CI	NNP
cord-263455-dquztf5l	414	27	30	30	CD
cord-263455-dquztf5l	414	28	-	-	SYM
cord-263455-dquztf5l	414	29	74	74	CD
cord-263455-dquztf5l	414	30	)	)	-RRB-
cord-263455-dquztf5l	414	31	demonstrated	demonstrate	VBD
cord-263455-dquztf5l	414	32	a	a	DT
cord-263455-dquztf5l	414	33	combined	combine	VBN
cord-263455-dquztf5l	414	34	protective	protective	JJ
cord-263455-dquztf5l	414	35	effect	effect	NN
cord-263455-dquztf5l	414	36	of	of	IN
cord-263455-dquztf5l	414	37	80	80	CD
cord-263455-dquztf5l	414	38	%	%	NN
cord-263455-dquztf5l	414	39	(	(	-LRB-
cord-263455-dquztf5l	414	40	95	95	CD
cord-263455-dquztf5l	414	41	%	%	NN
cord-263455-dquztf5l	414	42	CI	CI	NNP
cord-263455-dquztf5l	414	43	50	50	CD
cord-263455-dquztf5l	414	44	-	-	SYM
cord-263455-dquztf5l	414	45	92	92	CD
cord-263455-dquztf5l	414	46	)	)	-RRB-
cord-263455-dquztf5l	414	47	.	.	.
cord-263455-dquztf5l	415	1	98	98	CD
cord-263455-dquztf5l	416	1	After	after	IN
cord-263455-dquztf5l	416	2	the	the	DT
cord-263455-dquztf5l	416	3	findings	finding	NNS
cord-263455-dquztf5l	416	4	of	of	IN
cord-263455-dquztf5l	416	5	the	the	DT
cord-263455-dquztf5l	416	6	COLEP	COLEP	NNP
cord-263455-dquztf5l	416	7	trial	trial	NN
cord-263455-dquztf5l	416	8	,	,	,
cord-263455-dquztf5l	416	9	a	a	DT
cord-263455-dquztf5l	416	10	single	single	JJ
cord-263455-dquztf5l	416	11	-	-	HYPH
cord-263455-dquztf5l	416	12	center	center	NN
cord-263455-dquztf5l	416	13	,	,	,
cord-263455-dquztf5l	416	14	cluster	cluster	NN
cord-263455-dquztf5l	416	15	-	-	HYPH
cord-263455-dquztf5l	416	16	randomized	randomized	JJ
cord-263455-dquztf5l	416	17	controlled	control	VBN
cord-263455-dquztf5l	416	18	trial	trial	NN
cord-263455-dquztf5l	416	19	(	(	-LRB-
cord-263455-dquztf5l	416	20	MALTALEP	MALTALEP	NNP
cord-263455-dquztf5l	416	21	)	)	-RRB-
cord-263455-dquztf5l	416	22	was	be	VBD
cord-263455-dquztf5l	416	23	conducted	conduct	VBN
cord-263455-dquztf5l	416	24	to	to	TO
cord-263455-dquztf5l	416	25	determine	determine	VB
cord-263455-dquztf5l	416	26	whether	whether	IN
cord-263455-dquztf5l	416	27	possible	possible	JJ
cord-263455-dquztf5l	416	28	excess	excess	JJ
cord-263455-dquztf5l	416	29	cases	case	NNS
cord-263455-dquztf5l	416	30	in	in	IN
cord-263455-dquztf5l	416	31	the	the	DT
cord-263455-dquztf5l	416	32	first	first	JJ
cord-263455-dquztf5l	416	33	year	year	NN
cord-263455-dquztf5l	416	34	after	after	IN
cord-263455-dquztf5l	416	35	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	416	36	(	(	-LRB-
cord-263455-dquztf5l	416	37	with	with	IN
cord-263455-dquztf5l	416	38	BCG	BCG	NNP
cord-263455-dquztf5l	416	39	)	)	-RRB-
cord-263455-dquztf5l	416	40	could	could	MD
cord-263455-dquztf5l	416	41	be	be	VB
cord-263455-dquztf5l	416	42	prevented	prevent	VBN
cord-263455-dquztf5l	416	43	with	with	IN
cord-263455-dquztf5l	416	44	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	416	45	(	(	-LRB-
cord-263455-dquztf5l	416	46	with	with	IN
cord-263455-dquztf5l	416	47	SDR	SDR	NNP
cord-263455-dquztf5l	416	48	)	)	-RRB-
cord-263455-dquztf5l	416	49	without	without	IN
cord-263455-dquztf5l	416	50	affecting	affect	VBG
cord-263455-dquztf5l	416	51	BCG	BCG	NNP
cord-263455-dquztf5l	416	52	's	's	POS
cord-263455-dquztf5l	416	53	protective	protective	JJ
cord-263455-dquztf5l	416	54	effect	effect	NN
cord-263455-dquztf5l	416	55	.	.	.
cord-263455-dquztf5l	417	1	44	44	CD
cord-263455-dquztf5l	417	2	,	,	,
cord-263455-dquztf5l	417	3	125	125	CD
cord-263455-dquztf5l	418	1	In	in	IN
cord-263455-dquztf5l	418	2	the	the	DT
cord-263455-dquztf5l	418	3	intervention	intervention	NN
cord-263455-dquztf5l	418	4	group	group	NN
cord-263455-dquztf5l	418	5	(	(	-LRB-
cord-263455-dquztf5l	418	6	n	n	NN
cord-263455-dquztf5l	418	7	=	=	SYM
cord-263455-dquztf5l	418	8	7,609	7,609	CD
cord-263455-dquztf5l	418	9	)	)	-RRB-
cord-263455-dquztf5l	418	10	,	,	,
cord-263455-dquztf5l	418	11	BCG	BCG	NNP
cord-263455-dquztf5l	418	12	vaccination	vaccination	NN
cord-263455-dquztf5l	418	13	was	be	VBD
cord-263455-dquztf5l	418	14	followed	follow	VBN
cord-263455-dquztf5l	418	15	by	by	IN
cord-263455-dquztf5l	418	16	SDR	SDR	NNP
cord-263455-dquztf5l	418	17	after	after	IN
cord-263455-dquztf5l	418	18	8	8	CD
cord-263455-dquztf5l	418	19	-	-	SYM
cord-263455-dquztf5l	418	20	12	12	CD
cord-263455-dquztf5l	418	21	weeks	week	NNS
cord-263455-dquztf5l	418	22	.	.	.
cord-263455-dquztf5l	419	1	Controls	control	NNS
cord-263455-dquztf5l	419	2	(	(	-LRB-
cord-263455-dquztf5l	419	3	n	n	NN
cord-263455-dquztf5l	419	4	=	=	SYM
cord-263455-dquztf5l	419	5	7,379	7,379	CD
cord-263455-dquztf5l	419	6	)	)	-RRB-
cord-263455-dquztf5l	419	7	received	receive	VBD
cord-263455-dquztf5l	419	8	only	only	RB
cord-263455-dquztf5l	419	9	BCG	BCG	NNP
cord-263455-dquztf5l	419	10	.	.	.
cord-263455-dquztf5l	420	1	The	the	DT
cord-263455-dquztf5l	420	2	combined	combined	JJ
cord-263455-dquztf5l	420	3	preventive	preventive	JJ
cord-263455-dquztf5l	420	4	outcome	outcome	NN
cord-263455-dquztf5l	420	5	was	be	VBD
cord-263455-dquztf5l	420	6	expected	expect	VBN
cord-263455-dquztf5l	420	7	to	to	TO
cord-263455-dquztf5l	420	8	be	be	VB
cord-263455-dquztf5l	420	9	long	long	RB
cord-263455-dquztf5l	420	10	-	-	HYPH
cord-263455-dquztf5l	420	11	lasting	last	VBG
cord-263455-dquztf5l	420	12	and	and	CC
cord-263455-dquztf5l	420	13	better	well	JJR
cord-263455-dquztf5l	420	14	than	than	IN
cord-263455-dquztf5l	420	15	the	the	DT
cord-263455-dquztf5l	420	16	effect	effect	NN
cord-263455-dquztf5l	420	17	of	of	IN
cord-263455-dquztf5l	420	18	solely	solely	RB
cord-263455-dquztf5l	420	19	BCG	BCG	NNP
cord-263455-dquztf5l	420	20	or	or	CC
cord-263455-dquztf5l	420	21	SDR	SDR	NNP
cord-263455-dquztf5l	420	22	-	-	HYPH
cord-263455-dquztf5l	420	23	PEP	PEP	NNP
cord-263455-dquztf5l	420	24	.	.	.
cord-263455-dquztf5l	421	1	However	however	RB
cord-263455-dquztf5l	421	2	,	,	,
cord-263455-dquztf5l	421	3	it	-PRON-	PRP
cord-263455-dquztf5l	421	4	was	be	VBD
cord-263455-dquztf5l	421	5	found	find	VBN
cord-263455-dquztf5l	421	6	that	that	IN
cord-263455-dquztf5l	421	7	one	one	CD
cord-263455-dquztf5l	421	8	third	third	NN
cord-263455-dquztf5l	421	9	of	of	IN
cord-263455-dquztf5l	421	10	all	all	DT
cord-263455-dquztf5l	421	11	new	new	JJ
cord-263455-dquztf5l	421	12	leprosy	leprosy	NN
cord-263455-dquztf5l	421	13	cases	case	NNS
cord-263455-dquztf5l	421	14	among	among	IN
cord-263455-dquztf5l	421	15	contacts	contact	NNS
cord-263455-dquztf5l	421	16	had	have	VBD
cord-263455-dquztf5l	421	17	appeared	appear	VBN
cord-263455-dquztf5l	421	18	8	8	CD
cord-263455-dquztf5l	421	19	-	-	SYM
cord-263455-dquztf5l	421	20	12	12	CD
cord-263455-dquztf5l	421	21	weeks	week	NNS
cord-263455-dquztf5l	421	22	after	after	IN
cord-263455-dquztf5l	421	23	BCG	BCG	NNP
cord-263455-dquztf5l	421	24	vaccination	vaccination	NN
cord-263455-dquztf5l	421	25	,	,	,
cord-263455-dquztf5l	421	26	before	before	IN
cord-263455-dquztf5l	421	27	SDR	SDR	NNP
cord-263455-dquztf5l	421	28	-	-	HYPH
cord-263455-dquztf5l	421	29	PEP	PEP	NNP
cord-263455-dquztf5l	421	30	was	be	VBD
cord-263455-dquztf5l	421	31	administered	administer	VBN
cord-263455-dquztf5l	421	32	.	.	.
cord-263455-dquztf5l	422	1	This	this	DT
cord-263455-dquztf5l	422	2	made	make	VBD
cord-263455-dquztf5l	422	3	it	-PRON-	PRP
cord-263455-dquztf5l	422	4	impossible	impossible	JJ
cord-263455-dquztf5l	422	5	to	to	TO
cord-263455-dquztf5l	422	6	determine	determine	VB
cord-263455-dquztf5l	422	7	whether	whether	IN
cord-263455-dquztf5l	422	8	excess	excess	JJ
cord-263455-dquztf5l	422	9	cases	case	NNS
cord-263455-dquztf5l	422	10	in	in	IN
cord-263455-dquztf5l	422	11	the	the	DT
cord-263455-dquztf5l	422	12	first	first	JJ
cord-263455-dquztf5l	422	13	year	year	NN
cord-263455-dquztf5l	422	14	after	after	IN
cord-263455-dquztf5l	422	15	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	422	16	(	(	-LRB-
cord-263455-dquztf5l	422	17	with	with	IN
cord-263455-dquztf5l	422	18	BCG	BCG	NNP
cord-263455-dquztf5l	422	19	)	)	-RRB-
cord-263455-dquztf5l	422	20	could	could	MD
cord-263455-dquztf5l	422	21	be	be	VB
cord-263455-dquztf5l	422	22	prevented	prevent	VBN
cord-263455-dquztf5l	422	23	with	with	IN
cord-263455-dquztf5l	422	24	SDR	SDR	NNP
cord-263455-dquztf5l	422	25	-	-	HYPH
cord-263455-dquztf5l	422	26	PEP	PEP	NNP
cord-263455-dquztf5l	422	27	without	without	IN
cord-263455-dquztf5l	422	28	affecting	affect	VBG
cord-263455-dquztf5l	422	29	the	the	DT
cord-263455-dquztf5l	422	30	protective	protective	JJ
cord-263455-dquztf5l	422	31	effect	effect	NN
cord-263455-dquztf5l	422	32	of	of	IN
cord-263455-dquztf5l	422	33	BCG	BCG	NNP
cord-263455-dquztf5l	422	34	.	.	.
cord-263455-dquztf5l	423	1	126	126	CD
cord-263455-dquztf5l	424	1	This	this	DT
cord-263455-dquztf5l	424	2	increase	increase	NN
cord-263455-dquztf5l	424	3	of	of	IN
cord-263455-dquztf5l	424	4	cases	case	NNS
cord-263455-dquztf5l	424	5	after	after	IN
cord-263455-dquztf5l	424	6	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	424	7	administration	administration	NNP
cord-263455-dquztf5l	424	8	in	in	IN
cord-263455-dquztf5l	424	9	the	the	DT
cord-263455-dquztf5l	424	10	first	first	JJ
cord-263455-dquztf5l	424	11	year	year	NN
cord-263455-dquztf5l	424	12	is	be	VBZ
cord-263455-dquztf5l	424	13	consistent	consistent	JJ
cord-263455-dquztf5l	424	14	with	with	IN
cord-263455-dquztf5l	424	15	other	other	JJ
cord-263455-dquztf5l	424	16	studies	study	NNS
cord-263455-dquztf5l	424	17	.	.	.
cord-263455-dquztf5l	425	1	48	48	CD
cord-263455-dquztf5l	425	2	,	,	,
cord-263455-dquztf5l	425	3	51	51	CD
cord-263455-dquztf5l	425	4	,	,	,
cord-263455-dquztf5l	425	5	[	[	-LRB-
cord-263455-dquztf5l	425	6	127	127	CD
cord-263455-dquztf5l	425	7	]	]	-RRB-
cord-263455-dquztf5l	425	8	[	[	-LRB-
cord-263455-dquztf5l	425	9	128	128	CD
cord-263455-dquztf5l	425	10	]	]	-RRB-
cord-263455-dquztf5l	425	11	[	[	-LRB-
cord-263455-dquztf5l	425	12	129	129	CD
cord-263455-dquztf5l	425	13	]	]	-RRB-
cord-263455-dquztf5l	426	1	Therefore	therefore	RB
cord-263455-dquztf5l	426	2	,	,	,
cord-263455-dquztf5l	426	3	Richardus	Richardus	NNP
cord-263455-dquztf5l	426	4	et	et	NNP
cord-263455-dquztf5l	426	5	al	al	NNP
cord-263455-dquztf5l	426	6	concluded	conclude	VBD
cord-263455-dquztf5l	426	7	that	that	IN
cord-263455-dquztf5l	426	8	BCG	BCG	NNP
cord-263455-dquztf5l	426	9	vaccination	vaccination	NN
cord-263455-dquztf5l	426	10	followed	follow	VBN
cord-263455-dquztf5l	426	11	by	by	IN
cord-263455-dquztf5l	426	12	SDR	SDR	NNP
cord-263455-dquztf5l	426	13	as	as	IN
cord-263455-dquztf5l	426	14	a	a	DT
cord-263455-dquztf5l	426	15	routine	routine	JJ
cord-263455-dquztf5l	426	16	intervention	intervention	NN
cord-263455-dquztf5l	426	17	is	be	VBZ
cord-263455-dquztf5l	426	18	not	not	RB
cord-263455-dquztf5l	426	19	recommended	recommend	VBN
cord-263455-dquztf5l	426	20	in	in	IN
cord-263455-dquztf5l	426	21	leprosy	leprosy	NN
cord-263455-dquztf5l	426	22	control	control	NN
cord-263455-dquztf5l	426	23	.	.	.
cord-263455-dquztf5l	427	1	In	in	IN
cord-263455-dquztf5l	427	2	a	a	DT
cord-263455-dquztf5l	427	3	time	time	NN
cord-263455-dquztf5l	427	4	in	in	IN
cord-263455-dquztf5l	427	5	which	which	WDT
cord-263455-dquztf5l	427	6	a	a	DT
cord-263455-dquztf5l	427	7	new	new	JJ
cord-263455-dquztf5l	427	8	infectious	infectious	JJ
cord-263455-dquztf5l	427	9	disease	disease	NN
cord-263455-dquztf5l	427	10	,	,	,
cord-263455-dquztf5l	427	11	coronavirus	coronavirus	NN
cord-263455-dquztf5l	427	12	disease	disease	NN
cord-263455-dquztf5l	427	13	2019	2019	CD
cord-263455-dquztf5l	427	14	(	(	-LRB-
cord-263455-dquztf5l	427	15	COVID-19	COVID-19	NNP
cord-263455-dquztf5l	427	16	)	)	-RRB-
cord-263455-dquztf5l	427	17	,	,	,
cord-263455-dquztf5l	427	18	dominates	dominate	VBZ
cord-263455-dquztf5l	427	19	the	the	DT
cord-263455-dquztf5l	427	20	news	news	NN
cord-263455-dquztf5l	427	21	,	,	,
cord-263455-dquztf5l	427	22	it	-PRON-	PRP
cord-263455-dquztf5l	427	23	is	be	VBZ
cord-263455-dquztf5l	427	24	important	important	JJ
cord-263455-dquztf5l	427	25	to	to	TO
cord-263455-dquztf5l	427	26	also	also	RB
cord-263455-dquztf5l	427	27	keep	keep	VB
cord-263455-dquztf5l	427	28	paying	pay	VBG
cord-263455-dquztf5l	427	29	attention	attention	NN
cord-263455-dquztf5l	427	30	to	to	IN
cord-263455-dquztf5l	427	31	one	one	CD
cord-263455-dquztf5l	427	32	of	of	IN
cord-263455-dquztf5l	427	33	the	the	DT
cord-263455-dquztf5l	427	34	oldest	old	JJS
cord-263455-dquztf5l	427	35	diseases	disease	NNS
cord-263455-dquztf5l	427	36	known	know	VBN
cord-263455-dquztf5l	427	37	to	to	IN
cord-263455-dquztf5l	427	38	mankind	mankind	NN
cord-263455-dquztf5l	427	39	.	.	.
cord-263455-dquztf5l	428	1	Today	today	NN
cord-263455-dquztf5l	428	2	,	,	,
cord-263455-dquztf5l	428	3	leprosy	leprosy	NN
cord-263455-dquztf5l	428	4	still	still	RB
cord-263455-dquztf5l	428	5	has	have	VBZ
cord-263455-dquztf5l	428	6	devastating	devastating	JJ
cord-263455-dquztf5l	428	7	outcomes	outcome	NNS
cord-263455-dquztf5l	428	8	,	,	,
cord-263455-dquztf5l	428	9	mainly	mainly	RB
cord-263455-dquztf5l	428	10	affecting	affect	VBG
cord-263455-dquztf5l	428	11	the	the	DT
cord-263455-dquztf5l	428	12	most	most	RBS
cord-263455-dquztf5l	428	13	marginalized	marginalize	VBN
cord-263455-dquztf5l	428	14	.	.	.
cord-263455-dquztf5l	429	1	Preventive	preventive	JJ
cord-263455-dquztf5l	429	2	methods	method	NNS
cord-263455-dquztf5l	429	3	are	be	VBP
cord-263455-dquztf5l	429	4	needed	need	VBN
cord-263455-dquztf5l	429	5	to	to	TO
cord-263455-dquztf5l	429	6	stop	stop	VB
cord-263455-dquztf5l	429	7	the	the	DT
cord-263455-dquztf5l	429	8	transmission	transmission	NN
cord-263455-dquztf5l	429	9	of	of	IN
cord-263455-dquztf5l	429	10	this	this	DT
cord-263455-dquztf5l	429	11	disease	disease	NN
cord-263455-dquztf5l	429	12	.	.	.
cord-263455-dquztf5l	430	1	Globally	globally	RB
cord-263455-dquztf5l	430	2	,	,	,
cord-263455-dquztf5l	430	3	BCG	BCG	NNP
cord-263455-dquztf5l	430	4	vaccination	vaccination	NN
cord-263455-dquztf5l	430	5	is	be	VBZ
cord-263455-dquztf5l	430	6	mainly	mainly	RB
cord-263455-dquztf5l	430	7	used	use	VBN
cord-263455-dquztf5l	430	8	as	as	IN
cord-263455-dquztf5l	430	9	the	the	DT
cord-263455-dquztf5l	430	10	primary	primary	JJ
cord-263455-dquztf5l	430	11	TB	TB	NNP
cord-263455-dquztf5l	430	12	prevention	prevention	NN
cord-263455-dquztf5l	430	13	method	method	NN
cord-263455-dquztf5l	430	14	in	in	IN
cord-263455-dquztf5l	430	15	newborns	newborn	NNS
cord-263455-dquztf5l	430	16	.	.	.
cord-263455-dquztf5l	431	1	As	as	IN
cord-263455-dquztf5l	431	2	stated	state	VBN
cord-263455-dquztf5l	431	3	,	,	,
cord-263455-dquztf5l	431	4	in	in	IN
cord-263455-dquztf5l	431	5	its	-PRON-	PRP$
cord-263455-dquztf5l	431	6	2018	2018	CD
cord-263455-dquztf5l	431	7	Guidelines	Guidelines	NNPS
cord-263455-dquztf5l	431	8	for	for	IN
cord-263455-dquztf5l	431	9	the	the	DT
cord-263455-dquztf5l	431	10	Diagnosis	Diagnosis	NNP
cord-263455-dquztf5l	431	11	,	,	,
cord-263455-dquztf5l	431	12	Treatment	Treatment	NNP
cord-263455-dquztf5l	431	13	and	and	CC
cord-263455-dquztf5l	431	14	Prevention	Prevention	NNP
cord-263455-dquztf5l	431	15	of	of	IN
cord-263455-dquztf5l	431	16	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	431	17	,	,	,
cord-263455-dquztf5l	431	18	WHO	who	WP
cord-263455-dquztf5l	431	19	recommends	recommend	VBZ
cord-263455-dquztf5l	431	20	only	only	RB
cord-263455-dquztf5l	431	21	that	that	IN
cord-263455-dquztf5l	431	22	BCG	BCG	NNP
cord-263455-dquztf5l	431	23	at	at	IN
cord-263455-dquztf5l	431	24	birth	birth	NN
cord-263455-dquztf5l	431	25	should	should	MD
cord-263455-dquztf5l	431	26	be	be	VB
cord-263455-dquztf5l	431	27	maintained	maintain	VBN
cord-263455-dquztf5l	431	28	in	in	IN
cord-263455-dquztf5l	431	29	at	at	IN
cord-263455-dquztf5l	431	30	least	least	JJS
cord-263455-dquztf5l	431	31	all	all	DT
cord-263455-dquztf5l	431	32	leprosy	leprosy	NN
cord-263455-dquztf5l	431	33	high	high	JJ
cord-263455-dquztf5l	431	34	-	-	HYPH
cord-263455-dquztf5l	431	35	burden	burden	NN
cord-263455-dquztf5l	431	36	regions	region	NNS
cord-263455-dquztf5l	431	37	.	.	.
cord-263455-dquztf5l	432	1	7	7	CD
cord-263455-dquztf5l	433	1	Nevertheless	nevertheless	RB
cord-263455-dquztf5l	433	2	,	,	,
cord-263455-dquztf5l	433	3	since	since	IN
cord-263455-dquztf5l	433	4	the	the	DT
cord-263455-dquztf5l	433	5	early	early	JJ
cord-263455-dquztf5l	433	6	1990s	1990	NNS
cord-263455-dquztf5l	433	7	,	,	,
cord-263455-dquztf5l	433	8	the	the	DT
cord-263455-dquztf5l	433	9	Brazilian	Brazilian	NNP
cord-263455-dquztf5l	433	10	Ministry	Ministry	NNP
cord-263455-dquztf5l	433	11	of	of	IN
cord-263455-dquztf5l	433	12	Health	Health	NNP
cord-263455-dquztf5l	433	13	has	have	VBZ
cord-263455-dquztf5l	433	14	recommended	recommend	VBN
cord-263455-dquztf5l	433	15	intradermal	intradermal	JJ
cord-263455-dquztf5l	433	16	BCG	bcg	NN
cord-263455-dquztf5l	433	17	for	for	IN
cord-263455-dquztf5l	433	18	household	household	NN
cord-263455-dquztf5l	433	19	contacts	contact	NNS
cord-263455-dquztf5l	433	20	of	of	IN
cord-263455-dquztf5l	433	21	leprosy	leprosy	NN
cord-263455-dquztf5l	433	22	patients	patient	NNS
cord-263455-dquztf5l	433	23	.	.	.
cord-263455-dquztf5l	434	1	46	46	CD
cord-263455-dquztf5l	434	2	,	,	,
cord-263455-dquztf5l	434	3	130	130	CD
cord-263455-dquztf5l	434	4	Contacts	contact	NNS
cord-263455-dquztf5l	434	5	with	with	IN
cord-263455-dquztf5l	434	6	no	no	DT
cord-263455-dquztf5l	434	7	or	or	CC
cord-263455-dquztf5l	434	8	one	one	CD
cord-263455-dquztf5l	434	9	primary	primary	JJ
cord-263455-dquztf5l	434	10	scar	scar	NN
cord-263455-dquztf5l	434	11	receive	receive	VBP
cord-263455-dquztf5l	434	12	BCG	BCG	NNP
cord-263455-dquztf5l	434	13	;	;	:
cord-263455-dquztf5l	434	14	contacts	contact	NNS
cord-263455-dquztf5l	434	15	with	with	IN
cord-263455-dquztf5l	434	16	two	two	CD
cord-263455-dquztf5l	434	17	BCG	BCG	NNP
cord-263455-dquztf5l	434	18	scars	scar	NNS
cord-263455-dquztf5l	434	19	do	do	VBP
cord-263455-dquztf5l	434	20	not	not	RB
cord-263455-dquztf5l	434	21	receive	receive	VB
cord-263455-dquztf5l	434	22	another	another	DT
cord-263455-dquztf5l	434	23	BCG	BCG	NNP
cord-263455-dquztf5l	434	24	dosage	dosage	NN
cord-263455-dquztf5l	434	25	.	.	.
cord-263455-dquztf5l	435	1	46	46	CD
cord-263455-dquztf5l	435	2	,	,	,
cord-263455-dquztf5l	435	3	131	131	CD
cord-263455-dquztf5l	436	1	However	however	RB
cord-263455-dquztf5l	436	2	,	,	,
cord-263455-dquztf5l	436	3	scar	scar	NN
cord-263455-dquztf5l	436	4	reading	reading	NN
cord-263455-dquztf5l	436	5	is	be	VBZ
cord-263455-dquztf5l	436	6	not	not	RB
cord-263455-dquztf5l	436	7	fully	fully	RB
cord-263455-dquztf5l	436	8	reliable	reliable	JJ
cord-263455-dquztf5l	436	9	,	,	,
cord-263455-dquztf5l	436	10	and	and	CC
cord-263455-dquztf5l	436	11	scar	scar	NN
cord-263455-dquztf5l	436	12	formation	formation	NN
cord-263455-dquztf5l	436	13	does	do	VBZ
cord-263455-dquztf5l	436	14	not	not	RB
cord-263455-dquztf5l	436	15	always	always	RB
cord-263455-dquztf5l	436	16	occur	occur	VB
cord-263455-dquztf5l	436	17	.	.	.
cord-263455-dquztf5l	437	1	29	29	CD
cord-263455-dquztf5l	437	2	,	,	,
cord-263455-dquztf5l	437	3	37	37	CD
cord-263455-dquztf5l	438	1	For	for	IN
cord-263455-dquztf5l	438	2	example	example	NN
cord-263455-dquztf5l	438	3	,	,	,
cord-263455-dquztf5l	438	4	16	16	CD
cord-263455-dquztf5l	438	5	-	-	SYM
cord-263455-dquztf5l	438	6	24	24	CD
cord-263455-dquztf5l	438	7	%	%	NN
cord-263455-dquztf5l	438	8	of	of	IN
cord-263455-dquztf5l	438	9	BCG	BCG	NNP
cord-263455-dquztf5l	438	10	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	438	11	individuals	individual	NNS
cord-263455-dquztf5l	438	12	do	do	VBP
cord-263455-dquztf5l	438	13	not	not	RB
cord-263455-dquztf5l	438	14	develop	develop	VB
cord-263455-dquztf5l	438	15	a	a	DT
cord-263455-dquztf5l	438	16	scar	scar	NN
cord-263455-dquztf5l	438	17	.	.	.
cord-263455-dquztf5l	439	1	34	34	CD
cord-263455-dquztf5l	440	1	In	in	IN
cord-263455-dquztf5l	440	2	infants	infant	NNS
cord-263455-dquztf5l	440	3	vaccinated	vaccinate	VBN
cord-263455-dquztf5l	440	4	below	below	IN
cord-263455-dquztf5l	440	5	the	the	DT
cord-263455-dquztf5l	440	6	age	age	NN
cord-263455-dquztf5l	440	7	of	of	IN
cord-263455-dquztf5l	440	8	1	1	CD
cord-263455-dquztf5l	440	9	month	month	NN
cord-263455-dquztf5l	440	10	,	,	,
cord-263455-dquztf5l	440	11	which	which	WDT
cord-263455-dquztf5l	440	12	is	be	VBZ
cord-263455-dquztf5l	440	13	common	common	JJ
cord-263455-dquztf5l	440	14	when	when	WRB
cord-263455-dquztf5l	440	15	BCG	BCG	NNP
cord-263455-dquztf5l	440	16	vaccination	vaccination	NN
cord-263455-dquztf5l	440	17	is	be	VBZ
cord-263455-dquztf5l	440	18	routinely	routinely	RB
cord-263455-dquztf5l	440	19	given	give	VBN
cord-263455-dquztf5l	440	20	to	to	IN
cord-263455-dquztf5l	440	21	newborns	newborn	NNS
cord-263455-dquztf5l	440	22	(	(	-LRB-
cord-263455-dquztf5l	441	1	eg	eg	UH
cord-263455-dquztf5l	441	2	,	,	,
cord-263455-dquztf5l	441	3	in	in	IN
cord-263455-dquztf5l	441	4	Brazil	Brazil	NNP
cord-263455-dquztf5l	441	5	)	)	-RRB-
cord-263455-dquztf5l	441	6	,	,	,
cord-263455-dquztf5l	441	7	fewer	few	JJR
cord-263455-dquztf5l	441	8	than	than	IN
cord-263455-dquztf5l	441	9	80	80	CD
cord-263455-dquztf5l	441	10	%	%	NN
cord-263455-dquztf5l	441	11	have	have	VBP
cord-263455-dquztf5l	441	12	a	a	DT
cord-263455-dquztf5l	441	13	recognizable	recognizable	JJ
cord-263455-dquztf5l	441	14	scar	scar	NN
cord-263455-dquztf5l	441	15	at	at	IN
cord-263455-dquztf5l	441	16	the	the	DT
cord-263455-dquztf5l	441	17	age	age	NN
cord-263455-dquztf5l	441	18	of	of	IN
cord-263455-dquztf5l	441	19	4	4	CD
cord-263455-dquztf5l	441	20	.	.	.
cord-263455-dquztf5l	442	1	132	132	CD
cord-263455-dquztf5l	443	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	443	2	,	,	,
cord-263455-dquztf5l	443	3	the	the	DT
cord-263455-dquztf5l	443	4	evidence	evidence	NN
cord-263455-dquztf5l	443	5	regarding	regard	VBG
cord-263455-dquztf5l	443	6	the	the	DT
cord-263455-dquztf5l	443	7	effectiveness	effectiveness	NN
cord-263455-dquztf5l	443	8	of	of	IN
cord-263455-dquztf5l	443	9	BCG	BCG	NNP
cord-263455-dquztf5l	443	10	revaccination	revaccination	NN
cord-263455-dquztf5l	443	11	is	be	VBZ
cord-263455-dquztf5l	443	12	conflicting	conflict	VBG
cord-263455-dquztf5l	443	13	,	,	,
cord-263455-dquztf5l	443	14	because	because	IN
cord-263455-dquztf5l	443	15	of	of	IN
cord-263455-dquztf5l	443	16	the	the	DT
cord-263455-dquztf5l	443	17	wide	wide	JJ
cord-263455-dquztf5l	443	18	variation	variation	NN
cord-263455-dquztf5l	443	19	in	in	IN
cord-263455-dquztf5l	443	20	study	study	NN
cord-263455-dquztf5l	443	21	outcomes	outcome	NNS
cord-263455-dquztf5l	443	22	.	.	.
cord-263455-dquztf5l	444	1	23	23	CD
cord-263455-dquztf5l	444	2	,	,	,
cord-263455-dquztf5l	444	3	46	46	CD
cord-263455-dquztf5l	444	4	,	,	,
cord-263455-dquztf5l	444	5	52	52	CD
cord-263455-dquztf5l	444	6	,	,	,
cord-263455-dquztf5l	444	7	54	54	CD
cord-263455-dquztf5l	444	8	,	,	,
cord-263455-dquztf5l	444	9	128	128	CD
cord-263455-dquztf5l	444	10	,	,	,
cord-263455-dquztf5l	444	11	133	133	CD
cord-263455-dquztf5l	444	12	,	,	,
cord-263455-dquztf5l	444	13	134	134	CD
cord-263455-dquztf5l	444	14	When	when	WRB
cord-263455-dquztf5l	444	15	assessing	assess	VBG
cord-263455-dquztf5l	444	16	other	other	JJ
cord-263455-dquztf5l	444	17	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	444	18	agents	agent	NNS
cord-263455-dquztf5l	444	19	,	,	,
cord-263455-dquztf5l	444	20	BCG	BCG	NNP
cord-263455-dquztf5l	444	21	plus	plus	CC
cord-263455-dquztf5l	444	22	heat	heat	NN
cord-263455-dquztf5l	444	23	-	-	HYPH
cord-263455-dquztf5l	444	24	killed	kill	VBN
cord-263455-dquztf5l	444	25	M.	M.	NNP
cord-263455-dquztf5l	444	26	leprae	leprae	NNP
cord-263455-dquztf5l	444	27	was	be	VBD
cord-263455-dquztf5l	444	28	found	find	VBN
cord-263455-dquztf5l	444	29	not	not	RB
cord-263455-dquztf5l	444	30	to	to	TO
cord-263455-dquztf5l	444	31	have	have	VB
cord-263455-dquztf5l	444	32	an	an	DT
cord-263455-dquztf5l	444	33	additional	additional	JJ
cord-263455-dquztf5l	444	34	effect	effect	NN
cord-263455-dquztf5l	444	35	in	in	IN
cord-263455-dquztf5l	444	36	leprosy	leprosy	NN
cord-263455-dquztf5l	444	37	prevention	prevention	NN
cord-263455-dquztf5l	444	38	when	when	WRB
cord-263455-dquztf5l	444	39	compared	compare	VBN
cord-263455-dquztf5l	444	40	with	with	IN
cord-263455-dquztf5l	444	41	BCG	BCG	NNP
cord-263455-dquztf5l	444	42	alone	alone	RB
cord-263455-dquztf5l	444	43	.	.	.
cord-263455-dquztf5l	445	1	51	51	CD
cord-263455-dquztf5l	445	2	,	,	,
cord-263455-dquztf5l	445	3	53	53	CD
cord-263455-dquztf5l	445	4	,	,	,
cord-263455-dquztf5l	445	5	54	54	CD
cord-263455-dquztf5l	446	1	Even	even	RB
cord-263455-dquztf5l	446	2	if	if	IN
cord-263455-dquztf5l	446	3	BCG	BCG	NNP
cord-263455-dquztf5l	446	4	plus	plus	CC
cord-263455-dquztf5l	446	5	heat	heat	NN
cord-263455-dquztf5l	446	6	-	-	HYPH
cord-263455-dquztf5l	446	7	killed	kill	VBN
cord-263455-dquztf5l	446	8	M.	M.	NNP
cord-263455-dquztf5l	446	9	leprae	leprae	NNP
cord-263455-dquztf5l	446	10	provided	provide	VBD
cord-263455-dquztf5l	446	11	additional	additional	JJ
cord-263455-dquztf5l	446	12	protection	protection	NN
cord-263455-dquztf5l	446	13	,	,	,
cord-263455-dquztf5l	446	14	further	further	JJ
cord-263455-dquztf5l	446	15	development	development	NN
cord-263455-dquztf5l	446	16	of	of	IN
cord-263455-dquztf5l	446	17	a	a	DT
cord-263455-dquztf5l	446	18	vaccine	vaccine	NN
cord-263455-dquztf5l	446	19	containing	contain	VBG
cord-263455-dquztf5l	446	20	killed	kill	VBD
cord-263455-dquztf5l	446	21	M.	M.	NNP
cord-263455-dquztf5l	446	22	leprae	leprae	NNP
cord-263455-dquztf5l	446	23	is	be	VBZ
cord-263455-dquztf5l	446	24	challenging	challenging	JJ
cord-263455-dquztf5l	446	25	because	because	IN
cord-263455-dquztf5l	446	26	mass	mass	JJ
cord-263455-dquztf5l	446	27	production	production	NN
cord-263455-dquztf5l	446	28	would	would	MD
cord-263455-dquztf5l	446	29	need	need	VB
cord-263455-dquztf5l	446	30	to	to	TO
cord-263455-dquztf5l	446	31	occur	occur	VB
cord-263455-dquztf5l	446	32	in	in	IN
cord-263455-dquztf5l	446	33	armadillos	armadillo	NNS
cord-263455-dquztf5l	446	34	or	or	CC
cord-263455-dquztf5l	446	35	in	in	IN
cord-263455-dquztf5l	446	36	immune	immune	NN
cord-263455-dquztf5l	446	37	-	-	HYPH
cord-263455-dquztf5l	446	38	compromised	compromise	VBN
cord-263455-dquztf5l	446	39	mice	mouse	NNS
cord-263455-dquztf5l	446	40	.	.	.
cord-263455-dquztf5l	447	1	49	49	CD
cord-263455-dquztf5l	447	2	Studies	study	NNS
cord-263455-dquztf5l	447	3	on	on	IN
cord-263455-dquztf5l	447	4	the	the	DT
cord-263455-dquztf5l	447	5	ICRC	ICRC	NNP
cord-263455-dquztf5l	447	6	and	and	CC
cord-263455-dquztf5l	447	7	M.	M.	NNP
cord-263455-dquztf5l	447	8	vaccae	vaccae	NN
cord-263455-dquztf5l	447	9	vaccines	vaccine	NNS
cord-263455-dquztf5l	447	10	were	be	VBD
cord-263455-dquztf5l	447	11	limited	limit	VBN
cord-263455-dquztf5l	447	12	,	,	,
cord-263455-dquztf5l	447	13	rarely	rarely	RB
cord-263455-dquztf5l	447	14	focused	focus	VBD
cord-263455-dquztf5l	447	15	on	on	IN
cord-263455-dquztf5l	447	16	solely	solely	RB
cord-263455-dquztf5l	447	17	post	post	JJ
cord-263455-dquztf5l	447	18	-	-	JJ
cord-263455-dquztf5l	447	19	exposure	exposure	JJ
cord-263455-dquztf5l	447	20	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	447	21	,	,	,
cord-263455-dquztf5l	447	22	and	and	CC
cord-263455-dquztf5l	447	23	were	be	VBD
cord-263455-dquztf5l	447	24	often	often	RB
cord-263455-dquztf5l	447	25	of	of	IN
cord-263455-dquztf5l	447	26	debatable	debatable	JJ
cord-263455-dquztf5l	447	27	quality	quality	NN
cord-263455-dquztf5l	447	28	.	.	.
cord-263455-dquztf5l	448	1	It	-PRON-	PRP
cord-263455-dquztf5l	448	2	is	be	VBZ
cord-263455-dquztf5l	448	3	therefore	therefore	RB
cord-263455-dquztf5l	448	4	not	not	RB
cord-263455-dquztf5l	448	5	entirely	entirely	RB
cord-263455-dquztf5l	448	6	clear	clear	JJ
cord-263455-dquztf5l	448	7	if	if	IN
cord-263455-dquztf5l	448	8	these	these	DT
cord-263455-dquztf5l	448	9	two	two	CD
cord-263455-dquztf5l	448	10	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	448	11	agents	agent	NNS
cord-263455-dquztf5l	448	12	should	should	MD
cord-263455-dquztf5l	448	13	be	be	VB
cord-263455-dquztf5l	448	14	fully	fully	RB
cord-263455-dquztf5l	448	15	ruled	rule	VBN
cord-263455-dquztf5l	448	16	out	out	RP
cord-263455-dquztf5l	448	17	when	when	WRB
cord-263455-dquztf5l	448	18	trying	try	VBG
cord-263455-dquztf5l	448	19	to	to	TO
cord-263455-dquztf5l	448	20	prevent	prevent	VB
cord-263455-dquztf5l	448	21	leprosy	leprosy	NN
cord-263455-dquztf5l	448	22	transmission	transmission	NN
cord-263455-dquztf5l	448	23	.	.	.
cord-263455-dquztf5l	449	1	More	More	JJR
cord-263455-dquztf5l	449	2	research	research	NN
cord-263455-dquztf5l	449	3	is	be	VBZ
cord-263455-dquztf5l	449	4	also	also	RB
cord-263455-dquztf5l	449	5	needed	need	VBN
cord-263455-dquztf5l	449	6	on	on	IN
cord-263455-dquztf5l	449	7	newly	newly	RB
cord-263455-dquztf5l	449	8	developed	develop	VBN
cord-263455-dquztf5l	449	9	vaccines	vaccine	NNS
cord-263455-dquztf5l	449	10	like	like	IN
cord-263455-dquztf5l	449	11	LepVax	LepVax	NNP
cord-263455-dquztf5l	449	12	as	as	RB
cord-263455-dquztf5l	449	13	well	well	RB
cord-263455-dquztf5l	449	14	as	as	IN
cord-263455-dquztf5l	449	15	on	on	IN
cord-263455-dquztf5l	449	16	the	the	DT
cord-263455-dquztf5l	449	17	vaccine	vaccine	NN
cord-263455-dquztf5l	449	18	MiP	mip	NN
cord-263455-dquztf5l	449	19	(	(	-LRB-
cord-263455-dquztf5l	449	20	Mw	Mw	NNP
cord-263455-dquztf5l	449	21	)	)	-RRB-
cord-263455-dquztf5l	449	22	.	.	.
cord-263455-dquztf5l	450	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	450	2	,	,	,
cord-263455-dquztf5l	450	3	the	the	DT
cord-263455-dquztf5l	450	4	introduction	introduction	NN
cord-263455-dquztf5l	450	5	of	of	IN
cord-263455-dquztf5l	450	6	new	new	JJ
cord-263455-dquztf5l	450	7	TB	TB	NNP
cord-263455-dquztf5l	450	8	vaccines	vaccine	NNS
cord-263455-dquztf5l	450	9	,	,	,
cord-263455-dquztf5l	450	10	possibly	possibly	RB
cord-263455-dquztf5l	450	11	replacing	replace	VBG
cord-263455-dquztf5l	450	12	BCG	BCG	NNP
cord-263455-dquztf5l	450	13	,	,	,
cord-263455-dquztf5l	450	14	could	could	MD
cord-263455-dquztf5l	450	15	have	have	VB
cord-263455-dquztf5l	450	16	a	a	DT
cord-263455-dquztf5l	450	17	serious	serious	JJ
cord-263455-dquztf5l	450	18	impact	impact	NN
cord-263455-dquztf5l	450	19	on	on	IN
cord-263455-dquztf5l	450	20	leprosy	leprosy	NN
cord-263455-dquztf5l	450	21	.	.	.
cord-263455-dquztf5l	451	1	The	the	DT
cord-263455-dquztf5l	451	2	number	number	NN
cord-263455-dquztf5l	451	3	of	of	IN
cord-263455-dquztf5l	451	4	vaccine	vaccine	NN
cord-263455-dquztf5l	451	5	studies	study	NNS
cord-263455-dquztf5l	451	6	is	be	VBZ
cord-263455-dquztf5l	451	7	much	much	RB
cord-263455-dquztf5l	451	8	greater	great	JJR
cord-263455-dquztf5l	451	9	in	in	IN
cord-263455-dquztf5l	451	10	the	the	DT
cord-263455-dquztf5l	451	11	TB	TB	NNP
cord-263455-dquztf5l	451	12	world	world	NN
cord-263455-dquztf5l	451	13	,	,	,
cord-263455-dquztf5l	451	14	consistent	consistent	JJ
cord-263455-dquztf5l	451	15	with	with	IN
cord-263455-dquztf5l	451	16	the	the	DT
cord-263455-dquztf5l	451	17	incidence	incidence	NN
cord-263455-dquztf5l	451	18	numbers	number	NNS
cord-263455-dquztf5l	451	19	,	,	,
cord-263455-dquztf5l	451	20	compared	compare	VBN
cord-263455-dquztf5l	451	21	with	with	IN
cord-263455-dquztf5l	451	22	the	the	DT
cord-263455-dquztf5l	451	23	leprosy	leprosy	NN
cord-263455-dquztf5l	451	24	research	research	NN
cord-263455-dquztf5l	451	25	field	field	NN
cord-263455-dquztf5l	451	26	.	.	.
cord-263455-dquztf5l	452	1	56	56	CD
cord-263455-dquztf5l	453	1	Despite	despite	IN
cord-263455-dquztf5l	453	2	the	the	DT
cord-263455-dquztf5l	453	3	possibility	possibility	NN
cord-263455-dquztf5l	453	4	of	of	IN
cord-263455-dquztf5l	453	5	cross	cross	NN
cord-263455-dquztf5l	453	6	-	-	NN
cord-263455-dquztf5l	453	7	protection	protection	NN
cord-263455-dquztf5l	453	8	between	between	IN
cord-263455-dquztf5l	453	9	the	the	DT
cord-263455-dquztf5l	453	10	two	two	CD
cord-263455-dquztf5l	453	11	diseases	disease	NNS
cord-263455-dquztf5l	453	12	,	,	,
cord-263455-dquztf5l	453	13	the	the	DT
cord-263455-dquztf5l	453	14	potential	potential	JJ
cord-263455-dquztf5l	453	15	impact	impact	NN
cord-263455-dquztf5l	453	16	on	on	IN
cord-263455-dquztf5l	453	17	leprosy	leprosy	NN
cord-263455-dquztf5l	453	18	by	by	IN
cord-263455-dquztf5l	453	19	TB	TB	NNP
cord-263455-dquztf5l	453	20	vaccine	vaccine	NN
cord-263455-dquztf5l	453	21	candidates	candidate	NNS
cord-263455-dquztf5l	453	22	is	be	VBZ
cord-263455-dquztf5l	453	23	rarely	rarely	RB
cord-263455-dquztf5l	453	24	considered	consider	VBN
cord-263455-dquztf5l	453	25	in	in	IN
cord-263455-dquztf5l	453	26	TB	TB	NNP
cord-263455-dquztf5l	453	27	research	research	NN
cord-263455-dquztf5l	453	28	.	.	.
cord-263455-dquztf5l	454	1	49	49	CD
cord-263455-dquztf5l	454	2	,	,	,
cord-263455-dquztf5l	454	3	56	56	CD
cord-263455-dquztf5l	454	4	Only	only	RB
cord-263455-dquztf5l	454	5	two	two	CD
cord-263455-dquztf5l	454	6	recombinant	recombinant	JJ
cord-263455-dquztf5l	454	7	subunit	subunit	NN
cord-263455-dquztf5l	454	8	TB	TB	NNP
cord-263455-dquztf5l	454	9	vaccines	vaccine	NNS
cord-263455-dquztf5l	454	10	(	(	-LRB-
cord-263455-dquztf5l	454	11	ID83	ID83	NNP
cord-263455-dquztf5l	454	12	/	/	SYM
cord-263455-dquztf5l	454	13	GLA	GLA	NNP
cord-263455-dquztf5l	454	14	-	-	HYPH
cord-263455-dquztf5l	454	15	SE	SE	NNP
cord-263455-dquztf5l	454	16	and	and	CC
cord-263455-dquztf5l	454	17	ID93/	ID93/	NNP
cord-263455-dquztf5l	454	18	GLA	GLA	NNP
cord-263455-dquztf5l	454	19	-	-	HYPH
cord-263455-dquztf5l	454	20	SE	SE	NNP
cord-263455-dquztf5l	454	21	)	)	-RRB-
cord-263455-dquztf5l	454	22	have	have	VBP
cord-263455-dquztf5l	454	23	also	also	RB
cord-263455-dquztf5l	454	24	been	be	VBN
cord-263455-dquztf5l	454	25	laboratory	laboratory	NN
cord-263455-dquztf5l	454	26	tested	test	VBN
cord-263455-dquztf5l	454	27	for	for	IN
cord-263455-dquztf5l	454	28	their	-PRON-	PRP$
cord-263455-dquztf5l	454	29	potential	potential	JJ
cord-263455-dquztf5l	454	30	use	use	NN
cord-263455-dquztf5l	454	31	against	against	IN
cord-263455-dquztf5l	454	32	leprosy	leprosy	NN
cord-263455-dquztf5l	454	33	.	.	.
cord-263455-dquztf5l	455	1	56	56	CD
cord-263455-dquztf5l	455	2	,	,	,
cord-263455-dquztf5l	455	3	135	135	CD
cord-263455-dquztf5l	455	4	More	More	JJR
cord-263455-dquztf5l	455	5	integration	integration	NN
cord-263455-dquztf5l	455	6	and	and	CC
cord-263455-dquztf5l	455	7	harmonization	harmonization	NN
cord-263455-dquztf5l	455	8	between	between	IN
cord-263455-dquztf5l	455	9	the	the	DT
cord-263455-dquztf5l	455	10	TB	TB	NNP
cord-263455-dquztf5l	455	11	and	and	CC
cord-263455-dquztf5l	455	12	leprosy	leprosy	NN
cord-263455-dquztf5l	455	13	vaccine	vaccine	NN
cord-263455-dquztf5l	455	14	research	research	NN
cord-263455-dquztf5l	455	15	groups	group	NNS
cord-263455-dquztf5l	455	16	would	would	MD
cord-263455-dquztf5l	455	17	therefore	therefore	RB
cord-263455-dquztf5l	455	18	be	be	VB
cord-263455-dquztf5l	455	19	valuable	valuable	JJ
cord-263455-dquztf5l	455	20	.	.	.
cord-263455-dquztf5l	456	1	56	56	CD
cord-263455-dquztf5l	457	1	Additionally	additionally	RB
cord-263455-dquztf5l	457	2	,	,	,
cord-263455-dquztf5l	457	3	after	after	IN
cord-263455-dquztf5l	457	4	the	the	DT
cord-263455-dquztf5l	457	5	administration	administration	NN
cord-263455-dquztf5l	457	6	of	of	IN
cord-263455-dquztf5l	457	7	BCG	BCG	NNP
cord-263455-dquztf5l	457	8	and	and	CC
cord-263455-dquztf5l	457	9	other	other	JJ
cord-263455-dquztf5l	457	10	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	457	11	agents	agent	NNS
cord-263455-dquztf5l	457	12	for	for	IN
cord-263455-dquztf5l	457	13	leprosy	leprosy	NN
cord-263455-dquztf5l	457	14	prevention	prevention	NN
cord-263455-dquztf5l	457	15	,	,	,
cord-263455-dquztf5l	457	16	a	a	DT
cord-263455-dquztf5l	457	17	relative	relative	JJ
cord-263455-dquztf5l	457	18	increase	increase	NN
cord-263455-dquztf5l	457	19	in	in	IN
cord-263455-dquztf5l	457	20	the	the	DT
cord-263455-dquztf5l	457	21	number	number	NN
cord-263455-dquztf5l	457	22	of	of	IN
cord-263455-dquztf5l	457	23	new	new	JJ
cord-263455-dquztf5l	457	24	(	(	-LRB-
cord-263455-dquztf5l	457	25	paucibacillary	paucibacillary	JJ
cord-263455-dquztf5l	457	26	)	)	-RRB-
cord-263455-dquztf5l	457	27	leprosy	leprosy	NN
cord-263455-dquztf5l	457	28	patients	patient	NNS
cord-263455-dquztf5l	457	29	is	be	VBZ
cord-263455-dquztf5l	457	30	seen	see	VBN
cord-263455-dquztf5l	457	31	in	in	IN
cord-263455-dquztf5l	457	32	the	the	DT
cord-263455-dquztf5l	457	33	first	first	JJ
cord-263455-dquztf5l	457	34	follow	follow	NN
cord-263455-dquztf5l	457	35	-	-	HYPH
cord-263455-dquztf5l	457	36	up	up	NN
cord-263455-dquztf5l	457	37	year	year	NN
cord-263455-dquztf5l	457	38	.	.	.
cord-263455-dquztf5l	458	1	48	48	CD
cord-263455-dquztf5l	458	2	,	,	,
cord-263455-dquztf5l	458	3	51	51	CD
cord-263455-dquztf5l	458	4	,	,	,
cord-263455-dquztf5l	458	5	[	[	-LRB-
cord-263455-dquztf5l	458	6	127	127	CD
cord-263455-dquztf5l	458	7	]	]	-RRB-
cord-263455-dquztf5l	458	8	[	[	-LRB-
cord-263455-dquztf5l	458	9	128	128	CD
cord-263455-dquztf5l	458	10	]	]	-RRB-
cord-263455-dquztf5l	458	11	[	[	-LRB-
cord-263455-dquztf5l	458	12	129	129	CD
cord-263455-dquztf5l	458	13	]	]	-RRB-
cord-263455-dquztf5l	459	1	A	a	DT
cord-263455-dquztf5l	459	2	possible	possible	JJ
cord-263455-dquztf5l	459	3	explanation	explanation	NN
cord-263455-dquztf5l	459	4	for	for	IN
cord-263455-dquztf5l	459	5	this	this	DT
cord-263455-dquztf5l	459	6	is	be	VBZ
cord-263455-dquztf5l	459	7	that	that	IN
cord-263455-dquztf5l	459	8	BCG	BCG	NNP
cord-263455-dquztf5l	459	9	is	be	VBZ
cord-263455-dquztf5l	459	10	catalyzing	catalyze	VBG
cord-263455-dquztf5l	459	11	the	the	DT
cord-263455-dquztf5l	459	12	existing	exist	VBG
cord-263455-dquztf5l	459	13	anti	anti	JJ
cord-263455-dquztf5l	459	14	-	-	JJ
cord-263455-dquztf5l	459	15	mycobacterial	mycobacterial	JJ
cord-263455-dquztf5l	459	16	immunity	immunity	NN
cord-263455-dquztf5l	459	17	in	in	IN
cord-263455-dquztf5l	459	18	people	people	NNS
cord-263455-dquztf5l	459	19	infected	infect	VBN
cord-263455-dquztf5l	459	20	with	with	IN
cord-263455-dquztf5l	459	21	M.	M.	NNP
cord-263455-dquztf5l	459	22	leprae	leprae	NNP
cord-263455-dquztf5l	459	23	,	,	,
cord-263455-dquztf5l	459	24	resulting	result	VBG
cord-263455-dquztf5l	459	25	in	in	IN
cord-263455-dquztf5l	459	26	the	the	DT
cord-263455-dquztf5l	459	27	clinical	clinical	JJ
cord-263455-dquztf5l	459	28	appearance	appearance	NN
cord-263455-dquztf5l	459	29	of	of	IN
cord-263455-dquztf5l	459	30	tuberculoid	tuberculoid	NNP
cord-263455-dquztf5l	459	31	leprosy	leprosy	NN
cord-263455-dquztf5l	459	32	after	after	IN
cord-263455-dquztf5l	459	33	BCG	BCG	NNP
cord-263455-dquztf5l	459	34	vaccination	vaccination	NN
cord-263455-dquztf5l	459	35	.	.	.
cord-263455-dquztf5l	460	1	48	48	CD
cord-263455-dquztf5l	460	2	,	,	,
cord-263455-dquztf5l	460	3	127	127	CD
cord-263455-dquztf5l	460	4	Gormus	Gormus	NNP
cord-263455-dquztf5l	460	5	and	and	CC
cord-263455-dquztf5l	460	6	Meyers	Meyers	NNP
cord-263455-dquztf5l	460	7	described	describe	VBD
cord-263455-dquztf5l	460	8	the	the	DT
cord-263455-dquztf5l	460	9	reasoning	reasoning	NN
cord-263455-dquztf5l	460	10	for	for	IN
cord-263455-dquztf5l	460	11	the	the	DT
cord-263455-dquztf5l	460	12	doses	dose	NNS
cord-263455-dquztf5l	460	13	chosen	choose	VBN
cord-263455-dquztf5l	460	14	in	in	IN
cord-263455-dquztf5l	460	15	trials	trial	NNS
cord-263455-dquztf5l	460	16	with	with	IN
cord-263455-dquztf5l	460	17	integral	integral	JJ
cord-263455-dquztf5l	460	18	mycobacterial	mycobacterial	JJ
cord-263455-dquztf5l	460	19	vaccines	vaccine	NNS
cord-263455-dquztf5l	460	20	as	as	IN
cord-263455-dquztf5l	460	21	arbitrary	arbitrary	JJ
cord-263455-dquztf5l	460	22	.	.	.
cord-263455-dquztf5l	461	1	129	129	CD
cord-263455-dquztf5l	462	1	They	-PRON-	PRP
cord-263455-dquztf5l	462	2	argue	argue	VBP
cord-263455-dquztf5l	462	3	that	that	IN
cord-263455-dquztf5l	462	4	dosages	dosage	NNS
cord-263455-dquztf5l	462	5	may	may	MD
cord-263455-dquztf5l	462	6	be	be	VB
cord-263455-dquztf5l	462	7	too	too	RB
cord-263455-dquztf5l	462	8	high	high	JJ
cord-263455-dquztf5l	462	9	,	,	,
cord-263455-dquztf5l	462	10	resulting	result	VBG
cord-263455-dquztf5l	462	11	in	in	IN
cord-263455-dquztf5l	462	12	the	the	DT
cord-263455-dquztf5l	462	13	protection	protection	NN
cord-263455-dquztf5l	462	14	of	of	IN
cord-263455-dquztf5l	462	15	some	some	DT
cord-263455-dquztf5l	462	16	,	,	,
cord-263455-dquztf5l	462	17	but	but	CC
cord-263455-dquztf5l	462	18	also	also	RB
cord-263455-dquztf5l	462	19	resulting	result	VBG
cord-263455-dquztf5l	462	20	in	in	IN
cord-263455-dquztf5l	462	21	increased	increase	VBN
cord-263455-dquztf5l	462	22	susceptibility	susceptibility	NN
cord-263455-dquztf5l	462	23	to	to	IN
cord-263455-dquztf5l	462	24	leprosy	leprosy	NN
cord-263455-dquztf5l	462	25	in	in	IN
cord-263455-dquztf5l	462	26	other	other	JJ
cord-263455-dquztf5l	462	27	individuals	individual	NNS
cord-263455-dquztf5l	462	28	shortly	shortly	RB
cord-263455-dquztf5l	462	29	after	after	IN
cord-263455-dquztf5l	462	30	vaccination	vaccination	NN
cord-263455-dquztf5l	462	31	.	.	.
cord-263455-dquztf5l	463	1	An	an	DT
cord-263455-dquztf5l	463	2	individual	individual	NN
cord-263455-dquztf5l	463	3	's	's	POS
cord-263455-dquztf5l	463	4	prior	prior	JJ
cord-263455-dquztf5l	463	5	exposure	exposure	NN
cord-263455-dquztf5l	463	6	to	to	IN
cord-263455-dquztf5l	463	7	environmental	environmental	JJ
cord-263455-dquztf5l	463	8	mycobacteria	mycobacterium	NNS
cord-263455-dquztf5l	463	9	may	may	MD
cord-263455-dquztf5l	463	10	also	also	RB
cord-263455-dquztf5l	463	11	affect	affect	VB
cord-263455-dquztf5l	463	12	the	the	DT
cord-263455-dquztf5l	463	13	outcome	outcome	NN
cord-263455-dquztf5l	463	14	of	of	IN
cord-263455-dquztf5l	463	15	mycobacterial	mycobacterial	JJ
cord-263455-dquztf5l	463	16	vaccines	vaccine	NNS
cord-263455-dquztf5l	463	17	.	.	.
cord-263455-dquztf5l	464	1	43	43	CD
cord-263455-dquztf5l	464	2	Additional	additional	JJ
cord-263455-dquztf5l	464	3	research	research	NN
cord-263455-dquztf5l	464	4	with	with	IN
cord-263455-dquztf5l	464	5	varying	vary	VBG
cord-263455-dquztf5l	464	6	dosages	dosage	NNS
cord-263455-dquztf5l	464	7	and	and	CC
cord-263455-dquztf5l	464	8	in	in	IN
cord-263455-dquztf5l	464	9	different	different	JJ
cord-263455-dquztf5l	464	10	target	target	NN
cord-263455-dquztf5l	464	11	groups	group	NNS
cord-263455-dquztf5l	464	12	would	would	MD
cord-263455-dquztf5l	464	13	be	be	VB
cord-263455-dquztf5l	464	14	recommended	recommend	VBN
cord-263455-dquztf5l	464	15	.	.	.
cord-263455-dquztf5l	465	1	Richardus	Richardus	NNP
cord-263455-dquztf5l	465	2	et	et	NNP
cord-263455-dquztf5l	465	3	al	al	NNP
cord-263455-dquztf5l	465	4	concluded	conclude	VBD
cord-263455-dquztf5l	465	5	that	that	IN
cord-263455-dquztf5l	465	6	BCG	BCG	NNP
cord-263455-dquztf5l	465	7	vaccination	vaccination	NN
cord-263455-dquztf5l	465	8	followed	follow	VBN
cord-263455-dquztf5l	465	9	by	by	IN
cord-263455-dquztf5l	465	10	SDR	SDR	NNP
cord-263455-dquztf5l	465	11	as	as	IN
cord-263455-dquztf5l	465	12	a	a	DT
cord-263455-dquztf5l	465	13	routine	routine	JJ
cord-263455-dquztf5l	465	14	intervention	intervention	NN
cord-263455-dquztf5l	465	15	is	be	VBZ
cord-263455-dquztf5l	465	16	not	not	RB
cord-263455-dquztf5l	465	17	recommended	recommend	VBN
cord-263455-dquztf5l	465	18	in	in	IN
cord-263455-dquztf5l	465	19	leprosy	leprosy	NN
cord-263455-dquztf5l	465	20	control	control	NN
cord-263455-dquztf5l	465	21	.	.	.
cord-263455-dquztf5l	466	1	46	46	CD
cord-263455-dquztf5l	467	1	The	the	DT
cord-263455-dquztf5l	467	2	MALTALEP	MALTALEP	NNP
cord-263455-dquztf5l	467	3	study	study	NN
cord-263455-dquztf5l	467	4	was	be	VBD
cord-263455-dquztf5l	467	5	challenged	challenge	VBN
cord-263455-dquztf5l	467	6	in	in	IN
cord-263455-dquztf5l	467	7	finding	find	VBG
cord-263455-dquztf5l	467	8	significance	significance	NN
cord-263455-dquztf5l	467	9	because	because	IN
cord-263455-dquztf5l	467	10	of	of	IN
cord-263455-dquztf5l	467	11	insufficient	insufficient	JJ
cord-263455-dquztf5l	467	12	statistical	statistical	JJ
cord-263455-dquztf5l	467	13	power	power	NN
cord-263455-dquztf5l	467	14	.	.	.
cord-263455-dquztf5l	468	1	44	44	CD
cord-263455-dquztf5l	469	1	,	,	,
cord-263455-dquztf5l	469	2	125	125	CD
cord-263455-dquztf5l	469	3	A	a	DT
cord-263455-dquztf5l	469	4	well	well	RB
cord-263455-dquztf5l	469	5	-	-	HYPH
cord-263455-dquztf5l	469	6	powered	power	VBN
cord-263455-dquztf5l	469	7	study	study	NN
cord-263455-dquztf5l	469	8	focusing	focus	VBG
cord-263455-dquztf5l	469	9	on	on	IN
cord-263455-dquztf5l	469	10	the	the	DT
cord-263455-dquztf5l	469	11	reversed	reverse	VBN
cord-263455-dquztf5l	469	12	-	-	HYPH
cord-263455-dquztf5l	469	13	MALTALEP	MALTALEP	NNP
cord-263455-dquztf5l	469	14	order	order	NN
cord-263455-dquztf5l	469	15	(	(	-LRB-
cord-263455-dquztf5l	469	16	first	first	JJ
cord-263455-dquztf5l	469	17	SDR	SDR	NNP
cord-263455-dquztf5l	469	18	administration	administration	NN
cord-263455-dquztf5l	469	19	,	,	,
cord-263455-dquztf5l	469	20	followed	follow	VBN
cord-263455-dquztf5l	469	21	by	by	IN
cord-263455-dquztf5l	469	22	BCG	BCG	NNP
cord-263455-dquztf5l	469	23	)	)	-RRB-
cord-263455-dquztf5l	469	24	would	would	MD
cord-263455-dquztf5l	469	25	therefore	therefore	RB
cord-263455-dquztf5l	469	26	be	be	VB
cord-263455-dquztf5l	469	27	of	of	IN
cord-263455-dquztf5l	469	28	great	great	JJ
cord-263455-dquztf5l	469	29	value	value	NN
cord-263455-dquztf5l	469	30	.	.	.
cord-263455-dquztf5l	470	1	Considering	consider	VBG
cord-263455-dquztf5l	470	2	the	the	DT
cord-263455-dquztf5l	470	3	above	above	JJ
cord-263455-dquztf5l	470	4	results	result	NNS
cord-263455-dquztf5l	470	5	,	,	,
cord-263455-dquztf5l	470	6	contact	contact	NN
cord-263455-dquztf5l	470	7	screening	screen	VBG
cord-263455-dquztf5l	470	8	followup	followup	NN
cord-263455-dquztf5l	470	9	is	be	VBZ
cord-263455-dquztf5l	470	10	especially	especially	RB
cord-263455-dquztf5l	470	11	important	important	JJ
cord-263455-dquztf5l	470	12	in	in	IN
cord-263455-dquztf5l	470	13	the	the	DT
cord-263455-dquztf5l	470	14	first	first	JJ
cord-263455-dquztf5l	470	15	period	period	NN
cord-263455-dquztf5l	470	16	after	after	IN
cord-263455-dquztf5l	470	17	BCG	BCG	NNP
cord-263455-dquztf5l	470	18	administration	administration	NN
cord-263455-dquztf5l	470	19	,	,	,
cord-263455-dquztf5l	470	20	as	as	IN
cord-263455-dquztf5l	470	21	a	a	DT
cord-263455-dquztf5l	470	22	relatively	relatively	RB
cord-263455-dquztf5l	470	23	large	large	JJ
cord-263455-dquztf5l	470	24	number	number	NN
cord-263455-dquztf5l	470	25	of	of	IN
cord-263455-dquztf5l	470	26	new	new	JJ
cord-263455-dquztf5l	470	27	patients	patient	NNS
cord-263455-dquztf5l	470	28	presents	present	VBZ
cord-263455-dquztf5l	470	29	three	three	CD
cord-263455-dquztf5l	470	30	months	month	NNS
cord-263455-dquztf5l	470	31	post	post	NN
cord-263455-dquztf5l	470	32	-	-	NN
cord-263455-dquztf5l	470	33	vaccination	vaccination	NN
cord-263455-dquztf5l	470	34	.	.	.
cord-263455-dquztf5l	471	1	48	48	CD
cord-263455-dquztf5l	471	2	,	,	,
cord-263455-dquztf5l	471	3	51	51	CD
cord-263455-dquztf5l	471	4	,	,	,
cord-263455-dquztf5l	471	5	[	[	-LRB-
cord-263455-dquztf5l	471	6	127	127	CD
cord-263455-dquztf5l	471	7	]	]	-RRB-
cord-263455-dquztf5l	471	8	[	[	-LRB-
cord-263455-dquztf5l	471	9	128	128	CD
cord-263455-dquztf5l	471	10	]	]	-RRB-
cord-263455-dquztf5l	472	1	[	[	-LRB-
cord-263455-dquztf5l	472	2	129	129	CD
cord-263455-dquztf5l	472	3	]	]	-RRB-
cord-263455-dquztf5l	473	1	This	this	DT
cord-263455-dquztf5l	473	2	may	may	MD
cord-263455-dquztf5l	473	3	also	also	RB
cord-263455-dquztf5l	473	4	count	count	VB
cord-263455-dquztf5l	473	5	for	for	IN
cord-263455-dquztf5l	473	6	other	other	JJ
cord-263455-dquztf5l	473	7	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	473	8	agents	agent	NNS
cord-263455-dquztf5l	473	9	.	.	.
cord-263455-dquztf5l	474	1	As	as	IN
cord-263455-dquztf5l	474	2	discussed	discuss	VBN
cord-263455-dquztf5l	474	3	,	,	,
cord-263455-dquztf5l	474	4	many	many	JJ
cord-263455-dquztf5l	474	5	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	474	6	studies	study	NNS
cord-263455-dquztf5l	474	7	lacked	lack	VBD
cord-263455-dquztf5l	474	8	power	power	NN
cord-263455-dquztf5l	474	9	.	.	.
cord-263455-dquztf5l	475	1	More	more	RBR
cord-263455-dquztf5l	475	2	well	well	RB
cord-263455-dquztf5l	475	3	-	-	HYPH
cord-263455-dquztf5l	475	4	designed	design	VBN
cord-263455-dquztf5l	475	5	,	,	,
cord-263455-dquztf5l	475	6	sufficiently	sufficiently	RB
cord-263455-dquztf5l	475	7	powered	powered	JJ
cord-263455-dquztf5l	475	8	and	and	CC
cord-263455-dquztf5l	475	9	long	long	RB
cord-263455-dquztf5l	475	10	-	-	HYPH
cord-263455-dquztf5l	475	11	lasting	last	VBG
cord-263455-dquztf5l	475	12	(	(	-LRB-
cord-263455-dquztf5l	475	13	regarding	regard	VBG
cord-263455-dquztf5l	475	14	the	the	DT
cord-263455-dquztf5l	475	15	leprosy	leprosy	NN
cord-263455-dquztf5l	475	16	incubation	incubation	NN
cord-263455-dquztf5l	475	17	period	period	NN
cord-263455-dquztf5l	475	18	)	)	-RRB-
cord-263455-dquztf5l	476	1	studies	study	NNS
cord-263455-dquztf5l	476	2	in	in	IN
cord-263455-dquztf5l	476	3	this	this	DT
cord-263455-dquztf5l	476	4	field	field	NN
cord-263455-dquztf5l	476	5	are	be	VBP
cord-263455-dquztf5l	476	6	therefore	therefore	RB
cord-263455-dquztf5l	476	7	suggested	suggest	VBN
cord-263455-dquztf5l	476	8	.	.	.
cord-263455-dquztf5l	477	1	But	but	CC
cord-263455-dquztf5l	477	2	,	,	,
cord-263455-dquztf5l	477	3	given	give	VBN
cord-263455-dquztf5l	477	4	the	the	DT
cord-263455-dquztf5l	477	5	evidence	evidence	NN
cord-263455-dquztf5l	477	6	for	for	IN
cord-263455-dquztf5l	477	7	the	the	DT
cord-263455-dquztf5l	477	8	effectiveness	effectiveness	NN
cord-263455-dquztf5l	477	9	of	of	IN
cord-263455-dquztf5l	477	10	SDR	SDR	NNP
cord-263455-dquztf5l	477	11	-	-	HYPH
cord-263455-dquztf5l	477	12	PEP	PEP	NNP
cord-263455-dquztf5l	477	13	and	and	CC
cord-263455-dquztf5l	477	14	the	the	DT
cord-263455-dquztf5l	477	15	WHO	WHO	NNP
cord-263455-dquztf5l	477	16	guidelines	guideline	VBZ
cord-263455-dquztf5l	477	17	for	for	IN
cord-263455-dquztf5l	477	18	its	-PRON-	PRP$
cord-263455-dquztf5l	477	19	use	use	NN
cord-263455-dquztf5l	477	20	,	,	,
cord-263455-dquztf5l	477	21	the	the	DT
cord-263455-dquztf5l	477	22	ethics	ethic	NNS
cord-263455-dquztf5l	477	23	of	of	IN
cord-263455-dquztf5l	477	24	testing	test	VBG
cord-263455-dquztf5l	477	25	new	new	JJ
cord-263455-dquztf5l	477	26	post	post	JJ
cord-263455-dquztf5l	477	27	-	-	JJ
cord-263455-dquztf5l	477	28	exposure	exposure	JJ
cord-263455-dquztf5l	477	29	immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	477	30	approaches	approach	NNS
cord-263455-dquztf5l	477	31	for	for	IN
cord-263455-dquztf5l	477	32	leprosy	leprosy	NN
cord-263455-dquztf5l	477	33	prevention	prevention	NN
cord-263455-dquztf5l	477	34	without	without	IN
cord-263455-dquztf5l	477	35	combining	combine	VBG
cord-263455-dquztf5l	477	36	them	-PRON-	PRP
cord-263455-dquztf5l	477	37	with	with	IN
cord-263455-dquztf5l	477	38	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	477	39	in	in	IN
cord-263455-dquztf5l	477	40	both	both	CC
cord-263455-dquztf5l	477	41	the	the	DT
cord-263455-dquztf5l	477	42	intervention	intervention	NN
cord-263455-dquztf5l	477	43	and	and	CC
cord-263455-dquztf5l	477	44	control	control	NN
cord-263455-dquztf5l	477	45	group	group	NN
cord-263455-dquztf5l	477	46	needs	need	VBZ
cord-263455-dquztf5l	477	47	to	to	TO
cord-263455-dquztf5l	477	48	be	be	VB
cord-263455-dquztf5l	477	49	discussed	discuss	VBN
cord-263455-dquztf5l	477	50	.	.	.
cord-263455-dquztf5l	478	1	96	96	CD
cord-263455-dquztf5l	478	2	,	,	,
cord-263455-dquztf5l	478	3	98	98	CD
cord-263455-dquztf5l	478	4	,	,	,
cord-263455-dquztf5l	478	5	115	115	CD
cord-263455-dquztf5l	478	6	,	,	,
cord-263455-dquztf5l	478	7	126	126	CD
cord-263455-dquztf5l	478	8	,	,	,
cord-263455-dquztf5l	479	1	136	136	CD
cord-263455-dquztf5l	479	2	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	480	1	The	the	DT
cord-263455-dquztf5l	480	2	promising	promising	JJ
cord-263455-dquztf5l	480	3	findings	finding	NNS
cord-263455-dquztf5l	480	4	of	of	IN
cord-263455-dquztf5l	480	5	the	the	DT
cord-263455-dquztf5l	480	6	COLEP	COLEP	NNP
cord-263455-dquztf5l	480	7	study	study	NN
cord-263455-dquztf5l	480	8	,	,	,
cord-263455-dquztf5l	480	9	the	the	DT
cord-263455-dquztf5l	480	10	systematic	systematic	JJ
cord-263455-dquztf5l	480	11	reviews	review	NNS
cord-263455-dquztf5l	480	12	,	,	,
cord-263455-dquztf5l	480	13	and	and	CC
cord-263455-dquztf5l	480	14	the	the	DT
cord-263455-dquztf5l	480	15	2007	2007	CD
cord-263455-dquztf5l	480	16	workshop	workshop	NN
cord-263455-dquztf5l	480	17	recommendation	recommendation	NN
cord-263455-dquztf5l	480	18	on	on	IN
cord-263455-dquztf5l	480	19	additional	additional	JJ
cord-263455-dquztf5l	480	20	,	,	,
cord-263455-dquztf5l	480	21	operational	operational	JJ
cord-263455-dquztf5l	480	22	research	research	NN
cord-263455-dquztf5l	480	23	were	be	VBD
cord-263455-dquztf5l	480	24	not	not	RB
cord-263455-dquztf5l	480	25	immediately	immediately	RB
cord-263455-dquztf5l	480	26	pursued	pursue	VBN
cord-263455-dquztf5l	480	27	.	.	.
cord-263455-dquztf5l	481	1	This	this	DT
cord-263455-dquztf5l	481	2	was	be	VBD
cord-263455-dquztf5l	481	3	partly	partly	RB
cord-263455-dquztf5l	481	4	because	because	IN
cord-263455-dquztf5l	481	5	the	the	DT
cord-263455-dquztf5l	481	6	use	use	NN
cord-263455-dquztf5l	481	7	of	of	IN
cord-263455-dquztf5l	481	8	SDR	SDR	NNP
cord-263455-dquztf5l	481	9	-	-	HYPH
cord-263455-dquztf5l	481	10	PEP	PEP	NNP
cord-263455-dquztf5l	481	11	has	have	VBZ
cord-263455-dquztf5l	481	12	been	be	VBN
cord-263455-dquztf5l	481	13	criticized	criticize	VBN
cord-263455-dquztf5l	481	14	.	.	.
cord-263455-dquztf5l	482	1	[	[	-LRB-
cord-263455-dquztf5l	482	2	137	137	CD
cord-263455-dquztf5l	482	3	]	]	-RRB-
cord-263455-dquztf5l	482	4	[	[	-LRB-
cord-263455-dquztf5l	482	5	138	138	CD
cord-263455-dquztf5l	482	6	]	]	-RRB-
cord-263455-dquztf5l	483	1	[	[	-LRB-
cord-263455-dquztf5l	483	2	139	139	CD
cord-263455-dquztf5l	483	3	]	]	-RRB-
cord-263455-dquztf5l	483	4	[	[	-LRB-
cord-263455-dquztf5l	483	5	140	140	CD
cord-263455-dquztf5l	483	6	]	]	-RRB-
cord-263455-dquztf5l	484	1	Concerns	concern	NNS
cord-263455-dquztf5l	484	2	have	have	VBP
cord-263455-dquztf5l	484	3	been	be	VBN
cord-263455-dquztf5l	484	4	raised	raise	VBN
cord-263455-dquztf5l	484	5	about	about	IN
cord-263455-dquztf5l	484	6	the	the	DT
cord-263455-dquztf5l	484	7	fact	fact	NN
cord-263455-dquztf5l	484	8	that	that	IN
cord-263455-dquztf5l	484	9	it	-PRON-	PRP
cord-263455-dquztf5l	484	10	does	do	VBZ
cord-263455-dquztf5l	484	11	not	not	RB
cord-263455-dquztf5l	484	12	provide	provide	VB
cord-263455-dquztf5l	484	13	long	long	JJ
cord-263455-dquztf5l	484	14	-	-	HYPH
cord-263455-dquztf5l	484	15	term	term	NN
cord-263455-dquztf5l	484	16	protection	protection	NN
cord-263455-dquztf5l	484	17	like	like	IN
cord-263455-dquztf5l	484	18	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	484	19	,	,	,
cord-263455-dquztf5l	484	20	and	and	CC
cord-263455-dquztf5l	484	21	that	that	IN
cord-263455-dquztf5l	484	22	the	the	DT
cord-263455-dquztf5l	484	23	COLEP	COLEP	NNP
cord-263455-dquztf5l	484	24	study	study	NN
cord-263455-dquztf5l	484	25	revealed	reveal	VBD
cord-263455-dquztf5l	484	26	that	that	IN
cord-263455-dquztf5l	484	27	it	-PRON-	PRP
cord-263455-dquztf5l	484	28	provides	provide	VBZ
cord-263455-dquztf5l	484	29	an	an	DT
cord-263455-dquztf5l	484	30	overall	overall	JJ
cord-263455-dquztf5l	484	31	risk	risk	NN
cord-263455-dquztf5l	484	32	reduction	reduction	NN
cord-263455-dquztf5l	484	33	of	of	IN
cord-263455-dquztf5l	484	34	57	57	CD
cord-263455-dquztf5l	484	35	%	%	NN
cord-263455-dquztf5l	484	36	and	and	CC
cord-263455-dquztf5l	484	37	only	only	RB
cord-263455-dquztf5l	484	38	24	24	CD
cord-263455-dquztf5l	484	39	%	%	NN
cord-263455-dquztf5l	484	40	in	in	IN
cord-263455-dquztf5l	484	41	blood	blood	NN
cord-263455-dquztf5l	484	42	-	-	HYPH
cord-263455-dquztf5l	484	43	related	relate	VBN
cord-263455-dquztf5l	484	44	household	household	NN
cord-263455-dquztf5l	484	45	contacts	contact	NNS
cord-263455-dquztf5l	484	46	,	,	,
cord-263455-dquztf5l	484	47	though	though	IN
cord-263455-dquztf5l	484	48	the	the	DT
cord-263455-dquztf5l	484	49	latter	latter	JJ
cord-263455-dquztf5l	484	50	finding	finding	NN
cord-263455-dquztf5l	484	51	was	be	VBD
cord-263455-dquztf5l	484	52	not	not	RB
cord-263455-dquztf5l	484	53	significant	significant	JJ
cord-263455-dquztf5l	484	54	(	(	-LRB-
cord-263455-dquztf5l	484	55	p	p	NN
cord-263455-dquztf5l	484	56	=	=	SYM
cord-263455-dquztf5l	484	57	0.49	0.49	CD
cord-263455-dquztf5l	484	58	)	)	-RRB-
cord-263455-dquztf5l	484	59	because	because	IN
cord-263455-dquztf5l	484	60	the	the	DT
cord-263455-dquztf5l	484	61	study	study	NN
cord-263455-dquztf5l	484	62	was	be	VBD
cord-263455-dquztf5l	484	63	not	not	RB
cord-263455-dquztf5l	484	64	powered	power	VBN
cord-263455-dquztf5l	484	65	for	for	IN
cord-263455-dquztf5l	484	66	subgroup	subgroup	NN
cord-263455-dquztf5l	484	67	analysis	analysis	NN
cord-263455-dquztf5l	484	68	.	.	.
cord-263455-dquztf5l	485	1	112	112	CD
cord-263455-dquztf5l	485	2	,	,	,
cord-263455-dquztf5l	485	3	138	138	CD
cord-263455-dquztf5l	485	4	,	,	,
cord-263455-dquztf5l	485	5	139	139	CD
cord-263455-dquztf5l	486	1	However	however	RB
cord-263455-dquztf5l	486	2	,	,	,
cord-263455-dquztf5l	486	3	the	the	DT
cord-263455-dquztf5l	486	4	effect	effect	NN
cord-263455-dquztf5l	486	5	seen	see	VBN
cord-263455-dquztf5l	486	6	in	in	IN
cord-263455-dquztf5l	486	7	all	all	DT
cord-263455-dquztf5l	486	8	contact	contact	NN
cord-263455-dquztf5l	486	9	subgroups	subgroup	NNS
cord-263455-dquztf5l	486	10	trended	trend	VBD
cord-263455-dquztf5l	486	11	with	with	IN
cord-263455-dquztf5l	486	12	the	the	DT
cord-263455-dquztf5l	486	13	overall	overall	JJ
cord-263455-dquztf5l	486	14	risk	risk	NN
cord-263455-dquztf5l	486	15	reduction	reduction	NN
cord-263455-dquztf5l	486	16	of	of	IN
cord-263455-dquztf5l	486	17	57	57	CD
cord-263455-dquztf5l	486	18	%	%	NN
cord-263455-dquztf5l	486	19	.	.	.
cord-263455-dquztf5l	487	1	112	112	CD
cord-263455-dquztf5l	488	1	Other	other	JJ
cord-263455-dquztf5l	488	2	criticism	criticism	NN
cord-263455-dquztf5l	488	3	concerned	concern	VBD
cord-263455-dquztf5l	488	4	the	the	DT
cord-263455-dquztf5l	488	5	logistics	logistic	NNS
cord-263455-dquztf5l	488	6	and	and	CC
cord-263455-dquztf5l	488	7	cost	cost	NN
cord-263455-dquztf5l	488	8	-	-	HYPH
cord-263455-dquztf5l	488	9	effectiveness	effectiveness	NN
cord-263455-dquztf5l	488	10	of	of	IN
cord-263455-dquztf5l	488	11	the	the	DT
cord-263455-dquztf5l	488	12	intervention	intervention	NN
cord-263455-dquztf5l	488	13	.	.	.
cord-263455-dquztf5l	489	1	138	138	CD
cord-263455-dquztf5l	490	1	Though	though	RB
cord-263455-dquztf5l	490	2	,	,	,
cord-263455-dquztf5l	490	3	studies	study	NNS
cord-263455-dquztf5l	490	4	have	have	VBP
cord-263455-dquztf5l	490	5	demonstrated	demonstrate	VBN
cord-263455-dquztf5l	490	6	that	that	IN
cord-263455-dquztf5l	490	7	both	both	DT
cord-263455-dquztf5l	490	8	contact	contact	NN
cord-263455-dquztf5l	490	9	examination	examination	NN
cord-263455-dquztf5l	490	10	and	and	CC
cord-263455-dquztf5l	490	11	SDR	SDR	NNP
cord-263455-dquztf5l	490	12	-	-	HYPH
cord-263455-dquztf5l	490	13	PEP	PEP	NNP
cord-263455-dquztf5l	490	14	implementation	implementation	NN
cord-263455-dquztf5l	490	15	are	be	VBP
cord-263455-dquztf5l	490	16	cost	cost	NN
cord-263455-dquztf5l	490	17	-	-	HYPH
cord-263455-dquztf5l	490	18	effective	effective	JJ
cord-263455-dquztf5l	490	19	.	.	.
cord-263455-dquztf5l	491	1	97	97	CD
cord-263455-dquztf5l	491	2	,	,	,
cord-263455-dquztf5l	491	3	116	116	CD
cord-263455-dquztf5l	491	4	,	,	,
cord-263455-dquztf5l	491	5	141	141	CD
cord-263455-dquztf5l	491	6	Rodrigues	Rodrigues	NNP
cord-263455-dquztf5l	491	7	,	,	,
cord-263455-dquztf5l	491	8	Lockwood	Lockwood	NNP
cord-263455-dquztf5l	491	9	,	,	,
cord-263455-dquztf5l	491	10	Krishnamurthy	Krishnamurthy	NNP
cord-263455-dquztf5l	491	11	and	and	CC
cord-263455-dquztf5l	491	12	Penna	Penna	NNP
cord-263455-dquztf5l	491	13	also	also	RB
cord-263455-dquztf5l	491	14	argued	argue	VBD
cord-263455-dquztf5l	491	15	that	that	IN
cord-263455-dquztf5l	491	16	contact	contact	NN
cord-263455-dquztf5l	491	17	screening	screening	NN
cord-263455-dquztf5l	491	18	and	and	CC
cord-263455-dquztf5l	491	19	SDR	SDR	NNP
cord-263455-dquztf5l	491	20	-	-	HYPH
cord-263455-dquztf5l	491	21	PEP	PEP	NNP
cord-263455-dquztf5l	491	22	administration	administration	NN
cord-263455-dquztf5l	491	23	raise	raise	VB
cord-263455-dquztf5l	491	24	ethical	ethical	JJ
cord-263455-dquztf5l	491	25	problems	problem	NNS
cord-263455-dquztf5l	491	26	because	because	IN
cord-263455-dquztf5l	491	27	the	the	DT
cord-263455-dquztf5l	491	28	disclosure	disclosure	NN
cord-263455-dquztf5l	491	29	of	of	IN
cord-263455-dquztf5l	491	30	the	the	DT
cord-263455-dquztf5l	491	31	index	index	NN
cord-263455-dquztf5l	491	32	-	-	HYPH
cord-263455-dquztf5l	491	33	patients	patient	NNS
cord-263455-dquztf5l	491	34	'	'	POS
cord-263455-dquztf5l	491	35	diagnosis	diagnosis	NN
cord-263455-dquztf5l	491	36	to	to	IN
cord-263455-dquztf5l	491	37	their	-PRON-	PRP$
cord-263455-dquztf5l	491	38	contacts	contact	NNS
cord-263455-dquztf5l	491	39	is	be	VBZ
cord-263455-dquztf5l	491	40	required	require	VBN
cord-263455-dquztf5l	491	41	.	.	.
cord-263455-dquztf5l	492	1	138	138	CD
cord-263455-dquztf5l	493	1	,	,	,
cord-263455-dquztf5l	493	2	139	139	CD
cord-263455-dquztf5l	494	1	However	however	RB
cord-263455-dquztf5l	494	2	,	,	,
cord-263455-dquztf5l	494	3	the	the	DT
cord-263455-dquztf5l	494	4	LPEP	LPEP	NNP
cord-263455-dquztf5l	494	5	program	program	NN
cord-263455-dquztf5l	494	6	results	result	NNS
cord-263455-dquztf5l	494	7	in	in	IN
cord-263455-dquztf5l	494	8	Brazil	Brazil	NNP
cord-263455-dquztf5l	494	9	illustrated	illustrate	VBD
cord-263455-dquztf5l	494	10	that	that	IN
cord-263455-dquztf5l	494	11	it	-PRON-	PRP
cord-263455-dquztf5l	494	12	is	be	VBZ
cord-263455-dquztf5l	494	13	possible	possible	JJ
cord-263455-dquztf5l	494	14	to	to	TO
cord-263455-dquztf5l	494	15	distribute	distribute	VB
cord-263455-dquztf5l	494	16	SDR	SDR	NNP
cord-263455-dquztf5l	494	17	-	-	HYPH
cord-263455-dquztf5l	494	18	PEP	PEP	NNP
cord-263455-dquztf5l	494	19	without	without	IN
cord-263455-dquztf5l	494	20	disclosing	disclose	VBG
cord-263455-dquztf5l	494	21	the	the	DT
cord-263455-dquztf5l	494	22	identity	identity	NN
cord-263455-dquztf5l	494	23	of	of	IN
cord-263455-dquztf5l	494	24	the	the	DT
cord-263455-dquztf5l	494	25	index	index	NN
cord-263455-dquztf5l	494	26	case	case	NN
cord-263455-dquztf5l	494	27	by	by	IN
cord-263455-dquztf5l	494	28	solely	solely	RB
cord-263455-dquztf5l	494	29	saying	say	VBG
cord-263455-dquztf5l	494	30	:	:	:
cord-263455-dquztf5l	494	31	"	"	``
cord-263455-dquztf5l	494	32	There	there	EX
cord-263455-dquztf5l	494	33	is	be	VBZ
cord-263455-dquztf5l	494	34	leprosy	leprosy	NN
cord-263455-dquztf5l	494	35	in	in	IN
cord-263455-dquztf5l	494	36	your	-PRON-	PRP$
cord-263455-dquztf5l	494	37	area	area	NN
cord-263455-dquztf5l	494	38	,	,	,
cord-263455-dquztf5l	494	39	and	and	CC
cord-263455-dquztf5l	494	40	that	that	DT
cord-263455-dquztf5l	494	41	is	be	VBZ
cord-263455-dquztf5l	494	42	why	why	WRB
cord-263455-dquztf5l	494	43	we	-PRON-	PRP
cord-263455-dquztf5l	494	44	offer	offer	VBP
cord-263455-dquztf5l	494	45	people	people	NNS
cord-263455-dquztf5l	494	46	preventive	preventive	JJ
cord-263455-dquztf5l	494	47	treatment	treatment	NN
cord-263455-dquztf5l	494	48	against	against	IN
cord-263455-dquztf5l	494	49	leprosy	leprosy	NN
cord-263455-dquztf5l	494	50	"	"	''
cord-263455-dquztf5l	495	1	(	(	-LRB-
cord-263455-dquztf5l	495	2	Ignotti	Ignotti	NNP
cord-263455-dquztf5l	495	3	,	,	,
cord-263455-dquztf5l	495	4	unpublished	unpublished	JJ
cord-263455-dquztf5l	495	5	report	report	NN
cord-263455-dquztf5l	495	6	)	)	-RRB-
cord-263455-dquztf5l	495	7	.	.	.
cord-263455-dquztf5l	496	1	The	the	DT
cord-263455-dquztf5l	496	2	LPEP	LPEP	NNP
cord-263455-dquztf5l	496	3	program	program	NN
cord-263455-dquztf5l	496	4	successfully	successfully	RB
cord-263455-dquztf5l	496	5	addressed	address	VBD
cord-263455-dquztf5l	496	6	several	several	JJ
cord-263455-dquztf5l	496	7	concerns	concern	NNS
cord-263455-dquztf5l	496	8	by	by	IN
cord-263455-dquztf5l	496	9	demonstrating	demonstrate	VBG
cord-263455-dquztf5l	496	10	the	the	DT
cord-263455-dquztf5l	496	11	feasibility	feasibility	NN
cord-263455-dquztf5l	496	12	and	and	CC
cord-263455-dquztf5l	496	13	acceptability	acceptability	NN
cord-263455-dquztf5l	496	14	of	of	IN
cord-263455-dquztf5l	496	15	making	make	VBG
cord-263455-dquztf5l	496	16	prevention	prevention	NN
cord-263455-dquztf5l	496	17	,	,	,
cord-263455-dquztf5l	496	18	in	in	IN
cord-263455-dquztf5l	496	19	the	the	DT
cord-263455-dquztf5l	496	20	form	form	NN
cord-263455-dquztf5l	496	21	of	of	IN
cord-263455-dquztf5l	496	22	contact	contact	NN
cord-263455-dquztf5l	496	23	screening	screening	NN
cord-263455-dquztf5l	496	24	and	and	CC
cord-263455-dquztf5l	496	25	SDR	SDR	NNP
cord-263455-dquztf5l	496	26	-	-	HYPH
cord-263455-dquztf5l	496	27	PEP	PEP	NNP
cord-263455-dquztf5l	496	28	administration	administration	NN
cord-263455-dquztf5l	496	29	,	,	,
cord-263455-dquztf5l	496	30	part	part	NN
cord-263455-dquztf5l	496	31	of	of	IN
cord-263455-dquztf5l	496	32	leprosy	leprosy	NN
cord-263455-dquztf5l	496	33	control	control	NN
cord-263455-dquztf5l	496	34	.	.	.
cord-263455-dquztf5l	497	1	Embedding	embed	VBG
cord-263455-dquztf5l	497	2	the	the	DT
cord-263455-dquztf5l	497	3	approach	approach	NN
cord-263455-dquztf5l	497	4	in	in	IN
cord-263455-dquztf5l	497	5	existing	exist	VBG
cord-263455-dquztf5l	497	6	leprosy	leprosy	NN
cord-263455-dquztf5l	497	7	services	service	NNS
cord-263455-dquztf5l	497	8	invigorated	invigorate	VBD
cord-263455-dquztf5l	497	9	the	the	DT
cord-263455-dquztf5l	497	10	leprosy	leprosy	NN
cord-263455-dquztf5l	497	11	program	program	NN
cord-263455-dquztf5l	497	12	.	.	.
cord-263455-dquztf5l	498	1	Two	two	CD
cord-263455-dquztf5l	498	2	additional	additional	JJ
cord-263455-dquztf5l	498	3	systematic	systematic	JJ
cord-263455-dquztf5l	498	4	reviews	review	NNS
cord-263455-dquztf5l	498	5	of	of	IN
cord-263455-dquztf5l	498	6	quantitative	quantitative	JJ
cord-263455-dquztf5l	498	7	and	and	CC
cord-263455-dquztf5l	498	8	qualitative	qualitative	JJ
cord-263455-dquztf5l	498	9	data	datum	NNS
cord-263455-dquztf5l	498	10	and	and	CC
cord-263455-dquztf5l	498	11	a	a	DT
cord-263455-dquztf5l	498	12	meta	meta	JJ
cord-263455-dquztf5l	498	13	-	-	HYPH
cord-263455-dquztf5l	498	14	analysis	analysis	NN
cord-263455-dquztf5l	498	15	in	in	IN
cord-263455-dquztf5l	498	16	2017	2017	CD
cord-263455-dquztf5l	498	17	and	and	CC
cord-263455-dquztf5l	498	18	2018	2018	CD
cord-263455-dquztf5l	498	19	confirmed	confirm	VBD
cord-263455-dquztf5l	498	20	the	the	DT
cord-263455-dquztf5l	498	21	effectiveness	effectiveness	NN
cord-263455-dquztf5l	498	22	of	of	IN
cord-263455-dquztf5l	498	23	SDR	SDR	NNP
cord-263455-dquztf5l	498	24	as	as	IN
cord-263455-dquztf5l	498	25	PEP	pep	NN
cord-263455-dquztf5l	498	26	and	and	CC
cord-263455-dquztf5l	498	27	the	the	DT
cord-263455-dquztf5l	498	28	general	general	JJ
cord-263455-dquztf5l	498	29	acceptance	acceptance	NN
cord-263455-dquztf5l	498	30	of	of	IN
cord-263455-dquztf5l	498	31	the	the	DT
cord-263455-dquztf5l	498	32	approach	approach	NN
cord-263455-dquztf5l	498	33	.	.	.
cord-263455-dquztf5l	499	1	142	142	CD
cord-263455-dquztf5l	499	2	,	,	,
cord-263455-dquztf5l	499	3	143	143	CD
cord-263455-dquztf5l	499	4	Preventive	preventive	JJ
cord-263455-dquztf5l	499	5	chemotherapy	chemotherapy	NN
cord-263455-dquztf5l	499	6	has	have	VBZ
cord-263455-dquztf5l	499	7	become	become	VBN
cord-263455-dquztf5l	499	8	part	part	NN
cord-263455-dquztf5l	499	9	of	of	IN
cord-263455-dquztf5l	499	10	leprosy	leprosy	NN
cord-263455-dquztf5l	499	11	control	control	NN
cord-263455-dquztf5l	499	12	.	.	.
cord-263455-dquztf5l	500	1	This	this	DT
cord-263455-dquztf5l	500	2	is	be	VBZ
cord-263455-dquztf5l	500	3	needed	need	VBN
cord-263455-dquztf5l	500	4	,	,	,
cord-263455-dquztf5l	500	5	since	since	IN
cord-263455-dquztf5l	500	6	the	the	DT
cord-263455-dquztf5l	500	7	incidence	incidence	NN
cord-263455-dquztf5l	500	8	has	have	VBZ
cord-263455-dquztf5l	500	9	been	be	VBN
cord-263455-dquztf5l	500	10	more	more	RBR
cord-263455-dquztf5l	500	11	or	or	CC
cord-263455-dquztf5l	500	12	less	less	RBR
cord-263455-dquztf5l	500	13	stable	stable	JJ
cord-263455-dquztf5l	500	14	at	at	IN
cord-263455-dquztf5l	500	15	around	around	IN
cord-263455-dquztf5l	500	16	210,000	210,000	CD
cord-263455-dquztf5l	500	17	in	in	IN
cord-263455-dquztf5l	500	18	the	the	DT
cord-263455-dquztf5l	500	19	past	past	JJ
cord-263455-dquztf5l	500	20	10	10	CD
cord-263455-dquztf5l	500	21	years	year	NNS
cord-263455-dquztf5l	500	22	.	.	.
cord-263455-dquztf5l	501	1	7	7	CD
cord-263455-dquztf5l	502	1	Several	several	JJ
cord-263455-dquztf5l	502	2	high	high	JJ
cord-263455-dquztf5l	502	3	-	-	HYPH
cord-263455-dquztf5l	502	4	burden	burden	NN
cord-263455-dquztf5l	502	5	countries	country	NNS
cord-263455-dquztf5l	502	6	(	(	-LRB-
cord-263455-dquztf5l	502	7	eg	eg	RB
cord-263455-dquztf5l	502	8	,	,	,
cord-263455-dquztf5l	502	9	India	India	NNP
cord-263455-dquztf5l	502	10	and	and	CC
cord-263455-dquztf5l	502	11	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	502	12	)	)	-RRB-
cord-263455-dquztf5l	502	13	have	have	VBP
cord-263455-dquztf5l	502	14	embedded	embed	VBN
cord-263455-dquztf5l	502	15	SDR	SDR	NNP
cord-263455-dquztf5l	502	16	-	-	HYPH
cord-263455-dquztf5l	502	17	PEP	PEP	NNP
cord-263455-dquztf5l	502	18	into	into	IN
cord-263455-dquztf5l	502	19	routine	routine	JJ
cord-263455-dquztf5l	502	20	leprosy	leprosy	NN
cord-263455-dquztf5l	502	21	control	control	NN
cord-263455-dquztf5l	502	22	nationwide	nationwide	RB
cord-263455-dquztf5l	502	23	.	.	.
cord-263455-dquztf5l	503	1	122	122	CD
cord-263455-dquztf5l	503	2	,	,	,
cord-263455-dquztf5l	503	3	123	123	CD
cord-263455-dquztf5l	503	4	,	,	,
cord-263455-dquztf5l	503	5	144	144	CD
cord-263455-dquztf5l	503	6	Subsequent	subsequent	NN
cord-263455-dquztf5l	503	7	to	to	IN
cord-263455-dquztf5l	503	8	the	the	DT
cord-263455-dquztf5l	503	9	publication	publication	NN
cord-263455-dquztf5l	503	10	of	of	IN
cord-263455-dquztf5l	503	11	the	the	DT
cord-263455-dquztf5l	503	12	latest	late	JJS
cord-263455-dquztf5l	503	13	WHO	who	WP
cord-263455-dquztf5l	503	14	guidelines	guideline	NNS
cord-263455-dquztf5l	503	15	that	that	WDT
cord-263455-dquztf5l	503	16	recommend	recommend	VBP
cord-263455-dquztf5l	503	17	implementing	implement	VBG
cord-263455-dquztf5l	503	18	SDR	SDR	NNP
cord-263455-dquztf5l	503	19	-	-	HYPH
cord-263455-dquztf5l	503	20	PEP	PEP	NNP
cord-263455-dquztf5l	503	21	,	,	,
cord-263455-dquztf5l	503	22	many	many	JJ
cord-263455-dquztf5l	503	23	other	other	JJ
cord-263455-dquztf5l	503	24	countries	country	NNS
cord-263455-dquztf5l	503	25	are	be	VBP
cord-263455-dquztf5l	503	26	following	follow	VBG
cord-263455-dquztf5l	503	27	suit	suit	NN
cord-263455-dquztf5l	503	28	.	.	.
cord-263455-dquztf5l	504	1	52	52	CD
cord-263455-dquztf5l	505	1	Recent	recent	JJ
cord-263455-dquztf5l	505	2	modeling	modeling	NN
cord-263455-dquztf5l	505	3	studies	study	NNS
cord-263455-dquztf5l	505	4	at	at	IN
cord-263455-dquztf5l	505	5	Erasmus	Erasmus	NNP
cord-263455-dquztf5l	505	6	MC	MC	NNP
cord-263455-dquztf5l	505	7	Rotterdam	Rotterdam	NNP
cord-263455-dquztf5l	505	8	have	have	VBP
cord-263455-dquztf5l	505	9	estimated	estimate	VBN
cord-263455-dquztf5l	505	10	that	that	IN
cord-263455-dquztf5l	505	11	a	a	DT
cord-263455-dquztf5l	505	12	large	large	JJ
cord-263455-dquztf5l	505	13	-	-	HYPH
cord-263455-dquztf5l	505	14	scale	scale	NN
cord-263455-dquztf5l	505	15	roll	roll	NN
cord-263455-dquztf5l	505	16	-	-	HYPH
cord-263455-dquztf5l	505	17	out	out	NN
cord-263455-dquztf5l	505	18	of	of	IN
cord-263455-dquztf5l	505	19	SDR	SDR	NNP
cord-263455-dquztf5l	505	20	-	-	HYPH
cord-263455-dquztf5l	505	21	PEP	PEP	NNP
cord-263455-dquztf5l	505	22	may	may	MD
cord-263455-dquztf5l	505	23	reduce	reduce	VB
cord-263455-dquztf5l	505	24	the	the	DT
cord-263455-dquztf5l	505	25	incidence	incidence	NN
cord-263455-dquztf5l	505	26	of	of	IN
cord-263455-dquztf5l	505	27	leprosy	leprosy	NN
cord-263455-dquztf5l	505	28	by	by	IN
cord-263455-dquztf5l	505	29	50	50	CD
cord-263455-dquztf5l	505	30	%	%	NN
cord-263455-dquztf5l	505	31	in	in	IN
cord-263455-dquztf5l	505	32	5	5	CD
cord-263455-dquztf5l	505	33	-	-	SYM
cord-263455-dquztf5l	505	34	6	6	CD
cord-263455-dquztf5l	505	35	years	year	NNS
cord-263455-dquztf5l	506	1	(	(	-LRB-
cord-263455-dquztf5l	506	2	Taal	Taal	NNP
cord-263455-dquztf5l	506	3	et	et	NNP
cord-263455-dquztf5l	506	4	al	al	NNP
cord-263455-dquztf5l	506	5	,	,	,
cord-263455-dquztf5l	506	6	under	under	IN
cord-263455-dquztf5l	506	7	publication	publication	NN
cord-263455-dquztf5l	506	8	)	)	-RRB-
cord-263455-dquztf5l	506	9	.	.	.
cord-263455-dquztf5l	507	1	In	in	IN
cord-263455-dquztf5l	507	2	a	a	DT
cord-263455-dquztf5l	507	3	strategy	strategy	NN
cord-263455-dquztf5l	507	4	to	to	TO
cord-263455-dquztf5l	507	5	halt	halt	VB
cord-263455-dquztf5l	507	6	leprosy	leprosy	NN
cord-263455-dquztf5l	507	7	transmission	transmission	NN
cord-263455-dquztf5l	507	8	,	,	,
cord-263455-dquztf5l	507	9	a	a	DT
cord-263455-dquztf5l	507	10	possible	possible	JJ
cord-263455-dquztf5l	507	11	leprosy	leprosy	NN
cord-263455-dquztf5l	507	12	endgame	endgame	NN
cord-263455-dquztf5l	507	13	strategy	strategy	NN
cord-263455-dquztf5l	507	14	was	be	VBD
cord-263455-dquztf5l	507	15	described	describe	VBN
cord-263455-dquztf5l	507	16	comprising	comprise	VBG
cord-263455-dquztf5l	507	17	contact	contact	NN
cord-263455-dquztf5l	507	18	screening	screening	NN
cord-263455-dquztf5l	507	19	and	and	CC
cord-263455-dquztf5l	507	20	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	507	21	.	.	.
cord-263455-dquztf5l	508	1	110	110	CD
cord-263455-dquztf5l	509	1	Additionally	additionally	RB
cord-263455-dquztf5l	509	2	,	,	,
cord-263455-dquztf5l	509	3	the	the	DT
cord-263455-dquztf5l	509	4	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	509	5	Research	Research	NNP
cord-263455-dquztf5l	509	6	Initiative	Initiative	NNP
cord-263455-dquztf5l	509	7	(	(	-LRB-
cord-263455-dquztf5l	509	8	LRI	LRI	NNP
cord-263455-dquztf5l	509	9	)	)	-RRB-
cord-263455-dquztf5l	509	10	and	and	CC
cord-263455-dquztf5l	509	11	the	the	DT
cord-263455-dquztf5l	509	12	Global	Global	NNP
cord-263455-dquztf5l	509	13	Partnership	Partnership	NNP
cord-263455-dquztf5l	509	14	for	for	IN
cord-263455-dquztf5l	509	15	Zero	Zero	NNP
cord-263455-dquztf5l	509	16	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	510	1	(	(	-LRB-
cord-263455-dquztf5l	510	2	GPZL	GPZL	NNP
cord-263455-dquztf5l	510	3	)	)	-RRB-
cord-263455-dquztf5l	510	4	described	describe	VBD
cord-263455-dquztf5l	510	5	research	research	NN
cord-263455-dquztf5l	510	6	priorities	priority	NNS
cord-263455-dquztf5l	510	7	related	relate	VBN
cord-263455-dquztf5l	510	8	to	to	IN
cord-263455-dquztf5l	510	9	PEP	pep	NN
cord-263455-dquztf5l	510	10	.	.	.
cord-263455-dquztf5l	511	1	145	145	CD
cord-263455-dquztf5l	511	2	,	,	,
cord-263455-dquztf5l	511	3	146	146	CD
cord-263455-dquztf5l	511	4	,	,	,
cord-263455-dquztf5l	511	5	155	155	CD
cord-263455-dquztf5l	512	1	This	this	DT
cord-263455-dquztf5l	512	2	included	include	VBD
cord-263455-dquztf5l	512	3	the	the	DT
cord-263455-dquztf5l	512	4	need	need	NN
cord-263455-dquztf5l	512	5	to	to	TO
cord-263455-dquztf5l	512	6	seek	seek	VB
cord-263455-dquztf5l	512	7	more	more	RBR
cord-263455-dquztf5l	512	8	effective	effective	JJ
cord-263455-dquztf5l	512	9	regimens	regimen	NNS
cord-263455-dquztf5l	512	10	,	,	,
cord-263455-dquztf5l	512	11	especially	especially	RB
cord-263455-dquztf5l	512	12	for	for	IN
cord-263455-dquztf5l	512	13	household	household	NN
cord-263455-dquztf5l	512	14	and	and	CC
cord-263455-dquztf5l	512	15	blood	blood	NN
cord-263455-dquztf5l	512	16	-	-	HYPH
cord-263455-dquztf5l	512	17	related	relate	VBN
cord-263455-dquztf5l	512	18	contacts	contact	NNS
cord-263455-dquztf5l	512	19	.	.	.
cord-263455-dquztf5l	513	1	Investments	investment	NNS
cord-263455-dquztf5l	513	2	in	in	IN
cord-263455-dquztf5l	513	3	continued	continue	VBN
cord-263455-dquztf5l	513	4	(	(	-LRB-
cord-263455-dquztf5l	513	5	operational	operational	JJ
cord-263455-dquztf5l	513	6	)	)	-RRB-
cord-263455-dquztf5l	513	7	research	research	NN
cord-263455-dquztf5l	513	8	are	be	VBP
cord-263455-dquztf5l	513	9	needed	need	VBN
cord-263455-dquztf5l	513	10	to	to	TO
cord-263455-dquztf5l	513	11	discover	discover	VB
cord-263455-dquztf5l	513	12	the	the	DT
cord-263455-dquztf5l	513	13	most	most	RBS
cord-263455-dquztf5l	513	14	feasible	feasible	JJ
cord-263455-dquztf5l	513	15	and	and	CC
cord-263455-dquztf5l	513	16	acceptable	acceptable	JJ
cord-263455-dquztf5l	513	17	approaches	approach	NNS
cord-263455-dquztf5l	513	18	to	to	TO
cord-263455-dquztf5l	513	19	integrate	integrate	VB
cord-263455-dquztf5l	513	20	SDR	SDR	NNP
cord-263455-dquztf5l	513	21	-	-	HYPH
cord-263455-dquztf5l	513	22	PEP	PEP	NNP
cord-263455-dquztf5l	513	23	into	into	IN
cord-263455-dquztf5l	513	24	leprosy	leprosy	NN
cord-263455-dquztf5l	513	25	control	control	NN
cord-263455-dquztf5l	513	26	programs	program	NNS
cord-263455-dquztf5l	513	27	in	in	IN
cord-263455-dquztf5l	513	28	different	different	JJ
cord-263455-dquztf5l	513	29	contexts	context	NNS
cord-263455-dquztf5l	513	30	.	.	.
cord-263455-dquztf5l	514	1	Da	Da	NNP
cord-263455-dquztf5l	514	2	Cunha	Cunha	NNP
cord-263455-dquztf5l	514	3	et	et	NNP
cord-263455-dquztf5l	514	4	al	al	NNP
cord-263455-dquztf5l	514	5	recommended	recommend	VBD
cord-263455-dquztf5l	514	6	that	that	IN
cord-263455-dquztf5l	514	7	if	if	IN
cord-263455-dquztf5l	514	8	SDR	SDR	NNP
cord-263455-dquztf5l	514	9	-	-	HYPH
cord-263455-dquztf5l	514	10	PEP	PEP	NNP
cord-263455-dquztf5l	514	11	was	be	VBD
cord-263455-dquztf5l	514	12	implemented	implement	VBN
cord-263455-dquztf5l	514	13	in	in	IN
cord-263455-dquztf5l	514	14	Brazil	Brazil	NNP
cord-263455-dquztf5l	514	15	,	,	,
cord-263455-dquztf5l	514	16	it	-PRON-	PRP
cord-263455-dquztf5l	514	17	should	should	MD
cord-263455-dquztf5l	514	18	start	start	VB
cord-263455-dquztf5l	514	19	on	on	IN
cord-263455-dquztf5l	514	20	a	a	DT
cord-263455-dquztf5l	514	21	small	small	JJ
cord-263455-dquztf5l	514	22	scale	scale	NN
cord-263455-dquztf5l	514	23	,	,	,
cord-263455-dquztf5l	514	24	generating	generate	VBG
cord-263455-dquztf5l	514	25	new	new	JJ
cord-263455-dquztf5l	514	26	evidence	evidence	NN
cord-263455-dquztf5l	514	27	from	from	IN
cord-263455-dquztf5l	514	28	the	the	DT
cord-263455-dquztf5l	514	29	Brazilian	brazilian	JJ
cord-263455-dquztf5l	514	30	context	context	NN
cord-263455-dquztf5l	514	31	.	.	.
cord-263455-dquztf5l	515	1	147	147	CD
cord-263455-dquztf5l	516	1	Several	several	JJ
cord-263455-dquztf5l	516	2	post	post	JJ
cord-263455-dquztf5l	516	3	-	-	JJ
cord-263455-dquztf5l	516	4	exposure	exposure	JJ
cord-263455-dquztf5l	516	5	chemoprophylactic	chemoprophylactic	JJ
cord-263455-dquztf5l	516	6	studies	study	NNS
cord-263455-dquztf5l	516	7	against	against	IN
cord-263455-dquztf5l	516	8	leprosy	leprosy	NN
cord-263455-dquztf5l	516	9	are	be	VBP
cord-263455-dquztf5l	516	10	ongoing	ongoing	JJ
cord-263455-dquztf5l	516	11	.	.	.
cord-263455-dquztf5l	517	1	The	the	DT
cord-263455-dquztf5l	517	2	PEP4LEP	PEP4LEP	NNP
cord-263455-dquztf5l	517	3	project	project	NN
cord-263455-dquztf5l	517	4	in	in	IN
cord-263455-dquztf5l	517	5	Ethiopia	Ethiopia	NNP
cord-263455-dquztf5l	517	6	,	,	,
cord-263455-dquztf5l	517	7	Tanzania	Tanzania	NNP
cord-263455-dquztf5l	517	8	,	,	,
cord-263455-dquztf5l	517	9	and	and	CC
cord-263455-dquztf5l	517	10	Mozambique	Mozambique	NNP
cord-263455-dquztf5l	517	11	compares	compare	VBZ
cord-263455-dquztf5l	517	12	the	the	DT
cord-263455-dquztf5l	517	13	feasibility	feasibility	NN
cord-263455-dquztf5l	517	14	of	of	IN
cord-263455-dquztf5l	517	15	a	a	DT
cord-263455-dquztf5l	517	16	health	health	NN
cord-263455-dquztf5l	517	17	center	center	NN
cord-263455-dquztf5l	517	18	-	-	HYPH
cord-263455-dquztf5l	517	19	based	base	VBN
cord-263455-dquztf5l	517	20	contact	contact	NN
cord-263455-dquztf5l	517	21	approach	approach	NN
cord-263455-dquztf5l	517	22	to	to	IN
cord-263455-dquztf5l	517	23	acommunity	acommunity	NN
cord-263455-dquztf5l	517	24	skin	skin	NN
cord-263455-dquztf5l	517	25	camp	camp	NN
cord-263455-dquztf5l	517	26	-	-	HYPH
cord-263455-dquztf5l	517	27	based	base	VBN
cord-263455-dquztf5l	517	28	approach	approach	NN
cord-263455-dquztf5l	517	29	regarding	regard	VBG
cord-263455-dquztf5l	517	30	integrated	integrated	JJ
cord-263455-dquztf5l	517	31	skin	skin	NN
cord-263455-dquztf5l	517	32	screening	screening	NN
cord-263455-dquztf5l	517	33	and	and	CC
cord-263455-dquztf5l	517	34	SDR	SDR	NNP
cord-263455-dquztf5l	517	35	-	-	HYPH
cord-263455-dquztf5l	517	36	PEP	PEP	NNP
cord-263455-dquztf5l	517	37	administration	administration	NN
cord-263455-dquztf5l	518	1	(	(	-LRB-
cord-263455-dquztf5l	518	2	Schoenmakers	Schoenmakers	NNP
cord-263455-dquztf5l	518	3	et	et	NNP
cord-263455-dquztf5l	518	4	al	al	NNP
cord-263455-dquztf5l	518	5	,	,	,
cord-263455-dquztf5l	518	6	under	under	IN
cord-263455-dquztf5l	518	7	publication	publication	NN
cord-263455-dquztf5l	518	8	)	)	-RRB-
cord-263455-dquztf5l	518	9	.	.	.
cord-263455-dquztf5l	519	1	In	in	IN
cord-263455-dquztf5l	519	2	the	the	DT
cord-263455-dquztf5l	519	3	skin	skin	NN
cord-263455-dquztf5l	519	4	camp	camp	NN
cord-263455-dquztf5l	519	5	group	group	NN
cord-263455-dquztf5l	519	6	,	,	,
cord-263455-dquztf5l	519	7	disclosing	disclose	VBG
cord-263455-dquztf5l	519	8	the	the	DT
cord-263455-dquztf5l	519	9	disease	disease	NN
cord-263455-dquztf5l	519	10	status	status	NN
cord-263455-dquztf5l	519	11	of	of	IN
cord-263455-dquztf5l	519	12	an	an	DT
cord-263455-dquztf5l	519	13	(	(	-LRB-
cord-263455-dquztf5l	519	14	index	index	NN
cord-263455-dquztf5l	519	15	)	)	-RRB-
cord-263455-dquztf5l	519	16	leprosy	leprosy	NN
cord-263455-dquztf5l	519	17	patient	patient	NN
cord-263455-dquztf5l	519	18	is	be	VBZ
cord-263455-dquztf5l	519	19	not	not	RB
cord-263455-dquztf5l	519	20	expected	expect	VBN
cord-263455-dquztf5l	519	21	to	to	TO
cord-263455-dquztf5l	519	22	be	be	VB
cord-263455-dquztf5l	519	23	necessary	necessary	JJ
cord-263455-dquztf5l	519	24	.	.	.
cord-263455-dquztf5l	520	1	Other	other	JJ
cord-263455-dquztf5l	520	2	initiatives	initiative	NNS
cord-263455-dquztf5l	520	3	are	be	VBP
cord-263455-dquztf5l	520	4	working	work	VBG
cord-263455-dquztf5l	520	5	on	on	IN
cord-263455-dquztf5l	520	6	an	an	DT
cord-263455-dquztf5l	520	7	improved	improved	JJ
cord-263455-dquztf5l	520	8	regimen	regimen	NN
cord-263455-dquztf5l	520	9	as	as	IN
cord-263455-dquztf5l	520	10	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	520	11	for	for	IN
cord-263455-dquztf5l	520	12	leprosy	leprosy	NN
cord-263455-dquztf5l	520	13	.	.	.
cord-263455-dquztf5l	521	1	An	an	DT
cord-263455-dquztf5l	521	2	enhanced	enhanced	JJ
cord-263455-dquztf5l	521	3	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	521	4	regimen	regimen	NN
cord-263455-dquztf5l	521	5	is	be	VBZ
cord-263455-dquztf5l	521	6	being	be	VBG
cord-263455-dquztf5l	521	7	tested	test	VBN
cord-263455-dquztf5l	521	8	in	in	IN
cord-263455-dquztf5l	521	9	the	the	DT
cord-263455-dquztf5l	521	10	PEP++project	PEP++project	NNPS
cord-263455-dquztf5l	521	11	,	,	,
cord-263455-dquztf5l	521	12	conducted	conduct	VBN
cord-263455-dquztf5l	521	13	in	in	IN
cord-263455-dquztf5l	521	14	India	India	NNP
cord-263455-dquztf5l	521	15	,	,	,
cord-263455-dquztf5l	521	16	Brazil	Brazil	NNP
cord-263455-dquztf5l	521	17	,	,	,
cord-263455-dquztf5l	521	18	and	and	CC
cord-263455-dquztf5l	521	19	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	521	20	,	,	,
cord-263455-dquztf5l	521	21	comprising	comprise	VBG
cord-263455-dquztf5l	521	22	three	three	CD
cord-263455-dquztf5l	521	23	standard	standard	JJ
cord-263455-dquztf5l	521	24	weight	weight	NN
cord-263455-dquztf5l	521	25	-	-	HYPH
cord-263455-dquztf5l	521	26	adjusted	adjust	VBN
cord-263455-dquztf5l	521	27	single	single	JJ
cord-263455-dquztf5l	521	28	doses	dose	NNS
cord-263455-dquztf5l	521	29	of	of	IN
cord-263455-dquztf5l	521	30	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	521	31	plus	plus	CC
cord-263455-dquztf5l	521	32	clarithromycin	clarithromycin	NNP
cord-263455-dquztf5l	521	33	,	,	,
cord-263455-dquztf5l	521	34	given	give	VBN
cord-263455-dquztf5l	521	35	at	at	IN
cord-263455-dquztf5l	521	36	four	four	CD
cord-263455-dquztf5l	521	37	weekly	weekly	JJ
cord-263455-dquztf5l	521	38	intervals	interval	NNS
cord-263455-dquztf5l	521	39	.	.	.
cord-263455-dquztf5l	522	1	148	148	CD
cord-263455-dquztf5l	523	1	The	the	DT
cord-263455-dquztf5l	523	2	effectiveness	effectiveness	NN
cord-263455-dquztf5l	523	3	of	of	IN
cord-263455-dquztf5l	523	4	PEP++	pep++	NN
cord-263455-dquztf5l	523	5	still	still	RB
cord-263455-dquztf5l	523	6	has	have	VBZ
cord-263455-dquztf5l	523	7	to	to	TO
cord-263455-dquztf5l	523	8	be	be	VB
cord-263455-dquztf5l	523	9	established	establish	VBN
cord-263455-dquztf5l	523	10	but	but	CC
cord-263455-dquztf5l	523	11	is	be	VBZ
cord-263455-dquztf5l	523	12	promising	promise	VBG
cord-263455-dquztf5l	523	13	as	as	IN
cord-263455-dquztf5l	523	14	a	a	DT
cord-263455-dquztf5l	523	15	regimen	regimen	NN
cord-263455-dquztf5l	523	16	.	.	.
cord-263455-dquztf5l	524	1	The	the	DT
cord-263455-dquztf5l	524	2	expert	expert	NN
cord-263455-dquztf5l	524	3	meeting	meeting	NN
cord-263455-dquztf5l	524	4	on	on	IN
cord-263455-dquztf5l	524	5	defining	define	VBG
cord-263455-dquztf5l	524	6	an	an	DT
cord-263455-dquztf5l	524	7	enhanced	enhanced	JJ
cord-263455-dquztf5l	524	8	PEP	pep	NN
cord-263455-dquztf5l	524	9	regimen	regimen	NN
cord-263455-dquztf5l	524	10	for	for	IN
cord-263455-dquztf5l	524	11	leprosy	leprosy	NN
cord-263455-dquztf5l	524	12	discussed	discuss	VBD
cord-263455-dquztf5l	524	13	other	other	JJ
cord-263455-dquztf5l	524	14	options	option	NNS
cord-263455-dquztf5l	524	15	for	for	IN
cord-263455-dquztf5l	524	16	improving	improve	VBG
cord-263455-dquztf5l	524	17	PEP	pep	NN
cord-263455-dquztf5l	524	18	,	,	,
cord-263455-dquztf5l	524	19	including	include	VBG
cord-263455-dquztf5l	524	20	the	the	DT
cord-263455-dquztf5l	524	21	use	use	NN
cord-263455-dquztf5l	524	22	of	of	IN
cord-263455-dquztf5l	524	23	more	more	RBR
cord-263455-dquztf5l	524	24	potent	potent	JJ
cord-263455-dquztf5l	524	25	and/or	and/or	CC
cord-263455-dquztf5l	524	26	longer	long	RBR
cord-263455-dquztf5l	524	27	-	-	HYPH
cord-263455-dquztf5l	524	28	acting	act	VBG
cord-263455-dquztf5l	524	29	antibiotics	antibiotic	NNS
cord-263455-dquztf5l	524	30	,	,	,
cord-263455-dquztf5l	524	31	such	such	JJ
cord-263455-dquztf5l	524	32	as	as	IN
cord-263455-dquztf5l	524	33	bedaquiline	bedaquiline	NNP
cord-263455-dquztf5l	524	34	,	,	,
cord-263455-dquztf5l	524	35	rifapentine	rifapentine	NNP
cord-263455-dquztf5l	524	36	,	,	,
cord-263455-dquztf5l	524	37	oxazolidinone	oxazolidinone	CD
cord-263455-dquztf5l	524	38	,	,	,
cord-263455-dquztf5l	524	39	and	and	CC
cord-263455-dquztf5l	524	40	nitro	nitro	NN
cord-263455-dquztf5l	524	41	-	-	HYPH
cord-263455-dquztf5l	524	42	dihydro	dihydro	NN
cord-263455-dquztf5l	524	43	-	-	HYPH
cord-263455-dquztf5l	524	44	imidazo	imidazo	NNP
cord-263455-dquztf5l	524	45	-	-	HYPH
cord-263455-dquztf5l	524	46	oxazoles	oxazole	NNS
cord-263455-dquztf5l	524	47	.	.	.
cord-263455-dquztf5l	525	1	148	148	CD
cord-263455-dquztf5l	526	1	These	these	DT
cord-263455-dquztf5l	526	2	antibiotics	antibiotic	NNS
cord-263455-dquztf5l	526	3	were	be	VBD
cord-263455-dquztf5l	526	4	excluded	exclude	VBN
cord-263455-dquztf5l	526	5	at	at	IN
cord-263455-dquztf5l	526	6	the	the	DT
cord-263455-dquztf5l	526	7	time	time	NN
cord-263455-dquztf5l	526	8	because	because	IN
cord-263455-dquztf5l	526	9	they	-PRON-	PRP
cord-263455-dquztf5l	526	10	were	be	VBD
cord-263455-dquztf5l	526	11	not	not	RB
cord-263455-dquztf5l	526	12	yet	yet	RB
cord-263455-dquztf5l	526	13	registered	register	VBN
cord-263455-dquztf5l	526	14	in	in	IN
cord-263455-dquztf5l	526	15	the	the	DT
cord-263455-dquztf5l	526	16	countries	country	NNS
cord-263455-dquztf5l	526	17	included	include	VBN
cord-263455-dquztf5l	526	18	in	in	IN
cord-263455-dquztf5l	526	19	the	the	DT
cord-263455-dquztf5l	526	20	PEP++	PEP++	NNP
cord-263455-dquztf5l	526	21	study	study	NN
cord-263455-dquztf5l	526	22	(	(	-LRB-
cord-263455-dquztf5l	526	23	India	India	NNP
cord-263455-dquztf5l	526	24	,	,	,
cord-263455-dquztf5l	526	25	Brazil	Brazil	NNP
cord-263455-dquztf5l	526	26	,	,	,
cord-263455-dquztf5l	526	27	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	526	28	)	)	-RRB-
cord-263455-dquztf5l	526	29	or	or	CC
cord-263455-dquztf5l	526	30	because	because	IN
cord-263455-dquztf5l	526	31	no	no	DT
cord-263455-dquztf5l	526	32	experience	experience	NN
cord-263455-dquztf5l	526	33	was	be	VBD
cord-263455-dquztf5l	526	34	gained	gain	VBN
cord-263455-dquztf5l	526	35	with	with	IN
cord-263455-dquztf5l	526	36	these	these	DT
cord-263455-dquztf5l	526	37	drugs	drug	NNS
cord-263455-dquztf5l	526	38	in	in	IN
cord-263455-dquztf5l	526	39	leprosy	leprosy	NN
cord-263455-dquztf5l	526	40	treatment	treatment	NN
cord-263455-dquztf5l	526	41	.	.	.
cord-263455-dquztf5l	527	1	Clarithromycin	Clarithromycin	NNP
cord-263455-dquztf5l	527	2	was	be	VBD
cord-263455-dquztf5l	527	3	chosen	choose	VBN
cord-263455-dquztf5l	527	4	after	after	IN
cord-263455-dquztf5l	527	5	moxifloxacin	moxifloxacin	NNS
cord-263455-dquztf5l	527	6	was	be	VBD
cord-263455-dquztf5l	527	7	deemed	deem	VBN
cord-263455-dquztf5l	527	8	unsuitable	unsuitable	JJ
cord-263455-dquztf5l	527	9	for	for	IN
cord-263455-dquztf5l	527	10	prophylactic	prophylactic	JJ
cord-263455-dquztf5l	527	11	interventions	intervention	NNS
cord-263455-dquztf5l	527	12	because	because	IN
cord-263455-dquztf5l	527	13	of	of	IN
cord-263455-dquztf5l	527	14	the	the	DT
cord-263455-dquztf5l	527	15	potential	potential	JJ
cord-263455-dquztf5l	527	16	side	side	NN
cord-263455-dquztf5l	527	17	-	-	HYPH
cord-263455-dquztf5l	527	18	effects	effect	NNS
cord-263455-dquztf5l	527	19	(	(	-LRB-
cord-263455-dquztf5l	527	20	publication	publication	NN
cord-263455-dquztf5l	527	21	expected	expect	VBN
cord-263455-dquztf5l	527	22	)	)	-RRB-
cord-263455-dquztf5l	527	23	.	.	.
cord-263455-dquztf5l	528	1	149	149	CD
cord-263455-dquztf5l	529	1	In	in	IN
cord-263455-dquztf5l	529	2	the	the	DT
cord-263455-dquztf5l	529	3	meantime	meantime	NN
cord-263455-dquztf5l	529	4	,	,	,
cord-263455-dquztf5l	529	5	WHO	who	WP
cord-263455-dquztf5l	529	6	has	have	VBZ
cord-263455-dquztf5l	529	7	widely	widely	RB
cord-263455-dquztf5l	529	8	pushed	push	VBN
cord-263455-dquztf5l	529	9	the	the	DT
cord-263455-dquztf5l	529	10	licensing	licensing	NN
cord-263455-dquztf5l	529	11	of	of	IN
cord-263455-dquztf5l	529	12	selected	select	VBN
cord-263455-dquztf5l	529	13	antibiotics	antibiotic	NNS
cord-263455-dquztf5l	529	14	because	because	IN
cord-263455-dquztf5l	529	15	of	of	IN
cord-263455-dquztf5l	529	16	their	-PRON-	PRP$
cord-263455-dquztf5l	529	17	potential	potential	NN
cord-263455-dquztf5l	529	18	as	as	IN
cord-263455-dquztf5l	529	19	second	second	JJ
cord-263455-dquztf5l	529	20	-	-	HYPH
cord-263455-dquztf5l	529	21	line	line	NN
cord-263455-dquztf5l	529	22	treatment	treatment	NN
cord-263455-dquztf5l	529	23	in	in	IN
cord-263455-dquztf5l	529	24	multidrug	multidrug	NN
cord-263455-dquztf5l	529	25	-	-	HYPH
cord-263455-dquztf5l	529	26	resistant	resistant	JJ
cord-263455-dquztf5l	529	27	TB	TB	NNP
cord-263455-dquztf5l	529	28	(	(	-LRB-
cord-263455-dquztf5l	529	29	MDR	MDR	NNP
cord-263455-dquztf5l	529	30	-	-	HYPH
cord-263455-dquztf5l	529	31	TB	TB	NNP
cord-263455-dquztf5l	529	32	)	)	-RRB-
cord-263455-dquztf5l	529	33	,	,	,
cord-263455-dquztf5l	529	34	so	so	CC
cord-263455-dquztf5l	529	35	there	there	EX
cord-263455-dquztf5l	529	36	is	be	VBZ
cord-263455-dquztf5l	529	37	ample	ample	JJ
cord-263455-dquztf5l	529	38	opportunity	opportunity	NN
cord-263455-dquztf5l	529	39	to	to	TO
cord-263455-dquztf5l	529	40	research	research	VB
cord-263455-dquztf5l	529	41	their	-PRON-	PRP$
cord-263455-dquztf5l	529	42	efficacy	efficacy	NN
cord-263455-dquztf5l	529	43	in	in	IN
cord-263455-dquztf5l	529	44	preventive	preventive	JJ
cord-263455-dquztf5l	529	45	chemotherapy	chemotherapy	NN
cord-263455-dquztf5l	529	46	for	for	IN
cord-263455-dquztf5l	529	47	leprosy	leprosy	NN
cord-263455-dquztf5l	529	48	.	.	.
cord-263455-dquztf5l	530	1	The	the	DT
cord-263455-dquztf5l	530	2	advantages	advantage	NNS
cord-263455-dquztf5l	530	3	of	of	IN
cord-263455-dquztf5l	530	4	higher	high	JJR
cord-263455-dquztf5l	530	5	dosages	dosage	NNS
cord-263455-dquztf5l	530	6	of	of	IN
cord-263455-dquztf5l	530	7	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	530	8	as	as	IN
cord-263455-dquztf5l	530	9	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	530	10	are	be	VBP
cord-263455-dquztf5l	530	11	currently	currently	RB
cord-263455-dquztf5l	530	12	being	be	VBG
cord-263455-dquztf5l	530	13	investigated	investigate	VBN
cord-263455-dquztf5l	530	14	by	by	IN
cord-263455-dquztf5l	530	15	the	the	DT
cord-263455-dquztf5l	530	16	PEOPLE	PEOPLE	NNS
cord-263455-dquztf5l	530	17	project	project	NN
cord-263455-dquztf5l	530	18	.	.	.
cord-263455-dquztf5l	531	1	Ortuno	Ortuno	NNP
cord-263455-dquztf5l	531	2	-	-	HYPH
cord-263455-dquztf5l	531	3	Gutierrez	Gutierrez	NNP
cord-263455-dquztf5l	531	4	et	et	NNP
cord-263455-dquztf5l	531	5	al	al	NNP
cord-263455-dquztf5l	531	6	have	have	VBP
cord-263455-dquztf5l	531	7	published	publish	VBN
cord-263455-dquztf5l	531	8	the	the	DT
cord-263455-dquztf5l	531	9	protocol	protocol	NN
cord-263455-dquztf5l	531	10	of	of	IN
cord-263455-dquztf5l	531	11	this	this	DT
cord-263455-dquztf5l	531	12	study	study	NN
cord-263455-dquztf5l	531	13	which	which	WDT
cord-263455-dquztf5l	531	14	is	be	VBZ
cord-263455-dquztf5l	531	15	conducted	conduct	VBN
cord-263455-dquztf5l	531	16	on	on	IN
cord-263455-dquztf5l	531	17	the	the	DT
cord-263455-dquztf5l	531	18	Comoros	Comoros	NNP
cord-263455-dquztf5l	531	19	and	and	CC
cord-263455-dquztf5l	531	20	on	on	IN
cord-263455-dquztf5l	531	21	Madagascar	Madagascar	NNP
cord-263455-dquztf5l	531	22	.	.	.
cord-263455-dquztf5l	532	1	136	136	CD
cord-263455-dquztf5l	532	2	,	,	,
cord-263455-dquztf5l	532	3	146	146	CD
cord-263455-dquztf5l	532	4	Instead	instead	RB
cord-263455-dquztf5l	532	5	of	of	IN
cord-263455-dquztf5l	532	6	the	the	DT
cord-263455-dquztf5l	532	7	10	10	CD
cord-263455-dquztf5l	532	8	mg	mg	NNP
cord-263455-dquztf5l	532	9	/	/	SYM
cord-263455-dquztf5l	532	10	kg	kg	NNS
cord-263455-dquztf5l	532	11	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	532	12	dose	dose	NN
cord-263455-dquztf5l	532	13	which	which	WDT
cord-263455-dquztf5l	532	14	was	be	VBD
cord-263455-dquztf5l	532	15	used	use	VBN
cord-263455-dquztf5l	532	16	in	in	IN
cord-263455-dquztf5l	532	17	the	the	DT
cord-263455-dquztf5l	532	18	COLEP	COLEP	NNP
cord-263455-dquztf5l	532	19	study	study	NN
cord-263455-dquztf5l	532	20	and	and	CC
cord-263455-dquztf5l	532	21	the	the	DT
cord-263455-dquztf5l	532	22	LPEP	LPEP	NNP
cord-263455-dquztf5l	532	23	program	program	NN
cord-263455-dquztf5l	532	24	,	,	,
cord-263455-dquztf5l	532	25	a	a	DT
cord-263455-dquztf5l	532	26	double	double	JJ
cord-263455-dquztf5l	532	27	dose	dose	NN
cord-263455-dquztf5l	532	28	of	of	IN
cord-263455-dquztf5l	532	29	20	20	CD
cord-263455-dquztf5l	532	30	mg	mg	NNP
cord-263455-dquztf5l	532	31	/	/	SYM
cord-263455-dquztf5l	532	32	kg	kg	NNP
cord-263455-dquztf5l	532	33	is	be	VBZ
cord-263455-dquztf5l	532	34	used	use	VBN
cord-263455-dquztf5l	532	35	in	in	IN
cord-263455-dquztf5l	532	36	the	the	DT
cord-263455-dquztf5l	532	37	PEOPLE	PEOPLE	NNS
cord-263455-dquztf5l	532	38	project	project	NN
cord-263455-dquztf5l	532	39	.	.	.
cord-263455-dquztf5l	533	1	The	the	DT
cord-263455-dquztf5l	533	2	study	study	NN
cord-263455-dquztf5l	533	3	will	will	MD
cord-263455-dquztf5l	533	4	use	use	VB
cord-263455-dquztf5l	533	5	an	an	DT
cord-263455-dquztf5l	533	6	anti	anti	JJ
cord-263455-dquztf5l	533	7	-	-	JJ
cord-263455-dquztf5l	533	8	PGL	PGL	NNP
cord-263455-dquztf5l	533	9	-	-	:
cord-263455-dquztf5l	533	10	I	-PRON-	PRP
cord-263455-dquztf5l	533	11	test	test	VBP
cord-263455-dquztf5l	533	12	in	in	IN
cord-263455-dquztf5l	533	13	one	one	CD
cord-263455-dquztf5l	533	14	of	of	IN
cord-263455-dquztf5l	533	15	its	-PRON-	PRP$
cord-263455-dquztf5l	533	16	arms	arm	NNS
cord-263455-dquztf5l	533	17	,	,	,
cord-263455-dquztf5l	533	18	in	in	IN
cord-263455-dquztf5l	533	19	which	which	WDT
cord-263455-dquztf5l	533	20	the	the	DT
cord-263455-dquztf5l	533	21	SDR	SDR	NNP
cord-263455-dquztf5l	533	22	double	double	JJ
cord-263455-dquztf5l	533	23	dose	dose	NN
cord-263455-dquztf5l	533	24	will	will	MD
cord-263455-dquztf5l	533	25	be	be	VB
cord-263455-dquztf5l	533	26	administered	administer	VBN
cord-263455-dquztf5l	533	27	only	only	RB
cord-263455-dquztf5l	533	28	to	to	IN
cord-263455-dquztf5l	533	29	contacts	contact	NNS
cord-263455-dquztf5l	533	30	who	who	WP
cord-263455-dquztf5l	533	31	test	test	VBP
cord-263455-dquztf5l	533	32	positive	positive	JJ
cord-263455-dquztf5l	533	33	for	for	IN
cord-263455-dquztf5l	533	34	the	the	DT
cord-263455-dquztf5l	533	35	anti	anti	JJ
cord-263455-dquztf5l	533	36	-	-	JJ
cord-263455-dquztf5l	533	37	PGL	PGL	NNP
cord-263455-dquztf5l	533	38	-	-	:
cord-263455-dquztf5l	533	39	I	-PRON-	PRP
cord-263455-dquztf5l	533	40	test	test	VBP
cord-263455-dquztf5l	533	41	.	.	.
cord-263455-dquztf5l	534	1	Improved	improved	JJ
cord-263455-dquztf5l	534	2	understanding	understanding	NN
cord-263455-dquztf5l	534	3	of	of	IN
cord-263455-dquztf5l	534	4	leprosy	leprosy	NN
cord-263455-dquztf5l	534	5	transmission	transmission	NN
cord-263455-dquztf5l	534	6	routes	route	NNS
cord-263455-dquztf5l	534	7	will	will	MD
cord-263455-dquztf5l	534	8	facilitate	facilitate	VB
cord-263455-dquztf5l	534	9	the	the	DT
cord-263455-dquztf5l	534	10	design	design	NN
cord-263455-dquztf5l	534	11	of	of	IN
cord-263455-dquztf5l	534	12	targeted	target	VBN
cord-263455-dquztf5l	534	13	interventions	intervention	NNS
cord-263455-dquztf5l	534	14	that	that	WDT
cord-263455-dquztf5l	534	15	complement	complement	VBP
cord-263455-dquztf5l	534	16	early	early	JJ
cord-263455-dquztf5l	534	17	case	case	NN
cord-263455-dquztf5l	534	18	detection	detection	NN
cord-263455-dquztf5l	534	19	and	and	CC
cord-263455-dquztf5l	534	20	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	534	21	.	.	.
cord-263455-dquztf5l	535	1	When	when	WRB
cord-263455-dquztf5l	535	2	a	a	DT
cord-263455-dquztf5l	535	3	fieldfriendly	fieldfriendly	RB
cord-263455-dquztf5l	535	4	diagnostic	diagnostic	JJ
cord-263455-dquztf5l	535	5	(	(	-LRB-
cord-263455-dquztf5l	535	6	rapid	rapid	JJ
cord-263455-dquztf5l	535	7	)	)	-RRB-
cord-263455-dquztf5l	535	8	test	test	NN
cord-263455-dquztf5l	535	9	becomes	become	VBZ
cord-263455-dquztf5l	535	10	available	available	JJ
cord-263455-dquztf5l	535	11	-	-	:
cord-263455-dquztf5l	535	12	especially	especially	RB
cord-263455-dquztf5l	535	13	a	a	DT
cord-263455-dquztf5l	535	14	test	test	NN
cord-263455-dquztf5l	535	15	indicating	indicate	VBG
cord-263455-dquztf5l	535	16	who	who	WP
cord-263455-dquztf5l	535	17	is	be	VBZ
cord-263455-dquztf5l	535	18	infected	infect	VBN
cord-263455-dquztf5l	535	19	with	with	IN
cord-263455-dquztf5l	535	20	M.	M.	NNP
cord-263455-dquztf5l	535	21	leprae	leprae	NNP
cord-263455-dquztf5l	535	22	,	,	,
cord-263455-dquztf5l	535	23	incubating	incubate	VBG
cord-263455-dquztf5l	535	24	and	and	CC
cord-263455-dquztf5l	535	25	transmitting	transmit	VBG
cord-263455-dquztf5l	535	26	leprosy	leprosy	NN
cord-263455-dquztf5l	535	27	before	before	IN
cord-263455-dquztf5l	535	28	signs	sign	NNS
cord-263455-dquztf5l	535	29	or	or	CC
cord-263455-dquztf5l	535	30	symptoms	symptom	NNS
cord-263455-dquztf5l	535	31	occur	occur	VBP
cord-263455-dquztf5l	535	32	-	-	HYPH
cord-263455-dquztf5l	535	33	targeted	target	VBN
cord-263455-dquztf5l	535	34	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	535	35	for	for	IN
cord-263455-dquztf5l	535	36	leprosy	leprosy	NN
cord-263455-dquztf5l	535	37	in	in	IN
cord-263455-dquztf5l	535	38	certain	certain	JJ
cord-263455-dquztf5l	535	39	groups	group	NNS
cord-263455-dquztf5l	535	40	,	,	,
cord-263455-dquztf5l	535	41	such	such	JJ
cord-263455-dquztf5l	535	42	as	as	IN
cord-263455-dquztf5l	535	43	household	household	NN
cord-263455-dquztf5l	535	44	members	member	NNS
cord-263455-dquztf5l	535	45	,	,	,
cord-263455-dquztf5l	535	46	would	would	MD
cord-263455-dquztf5l	535	47	be	be	VB
cord-263455-dquztf5l	535	48	an	an	DT
cord-263455-dquztf5l	535	49	option	option	NN
cord-263455-dquztf5l	535	50	.	.	.
cord-263455-dquztf5l	536	1	146	146	CD
cord-263455-dquztf5l	536	2	,	,	,
cord-263455-dquztf5l	536	3	150	150	CD
cord-263455-dquztf5l	536	4	,	,	,
cord-263455-dquztf5l	536	5	151	151	CD
cord-263455-dquztf5l	536	6	Such	such	JJ
cord-263455-dquztf5l	536	7	a	a	DT
cord-263455-dquztf5l	536	8	test	test	NN
cord-263455-dquztf5l	536	9	would	would	MD
cord-263455-dquztf5l	536	10	allow	allow	VB
cord-263455-dquztf5l	536	11	a	a	DT
cord-263455-dquztf5l	536	12	more	more	RBR
cord-263455-dquztf5l	536	13	tailored	tailor	VBN
cord-263455-dquztf5l	536	14	approach	approach	NN
cord-263455-dquztf5l	536	15	at	at	IN
cord-263455-dquztf5l	536	16	the	the	DT
cord-263455-dquztf5l	536	17	individual	individual	JJ
cord-263455-dquztf5l	536	18	level	level	NN
cord-263455-dquztf5l	536	19	(	(	-LRB-
cord-263455-dquztf5l	536	20	personalized	personalized	JJ
cord-263455-dquztf5l	536	21	medicine	medicine	NN
cord-263455-dquztf5l	536	22	)	)	-RRB-
cord-263455-dquztf5l	536	23	,	,	,
cord-263455-dquztf5l	536	24	which	which	WDT
cord-263455-dquztf5l	536	25	may	may	MD
cord-263455-dquztf5l	536	26	increase	increase	VB
cord-263455-dquztf5l	536	27	efficacy	efficacy	NN
cord-263455-dquztf5l	536	28	of	of	IN
cord-263455-dquztf5l	536	29	PEP	pep	NN
cord-263455-dquztf5l	536	30	for	for	IN
cord-263455-dquztf5l	536	31	blood	blood	NN
cord-263455-dquztf5l	536	32	-	-	HYPH
cord-263455-dquztf5l	536	33	related	relate	VBN
cord-263455-dquztf5l	536	34	household	household	NN
cord-263455-dquztf5l	536	35	and	and	CC
cord-263455-dquztf5l	536	36	other	other	JJ
cord-263455-dquztf5l	536	37	high	high	JJ
cord-263455-dquztf5l	536	38	-	-	HYPH
cord-263455-dquztf5l	536	39	risk	risk	NN
cord-263455-dquztf5l	536	40	contacts	contact	NNS
cord-263455-dquztf5l	536	41	.	.	.
cord-263455-dquztf5l	537	1	146	146	CD
cord-263455-dquztf5l	538	1	The	the	DT
cord-263455-dquztf5l	538	2	GPZL	GPZL	NNP
cord-263455-dquztf5l	538	3	PEP	PEP	NNP
cord-263455-dquztf5l	538	4	research	research	NN
cord-263455-dquztf5l	538	5	agenda	agenda	NN
cord-263455-dquztf5l	538	6	includes	include	VBZ
cord-263455-dquztf5l	538	7	the	the	DT
cord-263455-dquztf5l	538	8	question	question	NN
cord-263455-dquztf5l	538	9	:	:	:
cord-263455-dquztf5l	538	10	"	"	``
cord-263455-dquztf5l	538	11	Which	which	WDT
cord-263455-dquztf5l	538	12	type	type	NN
cord-263455-dquztf5l	538	13	of	of	IN
cord-263455-dquztf5l	538	14	PEP	pep	NN
cord-263455-dquztf5l	538	15	intervention	intervention	NN
cord-263455-dquztf5l	538	16	fits	fit	VBZ
cord-263455-dquztf5l	538	17	best	best	RB
cord-263455-dquztf5l	538	18	with	with	IN
cord-263455-dquztf5l	538	19	which	which	WDT
cord-263455-dquztf5l	538	20	epidemiological	epidemiological	JJ
cord-263455-dquztf5l	538	21	setting	setting	NN
cord-263455-dquztf5l	538	22	?	?	.
cord-263455-dquztf5l	538	23	"	"	''
cord-263455-dquztf5l	538	24	,	,	,
cord-263455-dquztf5l	538	25	which	which	WDT
cord-263455-dquztf5l	538	26	requires	require	VBZ
cord-263455-dquztf5l	538	27	more	more	JJR
cord-263455-dquztf5l	538	28	operational	operational	JJ
cord-263455-dquztf5l	538	29	research	research	NN
cord-263455-dquztf5l	538	30	.	.	.
cord-263455-dquztf5l	539	1	146	146	CD
cord-263455-dquztf5l	540	1	In	in	IN
cord-263455-dquztf5l	540	2	very	very	RB
cord-263455-dquztf5l	540	3	high	high	RB
cord-263455-dquztf5l	540	4	-	-	HYPH
cord-263455-dquztf5l	540	5	endemic	endemic	JJ
cord-263455-dquztf5l	540	6	hotspot	hotspot	NN
cord-263455-dquztf5l	540	7	or	or	CC
cord-263455-dquztf5l	540	8	cluster	cluster	NN
cord-263455-dquztf5l	540	9	areas	area	NNS
cord-263455-dquztf5l	540	10	,	,	,
cord-263455-dquztf5l	540	11	a	a	DT
cord-263455-dquztf5l	540	12	total	total	JJ
cord-263455-dquztf5l	540	13	population	population	NN
cord-263455-dquztf5l	540	14	screening	screening	NN
cord-263455-dquztf5l	540	15	and	and	CC
cord-263455-dquztf5l	540	16	SDR	SDR	NNP
cord-263455-dquztf5l	540	17	-	-	HYPH
cord-263455-dquztf5l	540	18	PEP	PEP	NNP
cord-263455-dquztf5l	540	19	administration	administration	NN
cord-263455-dquztf5l	540	20	may	may	MD
cord-263455-dquztf5l	540	21	be	be	VB
cord-263455-dquztf5l	540	22	the	the	DT
cord-263455-dquztf5l	540	23	best	good	JJS
cord-263455-dquztf5l	540	24	approach	approach	NN
cord-263455-dquztf5l	540	25	.	.	.
cord-263455-dquztf5l	541	1	101	101	CD
cord-263455-dquztf5l	541	2	,	,	,
cord-263455-dquztf5l	541	3	116	116	CD
cord-263455-dquztf5l	542	1	However	however	RB
cord-263455-dquztf5l	542	2	,	,	,
cord-263455-dquztf5l	542	3	when	when	WRB
cord-263455-dquztf5l	542	4	screening	screen	VBG
cord-263455-dquztf5l	542	5	entire	entire	JJ
cord-263455-dquztf5l	542	6	populations	population	NNS
cord-263455-dquztf5l	542	7	is	be	VBZ
cord-263455-dquztf5l	542	8	neither	neither	CC
cord-263455-dquztf5l	542	9	feasible	feasible	JJ
cord-263455-dquztf5l	542	10	nor	nor	CC
cord-263455-dquztf5l	542	11	affordable	affordable	JJ
cord-263455-dquztf5l	542	12	,	,	,
cord-263455-dquztf5l	542	13	focal	focal	JJ
cord-263455-dquztf5l	542	14	mass	mass	JJ
cord-263455-dquztf5l	542	15	drug	drug	NN
cord-263455-dquztf5l	542	16	administration	administration	NNP
cord-263455-dquztf5l	542	17	(	(	-LRB-
cord-263455-dquztf5l	542	18	fMDA	fmda	NN
cord-263455-dquztf5l	542	19	)	)	-RRB-
cord-263455-dquztf5l	542	20	may	may	MD
cord-263455-dquztf5l	542	21	be	be	VB
cord-263455-dquztf5l	542	22	a	a	DT
cord-263455-dquztf5l	542	23	reasonable	reasonable	JJ
cord-263455-dquztf5l	542	24	alternative	alternative	NN
cord-263455-dquztf5l	542	25	.	.	.
cord-263455-dquztf5l	543	1	152	152	CD
cord-263455-dquztf5l	544	1	The	the	DT
cord-263455-dquztf5l	544	2	fMDA	fmda	JJ
cord-263455-dquztf5l	544	3	approach	approach	NN
cord-263455-dquztf5l	544	4	would	would	MD
cord-263455-dquztf5l	544	5	target	target	VB
cord-263455-dquztf5l	544	6	the	the	DT
cord-263455-dquztf5l	544	7	population	population	NN
cord-263455-dquztf5l	544	8	who	who	WP
cord-263455-dquztf5l	544	9	are	be	VBP
cord-263455-dquztf5l	544	10	not	not	RB
cord-263455-dquztf5l	544	11	included	include	VBN
cord-263455-dquztf5l	544	12	in	in	IN
cord-263455-dquztf5l	544	13	a	a	DT
cord-263455-dquztf5l	544	14	contact	contact	NN
cord-263455-dquztf5l	544	15	-	-	HYPH
cord-263455-dquztf5l	544	16	based	base	VBN
cord-263455-dquztf5l	544	17	PEP	pep	NN
cord-263455-dquztf5l	544	18	approach	approach	NN
cord-263455-dquztf5l	544	19	and	and	CC
cord-263455-dquztf5l	544	20	would	would	MD
cord-263455-dquztf5l	544	21	be	be	VB
cord-263455-dquztf5l	544	22	implemented	implement	VBN
cord-263455-dquztf5l	544	23	alongside	alongside	IN
cord-263455-dquztf5l	544	24	contact	contact	NN
cord-263455-dquztf5l	544	25	-	-	HYPH
cord-263455-dquztf5l	544	26	based	base	VBN
cord-263455-dquztf5l	544	27	PEP	pep	NN
cord-263455-dquztf5l	544	28	.	.	.
cord-263455-dquztf5l	545	1	The	the	DT
cord-263455-dquztf5l	545	2	effectiveness	effectiveness	NN
cord-263455-dquztf5l	545	3	and	and	CC
cord-263455-dquztf5l	545	4	feasibility	feasibility	NN
cord-263455-dquztf5l	545	5	of	of	IN
cord-263455-dquztf5l	545	6	such	such	PDT
cord-263455-dquztf5l	545	7	an	an	DT
cord-263455-dquztf5l	545	8	approach	approach	NN
cord-263455-dquztf5l	545	9	first	first	RB
cord-263455-dquztf5l	545	10	needs	need	VBZ
cord-263455-dquztf5l	545	11	to	to	TO
cord-263455-dquztf5l	545	12	be	be	VB
cord-263455-dquztf5l	545	13	tested	test	VBN
cord-263455-dquztf5l	545	14	in	in	IN
cord-263455-dquztf5l	545	15	a	a	DT
cord-263455-dquztf5l	545	16	randomized	randomized	JJ
cord-263455-dquztf5l	545	17	controlled	control	VBN
cord-263455-dquztf5l	545	18	trial	trial	NN
cord-263455-dquztf5l	545	19	.	.	.
cord-263455-dquztf5l	546	1	Variations	variation	NNS
cord-263455-dquztf5l	546	2	on	on	IN
cord-263455-dquztf5l	546	3	screening	screening	NN
cord-263455-dquztf5l	546	4	,	,	,
cord-263455-dquztf5l	546	5	such	such	JJ
cord-263455-dquztf5l	546	6	as	as	IN
cord-263455-dquztf5l	546	7	self	self	NN
cord-263455-dquztf5l	546	8	-	-	HYPH
cord-263455-dquztf5l	546	9	screening	screening	NN
cord-263455-dquztf5l	546	10	or	or	CC
cord-263455-dquztf5l	546	11	self	self	NN
cord-263455-dquztf5l	546	12	-	-	HYPH
cord-263455-dquztf5l	546	13	referred	refer	VBN
cord-263455-dquztf5l	546	14	screening	screening	NN
cord-263455-dquztf5l	546	15	only	only	RB
cord-263455-dquztf5l	546	16	,	,	,
cord-263455-dquztf5l	546	17	need	need	VBP
cord-263455-dquztf5l	546	18	to	to	TO
cord-263455-dquztf5l	546	19	be	be	VB
cord-263455-dquztf5l	546	20	evaluated	evaluate	VBN
cord-263455-dquztf5l	546	21	.	.	.
cord-263455-dquztf5l	547	1	An	an	DT
cord-263455-dquztf5l	547	2	additional	additional	JJ
cord-263455-dquztf5l	547	3	benefit	benefit	NN
cord-263455-dquztf5l	547	4	of	of	IN
cord-263455-dquztf5l	547	5	fMDA	fMDA	NNS
cord-263455-dquztf5l	547	6	would	would	MD
cord-263455-dquztf5l	547	7	be	be	VB
cord-263455-dquztf5l	547	8	that	that	IN
cord-263455-dquztf5l	547	9	it	-PRON-	PRP
cord-263455-dquztf5l	547	10	is	be	VBZ
cord-263455-dquztf5l	547	11	especially	especially	RB
cord-263455-dquztf5l	547	12	suitable	suitable	JJ
cord-263455-dquztf5l	547	13	in	in	IN
cord-263455-dquztf5l	547	14	areas	area	NNS
cord-263455-dquztf5l	547	15	where	where	WRB
cord-263455-dquztf5l	547	16	stigma	stigma	NN
cord-263455-dquztf5l	547	17	prevents	prevent	VBZ
cord-263455-dquztf5l	547	18	patients	patient	NNS
cord-263455-dquztf5l	547	19	from	from	IN
cord-263455-dquztf5l	547	20	disclosing	disclose	VBG
cord-263455-dquztf5l	547	21	their	-PRON-	PRP$
cord-263455-dquztf5l	547	22	disease	disease	NN
cord-263455-dquztf5l	547	23	status	status	NN
cord-263455-dquztf5l	547	24	.	.	.
cord-263455-dquztf5l	548	1	Questions	question	NNS
cord-263455-dquztf5l	548	2	concerning	concern	VBG
cord-263455-dquztf5l	548	3	disease	disease	NN
cord-263455-dquztf5l	548	4	concealment	concealment	NN
cord-263455-dquztf5l	548	5	for	for	IN
cord-263455-dquztf5l	548	6	index	index	NN
cord-263455-dquztf5l	548	7	patients	patient	NNS
cord-263455-dquztf5l	548	8	,	,	,
cord-263455-dquztf5l	548	9	optimal	optimal	JJ
cord-263455-dquztf5l	548	10	contact	contact	NN
cord-263455-dquztf5l	548	11	and	and	CC
cord-263455-dquztf5l	548	12	community	community	NN
cord-263455-dquztf5l	548	13	education	education	NN
cord-263455-dquztf5l	548	14	(	(	-LRB-
cord-263455-dquztf5l	548	15	eg	eg	RB
cord-263455-dquztf5l	548	16	,	,	,
cord-263455-dquztf5l	548	17	regarding	regard	VBG
cord-263455-dquztf5l	548	18	the	the	DT
cord-263455-dquztf5l	548	19	fact	fact	NN
cord-263455-dquztf5l	548	20	that	that	IN
cord-263455-dquztf5l	548	21	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	548	22	is	be	VBZ
cord-263455-dquztf5l	548	23	not	not	RB
cord-263455-dquztf5l	548	24	100	100	CD
cord-263455-dquztf5l	548	25	%	%	NN
cord-263455-dquztf5l	548	26	effective	effective	JJ
cord-263455-dquztf5l	548	27	)	)	-RRB-
cord-263455-dquztf5l	548	28	,	,	,
cord-263455-dquztf5l	548	29	and	and	CC
cord-263455-dquztf5l	548	30	the	the	DT
cord-263455-dquztf5l	548	31	quality	quality	NN
cord-263455-dquztf5l	548	32	of	of	IN
cord-263455-dquztf5l	548	33	leprosy	leprosy	NN
cord-263455-dquztf5l	548	34	screening	screening	NN
cord-263455-dquztf5l	548	35	by	by	IN
cord-263455-dquztf5l	548	36	health	health	NN
cord-263455-dquztf5l	548	37	workers	worker	NNS
cord-263455-dquztf5l	548	38	need	need	VBP
cord-263455-dquztf5l	548	39	to	to	TO
cord-263455-dquztf5l	548	40	be	be	VB
cord-263455-dquztf5l	548	41	addressed	address	VBN
cord-263455-dquztf5l	548	42	in	in	IN
cord-263455-dquztf5l	548	43	future	future	JJ
cord-263455-dquztf5l	548	44	research	research	NN
cord-263455-dquztf5l	548	45	projects	project	NNS
cord-263455-dquztf5l	548	46	.	.	.
cord-263455-dquztf5l	549	1	146	146	CD
cord-263455-dquztf5l	550	1	Another	another	DT
cord-263455-dquztf5l	550	2	important	important	JJ
cord-263455-dquztf5l	550	3	topic	topic	NN
cord-263455-dquztf5l	550	4	is	be	VBZ
cord-263455-dquztf5l	550	5	antibiotic	antibiotic	JJ
cord-263455-dquztf5l	550	6	resistance	resistance	NN
cord-263455-dquztf5l	550	7	.	.	.
cord-263455-dquztf5l	551	1	Even	even	RB
cord-263455-dquztf5l	551	2	though	though	IN
cord-263455-dquztf5l	551	3	the	the	DT
cord-263455-dquztf5l	551	4	risk	risk	NN
cord-263455-dquztf5l	551	5	of	of	IN
cord-263455-dquztf5l	551	6	inducing	induce	VBG
cord-263455-dquztf5l	551	7	rifampicin	rifampicin	NN
cord-263455-dquztf5l	551	8	resistance	resistance	NN
cord-263455-dquztf5l	551	9	in	in	IN
cord-263455-dquztf5l	551	10	M.	M.	NNP
cord-263455-dquztf5l	551	11	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	551	12	is	be	VBZ
cord-263455-dquztf5l	551	13	considered	consider	VBN
cord-263455-dquztf5l	551	14	negligible	negligible	JJ
cord-263455-dquztf5l	551	15	,	,	,
cord-263455-dquztf5l	551	16	regular	regular	JJ
cord-263455-dquztf5l	551	17	sampling	sampling	NN
cord-263455-dquztf5l	551	18	and	and	CC
cord-263455-dquztf5l	551	19	molecular	molecular	JJ
cord-263455-dquztf5l	551	20	monitoring	monitoring	NN
cord-263455-dquztf5l	551	21	for	for	IN
cord-263455-dquztf5l	551	22	mutations	mutation	NNS
cord-263455-dquztf5l	551	23	associated	associate	VBN
cord-263455-dquztf5l	551	24	with	with	IN
cord-263455-dquztf5l	551	25	rifampicin	rifampicin	JJ
cord-263455-dquztf5l	551	26	resistance	resistance	NN
cord-263455-dquztf5l	551	27	in	in	IN
cord-263455-dquztf5l	551	28	M.	M.	NNP
cord-263455-dquztf5l	551	29	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	551	30	and	and	CC
cord-263455-dquztf5l	551	31	in	in	IN
cord-263455-dquztf5l	551	32	M.	M.	NNP
cord-263455-dquztf5l	551	33	leprae	leprae	NNP
cord-263455-dquztf5l	551	34	as	as	IN
cord-263455-dquztf5l	551	35	recommended	recommend	VBN
cord-263455-dquztf5l	551	36	by	by	IN
cord-263455-dquztf5l	551	37	WHO	who	WP
cord-263455-dquztf5l	551	38	are	be	VBP
cord-263455-dquztf5l	551	39	encouraged	encourage	VBN
cord-263455-dquztf5l	551	40	in	in	IN
cord-263455-dquztf5l	551	41	areas	area	NNS
cord-263455-dquztf5l	551	42	with	with	IN
cord-263455-dquztf5l	551	43	a	a	DT
cord-263455-dquztf5l	551	44	high	high	JJ
cord-263455-dquztf5l	551	45	rate	rate	NN
cord-263455-dquztf5l	551	46	of	of	IN
cord-263455-dquztf5l	551	47	primary	primary	JJ
cord-263455-dquztf5l	551	48	MDR	MDR	NNP
cord-263455-dquztf5l	551	49	-	-	HYPH
cord-263455-dquztf5l	551	50	TB	TB	NNP
cord-263455-dquztf5l	551	51	and	and	CC
cord-263455-dquztf5l	551	52	among	among	IN
cord-263455-dquztf5l	551	53	recipients	recipient	NNS
cord-263455-dquztf5l	551	54	of	of	IN
cord-263455-dquztf5l	551	55	SDR	SDR	NNP
cord-263455-dquztf5l	551	56	-	-	HYPH
cord-263455-dquztf5l	551	57	PEP	PEP	NNP
cord-263455-dquztf5l	551	58	who	who	WP
cord-263455-dquztf5l	551	59	develop	develop	VBP
cord-263455-dquztf5l	551	60	leprosy	leprosy	NN
cord-263455-dquztf5l	551	61	.	.	.
cord-263455-dquztf5l	552	1	113	113	CD
cord-263455-dquztf5l	552	2	,	,	,
cord-263455-dquztf5l	552	3	146	146	CD
cord-263455-dquztf5l	552	4	,	,	,
cord-263455-dquztf5l	552	5	153	153	CD
cord-263455-dquztf5l	552	6	Additionally	additionally	RB
cord-263455-dquztf5l	552	7	,	,	,
cord-263455-dquztf5l	552	8	loose	loose	JJ
cord-263455-dquztf5l	552	9	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	552	10	that	that	WDT
cord-263455-dquztf5l	552	11	can	can	MD
cord-263455-dquztf5l	552	12	be	be	VB
cord-263455-dquztf5l	552	13	used	use	VBN
cord-263455-dquztf5l	552	14	as	as	IN
cord-263455-dquztf5l	552	15	SDR	SDR	NNP
cord-263455-dquztf5l	552	16	-	-	HYPH
cord-263455-dquztf5l	552	17	PEP	PEP	NNP
cord-263455-dquztf5l	552	18	for	for	IN
cord-263455-dquztf5l	552	19	leprosy	leprosy	NN
cord-263455-dquztf5l	552	20	prevention	prevention	NN
cord-263455-dquztf5l	552	21	is	be	VBZ
cord-263455-dquztf5l	552	22	urgently	urgently	RB
cord-263455-dquztf5l	552	23	needed	need	VBN
cord-263455-dquztf5l	552	24	and	and	CC
cord-263455-dquztf5l	552	25	should	should	MD
cord-263455-dquztf5l	552	26	be	be	VB
cord-263455-dquztf5l	552	27	made	make	VBN
cord-263455-dquztf5l	552	28	available	available	JJ
cord-263455-dquztf5l	552	29	on	on	IN
cord-263455-dquztf5l	552	30	a	a	DT
cord-263455-dquztf5l	552	31	global	global	JJ
cord-263455-dquztf5l	552	32	scale	scale	NN
cord-263455-dquztf5l	552	33	to	to	TO
cord-263455-dquztf5l	552	34	facilitate	facilitate	VB
cord-263455-dquztf5l	552	35	further	further	JJ
cord-263455-dquztf5l	552	36	SDR	SDR	NNP
cord-263455-dquztf5l	552	37	-	-	HYPH
cord-263455-dquztf5l	552	38	PEP	PEP	NNP
cord-263455-dquztf5l	552	39	implementation	implementation	NN
cord-263455-dquztf5l	552	40	.	.	.
cord-263455-dquztf5l	553	1	Rifampicin	Rifampicin	NNP
cord-263455-dquztf5l	553	2	is	be	VBZ
cord-263455-dquztf5l	553	3	relatively	relatively	RB
cord-263455-dquztf5l	553	4	cheap	cheap	JJ
cord-263455-dquztf5l	553	5	,	,	,
cord-263455-dquztf5l	553	6	and	and	CC
cord-263455-dquztf5l	553	7	its	-PRON-	PRP$
cord-263455-dquztf5l	553	8	cost	cost	NN
cord-263455-dquztf5l	553	9	-	-	HYPH
cord-263455-dquztf5l	553	10	effectiveness	effectiveness	NN
cord-263455-dquztf5l	553	11	was	be	VBD
cord-263455-dquztf5l	553	12	assessed	assess	VBN
cord-263455-dquztf5l	553	13	to	to	TO
cord-263455-dquztf5l	553	14	be	be	VB
cord-263455-dquztf5l	553	15	good	good	JJ
cord-263455-dquztf5l	553	16	in	in	IN
cord-263455-dquztf5l	553	17	the	the	DT
cord-263455-dquztf5l	553	18	COLEP	COLEP	NNP
cord-263455-dquztf5l	553	19	study	study	NN
cord-263455-dquztf5l	553	20	,	,	,
cord-263455-dquztf5l	553	21	and	and	CC
cord-263455-dquztf5l	553	22	also	also	RB
cord-263455-dquztf5l	553	23	in	in	IN
cord-263455-dquztf5l	553	24	India	India	NNP
cord-263455-dquztf5l	553	25	,	,	,
cord-263455-dquztf5l	553	26	based	base	VBN
cord-263455-dquztf5l	553	27	on	on	IN
cord-263455-dquztf5l	553	28	the	the	DT
cord-263455-dquztf5l	553	29	SIMCOLEP	SIMCOLEP	NNP
cord-263455-dquztf5l	553	30	model	model	NN
cord-263455-dquztf5l	553	31	and	and	CC
cord-263455-dquztf5l	553	32	the	the	DT
cord-263455-dquztf5l	553	33	LPEP	LPEP	NNP
cord-263455-dquztf5l	553	34	program	program	NN
cord-263455-dquztf5l	553	35	.	.	.
cord-263455-dquztf5l	554	1	97	97	CD
cord-263455-dquztf5l	554	2	,	,	,
cord-263455-dquztf5l	554	3	116	116	CD
cord-263455-dquztf5l	554	4	Through	through	IN
cord-263455-dquztf5l	554	5	the	the	DT
cord-263455-dquztf5l	554	6	Stop	Stop	NNP
cord-263455-dquztf5l	554	7	TB	TB	NNP
cord-263455-dquztf5l	554	8	Partnership	Partnership	NNP
cord-263455-dquztf5l	554	9	/	/	SYM
cord-263455-dquztf5l	554	10	Global	Global	NNP
cord-263455-dquztf5l	554	11	Drug	Drug	NNP
cord-263455-dquztf5l	554	12	Facility	Facility	NNP
cord-263455-dquztf5l	554	13	,	,	,
cord-263455-dquztf5l	554	14	100	100	CD
cord-263455-dquztf5l	554	15	dosages	dosage	NNS
cord-263455-dquztf5l	554	16	of	of	IN
cord-263455-dquztf5l	554	17	150	150	CD
cord-263455-dquztf5l	554	18	mg	mg	NNS
cord-263455-dquztf5l	554	19	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	554	20	cost	cost	VBD
cord-263455-dquztf5l	554	21	US$	us$	$
cord-263455-dquztf5l	554	22	6.33	6.33	CD
cord-263455-dquztf5l	554	23	,	,	,
cord-263455-dquztf5l	554	24	and	and	CC
cord-263455-dquztf5l	554	25	100	100	CD
cord-263455-dquztf5l	554	26	dosages	dosage	NNS
cord-263455-dquztf5l	554	27	of	of	IN
cord-263455-dquztf5l	554	28	300	300	CD
cord-263455-dquztf5l	554	29	mg	mg	NN
cord-263455-dquztf5l	554	30	cost	cost	VBD
cord-263455-dquztf5l	554	31	around	around	IN
cord-263455-dquztf5l	554	32	US$	us$	$
cord-263455-dquztf5l	554	33	10	10	CD
cord-263455-dquztf5l	554	34	.	.	.
cord-263455-dquztf5l	555	1	154	154	CD
cord-263455-dquztf5l	556	1	But	but	CC
cord-263455-dquztf5l	556	2	SDR	SDR	NNP
cord-263455-dquztf5l	556	3	-	-	HYPH
cord-263455-dquztf5l	556	4	PEP	PEP	NNP
cord-263455-dquztf5l	556	5	still	still	RB
cord-263455-dquztf5l	556	6	requires	require	VBZ
cord-263455-dquztf5l	556	7	an	an	DT
cord-263455-dquztf5l	556	8	initial	initial	JJ
cord-263455-dquztf5l	556	9	investment	investment	NN
cord-263455-dquztf5l	556	10	from	from	IN
cord-263455-dquztf5l	556	11	national	national	JJ
cord-263455-dquztf5l	556	12	leprosy	leprosy	NN
cord-263455-dquztf5l	556	13	control	control	NN
cord-263455-dquztf5l	556	14	programs	program	NNS
cord-263455-dquztf5l	556	15	in	in	IN
cord-263455-dquztf5l	556	16	often	often	RB
cord-263455-dquztf5l	556	17	resource	resource	NN
cord-263455-dquztf5l	556	18	-	-	HYPH
cord-263455-dquztf5l	556	19	poor	poor	JJ
cord-263455-dquztf5l	556	20	settings	setting	NNS
cord-263455-dquztf5l	556	21	,	,	,
cord-263455-dquztf5l	556	22	especially	especially	RB
cord-263455-dquztf5l	556	23	when	when	WRB
cord-263455-dquztf5l	556	24	SDR	SDR	NNP
cord-263455-dquztf5l	556	25	-	-	HYPH
cord-263455-dquztf5l	556	26	PEP	PEP	NNP
cord-263455-dquztf5l	556	27	administration	administration	NN
cord-263455-dquztf5l	556	28	is	be	VBZ
cord-263455-dquztf5l	556	29	-	-	:
cord-263455-dquztf5l	556	30	as	as	IN
cord-263455-dquztf5l	556	31	recommended	recommend	VBN
cord-263455-dquztf5l	556	32	-	-	HYPH
cord-263455-dquztf5l	556	33	combined	combine	VBN
cord-263455-dquztf5l	556	34	with	with	IN
cord-263455-dquztf5l	556	35	screening	screening	NN
cord-263455-dquztf5l	556	36	and	and	CC
cord-263455-dquztf5l	556	37	active	active	JJ
cord-263455-dquztf5l	556	38	case	case	NN
cord-263455-dquztf5l	556	39	-	-	HYPH
cord-263455-dquztf5l	556	40	finding	find	VBG
cord-263455-dquztf5l	556	41	activities	activity	NNS
cord-263455-dquztf5l	556	42	.	.	.
cord-263455-dquztf5l	557	1	52	52	CD
cord-263455-dquztf5l	557	2	,	,	,
cord-263455-dquztf5l	557	3	150	150	CD
cord-263455-dquztf5l	557	4	Free	free	JJ
cord-263455-dquztf5l	557	5	provision	provision	NN
cord-263455-dquztf5l	557	6	,	,	,
cord-263455-dquztf5l	557	7	similar	similar	JJ
cord-263455-dquztf5l	557	8	to	to	IN
cord-263455-dquztf5l	557	9	MDT	MDT	NNP
cord-263455-dquztf5l	557	10	,	,	,
cord-263455-dquztf5l	557	11	would	would	MD
cord-263455-dquztf5l	557	12	be	be	VB
cord-263455-dquztf5l	557	13	beneficial	beneficial	JJ
cord-263455-dquztf5l	557	14	on	on	IN
cord-263455-dquztf5l	557	15	a	a	DT
cord-263455-dquztf5l	557	16	global	global	JJ
cord-263455-dquztf5l	557	17	scale	scale	NN
cord-263455-dquztf5l	557	18	.	.	.
cord-263455-dquztf5l	558	1	Additionally	additionally	RB
cord-263455-dquztf5l	558	2	,	,	,
cord-263455-dquztf5l	558	3	registration	registration	NN
cord-263455-dquztf5l	558	4	of	of	IN
cord-263455-dquztf5l	558	5	the	the	DT
cord-263455-dquztf5l	558	6	new	new	JJ
cord-263455-dquztf5l	558	7	indication	indication	NN
cord-263455-dquztf5l	558	8	(	(	-LRB-
cord-263455-dquztf5l	558	9	post	post	JJ
cord-263455-dquztf5l	558	10	-	-	JJ
cord-263455-dquztf5l	558	11	exposure	exposure	JJ
cord-263455-dquztf5l	558	12	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	558	13	in	in	IN
cord-263455-dquztf5l	558	14	leprosy	leprosy	NN
cord-263455-dquztf5l	558	15	)	)	-RRB-
cord-263455-dquztf5l	558	16	of	of	IN
cord-263455-dquztf5l	558	17	loose	loose	JJ
cord-263455-dquztf5l	558	18	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	558	19	in	in	IN
cord-263455-dquztf5l	558	20	more	more	JJR
cord-263455-dquztf5l	558	21	national	national	JJ
cord-263455-dquztf5l	558	22	registers	register	NNS
cord-263455-dquztf5l	558	23	of	of	IN
cord-263455-dquztf5l	558	24	authorized	authorize	VBN
cord-263455-dquztf5l	558	25	medicines	medicine	NNS
cord-263455-dquztf5l	558	26	should	should	MD
cord-263455-dquztf5l	558	27	be	be	VB
cord-263455-dquztf5l	558	28	initiated	initiate	VBN
cord-263455-dquztf5l	558	29	by	by	IN
cord-263455-dquztf5l	558	30	ministries	ministry	NNS
cord-263455-dquztf5l	558	31	of	of	IN
cord-263455-dquztf5l	558	32	health	health	NN
cord-263455-dquztf5l	558	33	in	in	IN
cord-263455-dquztf5l	558	34	leprosy	leprosy	NN
cord-263455-dquztf5l	558	35	endemic	endemic	JJ
cord-263455-dquztf5l	558	36	countries	country	NNS
cord-263455-dquztf5l	558	37	.	.	.
cord-263455-dquztf5l	559	1	Furthermore	furthermore	RB
cord-263455-dquztf5l	559	2	,	,	,
cord-263455-dquztf5l	559	3	logistical	logistical	JJ
cord-263455-dquztf5l	559	4	structures	structure	NNS
cord-263455-dquztf5l	559	5	and	and	CC
cord-263455-dquztf5l	559	6	(	(	-LRB-
cord-263455-dquztf5l	559	7	national	national	JJ
cord-263455-dquztf5l	559	8	)	)	-RRB-
cord-263455-dquztf5l	559	9	registration	registration	NN
cord-263455-dquztf5l	559	10	systems	system	NNS
cord-263455-dquztf5l	559	11	,	,	,
cord-263455-dquztf5l	559	12	for	for	IN
cord-263455-dquztf5l	559	13	contacts	contact	NNS
cord-263455-dquztf5l	559	14	of	of	IN
cord-263455-dquztf5l	559	15	leprosy	leprosy	NN
cord-263455-dquztf5l	559	16	patients	patient	NNS
cord-263455-dquztf5l	559	17	and	and	CC
cord-263455-dquztf5l	559	18	PEP	PEP	NNP
cord-263455-dquztf5l	559	19	pharmaceutical	pharmaceutical	JJ
cord-263455-dquztf5l	559	20	stock	stock	NN
cord-263455-dquztf5l	559	21	,	,	,
cord-263455-dquztf5l	559	22	sould	sould	MD
cord-263455-dquztf5l	559	23	be	be	VB
cord-263455-dquztf5l	559	24	set	set	VBN
cord-263455-dquztf5l	559	25	up	up	RP
cord-263455-dquztf5l	559	26	.	.	.
cord-263455-dquztf5l	560	1	121	121	CD
cord-263455-dquztf5l	561	1	As	as	IN
cord-263455-dquztf5l	561	2	mentioned	mention	VBN
cord-263455-dquztf5l	561	3	,	,	,
cord-263455-dquztf5l	561	4	Taal	Taal	NNP
cord-263455-dquztf5l	561	5	et	et	NNP
cord-263455-dquztf5l	561	6	al	al	NNP
cord-263455-dquztf5l	561	7	have	have	VBP
cord-263455-dquztf5l	561	8	estimated	estimate	VBN
cord-263455-dquztf5l	561	9	the	the	DT
cord-263455-dquztf5l	561	10	number	number	NN
cord-263455-dquztf5l	561	11	of	of	IN
cord-263455-dquztf5l	561	12	persons	person	NNS
cord-263455-dquztf5l	561	13	that	that	WDT
cord-263455-dquztf5l	561	14	need	need	VBP
cord-263455-dquztf5l	561	15	to	to	TO
cord-263455-dquztf5l	561	16	be	be	VB
cord-263455-dquztf5l	561	17	treated	treat	VBN
cord-263455-dquztf5l	561	18	with	with	IN
cord-263455-dquztf5l	561	19	SDR	SDR	NNP
cord-263455-dquztf5l	561	20	-	-	HYPH
cord-263455-dquztf5l	561	21	PEP	PEP	NNP
cord-263455-dquztf5l	561	22	using	use	VBG
cord-263455-dquztf5l	561	23	the	the	DT
cord-263455-dquztf5l	561	24	SIMCOLEP	SIMCOLEP	NNP
cord-263455-dquztf5l	561	25	model	model	NN
cord-263455-dquztf5l	561	26	(	(	-LRB-
cord-263455-dquztf5l	561	27	Taal	Taal	NNP
cord-263455-dquztf5l	561	28	et	et	NNP
cord-263455-dquztf5l	561	29	al	al	NNP
cord-263455-dquztf5l	561	30	,	,	,
cord-263455-dquztf5l	561	31	under	under	IN
cord-263455-dquztf5l	561	32	publication	publication	NN
cord-263455-dquztf5l	561	33	)	)	-RRB-
cord-263455-dquztf5l	561	34	.	.	.
cord-263455-dquztf5l	562	1	The	the	DT
cord-263455-dquztf5l	562	2	model	model	NN
cord-263455-dquztf5l	562	3	not	not	RB
cord-263455-dquztf5l	562	4	only	only	RB
cord-263455-dquztf5l	562	5	predicts	predict	VBZ
cord-263455-dquztf5l	562	6	the	the	DT
cord-263455-dquztf5l	562	7	number	number	NN
cord-263455-dquztf5l	562	8	of	of	IN
cord-263455-dquztf5l	562	9	people	people	NNS
cord-263455-dquztf5l	562	10	who	who	WP
cord-263455-dquztf5l	562	11	need	need	VBP
cord-263455-dquztf5l	562	12	to	to	TO
cord-263455-dquztf5l	562	13	be	be	VB
cord-263455-dquztf5l	562	14	treated	treat	VBN
cord-263455-dquztf5l	562	15	with	with	IN
cord-263455-dquztf5l	562	16	SDR	SDR	NNP
cord-263455-dquztf5l	562	17	-	-	HYPH
cord-263455-dquztf5l	562	18	PEP	PEP	NNP
cord-263455-dquztf5l	562	19	to	to	TO
cord-263455-dquztf5l	562	20	achieve	achieve	VB
cord-263455-dquztf5l	562	21	a	a	DT
cord-263455-dquztf5l	562	22	50	50	CD
cord-263455-dquztf5l	562	23	%	%	NN
cord-263455-dquztf5l	562	24	reduction	reduction	NN
cord-263455-dquztf5l	562	25	in	in	IN
cord-263455-dquztf5l	562	26	new	new	JJ
cord-263455-dquztf5l	562	27	leprosy	leprosy	NN
cord-263455-dquztf5l	562	28	case	case	NN
cord-263455-dquztf5l	562	29	detection	detection	NN
cord-263455-dquztf5l	562	30	at	at	IN
cord-263455-dquztf5l	562	31	a	a	DT
cord-263455-dquztf5l	562	32	global	global	JJ
cord-263455-dquztf5l	562	33	level	level	NN
cord-263455-dquztf5l	562	34	,	,	,
cord-263455-dquztf5l	562	35	but	but	CC
cord-263455-dquztf5l	562	36	it	-PRON-	PRP
cord-263455-dquztf5l	562	37	also	also	RB
cord-263455-dquztf5l	562	38	estimates	estimate	VBZ
cord-263455-dquztf5l	562	39	how	how	WRB
cord-263455-dquztf5l	562	40	many	many	JJ
cord-263455-dquztf5l	562	41	people	people	NNS
cord-263455-dquztf5l	562	42	need	need	VBP
cord-263455-dquztf5l	562	43	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	562	44	with	with	IN
cord-263455-dquztf5l	562	45	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	562	46	for	for	IN
cord-263455-dquztf5l	562	47	a	a	DT
cord-263455-dquztf5l	562	48	90	90	CD
cord-263455-dquztf5l	562	49	%	%	NN
cord-263455-dquztf5l	562	50	leprosy	leprosy	NN
cord-263455-dquztf5l	562	51	case	case	NN
cord-263455-dquztf5l	562	52	reduction	reduction	NN
cord-263455-dquztf5l	562	53	.	.	.
cord-263455-dquztf5l	563	1	Predictions	prediction	NNS
cord-263455-dquztf5l	563	2	per	per	IN
cord-263455-dquztf5l	563	3	country	country	NN
cord-263455-dquztf5l	563	4	will	will	MD
cord-263455-dquztf5l	563	5	also	also	RB
cord-263455-dquztf5l	563	6	be	be	VB
cord-263455-dquztf5l	563	7	published	publish	VBN
cord-263455-dquztf5l	563	8	.	.	.
cord-263455-dquztf5l	564	1	This	this	DT
cord-263455-dquztf5l	564	2	model	model	NN
cord-263455-dquztf5l	564	3	and	and	CC
cord-263455-dquztf5l	564	4	the	the	DT
cord-263455-dquztf5l	564	5	other	other	JJ
cord-263455-dquztf5l	564	6	available	available	JJ
cord-263455-dquztf5l	564	7	evidence	evidence	NN
cord-263455-dquztf5l	564	8	make	make	VBP
cord-263455-dquztf5l	564	9	clear	clear	JJ
cord-263455-dquztf5l	564	10	that	that	IN
cord-263455-dquztf5l	564	11	the	the	DT
cord-263455-dquztf5l	564	12	implementation	implementation	NN
cord-263455-dquztf5l	564	13	of	of	IN
cord-263455-dquztf5l	564	14	evidence	evidence	NN
cord-263455-dquztf5l	564	15	-	-	HYPH
cord-263455-dquztf5l	564	16	based	base	VBN
cord-263455-dquztf5l	564	17	preventive	preventive	JJ
cord-263455-dquztf5l	564	18	interventions	intervention	NNS
cord-263455-dquztf5l	564	19	against	against	IN
cord-263455-dquztf5l	564	20	leprosy	leprosy	NN
cord-263455-dquztf5l	564	21	,	,	,
cord-263455-dquztf5l	564	22	like	like	IN
cord-263455-dquztf5l	564	23	SDR	SDR	NNP
cord-263455-dquztf5l	564	24	-	-	HYPH
cord-263455-dquztf5l	564	25	PEP	PEP	NNP
cord-263455-dquztf5l	564	26	,	,	,
cord-263455-dquztf5l	564	27	in	in	IN
cord-263455-dquztf5l	564	28	national	national	JJ
cord-263455-dquztf5l	564	29	programs	program	NNS
cord-263455-dquztf5l	564	30	needs	need	VBZ
cord-263455-dquztf5l	564	31	to	to	TO
cord-263455-dquztf5l	564	32	be	be	VB
cord-263455-dquztf5l	564	33	encouraged	encourage	VBN
cord-263455-dquztf5l	564	34	to	to	TO
cord-263455-dquztf5l	564	35	facilitate	facilitate	VB
cord-263455-dquztf5l	564	36	a	a	DT
cord-263455-dquztf5l	564	37	large	large	JJ
cord-263455-dquztf5l	564	38	-	-	HYPH
cord-263455-dquztf5l	564	39	scale	scale	NN
cord-263455-dquztf5l	564	40	roll	roll	NN
cord-263455-dquztf5l	564	41	-	-	HYPH
cord-263455-dquztf5l	564	42	out	out	NN
cord-263455-dquztf5l	564	43	of	of	IN
cord-263455-dquztf5l	564	44	PEP	pep	NN
cord-263455-dquztf5l	564	45	.	.	.
cord-263455-dquztf5l	565	1	This	this	DT
cord-263455-dquztf5l	565	2	will	will	MD
cord-263455-dquztf5l	565	3	help	help	VB
cord-263455-dquztf5l	565	4	prevent	prevent	VB
cord-263455-dquztf5l	565	5	those	those	DT
cord-263455-dquztf5l	565	6	at	at	IN
cord-263455-dquztf5l	565	7	risk	risk	NN
cord-263455-dquztf5l	565	8	from	from	IN
cord-263455-dquztf5l	565	9	developing	develop	VBG
cord-263455-dquztf5l	565	10	leprosy	leprosy	NN
cord-263455-dquztf5l	565	11	and	and	CC
cord-263455-dquztf5l	565	12	will	will	MD
cord-263455-dquztf5l	565	13	be	be	VB
cord-263455-dquztf5l	565	14	a	a	DT
cord-263455-dquztf5l	565	15	vital	vital	JJ
cord-263455-dquztf5l	565	16	step	step	NN
cord-263455-dquztf5l	565	17	to	to	TO
cord-263455-dquztf5l	565	18	stop	stop	VB
cord-263455-dquztf5l	565	19	further	further	JJ
cord-263455-dquztf5l	565	20	transmission	transmission	NN
cord-263455-dquztf5l	565	21	of	of	IN
cord-263455-dquztf5l	565	22	this	this	DT
cord-263455-dquztf5l	565	23	ancient	ancient	JJ
cord-263455-dquztf5l	565	24	disease	disease	NN
cord-263455-dquztf5l	565	25	.	.	.
cord-263455-dquztf5l	566	1	Last	last	JJ
cord-263455-dquztf5l	566	2	,	,	,
cord-263455-dquztf5l	566	3	but	but	CC
cord-263455-dquztf5l	566	4	not	not	RB
cord-263455-dquztf5l	566	5	least	least	JJS
cord-263455-dquztf5l	566	6	,	,	,
cord-263455-dquztf5l	566	7	it	-PRON-	PRP
cord-263455-dquztf5l	566	8	will	will	MD
cord-263455-dquztf5l	566	9	prevent	prevent	VB
cord-263455-dquztf5l	566	10	more	more	JJR
cord-263455-dquztf5l	566	11	people	people	NNS
cord-263455-dquztf5l	566	12	from	from	IN
cord-263455-dquztf5l	566	13	having	have	VBG
cord-263455-dquztf5l	566	14	to	to	TO
cord-263455-dquztf5l	566	15	live	live	VB
cord-263455-dquztf5l	566	16	with	with	IN
cord-263455-dquztf5l	566	17	leprosy	leprosy	NN
cord-263455-dquztf5l	566	18	and	and	CC
cord-263455-dquztf5l	566	19	its	-PRON-	PRP$
cord-263455-dquztf5l	566	20	physical	physical	JJ
cord-263455-dquztf5l	566	21	,	,	,
cord-263455-dquztf5l	566	22	psychological	psychological	JJ
cord-263455-dquztf5l	566	23	,	,	,
cord-263455-dquztf5l	566	24	and	and	CC
cord-263455-dquztf5l	566	25	socioeconomic	socioeconomic	JJ
cord-263455-dquztf5l	566	26	consequences	consequence	NNS
cord-263455-dquztf5l	566	27	.	.	.
cord-263455-dquztf5l	566	28	 	 	_SP
cord-263455-dquztf5l	567	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	567	2	:	:	:
cord-263455-dquztf5l	567	3	review	review	NN
cord-263455-dquztf5l	567	4	of	of	IN
cord-263455-dquztf5l	567	5	the	the	DT
cord-263455-dquztf5l	567	6	epidemiological	epidemiological	JJ
cord-263455-dquztf5l	567	7	,	,	,
cord-263455-dquztf5l	567	8	clinical	clinical	JJ
cord-263455-dquztf5l	567	9	,	,	,
cord-263455-dquztf5l	567	10	and	and	CC
cord-263455-dquztf5l	567	11	etiopathogenic	etiopathogenic	NNP
cord-263455-dquztf5l	567	12	aspects	aspect	NNS
cord-263455-dquztf5l	567	13	-part	-part	.
cord-263455-dquztf5l	568	1	1	1	LS
cord-263455-dquztf5l	569	1	A	a	DT
cord-263455-dquztf5l	569	2	strategy	strategy	NN
cord-263455-dquztf5l	569	3	to	to	TO
cord-263455-dquztf5l	569	4	halt	halt	VB
cord-263455-dquztf5l	569	5	leprosy	leprosy	NN
cord-263455-dquztf5l	569	6	transmission	transmission	NN
cord-263455-dquztf5l	569	7	World	World	NNP
cord-263455-dquztf5l	569	8	Health	Health	NNP
cord-263455-dquztf5l	569	9	Organization	Organization	NNP
cord-263455-dquztf5l	569	10	.	.	.
cord-263455-dquztf5l	570	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	570	2	-key	-key	HYPH
cord-263455-dquztf5l	570	3	facts	fact	NNS
cord-263455-dquztf5l	571	1	Neglected	neglected	JJ
cord-263455-dquztf5l	571	2	diseases	disease	NNS
cord-263455-dquztf5l	571	3	of	of	IN
cord-263455-dquztf5l	571	4	poverty	poverty	NN
cord-263455-dquztf5l	571	5	Leprosy	leprosy	NN
cord-263455-dquztf5l	571	6	:	:	:
cord-263455-dquztf5l	571	7	an	an	DT
cord-263455-dquztf5l	571	8	overview	overview	NN
cord-263455-dquztf5l	571	9	of	of	IN
cord-263455-dquztf5l	571	10	pathophysiology	pathophysiology	NN
cord-263455-dquztf5l	571	11	Current	current	JJ
cord-263455-dquztf5l	571	12	status	status	NN
cord-263455-dquztf5l	571	13	of	of	IN
cord-263455-dquztf5l	571	14	neglected	neglect	VBN
cord-263455-dquztf5l	571	15	tropical	tropical	JJ
cord-263455-dquztf5l	571	16	diseases	disease	NNS
cord-263455-dquztf5l	571	17	(	(	-LRB-
cord-263455-dquztf5l	571	18	NTDs	ntd	NNS
cord-263455-dquztf5l	571	19	)	)	-RRB-
cord-263455-dquztf5l	571	20	in	in	IN
cord-263455-dquztf5l	571	21	the	the	DT
cord-263455-dquztf5l	571	22	Philippines	Philippines	NNPS
cord-263455-dquztf5l	571	23	moving	move	VBG
cord-263455-dquztf5l	571	24	towards	towards	IN
cord-263455-dquztf5l	571	25	a	a	DT
cord-263455-dquztf5l	571	26	leprosy	leprosy	NN
cord-263455-dquztf5l	571	27	-	-	HYPH
cord-263455-dquztf5l	571	28	free	free	JJ
cord-263455-dquztf5l	571	29	world	world	NN
cord-263455-dquztf5l	571	30	Leprosy	leprosy	NN
cord-263455-dquztf5l	571	31	:	:	:
cord-263455-dquztf5l	571	32	the	the	DT
cord-263455-dquztf5l	571	33	disease	disease	NN
cord-263455-dquztf5l	571	34	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	571	35	in	in	IN
cord-263455-dquztf5l	571	36	the	the	DT
cord-263455-dquztf5l	571	37	armadillo	armadillo	NN
cord-263455-dquztf5l	571	38	:	:	:
cord-263455-dquztf5l	571	39	new	new	JJ
cord-263455-dquztf5l	571	40	model	model	NN
cord-263455-dquztf5l	571	41	for	for	IN
cord-263455-dquztf5l	571	42	biomedical	biomedical	JJ
cord-263455-dquztf5l	571	43	research	research	NN
cord-263455-dquztf5l	571	44	Application	Application	NNP
cord-263455-dquztf5l	571	45	of	of	IN
cord-263455-dquztf5l	571	46	the	the	DT
cord-263455-dquztf5l	571	47	thymectomized	thymectomize	VBN
cord-263455-dquztf5l	571	48	-	-	HYPH
cord-263455-dquztf5l	571	49	irradiated	irradiate	VBN
cord-263455-dquztf5l	571	50	mouse	mouse	NN
cord-263455-dquztf5l	571	51	to	to	IN
cord-263455-dquztf5l	571	52	the	the	DT
cord-263455-dquztf5l	571	53	detection	detection	NN
cord-263455-dquztf5l	571	54	of	of	IN
cord-263455-dquztf5l	571	55	persisting	persist	VBG
cord-263455-dquztf5l	571	56	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	571	57	leprae	leprae	NNP
cord-263455-dquztf5l	572	1	The	the	DT
cord-263455-dquztf5l	572	2	global	global	JJ
cord-263455-dquztf5l	572	3	campaign	campaign	NN
cord-263455-dquztf5l	572	4	to	to	TO
cord-263455-dquztf5l	572	5	eliminate	eliminate	VB
cord-263455-dquztf5l	572	6	leprosy	leprosy	NN
cord-263455-dquztf5l	572	7	Physical	physical	JJ
cord-263455-dquztf5l	572	8	distance	distance	NN
cord-263455-dquztf5l	572	9	,	,	,
cord-263455-dquztf5l	572	10	genetic	genetic	JJ
cord-263455-dquztf5l	572	11	relationship	relationship	NN
cord-263455-dquztf5l	572	12	,	,	,
cord-263455-dquztf5l	572	13	age	age	NN
cord-263455-dquztf5l	572	14	,	,	,
cord-263455-dquztf5l	572	15	and	and	CC
cord-263455-dquztf5l	572	16	leprosy	leprosy	NN
cord-263455-dquztf5l	572	17	classification	classification	NN
cord-263455-dquztf5l	572	18	are	be	VBP
cord-263455-dquztf5l	572	19	independent	independent	JJ
cord-263455-dquztf5l	572	20	risk	risk	NN
cord-263455-dquztf5l	572	21	factors	factor	NNS
cord-263455-dquztf5l	572	22	for	for	IN
cord-263455-dquztf5l	572	23	leprosy	leprosy	NN
cord-263455-dquztf5l	572	24	in	in	IN
cord-263455-dquztf5l	572	25	contacts	contact	NNS
cord-263455-dquztf5l	572	26	of	of	IN
cord-263455-dquztf5l	572	27	patients	patient	NNS
cord-263455-dquztf5l	572	28	with	with	IN
cord-263455-dquztf5l	572	29	leprosy	leprosy	NN
cord-263455-dquztf5l	572	30	Patient	Patient	NNP
cord-263455-dquztf5l	572	31	contact	contact	NN
cord-263455-dquztf5l	572	32	is	be	VBZ
cord-263455-dquztf5l	572	33	the	the	DT
cord-263455-dquztf5l	572	34	major	major	JJ
cord-263455-dquztf5l	572	35	determinant	determinant	NN
cord-263455-dquztf5l	572	36	in	in	IN
cord-263455-dquztf5l	572	37	incident	incident	NN
cord-263455-dquztf5l	572	38	leprosy	leprosy	NN
cord-263455-dquztf5l	572	39	:	:	:
cord-263455-dquztf5l	572	40	implications	implication	NNS
cord-263455-dquztf5l	572	41	for	for	IN
cord-263455-dquztf5l	572	42	future	future	JJ
cord-263455-dquztf5l	572	43	control	control	NN
cord-263455-dquztf5l	572	44	Social	Social	NNP
cord-263455-dquztf5l	572	45	distance	distance	NN
cord-263455-dquztf5l	572	46	and	and	CC
cord-263455-dquztf5l	572	47	spatial	spatial	JJ
cord-263455-dquztf5l	572	48	distance	distance	NN
cord-263455-dquztf5l	572	49	are	be	VBP
cord-263455-dquztf5l	572	50	not	not	RB
cord-263455-dquztf5l	572	51	the	the	DT
cord-263455-dquztf5l	572	52	same	same	JJ
cord-263455-dquztf5l	572	53	,	,	,
cord-263455-dquztf5l	572	54	observations	observation	NNS
cord-263455-dquztf5l	572	55	on	on	IN
cord-263455-dquztf5l	572	56	the	the	DT
cord-263455-dquztf5l	572	57	use	use	NN
cord-263455-dquztf5l	572	58	of	of	IN
cord-263455-dquztf5l	572	59	GIS	GIS	NNP
cord-263455-dquztf5l	572	60	in	in	IN
cord-263455-dquztf5l	572	61	leprosy	leprosy	NN
cord-263455-dquztf5l	572	62	epidemiology	epidemiology	NN
cord-263455-dquztf5l	572	63	Prophylaxis	Prophylaxis	NNP
cord-263455-dquztf5l	572	64	and	and	CC
cord-263455-dquztf5l	572	65	exclusion	exclusion	NN
cord-263455-dquztf5l	572	66	:	:	:
cord-263455-dquztf5l	572	67	compulsory	compulsory	JJ
cord-263455-dquztf5l	572	68	isolation	isolation	NN
cord-263455-dquztf5l	572	69	of	of	IN
cord-263455-dquztf5l	572	70	Hansen	Hansen	NNP
cord-263455-dquztf5l	572	71	's	's	POS
cord-263455-dquztf5l	572	72	disease	disease	NN
cord-263455-dquztf5l	572	73	patients	patient	NNS
cord-263455-dquztf5l	572	74	in	in	IN
cord-263455-dquztf5l	572	75	São	São	NNP
cord-263455-dquztf5l	572	76	Paulo	Paulo	NNP
cord-263455-dquztf5l	572	77	Editorials	editorial	NNS
cord-263455-dquztf5l	573	1	-first	-first	NNP
cord-263455-dquztf5l	573	2	congress	congress	NNP
cord-263455-dquztf5l	573	3	of	of	IN
cord-263455-dquztf5l	573	4	the	the	DT
cord-263455-dquztf5l	573	5	international	international	NNP
cord-263455-dquztf5l	573	6	leprosy	leprosy	NNP
cord-263455-dquztf5l	573	7	association	association	NNP
cord-263455-dquztf5l	573	8	.	.	.
cord-263455-dquztf5l	574	1	Fourth	fourth	JJ
cord-263455-dquztf5l	574	2	international	international	JJ
cord-263455-dquztf5l	574	3	leprosy	leprosy	NN
cord-263455-dquztf5l	574	4	conference	conference	NN
cord-263455-dquztf5l	574	5	Elimination	Elimination	NNP
cord-263455-dquztf5l	574	6	of	of	IN
cord-263455-dquztf5l	574	7	leprosy	leprosy	NN
cord-263455-dquztf5l	574	8	as	as	IN
cord-263455-dquztf5l	574	9	a	a	DT
cord-263455-dquztf5l	574	10	public	public	JJ
cord-263455-dquztf5l	574	11	health	health	NN
cord-263455-dquztf5l	574	12	problem	problem	NN
cord-263455-dquztf5l	574	13	:	:	:
cord-263455-dquztf5l	574	14	progress	progress	NN
cord-263455-dquztf5l	574	15	and	and	CC
cord-263455-dquztf5l	574	16	prospects	prospect	NNS
cord-263455-dquztf5l	575	1	The	the	DT
cord-263455-dquztf5l	575	2	future	future	JJ
cord-263455-dquztf5l	575	3	incidence	incidence	NN
cord-263455-dquztf5l	575	4	of	of	IN
cord-263455-dquztf5l	575	5	leprosy	leprosy	NN
cord-263455-dquztf5l	575	6	:	:	:
cord-263455-dquztf5l	576	1	a	a	DT
cord-263455-dquztf5l	576	2	scenario	scenario	NN
cord-263455-dquztf5l	576	3	analysis	analysis	NN
cord-263455-dquztf5l	576	4	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	576	5	against	against	IN
cord-263455-dquztf5l	576	6	leprosy	leprosy	NN
cord-263455-dquztf5l	576	7	:	:	:
cord-263455-dquztf5l	576	8	expectations	expectation	NNS
cord-263455-dquztf5l	576	9	and	and	CC
cord-263455-dquztf5l	576	10	methodology	methodology	NN
cord-263455-dquztf5l	576	11	of	of	IN
cord-263455-dquztf5l	576	12	a	a	DT
cord-263455-dquztf5l	576	13	trial	trial	NN
cord-263455-dquztf5l	577	1	The	the	DT
cord-263455-dquztf5l	577	2	missing	miss	VBG
cord-263455-dquztf5l	577	3	millions	million	NNS
cord-263455-dquztf5l	577	4	:	:	:
cord-263455-dquztf5l	577	5	a	a	DT
cord-263455-dquztf5l	577	6	threat	threat	NN
cord-263455-dquztf5l	577	7	to	to	IN
cord-263455-dquztf5l	577	8	the	the	DT
cord-263455-dquztf5l	577	9	elimination	elimination	NN
cord-263455-dquztf5l	577	10	of	of	IN
cord-263455-dquztf5l	577	11	leprosy	leprosy	NN
cord-263455-dquztf5l	577	12	Accelerating	accelerate	VBG
cord-263455-dquztf5l	577	13	Towards	towards	IN
cord-263455-dquztf5l	577	14	a	a	DT
cord-263455-dquztf5l	577	15	Leprosy	leprosy	NN
cord-263455-dquztf5l	577	16	-	-	HYPH
cord-263455-dquztf5l	577	17	Free	Free	NNP
cord-263455-dquztf5l	577	18	World	world	NN
cord-263455-dquztf5l	577	19	.	.	.
cord-263455-dquztf5l	578	1	World	World	NNP
cord-263455-dquztf5l	578	2	Health	Health	NNP
cord-263455-dquztf5l	578	3	Organization	Organization	NNP
cord-263455-dquztf5l	578	4	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	578	5	Control	Control	NNP
cord-263455-dquztf5l	579	1	-International	-international	RB
cord-263455-dquztf5l	580	1	Textbook	Textbook	NNP
cord-263455-dquztf5l	580	2	of	of	IN
cord-263455-dquztf5l	580	3	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	580	4	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	580	5	post	post	JJ
cord-263455-dquztf5l	580	6	-	-	JJ
cord-263455-dquztf5l	580	7	exposure	exposure	JJ
cord-263455-dquztf5l	580	8	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	580	9	(	(	-LRB-
cord-263455-dquztf5l	580	10	LPEP	LPEP	NNP
cord-263455-dquztf5l	580	11	)	)	-RRB-
cord-263455-dquztf5l	580	12	programme	programme	NN
cord-263455-dquztf5l	580	13	:	:	:
cord-263455-dquztf5l	580	14	study	study	NN
cord-263455-dquztf5l	580	15	protocol	protocol	NN
cord-263455-dquztf5l	580	16	for	for	IN
cord-263455-dquztf5l	580	17	evaluating	evaluate	VBG
cord-263455-dquztf5l	580	18	the	the	DT
cord-263455-dquztf5l	580	19	feasibility	feasibility	NN
cord-263455-dquztf5l	580	20	and	and	CC
cord-263455-dquztf5l	580	21	impact	impact	NN
cord-263455-dquztf5l	580	22	on	on	IN
cord-263455-dquztf5l	580	23	case	case	NN
cord-263455-dquztf5l	580	24	detection	detection	NN
cord-263455-dquztf5l	580	25	rates	rate	NNS
cord-263455-dquztf5l	580	26	of	of	IN
cord-263455-dquztf5l	580	27	contact	contact	NN
cord-263455-dquztf5l	580	28	tracing	tracing	NN
cord-263455-dquztf5l	580	29	and	and	CC
cord-263455-dquztf5l	580	30	single	single	JJ
cord-263455-dquztf5l	580	31	dose	dose	NN
cord-263455-dquztf5l	581	1	rifampicin	rifampicin	NNP
cord-263455-dquztf5l	581	2	Basri	Basri	NNP
cord-263455-dquztf5l	582	1	S	S	NNP
cord-263455-dquztf5l	582	2	Descriptive	descriptive	JJ
cord-263455-dquztf5l	582	3	analysis	analysis	NN
cord-263455-dquztf5l	582	4	and	and	CC
cord-263455-dquztf5l	582	5	text	text	NN
cord-263455-dquztf5l	582	6	analysis	analysis	NN
cord-263455-dquztf5l	582	7	in	in	IN
cord-263455-dquztf5l	582	8	systematic	systematic	JJ
cord-263455-dquztf5l	582	9	literature	literature	NN
cord-263455-dquztf5l	582	10	review	review	NN
cord-263455-dquztf5l	582	11	:	:	:
cord-263455-dquztf5l	582	12	a	a	DT
cord-263455-dquztf5l	582	13	review	review	NN
cord-263455-dquztf5l	582	14	of	of	IN
cord-263455-dquztf5l	582	15	master	master	NN
cord-263455-dquztf5l	582	16	data	datum	NNS
cord-263455-dquztf5l	582	17	management	management	NN
cord-263455-dquztf5l	582	18	Infolep	Infolep	NNP
cord-263455-dquztf5l	582	19	.	.	.
cord-263455-dquztf5l	583	1	International	international	JJ
cord-263455-dquztf5l	583	2	knowledge	knowledge	NN
cord-263455-dquztf5l	583	3	center	center	NN
cord-263455-dquztf5l	583	4	for	for	IN
cord-263455-dquztf5l	583	5	information	information	NN
cord-263455-dquztf5l	583	6	resources	resource	NNS
cord-263455-dquztf5l	583	7	on	on	IN
cord-263455-dquztf5l	583	8	leprosy	leprosy	NN
cord-263455-dquztf5l	583	9	|	|	HYPH
cord-263455-dquztf5l	583	10	infolep	infolep	NNP
cord-263455-dquztf5l	583	11	Preferred	preferred	JJ
cord-263455-dquztf5l	583	12	reporting	reporting	NN
cord-263455-dquztf5l	583	13	items	item	NNS
cord-263455-dquztf5l	583	14	for	for	IN
cord-263455-dquztf5l	583	15	systematic	systematic	JJ
cord-263455-dquztf5l	583	16	reviews	review	NNS
cord-263455-dquztf5l	583	17	and	and	CC
cord-263455-dquztf5l	583	18	meta	meta	NNP
cord-263455-dquztf5l	583	19	-	-	HYPH
cord-263455-dquztf5l	583	20	analyses	analysis	NNS
cord-263455-dquztf5l	584	1	:	:	:
cord-263455-dquztf5l	584	2	the	the	DT
cord-263455-dquztf5l	584	3	PRISMA	PRISMA	NNP
cord-263455-dquztf5l	584	4	statement	statement	NN
cord-263455-dquztf5l	585	1	History	history	NN
cord-263455-dquztf5l	585	2	of	of	IN
cord-263455-dquztf5l	585	3	BCG	BCG	NNP
cord-263455-dquztf5l	585	4	vaccine	vaccine	NN
cord-263455-dquztf5l	585	5	World	World	NNP
cord-263455-dquztf5l	585	6	Health	Health	NNP
cord-263455-dquztf5l	585	7	Organization	Organization	NNP
cord-263455-dquztf5l	585	8	.	.	.
cord-263455-dquztf5l	586	1	BCG	BCG	NNP
cord-263455-dquztf5l	586	2	vaccine	vaccine	NN
cord-263455-dquztf5l	586	3	:	:	:
cord-263455-dquztf5l	586	4	WHO	who	WP
cord-263455-dquztf5l	586	5	position	position	VBP
cord-263455-dquztf5l	586	6	paper	paper	NN
cord-263455-dquztf5l	586	7	Whole	whole	JJ
cord-263455-dquztf5l	586	8	genome	genome	NN
cord-263455-dquztf5l	586	9	sequence	sequence	NN
cord-263455-dquztf5l	586	10	analysis	analysis	NN
cord-263455-dquztf5l	586	11	of	of	IN
cord-263455-dquztf5l	586	12	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	586	13	bovis	bovis	NN
cord-263455-dquztf5l	586	14	bacillus	bacillus	NN
cord-263455-dquztf5l	586	15	Calmette	Calmette	NNP
cord-263455-dquztf5l	586	16	-	-	HYPH
cord-263455-dquztf5l	586	17	Guérin	Guérin	NNP
cord-263455-dquztf5l	586	18	(	(	-LRB-
cord-263455-dquztf5l	586	19	BCG	BCG	NNP
cord-263455-dquztf5l	586	20	)	)	-RRB-
cord-263455-dquztf5l	586	21	Tokyo	Tokyo	NNP
cord-263455-dquztf5l	586	22	172	172	CD
cord-263455-dquztf5l	586	23	:	:	:
cord-263455-dquztf5l	586	24	a	a	DT
cord-263455-dquztf5l	586	25	comparative	comparative	JJ
cord-263455-dquztf5l	586	26	study	study	NN
cord-263455-dquztf5l	586	27	of	of	IN
cord-263455-dquztf5l	586	28	BCG	BCG	NNP
cord-263455-dquztf5l	586	29	vaccine	vaccine	NN
cord-263455-dquztf5l	586	30	substrains	substrain	VBZ
cord-263455-dquztf5l	586	31	Bacillus	Bacillus	NNP
cord-263455-dquztf5l	586	32	Calmette	Calmette	NNP
cord-263455-dquztf5l	586	33	-	-	HYPH
cord-263455-dquztf5l	586	34	Guérin	Guérin	NNP
cord-263455-dquztf5l	586	35	(	(	-LRB-
cord-263455-dquztf5l	586	36	BCG	BCG	NNP
cord-263455-dquztf5l	586	37	)	)	-RRB-
cord-263455-dquztf5l	586	38	vaccine	vaccine	NN
cord-263455-dquztf5l	586	39	:	:	:
cord-263455-dquztf5l	586	40	a	a	DT
cord-263455-dquztf5l	586	41	global	global	JJ
cord-263455-dquztf5l	586	42	assessment	assessment	NN
cord-263455-dquztf5l	586	43	of	of	IN
cord-263455-dquztf5l	586	44	demand	demand	NN
cord-263455-dquztf5l	586	45	and	and	CC
cord-263455-dquztf5l	586	46	supply	supply	NN
cord-263455-dquztf5l	586	47	balance	balance	NN
cord-263455-dquztf5l	586	48	.	.	.
cord-263455-dquztf5l	587	1	Vaccine	vaccine	NN
cord-263455-dquztf5l	587	2	Vaccination	vaccination	NN
cord-263455-dquztf5l	587	3	against	against	IN
cord-263455-dquztf5l	587	4	leprosy	leprosy	NN
cord-263455-dquztf5l	587	5	Leprosy	leprosy	NN
cord-263455-dquztf5l	587	6	and	and	CC
cord-263455-dquztf5l	587	7	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	587	8	:	:	:
cord-263455-dquztf5l	587	9	antagonistic	antagonistic	JJ
cord-263455-dquztf5l	587	10	diseases	disease	NNS
cord-263455-dquztf5l	587	11	.	.	.
cord-263455-dquztf5l	588	1	A	a	DT
cord-263455-dquztf5l	588	2	M	M	NNP
cord-263455-dquztf5l	588	3	a	a	DT
cord-263455-dquztf5l	588	4	Arch	Arch	NNP
cord-263455-dquztf5l	588	5	Dermatology	Dermatology	NNP
cord-263455-dquztf5l	588	6	BCG	BCG	NNP
cord-263455-dquztf5l	588	7	and	and	CC
cord-263455-dquztf5l	588	8	adverse	adverse	JJ
cord-263455-dquztf5l	588	9	events	event	NNS
cord-263455-dquztf5l	588	10	in	in	IN
cord-263455-dquztf5l	588	11	the	the	DT
cord-263455-dquztf5l	588	12	context	context	NN
cord-263455-dquztf5l	588	13	of	of	IN
cord-263455-dquztf5l	588	14	leprosy	leprosy	NN
cord-263455-dquztf5l	589	1	The	the	DT
cord-263455-dquztf5l	589	2	role	role	NN
cord-263455-dquztf5l	589	3	of	of	IN
cord-263455-dquztf5l	589	4	BCG	BCG	NNP
cord-263455-dquztf5l	589	5	in	in	IN
cord-263455-dquztf5l	589	6	prevention	prevention	NN
cord-263455-dquztf5l	589	7	of	of	IN
cord-263455-dquztf5l	589	8	leprosy	leprosy	NN
cord-263455-dquztf5l	589	9	:	:	:
cord-263455-dquztf5l	589	10	a	a	DT
cord-263455-dquztf5l	589	11	meta	meta	JJ
cord-263455-dquztf5l	589	12	-	-	HYPH
cord-263455-dquztf5l	589	13	analysis	analysis	NN
cord-263455-dquztf5l	589	14	Protective	protective	JJ
cord-263455-dquztf5l	589	15	effect	effect	NN
cord-263455-dquztf5l	589	16	of	of	IN
cord-263455-dquztf5l	589	17	Bacillus	Bacillus	NNP
cord-263455-dquztf5l	589	18	Calmette	Calmette	NNP
cord-263455-dquztf5l	589	19	Guerin	Guerin	NNP
cord-263455-dquztf5l	589	20	(	(	-LRB-
cord-263455-dquztf5l	589	21	BCG	BCG	NNP
cord-263455-dquztf5l	589	22	)	)	-RRB-
cord-263455-dquztf5l	589	23	against	against	IN
cord-263455-dquztf5l	589	24	leprosy	leprosy	NN
cord-263455-dquztf5l	589	25	:	:	:
cord-263455-dquztf5l	589	26	a	a	DT
cord-263455-dquztf5l	589	27	population	population	NN
cord-263455-dquztf5l	589	28	-	-	HYPH
cord-263455-dquztf5l	589	29	based	base	VBN
cord-263455-dquztf5l	589	30	case	case	NN
cord-263455-dquztf5l	589	31	-	-	HYPH
cord-263455-dquztf5l	589	32	control	control	NN
cord-263455-dquztf5l	589	33	study	study	NN
cord-263455-dquztf5l	589	34	in	in	IN
cord-263455-dquztf5l	589	35	Nagpur	Nagpur	NNP
cord-263455-dquztf5l	589	36	BCG	BCG	NNP
cord-263455-dquztf5l	589	37	vaccination	vaccination	NN
cord-263455-dquztf5l	589	38	and	and	CC
cord-263455-dquztf5l	589	39	leprosy	leprosy	NN
cord-263455-dquztf5l	589	40	protection	protection	NN
cord-263455-dquztf5l	589	41	:	:	:
cord-263455-dquztf5l	589	42	review	review	NN
cord-263455-dquztf5l	589	43	of	of	IN
cord-263455-dquztf5l	589	44	current	current	JJ
cord-263455-dquztf5l	589	45	evidence	evidence	NN
cord-263455-dquztf5l	589	46	and	and	CC
cord-263455-dquztf5l	589	47	status	status	NN
cord-263455-dquztf5l	589	48	of	of	IN
cord-263455-dquztf5l	589	49	BCG	BCG	NNP
cord-263455-dquztf5l	589	50	in	in	IN
cord-263455-dquztf5l	589	51	leprosy	leprosy	NN
cord-263455-dquztf5l	589	52	control	control	NN
cord-263455-dquztf5l	589	53	Effectiveness	Effectiveness	NNP
cord-263455-dquztf5l	589	54	of	of	IN
cord-263455-dquztf5l	589	55	Bacillus	Bacillus	NNP
cord-263455-dquztf5l	590	1	Calmette	Calmette	NNP
cord-263455-dquztf5l	590	2	Guerin	Guerin	NNP
cord-263455-dquztf5l	590	3	(	(	-LRB-
cord-263455-dquztf5l	590	4	BCG	BCG	NNP
cord-263455-dquztf5l	590	5	)	)	-RRB-
cord-263455-dquztf5l	590	6	vaccination	vaccination	NN
cord-263455-dquztf5l	590	7	in	in	IN
cord-263455-dquztf5l	590	8	the	the	DT
cord-263455-dquztf5l	590	9	prevention	prevention	NN
cord-263455-dquztf5l	590	10	of	of	IN
cord-263455-dquztf5l	590	11	leprosy	leprosy	NN
cord-263455-dquztf5l	590	12	:	:	:
cord-263455-dquztf5l	591	1	a	a	DT
cord-263455-dquztf5l	591	2	population	population	NN
cord-263455-dquztf5l	591	3	-	-	HYPH
cord-263455-dquztf5l	591	4	based	base	VBN
cord-263455-dquztf5l	591	5	case	case	NN
cord-263455-dquztf5l	591	6	-	-	HYPH
cord-263455-dquztf5l	591	7	control	control	NN
cord-263455-dquztf5l	591	8	study	study	NN
cord-263455-dquztf5l	591	9	in	in	IN
cord-263455-dquztf5l	591	10	Yavatmal	Yavatmal	NNP
cord-263455-dquztf5l	591	11	District	District	NNP
cord-263455-dquztf5l	591	12	Long	Long	NNP
cord-263455-dquztf5l	591	13	lasting	last	VBG
cord-263455-dquztf5l	591	14	BCG	BCG	NNP
cord-263455-dquztf5l	591	15	protection	protection	NN
cord-263455-dquztf5l	591	16	against	against	IN
cord-263455-dquztf5l	591	17	leprosy	leprosy	NN
cord-263455-dquztf5l	592	1	The	the	DT
cord-263455-dquztf5l	592	2	effect	effect	NN
cord-263455-dquztf5l	592	3	of	of	IN
cord-263455-dquztf5l	592	4	BCG	BCG	NNP
cord-263455-dquztf5l	592	5	vaccination	vaccination	NN
cord-263455-dquztf5l	592	6	upon	upon	IN
cord-263455-dquztf5l	592	7	the	the	DT
cord-263455-dquztf5l	592	8	occurrence	occurrence	NN
cord-263455-dquztf5l	592	9	of	of	IN
cord-263455-dquztf5l	592	10	leprosy	leprosy	NN
cord-263455-dquztf5l	592	11	in	in	IN
cord-263455-dquztf5l	592	12	nursery	nursery	NN
cord-263455-dquztf5l	592	13	children	child	NNS
cord-263455-dquztf5l	592	14	BCG	BCG	NNP
cord-263455-dquztf5l	592	15	vaccination	vaccination	NN
cord-263455-dquztf5l	592	16	in	in	IN
cord-263455-dquztf5l	592	17	leprosy	leprosy	NN
cord-263455-dquztf5l	592	18	BCG	BCG	NNP
cord-263455-dquztf5l	592	19	vaccination	vaccination	NN
cord-263455-dquztf5l	592	20	of	of	IN
cord-263455-dquztf5l	592	21	children	child	NNS
cord-263455-dquztf5l	592	22	against	against	IN
cord-263455-dquztf5l	592	23	leprosy	leprosy	NN
cord-263455-dquztf5l	592	24	:	:	:
cord-263455-dquztf5l	592	25	fourteen	fourteen	CD
cord-263455-dquztf5l	592	26	-	-	HYPH
cord-263455-dquztf5l	592	27	year	year	NN
cord-263455-dquztf5l	592	28	findings	finding	NNS
cord-263455-dquztf5l	592	29	of	of	IN
cord-263455-dquztf5l	592	30	the	the	DT
cord-263455-dquztf5l	592	31	trial	trial	NN
cord-263455-dquztf5l	592	32	in	in	IN
cord-263455-dquztf5l	592	33	Burma	Burma	NNP
cord-263455-dquztf5l	593	1	The	the	DT
cord-263455-dquztf5l	593	2	combined	combined	JJ
cord-263455-dquztf5l	593	3	effect	effect	NN
cord-263455-dquztf5l	593	4	of	of	IN
cord-263455-dquztf5l	593	5	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	593	6	with	with	IN
cord-263455-dquztf5l	593	7	single	single	JJ
cord-263455-dquztf5l	593	8	dose	dose	NN
cord-263455-dquztf5l	593	9	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	593	10	and	and	CC
cord-263455-dquztf5l	593	11	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	593	12	with	with	IN
cord-263455-dquztf5l	593	13	BCG	BCG	NNP
cord-263455-dquztf5l	593	14	to	to	TO
cord-263455-dquztf5l	593	15	prevent	prevent	VB
cord-263455-dquztf5l	593	16	leprosy	leprosy	NN
cord-263455-dquztf5l	593	17	in	in	IN
cord-263455-dquztf5l	593	18	contacts	contact	NNS
cord-263455-dquztf5l	593	19	of	of	IN
cord-263455-dquztf5l	593	20	newly	newly	RB
cord-263455-dquztf5l	593	21	diagnosed	diagnose	VBN
cord-263455-dquztf5l	593	22	leprosy	leprosy	NN
cord-263455-dquztf5l	593	23	cases	case	NNS
cord-263455-dquztf5l	593	24	:	:	:
cord-263455-dquztf5l	593	25	a	a	DT
cord-263455-dquztf5l	593	26	cluster	cluster	NN
cord-263455-dquztf5l	593	27	randomized	randomize	VBN
cord-263455-dquztf5l	593	28	controlled	control	VBN
cord-263455-dquztf5l	593	29	trial	trial	NN
cord-263455-dquztf5l	593	30	(	(	-LRB-
cord-263455-dquztf5l	593	31	MALTALEP	MALTALEP	NNP
cord-263455-dquztf5l	593	32	study	study	NN
cord-263455-dquztf5l	593	33	)	)	-RRB-
cord-263455-dquztf5l	594	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	594	2	:	:	:
cord-263455-dquztf5l	594	3	diagnostic	diagnostic	JJ
cord-263455-dquztf5l	594	4	and	and	CC
cord-263455-dquztf5l	594	5	control	control	NN
cord-263455-dquztf5l	594	6	challenges	challenge	NNS
cord-263455-dquztf5l	594	7	for	for	IN
cord-263455-dquztf5l	594	8	a	a	DT
cord-263455-dquztf5l	594	9	worldwide	worldwide	JJ
cord-263455-dquztf5l	594	10	disease	disease	NN
cord-263455-dquztf5l	594	11	Leprosy	leprosy	NN
cord-263455-dquztf5l	594	12	epidemiology	epidemiology	NN
cord-263455-dquztf5l	594	13	in	in	IN
cord-263455-dquztf5l	594	14	a	a	DT
cord-263455-dquztf5l	594	15	cohort	cohort	NN
cord-263455-dquztf5l	594	16	of	of	IN
cord-263455-dquztf5l	594	17	household	household	NN
cord-263455-dquztf5l	594	18	contacts	contact	NNS
cord-263455-dquztf5l	594	19	in	in	IN
cord-263455-dquztf5l	594	20	Rio	Rio	NNP
cord-263455-dquztf5l	594	21	de	de	NNP
cord-263455-dquztf5l	594	22	Janeiro	Janeiro	NNP
cord-263455-dquztf5l	594	23	(	(	-LRB-
cord-263455-dquztf5l	594	24	1987	1987	CD
cord-263455-dquztf5l	594	25	-	-	SYM
cord-263455-dquztf5l	594	26	1991	1991	CD
cord-263455-dquztf5l	594	27	)	)	-RRB-
cord-263455-dquztf5l	594	28	.	.	.
cord-263455-dquztf5l	595	1	Cadernos	Cadernos	NNP
cord-263455-dquztf5l	595	2	De	De	NNP
cord-263455-dquztf5l	595	3	Saúde	Saúde	NNP
cord-263455-dquztf5l	595	4	Pública	Pública	NNP
cord-263455-dquztf5l	595	5	BCG	BCG	NNP
cord-263455-dquztf5l	595	6	vaccination	vaccination	NN
cord-263455-dquztf5l	595	7	of	of	IN
cord-263455-dquztf5l	595	8	children	child	NNS
cord-263455-dquztf5l	595	9	against	against	IN
cord-263455-dquztf5l	595	10	leprosy	leprosy	NN
cord-263455-dquztf5l	595	11	in	in	IN
cord-263455-dquztf5l	595	12	Uganda	Uganda	NNP
cord-263455-dquztf5l	595	13	:	:	:
cord-263455-dquztf5l	596	1	final	final	JJ
cord-263455-dquztf5l	596	2	results	result	NNS
cord-263455-dquztf5l	596	3	Effectiveness	Effectiveness	NNP
cord-263455-dquztf5l	596	4	of	of	IN
cord-263455-dquztf5l	596	5	BCG	BCG	NNP
cord-263455-dquztf5l	596	6	vaccination	vaccination	NN
cord-263455-dquztf5l	596	7	among	among	IN
cord-263455-dquztf5l	596	8	leprosy	leprosy	NN
cord-263455-dquztf5l	596	9	contacts	contact	NNS
cord-263455-dquztf5l	596	10	:	:	:
cord-263455-dquztf5l	597	1	a	a	DT
cord-263455-dquztf5l	597	2	cohort	cohort	NN
cord-263455-dquztf5l	597	3	study	study	NN
cord-263455-dquztf5l	597	4	Combination	Combination	NNP
cord-263455-dquztf5l	597	5	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	597	6	and	and	CC
cord-263455-dquztf5l	597	7	immunoprophylaxis	immunoprophylaxis	NNP
cord-263455-dquztf5l	597	8	in	in	IN
cord-263455-dquztf5l	597	9	reducing	reduce	VBG
cord-263455-dquztf5l	597	10	the	the	DT
cord-263455-dquztf5l	597	11	incidence	incidence	NN
cord-263455-dquztf5l	597	12	of	of	IN
cord-263455-dquztf5l	597	13	leprosy	leprosy	NN
cord-263455-dquztf5l	597	14	Immunoprophylactic	immunoprophylactic	JJ
cord-263455-dquztf5l	597	15	effects	effect	NNS
cord-263455-dquztf5l	597	16	of	of	IN
cord-263455-dquztf5l	597	17	the	the	DT
cord-263455-dquztf5l	597	18	anti	anti	JJ
cord-263455-dquztf5l	597	19	-	-	JJ
cord-263455-dquztf5l	597	20	leprosy	leprosy	JJ
cord-263455-dquztf5l	597	21	Mw	Mw	NNP
cord-263455-dquztf5l	597	22	vaccine	vaccine	NN
cord-263455-dquztf5l	597	23	in	in	IN
cord-263455-dquztf5l	597	24	household	household	NN
cord-263455-dquztf5l	597	25	contacts	contact	NNS
cord-263455-dquztf5l	597	26	of	of	IN
cord-263455-dquztf5l	597	27	leprosy	leprosy	NN
cord-263455-dquztf5l	597	28	patients	patient	NNS
cord-263455-dquztf5l	597	29	:	:	:
cord-263455-dquztf5l	597	30	clinical	clinical	JJ
cord-263455-dquztf5l	597	31	field	field	NN
cord-263455-dquztf5l	597	32	trials	trial	NNS
cord-263455-dquztf5l	597	33	with	with	IN
cord-263455-dquztf5l	597	34	a	a	DT
cord-263455-dquztf5l	597	35	follow	follow	NN
cord-263455-dquztf5l	597	36	up	up	IN
cord-263455-dquztf5l	597	37	of	of	IN
cord-263455-dquztf5l	597	38	8	8	CD
cord-263455-dquztf5l	597	39	-	-	SYM
cord-263455-dquztf5l	597	40	10	10	CD
cord-263455-dquztf5l	597	41	years	year	NNS
cord-263455-dquztf5l	597	42	Comparative	comparative	JJ
cord-263455-dquztf5l	597	43	leprosy	leprosy	NN
cord-263455-dquztf5l	597	44	vaccine	vaccine	NN
cord-263455-dquztf5l	597	45	trial	trial	NN
cord-263455-dquztf5l	597	46	in	in	IN
cord-263455-dquztf5l	597	47	south	south	JJ
cord-263455-dquztf5l	597	48	India	India	NNP
cord-263455-dquztf5l	597	49	World	World	NNP
cord-263455-dquztf5l	597	50	Health	Health	NNP
cord-263455-dquztf5l	597	51	Organization	Organization	NNP
cord-263455-dquztf5l	597	52	.	.	.
cord-263455-dquztf5l	598	1	Guidelines	guideline	NNS
cord-263455-dquztf5l	598	2	for	for	IN
cord-263455-dquztf5l	598	3	the	the	DT
cord-263455-dquztf5l	598	4	diagnosis	diagnosis	NN
cord-263455-dquztf5l	598	5	,	,	,
cord-263455-dquztf5l	598	6	treatment	treatment	NN
cord-263455-dquztf5l	598	7	and	and	CC
cord-263455-dquztf5l	598	8	prevention	prevention	NN
cord-263455-dquztf5l	598	9	of	of	IN
cord-263455-dquztf5l	598	10	leprosy	leprosy	NN
cord-263455-dquztf5l	598	11	Vaccination	Vaccination	NNP
cord-263455-dquztf5l	598	12	in	in	IN
cord-263455-dquztf5l	598	13	leprosy	leprosy	NN
cord-263455-dquztf5l	598	14	.	.	.
cord-263455-dquztf5l	599	1	Observations	observation	NNS
cord-263455-dquztf5l	599	2	and	and	CC
cord-263455-dquztf5l	599	3	interpretations	interpretation	NNS
cord-263455-dquztf5l	599	4	Randomised	randomised	JJ
cord-263455-dquztf5l	599	5	controlled	control	VBN
cord-263455-dquztf5l	599	6	trial	trial	NN
cord-263455-dquztf5l	599	7	of	of	IN
cord-263455-dquztf5l	599	8	single	single	JJ
cord-263455-dquztf5l	599	9	BCG	BCG	NNP
cord-263455-dquztf5l	599	10	,	,	,
cord-263455-dquztf5l	599	11	repeated	repeat	VBD
cord-263455-dquztf5l	599	12	BCG	BCG	NNP
cord-263455-dquztf5l	599	13	,	,	,
cord-263455-dquztf5l	599	14	or	or	CC
cord-263455-dquztf5l	599	15	combined	combine	VBN
cord-263455-dquztf5l	599	16	BCG	BCG	NNP
cord-263455-dquztf5l	599	17	and	and	CC
cord-263455-dquztf5l	599	18	killed	kill	VBD
cord-263455-dquztf5l	599	19	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	599	20	leprae	leprae	JJ
cord-263455-dquztf5l	599	21	vaccine	vaccine	NN
cord-263455-dquztf5l	599	22	for	for	IN
cord-263455-dquztf5l	599	23	prevention	prevention	NN
cord-263455-dquztf5l	599	24	of	of	IN
cord-263455-dquztf5l	599	25	leprosy	leprosy	NN
cord-263455-dquztf5l	599	26	and	and	CC
cord-263455-dquztf5l	599	27	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	599	28	in	in	IN
cord-263455-dquztf5l	599	29	Malawi	Malawi	NNP
cord-263455-dquztf5l	599	30	.	.	.
cord-263455-dquztf5l	600	1	Karonga	Karonga	NNP
cord-263455-dquztf5l	600	2	Prevention	Prevention	NNP
cord-263455-dquztf5l	600	3	Trial	Trial	NNP
cord-263455-dquztf5l	600	4	Group	Group	NNP
cord-263455-dquztf5l	600	5	Vaccination	Vaccination	NNP
cord-263455-dquztf5l	600	6	against	against	IN
cord-263455-dquztf5l	600	7	leprosy	leprosy	NN
cord-263455-dquztf5l	600	8	at	at	IN
cord-263455-dquztf5l	600	9	Ben	Ben	NNP
cord-263455-dquztf5l	600	10	San	San	NNP
cord-263455-dquztf5l	600	11	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	600	12	Centre	Centre	NNP
cord-263455-dquztf5l	600	13	Vaccines	Vaccines	NNPS
cord-263455-dquztf5l	600	14	for	for	IN
cord-263455-dquztf5l	600	15	leprosy	leprosy	NN
cord-263455-dquztf5l	600	16	and	and	CC
cord-263455-dquztf5l	600	17	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	600	18	:	:	:
cord-263455-dquztf5l	600	19	opportunities	opportunity	NNS
cord-263455-dquztf5l	600	20	for	for	IN
cord-263455-dquztf5l	600	21	shared	share	VBN
cord-263455-dquztf5l	600	22	research	research	NN
cord-263455-dquztf5l	600	23	,	,	,
cord-263455-dquztf5l	600	24	development	development	NN
cord-263455-dquztf5l	600	25	,	,	,
cord-263455-dquztf5l	600	26	and	and	CC
cord-263455-dquztf5l	600	27	application	application	NN
cord-263455-dquztf5l	600	28	LepVax	LepVax	NNP
cord-263455-dquztf5l	600	29	,	,	,
cord-263455-dquztf5l	600	30	a	a	DT
cord-263455-dquztf5l	600	31	defined	define	VBN
cord-263455-dquztf5l	600	32	subunit	subunit	NN
cord-263455-dquztf5l	600	33	vaccine	vaccine	NN
cord-263455-dquztf5l	600	34	that	that	WDT
cord-263455-dquztf5l	600	35	provides	provide	VBZ
cord-263455-dquztf5l	600	36	effective	effective	JJ
cord-263455-dquztf5l	600	37	pre	pre	JJ
cord-263455-dquztf5l	600	38	-	-	NN
cord-263455-dquztf5l	600	39	exposure	exposure	JJ
cord-263455-dquztf5l	600	40	and	and	CC
cord-263455-dquztf5l	600	41	post	post	JJ
cord-263455-dquztf5l	600	42	-	-	JJ
cord-263455-dquztf5l	600	43	exposure	exposure	JJ
cord-263455-dquztf5l	600	44	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	600	45	of	of	IN
cord-263455-dquztf5l	600	46	M.	M.	NNP
cord-263455-dquztf5l	600	47	leprae	leprae	NNP
cord-263455-dquztf5l	600	48	infection	infection	NN
cord-263455-dquztf5l	600	49	Addition	addition	NN
cord-263455-dquztf5l	600	50	of	of	IN
cord-263455-dquztf5l	600	51	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	600	52	indicus	indicus	NN
cord-263455-dquztf5l	600	53	pranii	pranii	NNP
cord-263455-dquztf5l	600	54	(	(	-LRB-
cord-263455-dquztf5l	600	55	MIP	MIP	NNP
cord-263455-dquztf5l	600	56	)	)	-RRB-
cord-263455-dquztf5l	600	57	vaccine	vaccine	NN
cord-263455-dquztf5l	600	58	as	as	IN
cord-263455-dquztf5l	600	59	an	an	DT
cord-263455-dquztf5l	600	60	immunotherapeutic	immunotherapeutic	NN
cord-263455-dquztf5l	600	61	with	with	IN
cord-263455-dquztf5l	600	62	standard	standard	JJ
cord-263455-dquztf5l	600	63	chemotherapy	chemotherapy	NN
cord-263455-dquztf5l	600	64	in	in	IN
cord-263455-dquztf5l	600	65	borderline	borderline	JJ
cord-263455-dquztf5l	600	66	leprosy	leprosy	NN
cord-263455-dquztf5l	600	67	:	:	:
cord-263455-dquztf5l	600	68	a	a	DT
cord-263455-dquztf5l	600	69	double	double	JJ
cord-263455-dquztf5l	600	70	blind	blind	JJ
cord-263455-dquztf5l	600	71	study	study	NN
cord-263455-dquztf5l	600	72	to	to	TO
cord-263455-dquztf5l	600	73	assess	assess	VB
cord-263455-dquztf5l	600	74	clinical	clinical	JJ
cord-263455-dquztf5l	600	75	improvement	improvement	NN
cord-263455-dquztf5l	600	76	(	(	-LRB-
cord-263455-dquztf5l	600	77	a	a	DT
cord-263455-dquztf5l	600	78	preliminary	preliminary	JJ
cord-263455-dquztf5l	600	79	report	report	NN
cord-263455-dquztf5l	600	80	)	)	-RRB-
cord-263455-dquztf5l	601	1	Review	Review	NNP
cord-263455-dquztf5l	601	2	of	of	IN
cord-263455-dquztf5l	601	3	global	global	JJ
cord-263455-dquztf5l	601	4	leprosy	leprosy	NN
cord-263455-dquztf5l	601	5	vaccine	vaccine	NN
cord-263455-dquztf5l	601	6	development	development	NN
cord-263455-dquztf5l	601	7	Second	second	RB
cord-263455-dquztf5l	601	8	coming	coming	NN
cord-263455-dquztf5l	601	9	:	:	:
cord-263455-dquztf5l	601	10	the	the	DT
cord-263455-dquztf5l	601	11	re	re	NN
cord-263455-dquztf5l	601	12	-	-	NN
cord-263455-dquztf5l	601	13	emergence	emergence	NN
cord-263455-dquztf5l	601	14	and	and	CC
cord-263455-dquztf5l	601	15	modernization	modernization	NN
cord-263455-dquztf5l	601	16	of	of	IN
cord-263455-dquztf5l	601	17	immunotherapy	immunotherapy	NN
cord-263455-dquztf5l	601	18	by	by	IN
cord-263455-dquztf5l	601	19	vaccines	vaccine	NNS
cord-263455-dquztf5l	601	20	as	as	IN
cord-263455-dquztf5l	601	21	a	a	DT
cord-263455-dquztf5l	601	22	component	component	NN
cord-263455-dquztf5l	601	23	of	of	IN
cord-263455-dquztf5l	601	24	leprosy	leprosy	NN
cord-263455-dquztf5l	601	25	control	control	NN
cord-263455-dquztf5l	601	26	Making	make	VBG
cord-263455-dquztf5l	601	27	of	of	IN
cord-263455-dquztf5l	601	28	a	a	DT
cord-263455-dquztf5l	601	29	highly	highly	RB
cord-263455-dquztf5l	601	30	useful	useful	JJ
cord-263455-dquztf5l	601	31	multipurpose	multipurpose	JJ
cord-263455-dquztf5l	601	32	vaccine	vaccine	NN
cord-263455-dquztf5l	602	1	The	the	DT
cord-263455-dquztf5l	602	2	use	use	NN
cord-263455-dquztf5l	602	3	of	of	IN
cord-263455-dquztf5l	602	4	the	the	DT
cord-263455-dquztf5l	602	5	name	name	NN
cord-263455-dquztf5l	602	6	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	602	7	w	w	NNP
cord-263455-dquztf5l	602	8	for	for	IN
cord-263455-dquztf5l	602	9	the	the	DT
cord-263455-dquztf5l	602	10	leprosy	leprosy	NN
cord-263455-dquztf5l	602	11	immunotherapeutic	immunotherapeutic	NNP
cord-263455-dquztf5l	602	12	bacillus	bacillus	NN
cord-263455-dquztf5l	602	13	creates	create	VBZ
cord-263455-dquztf5l	602	14	confusion	confusion	NN
cord-263455-dquztf5l	602	15	with	with	IN
cord-263455-dquztf5l	602	16	M.	M.	NNP
cord-263455-dquztf5l	602	17	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	602	18	-	-	HYPH
cord-263455-dquztf5l	602	19	W	W	NNP
cord-263455-dquztf5l	602	20	(	(	-LRB-
cord-263455-dquztf5l	602	21	Beijing	Beijing	NNP
cord-263455-dquztf5l	602	22	strain	strain	NN
cord-263455-dquztf5l	602	23	)	)	-RRB-
cord-263455-dquztf5l	602	24	:	:	:
cord-263455-dquztf5l	602	25	a	a	DT
cord-263455-dquztf5l	602	26	suggestion	suggestion	NN
cord-263455-dquztf5l	602	27	Clinical	clinical	JJ
cord-263455-dquztf5l	602	28	and	and	CC
cord-263455-dquztf5l	602	29	histopathological	histopathological	JJ
cord-263455-dquztf5l	602	30	evaluation	evaluation	NN
cord-263455-dquztf5l	602	31	of	of	IN
cord-263455-dquztf5l	602	32	the	the	DT
cord-263455-dquztf5l	602	33	effect	effect	NN
cord-263455-dquztf5l	602	34	of	of	IN
cord-263455-dquztf5l	602	35	addition	addition	NN
cord-263455-dquztf5l	602	36	of	of	IN
cord-263455-dquztf5l	602	37	immunotherapy	immunotherapy	NN
cord-263455-dquztf5l	602	38	with	with	IN
cord-263455-dquztf5l	602	39	Mw	Mw	NNP
cord-263455-dquztf5l	602	40	vaccine	vaccine	NN
cord-263455-dquztf5l	602	41	to	to	IN
cord-263455-dquztf5l	602	42	standard	standard	JJ
cord-263455-dquztf5l	602	43	chemotherapy	chemotherapy	NN
cord-263455-dquztf5l	602	44	in	in	IN
cord-263455-dquztf5l	602	45	borderline	borderline	JJ
cord-263455-dquztf5l	602	46	leprosy	leprosy	NN
cord-263455-dquztf5l	602	47	Addition	addition	NN
cord-263455-dquztf5l	602	48	of	of	IN
cord-263455-dquztf5l	602	49	immunotherapy	immunotherapy	NN
cord-263455-dquztf5l	602	50	to	to	IN
cord-263455-dquztf5l	602	51	chemotherapy	chemotherapy	NN
cord-263455-dquztf5l	602	52	in	in	IN
cord-263455-dquztf5l	602	53	pediatric	pediatric	JJ
cord-263455-dquztf5l	602	54	borderline	borderline	JJ
cord-263455-dquztf5l	602	55	leprosy	leprosy	NN
cord-263455-dquztf5l	602	56	:	:	:
cord-263455-dquztf5l	602	57	a	a	DT
cord-263455-dquztf5l	602	58	clinical	clinical	JJ
cord-263455-dquztf5l	602	59	evaluation	evaluation	NN
cord-263455-dquztf5l	602	60	International	International	NNP
cord-263455-dquztf5l	602	61	Federation	Federation	NNP
cord-263455-dquztf5l	602	62	of	of	IN
cord-263455-dquztf5l	602	63	Anti	Anti	NNP
cord-263455-dquztf5l	602	64	-	-	NNP
cord-263455-dquztf5l	602	65	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	602	66	Associations	Associations	NNPS
cord-263455-dquztf5l	602	67	.	.	.
cord-263455-dquztf5l	603	1	The	the	DT
cord-263455-dquztf5l	603	2	leprosy	leprosy	NN
cord-263455-dquztf5l	603	3	vaccine	vaccine	NN
cord-263455-dquztf5l	603	4	Prophylactic	prophylactic	JJ
cord-263455-dquztf5l	603	5	value	value	NN
cord-263455-dquztf5l	603	6	of	of	IN
cord-263455-dquztf5l	603	7	dapsone	dapsone	NN
cord-263455-dquztf5l	603	8	in	in	IN
cord-263455-dquztf5l	603	9	leprosy	leprosy	NN
cord-263455-dquztf5l	603	10	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	603	11	of	of	IN
cord-263455-dquztf5l	603	12	leprosy	leprosy	NN
cord-263455-dquztf5l	603	13	contacts	contact	NNS
cord-263455-dquztf5l	603	14	with	with	IN
cord-263455-dquztf5l	603	15	D.D.	D.D.	NNP
cord-263455-dquztf5l	603	16	S	S	NNP
cord-263455-dquztf5l	603	17	DDs	DDs	NNP
cord-263455-dquztf5l	603	18	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	603	19	against	against	IN
cord-263455-dquztf5l	603	20	leprosy	leprosy	NN
cord-263455-dquztf5l	603	21	Four	four	CD
cord-263455-dquztf5l	603	22	years	year	NNS
cord-263455-dquztf5l	603	23	'	'	POS
cord-263455-dquztf5l	603	24	experience	experience	NN
cord-263455-dquztf5l	603	25	with	with	IN
cord-263455-dquztf5l	603	26	dapsone	dapsone	NN
cord-263455-dquztf5l	603	27	as	as	IN
cord-263455-dquztf5l	603	28	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	603	29	against	against	IN
cord-263455-dquztf5l	604	1	leprosy	leprosy	NN
cord-263455-dquztf5l	604	2	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	604	3	among	among	IN
cord-263455-dquztf5l	604	4	contacts	contact	NNS
cord-263455-dquztf5l	604	5	of	of	IN
cord-263455-dquztf5l	604	6	non	non	JJ
cord-263455-dquztf5l	604	7	-	-	JJ
cord-263455-dquztf5l	604	8	lepromatous	lepromatous	JJ
cord-263455-dquztf5l	604	9	leprosy	leprosy	NN
cord-263455-dquztf5l	604	10	Long	long	JJ
cord-263455-dquztf5l	604	11	-	-	HYPH
cord-263455-dquztf5l	604	12	term	term	NN
cord-263455-dquztf5l	604	13	effects	effect	NNS
cord-263455-dquztf5l	604	14	of	of	IN
cord-263455-dquztf5l	604	15	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	604	16	among	among	IN
cord-263455-dquztf5l	604	17	contacts	contact	NNS
cord-263455-dquztf5l	604	18	of	of	IN
cord-263455-dquztf5l	604	19	lepromatous	lepromatous	JJ
cord-263455-dquztf5l	604	20	cases	case	NNS
cord-263455-dquztf5l	604	21	.	.	.
cord-263455-dquztf5l	605	1	Results	result	NNS
cord-263455-dquztf5l	605	2	of	of	IN
cord-263455-dquztf5l	605	3	a	a	DT
cord-263455-dquztf5l	605	4	8.5	8.5	CD
cord-263455-dquztf5l	605	5	years	year	NNS
cord-263455-dquztf5l	605	6	follow	follow	NN
cord-263455-dquztf5l	605	7	-	-	HYPH
cord-263455-dquztf5l	605	8	up	up	RP
cord-263455-dquztf5l	605	9	Antileprosy	Antileprosy	NNP
cord-263455-dquztf5l	605	10	measures	measure	NNS
cord-263455-dquztf5l	605	11	in	in	IN
cord-263455-dquztf5l	605	12	Bombay	Bombay	NNP
cord-263455-dquztf5l	605	13	,	,	,
cord-263455-dquztf5l	605	14	India	India	NNP
cord-263455-dquztf5l	605	15	:	:	:
cord-263455-dquztf5l	605	16	an	an	DT
cord-263455-dquztf5l	605	17	analysis	analysis	NN
cord-263455-dquztf5l	605	18	of	of	IN
cord-263455-dquztf5l	605	19	10	10	CD
cord-263455-dquztf5l	605	20	years	year	NNS
cord-263455-dquztf5l	605	21	'	'	POS
cord-263455-dquztf5l	605	22	work	work	NN
cord-263455-dquztf5l	605	23	Prevention	prevention	NN
cord-263455-dquztf5l	605	24	and	and	CC
cord-263455-dquztf5l	605	25	early	early	JJ
cord-263455-dquztf5l	605	26	detection	detection	NN
cord-263455-dquztf5l	605	27	of	of	IN
cord-263455-dquztf5l	605	28	leprosy	leprosy	NN
cord-263455-dquztf5l	605	29	in	in	IN
cord-263455-dquztf5l	605	30	children	child	NNS
cord-263455-dquztf5l	605	31	Management	Management	NNP
cord-263455-dquztf5l	605	32	of	of	IN
cord-263455-dquztf5l	605	33	household	household	NN
cord-263455-dquztf5l	605	34	contacts	contact	NNS
cord-263455-dquztf5l	605	35	of	of	IN
cord-263455-dquztf5l	605	36	leprosy	leprosy	NN
cord-263455-dquztf5l	605	37	patients	patient	NNS
cord-263455-dquztf5l	606	1	Repository	repository	NN
cord-263455-dquztf5l	606	2	acedapsone	acedapsone	NN
cord-263455-dquztf5l	606	3	in	in	IN
cord-263455-dquztf5l	606	4	leprosy	leprosy	NN
cord-263455-dquztf5l	606	5	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	606	6	and	and	CC
cord-263455-dquztf5l	606	7	treatment	treatment	NN
cord-263455-dquztf5l	606	8	Experience	experience	NN
cord-263455-dquztf5l	606	9	with	with	IN
cord-263455-dquztf5l	606	10	acedapsone	acedapsone	NN
cord-263455-dquztf5l	606	11	(	(	-LRB-
cord-263455-dquztf5l	606	12	DADDS	DADDS	NNP
cord-263455-dquztf5l	606	13	)	)	-RRB-
cord-263455-dquztf5l	606	14	in	in	IN
cord-263455-dquztf5l	606	15	the	the	DT
cord-263455-dquztf5l	606	16	therapeutic	therapeutic	JJ
cord-263455-dquztf5l	606	17	trial	trial	NN
cord-263455-dquztf5l	606	18	in	in	IN
cord-263455-dquztf5l	606	19	New	New	NNP
cord-263455-dquztf5l	606	20	Guinea	Guinea	NNP
cord-263455-dquztf5l	606	21	and	and	CC
cord-263455-dquztf5l	606	22	the	the	DT
cord-263455-dquztf5l	606	23	chemoprophylactic	chemoprophylactic	JJ
cord-263455-dquztf5l	606	24	trial	trial	NN
cord-263455-dquztf5l	606	25	in	in	IN
cord-263455-dquztf5l	606	26	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	606	27	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	606	28	against	against	IN
cord-263455-dquztf5l	606	29	leprosy	leprosy	NN
cord-263455-dquztf5l	606	30	with	with	IN
cord-263455-dquztf5l	606	31	acedapsone	acedapsone	NN
cord-263455-dquztf5l	606	32	Limited	Limited	NNP
cord-263455-dquztf5l	606	33	duration	duration	NN
cord-263455-dquztf5l	606	34	acedapsone	acedapsone	NN
cord-263455-dquztf5l	606	35	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	606	36	in	in	IN
cord-263455-dquztf5l	606	37	leprosy	leprosy	NN
cord-263455-dquztf5l	607	1	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	607	2	is	be	VBZ
cord-263455-dquztf5l	607	3	effective	effective	JJ
cord-263455-dquztf5l	607	4	in	in	IN
cord-263455-dquztf5l	607	5	the	the	DT
cord-263455-dquztf5l	607	6	prevention	prevention	NN
cord-263455-dquztf5l	607	7	of	of	IN
cord-263455-dquztf5l	607	8	leprosy	leprosy	NN
cord-263455-dquztf5l	607	9	in	in	IN
cord-263455-dquztf5l	607	10	endemic	endemic	JJ
cord-263455-dquztf5l	607	11	countries	country	NNS
cord-263455-dquztf5l	607	12	:	:	:
cord-263455-dquztf5l	607	13	a	a	DT
cord-263455-dquztf5l	607	14	systematic	systematic	JJ
cord-263455-dquztf5l	607	15	review	review	NN
cord-263455-dquztf5l	607	16	and	and	CC
cord-263455-dquztf5l	607	17	meta	meta	NNP
cord-263455-dquztf5l	607	18	-	-	HYPH
cord-263455-dquztf5l	607	19	analysis	analysis	NN
cord-263455-dquztf5l	607	20	.	.	.
cord-263455-dquztf5l	608	1	MILEP2	MILEP2	NNP
cord-263455-dquztf5l	608	2	study	study	NN
cord-263455-dquztf5l	608	3	group	group	NN
cord-263455-dquztf5l	608	4	.	.	.
cord-263455-dquztf5l	609	1	Mucosal	Mucosal	NNP
cord-263455-dquztf5l	609	2	immunology	immunology	NN
cord-263455-dquztf5l	609	3	of	of	IN
cord-263455-dquztf5l	609	4	leprosy	leprosy	NN
cord-263455-dquztf5l	609	5	Workshop	Workshop	NNP
cord-263455-dquztf5l	609	6	on	on	IN
cord-263455-dquztf5l	609	7	the	the	DT
cord-263455-dquztf5l	609	8	prevention	prevention	NN
cord-263455-dquztf5l	609	9	of	of	IN
cord-263455-dquztf5l	609	10	leprosy	leprosy	NN
cord-263455-dquztf5l	609	11	,	,	,
cord-263455-dquztf5l	609	12	Pohnpei	Pohnpei	NNP
cord-263455-dquztf5l	609	13	,	,	,
cord-263455-dquztf5l	609	14	Federated	Federated	NNP
cord-263455-dquztf5l	609	15	States	States	NNP
cord-263455-dquztf5l	609	16	of	of	IN
cord-263455-dquztf5l	609	17	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	609	18	Implementation	Implementation	NNP
cord-263455-dquztf5l	609	19	of	of	IN
cord-263455-dquztf5l	609	20	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	609	21	of	of	IN
cord-263455-dquztf5l	609	22	leprosy	leprosy	NN
cord-263455-dquztf5l	609	23	in	in	IN
cord-263455-dquztf5l	609	24	the	the	DT
cord-263455-dquztf5l	609	25	Southern	Southern	NNP
cord-263455-dquztf5l	609	26	Marquesas	Marquesas	NNP
cord-263455-dquztf5l	609	27	with	with	IN
cord-263455-dquztf5l	609	28	a	a	DT
cord-263455-dquztf5l	609	29	single	single	JJ
cord-263455-dquztf5l	609	30	dose	dose	NN
cord-263455-dquztf5l	609	31	of	of	IN
cord-263455-dquztf5l	609	32	25	25	CD
cord-263455-dquztf5l	609	33	mg	mg	NN
cord-263455-dquztf5l	609	34	per	per	IN
cord-263455-dquztf5l	609	35	kg	kg	NN
cord-263455-dquztf5l	610	1	rifampin	rifampin	UH
cord-263455-dquztf5l	610	2	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	610	3	of	of	IN
cord-263455-dquztf5l	610	4	leprosy	leprosy	NN
cord-263455-dquztf5l	610	5	with	with	IN
cord-263455-dquztf5l	610	6	a	a	DT
cord-263455-dquztf5l	610	7	single	single	JJ
cord-263455-dquztf5l	610	8	dose	dose	NN
cord-263455-dquztf5l	610	9	of	of	IN
cord-263455-dquztf5l	610	10	25	25	CD
cord-263455-dquztf5l	610	11	mg	mg	NN
cord-263455-dquztf5l	610	12	per	per	IN
cord-263455-dquztf5l	610	13	kg	kg	NN
cord-263455-dquztf5l	610	14	rifampin	rifampin	NN
cord-263455-dquztf5l	610	15	in	in	IN
cord-263455-dquztf5l	610	16	the	the	DT
cord-263455-dquztf5l	610	17	Southern	Southern	NNP
cord-263455-dquztf5l	610	18	Marquesas	Marquesas	NNP
cord-263455-dquztf5l	610	19	;	;	:
cord-263455-dquztf5l	610	20	Results	result	NNS
cord-263455-dquztf5l	610	21	after	after	IN
cord-263455-dquztf5l	610	22	four	four	CD
cord-263455-dquztf5l	610	23	years	year	NNS
cord-263455-dquztf5l	610	24	Monitoring	monitor	VBG
cord-263455-dquztf5l	610	25	the	the	DT
cord-263455-dquztf5l	610	26	effects	effect	NNS
cord-263455-dquztf5l	610	27	of	of	IN
cord-263455-dquztf5l	610	28	preventive	preventive	JJ
cord-263455-dquztf5l	610	29	therapy	therapy	NN
cord-263455-dquztf5l	610	30	in	in	IN
cord-263455-dquztf5l	610	31	the	the	DT
cord-263455-dquztf5l	610	32	Federated	Federated	NNP
cord-263455-dquztf5l	610	33	States	States	NNP
cord-263455-dquztf5l	610	34	of	of	IN
cord-263455-dquztf5l	610	35	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	610	36	Elimination	Elimination	NNP
cord-263455-dquztf5l	610	37	of	of	IN
cord-263455-dquztf5l	610	38	leprosy	leprosy	NN
cord-263455-dquztf5l	610	39	in	in	IN
cord-263455-dquztf5l	610	40	the	the	DT
cord-263455-dquztf5l	610	41	federated	federated	JJ
cord-263455-dquztf5l	610	42	states	states	NNP
cord-263455-dquztf5l	610	43	of	of	IN
cord-263455-dquztf5l	610	44	micronesia	micronesia	NNP
cord-263455-dquztf5l	610	45	by	by	IN
cord-263455-dquztf5l	610	46	intensive	intensive	JJ
cord-263455-dquztf5l	610	47	case	case	NN
cord-263455-dquztf5l	610	48	finding	finding	NN
cord-263455-dquztf5l	610	49	,	,	,
cord-263455-dquztf5l	610	50	treatment	treatment	NN
cord-263455-dquztf5l	610	51	with	with	IN
cord-263455-dquztf5l	610	52	WHO	WHO	NNP
cord-263455-dquztf5l	610	53	/	/	SYM
cord-263455-dquztf5l	610	54	MDT	MDT	NNP
cord-263455-dquztf5l	610	55	and	and	CC
cord-263455-dquztf5l	610	56	administration	administration	NN
cord-263455-dquztf5l	610	57	of	of	IN
cord-263455-dquztf5l	610	58	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	610	59	Implementation	Implementation	NNP
cord-263455-dquztf5l	610	60	of	of	IN
cord-263455-dquztf5l	610	61	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	610	62	in	in	IN
cord-263455-dquztf5l	610	63	Chuuk	Chuuk	NNP
cord-263455-dquztf5l	610	64	State	State	NNP
cord-263455-dquztf5l	610	65	,	,	,
cord-263455-dquztf5l	610	66	Federated	Federated	NNP
cord-263455-dquztf5l	610	67	States	States	NNP
cord-263455-dquztf5l	610	68	of	of	IN
cord-263455-dquztf5l	610	69	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	610	70	Implementation	Implementation	NNP
cord-263455-dquztf5l	610	71	of	of	IN
cord-263455-dquztf5l	610	72	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	610	73	in	in	IN
cord-263455-dquztf5l	610	74	Pohnpei	Pohnpei	NNP
cord-263455-dquztf5l	610	75	State	State	NNP
cord-263455-dquztf5l	610	76	,	,	,
cord-263455-dquztf5l	610	77	Federated	Federated	NNP
cord-263455-dquztf5l	610	78	States	States	NNP
cord-263455-dquztf5l	610	79	of	of	IN
cord-263455-dquztf5l	610	80	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	610	81	Population	Population	NNP
cord-263455-dquztf5l	610	82	screening	screening	NN
cord-263455-dquztf5l	610	83	and	and	CC
cord-263455-dquztf5l	610	84	mass	mass	NN
cord-263455-dquztf5l	610	85	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	610	86	in	in	IN
cord-263455-dquztf5l	610	87	Kiribati	Kiribati	NNP
cord-263455-dquztf5l	610	88	Population	Population	NNP
cord-263455-dquztf5l	610	89	screening	screening	NN
cord-263455-dquztf5l	610	90	and	and	CC
cord-263455-dquztf5l	610	91	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	610	92	for	for	IN
cord-263455-dquztf5l	610	93	household	household	NN
cord-263455-dquztf5l	610	94	contacts	contact	NNS
cord-263455-dquztf5l	610	95	of	of	IN
cord-263455-dquztf5l	610	96	leprosy	leprosy	NN
cord-263455-dquztf5l	610	97	patients	patient	NNS
cord-263455-dquztf5l	610	98	in	in	IN
cord-263455-dquztf5l	610	99	the	the	DT
cord-263455-dquztf5l	610	100	Republic	Republic	NNP
cord-263455-dquztf5l	610	101	of	of	IN
cord-263455-dquztf5l	610	102	the	the	DT
cord-263455-dquztf5l	610	103	Marshall	Marshall	NNP
cord-263455-dquztf5l	610	104	Islands	Islands	NNPS
cord-263455-dquztf5l	610	105	Drugs	drug	NNS
cord-263455-dquztf5l	610	106	and	and	CC
cord-263455-dquztf5l	610	107	regimens	regimen	NNS
cord-263455-dquztf5l	610	108	for	for	IN
cord-263455-dquztf5l	610	109	preventive	preventive	JJ
cord-263455-dquztf5l	610	110	therapy	therapy	NN
cord-263455-dquztf5l	610	111	against	against	IN
cord-263455-dquztf5l	610	112	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	610	113	,	,	,
cord-263455-dquztf5l	610	114	disseminated	disseminate	VBD
cord-263455-dquztf5l	610	115	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	610	116	avium	avium	NN
cord-263455-dquztf5l	610	117	complex	complex	JJ
cord-263455-dquztf5l	610	118	infection	infection	NN
cord-263455-dquztf5l	610	119	and	and	CC
cord-263455-dquztf5l	610	120	leprosy	leprosy	NN
cord-263455-dquztf5l	611	1	The	the	DT
cord-263455-dquztf5l	611	2	future	future	NN
cord-263455-dquztf5l	611	3	of	of	IN
cord-263455-dquztf5l	611	4	leprosy	leprosy	NN
cord-263455-dquztf5l	611	5	elimination	elimination	NN
cord-263455-dquztf5l	611	6	Rationale	rationale	NN
cord-263455-dquztf5l	611	7	for	for	IN
cord-263455-dquztf5l	611	8	the	the	DT
cord-263455-dquztf5l	611	9	preventive	preventive	JJ
cord-263455-dquztf5l	611	10	treatment	treatment	NN
cord-263455-dquztf5l	611	11	of	of	IN
cord-263455-dquztf5l	611	12	leprosy	leprosy	NN
cord-263455-dquztf5l	611	13	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	611	14	of	of	IN
cord-263455-dquztf5l	611	15	leprosy	leprosy	NN
cord-263455-dquztf5l	611	16	in	in	IN
cord-263455-dquztf5l	611	17	the	the	DT
cord-263455-dquztf5l	611	18	Southern	Southern	NNP
cord-263455-dquztf5l	611	19	Marquesas	Marquesas	NNP
cord-263455-dquztf5l	611	20	with	with	IN
cord-263455-dquztf5l	611	21	a	a	DT
cord-263455-dquztf5l	611	22	single	single	JJ
cord-263455-dquztf5l	611	23	25	25	CD
cord-263455-dquztf5l	611	24	mg	mg	NNP
cord-263455-dquztf5l	611	25	/	/	SYM
cord-263455-dquztf5l	611	26	kg	kg	NN
cord-263455-dquztf5l	611	27	dose	dose	NN
cord-263455-dquztf5l	611	28	of	of	IN
cord-263455-dquztf5l	611	29	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	611	30	.	.	.
cord-263455-dquztf5l	612	1	Results	result	NNS
cord-263455-dquztf5l	612	2	after	after	IN
cord-263455-dquztf5l	612	3	10	10	CD
cord-263455-dquztf5l	612	4	years	year	NNS
cord-263455-dquztf5l	612	5	Leprosy	leprosy	NN
cord-263455-dquztf5l	612	6	chemoprophylaxis	chemoprophylaxis	JJ
cord-263455-dquztf5l	612	7	in	in	IN
cord-263455-dquztf5l	612	8	Micronesia	Micronesia	NNP
cord-263455-dquztf5l	612	9	Eficacia	Eficacia	NNP
cord-263455-dquztf5l	612	10	de	de	NNP
cord-263455-dquztf5l	612	11	la	la	NNP
cord-263455-dquztf5l	612	12	rifampicina	rifampicina	NNP
cord-263455-dquztf5l	613	1	como	como	NNP
cord-263455-dquztf5l	613	2	profiláctico	profiláctico	NNP
cord-263455-dquztf5l	613	3	en	en	IN
cord-263455-dquztf5l	613	4	contactos	contactos	NNP
cord-263455-dquztf5l	613	5	de	de	FW
cord-263455-dquztf5l	613	6	primer	primer	NNP
cord-263455-dquztf5l	613	7	orden	orden	NNP
cord-263455-dquztf5l	613	8	de	de	NNP
cord-263455-dquztf5l	613	9	lepra	lepra	NNP
cord-263455-dquztf5l	613	10	A	a	DT
cord-263455-dquztf5l	613	11	study	study	NN
cord-263455-dquztf5l	613	12	on	on	IN
cord-263455-dquztf5l	613	13	transmission	transmission	NN
cord-263455-dquztf5l	613	14	and	and	CC
cord-263455-dquztf5l	613	15	a	a	DT
cord-263455-dquztf5l	613	16	trial	trial	NN
cord-263455-dquztf5l	613	17	of	of	IN
cord-263455-dquztf5l	613	18	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	613	19	in	in	IN
cord-263455-dquztf5l	613	20	contacts	contact	NNS
cord-263455-dquztf5l	613	21	of	of	IN
cord-263455-dquztf5l	613	22	leprosy	leprosy	NN
cord-263455-dquztf5l	613	23	patients	patient	NNS
cord-263455-dquztf5l	613	24	:	:	:
cord-263455-dquztf5l	614	1	design	design	NN
cord-263455-dquztf5l	614	2	,	,	,
cord-263455-dquztf5l	614	3	methodology	methodology	NN
cord-263455-dquztf5l	614	4	and	and	CC
cord-263455-dquztf5l	614	5	recruitment	recruitment	NN
cord-263455-dquztf5l	614	6	findings	finding	NNS
cord-263455-dquztf5l	614	7	of	of	IN
cord-263455-dquztf5l	614	8	COLEP	COLEP	NNP
cord-263455-dquztf5l	614	9	Effectiveness	Effectiveness	NNP
cord-263455-dquztf5l	614	10	of	of	IN
cord-263455-dquztf5l	614	11	single	single	JJ
cord-263455-dquztf5l	614	12	dose	dose	NN
cord-263455-dquztf5l	614	13	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	614	14	in	in	IN
cord-263455-dquztf5l	614	15	preventing	prevent	VBG
cord-263455-dquztf5l	614	16	leprosy	leprosy	NN
cord-263455-dquztf5l	614	17	in	in	IN
cord-263455-dquztf5l	614	18	close	close	JJ
cord-263455-dquztf5l	614	19	contacts	contact	NNS
cord-263455-dquztf5l	614	20	of	of	IN
cord-263455-dquztf5l	614	21	patients	patient	NNS
cord-263455-dquztf5l	614	22	with	with	IN
cord-263455-dquztf5l	614	23	newly	newly	RB
cord-263455-dquztf5l	614	24	diagnosed	diagnose	VBN
cord-263455-dquztf5l	614	25	leprosy	leprosy	NN
cord-263455-dquztf5l	614	26	:	:	:
cord-263455-dquztf5l	615	1	cluster	cluster	NN
cord-263455-dquztf5l	615	2	randomised	randomise	VBD
cord-263455-dquztf5l	615	3	controlled	control	VBN
cord-263455-dquztf5l	615	4	trial	trial	NN
cord-263455-dquztf5l	615	5	Cost	cost	NN
cord-263455-dquztf5l	615	6	-	-	HYPH
cord-263455-dquztf5l	615	7	effectiveness	effectiveness	NN
cord-263455-dquztf5l	615	8	of	of	IN
cord-263455-dquztf5l	615	9	a	a	DT
cord-263455-dquztf5l	615	10	chemoprophylactic	chemoprophylactic	JJ
cord-263455-dquztf5l	615	11	intervention	intervention	NN
cord-263455-dquztf5l	615	12	with	with	IN
cord-263455-dquztf5l	615	13	single	single	JJ
cord-263455-dquztf5l	615	14	dose	dose	NN
cord-263455-dquztf5l	615	15	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	615	16	in	in	IN
cord-263455-dquztf5l	615	17	contacts	contact	NNS
cord-263455-dquztf5l	615	18	of	of	IN
cord-263455-dquztf5l	615	19	new	new	JJ
cord-263455-dquztf5l	615	20	leprosy	leprosy	NN
cord-263455-dquztf5l	615	21	patients	patient	NNS
cord-263455-dquztf5l	615	22	Protective	protective	JJ
cord-263455-dquztf5l	615	23	effect	effect	NN
cord-263455-dquztf5l	615	24	of	of	IN
cord-263455-dquztf5l	615	25	the	the	DT
cord-263455-dquztf5l	615	26	combination	combination	NN
cord-263455-dquztf5l	615	27	BCG	BCG	NNP
cord-263455-dquztf5l	615	28	vaccination	vaccination	NN
cord-263455-dquztf5l	615	29	and	and	CC
cord-263455-dquztf5l	615	30	rifampicin	rifampicin	NN
cord-263455-dquztf5l	615	31	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	615	32	in	in	IN
cord-263455-dquztf5l	615	33	leprosy	leprosy	NN
cord-263455-dquztf5l	615	34	prevention	prevention	NN
cord-263455-dquztf5l	615	35	Acceptability	Acceptability	NNP
cord-263455-dquztf5l	615	36	of	of	IN
cord-263455-dquztf5l	615	37	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	615	38	for	for	IN
cord-263455-dquztf5l	615	39	household	household	NN
cord-263455-dquztf5l	615	40	contacts	contact	NNS
cord-263455-dquztf5l	615	41	of	of	IN
cord-263455-dquztf5l	615	42	leprosy	leprosy	NN
cord-263455-dquztf5l	615	43	patients	patient	NNS
cord-263455-dquztf5l	615	44	in	in	IN
cord-263455-dquztf5l	615	45	Bangladesh	Bangladesh	NNP
cord-263455-dquztf5l	615	46	:	:	:
cord-263455-dquztf5l	615	47	a	a	DT
cord-263455-dquztf5l	615	48	qualitative	qualitative	JJ
cord-263455-dquztf5l	615	49	study	study	NN
cord-263455-dquztf5l	615	50	Report	Report	NNP
cord-263455-dquztf5l	615	51	of	of	IN
cord-263455-dquztf5l	615	52	the	the	DT
cord-263455-dquztf5l	615	53	workshop	workshop	NN
cord-263455-dquztf5l	615	54	on	on	IN
cord-263455-dquztf5l	615	55	the	the	DT
cord-263455-dquztf5l	615	56	use	use	NN
cord-263455-dquztf5l	615	57	of	of	IN
cord-263455-dquztf5l	615	58	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	615	59	in	in	IN
cord-263455-dquztf5l	615	60	the	the	DT
cord-263455-dquztf5l	615	61	control	control	NN
cord-263455-dquztf5l	615	62	of	of	IN
cord-263455-dquztf5l	615	63	leprosy	leprosy	NN
cord-263455-dquztf5l	615	64	held	hold	VBN
cord-263455-dquztf5l	615	65	in	in	IN
cord-263455-dquztf5l	615	66	Amsterdam	Amsterdam	NNP
cord-263455-dquztf5l	615	67	,	,	,
cord-263455-dquztf5l	615	68	the	the	DT
cord-263455-dquztf5l	615	69	Netherlands	Netherlands	NNP
cord-263455-dquztf5l	615	70	on	on	IN
cord-263455-dquztf5l	615	71	14	14	CD
cord-263455-dquztf5l	615	72	Prevention	Prevention	NNP
cord-263455-dquztf5l	615	73	of	of	IN
cord-263455-dquztf5l	615	74	leprosy	leprosy	NN
cord-263455-dquztf5l	615	75	using	use	VBG
cord-263455-dquztf5l	615	76	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	615	77	as	as	IN
cord-263455-dquztf5l	615	78	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	615	79	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	615	80	in	in	IN
cord-263455-dquztf5l	615	81	contacts	contact	NNS
cord-263455-dquztf5l	615	82	of	of	IN
cord-263455-dquztf5l	615	83	patients	patient	NNS
cord-263455-dquztf5l	615	84	with	with	IN
cord-263455-dquztf5l	615	85	leprosy	leprosy	NN
cord-263455-dquztf5l	615	86	:	:	:
cord-263455-dquztf5l	615	87	systematic	systematic	JJ
cord-263455-dquztf5l	615	88	review	review	NN
cord-263455-dquztf5l	615	89	and	and	CC
cord-263455-dquztf5l	615	90	meta	meta	NNP
cord-263455-dquztf5l	615	91	-	-	HYPH
cord-263455-dquztf5l	615	92	analysis	analysis	NN
cord-263455-dquztf5l	615	93	Monitoring	Monitoring	NNP
cord-263455-dquztf5l	615	94	grade-2	grade-2	NNP
cord-263455-dquztf5l	615	95	disability	disability	NN
cord-263455-dquztf5l	615	96	rate	rate	NN
cord-263455-dquztf5l	615	97	and	and	CC
cord-263455-dquztf5l	615	98	applicability	applicability	NN
cord-263455-dquztf5l	615	99	of	of	IN
cord-263455-dquztf5l	615	100	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	615	101	in	in	IN
cord-263455-dquztf5l	615	102	leprosy	leprosy	NN
cord-263455-dquztf5l	615	103	control	control	NN
cord-263455-dquztf5l	615	104	:	:	:
cord-263455-dquztf5l	615	105	report	report	NN
cord-263455-dquztf5l	615	106	of	of	IN
cord-263455-dquztf5l	615	107	the	the	DT
cord-263455-dquztf5l	615	108	information	information	NN
cord-263455-dquztf5l	615	109	consultation	consultation	NN
cord-263455-dquztf5l	615	110	Review	Review	NNP
cord-263455-dquztf5l	615	111	of	of	IN
cord-263455-dquztf5l	615	112	leprosy	leprosy	NN
cord-263455-dquztf5l	615	113	research	research	NN
cord-263455-dquztf5l	615	114	evidence	evidence	NN
cord-263455-dquztf5l	615	115	(	(	-LRB-
cord-263455-dquztf5l	615	116	2002	2002	CD
cord-263455-dquztf5l	615	117	-	-	SYM
cord-263455-dquztf5l	615	118	2009	2009	CD
cord-263455-dquztf5l	615	119	)	)	-RRB-
cord-263455-dquztf5l	615	120	and	and	CC
cord-263455-dquztf5l	615	121	implications	implication	NNS
cord-263455-dquztf5l	615	122	for	for	IN
cord-263455-dquztf5l	615	123	current	current	JJ
cord-263455-dquztf5l	615	124	policy	policy	NN
cord-263455-dquztf5l	615	125	and	and	CC
cord-263455-dquztf5l	615	126	practice	practice	NN
cord-263455-dquztf5l	615	127	Trend	Trend	NNP
cord-263455-dquztf5l	615	128	analysis	analysis	NN
cord-263455-dquztf5l	615	129	of	of	IN
cord-263455-dquztf5l	615	130	leprosy	leprosy	NN
cord-263455-dquztf5l	615	131	in	in	IN
cord-263455-dquztf5l	615	132	Morocco	Morocco	NNP
cord-263455-dquztf5l	615	133	between	between	IN
cord-263455-dquztf5l	615	134	2000	2000	CD
cord-263455-dquztf5l	615	135	and	and	CC
cord-263455-dquztf5l	615	136	2017	2017	CD
cord-263455-dquztf5l	616	1	:	:	:
cord-263455-dquztf5l	616	2	evidence	evidence	NN
cord-263455-dquztf5l	616	3	on	on	IN
cord-263455-dquztf5l	616	4	the	the	DT
cord-263455-dquztf5l	616	5	single	single	JJ
cord-263455-dquztf5l	616	6	dose	dose	NN
cord-263455-dquztf5l	616	7	rifampicin	rifampicin	NN
cord-263455-dquztf5l	616	8	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	617	1	The	the	DT
cord-263455-dquztf5l	617	2	long	long	JJ
cord-263455-dquztf5l	617	3	term	term	NN
cord-263455-dquztf5l	617	4	effect	effect	NN
cord-263455-dquztf5l	617	5	of	of	IN
cord-263455-dquztf5l	617	6	current	current	JJ
cord-263455-dquztf5l	617	7	and	and	CC
cord-263455-dquztf5l	617	8	new	new	JJ
cord-263455-dquztf5l	617	9	interventions	intervention	NNS
cord-263455-dquztf5l	617	10	on	on	IN
cord-263455-dquztf5l	617	11	the	the	DT
cord-263455-dquztf5l	617	12	new	new	JJ
cord-263455-dquztf5l	617	13	case	case	NN
cord-263455-dquztf5l	617	14	detection	detection	NN
cord-263455-dquztf5l	617	15	of	of	IN
cord-263455-dquztf5l	617	16	leprosy	leprosy	NN
cord-263455-dquztf5l	617	17	:	:	:
cord-263455-dquztf5l	617	18	a	a	DT
cord-263455-dquztf5l	617	19	modeling	modeling	NN
cord-263455-dquztf5l	617	20	study	study	NN
cord-263455-dquztf5l	617	21	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	617	22	new	new	JJ
cord-263455-dquztf5l	617	23	case	case	NN
cord-263455-dquztf5l	617	24	detection	detection	NN
cord-263455-dquztf5l	617	25	trends	trend	NNS
cord-263455-dquztf5l	617	26	and	and	CC
cord-263455-dquztf5l	617	27	the	the	DT
cord-263455-dquztf5l	617	28	future	future	JJ
cord-263455-dquztf5l	617	29	effect	effect	NN
cord-263455-dquztf5l	617	30	of	of	IN
cord-263455-dquztf5l	617	31	preventive	preventive	JJ
cord-263455-dquztf5l	617	32	interventions	intervention	NNS
cord-263455-dquztf5l	617	33	in	in	IN
cord-263455-dquztf5l	617	34	Pará	Pará	NNP
cord-263455-dquztf5l	617	35	State	State	NNP
cord-263455-dquztf5l	617	36	,	,	,
cord-263455-dquztf5l	617	37	Brazil	Brazil	NNP
cord-263455-dquztf5l	617	38	:	:	:
cord-263455-dquztf5l	617	39	a	a	DT
cord-263455-dquztf5l	617	40	modelling	modelling	NN
cord-263455-dquztf5l	617	41	study	study	NN
cord-263455-dquztf5l	617	42	Predicting	predict	VBG
cord-263455-dquztf5l	617	43	the	the	DT
cord-263455-dquztf5l	617	44	impact	impact	NN
cord-263455-dquztf5l	617	45	of	of	IN
cord-263455-dquztf5l	617	46	household	household	NN
cord-263455-dquztf5l	617	47	contact	contact	NN
cord-263455-dquztf5l	617	48	and	and	CC
cord-263455-dquztf5l	617	49	mass	mass	NN
cord-263455-dquztf5l	617	50	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	617	51	on	on	IN
cord-263455-dquztf5l	617	52	future	future	JJ
cord-263455-dquztf5l	617	53	new	new	JJ
cord-263455-dquztf5l	617	54	leprosy	leprosy	NN
cord-263455-dquztf5l	617	55	cases	case	NNS
cord-263455-dquztf5l	617	56	in	in	IN
cord-263455-dquztf5l	617	57	South	South	NNP
cord-263455-dquztf5l	617	58	Tarawa	Tarawa	NNP
cord-263455-dquztf5l	617	59	,	,	,
cord-263455-dquztf5l	617	60	Kiribati	Kiribati	NNP
cord-263455-dquztf5l	617	61	:	:	:
cord-263455-dquztf5l	617	62	a	a	DT
cord-263455-dquztf5l	617	63	modelling	modelling	NN
cord-263455-dquztf5l	617	64	study	study	NN
cord-263455-dquztf5l	617	65	Role	role	NN
cord-263455-dquztf5l	617	66	of	of	IN
cord-263455-dquztf5l	617	67	contact	contact	NN
cord-263455-dquztf5l	617	68	tracing	tracing	NN
cord-263455-dquztf5l	617	69	and	and	CC
cord-263455-dquztf5l	617	70	prevention	prevention	NN
cord-263455-dquztf5l	617	71	strategies	strategy	NNS
cord-263455-dquztf5l	617	72	in	in	IN
cord-263455-dquztf5l	617	73	the	the	DT
cord-263455-dquztf5l	617	74	interruption	interruption	NN
cord-263455-dquztf5l	617	75	of	of	IN
cord-263455-dquztf5l	617	76	leprosy	leprosy	NN
cord-263455-dquztf5l	617	77	transmission	transmission	NN
cord-263455-dquztf5l	617	78	Close	close	JJ
cord-263455-dquztf5l	617	79	contacts	contact	NNS
cord-263455-dquztf5l	617	80	with	with	IN
cord-263455-dquztf5l	617	81	leprosy	leprosy	NN
cord-263455-dquztf5l	617	82	in	in	IN
cord-263455-dquztf5l	617	83	newly	newly	RB
cord-263455-dquztf5l	617	84	diagnosed	diagnose	VBN
cord-263455-dquztf5l	617	85	leprosy	leprosy	NN
cord-263455-dquztf5l	617	86	patients	patient	NNS
cord-263455-dquztf5l	617	87	in	in	IN
cord-263455-dquztf5l	617	88	a	a	DT
cord-263455-dquztf5l	617	89	high	high	JJ
cord-263455-dquztf5l	617	90	and	and	CC
cord-263455-dquztf5l	617	91	low	low	JJ
cord-263455-dquztf5l	617	92	endemic	endemic	JJ
cord-263455-dquztf5l	617	93	area	area	NN
cord-263455-dquztf5l	617	94	:	:	:
cord-263455-dquztf5l	617	95	comparison	comparison	NN
cord-263455-dquztf5l	617	96	between	between	IN
cord-263455-dquztf5l	617	97	Bangladesh	Bangladesh	NNP
cord-263455-dquztf5l	617	98	and	and	CC
cord-263455-dquztf5l	617	99	Thailand	Thailand	NNP
cord-263455-dquztf5l	617	100	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	617	101	:	:	:
cord-263455-dquztf5l	617	102	sufficient	sufficient	JJ
cord-263455-dquztf5l	617	103	evidence	evidence	NN
cord-263455-dquztf5l	617	104	for	for	IN
cord-263455-dquztf5l	617	105	starting	start	VBG
cord-263455-dquztf5l	617	106	implementation	implementation	NN
cord-263455-dquztf5l	617	107	pilots	pilot	NNS
cord-263455-dquztf5l	617	108	Negligible	negligible	JJ
cord-263455-dquztf5l	617	109	risk	risk	NN
cord-263455-dquztf5l	617	110	of	of	IN
cord-263455-dquztf5l	617	111	inducing	induce	VBG
cord-263455-dquztf5l	617	112	resistance	resistance	NN
cord-263455-dquztf5l	617	113	in	in	IN
cord-263455-dquztf5l	617	114	Mycobacterium	Mycobacterium	NNP
cord-263455-dquztf5l	617	115	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	617	116	with	with	IN
cord-263455-dquztf5l	617	117	single	single	JJ
cord-263455-dquztf5l	617	118	-	-	HYPH
cord-263455-dquztf5l	617	119	dose	dose	NN
cord-263455-dquztf5l	617	120	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	617	121	as	as	IN
cord-263455-dquztf5l	617	122	post	post	JJ
cord-263455-dquztf5l	617	123	-	-	JJ
cord-263455-dquztf5l	617	124	exposure	exposure	JJ
cord-263455-dquztf5l	617	125	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	617	126	for	for	IN
cord-263455-dquztf5l	617	127	leprosy	leprosy	NN
cord-263455-dquztf5l	618	1	The	the	DT
cord-263455-dquztf5l	618	2	leprosy	leprosy	NN
cord-263455-dquztf5l	618	3	post	post	NN
cord-263455-dquztf5l	618	4	-	-	JJ
cord-263455-dquztf5l	618	5	exposure	exposure	JJ
cord-263455-dquztf5l	618	6	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	618	7	(	(	-LRB-
cord-263455-dquztf5l	618	8	LPEP	LPEP	NNP
cord-263455-dquztf5l	618	9	)	)	-RRB-
cord-263455-dquztf5l	618	10	programme	programme	NN
cord-263455-dquztf5l	618	11	:	:	:
cord-263455-dquztf5l	619	1	update	update	NN
cord-263455-dquztf5l	619	2	and	and	CC
cord-263455-dquztf5l	619	3	interim	interim	JJ
cord-263455-dquztf5l	619	4	analysis	analysis	NN
cord-263455-dquztf5l	619	5	Abstracts	abstract	NNS
cord-263455-dquztf5l	619	6	of	of	IN
cord-263455-dquztf5l	619	7	oral	oral	JJ
cord-263455-dquztf5l	619	8	presentations	presentation	NNS
cord-263455-dquztf5l	619	9	-175	-175	VBD
cord-263455-dquztf5l	619	10	feasibility	feasibility	NN
cord-263455-dquztf5l	619	11	and	and	CC
cord-263455-dquztf5l	619	12	impact	impact	NN
cord-263455-dquztf5l	619	13	of	of	IN
cord-263455-dquztf5l	619	14	leprosy	leprosy	NN
cord-263455-dquztf5l	619	15	post	post	JJ
cord-263455-dquztf5l	619	16	-	-	JJ
cord-263455-dquztf5l	619	17	exposure	exposure	JJ
cord-263455-dquztf5l	619	18	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	619	19	:	:	:
cord-263455-dquztf5l	619	20	evidence	evidence	NN
cord-263455-dquztf5l	619	21	from	from	IN
cord-263455-dquztf5l	619	22	LPEP	LPEP	NNP
cord-263455-dquztf5l	619	23	,	,	,
cord-263455-dquztf5l	619	24	a	a	DT
cord-263455-dquztf5l	619	25	multi	multi	JJ
cord-263455-dquztf5l	619	26	-	-	JJ
cord-263455-dquztf5l	619	27	country	country	JJ
cord-263455-dquztf5l	619	28	,	,	,
cord-263455-dquztf5l	619	29	5-year	5-year	CD
cord-263455-dquztf5l	619	30	implementation	implementation	NN
cord-263455-dquztf5l	619	31	research	research	NN
cord-263455-dquztf5l	619	32	program	program	NN
cord-263455-dquztf5l	620	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	620	2	post	post	NN
cord-263455-dquztf5l	620	3	-	-	JJ
cord-263455-dquztf5l	620	4	exposure	exposure	JJ
cord-263455-dquztf5l	620	5	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	620	6	in	in	IN
cord-263455-dquztf5l	620	7	the	the	DT
cord-263455-dquztf5l	620	8	Indian	indian	JJ
cord-263455-dquztf5l	620	9	health	health	NN
cord-263455-dquztf5l	620	10	system	system	NN
cord-263455-dquztf5l	620	11	:	:	:
cord-263455-dquztf5l	620	12	A	a	DT
cord-263455-dquztf5l	620	13	cost	cost	NN
cord-263455-dquztf5l	620	14	-	-	HYPH
cord-263455-dquztf5l	620	15	effectiveness	effectiveness	NN
cord-263455-dquztf5l	620	16	analysis	analysis	NN
cord-263455-dquztf5l	621	1	An	an	DT
cord-263455-dquztf5l	621	2	innovative	innovative	JJ
cord-263455-dquztf5l	621	3	approach	approach	NN
cord-263455-dquztf5l	621	4	to	to	IN
cord-263455-dquztf5l	621	5	screening	screening	NN
cord-263455-dquztf5l	621	6	and	and	CC
cord-263455-dquztf5l	621	7	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	621	8	among	among	IN
cord-263455-dquztf5l	621	9	contacts	contact	NNS
cord-263455-dquztf5l	621	10	of	of	IN
cord-263455-dquztf5l	621	11	leprosy	leprosy	NN
cord-263455-dquztf5l	621	12	patients	patient	NNS
cord-263455-dquztf5l	621	13	in	in	IN
cord-263455-dquztf5l	621	14	low	low	JJ
cord-263455-dquztf5l	621	15	endemic	endemic	JJ
cord-263455-dquztf5l	621	16	settings	setting	NNS
cord-263455-dquztf5l	621	17	:	:	:
cord-263455-dquztf5l	621	18	experiences	experience	NNS
cord-263455-dquztf5l	621	19	from	from	IN
cord-263455-dquztf5l	621	20	Cambodia	Cambodia	NNP
cord-263455-dquztf5l	622	1	A	a	DT
cord-263455-dquztf5l	622	2	single	single	JJ
cord-263455-dquztf5l	622	3	dose	dose	NN
cord-263455-dquztf5l	622	4	of	of	IN
cord-263455-dquztf5l	622	5	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	622	6	to	to	TO
cord-263455-dquztf5l	622	7	prevent	prevent	VB
cord-263455-dquztf5l	622	8	leprosy	leprosy	NN
cord-263455-dquztf5l	622	9	:	:	:
cord-263455-dquztf5l	622	10	qualitative	qualitative	JJ
cord-263455-dquztf5l	622	11	analysis	analysis	NN
cord-263455-dquztf5l	622	12	of	of	IN
cord-263455-dquztf5l	622	13	perceptions	perception	NNS
cord-263455-dquztf5l	622	14	of	of	IN
cord-263455-dquztf5l	622	15	persons	person	NNS
cord-263455-dquztf5l	622	16	affected	affect	VBN
cord-263455-dquztf5l	622	17	,	,	,
cord-263455-dquztf5l	622	18	contacts	contact	NNS
cord-263455-dquztf5l	622	19	,	,	,
cord-263455-dquztf5l	622	20	community	community	NN
cord-263455-dquztf5l	622	21	members	member	NNS
cord-263455-dquztf5l	622	22	and	and	CC
cord-263455-dquztf5l	622	23	health	health	NN
cord-263455-dquztf5l	622	24	professionals	professional	NNS
cord-263455-dquztf5l	622	25	towards	towards	IN
cord-263455-dquztf5l	622	26	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	622	27	and	and	CC
cord-263455-dquztf5l	622	28	the	the	DT
cord-263455-dquztf5l	622	29	impact	impact	NN
cord-263455-dquztf5l	622	30	on	on	IN
cord-263455-dquztf5l	622	31	their	-PRON-	PRP$
cord-263455-dquztf5l	622	32	attitudes	attitude	NNS
cord-263455-dquztf5l	622	33	in	in	IN
cord-263455-dquztf5l	622	34	India	India	NNP
cord-263455-dquztf5l	622	35	,	,	,
cord-263455-dquztf5l	622	36	Nepal	Nepal	NNP
cord-263455-dquztf5l	622	37	and	and	CC
cord-263455-dquztf5l	622	38	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	622	39	Acceptability	Acceptability	NNP
cord-263455-dquztf5l	622	40	of	of	IN
cord-263455-dquztf5l	622	41	contact	contact	NN
cord-263455-dquztf5l	622	42	screening	screening	NN
cord-263455-dquztf5l	622	43	and	and	CC
cord-263455-dquztf5l	623	1	single	single	JJ
cord-263455-dquztf5l	623	2	dose	dose	NN
cord-263455-dquztf5l	623	3	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	623	4	as	as	IN
cord-263455-dquztf5l	623	5	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	623	6	for	for	IN
cord-263455-dquztf5l	623	7	leprosy	leprosy	NN
cord-263455-dquztf5l	623	8	in	in	IN
cord-263455-dquztf5l	623	9	Dadra	Dadra	NNP
cord-263455-dquztf5l	623	10	and	and	CC
cord-263455-dquztf5l	623	11	Nagar	Nagar	NNP
cord-263455-dquztf5l	623	12	Haveli	Haveli	NNP
cord-263455-dquztf5l	623	13	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	623	14	post	post	NN
cord-263455-dquztf5l	623	15	-	-	JJ
cord-263455-dquztf5l	623	16	exposure	exposure	JJ
cord-263455-dquztf5l	623	17	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	623	18	with	with	IN
cord-263455-dquztf5l	623	19	single	single	JJ
cord-263455-dquztf5l	623	20	-	-	HYPH
cord-263455-dquztf5l	623	21	dose	dose	NN
cord-263455-dquztf5l	623	22	rifampicin	rifampicin	NN
cord-263455-dquztf5l	623	23	:	:	:
cord-263455-dquztf5l	623	24	toolkit	toolkit	NN
cord-263455-dquztf5l	623	25	for	for	IN
cord-263455-dquztf5l	623	26	implementation	implementation	NN
cord-263455-dquztf5l	623	27	Minimal	minimal	JJ
cord-263455-dquztf5l	623	28	essential	essential	JJ
cord-263455-dquztf5l	623	29	data	datum	NNS
cord-263455-dquztf5l	623	30	to	to	TO
cord-263455-dquztf5l	623	31	document	document	VB
cord-263455-dquztf5l	623	32	contact	contact	NN
cord-263455-dquztf5l	623	33	tracing	tracing	NN
cord-263455-dquztf5l	623	34	and	and	CC
cord-263455-dquztf5l	623	35	single	single	JJ
cord-263455-dquztf5l	623	36	dose	dose	NN
cord-263455-dquztf5l	624	1	rifampicin	rifampicin	NNP
cord-263455-dquztf5l	624	2	(	(	-LRB-
cord-263455-dquztf5l	624	3	SDR	SDR	NNP
cord-263455-dquztf5l	624	4	)	)	-RRB-
cord-263455-dquztf5l	624	5	for	for	IN
cord-263455-dquztf5l	624	6	leprosy	leprosy	NN
cord-263455-dquztf5l	624	7	control	control	NN
cord-263455-dquztf5l	624	8	in	in	IN
cord-263455-dquztf5l	624	9	routine	routine	JJ
cord-263455-dquztf5l	624	10	settings	setting	NNS
cord-263455-dquztf5l	624	11	:	:	:
cord-263455-dquztf5l	624	12	a	a	DT
cord-263455-dquztf5l	624	13	practical	practical	JJ
cord-263455-dquztf5l	624	14	guide	guide	NN
cord-263455-dquztf5l	625	1	Global	global	JJ
cord-263455-dquztf5l	625	2	practices	practice	NNS
cord-263455-dquztf5l	625	3	in	in	IN
cord-263455-dquztf5l	625	4	regard	regard	NN
cord-263455-dquztf5l	625	5	to	to	IN
cord-263455-dquztf5l	625	6	implementation	implementation	NN
cord-263455-dquztf5l	625	7	of	of	IN
cord-263455-dquztf5l	625	8	preventive	preventive	JJ
cord-263455-dquztf5l	625	9	measures	measure	NNS
cord-263455-dquztf5l	625	10	for	for	IN
cord-263455-dquztf5l	625	11	leprosy	leprosy	NN
cord-263455-dquztf5l	625	12	Peraturan	Peraturan	NNP
cord-263455-dquztf5l	625	13	Menteri	Menteri	NNP
cord-263455-dquztf5l	625	14	Kesehatan	Kesehatan	NNP
cord-263455-dquztf5l	625	15	Republik	Republik	NNP
cord-263455-dquztf5l	625	16	Indonesia	Indonesia	NNP
cord-263455-dquztf5l	625	17	,	,	,
cord-263455-dquztf5l	625	18	Nomor	Nomor	NNP
cord-263455-dquztf5l	625	19	11	11	CD
cord-263455-dquztf5l	625	20	Tahun	Tahun	NNP
cord-263455-dquztf5l	625	21	2019	2019	CD
cord-263455-dquztf5l	626	1	Tentang	Tentang	NNP
cord-263455-dquztf5l	627	1	Penanggulangan	Penanggulangan	NNP
cord-263455-dquztf5l	627	2	Kusta	Kusta	NNP
cord-263455-dquztf5l	627	3	Evidence	evidence	NN
cord-263455-dquztf5l	627	4	,	,	,
cord-263455-dquztf5l	627	5	opportunity	opportunity	NN
cord-263455-dquztf5l	627	6	,	,	,
cord-263455-dquztf5l	627	7	ethics	ethic	NNS
cord-263455-dquztf5l	627	8	,	,	,
cord-263455-dquztf5l	627	9	and	and	CC
cord-263455-dquztf5l	627	10	the	the	DT
cord-263455-dquztf5l	627	11	allure	allure	NN
cord-263455-dquztf5l	627	12	of	of	IN
cord-263455-dquztf5l	627	13	zero	zero	CD
cord-263455-dquztf5l	627	14	leprosy	leprosy	NN
cord-263455-dquztf5l	627	15	Reply	Reply	NNP
cord-263455-dquztf5l	627	16	to	to	IN
cord-263455-dquztf5l	627	17	:	:	:
cord-263455-dquztf5l	627	18	single	single	JJ
cord-263455-dquztf5l	627	19	-	-	HYPH
cord-263455-dquztf5l	627	20	dose	dose	NN
cord-263455-dquztf5l	627	21	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	627	22	and	and	CC
cord-263455-dquztf5l	627	23	BCG	BCG	NNP
cord-263455-dquztf5l	627	24	to	to	TO
cord-263455-dquztf5l	627	25	prevent	prevent	VB
cord-263455-dquztf5l	627	26	leprosy	leprosy	NN
cord-263455-dquztf5l	627	27	Effectiveness	Effectiveness	NNP
cord-263455-dquztf5l	627	28	of	of	IN
cord-263455-dquztf5l	627	29	single	single	JJ
cord-263455-dquztf5l	627	30	-	-	HYPH
cord-263455-dquztf5l	627	31	dose	dose	NN
cord-263455-dquztf5l	627	32	rifampicin	rifampicin	NNS
cord-263455-dquztf5l	627	33	after	after	IN
cord-263455-dquztf5l	627	34	BCG	BCG	NNP
cord-263455-dquztf5l	627	35	vaccination	vaccination	NN
cord-263455-dquztf5l	627	36	to	to	TO
cord-263455-dquztf5l	627	37	prevent	prevent	VB
cord-263455-dquztf5l	627	38	leprosy	leprosy	NN
cord-263455-dquztf5l	627	39	in	in	IN
cord-263455-dquztf5l	627	40	close	close	JJ
cord-263455-dquztf5l	627	41	contacts	contact	NNS
cord-263455-dquztf5l	627	42	of	of	IN
cord-263455-dquztf5l	627	43	patients	patient	NNS
cord-263455-dquztf5l	627	44	with	with	IN
cord-263455-dquztf5l	627	45	newly	newly	RB
cord-263455-dquztf5l	627	46	diagnosed	diagnose	VBN
cord-263455-dquztf5l	627	47	leprosy	leprosy	NN
cord-263455-dquztf5l	627	48	:	:	:
cord-263455-dquztf5l	627	49	a	a	DT
cord-263455-dquztf5l	627	50	cluster	cluster	NN
cord-263455-dquztf5l	627	51	randomized	randomize	VBN
cord-263455-dquztf5l	627	52	controlled	control	VBN
cord-263455-dquztf5l	627	53	trial	trial	NN
cord-263455-dquztf5l	627	54	Clinical	clinical	JJ
cord-263455-dquztf5l	627	55	manifestations	manifestation	NNS
cord-263455-dquztf5l	627	56	of	of	IN
cord-263455-dquztf5l	627	57	leprosy	leprosy	NN
cord-263455-dquztf5l	627	58	after	after	IN
cord-263455-dquztf5l	627	59	BCG	BCG	NNP
cord-263455-dquztf5l	627	60	vaccination	vaccination	NN
cord-263455-dquztf5l	627	61	:	:	:
cord-263455-dquztf5l	627	62	an	an	DT
cord-263455-dquztf5l	627	63	observational	observational	JJ
cord-263455-dquztf5l	627	64	study	study	NN
cord-263455-dquztf5l	627	65	in	in	IN
cord-263455-dquztf5l	627	66	Bangladesh	Bangladesh	NNP
cord-263455-dquztf5l	627	67	BCG	BCG	NNP
cord-263455-dquztf5l	627	68	vaccine	vaccine	NN
cord-263455-dquztf5l	627	69	and	and	CC
cord-263455-dquztf5l	627	70	leprosy	leprosy	NN
cord-263455-dquztf5l	627	71	household	household	NN
cord-263455-dquztf5l	627	72	contacts	contact	NNS
cord-263455-dquztf5l	627	73	:	:	:
cord-263455-dquztf5l	627	74	protective	protective	JJ
cord-263455-dquztf5l	627	75	effect	effect	NN
cord-263455-dquztf5l	627	76	and	and	CC
cord-263455-dquztf5l	627	77	probability	probability	NN
cord-263455-dquztf5l	627	78	to	to	IN
cord-263455-dquztf5l	627	79	becoming	become	VBG
cord-263455-dquztf5l	627	80	sick	sick	JJ
cord-263455-dquztf5l	627	81	during	during	IN
cord-263455-dquztf5l	627	82	follow	follow	NN
cord-263455-dquztf5l	627	83	-	-	HYPH
cord-263455-dquztf5l	627	84	up	up	NN
cord-263455-dquztf5l	627	85	Under	under	RB
cord-263455-dquztf5l	627	86	-	-	HYPH
cord-263455-dquztf5l	627	87	explored	explore	VBN
cord-263455-dquztf5l	627	88	experimental	experimental	JJ
cord-263455-dquztf5l	627	89	topics	topic	NNS
cord-263455-dquztf5l	627	90	related	relate	VBN
cord-263455-dquztf5l	627	91	to	to	IN
cord-263455-dquztf5l	627	92	integral	integral	JJ
cord-263455-dquztf5l	627	93	mycobacterial	mycobacterial	JJ
cord-263455-dquztf5l	627	94	vaccines	vaccine	NNS
cord-263455-dquztf5l	627	95	for	for	IN
cord-263455-dquztf5l	627	96	leprosy	leprosy	NN
cord-263455-dquztf5l	627	97	Risk	risk	NN
cord-263455-dquztf5l	627	98	and	and	CC
cord-263455-dquztf5l	627	99	protective	protective	JJ
cord-263455-dquztf5l	627	100	factors	factor	NNS
cord-263455-dquztf5l	627	101	for	for	IN
cord-263455-dquztf5l	627	102	leprosy	leprosy	NN
cord-263455-dquztf5l	627	103	development	development	NN
cord-263455-dquztf5l	627	104	determined	determine	VBN
cord-263455-dquztf5l	627	105	by	by	IN
cord-263455-dquztf5l	627	106	epidemiological	epidemiological	JJ
cord-263455-dquztf5l	627	107	surveillance	surveillance	NN
cord-263455-dquztf5l	627	108	of	of	IN
cord-263455-dquztf5l	627	109	household	household	NN
cord-263455-dquztf5l	627	110	contacts	contact	NNS
cord-263455-dquztf5l	628	1	Portaria	Portaria	NNP
cord-263455-dquztf5l	628	2	N	n	CD
cord-263455-dquztf5l	629	1	o	o	UH
cord-263455-dquztf5l	630	1	3.125,de	3.125,de	CD
cord-263455-dquztf5l	630	2	7	7	CD
cord-263455-dquztf5l	630	3	de	de	NNP
cord-263455-dquztf5l	630	4	Outubro	Outubro	NNP
cord-263455-dquztf5l	630	5	de	de	NNP
cord-263455-dquztf5l	630	6	2010	2010	CD
cord-263455-dquztf5l	630	7	.	.	.
cord-263455-dquztf5l	631	1	Diretrizes	Diretrizes	NNP
cord-263455-dquztf5l	631	2	Para	Para	NNP
cord-263455-dquztf5l	631	3	Vigilância	Vigilância	NNP
cord-263455-dquztf5l	631	4	,	,	,
cord-263455-dquztf5l	631	5	Atenção	Atenção	NNP
cord-263455-dquztf5l	631	6	e	e	NN
cord-263455-dquztf5l	631	7	Controle	Controle	NNP
cord-263455-dquztf5l	631	8	Da	Da	NNP
cord-263455-dquztf5l	631	9	Hansenías	Hansenías	NNP
cord-263455-dquztf5l	631	10	E	E	NNP
cord-263455-dquztf5l	631	11	BCG	BCG	NNP
cord-263455-dquztf5l	631	12	scars	scar	NNS
cord-263455-dquztf5l	631	13	in	in	IN
cord-263455-dquztf5l	631	14	northern	northern	JJ
cord-263455-dquztf5l	631	15	Malawi	Malawi	NNP
cord-263455-dquztf5l	631	16	:	:	:
cord-263455-dquztf5l	631	17	sensitivity	sensitivity	NN
cord-263455-dquztf5l	631	18	and	and	CC
cord-263455-dquztf5l	631	19	repeatability	repeatability	NN
cord-263455-dquztf5l	631	20	of	of	IN
cord-263455-dquztf5l	631	21	scar	scar	NN
cord-263455-dquztf5l	631	22	reading	reading	NN
cord-263455-dquztf5l	631	23	,	,	,
cord-263455-dquztf5l	631	24	and	and	CC
cord-263455-dquztf5l	631	25	factors	factor	NNS
cord-263455-dquztf5l	631	26	affecting	affect	VBG
cord-263455-dquztf5l	631	27	scar	scar	NN
cord-263455-dquztf5l	631	28	size	size	NN
cord-263455-dquztf5l	631	29	Risk	risk	NN
cord-263455-dquztf5l	631	30	and	and	CC
cord-263455-dquztf5l	631	31	protective	protective	JJ
cord-263455-dquztf5l	631	32	factors	factor	NNS
cord-263455-dquztf5l	631	33	for	for	IN
cord-263455-dquztf5l	631	34	leprosy	leprosy	NN
cord-263455-dquztf5l	631	35	development	development	NN
cord-263455-dquztf5l	631	36	determined	determine	VBN
cord-263455-dquztf5l	631	37	by	by	IN
cord-263455-dquztf5l	631	38	epidemiological	epidemiological	JJ
cord-263455-dquztf5l	631	39	surveillance	surveillance	NN
cord-263455-dquztf5l	631	40	of	of	IN
cord-263455-dquztf5l	631	41	household	household	NN
cord-263455-dquztf5l	631	42	contacts	contact	NNS
cord-263455-dquztf5l	632	1	BCG	BCG	NNP
cord-263455-dquztf5l	632	2	revaccination	revaccination	NN
cord-263455-dquztf5l	632	3	does	do	VBZ
cord-263455-dquztf5l	632	4	not	not	RB
cord-263455-dquztf5l	632	5	protect	protect	VB
cord-263455-dquztf5l	632	6	against	against	IN
cord-263455-dquztf5l	632	7	leprosy	leprosy	NN
cord-263455-dquztf5l	632	8	in	in	IN
cord-263455-dquztf5l	632	9	the	the	DT
cord-263455-dquztf5l	632	10	Brazilian	brazilian	JJ
cord-263455-dquztf5l	632	11	Amazon	Amazon	NNP
cord-263455-dquztf5l	632	12	:	:	:
cord-263455-dquztf5l	632	13	a	a	DT
cord-263455-dquztf5l	632	14	cluster	cluster	NN
cord-263455-dquztf5l	632	15	randomised	randomised	JJ
cord-263455-dquztf5l	632	16	trial	trial	NN
cord-263455-dquztf5l	632	17	Protection	Protection	NNP
cord-263455-dquztf5l	632	18	against	against	IN
cord-263455-dquztf5l	632	19	M.	M.	NNP
cord-263455-dquztf5l	632	20	leprae	leprae	JJ
cord-263455-dquztf5l	632	21	infection	infection	NN
cord-263455-dquztf5l	632	22	by	by	IN
cord-263455-dquztf5l	632	23	the	the	DT
cord-263455-dquztf5l	632	24	ID83	ID83	NNP
cord-263455-dquztf5l	632	25	/	/	SYM
cord-263455-dquztf5l	632	26	GLA	GLA	NNP
cord-263455-dquztf5l	632	27	-	-	HYPH
cord-263455-dquztf5l	632	28	SE	SE	NNP
cord-263455-dquztf5l	632	29	and	and	CC
cord-263455-dquztf5l	632	30	ID93	ID93	NNP
cord-263455-dquztf5l	632	31	/	/	SYM
cord-263455-dquztf5l	632	32	GLA	GLA	NNP
cord-263455-dquztf5l	632	33	-	-	HYPH
cord-263455-dquztf5l	632	34	SE	SE	NNP
cord-263455-dquztf5l	632	35	vaccines	vaccine	NNS
cord-263455-dquztf5l	632	36	developed	develop	VBN
cord-263455-dquztf5l	632	37	for	for	IN
cord-263455-dquztf5l	632	38	tuberculosis	tuberculosis	NN
cord-263455-dquztf5l	632	39	Protocol	Protocol	NNP
cord-263455-dquztf5l	632	40	,	,	,
cord-263455-dquztf5l	632	41	rationale	rationale	NN
cord-263455-dquztf5l	632	42	and	and	CC
cord-263455-dquztf5l	632	43	design	design	NN
cord-263455-dquztf5l	632	44	of	of	IN
cord-263455-dquztf5l	632	45	PEOPLE	PEOPLE	NNS
cord-263455-dquztf5l	633	1	(	(	-LRB-
cord-263455-dquztf5l	633	2	Post	Post	NNP
cord-263455-dquztf5l	633	3	ExpOsure	ExpOsure	NNP
cord-263455-dquztf5l	633	4	Prophylaxis	Prophylaxis	NNP
cord-263455-dquztf5l	633	5	for	for	IN
cord-263455-dquztf5l	633	6	LEprosy	LEprosy	NNP
cord-263455-dquztf5l	633	7	in	in	IN
cord-263455-dquztf5l	633	8	the	the	DT
cord-263455-dquztf5l	633	9	Comoros	Comoros	NNP
cord-263455-dquztf5l	633	10	and	and	CC
cord-263455-dquztf5l	633	11	Madagascar	Madagascar	NNP
cord-263455-dquztf5l	633	12	)	)	-RRB-
cord-263455-dquztf5l	633	13	:	:	:
cord-263455-dquztf5l	634	1	a	a	DT
cord-263455-dquztf5l	634	2	cluster	cluster	NN
cord-263455-dquztf5l	634	3	randomized	randomize	VBN
cord-263455-dquztf5l	634	4	trial	trial	NN
cord-263455-dquztf5l	634	5	on	on	IN
cord-263455-dquztf5l	634	6	effectiveness	effectiveness	NN
cord-263455-dquztf5l	634	7	of	of	IN
cord-263455-dquztf5l	634	8	different	different	JJ
cord-263455-dquztf5l	634	9	modalities	modality	NNS
cord-263455-dquztf5l	634	10	of	of	IN
cord-263455-dquztf5l	634	11	implementation	implementation	NN
cord-263455-dquztf5l	634	12	of	of	IN
cord-263455-dquztf5l	634	13	post	post	JJ
cord-263455-dquztf5l	634	14	-	-	JJ
cord-263455-dquztf5l	634	15	exposure	exposure	JJ
cord-263455-dquztf5l	634	16	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	634	17	of	of	IN
cord-263455-dquztf5l	634	18	leprosy	leprosy	NN
cord-263455-dquztf5l	634	19	contacts	contact	NNS
cord-263455-dquztf5l	634	20	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	634	21	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	635	1	:	:	:
cord-263455-dquztf5l	635	2	what	what	WP
cord-263455-dquztf5l	635	3	's	be	VBZ
cord-263455-dquztf5l	635	4	the	the	DT
cord-263455-dquztf5l	635	5	need	need	NN
cord-263455-dquztf5l	635	6	?	?	.
cord-263455-dquztf5l	636	1	Leprosy	leprosy	NN
cord-263455-dquztf5l	636	2	now	now	RB
cord-263455-dquztf5l	636	3	:	:	:
cord-263455-dquztf5l	636	4	epidemiology	epidemiology	NN
cord-263455-dquztf5l	636	5	,	,	,
cord-263455-dquztf5l	636	6	progress	progress	NN
cord-263455-dquztf5l	636	7	,	,	,
cord-263455-dquztf5l	636	8	challenges	challenge	NNS
cord-263455-dquztf5l	636	9	,	,	,
cord-263455-dquztf5l	636	10	and	and	CC
cord-263455-dquztf5l	636	11	research	research	NN
cord-263455-dquztf5l	636	12	gaps	gap	NNS
cord-263455-dquztf5l	636	13	Reply	Reply	NNP
cord-263455-dquztf5l	636	14	to	to	IN
cord-263455-dquztf5l	636	15	the	the	DT
cord-263455-dquztf5l	636	16	role	role	NN
cord-263455-dquztf5l	636	17	of	of	IN
cord-263455-dquztf5l	636	18	contact	contact	NN
cord-263455-dquztf5l	636	19	tracing	tracing	NN
cord-263455-dquztf5l	636	20	and	and	CC
cord-263455-dquztf5l	636	21	prevention	prevention	NN
cord-263455-dquztf5l	636	22	strategies	strategy	NNS
cord-263455-dquztf5l	636	23	in	in	IN
cord-263455-dquztf5l	636	24	the	the	DT
cord-263455-dquztf5l	636	25	interruption	interruption	NN
cord-263455-dquztf5l	636	26	of	of	IN
cord-263455-dquztf5l	636	27	leprosy	leprosy	NN
cord-263455-dquztf5l	636	28	transmission	transmission	NN
cord-263455-dquztf5l	637	1	-chemoprophylaxis	-chemoprophylaxis	:
cord-263455-dquztf5l	638	1	:	:	:
cord-263455-dquztf5l	638	2	a	a	DT
cord-263455-dquztf5l	638	3	call	call	NN
cord-263455-dquztf5l	638	4	for	for	IN
cord-263455-dquztf5l	638	5	more	more	JJR
cord-263455-dquztf5l	638	6	research	research	NN
cord-263455-dquztf5l	638	7	Single	single	JJ
cord-263455-dquztf5l	638	8	-	-	HYPH
cord-263455-dquztf5l	638	9	dose	dose	NN
cord-263455-dquztf5l	638	10	rifampicin	rifampicin	NN
cord-263455-dquztf5l	638	11	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	638	12	protects	protect	VBZ
cord-263455-dquztf5l	638	13	those	those	DT
cord-263455-dquztf5l	638	14	who	who	WP
cord-263455-dquztf5l	638	15	need	need	VBP
cord-263455-dquztf5l	638	16	it	-PRON-	PRP
cord-263455-dquztf5l	638	17	least	least	JJS
cord-263455-dquztf5l	638	18	and	and	CC
cord-263455-dquztf5l	638	19	is	be	VBZ
cord-263455-dquztf5l	638	20	not	not	RB
cord-263455-dquztf5l	638	21	a	a	DT
cord-263455-dquztf5l	638	22	cost	cost	NN
cord-263455-dquztf5l	638	23	-	-	HYPH
cord-263455-dquztf5l	638	24	effective	effective	JJ
cord-263455-dquztf5l	638	25	intervention	intervention	NN
cord-263455-dquztf5l	638	26	Cost	cost	NN
cord-263455-dquztf5l	638	27	-	-	HYPH
cord-263455-dquztf5l	638	28	effectiveness	effectiveness	NN
cord-263455-dquztf5l	638	29	analysis	analysis	NN
cord-263455-dquztf5l	638	30	of	of	IN
cord-263455-dquztf5l	638	31	three	three	CD
cord-263455-dquztf5l	638	32	leprosy	leprosy	NN
cord-263455-dquztf5l	638	33	case	case	NN
cord-263455-dquztf5l	638	34	detection	detection	NN
cord-263455-dquztf5l	638	35	methods	method	NNS
cord-263455-dquztf5l	638	36	in	in	IN
cord-263455-dquztf5l	638	37	northern	northern	JJ
cord-263455-dquztf5l	638	38	Nigeria	Nigeria	NNP
cord-263455-dquztf5l	638	39	Effectiveness	Effectiveness	NNP
cord-263455-dquztf5l	638	40	of	of	IN
cord-263455-dquztf5l	638	41	rifampicin	rifampicin	NN
cord-263455-dquztf5l	638	42	chemoprophylaxis	chemoprophylaxis	NNP
cord-263455-dquztf5l	638	43	in	in	IN
cord-263455-dquztf5l	638	44	preventing	prevent	VBG
cord-263455-dquztf5l	638	45	leprosy	leprosy	NN
cord-263455-dquztf5l	638	46	in	in	IN
cord-263455-dquztf5l	638	47	patient	patient	NN
cord-263455-dquztf5l	638	48	contacts	contact	NNS
cord-263455-dquztf5l	638	49	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	638	50	for	for	IN
cord-263455-dquztf5l	638	51	contacts	contact	NNS
cord-263455-dquztf5l	638	52	of	of	IN
cord-263455-dquztf5l	638	53	leprosy	leprosy	NN
cord-263455-dquztf5l	638	54	patients	patient	NNS
cord-263455-dquztf5l	638	55	:	:	:
cord-263455-dquztf5l	638	56	a	a	DT
cord-263455-dquztf5l	638	57	systematic	systematic	JJ
cord-263455-dquztf5l	638	58	review	review	NN
cord-263455-dquztf5l	638	59	and	and	CC
cord-263455-dquztf5l	638	60	meta	meta	NNP
cord-263455-dquztf5l	638	61	-	-	HYPH
cord-263455-dquztf5l	638	62	analysis	analysis	NNP
cord-263455-dquztf5l	638	63	National	National	NNP
cord-263455-dquztf5l	638	64	Health	Health	NNP
cord-263455-dquztf5l	638	65	Portal	Portal	NNP
cord-263455-dquztf5l	638	66	of	of	IN
cord-263455-dquztf5l	638	67	India	India	NNP
cord-263455-dquztf5l	638	68	TM	TM	NNP
cord-263455-dquztf5l	638	69	of	of	IN
cord-263455-dquztf5l	638	70	H	H	NNP
cord-263455-dquztf5l	638	71	and	and	CC
cord-263455-dquztf5l	638	72	FWG	FWG	NNP
cord-263455-dquztf5l	638	73	of	of	IN
cord-263455-dquztf5l	638	74	I.	I.	NNP
cord-263455-dquztf5l	638	75	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	638	76	.	.	.
cord-263455-dquztf5l	639	1	Prevention	prevention	NN
cord-263455-dquztf5l	639	2	Reviewing	review	VBG
cord-263455-dquztf5l	639	3	research	research	NN
cord-263455-dquztf5l	639	4	priorities	priority	NNS
cord-263455-dquztf5l	639	5	of	of	IN
cord-263455-dquztf5l	639	6	the	the	DT
cord-263455-dquztf5l	639	7	leprosy	leprosy	NN
cord-263455-dquztf5l	639	8	research	research	NN
cord-263455-dquztf5l	639	9	initiative	initiative	NN
cord-263455-dquztf5l	639	10	(	(	-LRB-
cord-263455-dquztf5l	639	11	LRI	LRI	NNP
cord-263455-dquztf5l	639	12	)	)	-RRB-
cord-263455-dquztf5l	639	13	:	:	:
cord-263455-dquztf5l	639	14	a	a	DT
cord-263455-dquztf5l	639	15	stakeholder	stakeholder	NN
cord-263455-dquztf5l	639	16	's	's	POS
cord-263455-dquztf5l	639	17	consultation	consultation	NN
cord-263455-dquztf5l	639	18	Global	global	JJ
cord-263455-dquztf5l	639	19	partnership	partnership	NN
cord-263455-dquztf5l	639	20	for	for	IN
cord-263455-dquztf5l	639	21	zero	zero	CD
cord-263455-dquztf5l	639	22	leprosy	leprosy	NN
cord-263455-dquztf5l	639	23	research	research	NN
cord-263455-dquztf5l	639	24	agenda	agenda	NN
cord-263455-dquztf5l	639	25	working	work	VBG
cord-263455-dquztf5l	639	26	group	group	NN
cord-263455-dquztf5l	639	27	subgroup	subgroup	NN
cord-263455-dquztf5l	639	28	on	on	IN
cord-263455-dquztf5l	639	29	post	post	JJ
cord-263455-dquztf5l	639	30	-	-	JJ
cord-263455-dquztf5l	639	31	exposure	exposure	JJ
cord-263455-dquztf5l	639	32	prophylaxis	prophylaxis	NN
cord-263455-dquztf5l	639	33	Chemoprophylaxis	Chemoprophylaxis	NNP
cord-263455-dquztf5l	639	34	to	to	TO
cord-263455-dquztf5l	639	35	control	control	VB
cord-263455-dquztf5l	639	36	leprosy	leprosy	NN
cord-263455-dquztf5l	639	37	and	and	CC
cord-263455-dquztf5l	639	38	the	the	DT
cord-263455-dquztf5l	639	39	perspective	perspective	NN
cord-263455-dquztf5l	639	40	of	of	IN
cord-263455-dquztf5l	639	41	its	-PRON-	PRP$
cord-263455-dquztf5l	639	42	implementation	implementation	NN
cord-263455-dquztf5l	639	43	in	in	IN
cord-263455-dquztf5l	639	44	Brazil	Brazil	NNP
cord-263455-dquztf5l	639	45	:	:	:
cord-263455-dquztf5l	639	46	a	a	DT
cord-263455-dquztf5l	639	47	primer	primer	NN
cord-263455-dquztf5l	639	48	for	for	IN
cord-263455-dquztf5l	639	49	non	non	NNS
cord-263455-dquztf5l	639	50	-	-	NNS
cord-263455-dquztf5l	639	51	epidemiologists	epidemiologist	NNS
cord-263455-dquztf5l	639	52	[	[	-LRB-
cord-263455-dquztf5l	639	53	Quimioprofilaxia	Quimioprofilaxia	NNP
cord-263455-dquztf5l	639	54	para	para	NNP
cord-263455-dquztf5l	639	55	prevenção	prevenção	NNP
cord-263455-dquztf5l	639	56	de	de	FW
cord-263455-dquztf5l	639	57	hanseníase	hanseníase	FW
cord-263455-dquztf5l	639	58	e	e	NN
cord-263455-dquztf5l	639	59	sua	sua	NN
cord-263455-dquztf5l	639	60	implantação	implantação	NN
cord-263455-dquztf5l	639	61	no	no	DT
cord-263455-dquztf5l	639	62	Brasil	Brasil	NNP
cord-263455-dquztf5l	639	63	:	:	:
cord-263455-dquztf5l	640	1	uma	uma	NNP
cord-263455-dquztf5l	640	2	explicação	explicação	NNP
cord-263455-dquztf5l	640	3	introdutória	introdutória	NNP
cord-263455-dquztf5l	640	4	para	para	NNP
cord-263455-dquztf5l	640	5	não	não	NNP
cord-263455-dquztf5l	640	6	epidemiologistas	epidemiologistas	NNP
cord-263455-dquztf5l	641	1	An	an	DT
cord-263455-dquztf5l	641	2	enhanced	enhanced	JJ
cord-263455-dquztf5l	641	3	regimen	regimen	NN
cord-263455-dquztf5l	641	4	as	as	IN
cord-263455-dquztf5l	641	5	post	post	JJ
cord-263455-dquztf5l	641	6	-	-	JJ
cord-263455-dquztf5l	641	7	exposure	exposure	JJ
cord-263455-dquztf5l	641	8	chemoprophylaxis	chemoprophylaxis	NN
cord-263455-dquztf5l	641	9	for	for	IN
cord-263455-dquztf5l	641	10	leprosy	leprosy	NN
cord-263455-dquztf5l	641	11	:	:	:
cord-263455-dquztf5l	642	1	PEP++	PEP++	NNP
cord-263455-dquztf5l	642	2	Quinolone	Quinolone	NNP
cord-263455-dquztf5l	642	3	-	-	:
cord-263455-dquztf5l	642	4	and	and	CC
cord-263455-dquztf5l	642	5	fluoroquinolonecontaining	fluoroquinolonecontaine	VBG
cord-263455-dquztf5l	642	6	medicinal	medicinal	JJ
cord-263455-dquztf5l	642	7	products	product	NNS
cord-263455-dquztf5l	642	8	Prevention	Prevention	NNP
cord-263455-dquztf5l	642	9	of	of	IN
cord-263455-dquztf5l	642	10	transmission	transmission	NN
cord-263455-dquztf5l	642	11	of	of	IN
cord-263455-dquztf5l	642	12	leprosy	leprosy	NN
cord-263455-dquztf5l	642	13	:	:	:
cord-263455-dquztf5l	642	14	the	the	DT
cord-263455-dquztf5l	642	15	current	current	JJ
cord-263455-dquztf5l	642	16	scenario	scenario	NN
cord-263455-dquztf5l	642	17	World	World	NNP
cord-263455-dquztf5l	642	18	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	642	19	Day	Day	NNP
cord-263455-dquztf5l	642	20	2018	2018	CD
cord-263455-dquztf5l	642	21	:	:	:
cord-263455-dquztf5l	642	22	How	how	WRB
cord-263455-dquztf5l	642	23	forward	forward	RB
cord-263455-dquztf5l	642	24	respecting	respect	VBG
cord-263455-dquztf5l	642	25	the	the	DT
cord-263455-dquztf5l	642	26	past	past	NN
cord-263455-dquztf5l	642	27	?	?	.
cord-263455-dquztf5l	643	1	Workshop	workshop	NN
cord-263455-dquztf5l	643	2	explores	explore	VBZ
cord-263455-dquztf5l	643	3	how	how	WRB
cord-263455-dquztf5l	643	4	to	to	TO
cord-263455-dquztf5l	643	5	scale	scale	VB
cord-263455-dquztf5l	643	6	up	up	RP
cord-263455-dquztf5l	643	7	PEP	pep	NN
cord-263455-dquztf5l	643	8	and	and	CC
cord-263455-dquztf5l	643	9	advance	advance	NN
cord-263455-dquztf5l	643	10	research	research	NN
cord-263455-dquztf5l	643	11	|	|	NNP
cord-263455-dquztf5l	643	12	Global	Global	NNP
cord-263455-dquztf5l	643	13	Partnership	Partnership	NNP
cord-263455-dquztf5l	643	14	for	for	IN
cord-263455-dquztf5l	643	15	Zero	Zero	NNP
cord-263455-dquztf5l	643	16	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	643	17	.	.	.
cord-263455-dquztf5l	644	1	Global	Global	NNP
cord-263455-dquztf5l	644	2	Partnership	Partnership	NNP
cord-263455-dquztf5l	644	3	for	for	IN
cord-263455-dquztf5l	644	4	Zero	Zero	NNP
cord-263455-dquztf5l	644	5	Leprosy	Leprosy	NNP
cord-263455-dquztf5l	644	6	World	World	NNP
cord-263455-dquztf5l	644	7	Health	Health	NNP
cord-263455-dquztf5l	644	8	Organization	Organization	NNP
cord-263455-dquztf5l	644	9	.	.	.
cord-263455-dquztf5l	645	1	A	a	DT
cord-263455-dquztf5l	645	2	guide	guide	NN
cord-263455-dquztf5l	645	3	for	for	IN
cord-263455-dquztf5l	645	4	surveillance	surveillance	NN
cord-263455-dquztf5l	645	5	of	of	IN
cord-263455-dquztf5l	645	6	antimicrobial	antimicrobial	JJ
cord-263455-dquztf5l	645	7	resistance	resistance	NN
cord-263455-dquztf5l	645	8	in	in	IN
cord-263455-dquztf5l	645	9	leprosy	leprosy	NN
cord-263455-dquztf5l	645	10	:	:	:
cord-263455-dquztf5l	645	11	2017	2017	CD
cord-263455-dquztf5l	645	12	update	update	NN
cord-263455-dquztf5l	645	13	.	.	.
cord-263455-dquztf5l	646	1	WHO	who	WP
cord-263455-dquztf5l	646	2	medicines	medicine	NNS
cord-263455-dquztf5l	646	3	catalog	catalog	NN
cord-263455-dquztf5l	646	4	-global	-global	JJ
cord-263455-dquztf5l	646	5	drug	drug	NN
cord-263455-dquztf5l	646	6	facility	facility	NN
cord-263455-dquztf5l	646	7	(	(	-LRB-
cord-263455-dquztf5l	646	8	GDF	GDF	NNP
cord-263455-dquztf5l	646	9	)	)	-RRB-
cord-263455-dquztf5l	646	10	Research	Research	NNP
cord-263455-dquztf5l	646	11	and	and	CC
cord-263455-dquztf5l	646	12	Reports	Reports	NNPS
cord-263455-dquztf5l	646	13	in	in	IN
cord-263455-dquztf5l	646	14	Tropical	Tropical	NNP
cord-263455-dquztf5l	646	15	Medicine	Medicine	NNP
cord-263455-dquztf5l	646	16	is	be	VBZ
cord-263455-dquztf5l	646	17	an	an	DT
cord-263455-dquztf5l	646	18	international	international	JJ
cord-263455-dquztf5l	646	19	,	,	,
cord-263455-dquztf5l	646	20	peerreviewed	peerreviewed	JJ
cord-263455-dquztf5l	646	21	,	,	,
cord-263455-dquztf5l	646	22	open	open	JJ
cord-263455-dquztf5l	646	23	access	access	NN
cord-263455-dquztf5l	646	24	journal	journal	NN
cord-263455-dquztf5l	646	25	publishing	publish	VBG
cord-263455-dquztf5l	646	26	original	original	JJ
cord-263455-dquztf5l	646	27	research	research	NN
cord-263455-dquztf5l	646	28	,	,	,
cord-263455-dquztf5l	646	29	case	case	NN
cord-263455-dquztf5l	646	30	reports	report	NNS
cord-263455-dquztf5l	646	31	,	,	,
cord-263455-dquztf5l	646	32	editorials	editorial	NNS
cord-263455-dquztf5l	646	33	,	,	,
cord-263455-dquztf5l	646	34	reviews	review	NNS
cord-263455-dquztf5l	646	35	and	and	CC
cord-263455-dquztf5l	646	36	commentaries	commentary	NNS
cord-263455-dquztf5l	646	37	on	on	IN
cord-263455-dquztf5l	646	38	all	all	DT
cord-263455-dquztf5l	646	39	areas	area	NNS
cord-263455-dquztf5l	646	40	of	of	IN
cord-263455-dquztf5l	646	41	tropical	tropical	JJ
cord-263455-dquztf5l	646	42	medicine	medicine	NN
cord-263455-dquztf5l	646	43	,	,	,
cord-263455-dquztf5l	646	44	including	include	VBG
cord-263455-dquztf5l	646	45	:	:	:
cord-263455-dquztf5l	646	46	Diseases	disease	NNS
cord-263455-dquztf5l	646	47	and	and	CC
cord-263455-dquztf5l	646	48	medicine	medicine	NN
cord-263455-dquztf5l	646	49	in	in	IN
cord-263455-dquztf5l	646	50	tropical	tropical	JJ
cord-263455-dquztf5l	646	51	regions	region	NNS
cord-263455-dquztf5l	646	52	;	;	:
cord-263455-dquztf5l	646	53	Entomology	entomology	NN
cord-263455-dquztf5l	646	54	;	;	:
cord-263455-dquztf5l	646	55	Epidemiology	epidemiology	NN
cord-263455-dquztf5l	646	56	;	;	:
cord-263455-dquztf5l	646	57	Health	health	NN
cord-263455-dquztf5l	646	58	economics	economics	NN
cord-263455-dquztf5l	646	59	issues	issue	NNS
cord-263455-dquztf5l	646	60	;	;	:
cord-263455-dquztf5l	646	61	Infectious	infectious	JJ
cord-263455-dquztf5l	646	62	disease	disease	NN
cord-263455-dquztf5l	646	63	;	;	:
cord-263455-dquztf5l	646	64	Laboratory	laboratory	NN
cord-263455-dquztf5l	646	65	science	science	NN
cord-263455-dquztf5l	646	66	and	and	CC
cord-263455-dquztf5l	646	67	new	new	JJ
cord-263455-dquztf5l	646	68	technology	technology	NN
cord-263455-dquztf5l	646	69	in	in	IN
cord-263455-dquztf5l	646	70	tropical	tropical	JJ
cord-263455-dquztf5l	646	71	medicine;Parasitology	medicine;parasitology	NN
cord-263455-dquztf5l	646	72	;	;	:
cord-263455-dquztf5l	646	73	Public	public	JJ
cord-263455-dquztf5l	646	74	health	health	NN
cord-263455-dquztf5l	646	75	medicine	medicine	NN
cord-263455-dquztf5l	646	76	/	/	SYM
cord-263455-dquztf5l	646	77	health	health	NN
cord-263455-dquztf5l	646	78	care	care	NN
cord-263455-dquztf5l	646	79	policy	policy	NN
cord-263455-dquztf5l	646	80	in	in	IN
cord-263455-dquztf5l	646	81	tropical	tropical	JJ
cord-263455-dquztf5l	646	82	regions	region	NNS
cord-263455-dquztf5l	646	83	;	;	:
cord-263455-dquztf5l	646	84	and	and	CC
cord-263455-dquztf5l	646	85	Microbiology	Microbiology	NNP
cord-263455-dquztf5l	646	86	.	.	.
cord-263455-dquztf5l	647	1	The	the	DT
cord-263455-dquztf5l	647	2	manuscript	manuscript	NN
cord-263455-dquztf5l	647	3	management	management	NN
cord-263455-dquztf5l	647	4	system	system	NN
cord-263455-dquztf5l	647	5	is	be	VBZ
cord-263455-dquztf5l	647	6	completely	completely	RB
cord-263455-dquztf5l	647	7	online	online	JJ
cord-263455-dquztf5l	647	8	and	and	CC
cord-263455-dquztf5l	647	9	includes	include	VBZ
cord-263455-dquztf5l	647	10	a	a	DT
cord-263455-dquztf5l	647	11	very	very	RB
cord-263455-dquztf5l	647	12	quick	quick	JJ
cord-263455-dquztf5l	647	13	and	and	CC
cord-263455-dquztf5l	647	14	fair	fair	JJ
cord-263455-dquztf5l	647	15	peer	peer	NN
cord-263455-dquztf5l	647	16	-	-	HYPH
cord-263455-dquztf5l	647	17	review	review	NN
cord-263455-dquztf5l	647	18	system	system	NN
cord-263455-dquztf5l	647	19	.	.	.
cord-263455-dquztf5l	648	1	Visit	visit	VB
cord-263455-dquztf5l	648	2	http://www.dovepress.com/testimonials.php	http://www.dovepress.com/testimonials.php	NNP
cord-263455-dquztf5l	648	3	to	to	TO
cord-263455-dquztf5l	648	4	read	read	VB
cord-263455-dquztf5l	648	5	real	real	JJ
cord-263455-dquztf5l	648	6	quotes	quote	NNS
cord-263455-dquztf5l	648	7	from	from	IN
cord-263455-dquztf5l	648	8	published	publish	VBN
cord-263455-dquztf5l	648	9	authors	author	NNS
cord-263455-dquztf5l	648	10	.	.	.
cord-263455-dquztf5l	649	1	Submit	submit	VB
cord-263455-dquztf5l	649	2	your	-PRON-	PRP$
cord-263455-dquztf5l	649	3	manuscript	manuscript	NN
cord-263455-dquztf5l	649	4	here	here	RB
cord-263455-dquztf5l	649	5	:	:	:
cord-263455-dquztf5l	650	1	http://www.dovepress.com/research-and-reports-in-tropical-medicine-journal	http://www.dovepress.com/research-and-reports-in-tropical-medicine-journal	JJ